The	O
Caenorhabditis	O
elegans	O
sex	O
determination	O
gene	O
mog-1	B
encodes	O
a	O
member	O
of	O
the	O
DEAH	O
-	O
Box	O
protein	O
family	O
.	O

In	O
the	O
Caenorhabditis	O
elegans	O
hermaphrodite	O
germ	O
line	O
,	O
the	O
sex	O
-	O
determining	O
gene	O
fem-3	B
is	O
repressed	O
posttranscriptionally	O
to	O
arrest	O
spermatogenesis	O
and	O
permit	O
oogenesis	O
.	O

This	O
repression	O
requires	O
a	O
cis	O
-	O
acting	O
regulatory	O
element	O
in	O
the	O
fem-3	B
3	O
'	O
untranslated	O
region	O
;	O
the	O
FBF	B
protein	O
,	O
which	O
binds	O
to	O
this	O
element	O
;	O
and	O
at	O
least	O
six	O
mog	B
genes	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
molecular	O
characterization	O
of	O
mog-1	B
as	O
well	O
as	O
additional	O
phenotypic	O
characterization	O
of	O
this	O
gene	O
.	O

The	O
mog-1	B
gene	O
encodes	O
a	O
member	O
of	O
the	O
DEAH	O
-	O
box	O
family	O
.	O

Three	O
mog-1	B
alleles	O
possess	O
premature	O
stop	O
codons	O
and	O
are	O
likely	O
to	O
be	O
null	O
alleles	O
,	O
and	O
one	O
is	O
a	O
missense	O
mutation	O
and	O
is	O
likely	O
to	O
retain	O
residual	O
activity	O
.	O

mog-1	B
mRNA	O
is	O
expressed	O
in	O
both	O
germ	O
line	O
and	O
somatic	O
tissues	O
and	O
appears	O
to	O
be	O
ubiquitous	O
.	O

The	O
MOG-1	B
DEAH	O
-	O
box	O
protein	O
is	O
most	O
closely	O
related	O
to	O
proteins	O
essential	O
for	O
splicing	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
but	O
splicing	O
appears	O
to	O
occur	O
normally	O
in	O
a	O
mog-1	B
-	O
null	O
mutant	O
.	O

In	O
addition	O
to	O
its	O
involvement	O
in	O
the	O
sperm	O
-	O
oocyte	O
switch	O
and	O
control	O
of	O
fem-3	B
,	O
zygotic	O
mog-1	B
is	O
required	O
for	O
robust	O
germ	O
line	O
proliferation	O
and	O
for	O
normal	O
growth	O
during	O
development	O
.	O

We	O
suggest	O
that	O
mog-1	B
plays	O
a	O
broader	O
role	O
in	O
RNA	O
regulation	O
than	O
previously	O
considered	O
.	O

A	O
novel	O
PDZ	O
domain	O
containing	O
guanine	B
nucleotide	I
exchange	I
factor	I
links	O
heterotrimeric	B
G	I
proteins	I
to	O
Rho	B
.	O

Small	B
GTP	I
-	I
binding	I
proteins	I
of	I
the	I
Rho	I
family	I
play	O
a	O
critical	O
role	O
in	O
signal	O
transduction	O
.	O

However	O
,	O
there	O
is	O
still	O
very	O
limited	O
information	O
on	O
how	O
they	O
are	O
activated	O
by	O
cell	O
surface	O
receptors	O
.	O

Here	O
,	O
we	O
used	O
a	O
consensus	O
sequence	O
for	O
Dbl	B
domains	O
of	O
Rho	B
guanine	I
nucleotide	I
exchange	I
factors	I
(	O
GEFs	B
)	O
to	O
search	O
DNA	O
data	O
bases	O
,	O
and	O
identified	O
a	O
novel	O
human	O
GEF	B
for	O
Rho	B
-	O
related	O
GTPases	B
harboring	O
structural	O
features	O
indicative	O
of	O
its	O
possible	O
regulatory	O
mechanism	O
(	O
s	O
)	O
.	O

This	O
protein	O
contained	O
a	O
tandem	O
DH	O
/	O
PH	O
domain	O
closely	O
related	O
to	O
those	O
of	O
Rho	B
-	I
specific	I
GEFs	I
,	O
a	O
PDZ	O
domain	O
,	O
a	O
proline	O
-	O
rich	O
domain	O
,	O
and	O
an	O
area	O
of	O
homology	O
to	O
Lsc	B
,	O
p115	B
-	I
RhoGEF	I
,	O
and	O
a	O
Drosophila	O
RhoGEF	B
that	O
was	O
termed	O
Lsc	B
-	O
homology	O
(	O
LH	O
)	O
domain	O
.	O

This	O
novel	O
molecule	O
,	O
designated	O
PDZ	B
-	I
RhoGEF	I
,	O
activated	O
biological	O
and	O
biochemical	O
pathways	O
specific	O
for	O
Rho	B
,	O
and	O
activation	O
of	O
these	O
pathways	O
required	O
an	O
intact	O
DH	O
and	O
PH	O
domain	O
.	O

However	O
,	O
the	O
PDZ	O
domain	O
was	O
dispensable	O
for	O
these	O
functions	O
,	O
and	O
mutants	O
lacking	O
the	O
LH	O
domain	O
were	O
more	O
active	O
,	O
suggesting	O
a	O
negative	O
regulatory	O
role	O
for	O
the	O
LH	O
domain	O
.	O

A	O
search	O
for	O
additional	O
molecules	O
exhibiting	O
an	O
LH	O
domain	O
revealed	O
a	O
limited	O
homology	O
with	O
the	O
catalytic	O
region	O
of	O
a	O
newly	O
identified	O
GTPase	B
-	I
activating	I
protein	I
for	O
heterotrimeric	B
G	I
proteins	I
,	O
RGS14	B
.	O

This	O
prompted	O
us	O
to	O
investigate	O
whether	O
PDZ	B
-	I
RhoGEF	I
could	O
interact	O
with	O
representative	O
members	O
of	O
each	O
G	B
protein	I
family	I
.	O

We	O
found	O
that	O
PDZ	B
-	I
RhoGEF	I
was	O
able	O
to	O
form	O
,	O
in	O
vivo	O
,	O
stable	O
complexes	O
with	O
two	O
members	O
of	O
the	O
Galpha12	B
family	I
,	O
Galpha12	B
and	O
Galpha13	B
,	O
and	O
that	O
this	O
interaction	O
was	O
mediated	O
by	O
the	O
LH	O
domain	O
.	O

Furthermore	O
,	O
we	O
obtained	O
evidence	O
to	O
suggest	O
that	O
PDZ	B
-	I
RhoGEF	I
mediates	O
the	O
activation	O
of	O
Rho	B
by	O
Galpha12	B
and	O
Galpha13	B
.	O

Together	O
,	O
these	O
findings	O
suggest	O
the	O
existence	O
of	O
a	O
novel	O
mechanism	O
whereby	O
the	O
large	O
family	O
of	O
cell	O
surface	O
receptors	O
that	O
transmit	O
signals	O
through	O
heterotrimeric	B
G	I
proteins	I
activate	O
Rho	B
-	O
dependent	O
pathways	O
:	O
by	O
stimulating	O
the	O
activity	O
of	O
members	O
of	O
the	O
Galpha12	B
family	I
which	O
,	O
in	O
turn	O
,	O
activate	O
an	O
exchange	B
factor	I
acting	O
on	O
Rho	B
.	O

The	O
gene	O
bglH	B
present	O
in	O
the	O
bgl	B
operon	I
of	O
Escherichia	O
coli	O
,	O
responsible	O
for	O
uptake	O
and	O
fermentation	O
of	O
beta	O
-	O
glucosides	O
encodes	O
for	O
a	O
carbohydrate	O
-	O
specific	O
outer	O
membrane	O
porin	B
.	O

The	O
cryptic	O
gene	O
bglH	B
from	O
the	O
Escherichia	O
coli	O
chromosome	O
was	O
cloned	O
into	O
a	O
tacOP	O
-	O
driven	O
expression	O
vector	O
.	O

The	O
resulting	O
plasmid	O
was	O
transferred	O
into	O
the	O
porin	B
-	O
deficient	O
E.	O
coli	O
strain	O
KS26	O
and	O
the	O
protein	O
was	O
expressed	O
by	O
addition	O
of	O
IPTG	O
.	O

The	O
BglH	B
protein	O
was	O
localized	O
in	O
the	O
outer	O
membrane	O
.	O

It	O
was	O
purified	O
to	O
homogeneity	O
using	O
standard	O
methods	O
.	O

Reconstitution	O
experiments	O
with	O
lipid	O
bilayer	O
membranes	O
defined	O
BglH	B
as	O
a	O
channel	O
-	O
forming	O
component	O
,	O
i.e.	O
it	O
is	O
an	O
outer	O
membrane	O
porin	B
.	O

The	O
single	O
-	O
channel	O
conductance	O
of	O
BglH	B
(	O
560	O
pS	O
in	O
1	O
M	O
KCl	O
)	O
was	O
only	O
one	O
-	O
third	O
of	O
that	O
of	O
the	O
general	O
diffusion	O
porins	B
of	O
E.	O
coli	O
outer	O
membrane	O
.	O

The	O
presence	O
of	O
carbohydrates	O
in	O
the	O
aqueous	O
phase	O
led	O
to	O
a	O
dose	O
-	O
dependent	O
block	O
of	O
ion	O
transport	O
through	O
the	O
channel	O
,	O
similar	O
to	O
that	O
found	O
for	O
LamB	B
(	O
maltoporin	B
)	O
of	O
E.	O
coli	O
and	O
Salmonella	O
typhimurium	O
,	O
which	O
means	O
that	O
BglH	B
is	O
a	O
porin	B
specific	O
for	O
the	O
uptake	O
of	O
carbohydrates	O
.	O

The	O
binding	O
constants	O
of	O
a	O
variety	O
of	O
different	O
carbohydrates	O
were	O
calculated	O
from	O
titration	O
experiments	O
of	O
the	O
BglH	B
-	O
induced	O
membrane	O
conductance	O
.	O

The	O
tightest	O
binding	O
was	O
observed	O
with	O
the	O
aromatic	O
beta	O
-	O
D	O
-	O
glucosides	O
arbutin	O
and	O
salicin	O
,	O
and	O
with	O
gentibiose	O
and	O
cellobiose	O
.	O

Binding	O
of	O
maltooligosaccharides	O
to	O
BglH	B
was	O
in	O
contrast	O
to	O
their	O
binding	O
to	O
LamB	B
in	O
that	O
it	O
was	O
much	O
weaker	O
,	O
indicating	O
that	O
the	O
binding	O
site	O
of	O
BglH	B
for	O
carbohydrates	O
is	O
different	O
from	O
that	O
of	O
LamB	B
(	O
maltoporin	B
)	O
.	O

The	O
kinetics	O
of	O
cellopentaose	O
binding	O
to	O
BglH	B
was	O
investigated	O
using	O
the	O
carbohydrate	O
-	O
induced	O
current	O
noise	O
and	O
was	O
compared	O
with	O
that	O
of	O
cellopentaose	O
binding	O
to	O
LamB	B
(	O
maltoporin	B
)	O
and	O
ScrY	B
(	O
sucroseporin	B
)	O
.	O

The	O
cyclic	B
AMP	I
receptor	I
protein	I
is	O
dependent	O
on	O
GcvA	B
for	O
regulation	O
of	O
the	O
gcv	B
operon	I
.	O

The	O
Escherichia	O
coli	O
gcv	B
operon	I
is	O
transcriptionally	O
regulated	O
by	O
the	O
GcvA	B
,	O
GcvR	B
,	O
Lrp	B
,	O
and	O
PurR	B
proteins	O
.	O

In	O
this	O
study	O
,	O
the	O
cyclic	B
AMP	I
(	I
cAMP	I
)	I
receptor	I
protein	I
(	O
CRP	B
)	O
is	O
shown	O
to	O
be	O
involved	O
in	O
positive	O
regulation	O
of	O
the	O
gcv	B
operon	I
.	O

A	O
crp	B
deletion	O
reduced	O
expression	O
of	O
a	O
gcvT	B
-	O
lacZ	B
fusion	O
almost	O
fourfold	O
in	O
glucose	O
minimal	O
(	O
GM	O
)	O
medium	O
.	O

The	O
phenotype	O
was	O
complemented	O
by	O
both	O
the	O
wild	O
-	O
type	O
crp	B
gene	O
and	O
four	O
crp	B
alleles	O
that	O
encode	O
proteins	O
with	O
amino	O
acid	O
substitutions	O
in	O
known	O
activating	O
regions	O
of	O
CRP	B
.	O

A	O
cyaA	B
deletion	O
also	O
resulted	O
in	O
a	O
fourfold	O
decrease	O
in	O
gcvT	B
-	O
lacZ	B
expression	O
,	O
and	O
wild	O
-	O
type	O
expression	O
was	O
restored	O
by	O
the	O
addition	O
of	O
cAMP	O
to	O
the	O
growth	O
medium	O
.	O

A	O
cyaA	B
crp	B
double	O
deletion	O
resulted	O
in	O
levels	O
of	O
gcvT	B
-	O
lacZ	B
expression	O
identical	O
to	O
those	O
observed	O
with	O
either	O
single	O
mutation	O
,	O
showing	O
that	O
CRP	B
and	O
cAMP	O
regulate	O
through	O
the	O
same	O
mechanism	O
.	O

Growth	O
in	O
GM	O
medium	O
plus	O
cAMP	O
or	O
glycerol	O
minimal	O
medium	O
did	O
not	O
result	O
in	O
a	O
significant	O
increase	O
in	O
gcvT	B
-	O
lacZ	B
expression	O
.	O

Thus	O
,	O
the	O
level	O
of	O
cAMP	O
present	O
in	O
GM	O
medium	O
appears	O
to	O
be	O
sufficient	O
for	O
regulation	O
by	O
CRP	B
.	O

DNase	B
I	I
footprint	O
analysis	O
showed	O
that	O
CRP	B
binds	O
and	O
protects	O
two	O
sites	O
centered	O
at	O
bp	O
-	O
313	O
(	O
site	O
1	O
)	O
and	O
bp	O
-	O
140	O
(	O
site	O
2	O
)	O
relative	O
to	O
the	O
transcription	O
initiation	O
site	O
,	O
but	O
a	O
mutational	O
analysis	O
demonstrated	O
that	O
only	O
site	O
1	O
is	O
required	O
for	O
CRP	B
-	O
mediated	O
regulation	O
of	O
gcvT	B
-	O
lacZ	B
expression	O
.	O

Expression	O
of	O
the	O
gcvT	B
-	O
lacZ	B
fusion	O
in	O
a	O
crp	B
gcvA	B
double	O
mutant	O
suggested	O
that	O
CRP	B
's	O
role	O
is	O
dependent	O
on	O
the	O
GcvA	B
protein	O
.	O

Identification	O
of	O
a	O
new	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
family	I
and	O
its	O
receptor	O
,	O
a	O
human	O
ortholog	O
of	O
mouse	O
GITR	B
.	O

The	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
and	I
TNF	I
receptor	I
(	I
TNFR	I
)	I
gene	I
superfamilies	I
regulate	O
diverse	O
biological	O
functions	O
,	O
including	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
[	O
1	O
]	O
[	O
2	O
]	O
[	O
3	O
]	O
.	O

We	O
have	O
identified	O
a	O
new	O
TNF	B
-	O
related	O
ligand	O
,	O
designated	O
human	O
GITR	B
ligand	I
(	O
hGITRL	B
)	O
,	O
and	O
its	O
human	O
receptor	O
(	O
hGITR	B
)	O
,	O
an	O
ortholog	O
of	O
the	O
recently	O
discovered	O
murine	O
glucocorticoid	O
-	O
induced	O
TNFR	B
-	O
related	O
(	O
mGITR	B
)	O
protein	O
[	O
4	O
]	O
.	O

The	O
hGITRL	B
gene	O
mapped	O
to	O
chromosome	O
1q23	O
,	O
near	O
the	O
gene	O
for	O
the	O
TNF	B
homolog	O
Fas	B
/	I
CD95	I
ligand	I
[	O
5	O
]	O
.	O

The	O
hGITR	B
gene	O
mapped	O
to	O
chromosome	O
1p36	O
,	O
near	O
a	O
cluster	O
of	O
five	O
genes	O
encoding	O
TNFR	B
homologs	O
[	O
1	O
]	O
[	O
6	O
]	O
.	O

We	O
found	O
hGITRL	B
mRNA	O
in	O
several	O
peripheral	O
tissues	O
,	O
and	O
detected	O
hGITRL	B
protein	O
on	O
cultured	O
vascular	O
endothelial	O
cells	O
.	O

The	O
levels	O
of	O
hGITR	B
mRNA	O
in	O
tissues	O
were	O
generally	O
low	O
;	O
in	O
peripheral	O
blood	O
T	O
cells	O
,	O
however	O
,	O
antigen	O
-	O
receptor	O
stimulation	O
led	O
to	O
a	O
substantial	O
induction	O
of	O
hGITR	B
transcripts	O
.	O

Cotransfection	O
of	O
hGITRL	B
and	O
hGITR	B
in	O
embryonic	O
kidney	O
293	O
cells	O
activated	O
the	O
anti	O
-	O
apoptotic	O
transcription	O
factor	O
NF	B
-	I
kappaB	I
,	O
via	O
a	O
pathway	O
that	O
appeared	O
to	O
involve	O
TNFR	B
-	I
associated	I
factor	I
2	I
(	O
TRAF2	B
)	O
[	O
7	O
]	O
and	O
NF	B
-	I
kappaB	I
-	I
inducing	I
kinase	I
(	O
NIK	B
)	O
[	O
8	O
]	O
.	O

Cotransfection	O
of	O
hGITRL	B
and	O
hGITR	B
in	O
Jurkat	O
T	O
leukemia	O
cells	O
inhibited	O
antigen	O
-	O
receptor	O
-	O
induced	O
cell	O
death	O
.	O

Thus	O
,	O
hGITRL	B
and	O
hGITR	B
may	O
modulate	O
T	O
lymphocyte	O
survival	O
in	O
peripheral	O
tissues	O
.	O

Negative	O
regulation	O
by	O
the	O
Bacillus	O
subtilis	O
GerE	B
protein	O
.	O

GerE	B
is	O
a	O
transcription	B
factor	I
produced	O
in	O
the	O
mother	O
cell	O
compartment	O
of	O
sporulating	O
Bacillus	O
subtilis	O
.	O

It	O
is	O
a	O
critical	O
regulator	O
of	O
cot	B
genes	O
encoding	O
proteins	O
that	O
form	O
the	O
spore	O
coat	O
late	O
in	O
development	O
.	O

Most	O
cot	B
genes	O
,	O
and	O
the	O
gerE	B
gene	O
,	O
are	O
transcribed	O
by	O
sigmaK	B
RNA	B
polymerase	I
.	O

Previously	O
,	O
it	O
was	O
shown	O
that	O
the	O
GerE	B
protein	O
inhibits	O
transcription	O
in	O
vitro	O
of	O
the	O
sigK	B
gene	O
encoding	O
sigmaK	B
.	O

Here	O
,	O
we	O
show	O
that	O
GerE	B
binds	O
near	O
the	O
sigK	B
transcriptional	O
start	O
site	O
,	O
to	O
act	O
as	O
a	O
repressor	O
.	O

A	O
sigK	B
-	O
lacZ	B
fusion	O
containing	O
the	O
GerE	B
-	O
binding	O
site	O
in	O
the	O
promoter	O
region	O
was	O
expressed	O
at	O
a	O
2	O
-	O
fold	O
lower	O
level	O
during	O
sporulation	O
of	O
wild	O
-	O
type	O
cells	O
than	O
gerE	B
mutant	O
cells	O
.	O

Likewise	O
,	O
the	O
level	O
of	O
SigK	B
protein	O
(	O
i.	O
e.	O
pro	O
-	O
sigmaK	B
and	O
sigmaK	B
)	O
was	O
lower	O
in	O
sporulating	O
wild	O
-	O
type	O
cells	O
than	O
in	O
a	O
gerE	B
mutant	O
.	O

These	O
results	O
demonstrate	O
that	O
sigmaK	B
-	O
dependent	O
transcription	O
of	O
gerE	B
initiates	O
a	O
negative	O
feedback	O
loop	O
in	O
which	O
GerE	B
acts	O
as	O
a	O
repressor	O
to	O
limit	O
production	O
of	O
sigmaK	B
.	O

In	O
addition	O
,	O
GerE	B
directly	O
represses	O
transcription	O
of	O
particular	O
cot	B
genes	O
.	O

We	O
show	O
that	O
GerE	B
binds	O
to	O
two	O
sites	O
that	O
span	O
the	O
-	O
35	O
region	O
of	O
the	O
cotD	B
promoter	O
.	O

A	O
low	O
level	O
of	O
GerE	B
activated	O
transcription	O
of	O
cotD	B
by	O
sigmaK	B
RNA	B
polymerase	I
in	O
vitro	O
,	O
but	O
a	O
higher	O
level	O
of	O
GerE	B
repressed	O
cotD	B
transcription	O
.	O

The	O
upstream	O
GerE	B
-	O
binding	O
site	O
was	O
required	O
for	O
activation	O
but	O
not	O
for	O
repression	O
.	O

These	O
results	O
suggest	O
that	O
a	O
rising	O
level	O
of	O
GerE	B
in	O
sporulating	O
cells	O
may	O
first	O
activate	O
cotD	B
transcription	O
from	O
the	O
upstream	O
site	O
then	O
repress	O
transcription	O
as	O
the	O
downstream	O
site	O
becomes	O
occupied	O
.	O

Negative	O
regulation	O
by	O
GerE	B
,	O
in	O
addition	O
to	O
its	O
positive	O
effects	O
on	O
transcription	O
,	O
presumably	O
ensures	O
that	O
sigmaK	B
and	O
spore	O
coat	O
proteins	O
are	O
synthesized	O
at	O
optimal	O
levels	O
to	O
produce	O
a	O
germination	O
-	O
competent	O
spore	O
.	O

Role	O
of	O
bkdR	B
,	O
a	O
transcriptional	O
activator	O
of	O
the	O
sigL	B
-	O
dependent	O
isoleucine	O
and	O
valine	O
degradation	O
pathway	O
in	O
Bacillus	O
subtilis	O
.	O

A	O
new	O
gene	O
,	O
bkdR	B
(	O
formerly	O
called	O
yqiR	B
)	O
,	O
encoding	O
a	O
regulator	O
with	O
a	O
central	O
(	O
catalytic	O
)	O
domain	O
was	O
found	O
in	O
Bacillus	O
subtilis	O
.	O

This	O
gene	O
controls	O
the	O
utilization	O
of	O
isoleucine	O
and	O
valine	O
as	O
sole	O
nitrogen	O
sources	O
.	O

Seven	O
genes	O
,	O
previously	O
called	O
yqiS	B
,	O
yqiT	B
,	O
yqiU	B
,	O
yqiV	B
,	O
bfmBAA	B
,	O
bfmBAB	B
,	O
and	O
bfmBB	B
and	O
now	O
referred	O
to	O
as	O
ptb	B
,	O
bcd	B
,	O
buk	B
,	O
lpd	B
,	O
bkdA1	B
,	O
bkdA2	B
,	O
and	O
bkdB	B
,	O
are	O
located	O
downstream	O
from	O
the	O
bkdR	B
gene	O
in	O
B.	O
subtilis	O
.	O

The	O
products	O
of	O
these	O
genes	O
are	O
similar	O
to	O
phosphate	B
butyryl	I
coenzyme	I
A	I
transferase	I
,	O
leucine	B
dehydrogenase	I
,	O
butyrate	B
kinase	I
,	O
and	O
four	O
components	O
of	O
the	O
branched	B
-	I
chain	I
keto	I
acid	I
dehydrogenase	I
complex	I
:	I
E3	I
(	O
dihydrolipoamide	B
dehydrogenase	I
)	O
,	O
E1alpha	B
(	I
dehydrogenase	I
)	I
,	O
E1beta	B
(	I
decarboxylase	I
)	I
,	O
and	O
E2	B
(	I
dihydrolipoamide	I
acyltransferase	I
)	I
.	O

Isoleucine	O
and	O
valine	O
utilization	O
was	O
abolished	O
in	O
bcd	B
and	O
bkdR	B
null	O
mutants	O
of	O
B.	O
subtilis	O
.	O

The	O
seven	O
genes	O
appear	O
to	O
be	O
organized	O
as	O
an	O
operon	O
,	O
bkd	B
,	O
transcribed	O
from	O
a	O
-	O
12	O
,	O
-	O
24	O
promoter	O
.	O

The	O
expression	O
of	O
the	O
bkd	B
operon	I
was	O
induced	O
by	O
the	O
presence	O
of	O
isoleucine	O
or	O
valine	O
in	O
the	O
growth	O
medium	O
and	O
depended	O
upon	O
the	O
presence	O
of	O
the	O
sigma	B
factor	I
SigL	B
,	O
a	O
member	O
of	O
the	O
sigma	B
54	I
family	I
.	O

Transcription	O
of	O
this	O
operon	O
was	O
abolished	O
in	O
strains	O
containing	O
a	O
null	O
mutation	O
in	O
the	O
regulatory	O
gene	O
bkdR	B
.	O

Deletion	O
analysis	O
showed	O
that	O
upstream	O
activating	O
sequences	O
are	O
involved	O
in	O
the	O
expression	O
of	O
the	O
bkd	B
operon	I
and	O
are	O
probably	O
the	O
target	O
of	O
bkdR	B
.	O

Transcription	O
of	O
the	O
bkd	B
operon	I
is	O
also	O
negatively	O
controlled	O
by	O
CodY	B
,	O
a	O
global	O
regulator	O
of	O
gene	O
expression	O
in	O
response	O
to	O
nutritional	O
conditions	O
.	O

The	O
acid	O
-	O
inducible	O
asr	B
gene	O
in	O
Escherichia	O
coli	O
:	O
transcriptional	O
control	O
by	O
the	O
phoBR	B
operon	I
.	O

Escherichia	O
coli	O
responds	O
to	O
external	O
acidification	O
(	O
pH	O
4.0	O
to	O
5.0	O
)	O
by	O
synthesizing	O
a	O
newly	O
identified	O
,	O
approximately	O
450	O
-	O
nucleotide	O
RNA	O
component	O
.	O

At	O
maximal	O
levels	O
of	O
induction	O
it	O
is	O
one	O
of	O
the	O
most	O
abundant	O
small	O
RNAs	O
in	O
the	O
cell	O
and	O
is	O
relatively	O
stable	O
bacterial	O
RNA	O
.	O

The	O
acid	O
-	O
inducible	O
RNA	O
was	O
purified	O
,	O
and	O
the	O
gene	O
encoding	O
it	O
,	O
designated	O
asr	B
(	O
for	O
acid	B
shock	I
RNA	I
)	O
,	O
mapped	O
at	O
35.98	O
min	O
on	O
the	O
E.	O
coli	O
chromosome	O
.	O

Analysis	O
of	O
the	O
asr	B
DNA	O
sequence	O
revealed	O
an	O
open	O
reading	O
frame	O
coding	O
for	O
a	O
111	O
-	O
amino	O
-	O
acid	O
polypeptide	O
with	O
a	O
deduced	O
molecular	O
mass	O
of	O
approximately	O
11.6	O
kDa	O
.	O

According	O
to	O
computer	O
-	O
assisted	O
analysis	O
,	O
the	O
predicted	O
polypeptide	O
contains	O
a	O
typical	O
signal	O
sequence	O
of	O
30	O
amino	O
acids	O
and	O
might	O
represent	O
either	O
a	O
periplasmic	O
or	O
an	O
outer	O
membrane	O
protein	O
.	O

The	O
asr	B
gene	O
cloned	O
downstream	O
from	O
a	O
T7	O
promoter	O
was	O
translated	O
in	O
vivo	O
after	O
transcription	O
using	O
a	O
T7	O
RNA	B
polymerase	I
transcription	O
system	O
.	O

Expression	O
of	O
a	O
plasmid	O
-	O
encoded	O
asr	B
:	O
:	O
lacZ	B
fusion	O
under	O
a	O
native	O
asr	O
promoter	O
was	O
reduced	O
approximately	O
15	O
-	O
fold	O
in	O
a	O
complex	O
medium	O
,	O
such	O
as	O
Luria	O
-	O
Bertani	O
medium	O
,	O
versus	O
the	O
minimal	O
medium	O
.	O

Transcription	O
of	O
the	O
chromosomal	O
asr	O
was	O
abolished	O
in	O
the	O
presence	O
of	O
a	O
phoB	B
-	O
phoR	B
(	O
a	O
two	O
-	O
component	O
regulatory	O
system	O
,	O
controlling	O
the	O
pho	B
regulon	O
inducible	O
by	O
phosphate	O
starvation	O
)	O
deletion	O
mutant	O
.	O

Acid	O
-	O
mediated	O
induction	O
of	O
the	O
asr	B
gene	O
in	O
the	O
Delta	O
(	O
phoB	B
-	O
phoR	B
)	O
mutant	O
strain	O
was	O
restored	O
by	O
introduction	O
of	O
the	O
plasmid	O
with	O
cloned	O
phoB	B
-	O
phoR	B
genes	O
.	O

Primer	O
extension	O
analysis	O
of	O
the	O
asr	B
transcript	O
revealed	O
a	O
region	O
similar	O
to	O
the	O
Pho	B
box	O
(	O
the	O
consensus	O
sequence	O
found	O
in	O
promoters	O
transcriptionally	O
activated	O
by	O
the	O
PhoB	B
protein	O
)	O
upstream	O
from	O
the	O
determined	O
transcription	O
start	O
.	O

The	O
asr	B
promoter	O
DNA	O
region	O
was	O
demonstrated	O
to	O
bind	O
PhoB	B
protein	O
in	O
vitro	O
.	O

We	O
discuss	O
our	O
results	O
in	O
terms	O
of	O
how	O
bacteria	O
might	O
employ	O
the	O
phoB	B
-	O
phoR	B
regulatory	O
system	O
to	O
sense	O
an	O
external	O
acidity	O
and	O
regulate	O
transcription	O
of	O
the	O
asr	B
gene	O
.	O

Double	O
blind	O
,	O
randomised	O
study	O
of	O
continuous	O
terbinafine	O
compared	O
with	O
intermittent	O
itraconazole	O
in	O
treatment	O
of	O
toenail	O
onychomycosis	O
.	O

The	O
LION	O
Study	O
Group	O
.	O

OBJECTIVE	O
:	O

To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
continuous	O
terbinafine	O
with	O
intermittent	O
itraconazole	O
in	O
the	O
treatment	O
of	O
toenail	O
onychomycosis	O
.	O

DESIGN	O
:	O

Prospective	O
,	O
randomised	O
,	O
double	O
blind	O
,	O
double	O
dummy	O
,	O
multicentre	O
,	O
parallel	O
group	O
study	O
lasting	O
72	O
weeks	O
.	O

SETTING	O
:	O

35	O
centres	O
in	O
six	O
European	O
countries	O
.	O

SUBJECTS	O
:	O

496	O
patients	O
aged	O
18	O
to	O
75	O
years	O
with	O
a	O
clinical	O
and	O
mycological	O
diagnosis	O
of	O
dermatophyte	O
onychomycosis	O
of	O
the	O
toenail	O
.	O

INTERVENTIONS	O
:	O

Study	O
patients	O
were	O
randomly	O
divided	O
into	O
four	O
parallel	O
groups	O
to	O
receive	O
either	O
terbinafine	O
250	O
mg	O
a	O
day	O
for	O
12	O
or	O
16	O
weeks	O
(	O
groups	O
T12	O
and	O
T16	O
)	O
or	O
itraconazole	O
400	O
mg	O
a	O
day	O
for	O
1	O
week	O
in	O
every	O
4	O
weeks	O
for	O
12	O
or	O
16	O
weeks	O
(	O
groups	O
I3	O
and	O
I4	O
)	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O

Assessment	O
of	O
primary	O
efficacy	O
at	O
week	O
72	O
was	O
mycological	O
cure	O
,	O
defined	O
as	O
negative	O
results	O
on	O
microscopy	O
and	O
culture	O
of	O
samples	O
from	O
the	O
target	O
toenail	O
.	O

RESULTS	O
:	O

At	O
week	O
72	O
the	O
mycological	O
cure	O
rates	O
were	O
75.7	O
%	O
(	O
81	O
/	O
107	O
)	O
in	O
the	O
T12	O
group	O
and	O
80	O
.	O
8	O
%	O
(	O
80	O
/	O
99	O
)	O
in	O
the	O
T16	O
group	O
compared	O
with	O
38.3	O
%	O
(	O
41	O
/	O
107	O
)	O
in	O
the	O
I3	O
group	O
and	O
49.1	O
%	O
(	O
53	O
/	O
108	O
)	O
in	O
the	O
I4	O
group	O
.	O

All	O
comparisons	O
(	O
T12	O
v	O
I3	O
,	O
T12	O
v	O
I4	O
,	O
T16	O
v	O
I3	O
,	O
T16	O
v	O
I4	O
)	O
showed	O
significantly	O
higher	O
cure	O
rates	O
in	O
the	O
terbinafine	O
groups	O
(	O
all	O
P	O
<	O
0.0001	O
)	O
.	O

Also	O
,	O
all	O
secondary	O
clinical	O
outcome	O
measures	O
were	O
significantly	O
in	O
favour	O
of	O
terbinafine	O
at	O
week	O
72	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
number	O
or	O
type	O
of	O
adverse	O
events	O
recorded	O
in	O
the	O
terbinafine	O
or	O
itraconazole	O
groups	O
.	O

CONCLUSION	O
:	O

Continuous	O
terbinafine	O
is	O
significantly	O
more	O
effective	O
than	O
intermittent	O
itraconazole	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
toenail	O
onychomycosis	O
.	O

[	O
Endotracheal	O
tube	O
cuff	O
pressure	O
.	O
Monitoring	O
during	O
general	O
anesthesia	O
]	O

BACKGROUND	O
:	O

To	O
value	O
changes	O
of	O
endotracheal	O
tube	O
cuff	O
pressure	O
during	O
anaesthesia	O
with	O
N2O	O
,	O
using	O
standard	O
tubes	O
or	O
Brandt	O
-	O
system	O
tubes	O
.	O

METHODS	O
:	O

Endotracheal	O
cuff	O
pressure	O
during	O
anaesthesia	O
in	O
three	O
groups	O
of	O
patients	O
has	O
been	O
monitored	O
:	O
Group	O
1	O
(	O
n.	O
41	O
)	O
:	O
endotracheal	O
tube	O
with	O
low	O
-	O
pressure	O
cuff	O
using	O
N2O	O
/	O
O2	O
(	O
2:1	O
or	O
1	O
:	O
1	O
)	O
;	O
Group	O
2	O
(	O
n.	O
55	O
)	O
:	O
Brandt	O
's	O
double	O
cuff	O
-	O
tubes	O
using	O
N2O	O
/	O
O2	O
(	O
2	O
:	O
1	O
or	O
1:1	O
)	O
;	O
Group	O
3	O
(	O
n.	O
20	O
-	O
control	O
group	O
)	O
:	O
tubes	O
with	O
low	O
-	O
pressure	O
cuff	O
using	O
O2	O
/	O
air	O
.	O

Values	O
of	O
pressure	O
(	O
M	O
+	O
/-	O
DS	O
:	O
p	O
<	O
0.05	O
)	O
have	O
been	O
compared	O
with	O
ANOVA	O
,	O
Bonferroni	O
's	O
method	O
(	O
p	O
<	O
0.017	O
)	O
.	O

RESULTS	O
AND	O
CONCLUSIONS	O
:	O

Brandt	O
's	O
double	O
cuff	O
-	O
tubes	O
(	O
G2	O
)	O
succeed	O
in	O
avoiding	O
uncontrolled	O
increase	O
of	O
cuff	O
-	O
pressure	O
during	O
anaesthesia	O
with	O
N2O	O
.	O

Standard	O
low	O
-	O
pressure	O
tubes	O
(	O
G1	O
)	O
shown	O
increase	O
of	O
cuff	O
pressure	O
during	O
anaesthesia	O
with	O
N2O	O
which	O
is	O
absent	O
using	O
no	O
N2O	O
(	O
G3	O
)	O
.	O

Molecular	O
characterization	O
of	O
the	O
follicle	O
defects	O
in	O
the	O
growth	B
differentiation	I
factor	I
9	I
-	O
deficient	O
ovary	O
.	O

Growth	B
differentiation	I
factor-9	I
(	O
GDF-9	B
)	O
,	O
a	O
secreted	O
member	O
of	O
the	O
transforming	B
growth	I
factor	I
-	I
beta	I
superfamily	I
,	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
mammalian	O
oocyte	O
beginning	O
at	O
the	O
type	O
3a	O
primary	O
follicle	O
stage	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
GDF-9	B
-	O
deficient	O
female	O
mice	O
are	O
infertile	O
because	O
of	O
an	O
early	O
block	O
in	O
folliculogenesis	O
at	O
the	O
type	O
3b	O
primary	O
follicle	O
stage	O
.	O

To	O
address	O
the	O
molecular	O
defects	O
that	O
result	O
from	O
the	O
absence	O
of	O
GDF-9	B
,	O
we	O
have	O
analyzed	O
the	O
expression	O
of	O
several	O
important	O
ovarian	O
marker	O
genes	O
.	O

The	O
major	O
findings	O
of	O
our	O
studies	O
are	O
as	O
follows	O
:	O
1	O
)	O
There	O
are	O
no	O
detectable	O
signals	O
around	O
GDF-9	B
-	O
deficient	O
follicles	O
for	O
several	O
theca	O
cell	O
layer	O
markers	O
[	O
i.e.	O
17alpha	B
-	I
hydroxylase	I
,	O
LH	B
receptor	I
(	O
LHR	B
)	O
,	O
and	O
c	B
-	I
kit	I
,	O
the	O
receptor	O
for	O
kit	B
ligand	I
]	O
.	O

This	O
demonstrates	O
that	O
in	O
the	O
absence	O
of	O
GDF-9	B
,	O
the	O
follicles	O
are	O
incompetent	O
to	O
emit	O
a	O
signal	O
that	O
recruits	O
theca	O
cell	O
precursors	O
to	O
surround	O
the	O
follicle	O
;	O
2	O
)	O
The	O
primary	O
follicles	O
of	O
GDF-9	B
-	O
deficient	O
mice	O
demonstrate	O
an	O
up	O
-	O
regulation	O
of	O
kit	B
ligand	I
and	O
inhibin	B
-	I
alpha	I
.	O

This	O
suggests	O
that	O
these	O
two	O
important	O
secreted	O
growth	B
factors	I
,	O
expressed	O
in	O
the	O
granulosa	O
cells	O
,	O
may	O
be	O
directly	O
regulated	O
in	O
a	O
paracrine	O
fashion	O
by	O
GDF	B
-	I
9	I
.	O

Up	O
-	O
regulation	O
of	O
kit	B
ligand	I
,	O
via	O
signaling	O
through	O
c	B
-	I
kit	I
on	O
the	O
oocyte	O
,	O
may	O
be	O
directly	O
involved	O
in	O
the	O
increased	O
size	O
of	O
GDF-9	B
-	O
deficient	O
oocytes	O
and	O
the	O
eventual	O
demise	O
of	O
the	O
oocyte	O
;	O
3	O
)	O
After	O
loss	O
of	O
the	O
oocyte	O
,	O
the	O
cells	O
of	O
the	O
GDF-9	B
-	O
deficient	O
follicles	O
remain	O
in	O
a	O
steroidogenic	O
cluster	O
that	O
histologically	O
resembles	O
small	O
corpora	O
lutea	O
.	O

However	O
,	O
at	O
the	O
molecular	O
level	O
,	O
these	O
cells	O
are	O
positive	O
for	O
both	O
luteal	O
markers	O
(	O
e.g.	O
LHR	B
and	O
P-450	B
side	I
chain	I
cleavage	I
)	O
and	O
nonluteal	O
markers	O
(	O
e.g.	O
inhibin	B
alpha	I
and	O
P-450	B
aromatase	I
)	O
.	O

This	O
demonstrates	O
that	O
initially	O
the	O
presence	O
of	O
the	O
oocyte	O
prevents	O
the	O
expression	O
of	O
luteinized	O
markers	O
,	O
but	O
that	O
the	O
absence	O
of	O
GDF-9	B
at	O
an	O
early	O
timepoint	O
alters	O
the	O
differentiation	O
program	O
of	O
the	O
granulosa	O
cells	O
;	O
and	O
4	O
)	O
As	O
demonstrated	O
by	O
staining	O
with	O
either	O
proliferating	B
cell	I
nuclear	I
antigen	I
(	O
PCNA	B
)	O
or	O
Ki-67	O
and	O
TUNEL	O
(	O
terminal	B
deoxynucleotidyl	I
transferase	I
-	O
mediated	O
dUTP	O
nick	O
end	O
labeling	O
)	O
labeling	O
,	O
the	O
granulosa	O
cells	O
of	O
GDF-9	B
-	O
deficient	O
type	O
3b	O
primary	O
follicles	O
fail	O
to	O
proliferate	O
but	O
also	O
fail	O
to	O
undergo	O
cell	O
death	O
.	O

This	O
suggests	O
that	O
granulosa	O
cells	O
of	O
type	O
3b	O
follicles	O
require	O
GDF-9	B
for	O
continued	O
growth	O
and	O
also	O
to	O
become	O
competent	O
to	O
undergo	O
apoptosis	O
,	O
possibly	O
through	O
a	O
differentiation	O
event	O
Thus	O
,	O
these	O
studies	O
have	O
enlightened	O
us	O
as	O
to	O
the	O
paracrine	O
roles	O
of	O
GDF-9	B
as	O
well	O
as	O
the	O
normal	O
steps	O
of	O
granulosa	O
cell	O
and	O
theca	O
cell	O
growth	O
and	O
differentiation	O
within	O
ovarian	O
follicles	O
.	O

A	O
novel	O
mechanism	O
for	O
cytokine	B
regulation	O
:	O
screening	O
,	O
selection	O
,	O
and	O
characterization	O
of	O
anticytokine	O
monoclonal	O
and	O
polyclonal	O
autoantibodies	O
.	O

We	O
have	O
recently	O
described	O
an	O
immunoregulatory	O
mechanism	O
involving	O
release	O
of	O
neutralizing	O
autoantibodies	O
(	O
Aab	O
)	O
to	O
cytokines	B
during	O
bacterial	O
infections	O
.	O

Intraperitoneal	O
inoculation	O
of	O
Haemophilus	O
influenzae	O
type	O
b	O
(	O
Hib	O
)	O
into	O
Sprague	O
-	O
Dawley	O
rats	O
resulted	O
in	O
high	O
levels	O
of	O
inflammatory	O
mediators	O
early	O
after	O
infection	O
.	O

Increased	O
titers	O
of	O
cytokine	B
Aab	O
were	O
observed	O
,	O
with	O
a	O
peak	O
at	O
day	O
7	O
.	O

We	O
cloned	O
Aab	O
-	O
producing	O
B	O
cells	O
.	O

Screening	O
of	O
the	O
clones	O
with	O
five	O
different	O
cytokines	B
resulted	O
in	O
detection	O
of	O
Aab	O
-	O
producing	O
clones	O
reactive	O
with	O
each	O
cytokine	B
.	O

After	O
repeated	O
subcloning	O
,	O
monoclonal	O
Aab	O
(	O
mAab	O
)	O
were	O
selected	O
and	O
characterized	O
for	O
their	O
specificity	O
,	O
isotypes	O
,	O
and	O
affinities	O
.	O

To	O
elucidate	O
regulatory	O
importance	O
,	O
mAab	O
to	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
dose	O
-	O
dependently	O
inhibited	O
IFN	B
-	I
gamma	I
-	O
induced	O
MHC	B
expression	O
by	O
peritoneal	O
macrophages	O
and	O
TNF	B
-	I
alpha	I
-	O
induced	O
thymocyte	O
proliferation	O
,	O
respectively	O
.	O

Fab	O
fragments	O
exhibited	O
binding	O
and	O
neutralizing	O
effects	O
,	O
confirming	O
specificities	O
.	O

Cross	O
-	O
reactivity	O
with	O
other	O
rat	O
cytokines	B
was	O
excluded	O
.	O

Pools	O
of	O
clones	O
containing	O
several	O
mAab	O
to	O
each	O
cytokine	B
were	O
obtained	O
and	O
served	O
as	O
polyclonal	O
Aab	O
.	O

The	O
relative	O
affinity	O
of	O
the	O
Aab	O
was	O
determined	O
and	O
found	O
to	O
be	O
of	O
high	O
index	O
.	O

The	O
characterized	O
Aab	O
were	O
tested	O
in	O
methodologic	O
assays	O
for	O
cytokine	B
detection	O
,	O
revealing	O
that	O
some	O
Aab	O
were	O
useful	O
in	O
a	O
cell	O
release	O
capturing	O
(	O
CRC	O
)	O
ELISA	O
.	O

ZntR	B
is	O
an	O
autoregulatory	O
protein	O
and	O
negatively	O
regulates	O
the	O
chromosomal	O
zinc	O
resistance	O
operon	B
znt	I
of	O
Staphylococcus	O
aureus	O
.	O

A	O
chromosomally	O
encoded	O
znt	B
operon	I
of	O
Staphylococcus	O
aureus	O
consists	O
of	O
two	O
consecutive	O
putative	O
genes	O
designated	O
zntR	B
and	O
zntA	B
.	O

The	O
zntA	B
gene	O
encodes	O
a	O
transmembrane	O
protein	O
that	O
facilitates	O
extrusion	O
of	O
Zn2	O
+	O
and	O
Co2	O
+	O
,	O
whereas	O
the	O
zntR	B
gene	O
encodes	O
a	O
putative	O
regulatory	O
protein	O
that	O
controls	O
the	O
expression	O
of	O
the	O
znt	B
operon	I
.	O

The	O
zntR	B
gene	O
was	O
amplified	O
using	O
the	O
polymerase	O
chain	O
reaction	O
,	O
cloned	O
into	O
Escherichia	O
coli	O
for	O
overexpression	O
as	O
His	O
-	O
tagged	O
ZntR	B
and	O
purified	O
by	O
Ni2	O
+	O
-	O
affinity	O
column	O
.	O

His	O
-	O
tag	O
-	O
free	O
ZntR	B
was	O
purified	O
to	O
near	O
homogeneity	O
after	O
digestion	O
with	O
enterokinase	B
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
indicated	O
that	O
the	O
ZntR	B
bound	O
to	O
a	O
fragment	O
of	O
DNA	O
corresponding	O
to	O
the	O
chromosomal	O
znt	B
promoter	O
region	O
with	O
an	O
affinity	O
of	O
about	O
8.0	O
x	O
10	O
-	O
12	O
M	O
.	O

The	O
addition	O
of	O
25	O
microM	O
Zn2	O
+	O
or	O
Co2	O
+	O
in	O
the	O
binding	O
reaction	O
completely	O
or	O
significantly	O
inhibited	O
association	O
of	O
ZntR	B
with	O
the	O
znt	B
promoter	O
.	O

DNase	B
I	I
footprinting	O
assays	O
identified	O
a	O
ZntR	B
binding	O
site	O
encompassing	O
49	O
nucleotides	O
in	O
the	O
znt	B
promoter	O
region	O
that	O
contained	O
repeated	O
TGAA	O
sequences	O
.	O

These	O
sequences	O
have	O
been	O
proposed	O
to	O
be	O
the	O
binding	O
sites	O
for	O
SmtB	B
,	O
a	O
metallorepressor	O
protein	O
from	O
the	O
cyanobacterium	O
Synechococcus	O
,	O
to	O
its	O
corresponding	O
operator	O
/	O
promoter	O
.	O

In	O
vitro	O
transcription	O
assays	O
,	O
using	O
S.	O
aureus	O
RNA	B
polymerase	I
,	O
revealed	O
that	O
ZntR	B
represses	O
transcription	O
from	O
the	O
znt	B
promoter	O
in	O
a	O
concentration	O
-	O
dependent	O
fashion	O
.	O

The	O
EMSAs	O
,	O
DNase	B
I	I
footprinting	O
and	O
in	O
vitro	O
transcription	O
assays	O
indicate	O
that	O
ZntR	B
is	O
a	O
trans	O
-	O
acting	O
repressor	O
protein	O
that	O
binds	O
to	O
the	O
znt	B
promoter	O
region	O
and	O
regulates	O
its	O
own	O
transcription	O
together	O
with	O
that	O
of	O
zntA	B
.	O

Molecular	O
determinants	O
of	O
the	O
interaction	O
between	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
Alzheimer	O
's	O
beta	B
-	I
amyloid	I
peptide	I
and	O
apolipoprotein	B
E	I
alpha	O
-	O
helices	O
.	O

In	O
a	O
previous	O
work	O
,	O
we	O
predicted	O
and	O
demonstrated	O
that	O
the	O
29	O
-	O
42-residue	O
fragment	O
of	O
beta	B
-	I
amyloid	I
peptide	I
(	O
Abeta	B
peptide	I
)	O
has	O
in	O
vitro	O
capacities	O
close	O
to	O
those	O
of	O
the	O
tilted	O
fragment	O
of	O
viral	O
fusion	O
proteins	O
.	O

We	O
further	O
demonstrated	O
that	O
apolipoprotein	B
E2	I
and	O
E3	O
but	O
not	O
apolipoprotein	B
E4	I
can	O
decrease	O
the	O
fusogenic	O
activity	O
of	O
Abeta	B
(	O
29	O
-	O
42	O
)	O
via	O
a	O
direct	O
interaction	O
.	O

Therefore	O
,	O
we	O
suggested	O
that	O
this	O
fragment	O
is	O
implicated	O
in	O
the	O
neurotoxicity	O
of	O
Abeta	B
and	O
in	O
the	O
protective	O
effects	O
of	O
apolipoprotein	B
E	I
in	O
Alzheimer	O
's	O
disease	O
.	O

Because	O
structurally	O
related	O
apolipoproteins	B
do	O
not	O
interact	O
with	O
the	O
Abeta	B
C	O
-	O
terminal	O
domain	O
but	O
inhibit	O
viral	O
fusion	O
,	O
we	O
suggested	O
that	O
interactions	O
existing	O
between	O
fusogenic	O
peptides	O
and	O
apolipoproteins	B
are	O
selective	O
and	O
responsible	O
for	O
the	O
inhibition	O
of	O
fusion	O
.	O

In	O
this	O
study	O
,	O
we	O
simulated	O
interactions	O
of	O
all	O
amphipathic	O
helices	O
of	O
apolipoproteins	B
E	I
and	I
A	I
-	I
I	I
with	O
Abeta	B
and	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
fusogenic	O
fragments	O
by	O
molecular	O
modeling	O
.	O

We	O
further	O
calculated	O
cross	O
-	O
interactions	O
that	O
do	O
not	O
inhibit	O
fusion	O
in	O
vitro	O
.	O

The	O
results	O
suggest	O
that	O
interactions	O
of	O
hydrophobic	O
residues	O
are	O
the	O
major	O
event	O
to	O
inhibit	O
the	O
fusogenic	O
capacities	O
of	O
Abeta	B
(	O
29	O
-	O
42	O
)	O
and	O
SIV	O
peptides	O
.	O

Selectivity	O
of	O
those	O
interactions	O
is	O
due	O
to	O
the	O
steric	O
complementarity	O
between	O
bulky	O
hydrophobic	O
residues	O
in	O
the	O
fusogenic	O
fragments	O
and	O
hydrophobic	O
residues	O
in	O
the	O
apolipoprotein	B
C	I
-	O
terminal	O
amphipathic	O
helices	O
.	O

Molecular	O
dissection	O
of	O
the	O
folding	O
mechanism	O
of	O
the	O
alpha	B
subunit	I
of	I
tryptophan	I
synthase	I
:	O
an	O
amino	O
-	O
terminal	O
autonomous	O
folding	O
unit	O
controls	O
several	O
rate	O
-	O
limiting	O
steps	O
in	O
the	O
folding	O
of	O
a	O
single	O
domain	O
protein	O
.	O

The	O
alpha	O
subunit	O
of	O
tryptophan	B
synthase	I
(	O
alphaTS	B
)	O
from	O
Escherichia	O
coli	O
is	O
a	O
268	O
-	O
residue	O
8-stranded	O
beta	O
/	O
alpha	O
barrel	O
protein	O
.	O

Two	O
autonomous	O
folding	O
units	O
,	O
comprising	O
the	O
first	O
six	O
strands	O
(	O
residues	O
1	O
-	O
188	O
)	O
and	O
the	O
last	O
two	O
strands	O
(	O
residues	O
189	O
-	O
268	O
)	O
,	O
have	O
been	O
previously	O
identified	O
in	O
this	O
single	O
structural	O
domain	O
protein	O
by	O
tryptic	O
digestion	O
[	O
Higgins	O
,	O
W.	O
,	O
Fairwell	O
,	O
T.	O
,	O
and	O
Miles	O
,	O
E.	O
W.	O
(	O
1979	O
)	O
Biochemistry	O
18	O
,	O
4827	O
-	O
4835	O
]	O
.	O

The	O
larger	O
,	O
amino	O
-	O
terminal	O
fragment	O
,	O
alphaTS	B
(	O
1	O
-	O
188	O
)	O
,	O
was	O
overexpressed	O
and	O
independently	O
purified	O
,	O
and	O
its	O
equilibrium	O
and	O
kinetic	O
folding	O
properties	O
were	O
studied	O
by	O
absorbance	O
,	O
fluorescence	O
,	O
and	O
near	O
-	O
and	O
far	O
-	O
UV	O
circular	O
dichroism	O
spectroscopies	O
.	O

The	O
native	O
state	O
of	O
the	O
fragment	O
unfolds	O
cooperatively	O
in	O
an	O
apparent	O
two	O
-	O
state	O
transition	O
with	O
a	O
stability	O
of	O
3.98	O
+	O
/-	O
0.19	O
kcal	O
mol	O
(	O
-1	O
)	O
in	O
the	O
absence	O
of	O
denaturant	O
and	O
a	O
corresponding	O
m	O
value	O
of	O
1.07	O
+	O
/-	O
0.05	O
kcal	O
mol	O
(	O
-1	O
)	O
M	O
(	O
-1	O
)	O
.	O

Similar	O
to	O
the	O
full	O
-	O
length	O
protein	O
,	O
the	O
unfolding	O
of	O
the	O
fragment	O
shows	O
two	O
kinetic	O
phases	O
which	O
arise	O
from	O
the	O
presence	O
of	O
two	O
discrete	O
native	O
state	O
populations	O
.	O

Additionally	O
,	O
the	O
fragment	O
exhibits	O
a	O
significant	O
burst	O
phase	O
in	O
unfolding	O
,	O
indicating	O
that	O
a	O
fraction	O
of	O
the	O
folded	O
state	O
ensemble	O
under	O
native	O
conditions	O
has	O
properties	O
similar	O
to	O
those	O
of	O
the	O
equilibrium	O
intermediate	O
populated	O
at	O
3	O
M	O
urea	O
in	O
full	O
-	O
length	O
alphaTS	B
.	O

Refolding	O
of	O
alphaTS	B
(	O
1	O
-	O
188	O
)	O
is	O
also	O
complex	O
,	O
exhibiting	O
two	O
detectable	O
kinetic	O
phases	O
and	O
a	O
burst	O
phase	O
that	O
is	O
complete	O
within	O
5	O
ms	O
.	O

The	O
two	O
slowest	O
isomerization	O
phases	O
observed	O
in	O
the	O
refolding	O
of	O
the	O
full	O
-	O
length	O
protein	O
are	O
absent	O
in	O
the	O
fragment	O
,	O
suggesting	O
that	O
these	O
phases	O
reflect	O
contributions	O
from	O
the	O
carboxy	O
-	O
terminal	O
segment	O
.	O

The	O
folding	O
mechanism	O
of	O
alphaTS	B
(	O
1	O
-	O
188	O
)	O
appears	O
to	O
be	O
a	O
simplified	O
version	O
of	O
the	O
mechanism	O
for	O
the	O
full	O
-	O
length	O
protein	O
[	O
Bilsel	O
,	O
O.	O
,	O
Zitzewitz	O
,	O
J.	O
A.	O
,	O
Bowers	O
,	O
K.E	O
,	O
and	O
Matthews	O
,	O
C.	O
R.	O
(	O
1999	O
)	O
Biochemistry	O
38	O
,	O
1018	O
-	O
1029	O
]	O
.	O

Four	O
parallel	O
channels	O
in	O
the	O
full	O
-	O
length	O
protein	O
are	O
reduced	O
to	O
a	O
pair	O
of	O
channels	O
that	O
most	O
likely	O
reflect	O
a	O
cis	O
/	O
trans	O
proline	O
isomerization	O
reaction	O
in	O
the	O
amino	O
-	O
terminal	O
fragment	O
.	O

The	O
off	O
-	O
and	O
on	O
-	O
pathway	O
intermediates	O
that	O
exist	O
for	O
both	O
full	O
-	O
length	O
alphaTS	B
and	O
alphaTS	B
(	O
1	O
-	O
188	O
)	O
may	O
reflect	O
the	O
preponderance	O
of	O
local	O
interactions	O
in	O
the	O
beta	O
/	O
alpha	O
barrel	O
motif	O
.	O

Body	O
fat	O
,	O
caloric	O
intake	O
,	O
and	O
plasma	O
leptin	B
levels	O
in	O
women	O
with	O
anorexia	O
nervosa	O
.	O

OBJECTIVE	O
:	O

To	O
measure	O
serum	O
leptin	B
concentrations	O
in	O
women	O
with	O
anorexia	O
nervosa	O
(	O
AN	O
)	O
and	O
to	O
identify	O
independent	O
predictors	O
of	O
leptin	B
levels	O
,	O
thereby	O
allowing	O
hormone	O
levels	O
to	O
be	O
modeled	O
using	O
regression	O
analysis	O
.	O

METHODS	O
:	O

A	O
cross	O
-	O
sectional	O
study	O
of	O
15	O
AN	O
inpatients	O
and	O
16	O
healthy	O
control	O
subjects	O
.	O

Age	O
,	O
height	O
,	O
weight	O
,	O
percent	O
body	O
fat	O
,	O
total	O
caloric	O
intake	O
,	O
fat	O
intake	O
,	O
and	O
fasting	O
plasma	O
leptin	B
levels	O
were	O
recorded	O
.	O

Stepwise	O
forward	O
regression	O
analysis	O
was	O
carried	O
out	O
to	O
identify	O
predictors	O
of	O
leptin	B
levels	O
.	O

RESULTS	O
:	O

Circulating	O
leptin	B
concentrations	O
in	O
AN	O
were	O
3.5	O
+	O
/-	O
0.5	O
versus	O
7.6	O
+	O
/-	O
1.2	O
ng	O
/	O
ml	O
in	O
control	O
subjects	O
.	O

Percent	O
body	O
fat	O
correlated	O
best	O
with	O
leptin	B
levels	O
in	O
anorexic	O
and	O
control	O
subjects	O
(	O
r	O
=	O
.63	O
;	O
p	O
=	O
.0002	O
)	O
,	O
with	O
caloric	O
intake	O
showing	O
only	O
a	O
moderate	O
correlation	O
(	O
r	O
=	O
.47	O
;	O
p	O
=	O
.008	O
)	O
.	O

Only	O
percent	O
body	O
fat	O
was	O
a	O
significant	O
predictor	O
of	O
plasma	O
leptin	B
levels	O
in	O
our	O
regression	O
model	O
.	O

DISCUSSION	O
:	O

Leptin	B
levels	O
are	O
proportionately	O
lower	O
in	O
AN	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

It	O
appears	O
that	O
physiological	O
regulation	O
of	O
plasma	O
levels	O
with	O
respect	O
to	O
percent	O
body	O
fat	O
is	O
maintained	O
in	O
individuals	O
with	O
little	O
body	O
fat	O
.	O

Transcription	O
of	O
genes	O
near	O
the	O
sspE	B
locus	O
of	O
the	O
Bacillus	O
subtilis	O
genome	O
.	O

The	O
yfhP	B
,	O
yfhQ	B
(	O
mutY	B
homologue	O
)	O
,	O
yfhS	B
and	O
yfhR	B
(	O
oxidoreductase	B
homologue	O
)	O
genes	O
,	O
which	O
are	O
located	O
upstream	O
of	O
the	O
sspE	B
locus	O
,	O
have	O
been	O
identified	O
in	O
the	O
Bacillus	O
subtilis	O
genome	O
.	O

Transcriptional	O
analysis	O
showed	O
that	O
yfhP	B
,	O
yfhQ	B
and	O
yfhR	B
are	O
transcribed	O
during	O
the	O
exponential	O
growth	O
phase	O
,	O
and	O
sspE	B
is	O
monocistronically	O
transcribed	O
in	O
the	O
late	O
sporulation	O
phase	O
and	O
co	O
-	O
transcribed	O
with	O
yfhQ	B
and/or	O
yfhR	B
during	O
exponential	O
growth	O
.	O

However	O
,	O
SspE	B
was	O
not	O
translated	O
during	O
this	O
period	O
.	O

Northern	O
blot	O
and	O
primer	O
extension	O
analyses	O
indicated	O
that	O
yfhS	B
is	O
transcribed	O
by	O
E	B
sigma	I
E	I
during	O
sporulation	O
.	O

No	O
significant	O
difference	O
between	O
wild	O
-	O
type	O
and	O
yfhS	B
mutant	O
strains	O
was	O
found	O
in	O
the	O
rate	O
of	O
sporulation	O
or	O
germination	O
,	O
the	O
heat	O
tolerance	O
of	O
spores	O
or	O
the	O
transcription	O
of	O
the	O
sspE	B
locus	O
during	O
sporulation	O
.	O

The	O
transcription	O
of	O
the	O
yfhP	B
and	O
yfhQ	B
-	O
yfhR	B
-	O
sspE	B
loci	O
increased	O
2.5	O
-	O
and	O
5.3	O
-	O
fold	O
in	O
a	O
yfhP	B
-	O
deficient	O
strain	O
compared	O
to	O
the	O
wild	O
-	O
type	O
strain	O
at	O
t-2	O
(	O
2	O
h	O
before	O
initiation	O
of	O
sporulation	O
)	O
.	O

In	O
addition	O
,	O
transcription	O
corresponding	O
to	O
the	O
yfhR	B
-	O
sspE	B
loci	O
increased	O
more	O
than	O
twofold	O
with	O
maximum	O
values	O
observed	O
at	O
t	O
-	O
1.5	O
.	O

These	O
results	O
suggest	O
that	O
YfhP	B
may	O
act	O
as	O
a	O
negative	O
regulator	O
for	O
the	O
transcription	O
of	O
yfhQ	B
,	O
yfhR	B
,	O
sspE	B
and	O
yfhP	B
.	O

Cytoskeletal	O
reorganization	O
leads	O
to	O
induction	O
of	O
the	O
urokinase	B
-	I
type	I
plasminogen	I
activator	I
gene	O
by	O
activating	O
FAK	B
and	O
Src	B
and	O
subsequently	O
the	O
Ras	B
/	O
Erk	B
signaling	O
pathway	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
cytoskeletal	O
reorganization	O
(	O
CSR	O
)	O
induced	O
by	O
colchicine	O
or	O
cyochalasins	O
leads	O
to	O
activation	O
of	O
the	O
urokinase	B
-	I
type	I
plasminogen	I
activator	I
(	O
uPA	B
)	O
gene	O
in	O
LLC	O
-	O
PK	O
(	O
1	O
)	O
cells	O
via	O
the	O
Ras	B
/	O
Erk	B
signaling	O
pathway	O
[	O
Irigoyen	O
et	O
al.	O
(	O
1997	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
272	O
,	O
1904	O
]	O
.	O

It	O
remained	O
to	O
be	O
seen	O
how	O
CSR	O
activates	O
Ras	B
/	O
Erk	B
signaling	O
.	O

Changes	O
in	O
cell	O
morphology	O
triggered	O
by	O
extracellular	O
signals	O
are	O
often	O
mediated	O
by	O
integrin	B
-	O
associated	O
proteins	O
,	O
such	O
as	O
focal	B
adhesion	I
kinase	I
(	O
FAK	B
)	O
and	O
Src	B
.	O

We	O
found	O
that	O
CSR	O
induced	O
the	O
activation	O
of	O
FAK	B
and	O
Src	B
and	O
the	O
association	O
of	O
FAK	B
and	O
Shc	B
,	O
a	O
signaling	O
molecule	O
linking	O
growth	B
factor	I
receptor	I
tyrosine	I
kinase	I
and	O
Grb2	B
.	O

Furthermore	O
,	O
expression	O
of	O
either	O
FRNK	B
,	O
a	O
kinase	B
-	O
minus	O
FAK	B
-	O
like	O
molecule	O
acting	O
as	O
a	O
dominant	O
negative	O
FAK	B
,	O
or	O
a	O
dominant	O
negative	O
Src	B
suppressed	O
CSR	O
-	O
induced	O
uPA	B
gene	O
promoter	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
cells	O
respond	O
to	O
a	O
morphology	O
change	O
,	O
using	O
the	O
cytoskeleton	O
as	O
a	O
sensor	O
,	O
by	O
activating	O
FAK	B
and	O
Src	B
and	O
subsequently	O
the	O
Ras	B
/	O
Erk	B
signaling	O
pathway	O
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
cytokines	B
and	O
soluble	O
cytokine	B
receptors	I
in	O
peripheral	O
blood	O
of	O
patients	O
with	O
juvenile	O
rheumatoid	O
arthritis	O
.	O

Plasma	O
levels	O
of	O
interleukin-1beta	B
(	O
IL-1beta	B
)	O
,	O
IL-2	B
,	O
soluble	O
IL-2	B
receptor	I
(	O
sIL-2R	B
)	O
,	O
IL-6	B
,	O
IL-8	B
,	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
and	O
the	O
p60	B
soluble	I
TNF	I
receptor	I
(	O
sTNFR	B
)	O
were	O
repeatedly	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISA	O
)	O
in	O
35	O
patients	O
with	O
different	O
subtypes	O
of	O
juvenile	O
rheumatoid	O
arthritis	O
(	O
JRA	O
)	O
during	O
an	O
observation	O
period	O
of	O
up	O
to	O
36	O
months	O
.	O

The	O
data	O
were	O
related	O
to	O
conventional	O
inflammatory	O
parameters	O
and	O
disease	O
activity	O
.	O

Patients	O
with	O
systemic	O
disease	O
showed	O
the	O
most	O
pronounced	O
elevations	O
of	O
plasma	O
cytokines	B
,	O
followed	O
by	O
polyarticular	O
and	O
pauciarticular	O
JRA	O
.	O

Soluble	O
receptors	O
sIL-2R	B
and	O
sTNFR	B
were	O
consistently	O
elevated	O
in	O
patients	O
of	O
all	O
JRA	O
subtypes	O
and	O
indicated	O
disease	O
activity	O
even	O
in	O
patients	O
with	O
normal	O
C	B
-	I
reactive	I
protein	I
(	O
CRP	B
)	O
.	O

In	O
contrast	O
,	O
the	O
determination	O
of	O
IL-1beta	B
,	O
IL-2	B
,	O
IL-8	B
,	O
and	O
TNF	B
-	I
alpha	I
revealed	O
strikingly	O
different	O
individual	O
profiles	O
in	O
patients	O
of	O
the	O
same	O
clinical	O
subtype	O
of	O
JRA	O
and	O
irrespective	O
of	O
disease	O
activity	O
.	O

It	O
is	O
concluded	O
that	O
the	O
determination	O
of	O
sIL-2R	B
and	O
sTNFR	B
may	O
be	O
relevant	O
for	O
monitoring	O
JRA	O
,	O
as	O
they	O
indicate	O
disease	O
activity	O
also	O
in	O
cases	O
with	O
unaltered	O
conventional	O
inflammatory	O
parameters	O
.	O

The	O
different	O
individual	O
cytokine	B
profiles	O
of	O
patients	O
within	O
identical	O
subtypes	O
of	O
disease	O
suggest	O
JRA	O
to	O
be	O
even	O
more	O
heterogeneous	O
than	O
hitherto	O
assumed	O
.	O

The	O
data	O
should	O
be	O
considered	O
in	O
attempts	O
to	O
develop	O
anticytokine	O
strategies	O
in	O
the	O
therapy	O
of	O
JRA	O
.	O

Role	O
of	O
a	O
polycyclic	O
aromatic	O
hydrocarbon	O
bay	O
region	O
ring	O
in	O
modulating	O
DNA	O
adduct	O
structure	O
:	O
the	O
non	O
-	O
bay	O
region	O
(	O
8S,9R,10S	O
,	O
11R	O
)	O
-	O
N	O
(	O
6	O
)	O
-	O
[	O
11-	O
(	O
8,9,10,11-tetrahydro-8,9	O
,	O
10-trihydroxybenz	O
[	O
a	O
]	O
anthracenyl	O
)	O
]	O
-2	O
'	O
-	O
deoxyadenosyl	O
adduct	O
in	O
codon	O
61	O
of	O
the	O
human	O
N	B
-	I
ras	I
protooncogene	O
.	O

The	O
structure	O
of	O
the	O
non	O
-	O
bay	O
region	O
(	O
8S,9R,10S,11R	O
)	O
-N	O
(	O
6	O
)	O
-	O
[	O
11-	O
(	O
8,9,10	O
,	O
11-tetrahydro-8,9,10-trihydroxybenz	O
[	O
a	O
]	O
anthracenyl	O
)	O
]	O
-2'-de	O
oxyadenosyl	O
adduct	O
at	O
X	O
(	O
6	O
)	O
of	O
5'-d	O
(	O
CGGACXAGAAG	O
)	O
-3'.5'-d	O
(	O
CTTCTTGTCCG	O
)	O
-3	O
'	O
,	O
incorporating	O
codons	O
60	O
,	O
61	O
(	O
underlined	O
)	O
,	O
and	O
62	O
of	O
the	O
human	O
N	B
-	I
ras	I
protooncogene	O
,	O
was	O
determined	O
.	O

Molecular	O
dynamics	O
simulations	O
were	O
restrained	O
by	O
475	O
NOEs	O
from	O
(	O
1	O
)	O
H	O
NMR	O
.	O

The	O
benz	O
[	O
a	O
]	O
anthracene	O
moiety	O
intercalated	O
above	O
the	O
5	O
'	O
-	O
face	O
of	O
the	O
modified	O
base	O
pair	O
and	O
from	O
the	O
major	O
groove	O
.	O

The	O
duplex	O
suffered	O
distortion	O
at	O
and	O
immediately	O
adjacent	O
to	O
the	O
adduct	O
site	O
.	O

This	O
was	O
evidenced	O
by	O
the	O
disruption	O
of	O
the	O
Watson	O
-	O
Crick	O
base	O
pairing	O
for	O
X	O
(	O
6	O
)	O
x	O
T	O
(	O
17	O
)	O
and	O
A	O
(	O
7	O
)	O
x	O
T	O
(	O
16	O
)	O
and	O
the	O
increased	O
rise	O
of	O
7.7	O
A	O
between	O
base	O
pairs	O
C	O
(	O
5	O
)	O
x	O
G	O
(	O
18	O
)	O
and	O
X	O
(	O
6	O
)	O
x	O
T	O
(	O
17	O
)	O
.	O

Increased	O
disorder	O
was	O
observed	O
as	O
excess	O
line	O
width	O
of	O
proton	O
resonances	O
near	O
the	O
lesion	O
site	O
.	O

Comparison	O
with	O
the	O
bay	O
region	O
benzo	O
[	O
a	O
]	O
pyrene	O
[	O
Zegar	O
,	O
I.	O
S.	O
,	O
Kim	O
,	O
S.	O
J.	O
,	O
Johansen	O
,	O
T.	O
N.	O
,	O
Horton	O
,	O
P.	O
J.	O
,	O
Harris	O
,	O
C.	O
M.	O
,	O
Harris	O
,	O
T.	O
M.	O
,	O
and	O
Stone	O
,	O
M.	O
P.	O
(	O
1996	O
)	O
Biochemistry	O
35	O
,	O
6212	O
-	O
6224	O
]	O
and	O
bay	O
region	O
benz	O
[	O
a	O
]	O
anthracene	O
[	O
Li	O
,	O
Z.	O
,	O
Mao	O
,	O
H.	O
,	O
Kim	O
,	O
H.	O
-	O
Y.	O
,	O
Tamura	O
,	O
P.	O
J.	O
,	O
Harris	O
,	O
C.	O
M.	O
,	O
Harris	O
,	O
T.	O
M.	O
,	O
and	O
Stone	O
,	O
M.	O
P.	O
(	O
1999	O
)	O
Biochemistry	O
38	O
,	O
2969	O
-	O
2981	O
]	O
adducts	O
with	O
the	O
corresponding	O
stereochemistry	O
and	O
at	O
the	O
same	O
site	O
shows	O
that	O
this	O
non	O
-	O
bay	O
region	O
benz	O
[	O
a	O
]	O
anthracene	O
lesion	O
assumes	O
different	O
base	O
pair	O
geometry	O
,	O
in	O
addition	O
to	O
exhibiting	O
greater	O
disorder	O
.	O

These	O
differences	O
are	O
attributed	O
to	O
the	O
loss	O
of	O
the	O
bay	O
region	O
ring	O
.	O

The	O
results	O
suggest	O
the	O
bay	O
region	O
ring	O
contributes	O
to	O
base	O
stacking	O
interactions	O
at	O
the	O
lesion	O
site	O
.	O

These	O
structural	O
differences	O
between	O
the	O
non	O
-	O
bay	O
and	O
bay	O
region	O
lesions	O
are	O
correlated	O
with	O
site	O
-	O
specific	O
mutagenesis	O
data	O
.	O

The	O
bay	O
region	O
benzo	O
[	O
a	O
]	O
pyrene	O
and	O
bay	O
region	O
benz	O
[	O
a	O
]	O
anthracene	O
adducts	O
were	O
poorly	O
replicated	O
in	O
vivo	O
,	O
and	O
induced	O
A	O
--	O
>	O
G	O
mutations	O
.	O

In	O
contrast	O
,	O
the	O
non	O
-	O
bay	O
region	O
benz	O
[	O
a	O
]	O
anthracene	O
adduct	O
was	O
easily	O
bypassed	O
in	O
vivo	O
and	O
was	O
nonmutagenic	O
.	O

Efficacy	O
of	O
methods	O
for	O
determining	O
ovulation	O
in	O
a	O
natural	O
family	O
planning	O
program	O
.	O

This	O
methodological	O
study	O
aims	O
to	O
evaluate	O
the	O
efficacy	O
of	O
methods	O
used	O
for	O
determining	O
ovulation	O
in	O
a	O
natural	O
family	O
planning	O
in	O
comparison	O
with	O
pelvic	O
ultrasonography	O
.	O

Prospective	O
analysis	O
of	O
ovulation	O
detection	O
methods	O
was	O
conducted	O
with	O
40	O
women	O
.	O

Ovulation	O
-	O
detection	O
methods	O
employed	O
in	O
the	O
study	O
include	O
transvaginal	O
ultrasonography	O
,	O
daily	O
morning	O
urinary	O
luteinizing	B
hormone	I
(	O
LH	B
)	O
determinations	O
,	O
determination	O
of	O
salivary	O
beta	B
-	I
glucuronidase	I
activity	O
,	O
salivary	O
ferning	O
test	O
,	O
determination	O
of	O
cervical	O
mucus	O
levels	O
and	O
characteristics	O
,	O
and	O
measurement	O
of	O
rectal	O
or	O
oral	O
basal	O
body	O
temperature	O
.	O

Results	O
revealed	O
a	O
100	O
%	O
correlation	O
between	O
urinary	O
LH	B
level	O
and	O
ovulation	O
diagnosis	O
obtained	O
from	O
ultrasonographic	O
examination	O
.	O

Other	O
ovulation	O
-	O
detection	O
methods	O
contain	O
the	O
following	O
correlation	O
results	O
:	O
mucus	O
sensations	O
and	O
characteristics	O
,	O
48.3	O
%	O
;	O
alpha	B
-	I
glucuronidase	I
,	O
27.7	O
%	O
;	O
and	O
salivary	O
ferning	O
test	O
,	O
36.8	O
%	O
.	O

These	O
findings	O
draw	O
the	O
researchers	O
to	O
conclude	O
that	O
self	O
-	O
determination	O
of	O
LH	B
levels	O
could	O
be	O
an	O
excellent	O
method	O
in	O
ovulation	O
determination	O
.	O

Outcomes	O
of	O
high	O
-	O
dose	O
chemotherapy	O
and	O
autologous	O
stem	O
-	O
cell	O
transplantation	O
in	O
stage	O
IIIB	O
inflammatory	O
breast	O
cancer	O
.	O

PURPOSE	O
:	O

To	O
evaluate	O
the	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
prognostic	O
factors	O
,	O
and	O
treatment	O
-	O
related	O
mortality	O
of	O
women	O
with	O
stage	O
IIIB	O
inflammatory	O
breast	O
cancer	O
(	O
IBC	O
)	O
treated	O
with	O
combined	O
modality	O
therapy	O
(	O
CMT	O
)	O
and	O
high	O
-	O
dose	O
chemotherapy	O
(	O
HDCT	O
)	O
with	O
autologous	O
stem	O
-	O
cell	O
transplantation	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O

Between	O
1989	O
and	O
1997	O
,	O
47	O
consecutive	O
patients	O
with	O
stage	O
IIIB	O
IBC	O
were	O
treated	O
with	O
CMT	O
and	O
HDCT	O
and	O
were	O
the	O
subject	O
of	O
this	O
retrospective	O
analysis	O
.	O

Chemotherapy	O
was	O
administered	O
to	O
all	O
patients	O
before	O
and/or	O
after	O
definitive	O
surgery	O
.	O

Neoadjuvant	O
and	O
adjuvant	O
chemotherapy	O
was	O
administered	O
to	O
33	O
and	O
34	O
patients	O
,	O
respectively	O
,	O
and	O
20	O
patients	O
received	O
both	O
.	O

All	O
patients	O
received	O
HDCT	O
with	O
autologous	O
stem	O
-	O
cell	O
transplantation	O
,	O
and	O
41	O
patients	O
received	O
locoregional	O
radiation	O
therapy	O
.	O

Tamoxifen	O
was	O
prescribed	O
to	O
patients	O
with	O
estrogen	B
receptor	I
(	O
ER	B
)	O
-	O
positive	O
cancer	O
.	O

RESULTS	O
:	O

The	O
mean	O
duration	O
of	O
follow	O
-	O
up	O
from	O
diagnosis	O
was	O
30	O
months	O
(	O
range	O
,	O
6	O
to	O
91	O
months	O
)	O
and	O
from	O
HDCT	O
was	O
22	O
months	O
(	O
range	O
,	O
0.5	O
to	O
82	O
months	O
)	O
.	O

At	O
30	O
months	O
,	O
the	O
Kaplan	O
-	O
Meier	O
estimates	O
of	O
DFS	O
and	O
OS	O
from	O
diagnosis	O
were	O
57.7	O
%	O
and	O
59.1	O
%	O
,	O
respectively	O
.	O

At	O
4	O
years	O
,	O
the	O
Kaplan	O
-	O
Meier	O
estimates	O
of	O
DFS	O
and	O
OS	O
from	O
diagnosis	O
were	O
51.3	O
%	O
and	O
51.7	O
%	O
,	O
respectively	O
.	O

In	O
a	O
multivariate	O
analysis	O
,	O
the	O
only	O
factors	O
associated	O
with	O
better	O
survival	O
were	O
favorable	O
response	O
to	O
neoadjuvant	O
chemotherapy	O
(	O
P	O
=	O
.04	O
)	O
and	O
receipt	O
of	O
tamoxifen	O
(	O
P	O
=	O
.06	O
)	O
;	O
however	O
,	O
the	O
benefit	O
of	O
tamoxifen	O
was	O
only	O
demonstrated	O
in	O
patients	O
with	O
ER	B
-	O
positive	O
breast	O
cancer	O
.	O

At	O
last	O
follow	O
-	O
up	O
,	O
28	O
patients	O
(	O
59	O
.	O
6	O
%	O
)	O
were	O
alive	O
and	O
disease	O
-	O
free	O
.	O

Seventeen	O
patients	O
(	O
36.2	O
%	O
)	O
developed	O
recurrent	O
breast	O
cancer	O
.	O

Seventeen	O
patients	O
died	O
:	O
15	O
from	O
disease	O
recurrence	O
and	O
two	O
(	O
4.2	O
%	O
)	O
from	O
treatment	O
-	O
related	O
mortality	O
due	O
to	O
HDCT	O
.	O

CONCLUSION	O
:	O

In	O
this	O
analysis	O
,	O
the	O
early	O
results	O
of	O
treatment	O
with	O
CMT	O
and	O
HDCT	O
compare	O
favorably	O
with	O
other	O
series	O
of	O
patients	O
with	O
stage	O
IIIB	O
IBC	O
treated	O
with	O
CMT	O
alone	O
.	O

These	O
outcomes	O
must	O
be	O
confirmed	O
with	O
longer	O
follow	O
-	O
up	O
and	O
controlled	O
studies	O
.	O

Glycosylation	O
of	O
homologous	O
immunodominant	O
proteins	O
of	O
Ehrlichia	O
chaffeensis	O
and	O
Ehrlichia	O
canis	O
.	O

The	O
glycoprotein	O
genes	O
of	O
Ehrlichia	O
chaffeensis	O
(	O
1	O
,	O
644	O
bp	O
)	O
and	O
Ehrlichia	O
canis	O
(	O
2	O
,	O
064	O
bp	O
)	O
encode	O
proteins	O
of	O
548	O
to	O
688	O
amino	O
acids	O
with	O
predicted	O
molecular	O
masses	O
of	O
only	O
61	O
and	O
73	O
kDa	O
but	O
with	O
electrophoretic	O
mobilities	O
of	O
120	O
kDa	O
(	O
P120	O
)	O
and	O
140	O
kDa	O
(	O
P140	O
)	O
,	O
respectively	O
.	O

The	O
120	O
-	O
kDa	O
protein	O
gene	O
of	O
E.	O
chaffeensis	O
contains	O
four	O
identical	O
240	O
-	O
bp	O
tandem	O
repeat	O
units	O
,	O
and	O
the	O
140	O
-	O
kDa	O
protein	O
gene	O
of	O
E.	O
canis	O
has	O
14	O
nearly	O
identical	O
,	O
tandemly	O
arranged	O
108	O
-	O
bp	O
repeat	O
units	O
.	O

Conserved	O
serine	O
-	O
rich	O
motifs	O
identified	O
in	O
the	O
repeat	O
units	O
of	O
P120	O
and	O
P140	O
were	O
also	O
found	O
in	O
the	O
repeat	O
units	O
of	O
the	O
human	O
granulocytotropic	O
ehrlichiosis	O
agent	O
130	O
-	O
kDa	O
protein	O
and	O
of	O
the	O
fimbria	B
-	I
associated	I
adhesin	I
protein	I
Fap1	I
of	O
Streptococcus	O
parasanguis	O
.	O

Nearly	O
the	O
entire	O
(	O
99	O
%	O
)	O
E.	O
chaffeensis	O
P120	O
gene	O
(	O
1	O
,	O
616	O
bp	O
)	O
,	O
the	O
14	O
-	O
repeat	O
region	O
(	O
78	O
%	O
)	O
of	O
the	O
E.	O
canis	O
P140	O
gene	O
(	O
1	O
,	O
620	O
bp	O
)	O
,	O
and	O
a	O
2	O
-	O
repeat	O
region	O
from	O
the	O
E.	O
chaffeensis	O
P120	O
gene	O
(	O
520	O
bp	O
)	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
recombinant	O
proteins	O
exhibited	O
molecular	O
masses	O
ranging	O
from	O
1.6	O
to	O
2	O
times	O
larger	O
than	O
those	O
predicted	O
by	O
the	O
amino	O
acid	O
sequences	O
.	O

Antibodies	O
against	O
the	O
recombinant	O
proteins	O
reacted	O
with	O
E.	O
chaffeensis	O
P120	O
and	O
E.	O
canis	O
P140	O
,	O
respectively	O
.	O

Carbohydrate	O
was	O
detected	O
on	O
the	O
E.	O
chaffeensis	O
and	O
E.	O
canis	O
recombinant	O
proteins	O
,	O
including	O
the	O
two	O
-	O
repeat	O
polypeptide	O
region	O
of	O
E.	O
chaffeensis	O
P120	O
.	O

A	O
carbohydrate	O
compositional	O
analysis	O
identified	O
glucose	O
,	O
galactose	O
,	O
and	O
xylose	O
on	O
the	O
recombinant	O
proteins	O
.	O

The	O
presence	O
of	O
only	O
one	O
site	O
for	O
N	O
-	O
linked	O
(	O
Asn	O
-	O
Xaa	O
-	O
Ser	O
/	O
Thr	O
)	O
glycosylation	O
,	O
a	O
lack	O
of	O
effect	O
of	O
N	B
-	I
glycosidase	I
F	I
,	O
the	O
presence	O
of	O
70	O
and	O
126	O
Ser	O
/	O
Thr	O
glycosylation	O
sites	O
in	O
the	O
repeat	O
regions	O
of	O
P120	O
and	O
P140	O
,	O
respectively	O
,	O
and	O
a	O
high	O
molar	O
ratio	O
of	O
carbohydrate	O
to	O
protein	O
suggest	O
that	O
the	O
glycans	O
may	O
be	O
O	O
linked	O
.	O

Flt3	B
ligand	I
(	O
FL	B
)	O
and	O
its	O
influence	O
on	O
immune	O
reactivity	O
.	O

Flt3	B
(	I
fms	I
-	I
like	I
tyrosine	I
kinase	I
3	I
)	I
ligand	I
(	O
FL	B
)	O
is	O
a	O
potent	O
hematopoietic	O
cytokine	B
that	O
affects	O
the	O
growth	O
and	O
differentiation	O
of	O
progenitor	O
and	O
stem	O
cells	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Its	O
capacity	O
to	O
augment	O
strikingly	O
the	O
numbers	O
of	O
dendritic	O
cells	O
(	O
rare	O
antigen	O
-	O
presenting	O
cells	O
that	O
induce	O
and	O
regulate	O
immune	O
responses	O
)	O
in	O
mice	O
and	O
humans	O
has	O
stimulated	O
considerable	O
interest	O
in	O
its	O
value	O
as	O
an	O
investigational	O
tool	O
and	O
therapeutic	O
agent	O
.	O

In	O
this	O
review	O
,	O
we	O
survey	O
the	O
hematopoietic	O
properties	O
and	O
immunobiology	O
of	O
FL	B
,	O
and	O
examine	O
its	O
therapeutic	O
potential	O
.	O

The	O
impact	O
of	O
apolipoprotein	B
E	I
genotypes	O
on	O
age	O
at	O
onset	O
of	O
symptoms	O
and	O
phenotypic	O
expression	O
in	O
Wilson	O
's	O
disease	O
.	O

Wilson	O
's	O
disease	O
is	O
a	O
disorder	O
of	O
biliary	O
copper	O
excretion	O
that	O
may	O
result	O
in	O
severe	O
neurological	O
symptoms	O
and	O
advanced	O
liver	O
disease	O
.	O

The	O
wide	O
variation	O
of	O
phenotypic	O
disease	O
expression	O
can	O
not	O
be	O
fully	O
explained	O
by	O
the	O
different	O
mutations	O
of	O
the	O
Wilson	B
disease	I
gene	I
.	O

In	O
neurological	O
disorders	O
,	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
temporal	O
lobe	O
epilepsy	O
and	O
cerebral	O
trauma	O
,	O
the	O
presence	O
of	O
the	O
apolipoprotein	B
E	I
(	O
ApoE	B
)	O
allele	O
epsilon4	O
is	O
associated	O
with	O
an	O
increased	O
vulnerability	O
of	O
the	O
brain	O
to	O
the	O
effects	O
of	O
the	O
disease	O
,	O
whereas	O
the	O
presence	O
of	O
the	O
ApoE	B
genotype	O
epsilon3	O
/	O
3	O
appears	O
to	O
provide	O
moderate	O
neuroprotection	O
.	O

We	O
examined	O
whether	O
this	O
hypothesis	O
holds	O
true	O
for	O
the	O
development	O
of	O
neurological	O
symptoms	O
in	O
patients	O
with	O
Wilson	O
's	O
disease	O
.	O

The	O
ApoE	B
genotype	O
and	O
the	O
H1069Q	O
mutation	O
(	O
the	O
most	O
common	O
in	O
Wilson	O
's	O
disease	O
)	O
status	O
were	O
determined	O
by	O
polymerase	B
chain	O
reaction	O
-	O
based	O
mutation	O
assays	O
in	O
121	O
well	O
-	O
characterized	O
,	O
symptomatic	O
index	O
patients	O
with	O
Wilson	O
's	O
disease	O
.	O

An	O
investigation	O
profile	O
was	O
established	O
in	O
which	O
the	O
patients	O
were	O
grouped	O
according	O
to	O
the	O
clinical	O
symptoms	O
at	O
presentation	O
,	O
the	O
ApoE	B
genotypes	O
and	O
the	O
status	O
of	O
the	O
H1069Q	O
mutation	O
.	O

Fifty	O
-	O
nine	O
per	O
cent	O
of	O
the	O
121	O
patients	O
had	O
the	O
allele	O
combination	O
ApoE	B
epsilon3	O
/	O
3	O
(	O
21	O
%	O
ApoE	B
epsilon3	O
/	O
4	O
,	O
19	O
%	O
ApoE	B
epsilon3	O
/	O
2	O
,	O
1	O
%	O
ApoE	B
epsilon4	O
/	O
2	O
)	O
.	O

The	O
distribution	O
of	O
ApoE	B
genotypes	O
did	O
not	O
deviate	O
from	O
known	O
distributions	O
in	O
healthy	O
European	O
subjects	O
.	O

Within	O
the	O
group	O
of	O
40	O
H1069Q	O
-	O
homozygous	O
patients	O
,	O
the	O
onset	O
of	O
symptoms	O
was	O
significantly	O
delayed	O
in	O
patients	O
with	O
the	O
ApoE	B
epsilon3	O
/	O
3	O
genotype	O
(	O
25	O
+	O
/-	O
6	O
years	O
at	O
presentation	O
)	O
compared	O
with	O
patients	O
with	O
the	O
ApoE	B
epsilon3	O
/	O
4	O
genotype	O
(	O
20	O
+	O
/-	O
3	O
years	O
at	O
presentation	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
ApoE	B
genotype	O
was	O
established	O
as	O
an	O
important	O
factor	O
delaying	O
the	O
onset	O
of	O
neurological	O
and	O
hepatic	O
symptoms	O
,	O
but	O
not	O
modifying	O
phenotypic	O
disease	O
expression	O
in	O
a	O
homogeneous	O
group	O
of	O
patients	O
with	O
Wilson	O
's	O
disease	O
(	O
all	O
H1069Q	O
-	O
homozygotes	O
,	O
similar	O
genetic	O
background	O
)	O
.	O

The	O
presence	O
of	O
ApoE	B
epsilon3	O
/	O
3	O
attenuates	O
clinical	O
manifestations	O
in	O
Wilson	O
's	O
disease	O
by	O
mechanisms	O
which	O
might	O
involve	O
the	O
antioxidant	O
and	O
membrane	O
-	O
stabilizing	O
properties	O
of	O
the	O
ApoE	B
3	O
protein	O
.	O

Expression	O
of	O
5alpha	B
-	I
reductase	I
and	O
3alpha	B
-	I
hydroxisteroid	I
oxidoreductase	I
in	O
the	O
hippocampus	O
of	O
patients	O
with	O
chronic	O
temporal	O
lobe	O
epilepsy	O
.	O

PURPOSE	O
:	O

The	O
hippocampus	O
is	O
one	O
of	O
the	O
principal	O
target	O
areas	O
for	O
neurosteroidal	O
action	O
,	O
and	O
the	O
major	O
neuroendocrine	O
conversion	O
of	O
progesterone	O
appears	O
to	O
be	O
5alpha	O
-	O
reduction	O
and	O
3alpha	O
-	O
hydroxysteroid	O
oxidoreduction	O
,	O
leading	O
to	O
the	O
potent	O
neurosteroid	O
3alpha,5alpha	O
-	O
tetrahydroxyprogesterone	O
.	O

To	O
investigate	O
whether	O
the	O
human	O
hippocampus	O
is	O
equipped	O
with	O
the	O
enzymes	O
5alpha	B
-	I
reductase	I
and	O
3alpha	B
-	I
hydroxysteroid	I
oxidoreductase	I
(	O
3alpha	B
-	I
HSOR	I
)	O
,	O
we	O
studied	O
the	O
expression	O
of	O
5alpha	B
-	I
reductase	I
types	I
1	I
and	I
2	I
and	O
3alpha	B
-	I
HSOR	I
types	I
1	I
and	I
2	I
in	O
the	O
resected	O
hippocampi	O
of	O
patients	O
with	O
medically	O
intractable	O
chronic	O
temporal	O
lobe	O
epilepsy	O
.	O

METHODS	O
:	O

We	O
studied	O
tissue	O
specimens	O
from	O
the	O
hippocampi	O
of	O
13	O
women	O
,	O
25	O
men	O
,	O
and	O
four	O
children	O
.	O

Quantification	O
of	O
different	O
mRNAs	O
was	O
achieved	O
by	O
competitive	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

RESULTS	O
:	O

5Alpha	B
-	I
reductase	I
1	I
mRNA	O
and	O
3alpha	B
-	I
HSOR	I
2	I
mRNA	O
were	O
expressed	O
in	O
hippocampi	O
of	O
children	O
and	O
adults	O
,	O
whereas	O
5alpha	B
-	I
reductase	I
2	I
mRNA	O
and	O
3alpha	B
-	I
HSOR	I
1	I
mRNA	O
were	O
not	O
expressed	O
.	O

Neither	O
5alpha	B
-	I
reductase	I
1	I
mRNA	O
nor	O
3alpha	B
-	I
HSOR	I
2	I
mRNA	O
concentrations	O
in	O
hippocampal	O
tissue	O
showed	O
any	O
statistically	O
significant	O
differences	O
between	O
women	O
and	O
men	O
or	O
between	O
children	O
and	O
adults	O
.	O

CONCLUSIONS	O
:	O

This	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
mRNA	O
expression	O
of	O
the	O
type	B
1	I
isozyme	I
of	I
5alpha	I
-	I
reductase	I
and	O
the	O
type	B
2	I
isozyme	I
of	I
3alpha	I
-	I
HSOR	I
in	O
the	O
human	O
hippocampus	O
.	O

The	O
finding	O
that	O
both	O
5alpha	B
-	I
reductase	I
and	O
3alpha	B
-	I
HSOR	I
are	O
present	O
in	O
the	O
hippocampus	O
leads	O
us	O
to	O
assume	O
the	O
synthesis	O
of	O
neuroactive	O
steroids	O
in	O
this	O
human	O
brain	O
area	O
.	O

Activation	O
of	O
PLC	B
and	O
PI	B
3	I
kinase	I
by	O
PDGF	B
receptor	I
alpha	I
is	O
not	O
sufficient	O
for	O
mitogenesis	O
and	O
migration	O
in	O
mesangial	O
cells	O
.	O

BACKGROUND	O
:	O

Platelet	B
-	I
derived	I
growth	I
factor	I
(	O
PDGF	B
)	O
isoforms	O
act	O
through	O
two	O
distinct	O
cell	O
surface	O
alpha	O
and	O
beta	O
receptors	O
.	O

Glomerular	O
mesangial	O
cells	O
express	O
both	O
receptors	O
.	O

PDGF	B
BB	I
and	O
AB	O
are	O
potent	O
mitogens	O
for	O
glomerular	O
mesangial	O
cells	O
,	O
and	O
PDGF	B
BB	I
stimulates	O
cell	O
migration	O
in	O
a	O
phosphatidylinositol	B
3	I
(	I
PI	I
3	I
)	I
kinase	I
-	O
dependent	O
manner	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
PDGF	B
AA	I
on	O
cell	O
migration	O
,	O
PI	B
3	I
kinase	I
and	O
phospholipase	B
C	I
(	O
PLC	B
)	O
activation	O
,	O
and	O
the	O
role	O
of	O
these	O
two	O
enzymes	O
in	O
mediating	O
biological	O
responses	O
in	O
these	O
cells	O
in	O
response	O
to	O
all	O
three	O
isoforms	O
.	O

METHODS	O
:	O

3H	O
-	O
thymidine	O
incorporation	O
and	O
modified	O
Boyden	O
chamber	O
assay	O
were	O
used	O
to	O
determine	O
DNA	O
synthesis	O
and	O
directed	O
migration	O
,	O
respectively	O
,	O
in	O
response	O
to	O
all	O
three	O
PDGF	O
isoforms	O
.	O

Differential	O
activation	O
of	O
alpha	O
and	O
beta	O
receptors	O
was	O
studied	O
by	O
immunecomplex	O
tyrosine	B
kinase	I
assay	O
of	O
corresponding	O
receptor	O
immunoprecipitates	O
.	O

PLC	B
gamma	I
1	I
activity	O
was	O
determined	O
by	O
measuring	O
total	O
inositol	O
phosphates	O
in	O
response	O
to	O
different	O
PDGF	B
isoforms	O
.	O

PI	B
3	I
kinase	I
activity	O
was	O
determined	O
in	O
antiphosphotyrosine	O
or	O
PDGF	B
receptor	I
immunoprecipitates	O
.	O

RESULTS	O
:	O

Both	O
PDGF	B
BB	I
and	O
AB	O
resulted	O
in	O
stimulation	O
of	O
DNA	O
synthesis	O
and	O
directed	O
migration	O
of	O
mesangial	O
cells	O
.	O

AA	O
was	O
neither	O
chemotactic	O
nor	O
mitogenic	O
.	O

However	O
,	O
all	O
three	O
isoforms	O
increased	O
tyrosine	O
phosphorylation	O
of	O
a	O
180	O
kD	O
protein	O
in	O
antiphosphotyrosine	O
immunoprecipitates	O
,	O
suggesting	O
activation	O
of	O
respective	O
receptors	O
.	O

Direct	O
immunecomplex	O
tyrosine	B
kinase	I
assay	O
of	O
alpha	O
and	O
beta	O
receptors	O
demonstrated	O
significant	O
activation	O
of	O
both	O
of	O
these	O
receptors	O
when	O
cells	O
are	O
treated	O
with	O
PDGF	B
BB	I
or	O
AB	O
.	O

PDGF	B
AA	I
increased	O
tyrosine	B
kinase	I
activity	O
of	O
the	O
alpha	O
receptor	O
but	O
not	O
the	O
beta	O
receptor	O
.	O

All	O
three	O
isoforms	O
significantly	O
stimulated	O
the	O
production	O
of	O
inositol	O
phosphates	O
with	O
order	O
of	O
potency	O
being	O
BB	O
>	O
AB	O
>	O
AA	O
.	O

PDGF	B
AA	I
also	O
dose	O
dependently	O
stimulated	O
PI	B
3	I
kinase	I
activity	O
measured	O
in	O
antiphosphotyrosine	O
immunoprecipitates	O
of	O
treated	O
cells	O
.	O

A	O
comparison	O
of	O
PI	B
3	I
kinase	I
activity	O
in	O
antiphosphotyrosine	O
immunoprecipitates	O
from	O
mesangial	O
cells	O
stimulated	O
with	O
three	O
different	O
PDGF	B
isoforms	O
showed	O
significant	O
activation	O
of	O
this	O
enzyme	O
with	O
a	O
decreasing	O
order	O
of	O
activity	O
:	O
BB	O
>	O
AB	O
>	O
AA	O
.	O

CONCLUSION	O
:	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
all	O
three	O
isoforms	O
of	O
PDGF	B
significantly	O
stimulate	O
PLC	B
gamma	I
1	I
and	O
PI	B
3	I
kinase	I
,	O
two	O
enzymes	O
necessary	O
for	O
both	O
DNA	O
synthesis	O
and	O
directed	O
migration	O
.	O

However	O
,	O
activation	O
of	O
alpha	O
receptor	O
by	O
PDGF	B
AA	I
with	O
a	O
subsequent	O
increase	O
in	O
PLC	B
and	O
PI	B
3	I
kinase	I
activities	O
is	O
not	O
sufficient	O
to	O
induce	O
these	O
biological	O
responses	O
in	O
mesangial	O
cells	O
.	O

These	O
data	O
indicate	O
that	O
the	O
extent	O
of	O
activation	O
of	O
signal	O
transduction	O
pathways	O
may	O
be	O
a	O
major	O
determinant	O
of	O
the	O
biological	O
activity	O
of	O
different	O
PDGF	B
isoforms	O
in	O
mesangial	O
cells	O
.	O

Elucidating	O
the	O
essential	O
role	O
of	O
the	O
A14	B
phosphoprotein	O
in	O
vaccinia	O
virus	O
morphogenesis	O
:	O
construction	O
and	O
characterization	O
of	O
a	O
tetracycline	O
-	O
inducible	O
recombinant	O
.	O

We	O
have	O
previously	O
reported	O
the	O
construction	O
and	O
characterization	O
of	O
vindH1	O
,	O
an	O
inducible	O
recombinant	O
in	O
which	O
expression	O
of	O
the	O
vaccinia	O
virus	O
H1	B
phosphatase	I
is	O
regulated	O
experimentally	O
by	O
IPTG	O
(	O
isopropyl	O
-	O
beta	O
-	O
D	O
-	O
thiogalactopyranoside	O
)	O
(	O
35	O
)	O
.	O

In	O
the	O
absence	O
of	O
H1	B
expression	O
,	O
the	O
transcriptional	O
competence	O
and	O
infectivity	O
of	O
nascent	O
virions	O
are	O
severely	O
compromised	O
.	O

We	O
have	O
sought	O
to	O
identify	O
H1	B
substrates	O
by	O
characterizing	O
proteins	O
that	O
are	O
hyperphosphorylated	O
in	O
H1	B
-	O
deficient	O
virions	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
A14	B
protein	O
,	O
a	O
component	O
of	O
the	O
virion	O
membrane	O
,	O
is	O
indeed	O
an	O
H1	B
phosphatase	I
substrate	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

A14	B
is	O
hyperphosphorylated	O
on	O
serine	O
residues	O
in	O
the	O
absence	O
of	O
H1	B
expression	O
.	O

To	O
enable	O
a	O
genetic	O
analysis	O
of	O
A14	B
's	O
function	O
during	O
the	O
viral	O
life	O
cycle	O
,	O
we	O
have	O
adopted	O
the	O
regulatory	O
components	O
of	O
the	O
tetracycline	O
(	O
TET	O
)	O
operon	O
and	O
created	O
new	O
reagents	O
for	O
the	O
construction	O
of	O
TET	O
-	O
inducible	O
vaccinia	O
virus	O
recombinants	O
.	O

In	O
the	O
context	O
of	O
a	O
virus	O
expressing	O
the	O
TET	B
repressor	I
(	O
tetR	B
)	O
,	O
insertion	O
of	O
the	O
TET	O
operator	O
between	O
the	O
transcriptional	O
and	O
translational	O
start	O
sites	O
of	O
a	O
late	O
viral	O
gene	O
enables	O
its	O
expression	O
to	O
be	O
tightly	O
regulated	O
by	O
TET	O
.	O

We	O
constructed	O
a	O
TET	O
-	O
inducible	O
recombinant	O
for	O
the	O
A14	B
gene	O
,	O
vindA14	O
.	O

In	O
the	O
absence	O
of	O
TET	O
,	O
vindA14	O
fails	O
to	O
form	O
plaques	O
and	O
the	O
24	O
-	O
h	O
yield	O
of	O
infectious	O
progeny	O
is	O
reduced	O
by	O
3	O
orders	O
of	O
magnitude	O
.	O

The	O
infection	O
arrests	O
early	O
during	O
viral	O
morphogenesis	O
,	O
with	O
the	O
accumulation	O
of	O
large	O
numbers	O
of	O
vesicles	O
and	O
the	O
appearance	O
of	O
""""	O
empty	O
""""	O
crescents	O
that	O
appear	O
to	O
adhere	O
only	O
loosely	O
to	O
virosomes	O
.	O

This	O
phenotype	O
corresponds	O
closely	O
to	O
that	O
observed	O
for	O
an	O
IPTG	O
-	O
inducible	O
A14	B
recombinant	O
whose	O
construction	O
and	O
characterization	O
were	O
reported	O
while	O
our	O
work	O
was	O
ongoing	O
(	O
47	O
)	O
.	O

The	O
consistency	O
in	O
the	O
phenotypes	O
seen	O
for	O
the	O
IPTG	O
-	O
and	O
TET	O
-	O
inducible	O
recombinants	O
confirms	O
the	O
efficacy	O
of	O
the	O
TET	O
-	O
inducible	O
system	O
and	O
reinforces	O
the	O
value	O
of	O
having	O
a	O
second	O
,	O
independent	O
system	O
available	O
for	O
generating	O
inducible	O
recombinants	O
.	O

The	O
motif	O
for	O
peptide	O
binding	O
to	O
the	O
insulin	B
-	O
dependent	O
diabetes	O
mellitus	O
-	O
associated	O
class	B
II	I
MHC	I
molecule	O
I	B
-	I
Ag7	I
validated	O
by	O
phage	O
display	O
library	O
.	O

The	O
MHC	B
class	I
II	I
molecule	O
I	B
-	I
Ag7	I
is	O
essential	O
for	O
the	O
development	O
of	O
insulin	B
-	O
dependent	O
diabetes	O
mellitus	O
(	O
IDDM	O
)	O
in	O
the	O
non	O
-	O
obese	O
diabetic	O
(	O
NOD	O
)	O
mouse	O
but	O
the	O
requirements	O
for	O
peptide	O
binding	O
to	O
I	B
-	I
Ag7	I
are	O
still	O
controversial	O
.	O

We	O
have	O
now	O
isolated	O
I	B
-	I
Ag7	I
-	O
binding	O
phage	O
from	O
a	O
large	O
phage	O
display	O
library	O
encoding	O
random	O
nonamer	O
peptides	O
.	O

Ninety	O
peptide	O
-	O
encoding	O
regions	O
of	O
phage	O
eluted	O
from	O
I	B
-	I
Ag7	I
were	O
sequenced	O
and	O
>	O
75	O
%	O
of	O
the	O
corresponding	O
synthetic	O
peptides	O
bound	O
to	O
I	B
-	I
Ag7	I
.	O

Peptide	O
alignment	O
led	O
to	O
the	O
identification	O
of	O
position	O
-	O
specific	O
anchor	O
residues	O
.	O

Hydrophobic	O
(	O
V	O
and	O
P	O
)	O
and	O
positively	O
charged	O
(	O
K	O
)	O
residues	O
were	O
highly	O
enriched	O
at	O
P6	O
and	O
positively	O
charged	O
(	O
R	O
and	O
K	O
)	O
,	O
aromatic	O
(	O
Y	O
)	O
or	O
hydrophobic	O
(	O
L	O
)	O
residues	O
at	O
P9	O
.	O

In	O
addition	O
,	O
small	O
amino	O
acid	O
residues	O
(	O
G	O
and	O
A	O
)	O
were	O
enriched	O
at	O
P7	O
and	O
G	O
at	O
P8	O
.	O

The	O
primary	O
anchors	O
at	O
P6	O
and	O
P9	O
defining	O
the	O
phage	O
-	O
derived	O
motif	O
were	O
present	O
in	O
most	O
high	O
-	O
affinity	O
I	B
-	I
Ag7	I
-	O
binding	O
peptides	O
from	O
IDDM	O
candidate	O
antigens	O
but	O
only	O
in	O
<	O
or	O
=	O
25	O
%	O
of	O
peptides	O
that	O
were	O
low	O
-	O
affinity	O
binders	O
or	O
failed	O
to	O
bind	O
to	O
I	B
-	I
Ag7	I
.	O

A	O
comparison	O
of	O
these	O
results	O
with	O
the	O
proposed	O
motifs	O
for	O
peptide	O
binding	O
to	O
I	B
-	I
Ag7	I
validates	O
the	O
one	O
we	O
have	O
previously	O
described	O
.	O

The	O
genomic	O
organization	O
,	O
complete	O
mRNA	O
sequence	O
,	O
cloning	O
,	O
and	O
expression	O
of	O
a	O
novel	O
human	O
intracellular	B
membrane	I
-	I
associated	I
calcium	I
-	I
independent	I
phospholipase	I
A	I
(	I
2	I
)	I
.	O

During	O
the	O
sequencing	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
7	O
in	O
the	O
Human	O
Genome	O
Project	O
,	O
a	O
predicted	O
protein	O
product	O
of	O
40	O
kDa	O
was	O
identified	O
,	O
which	O
contained	O
two	O
approximately	O
10	O
-	O
amino	O
acid	O
segments	O
homologous	O
to	O
the	O
ATP	O
and	O
lipase	B
consensus	O
sequences	O
present	O
in	O
the	O
founding	O
members	O
of	O
a	O
family	B
of	I
calcium	I
-	I
independent	I
phospholipases	I
A	I
(	I
2	I
)	I
.	O

Detailed	O
inspection	O
of	O
the	O
identified	O
sequence	O
(	O
residues	O
79	O
,	O
671	O
-	O
109	O
,	O
912	O
GenBank	O
accession	O
no.	O
AC005058	O
)	O
demonstrated	O
that	O
it	O
represented	O
only	O
a	O
partial	O
sequence	O
of	O
a	O
larger	O
undefined	O
polypeptide	O
product	O
.	O

Accordingly	O
,	O
we	O
identified	O
the	O
complete	O
genomic	O
organization	O
of	O
this	O
putative	O
phospholipase	B
A	I
(	I
2	I
)	I
through	O
analyses	O
of	O
previously	O
published	O
expressed	O
sequence	O
tags	O
,	O
PCR	O
of	O
human	O
heart	O
cDNA	O
,	O
and	O
5'-rapid	O
amplification	O
of	O
cDNA	O
ends	O
.	O

Polymerase	O
chain	O
reaction	O
and	O
Northern	O
blotting	O
demonstrated	O
a	O
3.4	O
-	O
kilobase	O
message	O
,	O
which	O
encoded	O
a	O
polypeptide	O
with	O
a	O
maximum	O
calculated	O
molecular	O
weight	O
of	O
88476.9	O
.	O

This	O
3.4	O
-	O
kilobase	O
message	O
was	O
present	O
in	O
multiple	O
human	O
parenchymal	O
tissues	O
including	O
heart	O
,	O
skeletal	O
muscle	O
,	O
placenta	O
,	O
brain	O
,	O
liver	O
,	O
and	O
pancreas	O
.	O

Cloning	O
and	O
expression	O
of	O
the	O
protein	O
encoded	O
by	O
this	O
message	O
in	O
Sf9	O
cells	O
resulted	O
in	O
the	O
production	O
of	O
two	O
proteins	O
of	O
apparent	O
molecular	O
masses	O
of	O
77	O
and	O
63	O
kDa	O
as	O
assessed	O
by	O
Western	O
analyses	O
utilizing	O
immunoaffinity	O
-	O
purified	O
antibody	O
.	O

Membranes	O
from	O
Sf9	O
cells	O
expressing	O
recombinant	O
protein	O
released	O
fatty	O
acid	O
from	O
sn-2-radiolabeled	O
phosphatidylcholine	O
and	O
plasmenylcholine	O
up	O
to	O
10	O
-	O
fold	O
more	O
rapidly	O
than	O
controls	O
.	O

The	O
initial	O
rate	O
of	O
fatty	O
acid	O
release	O
from	O
the	O
membrane	O
fraction	O
was	O
0	O
.	O
3	O
nmol	O
/	O
mg.min	O
.	O

The	O
recombinant	O
protein	O
was	O
entirely	O
calcium	O
-	O
independent	O
,	O
had	O
a	O
pH	O
optimum	O
of	O
8.0	O
,	O
was	O
inhibited	O
by	O
(	O
E	O
)	O
-6-	O
(	O
bromomethylene	O
)	O
-3-	O
(	O
1-naphthalenyl	O
)	O
-2H	O
-	O
tetrahydropyran-2-one	O
(	O
IC	O
(	O
50	O
)	O
=	O
3	O
microM	O
)	O
,	O
and	O
was	O
predominantly	O
present	O
in	O
the	O
membrane	O
-	O
associated	O
fraction	O
.	O

Collectively	O
,	O
these	O
results	O
describe	O
the	O
genomic	O
organization	O
,	O
complete	O
mRNA	O
sequence	O
,	O
and	O
sn-2-lipase	B
activity	O
of	O
a	O
novel	O
intracellular	B
calcium	I
-	I
independent	I
membrane	I
-	I
associated	I
phospholipase	I
A	I
(	I
2	I
)	I
.	O

Specific	O
angiotensin	B
II	I
receptor	I
blockage	O
improves	O
intestinal	O
perfusion	O
during	O
graded	O
hypovolemia	O
in	O
pigs	O
.	O

OBJECTIVE	O
:	O

To	O
investigate	O
the	O
potential	O
of	O
specific	O
angiotensin	B
II	I
subtype	I
1	I
(	I
AT1	I
)	I
receptor	I
blockade	O
to	O
modify	O
the	O
mesenteric	O
hemodynamic	O
response	O
to	O
acute	O
hypovolemia	O
and	O
retransfusion	O
.	O

DESIGN	O
:	O

Prospective	O
,	O
randomized	O
,	O
controlled	O
experimental	O
study	O
.	O

SETTING	O
:	O

University	O
-	O
affiliated	O
animal	O
research	O
laboratory	O
.	O

SUBJECTS	O
:	O

Fasted	O
,	O
anesthetized	O
,	O
ventilated	O
,	O
juvenile	O
domestic	O
pigs	O
of	O
both	O
sexes	O
.	O

INTERVENTIONS	O
:	O

Acute	O
,	O
graded	O
hypovolemia	O
by	O
20	O
%	O
and	O
40	O
%	O
of	O
the	O
total	O
estimated	O
blood	O
volume	O
followed	O
by	O
retransfusion	O
in	O
control	O
animals	O
(	O
CTRL	O
;	O
n	O
=	O
10	O
)	O
and	O
animals	O
pretreated	O
with	O
the	O
AT1	B
receptor	O
blocker	O
candesartan	O
(	O
CAND	O
;	O
n	O
=	O
10	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O

Invasive	O
monitoring	O
of	O
arterial	O
and	O
central	O
venous	O
blood	O
pressures	O
,	O
cardiac	O
output	O
,	O
portal	O
venous	O
blood	O
flow	O
,	O
and	O
jejunal	O
mucosal	O
blood	O
flow	O
.	O

Blood	O
gases	O
were	O
repeatedly	O
analyzed	O
to	O
calculate	O
oxygen	O
delivery	O
and	O
consumption	O
.	O

Thirty	O
minutes	O
after	O
each	O
level	O
of	O
hypovolemia	O
at	O
20	O
%	O
and	O
40	O
%	O
,	O
cardiac	O
output	O
was	O
decreased	O
in	O
CTRL	O
animals	O
from	O
a	O
baseline	O
of	O
2.9	O
+	O
/	O
-	O
0.1	O
to	O
1.8	O
+	O
/	O
-	O
0.2	O
and	O
1.1	O
+	O
/-	O
0.2	O
L	O
/	O
min	O
,	O
with	O
no	O
differences	O
compared	O
with	O
CAND	O
animals	O
.	O

Cardiac	O
output	O
was	O
restored	O
to	O
3.0	O
+	O
/-	O
0.3	O
L	O
/	O
min	O
30	O
mins	O
after	O
retransfusion	O
in	O
CTRL	O
animals	O
,	O
with	O
no	O
significant	O
intergroup	O
differences	O
.	O

Baseline	O
portal	O
venous	O
blood	O
flow	O
(	O
Q	O
(	O
MES	O
)	O
)	O
and	O
jejunal	O
mucosal	O
perfusion	O
(	O
PU	O
(	O
JEJ	O
)	O
)	O
were	O
greater	O
in	O
CAND	O
animals	O
compared	O
with	O
CTRL	O
animals	O
.	O

During	O
graded	O
hypovolemia	O
,	O
CAND	O
animals	O
maintained	O
Q	O
(	O
MES	O
)	O
and	O
PU	O
(	O
JEJ	O
)	O
at	O
significantly	O
higher	O
levels	O
compared	O
with	O
CTRL	O
animals	O
,	O
particularly	O
after	O
40	O
%	O
hemorrhage	O
(	O
+	O
221	O
%	O
and	O
+	O
244	O
%	O
,	O
respectively	O
,	O
relative	O
to	O
the	O
mean	O
values	O
in	O
CTRL	O
animals	O
)	O
.	O

The	O
same	O
pattern	O
was	O
observed	O
after	O
retransfusion	O
.	O

Moreover	O
,	O
the	O
calculated	O
mesenteric	O
critical	O
oxygen	O
delivery	O
was	O
significantly	O
greater	O
in	O
CTRL	O
animals	O
(	O
74	O
mL	O
/	O
min	O
)	O
compared	O
with	O
CAND	O
animals	O
(	O
34	O
mL	O
/	O
min	O
)	O
.	O

No	O
animals	O
died	O
in	O
the	O
CAND	O
group	O
,	O
whereas	O
four	O
animals	O
died	O
during	O
40	O
%	O
hypovolemia	O
or	O
retransfusion	O
in	O
the	O
CTRL	O
group	O
.	O

CONCLUSIONS	O
:	O

Specific	O
AT1	B
blockade	O
before	O
acute	O
hypovolemia	O
significantly	O
ameliorated	O
mesenteric	O
and	O
,	O
in	O
particular	O
,	O
jejunal	O
mucosal	O
hypoperfusion	O
.	O

In	O
addition	O
,	O
cardiovascular	O
stability	O
was	O
improved	O
,	O
and	O
mortality	O
in	O
conjunction	O
with	O
acute	O
hypovolemia	O
and	O
retransfusion	O
could	O
be	O
completely	O
avoided	O
.	O

These	O
findings	O
support	O
a	O
fundamental	O
role	O
of	O
the	O
renin	B
-	O
angiotensin	B
system	O
in	O
the	O
mesenteric	O
response	O
to	O
acute	O
hypovolemia	O
and	O
indicate	O
a	O
substantial	O
interventional	O
potential	O
for	O
candesartan	O
in	O
conjunction	O
with	O
circulatory	O
stress	O
.	O

Monoclonal	O
antibody	O
screening	O
of	O
a	O
phage	O
-	O
displayed	O
random	O
peptide	O
library	O
reveals	O
mimotopes	O
of	O
chemokine	B
receptor	I
CCR5	B
:	O
implications	O
for	O
the	O
tertiary	O
structure	O
of	O
the	O
receptor	O
and	O
for	O
an	O
N	O
-	O
terminal	O
binding	O
site	O
for	O
HIV	O
-	O
1	O
gp120	B
.	O

The	O
chemokine	B
receptor	I
CCR5	B
contains	O
seven	O
transmembrane	O
-	O
spanning	O
domains	O
.	O

It	O
binds	O
chemokines	B
and	O
acts	O
as	O
co	O
-	O
receptor	O
for	O
macrophage	O
(	O
m	O
)	O
-	O
tropic	O
(	O
or	O
R5	O
)	O
strains	O
of	O
HIV-1	O
.	O

Monoclonal	O
antibodies	O
(	O
mAb	O
)	O
to	O
CCR5	B
,	O
3A9	O
and	O
5C7	O
,	O
were	O
used	O
for	O
biopanning	O
a	O
nonapeptide	O
cysteine	O
(	O
C	O
)	O
-	O
constrained	O
phage	O
-	O
displayed	O
random	O
peptide	O
library	O
to	O
ascertain	O
contact	O
residues	O
and	O
define	O
tertiary	O
structures	O
of	O
possible	O
epitopes	O
on	O
CCR5	B
.	O

Reactivity	O
of	O
antibodies	O
with	O
phagotopes	O
was	O
established	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

mAb	O
3A9	O
identified	O
a	O
phagotope	O
C	O
-	O
HASIYDFGS	O
-	O
C	O
(	O
3A9	O
/	O
1	O
)	O
,	O
and	O
5C7	O
most	O
frequently	O
identified	O
C	O
-	O
PHWLRDLRV	O
-	O
C	O
(	O
5C7	O
/	O
1	O
)	O
.	O

Corresponding	O
peptides	O
were	O
synthesized	O
.	O

Phagotopes	O
and	O
synthetic	O
peptides	O
reacted	O
in	O
ELISA	O
with	O
corresponding	O
antibodies	O
and	O
synthetic	O
peptides	O
inhibited	O
antibody	O
binding	O
to	O
the	O
phagotopes	O
.	O

Reactivity	O
by	O
immunofluorescence	O
of	O
3A9	O
with	O
CCR5	B
was	O
strongly	O
inhibited	O
by	O
the	O
corresponding	O
peptide	O
.	O

Both	O
mAb	O
3A9	O
and	O
5C7	O
reacted	O
similarly	O
with	O
phagotopes	O
and	O
the	O
corresponding	O
peptide	O
selected	O
by	O
the	O
alternative	O
mAb	O
.	O

The	O
sequences	O
of	O
peptide	O
inserts	O
of	O
phagotopes	O
could	O
be	O
aligned	O
as	O
mimotopes	O
of	O
the	O
sequence	O
of	O
CCR5	B
.	O

For	O
phage	O
3A9	O
/	O
1	O
,	O
the	O
motif	O
SIYD	O
aligned	O
to	O
residues	O
at	O
the	O
N	O
terminus	O
and	O
FG	O
to	O
residues	O
on	O
the	O
first	O
extracellular	O
loop	O
;	O
for	O
5C7	O
/	O
1	O
,	O
residues	O
at	O
the	O
N	O
terminus	O
,	O
first	O
extracellular	O
loop	O
,	O
and	O
possibly	O
the	O
third	O
extracellular	O
loop	O
could	O
be	O
aligned	O
and	O
so	O
would	O
contribute	O
to	O
the	O
mimotope	O
.	O

The	O
synthetic	O
peptides	O
corresponding	O
to	O
the	O
isolated	O
phagotopes	O
showed	O
a	O
CD4	B
-	O
dependent	O
reactivity	O
with	O
gp120	B
of	O
a	O
primary	O
,	O
m	O
-	O
tropic	O
HIV	O
-	O
1	O
isolate	O
.	O

Thus	O
reactivity	O
of	O
antibodies	O
raised	O
to	O
CCR5	B
against	O
phage	O
-	O
displayed	O
peptides	O
defined	O
mimotopes	O
that	O
reflect	O
binding	O
sites	O
for	O
these	O
antibodies	O
and	O
reveal	O
a	O
part	O
of	O
the	O
gp120	B
binding	O
sites	O
on	O
CCR5	B
.	O

nef	B
/	O
long	O
terminal	O
repeat	O
quasispecies	O
from	O
HIV	O
type	O
1	O
-	O
infected	O
Mexican	O
patients	O
with	O
different	O
progression	O
patterns	O
and	O
their	O
pathogenesis	O
in	O
hu	O
-	O
PBL	O
-	O
SCID	O
mice	O
.	O

To	O
examine	O
the	O
genetic	O
features	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
derived	O
from	O
six	O
HIV-1	O
-	O
infected	O
individuals	O
enrolled	O
in	O
the	O
Mexico	O
City	O
Cohort	O
,	O
we	O
cloned	O
and	O
sequenced	O
a	O
505	O
-	O
bp	O
fragment	O
of	O
the	O
proviral	O
LTR	O
from	O
their	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
.	O

All	O
patients	O
harbored	O
HIV-1	O
LTR	O
quasispecies	O
corresponding	O
to	O
the	O
B	O
subtype	O
.	O

Three	O
patients	O
with	O
high	O
CD4	B
+	O
T	O
cell	O
counts	O
(	O
>	O
500	O
/	O
mm3	O
)	O
presented	O
LTR	O
sequences	O
with	O
point	O
mutations	O
in	O
the	O
TAR	O
bulge	O
.	O

The	O
LTR	O
sequence	O
from	O
a	O
patient	O
classified	O
as	O
a	O
long	O
-	O
term	O
nonprogressor	O
(	O
LTNP	O
)	O
presented	O
the	O
most	O
frequent	O
naturally	O
occurring	O
length	O
polymorphism	O
(	O
MFNLP	O
)	O
and	O
two	O
substitutions	O
in	O
the	O
TAR	O
region	O
that	O
were	O
predicted	O
to	O
result	O
in	O
two	O
alternative	O
secondary	O
RNA	O
structures	O
.	O

A	O
novel	O
18	O
-	O
bp	O
deletion	O
,	O
which	O
eliminates	O
part	O
of	O
the	O
putative	O
binding	O
site	O
for	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT-1	B
)	O
,	O
was	O
identified	O
in	O
the	O
overlapping	O
nef	B
/	O
LTR	O
sequence	O
derived	O
from	O
a	O
patient	O
progressing	O
to	O
AIDS	O
.	O

This	O
deletion	O
coincides	O
with	O
the	O
ability	O
of	O
this	O
virus	O
to	O
consistently	O
replicate	O
at	O
low	O
levels	O
in	O
vivo	O
(	O
viral	O
load	O
<	O
500	O
RNA	O
copies	O
/	O
ml	O
)	O
and	O
in	O
vitro	O
(	O
unsuccessful	O
virus	O
isolation	O
)	O
.	O

On	O
one	O
occasion	O
,	O
when	O
virus	O
isolation	O
was	O
successful	O
,	O
the	O
18	O
-	O
bp	O
deletion	O
was	O
no	O
longer	O
evident	O
and	O
LTR	O
sequences	O
with	O
intact	O
NFAT-1	B
-	O
binding	O
sites	O
were	O
observed	O
.	O

Inoculation	O
of	O
hu	O
-	O
PBL	O
-	O
SCID	O
mice	O
with	O
viruses	O
from	O
several	O
Mexican	O
patients	O
resulted	O
in	O
differential	O
CD4	B
+	O
T	O
cell	O
depletion	O
patterns	O
15	O
days	O
postinfection	O
,	O
which	O
agree	O
with	O
the	O
in	O
vivo	O
CD4	B
+	O
T	O
cell	O
count	O
data	O
from	O
each	O
patient	O
.	O

[	O
Cloning	O
and	O
expression	O
of	O
the	O
lux	B
-	I
operon	I
of	O
Photorhabdus	O
luminescens	O
,	O
strain	O
Zm1	O
:	O
nucleotide	O
sequence	O
of	O
luxAB	B
genes	O
and	O
basic	O
properties	O
of	O
luciferase	B
]	O

A	O
chromosomal	O
fragment	O
of	O
bacteria	O
Photorhabdus	O
luminescence	O
Zm1	O
,	O
which	O
contains	O
the	O
lux	B
operon	I
,	O
was	O
cloned	O
into	O
the	O
vector	O
pUC18	O
.	O

The	O
hybrid	O
clone	O
containing	O
plasmid	O
pXen7	O
with	O
the	O
EcoRI	B
fragment	O
approximately	O
7	O
-	O
kb	O
was	O
shown	O
to	O
manifest	O
a	O
high	O
level	O
of	O
bioluminescence	O
.	O

By	O
subcloning	O
and	O
restriction	O
analysis	O
of	O
the	O
EcoRI	B
fragment	O
,	O
the	O
location	O
of	O
luxCDABE	B
genes	O
relative	O
to	O
restriction	O
sites	O
was	O
determined	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
DNA	O
fragment	O
containing	O
the	O
luxA	B
and	O
luxB	B
genes	O
encoding	O
alpha	O
-	O
and	O
beta	O
-	O
subunits	O
of	O
luciferase	B
was	O
determined	O
.	O

A	O
comparison	O
with	O
the	O
nucleotide	O
sequences	O
of	O
luxAB	B
genes	O
in	O
Hm	O
and	O
Hw	O
strains	O
of	O
Ph	O
.	O
luminescence	O
revealed	O
94.5	O
and	O
89.7	O
%	O
homology	O
,	O
respectively	O
.	O

The	O
enterobacterial	O
repetitive	O
intergenic	O
sequence	O
(	O
ERIC	O
)	O
of	O
126	O
bp	O
typical	O
for	O
Hw	O
strains	O
was	O
identified	O
in	O
the	O
spacer	O
between	O
the	O
luxD	B
and	O
luxA	B
genes	O
.	O

The	O
lux	B
operon	I
of	O
Zm1	O
is	O
assumed	O
to	O
emerge	O
through	O
recombination	O
between	O
Hm	O
and	O
Hw	O
strains	O
.	O

Luciferase	B
of	O
Ph	O
.	O
luminescence	O
was	O
shown	O
to	O
possess	O
a	O
high	O
thermal	O
stability	O
:	O
its	O
activity	O
decreased	O
by	O
a	O
factor	O
of	O
10	O
at	O
44	O
degrees	O
C	O
for	O
30	O
min	O
,	O
whereas	O
luciferases	B
of	O
marine	O
bacteria	O
Vibrio	O
fischeri	O
and	O
Vibrio	O
harveyi	O
were	O
inactivated	O
by	O
one	O
order	O
of	O
magnitude	O
at	O
44	O
degrees	O
C	O
for	O
1	O
and	O
6	O
min	O
,	O
respectively	O
.	O

The	O
lux	B
genes	O
of	O
Ph	O
.	O
luminescence	O
are	O
suggested	O
for	O
use	O
in	O
gene	O
engineering	O
and	O
biotechnology	O
.	O

Characterization	O
of	O
human	O
retinal	B
fascin	I
gene	O
(	O
FSCN2	B
)	O
at	O
17q25	O
:	O
close	O
physical	O
linkage	O
of	O
fascin	B
and	O
cytoplasmic	O
actin	B
genes	O
.	O

Retinal	B
fascin	I
is	O
a	O
newly	O
identified	O
photoreceptor	B
-	O
specific	O
paralog	O
of	O
the	O
actin	B
-	O
bundling	O
protein	O
fascin	B
.	O

Fascins	B
crosslink	O
f	B
-	I
actin	I
into	O
highly	O
ordered	O
bundles	O
within	O
dynamic	O
cell	O
extensions	O
such	O
as	O
neuronal	O
growth	O
cone	O
filopodia	O
.	O

We	O
have	O
isolated	O
cDNA	O
and	O
genomic	O
clones	O
of	O
human	O
retinal	B
fascin	I
and	O
characterized	O
the	O
structure	O
of	O
the	O
human	O
retinal	B
fascin	I
gene	O
(	O
FSCN2	B
)	O
.	O

The	O
cDNA	O
predicts	O
a	O
protein	O
of	O
492	O
amino	O
acids	O
and	O
molecular	O
mass	O
55	O
,	O
057	O
that	O
shows	O
94	O
%	O
identity	O
to	O
bovine	O
retinal	B
fascin	I
and	O
56	O
%	O
identity	O
to	O
human	O
fascin	B
.	O

Promoter	O
analysis	O
reveals	O
a	O
consensus	O
retinoic	O
acid	O
response	O
element	O
and	O
several	O
potential	O
binding	O
sites	O
for	O
transcription	B
factors	I
Crx	B
and	O
Nrl	B
,	O
which	O
correlates	O
with	O
the	O
retina	O
-	O
specific	O
expression	O
of	O
FSCN2	B
mRNA	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
analysis	O
and	O
genomic	O
clone	O
sequencing	O
indicate	O
that	O
the	O
FSCN2	B
gene	O
lies	O
within	O
200	O
kb	O
of	O
the	O
actin	B
gene	O
ACTG1	B
at	O
17q25	O
.	O

Database	O
searches	O
revealed	O
that	O
the	O
human	O
fascin	B
gene	O
FSCN1	B
and	O
actin	B
gene	O
ACTB	B
at	O
7p22	O
also	O
coexist	O
within	O
a	O
200	O
-	O
kb	O
genomic	O
clone	O
.	O

The	O
close	O
physical	O
linkage	O
of	O
these	O
fascin	B
/	O
actin	B
gene	O
pairs	O
suggests	O
that	O
they	O
derive	O
from	O
a	O
common	O
gene	O
duplication	O
event	O
and	O
allows	O
comparison	O
of	O
fascin	B
and	O
actin	B
phylogenetic	O
analyses	O
.	O

Finally	O
,	O
a	O
possible	O
link	O
to	O
the	O
retinitis	O
pigmentosa	O
17	O
allele	O
(	O
RP17	O
)	O
at	O
distal	O
17q	O
was	O
excluded	O
by	O
demonstration	O
of	O
multiple	O
independent	O
segregation	O
events	O
in	O
two	O
RP17	O
kindreds	O
.	O

Informative	O
FSCN2	B
polymorphisms	O
were	O
identified	O
and	O
will	O
serve	O
as	O
useful	O
markers	O
in	O
future	O
linkage	O
studies	O
.	O

The	O
likely	O
function	O
of	O
retinal	O
fascin	B
,	O
in	O
light	O
of	O
known	O
fascin	B
roles	O
in	O
other	O
cell	O
types	O
,	O
is	O
to	O
assemble	O
actin	B
microfilaments	O
in	O
support	O
of	O
photoreceptor	B
disk	O
morphogenesis	O
.	O

The	O
chromosomal	O
arsenic	B
resistance	I
genes	O
of	O
Thiobacillus	O
ferrooxidans	O
have	O
an	O
unusual	O
arrangement	O
and	O
confer	O
increased	O
arsenic	O
and	O
antimony	O
resistance	O
to	O
Escherichia	O
coli	O
.	O

The	O
chromosomal	O
arsenic	B
resistance	I
genes	O
of	O
the	O
acidophilic	O
,	O
chemolithoautotrophic	O
,	O
biomining	O
bacterium	O
Thiobacillus	O
ferrooxidans	O
were	O
cloned	O
and	O
sequenced	O
.	O

Homologues	O
of	O
four	O
arsenic	B
resistance	I
genes	O
,	O
arsB	B
,	O
arsC	B
,	O
arsH	B
,	O
and	O
a	O
putative	O
arsR	B
gene	O
,	O
were	O
identified	O
.	O

The	O
T.	O
ferrooxidans	O
arsB	B
(	O
arsenite	O
export	O
)	O
and	O
arsC	B
(	O
arsenate	B
reductase	I
)	O
gene	O
products	O
were	O
functional	O
when	O
they	O
were	O
cloned	O
in	O
an	O
Escherichia	O
coli	O
ars	B
deletion	O
mutant	O
and	O
conferred	O
increased	O
resistance	O
to	O
arsenite	O
,	O
arsenate	O
,	O
and	O
antimony	O
.	O

Therefore	O
,	O
despite	O
the	O
fact	O
that	O
the	O
ars	B
genes	O
originated	O
from	O
an	O
obligately	O
acidophilic	O
bacterium	O
,	O
they	O
were	O
functional	O
in	O
E.	O
coli	O
.	O

Although	O
T.	O
ferrooxidans	O
is	O
gram	O
negative	O
,	O
its	O
ArsC	B
was	O
more	O
closely	O
related	O
to	O
the	O
ArsC	B
molecules	O
of	O
gram	O
-	O
positive	O
bacteria	O
.	O

Furthermore	O
,	O
a	O
functional	O
trxA	B
(	O
thioredoxin	B
)	O
gene	O
was	O
required	O
for	O
ArsC	B
-	O
mediated	O
arsenate	O
resistance	O
in	O
E.	O
coli	O
;	O
this	O
finding	O
confirmed	O
the	O
gram	O
-	O
positive	O
ArsC	B
-	O
like	O
status	O
of	O
this	O
resistance	O
and	O
indicated	O
that	O
the	O
division	O
of	O
ArsC	B
molecules	O
based	O
on	O
Gram	O
staining	O
results	O
is	O
artificial	O
.	O

Although	O
arsH	B
was	O
expressed	O
in	O
an	O
E.	O
coli	O
-	O
derived	O
in	O
vitro	O
transcription	O
-	O
translation	O
system	O
,	O
ArsH	B
was	O
not	O
required	O
for	O
and	O
did	O
not	O
enhance	O
arsenic	O
resistance	O
in	O
E.	O
coli	O
.	O

The	O
T.	O
ferrooxidans	O
ars	B
genes	O
were	O
arranged	O
in	O
an	O
unusual	O
manner	O
,	O
and	O
the	O
putative	O
arsR	B
and	O
arsC	B
genes	O
and	O
the	O
arsBH	B
genes	O
were	O
translated	O
in	O
opposite	O
directions	O
.	O

This	O
divergent	O
orientation	O
was	O
conserved	O
in	O
the	O
four	O
T.	O
ferrooxidans	O
strains	O
investigated	O
.	O

Transactivation	O
properties	O
of	O
parsley	O
proline	O
-	O
rich	O
bZIP	O
transcription	B
factors	I
.	O

Light	O
-	O
responsive	O
chalcone	B
synthase	I
(	O
CHS	B
)	O
gene	O
activation	O
requires	O
LRUCHS	O
,	O
a	O
light	O
regulatory	O
promoter	O
unit	O
including	O
the	O
MYB	B
recognition	O
element	O
MRECHS	O
and	O
the	O
ACGT	O
-	O
containing	O
element	O
ACECHS	O
.	O

ACECHS	O
is	O
bound	O
by	O
the	O
parsley	O
basic	O
region	O
/	O
leucine	O
zipper	O
(	O
bZIP	O
)	O
factors	O
CPRF1	B
and	I
4	I
.	O

Factors	O
containing	O
the	O
bZIP	O
domain	O
exist	O
in	O
animals	O
,	O
plants	O
and	O
yeast	O
,	O
and	O
recognize	O
DNA	O
sequence	O
-	O
specifically	O
after	O
formation	O
of	O
homo	O
-	O
or	O
heterodimers	O
.	O

To	O
determine	O
the	O
potential	O
role	O
of	O
CPRFs	B
in	O
the	O
regulation	O
of	O
CHS	B
promoter	O
activity	O
,	O
we	O
investigated	O
the	O
functions	O
of	O
distinct	O
CPRF	B
domains	O
in	O
a	O
homologous	O
co	O
-	O
transfection	O
system	O
.	O

The	O
proline	O
-	O
rich	O
domains	O
of	O
CPRF1	B
and	O
CPRF4	B
activate	O
transcription	O
,	O
indicating	O
that	O
CPRF1	B
and	O
CPRF4	B
have	O
transactivating	O
properties	O
.	O

Over	O
-	O
expression	O
of	O
the	O
CPRF1	B
bZIP	O
domain	O
caused	O
a	O
reduction	O
of	O
LRUCHS	O
-	O
mediated	O
light	O
inducibility	O
,	O
and	O
point	O
mutations	O
throughout	O
ACECHS	O
affected	O
both	O
responsiveness	O
to	O
UV	O
-	O
containing	O
white	O
light	O
and	O
transactivation	O
by	O
CPRF1	B
:	O
VP16	B
.	O

The	O
data	O
suggest	O
that	O
a	O
CPRF1	B
-	O
containing	O
bZIP	O
heterodimer	O
interacts	O
with	O
ACECHS	O
in	O
vivo	O
.	O

We	O
discuss	O
regulatory	O
steps	O
in	O
light	O
-	O
induced	O
CHS	B
transcription	O
that	O
may	O
be	O
influenced	O
by	O
CPRF1	B
and/or	O
related	O
bZIP	O
factors	O
.	O

Bivalent	O
sequential	O
binding	O
model	O
of	O
a	O
Bacillus	O
thuringiensis	O
toxin	O
to	O
gypsy	O
moth	O
aminopeptidase	B
N	I
receptor	O
.	O

Specificity	O
for	O
target	O
insects	O
of	O
Bacillus	O
thuringiensis	O
insecticidal	O
Cry	B
toxins	O
is	O
largely	O
determined	O
by	O
toxin	O
affinity	O
for	O
insect	O
midgut	O
receptors	O
.	O

The	O
mode	O
of	O
binding	O
for	O
one	O
such	O
toxin	O
-	O
receptor	O
complex	O
was	O
investigated	O
by	O
extensive	O
toxin	O
mutagenesis	O
,	O
followed	O
by	O
real	O
-	O
time	O
receptor	O
binding	O
analysis	O
using	O
an	O
optical	O
biosensor	O
(	O
BIAcore	O
)	O
.	O

Wild	O
-	O
type	O
Cry1Ac	B
,	O
a	O
three	O
-	O
domain	O
,	O
lepidopteran	O
-	O
specific	O
toxin	O
,	O
bound	O
purified	O
gypsy	O
moth	O
(	O
Lymantria	O
dispar	O
)	O
aminopeptidase	B
N	I
(	O
APN	B
)	O
biphasically	O
.	O

Site	O
1	O
displayed	O
fast	O
association	O
and	O
dissociation	O
kinetics	O
,	O
while	O
site	O
2	O
possessed	O
slower	O
kinetics	O
,	O
yet	O
tighter	O
affinity	O
.	O

We	O
empirically	O
determined	O
that	O
two	O
Cry1Ac	B
surface	O
regions	O
are	O
involved	O
in	O
in	O
vivo	O
toxicity	O
and	O
APN	B
binding	O
.	O

Mutations	O
within	O
domain	O
III	O
affected	O
binding	O
rates	O
to	O
APN	B
site	O
1	O
,	O
whereas	O
mutations	O
in	O
domain	O
II	O
affected	O
binding	O
rates	O
to	O
APN	B
site	O
2	O
.	O

Furthermore	O
,	O
domain	O
III	O
contact	O
is	O
completely	O
inhibited	O
in	O
the	O
presence	O
of	O
N	O
-	O
acetylgalactosamine	O
,	O
indicating	O
loss	O
of	O
domain	O
III	O
binding	O
eliminates	O
all	O
APN	B
binding	O
.	O

Based	O
upon	O
these	O
observations	O
,	O
the	O
following	O
model	O
is	O
proposed	O
.	O

A	O
cavity	O
in	O
lectin	B
-	O
like	O
domain	O
III	O
initiates	O
docking	O
through	O
recognition	O
of	O
an	O
N	O
-	O
acetylgalactosamine	O
moiety	O
on	O
L.	O
dispar	O
APN	B
.	O

Following	O
primary	O
docking	O
,	O
a	O
higher	O
affinity	O
domain	O
II	O
binding	O
mechanism	O
occurs	O
,	O
which	O
is	O
critical	O
for	O
insecticidal	O
activity	O
.	O

L	B
-	I
aspartase	I
:	O
new	O
tricks	O
from	O
an	O
old	O
enzyme	O
.	O

The	O
enzyme	O
L	B
-	I
aspartate	I
ammonia	I
-	I
lyase	I
(	O
aspartase	B
)	O
catalyzes	O
the	O
reversible	O
deamination	O
of	O
the	O
amino	O
acid	O
L	O
-	O
aspartic	O
acid	O
,	O
using	O
a	O
carbanion	O
mechanism	O
to	O
produce	O
fumaric	O
acid	O
and	O
ammonium	O
ion	O
.	O

Aspartase	B
is	O
among	O
the	O
most	O
specific	O
enzymes	O
known	O
with	O
extensive	O
studies	O
failing	O
,	O
until	O
recently	O
,	O
to	O
identify	O
any	O
alternative	O
amino	O
acid	O
substrates	O
that	O
can	O
replace	O
L	O
-	O
aspartic	O
acid	O
.	O

Aspartases	B
from	O
different	O
organisms	O
show	O
high	O
sequence	O
homology	O
,	O
and	O
this	O
homology	O
extends	O
to	O
functionally	O
related	O
enzymes	O
such	O
as	O
the	O
class	O
II	O
fumarases	B
,	O
the	O
argininosuccinate	B
and	I
adenylosuccinate	I
lyases	I
.	O

The	O
high	O
-	O
resolution	O
structure	O
of	O
aspartase	B
reveals	O
a	O
monomer	O
that	O
is	O
composed	O
of	O
three	O
domains	O
oriented	O
in	O
an	O
elongated	O
S	O
-	O
shape	O
.	O

The	O
central	O
domain	O
,	O
comprised	O
of	O
five	O
-	O
helices	O
,	O
provides	O
the	O
subunit	O
contacts	O
in	O
the	O
functionally	O
active	O
tetramer	O
.	O

The	O
active	O
sites	O
are	O
located	O
in	O
clefts	O
between	O
the	O
subunits	O
and	O
structural	O
and	O
mutagenic	O
studies	O
have	O
identified	O
several	O
of	O
the	O
active	O
site	O
functional	O
groups	O
.	O

While	O
the	O
catalytic	O
activity	O
of	O
this	O
enzyme	O
has	O
been	O
known	O
for	O
nearly	O
100	O
years	O
,	O
a	O
number	O
of	O
recent	O
studies	O
have	O
revealed	O
some	O
interesting	O
and	O
unexpected	O
new	O
properties	O
of	O
this	O
reasonably	O
well	O
-	O
characterized	O
enzyme	O
.	O

The	O
non	O
-	O
linear	O
kinetics	O
that	O
are	O
seen	O
under	O
certain	O
conditions	O
have	O
been	O
shown	O
to	O
be	O
caused	O
by	O
the	O
presence	O
of	O
a	O
separate	O
regulatory	O
site	O
.	O

The	O
substrate	O
,	O
aspartic	O
acid	O
,	O
can	O
also	O
play	O
the	O
role	O
of	O
an	O
activator	O
,	O
binding	O
at	O
this	O
site	O
along	O
with	O
a	O
required	O
divalent	O
metal	O
ion	O
.	O

Truncation	O
of	O
the	O
carboxyl	O
terminus	O
of	O
aspartase	B
at	O
specific	O
positions	O
leads	O
to	O
an	O
enhancement	O
of	O
the	O
catalytic	O
activity	O
of	O
the	O
enzyme	O
.	O

Truncations	O
in	O
this	O
region	O
also	O
have	O
been	O
found	O
to	O
introduce	O
a	O
new	O
,	O
non	O
-	O
enzymatic	O
biological	O
activity	O
into	O
aspartase	B
,	O
the	O
ability	O
to	O
specifically	O
enhance	O
the	O
activation	O
of	O
plasminogen	B
to	O
plasmin	B
by	O
tissue	B
plasminogen	I
activator	I
.	O

Even	O
after	O
a	O
century	O
of	O
investigation	O
there	O
are	O
clearly	O
a	O
number	O
of	O
aspects	O
of	O
this	O
multifaceted	O
enzyme	O
that	O
remain	O
to	O
be	O
explored	O
.	O

The	O
major	B
head	I
protein	I
of	O
bacteriophage	O
T4	O
binds	O
specifically	O
to	O
elongation	B
factor	I
Tu	I
.	O

The	O
Lit	B
protease	B
in	O
Escherichia	O
coli	O
K-12	O
strains	O
induces	O
cell	O
death	O
in	O
response	O
to	O
bacteriophage	O
T4	O
infection	O
by	O
cleaving	O
translation	O
elongation	B
factor	I
(	I
EF	I
)	I
Tu	I
and	O
shutting	O
down	O
translation	O
.	O

Suicide	O
of	O
the	O
cell	O
is	O
timed	O
to	O
the	O
appearance	O
late	O
in	O
the	O
maturation	O
of	O
the	O
phage	O
of	O
a	O
short	O
peptide	O
sequence	O
in	O
the	O
major	B
head	I
protein	I
,	O
the	O
Gol	O
peptide	O
,	O
which	O
activates	O
proteolysis	O
.	O

In	O
the	O
present	O
work	O
we	O
demonstrate	O
that	O
the	O
Gol	O
peptide	O
binds	O
specifically	O
to	O
domains	O
II	O
and	O
III	O
of	O
EF	B
-	I
Tu	I
,	O
creating	O
the	O
unique	O
substrate	O
for	O
the	O
Lit	B
protease	B
,	O
which	O
then	O
cleaves	O
domain	O
I	O
,	O
the	O
guanine	O
nucleotide	O
binding	O
domain	O
.	O

The	O
conformation	O
of	O
EF	B
-	I
Tu	I
is	O
important	O
for	O
binding	O
and	O
Lit	B
cleavage	O
,	O
because	O
both	O
are	O
sensitive	O
to	O
the	O
identity	O
of	O
the	O
bound	O
nucleotide	O
,	O
with	O
GDP	O
being	O
preferred	O
over	O
GTP	O
.	O

We	O
propose	O
that	O
association	O
of	O
the	O
T4	O
coat	B
protein	I
with	O
EF	B
-	I
Tu	I
plays	O
a	O
role	O
in	O
phage	O
head	O
assembly	O
but	O
that	O
this	O
association	O
marks	O
infected	O
cells	O
for	O
suicide	O
when	O
Lit	B
is	O
present	O
.	O

Based	O
on	O
these	O
data	O
and	O
recent	O
observations	O
on	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
maturation	O
,	O
we	O
speculate	O
that	O
associations	O
between	O
host	O
translation	B
factors	I
and	O
coat	B
proteins	I
may	O
be	O
integral	O
to	O
viral	O
assembly	O
in	O
both	O
prokaryotes	O
and	O
eukaryotes	O
.	O

Molecular	O
cloning	O
and	O
expression	O
patterns	O
of	O
mouse	O
cartilage	B
oligomeric	I
matrix	I
protein	I
gene	O
.	O

OBJECTIVE	O
:	O

To	O
develop	O
transgenic	O
mice	O
harboring	O
mutations	O
in	O
the	O
COMP	B
gene	O
as	O
animal	O
models	O
for	O
pseudoachondroplasia	O
(	O
PSACH	O
)	O
and	O
multiple	O
epiphyseal	O
dysplasia	O
(	O
MED	O
)	O
,	O
autosomal	O
dominant	O
disorders	O
characterized	O
by	O
early	O
onset	O
osteoarthritis	O
and	O
epiphyseal	O
abnormalities	O
.	O

As	O
a	O
first	O
step	O
in	O
generating	O
a	O
mouse	O
model	O
for	O
COMP	B
mutations	O
,	O
we	O
have	O
cloned	O
the	O
cDNA	O
of	O
mouse	O
COMP	B
and	O
examined	O
its	O
tissue	O
expression	O
pattern	O
.	O

DESIGN	O
:	O

Total	O
mRNA	O
was	O
isolated	O
from	O
the	O
skeletal	O
tissues	O
of	O
newborn	O
C57BL	O
/	O
6j	O
mice	O
and	O
used	O
as	O
a	O
template	O
for	O
oligo	O
(	O
dT	O
)	O
first	O
-	O
strand	O
cDNA	O
synthesis	O
.	O

The	O
cDNA	O
was	O
used	O
for	O
PCR	O
amplification	O
of	O
COMP	B
using	O
three	O
oligonucleotide	O
primer	O
pairs	O
designed	O
from	O
the	O
published	O
rat	O
COMP	B
cDNA	O
sequence	O
.	O

Nested	O
PCR	O
was	O
used	O
to	O
complete	O
the	O
sequence	O
between	O
the	O
amplified	O
fragments	O
.	O

The	O
entire	O
cDNA	O
was	O
sequenced	O
and	O
the	O
expression	O
pattern	O
of	O
the	O
corresponding	O
transcripts	O
examined	O
by	O
Northern	O
hybridizations	O
.	O

RESULTS	O
:	O

A	O
full	O
-	O
length	O
COMP	B
cDNA	O
was	O
isolated	O
.	O

Analysis	O
showed	O
that	O
the	O
entire	O
translated	O
region	O
of	O
the	O
mouse	O
COMP	B
gene	O
is	O
2268	O
bp	O
and	O
the	O
derived	O
amino	O
acid	O
sequence	O
shows	O
90	O
%	O
homology	O
to	O
human	O
COMP	B
.	O

Of	O
eight	O
adult	O
mouse	O
non	O
-	O
cartilage	O
tissues	O
tested	O
,	O
COMP	B
expression	O
was	O
detected	O
only	O
in	O
testis	O
.	O

Cloning	O
of	O
two	O
human	O
thyroid	O
cDNAs	O
encoding	O
new	O
members	O
of	O
the	O
NADPH	B
oxidase	I
family	I
.	O

Two	O
cDNAs	O
encoding	O
NADPH	B
oxidases	I
and	O
constituting	O
the	O
thyroid	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
generating	O
system	O
have	O
been	O
cloned	O
.	O

The	O
strategy	O
of	O
cloning	O
was	O
based	O
on	O
the	O
functional	O
similarities	O
between	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
generation	O
in	O
leukocytes	O
and	O
the	O
thyroid	O
,	O
according	O
to	O
the	O
hypothesis	O
that	O
one	O
of	O
the	O
components	O
of	O
the	O
thyroid	O
system	O
would	O
belong	O
to	O
the	O
gp91	B
(	I
Phox	I
)	I
/	I
Mox1	I
gene	I
family	I
and	O
display	O
sequence	O
similarities	O
with	O
gp91	B
(	I
Phox	I
)	I
.	O

Screening	O
at	O
low	O
stringency	O
with	O
a	O
gp91	B
(	I
Phox	I
)	I
probe	O
of	O
cDNA	O
libraries	O
from	O
thyroid	O
cells	O
in	O
primary	O
culture	O
yielded	O
two	O
distinct	O
human	O
cDNA	O
clones	O
harboring	O
open	O
reading	O
frames	O
of	O
1551	O
(	O
ThOX1	B
)	O
and	O
1548	O
amino	O
acids	O
(	O
ThOX2	B
)	O
,	O
respectively	O
.	O

The	O
encoded	O
polypeptides	O
display	O
83	O
%	O
sequence	O
similarity	O
and	O
are	O
clearly	O
related	O
to	O
gp91	B
(	I
Phox	I
)	I
(	O
53	O
and	O
47	O
%	O
similarity	O
)	O
.	O

The	O
theoretical	O
molecular	O
mass	O
of	O
177	O
kDa	O
is	O
close	O
to	O
the	O
apparent	O
molecular	O
mass	O
of	O
180	O
kDa	O
of	O
the	O
native	O
corresponding	O
porcine	O
flavoprotein	O
and	O
the	O
protein	O
(	O
s	O
)	O
detected	O
by	O
Western	O
blot	O
in	O
dog	O
and	O
human	O
thyroid	O
.	O

ThOX1	B
and	O
ThOX2	B
display	O
sequence	O
similarities	O
of	O
53	O
%	O
and	O
61	O
%	O
,	O
respectively	O
,	O
with	O
a	O
predicted	O
protein	O
of	O
Caenorhabditis	O
elegans	O
over	O
their	O
entire	O
length	O
.	O

They	O
show	O
along	O
their	O
first	O
500	O
amino	O
acids	O
a	O
similarity	O
of	O
43	O
%	O
with	O
thyroperoxidase	B
.	O

The	O
corresponding	O
genes	O
of	O
ThOX1	B
and	O
ThOX2	B
are	O
closely	O
linked	O
on	O
chromosome	O
15q15.3	O
.	O

The	O
dog	O
mRNA	O
expression	O
is	O
thyroid	O
-	O
specific	O
and	O
up	O
-	O
regulated	O
by	O
agents	O
activating	O
the	O
cAMP	O
pathway	O
as	O
is	O
the	O
synthesis	O
of	O
the	O
polypeptides	O
they	O
are	O
coding	O
for	O
.	O

In	O
human	O
thyroid	O
the	O
positive	O
regulation	O
by	O
cAMP	O
is	O
less	O
pronounced	O
.	O

The	O
proteins	O
ThOX1	B
and	O
ThOX2	B
accumulate	O
at	O
the	O
apical	O
membrane	O
of	O
thyrocytes	O
and	O
are	O
co	O
-	O
localized	O
with	O
thyroperoxidase	B
.	O

GCN5	B
and	O
ADA	B
adaptor	I
proteins	I
regulate	O
triiodothyronine	O
/	O
GRIP1	B
and	O
SRC-1	B
coactivator	O
-	O
dependent	O
gene	O
activation	O
by	O
the	O
human	O
thyroid	B
hormone	I
receptor	I
.	O

We	O
have	O
used	O
yeast	O
genetics	O
and	O
in	O
vitro	O
protein	O
-	O
protein	O
interaction	O
experiments	O
to	O
explore	O
the	O
possibility	O
that	O
GCN5	B
(	O
general	B
control	I
nonrepressed	I
protein	I
5	I
)	O
and	O
several	O
other	O
ADA	B
(	I
alteration	I
/	I
deficiency	I
in	I
activation	I
)	I
adaptor	I
proteins	I
of	O
the	O
multimeric	O
SAGA	B
complex	I
can	O
regulate	O
T3	O
/	O
GRIP1	B
(	O
glucocorticoid	B
receptor	I
interacting	I
protein	I
1	I
)	O
and	O
SRC-1	B
(	O
steroid	B
receptor	I
coactivator-1	I
)	O
coactivator	O
-	O
dependent	O
activation	O
of	O
transcription	O
by	O
the	O
human	O
T3	B
receptor	I
beta1	I
(	O
hTRbeta1	B
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
in	O
vivo	O
activation	O
of	O
a	O
T3	O
/	O
GRIP1	B
or	O
SRC	B
-	I
1	I
coactivator	O
-	O
dependent	O
T3	O
hormone	O
response	O
element	O
by	O
hTRbeta1	B
is	O
dependent	O
upon	O
the	O
presence	O
of	O
yeast	O
GCN5	B
,	O
ADA2	B
,	O
ADA1	B
,	O
or	O
ADA3	B
adaptor	B
proteins	I
and	O
that	O
the	O
histone	B
acetyltransferase	I
(	O
HAT	B
)	O
domains	O
and	O
bromodomain	O
(	O
BrD	O
)	O
of	O
yGCN5	B
must	O
be	O
intact	O
for	O
maximal	O
activation	O
of	O
transcription	O
.	O

We	O
also	O
observed	O
that	O
hTRbeta1	B
can	O
bind	O
directly	O
to	O
yeast	O
or	O
human	O
GCN5	B
as	O
well	O
as	O
hADA2	B
,	O
and	O
that	O
the	O
hGCN5	B
(	O
387	O
-	O
837	O
)	O
sequence	O
could	O
bind	O
directly	O
to	O
either	O
GRIP1	B
or	O
SRC-1	B
coactivator	O
.	O

Importantly	O
,	O
the	O
T3	O
-	O
dependent	O
binding	O
of	O
hTRbeta1	B
to	O
hGCN5	B
(	O
387	O
-	O
837	O
)	O
could	O
be	O
markedly	O
increased	O
by	O
the	O
presence	O
of	O
GRIP1	B
or	O
SRC1	B
.	O

Mutagenesis	O
of	O
GRIP1	B
nuclear	B
receptor	I
(	O
NR	B
)	O
Box	O
II	O
and	O
III	O
LXXLL	O
motifs	O
also	O
substantially	O
decreased	O
both	O
in	O
vivo	O
activation	O
of	O
transcription	O
and	O
in	O
vitro	O
T3	O
-	O
dependent	O
binding	O
of	O
hTRbeta1	B
to	O
hGCN5	B
.	O

Taken	O
together	O
,	O
these	O
experiments	O
support	O
a	O
multistep	O
model	O
of	O
transcriptional	O
initiation	O
wherein	O
the	O
binding	O
of	O
T3	O
to	O
hTRbeta1	B
initiates	O
the	O
recruitment	O
of	O
p160	O
coactivators	O
and	O
GCN5	B
to	O
form	O
a	O
trimeric	O
transcriptional	O
complex	O
that	O
activates	O
target	O
genes	O
through	O
interactions	O
with	O
ADA	B
/	I
SAGA	I
adaptor	I
proteins	I
and	O
nucleosomal	O
histones	B
.	O

Apoptotic	B
protease	I
activating	I
factor	I
1	I
(	O
Apaf-1	B
)	O
-	O
independent	O
cell	O
death	O
suppression	O
by	O
Bcl-2	B
.	O

Reportedly	O
,	O
antiapoptotic	O
Bcl-2	B
family	I
proteins	O
suppress	O
apoptosis	O
by	O
binding	O
to	O
and	O
inhibiting	O
members	O
of	O
the	O
CED-4	B
family	I
of	O
caspase	B
activators	I
.	O

To	O
explore	O
this	O
question	O
,	O
we	O
used	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
in	O
which	O
one	O
(	O
-	O
/	O
+	O
)	O
or	O
both	O
(	O
-	O
/	O
-	O
)	O
copies	O
of	O
the	O
gene	O
encoding	O
apoptotic	B
protease	I
activating	I
factor	I
1	I
(	O
Apaf-1	B
)	O
,	O
a	O
CED-4	B
homologue	O
,	O
were	O
disrupted	O
by	O
homologous	O
recombination	O
.	O

Stable	O
clones	O
of	O
heterozygous	O
(	O
-	O
/	O
+	O
)	O
and	O
homozygous	O
(	O
-	O
/	O
-	O
)	O
Apaf-1	B
knockout	O
ES	O
cells	O
that	O
overexpressed	O
Bcl-2	B
were	O
generated	O
.	O

Withdrawal	O
of	O
serum	O
growth	B
factors	I
or	O
stimulation	O
of	O
heterozygous	O
ES	O
cells	O
with	O
staurosporine	O
(	O
STS	O
)	O
,	O
ultraviolet	O
(	O
UV	O
)	O
B	O
irradiation	O
,	O
etoposide	O
(	O
VP16	O
)	O
,	O
or	O
cisplatin	O
induced	O
apoptosis	O
followed	O
by	O
cell	O
death	O
(	O
determined	O
by	O
failure	O
to	O
exclude	O
propidium	O
iodide	O
dye	O
)	O
.	O

These	O
cell	O
death	O
stimuli	O
also	O
induced	O
activation	O
of	O
several	O
types	O
of	O
caspases	B
and	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
(	O
DeltaPsi	O
)	O
in	O
heterozygous	O
(	O
+	O
/-	O
)	O
Apaf-1	B
knockout	O
ES	O
cells	O
.	O

In	O
addition	O
,	O
overexpression	O
of	O
Bcl-2	B
protected	O
against	O
these	O
events	O
in	O
Apaf-1	B
-	O
expressing	O
ES	O
cells	O
.	O

In	O
contrast	O
,	O
STS	O
,	O
UVB	O
,	O
and	O
VP16	O
induced	O
little	O
or	O
no	O
caspase	B
activation	O
and	O
apoptosis	O
in	O
homozygous	O
(	O
-	O
/	O
-	O
)	O
Apaf-1	B
knockout	O
ES	O
cells	O
.	O

Nevertheless	O
,	O
Apaf-1	B
-	O
deficient	O
ES	O
cells	O
subjected	O
to	O
these	O
cell	O
death	O
stimuli	O
or	O
deprived	O
of	O
growth	B
factors	I
did	O
eventually	O
die	O
through	O
a	O
nonapoptotic	O
mechanism	O
associated	O
with	O
loss	O
of	O
DeltaPsi	O
.	O

Moreover	O
,	O
Bcl-2	B
overprotection	O
preserved	O
DeltaPsi	O
,	O
reduced	O
the	O
percentage	O
of	O
Apaf-1	B
(	O
-	O
/	O
)	O
-	O
ES	O
cells	O
undergoing	O
cell	O
death	O
,	O
and	O
increased	O
clonigenic	O
survival	O
.	O

The	O
extent	O
of	O
Bcl-2	B
-	O
mediated	O
cytoprotection	O
was	O
not	O
significantly	O
different	O
for	O
heterozygous	O
(	O
-	O
/	O
+	O
)	O
versus	O
homozygous	O
(	O
-	O
/	O
-	O
)	O
Apaf-1	B
knockout	O
cells	O
.	O

Furthermore	O
,	O
although	O
Bcl-2	B
could	O
be	O
readily	O
coimmunoprecipitated	O
with	O
Bax	B
,	O
associations	O
with	O
Apaf-1	B
were	O
undetectable	O
under	O
conditions	O
where	O
Apaf-1	B
interactions	O
with	O
procaspase	B
-	I
9	I
were	O
observed	O
.	O

We	O
conclude	O
that	O
Bcl-2	B
has	O
cytoprotective	O
functions	O
independent	O
of	O
Apaf-1	B
,	O
preserving	O
mitochondrial	O
function	O
through	O
a	O
caspase	B
-	O
independent	O
mechanism	O
.	O

Molecular	O
modeling	O
of	O
the	O
catalytic	O
domain	O
of	O
serine	B
/	I
threonine	I
phosphatase-1	I
with	O
the	O
Zn2	O
+	O
and	O
Mn2	O
+	O
di	O
-	O
nuclear	O
ion	O
centers	O
in	O
the	O
active	O
site	O
.	O

Catalytic	O
domains	O
of	O
the	O
metalloenzymes	O
protein	B
phosphatases	I
(	I
PPP	I
)	I
1	I
,	I
2A	I
and	I
2B	I
(	O
PP1	B
,	O
PP2A	B
and	O
PP2B	B
,	O
respectively	O
)	O
are	O
homologous	O
to	O
approximately	O
45	O
%	O
,	O
with	O
the	O
residues	O
in	O
the	O
enzymatic	O
centers	O
strictly	O
conserved	O
.	O

PP1	B
,	O
PP2A	B
and	O
PP2B	B
are	O
abundant	O
in	O
cells	O
and	O
they	O
dephosphorylate	O
serine	O
and/or	O
threonine	O
residues	O
in	O
a	O
variety	O
of	O
proteins	O
serving	O
as	O
cellular	O
phospho	O
switches	O
.	O

The	O
active	O
enzymes	O
work	O
as	O
invariant	O
catalytic	O
subunits	O
PP1c	B
,	O
PP2Ac	B
and	O
PP2Bc	B
,	O
respectively	O
,	O
complexed	O
with	O
diverse	O
regulatory	O
subunits	O
,	O
dependent	O
on	O
the	O
enzymes	O
'	O
specific	O
location	O
and	O
biological	O
function	O
.	O

The	O
crystal	O
structures	O
of	O
PP1c	B
and	O
PP2B	B
(	O
calcineurin	B
)	O
heterotetramer	O
calcineurinA	B
x	O
calcineurinB	B
x	O
FKBP	B
x	O
FK506	O
have	O
been	O
determined	O
.	O

A	O
comparison	O
of	O
the	O
catalytic	O
subunits	O
of	O
both	O
enzymes	O
indicates	O
their	O
significant	O
structural	O
homology	O
and	O
virtual	O
identity	O
within	O
the	O
catalytic	O
centers	O
,	O
each	O
including	O
a	O
set	O
of	O
conservative	O
amino	O
acids	O
,	O
two	O
metal	O
ions	O
and	O
a	O
phosphate	O
;	O
thus	O
confirming	O
a	O
hypothesis	O
on	O
their	O
common	O
enzymatic	O
mechanisms	O
.	O

The	O
elongated	O
substrate	O
cleft	O
at	O
the	O
active	O
centre	O
is	O
kinked	O
by	O
approximately	O
120	O
degrees	O
at	O
the	O
active	O
center	O
in	O
its	O
middle	O
and	O
thus	O
divided	O
into	O
a	O
pre	O
-	O
phospho	O
-	O
Ser	O
/	O
Thr	O
(	O
ligand	O
N	O
-	O
terminal	O
)	O
and	O
a	O
post	O
-	O
phospho	O
-	O
Ser	O
/	O
Thr	O
(	O
ligand	O
C	O
-	O
terminal	O
)	O
section	O
.	O

In	O
PP1c	B
the	O
N	O
-	O
terminal	O
section	O
is	O
highly	O
acidic	O
while	O
in	O
PP2Bc	B
is	O
not	O
.	O

This	O
feature	O
is	O
likely	O
pertinent	O
but	O
not	O
sufficient	O
to	O
the	O
enzymes	O
'	O
selectivity	O
,	O
which	O
is	O
also	O
controlled	O
by	O
regulatory	O
subunits	O
,	O
diverse	O
in	O
various	O
tissues	O
.	O

The	O
metalloenzymes	O
in	O
general	O
and	O
PPP	B
in	O
particular	O
are	O
hard	O
to	O
deal	O
with	O
using	O
theoretical	O
simulations	O
due	O
to	O
parameterization	O
problems	O
for	O
the	O
metal	O
cations	O
.	O

In	O
fact	O
,	O
there	O
are	O
only	O
a	O
few	O
PP1c	B
simulations	O
reported	O
,	O
with	O
the	O
metal	O
di	O
-	O
cations	O
treated	O
quite	O
crudely	O
.	O

This	O
is	O
a	O
preliminary	O
work	O
,	O
in	O
which	O
we	O
introduce	O
and	O
test	O
against	O
some	O
experimental	O
evidence	O
a	O
concept	O
of	O
pseudomolecules	O
of	O
proper	O
geometry	O
,	O
composed	O
of	O
double	O
metal	O
(	O
2Zn2	O
+	O
or	O
2Mn2	O
+	O
)	O
cation	O
,	O
and	O
the	O
OH	O
-	O
nuclephile	O
incorporated	O
into	O
the	O
PP1c	B
catalytic	O
site	O
.	O

Both	O
models	O
are	O
associated	O
with	O
either	O
the	O
phosphate	O
(	O
a	O
free	O
enzyme	O
)	O
or	O
the	O
phosphorylated	O
dodecapeptide	O
RRRRPpTPAMLFR	O
,	O
an	O
active	O
fragment	O
(	O
residues	O
29	O
-	O
40	O
)	O
of	O
a	O
regulatory	O
subunit	O
DARPP-32	B
inhibitor	O
(	O
PP1c	B
-	O
inhibitor	O
complex	O
)	O
;	O
four	O
models	O
total	O
.	O

We	O
have	O
parameterized	O
both	O
pseudomolecules	O
within	O
the	O
AMBER	O
force	O
field	O
.	O

Subsequently	O
,	O
using	O
molecular	O
dynamic	O
in	O
water	O
,	O
we	O
have	O
found	O
the	O
free	O
PP1c	B
subunits	O
to	O
be	O
less	O
stable	O
than	O
the	O
complexed	O
ones	O
and	O
we	O
have	O
speculated	O
on	O
possible	O
reasons	O
for	O
this	O
feature	O
.	O

Genetic	O
analysis	O
of	O
insulin	B
-	I
like	I
growth	I
factor	I
II	I
and	O
HLA	B
-	I
G	I
in	O
pre	O
-	O
eclampsia	O
.	O

Pre	O
-	O
eclampsia	O
(	O
PE	O
)	O
is	O
uniquely	O
a	O
disease	O
of	O
pregnancy	O
and	O
is	O
the	O
major	O
cause	O
of	O
foetal	O
and	O
maternal	O
morbidity	O
and	O
mortality	O
.	O

Epidemiological	O
studies	O
show	O
that	O
PE	O
is	O
highly	O
heritable	O
,	O
with	O
a	O
high	O
incidence	O
in	O
all	O
populations	O
.	O

The	O
underlying	O
pathology	O
indicates	O
that	O
absent	O
or	O
shallow	O
invasion	O
of	O
foetal	O
trophoblasts	O
into	O
maternal	O
arteries	O
is	O
a	O
feature	O
of	O
true	O
PE	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
genetic	O
factors	O
influencing	O
PE	O
.	O

A	O
large	O
number	O
of	O
mother	O
-	O
father	O
-	O
baby	O
trios	O
were	O
collected	O
in	O
which	O
the	O
first	O
pregnancy	O
was	O
complicated	O
by	O
severe	O
PE	O
.	O

After	O
careful	O
examination	O
of	O
the	O
epidemiology	O
and	O
pathology	O
of	O
the	O
disease	O
,	O
two	O
plausible	O
candidate	O
genes	O
,	O
namely	O
insulin	B
-	I
like	I
growth	I
factor	I
II	I
(	O
IGF	B
-	I
II	I
)	O
and	O
HLA	B
-	I
G	I
,	O
were	O
analysed	O
for	O
association	O
with	O
PE	O
.	O

No	O
association	O
was	O
found	O
between	O
a	O
commonly	O
occurring	O
polymorphism	O
in	O
IGF	B
-	I
II	I
and	O
PE	O
.	O

Three	O
polymorphisms	O
in	O
HLA	B
-	I
G	I
were	O
analysed	O
in	O
the	O
sample	O
cohorts	O
.	O

No	O
association	O
was	O
found	O
between	O
three	O
polymorphisms	O
in	O
HLA	B
-	I
G	I
and	O
PE	O
.	O

However	O
,	O
the	O
frequency	O
of	O
the	O
HLA	B
-	I
G	I
insertion	O
/	O
deletion	O
polymorphism	O
in	O
exon	O
8	O
deviated	O
significantly	O
from	O
Hardy	O
-	O
Weinberg	O
expectations	O
in	O
PE	O
off	O
-	O
spring	O
,	O
reflecting	O
an	O
excess	O
of	O
heterozygotes	O
for	O
these	O
polymorphisms	O
in	O
PE	O
offspring	O
.	O

The	O
significance	O
of	O
this	O
deviation	O
is	O
not	O
clear	O
and	O
further	O
genetic	O
analysis	O
will	O
be	O
necessary	O
to	O
confirm	O
this	O
finding	O
and	O
to	O
explore	O
further	O
the	O
candidacy	O
of	O
HLA	B
-	I
G	I
in	O
PE	O
.	O

Characterization	O
of	O
the	O
pcbE	B
gene	O
encoding	O
2-hydroxypenta-2,4-dienoate	B
hydratase	I
in	O
Pseudomonas	O
sp.	O
DJ-12	O
.	O

Nucleotide	O
sequence	O
extending	O
2,3-dihydroxybiphenyl	B
1,2-dioxygenase	I
gene	O
(	O
pcbC	B
)	O
and	O
2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate	B
hydrolase	I
gene	O
(	O
pcbD	B
)	O
of	O
Pseudomonas	O
sp.	O
DJ-12	O
was	O
previously	O
analyzed	O
and	O
the	O
two	O
genes	O
were	O
present	O
in	O
the	O
order	O
of	O
pcbD	B
-	O
pcbC	B
preceded	O
by	O
a	O
promoter	O
from	O
Pseudomonas	O
sp.	O
DJ-12	O
.	O

In	O
this	O
study	O
,	O
a	O
3.8	O
-	O
kb	O
nucleotide	O
sequence	O
located	O
downstream	O
of	O
the	O
pcbC	B
gene	O
was	O
analyzed	O
to	O
have	O
three	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
that	O
are	O
designated	O
as	O
orf1	O
,	O
pcbE	B
and	O
orf2	O
genes	O
.	O

All	O
of	O
the	O
ORFs	O
were	O
preceded	O
by	O
each	O
ribosome	O
-	O
binding	O
sequence	O
of	O
5-GGAXA-3	O
(	O
X	O
=	O
G	O
or	O
A	O
)	O
.	O

However	O
,	O
no	O
promoter	O
-	O
like	O
sequence	O
and	O
transcription	O
terminator	O
sequence	O
were	O
found	O
in	O
the	O
analyzed	O
region	O
,	O
downstream	O
of	O
pcbC	B
gene	O
.	O

Therefore	O
,	O
the	O
gene	O
cluster	O
appeared	O
to	O
be	O
present	O
in	O
the	O
order	O
of	O
pcbD	B
-	O
pcbC	B
-	O
orf1	O
-	O
pcbE	B
-	O
orf2	O
as	O
an	O
operon	O
,	O
which	O
is	O
unique	O
organization	O
characterized	O
so	O
far	O
in	O
biphenyl	O
-	O
and	O
PCB	O
-	O
degrading	O
bacteria	O
.	O

The	O
orf1	O
gene	O
was	O
composed	O
of	O
1	O
,	O
224	O
base	O
pairs	O
which	O
can	O
encode	O
a	O
polypeptide	O
of	O
molecular	O
weight	O
44	O
,	O
950	O
containing	O
405	O
amino	O
acid	O
residues	O
.	O

A	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
orf1	O
gene	O
product	O
exhibited	O
21	O
-	O
33	O
%	O
identity	O
with	O
those	O
of	O
indole	B
dioxygenase	I
and	O
phenol	B
hydroxylase	I
components	O
.	O

The	O
pcbE	B
gene	O
was	O
composed	O
of	O
783	O
base	O
pairs	O
encoding	O
2-hydroxypenta-2,4-dienoate	B
hydratase	I
involved	O
in	O
the	O
4-chlorobiphenyl	O
catabolism	O
.	O

The	O
orf2	O
gene	O
was	O
composed	O
of	O
1	O
,	O
017	O
base	O
pairs	O
encoding	O
a	O
polypeptide	O
of	O
molecular	O
weight	O
37	O
,	O
378	O
containing	O
338	O
amino	O
acid	O
residues	O
.	O

A	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
orf2	O
gene	O
product	O
exhibited	O
31	O
%	O
identity	O
with	O
that	O
of	O
a	O
nitrilotriacetate	B
monooxygenase	I
component	O
.	O

Roles	O
of	O
cyclic	B
AMP	I
receptor	I
protein	I
and	O
the	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
the	O
alpha	O
subunit	O
in	O
transcription	O
activation	O
of	O
the	O
Escherichia	O
coli	O
rhaBAD	B
operon	I
.	O

The	O
Escherichia	O
coli	O
rhaBAD	B
operon	I
encodes	O
the	O
enzymes	O
for	O
catabolism	O
of	O
the	O
sugar	O
L	O
-	O
rhamnose	O
.	O

Full	O
rhaBAD	B
activation	O
requires	O
the	O
AraC	B
family	I
activator	O
RhaS	B
(	O
bound	O
to	O
a	O
site	O
that	O
overlaps	O
the	O
-	O
35	O
region	O
of	O
the	O
promoter	O
)	O
and	O
the	O
cyclic	B
AMP	I
receptor	I
protein	I
(	O
CRP	B
;	O
bound	O
immediately	O
upstream	O
of	O
RhaS	B
at	O
-	O
92.5	O
)	O
.	O

We	O
tested	O
alanine	O
substitutions	O
in	O
activating	O
regions	O
(	O
AR	O
)	O
1	O
and	O
2	O
of	O
CRP	B
for	O
their	O
effect	O
on	O
rhaBAD	B
activation	O
.	O

Some	O
,	O
but	O
not	O
all	O
,	O
of	O
the	O
substitutions	O
in	O
both	O
AR1	O
and	O
AR2	O
resulted	O
in	O
approximately	O
twofold	O
defects	O
in	O
expression	O
from	O
rhaBAD	B
promoter	O
fusions	O
.	O

We	O
also	O
expressed	O
a	O
derivative	O
of	O
the	O
alpha	B
subunit	I
of	I
RNA	I
polymerase	I
deleted	O
for	O
the	O
entire	O
C	O
-	O
terminal	O
domain	O
(	O
alpha	O
-	O
Delta235	O
)	O
and	O
assayed	O
expression	O
from	O
rhaBAD	B
promoter	O
fusions	O
.	O

The	O
greatest	O
defect	O
(	O
54	O
-	O
fold	O
)	O
occurred	O
at	O
a	O
truncated	O
promoter	O
where	O
RhaS	B
was	O
the	O
only	O
activator	O
,	O
while	O
the	O
defect	O
at	O
the	O
full	O
-	O
length	O
promoter	O
(	O
RhaS	B
plus	O
CRP	B
)	O
was	O
smaller	O
(	O
13	O
-	O
fold	O
)	O
.	O

Analysis	O
of	O
a	O
plasmid	O
library	O
expressing	O
alanine	O
substitutions	O
at	O
every	O
residue	O
in	O
the	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
the	O
alpha	O
subunit	O
(	O
alpha	O
-	O
CTD	O
)	O
identified	O
15	O
residues	O
(	O
mostly	O
in	O
the	O
DNA	O
-	O
binding	O
determinant	O
)	O
that	O
were	O
important	O
at	O
both	O
the	O
full	O
-	O
length	O
and	O
truncated	O
promoters	O
.	O

Only	O
one	O
substitution	O
was	O
defective	O
at	O
the	O
full	O
-	O
length	O
but	O
not	O
the	O
truncated	O
promoter	O
,	O
and	O
this	O
residue	O
was	O
located	O
in	O
the	O
DNA	O
-	O
binding	O
determinant	O
.	O

Six	O
substitutions	O
were	O
defective	O
only	O
at	O
the	O
promoter	O
activated	O
by	O
RhaS	B
alone	O
,	O
and	O
these	O
may	O
define	O
a	O
protein	O
-	O
contacting	O
determinant	O
on	O
alpha	O
-	O
CTD	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
CRP	B
interaction	O
with	O
alpha	O
-	O
CTD	O
may	O
not	O
be	O
required	O
for	O
rhaBAD	B
activation	O
;	O
however	O
,	O
alpha	O
-	O
CTD	O
does	O
contribute	O
to	O
full	O
activation	O
,	O
probably	O
through	O
interactions	O
with	O
DNA	O
and	O
possibly	O
RhaS	B
.	O

Norwalk	O
virus	O
open	O
reading	O
frame	O
3	O
encodes	O
a	O
minor	O
structural	B
protein	I
.	O

Norwalk	O
virus	O
(	O
NV	O
)	O
is	O
a	O
causative	O
agent	O
of	O
acute	O
epidemic	O
nonbacterial	O
gastroenteritis	O
in	O
humans	O
.	O

The	O
inability	O
to	O
cultivate	O
NV	O
has	O
required	O
the	O
use	O
of	O
molecular	O
techniques	O
to	O
examine	O
the	O
genome	O
organization	O
and	O
functions	O
of	O
the	O
viral	O
proteins	O
.	O

The	O
function	O
of	O
the	O
NV	O
protein	O
encoded	O
by	O
open	O
reading	O
frame	O
3	O
(	O
ORF	O
3	O
)	O
has	O
been	O
unknown	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
characterization	O
of	O
the	O
NV	O
ORF	O
3	O
protein	O
expressed	O
in	O
a	O
cell	O
-	O
free	O
translation	O
system	O
and	O
in	O
insect	O
cells	O
and	O
show	O
its	O
association	O
with	O
recombinant	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
and	O
NV	O
virions	O
.	O

Expression	O
of	O
the	O
ORF	O
3	O
coding	O
region	O
in	O
rabbit	O
reticulocyte	O
lysates	O
resulted	O
in	O
the	O
production	O
of	O
a	O
single	O
protein	O
with	O
an	O
apparent	O
molecular	O
weight	O
of	O
23,000	O
(	O
23	O
K	O
protein	O
)	O
,	O
which	O
is	O
not	O
modified	O
by	O
N	O
-	O
linked	O
glycosylation	O
.	O

The	O
ORF	O
3	O
protein	O
was	O
expressed	O
in	O
insect	O
cells	O
by	O
using	O
two	O
different	O
baculovirus	O
recombinants	O
;	O
one	O
recombinant	O
contained	O
the	O
entire	O
3	O
'	O
end	O
of	O
the	O
genome	O
beginning	O
with	O
the	O
ORF	O
2	O
coding	O
sequences	O
(	O
ORFs	O
2	O
+	O
3	O
)	O
,	O
and	O
the	O
second	O
recombinant	O
contained	O
ORF	O
3	O
alone	O
.	O

Expression	O
from	O
the	O
construct	O
containing	O
both	O
ORF	O
2	O
and	O
ORF	O
3	O
resulted	O
in	O
the	O
expression	O
of	O
a	O
single	O
protein	O
(	O
23	O
K	O
protein	O
)	O
detected	O
by	O
Western	O
blot	O
analysis	O
with	O
ORF	O
3	O
-	O
specific	O
peptide	O
antisera	O
.	O

However	O
,	O
expression	O
from	O
a	O
construct	O
containing	O
only	O
the	O
ORF	O
3	O
coding	O
sequences	O
resulted	O
in	O
the	O
production	O
of	O
multiple	O
forms	O
of	O
the	O
ORF	O
3	O
protein	O
ranging	O
in	O
size	O
from	O
23,000	O
to	O
35,000	O
.	O

Indirect	O
-	O
immunofluorescence	O
studies	O
using	O
an	O
ORF	O
3	O
peptide	O
antiserum	O
showed	O
that	O
the	O
ORF	O
3	O
protein	O
is	O
localized	O
to	O
the	O
cytoplasm	O
of	O
infected	O
insect	O
cells	O
.	O

The	O
23	O
K	O
ORF	O
3	O
protein	O
was	O
consistently	O
associated	O
with	O
recombinant	O
VLPs	O
purified	O
from	O
the	O
media	O
of	O
insect	O
cells	O
infected	O
with	O
a	O
baculovirus	O
recombinant	O
containing	O
the	O
entire	O
3	O
'	O
end	O
of	O
the	O
NV	O
genome	O
.	O

Western	O
blot	O
analysis	O
of	O
NV	O
purified	O
from	O
the	O
stools	O
of	O
NV	O
-	O
infected	O
volunteers	O
revealed	O
the	O
presence	O
of	O
a	O
35	O
K	O
protein	O
as	O
well	O
as	O
multiple	O
higher	O
-	O
molecular	O
-	O
weight	O
bands	O
specifically	O
recognized	O
by	O
an	O
ORF	O
3	O
peptide	O
antiserum	O
.	O

These	O
results	O
indicate	O
that	O
the	O
ORF	O
3	O
protein	O
is	O
a	O
minor	O
structural	O
protein	O
of	O
the	O
virion	O
.	O

Dietary	O
cholic	O
acid	O
lowers	O
plasma	O
levels	O
of	O
mouse	O
and	O
human	O
apolipoprotein	B
A	I
-	I
I	I
primarily	O
via	O
a	O
transcriptional	O
mechanism	O
.	O

To	O
induce	O
dietary	O
atherosclerosis	O
in	O
mice	O
,	O
high	O
-	O
fat	O
/	O
high	O
-	O
cholesterol	O
(	O
HF	O
)	O
diets	O
are	O
frequently	O
supplemented	O
with	O
cholic	O
acid	O
(	O
CA	O
)	O
.	O

This	O
diet	O
produces	O
low	O
plasma	O
levels	O
of	O
high	B
-	I
density	I
lipoprotein	I
(	O
HDL	B
)	O
and	O
high	O
levels	O
of	O
low	B
-	I
density	I
lipoprotein	I
(	O
LDL	B
)	O
.	O

However	O
,	O
HF	O
diets	O
without	O
any	O
added	O
CA	O
,	O
which	O
more	O
closely	O
resemble	O
human	O
diets	O
,	O
increase	O
levels	O
of	O
both	O
HDL	B
and	O
LDL	B
,	O
suggesting	O
that	O
CA	O
may	O
be	O
responsible	O
for	O
the	O
lowering	O
of	O
HDL	B
.	O

Our	O
aim	O
was	O
to	O
examine	O
the	O
potential	O
mechanism	O
responsible	O
for	O
the	O
lowering	O
of	O
HDL	B
.	O

Nontransgenic	O
(	O
NTg	O
)	O
C57BL	O
mice	O
and	O
apoA	B
-	I
I	I
-	O
transgenic	O
(	O
apoAI	B
-	O
Tg	O
)	O
mice	O
,	O
with	O
greatly	O
increased	O
basal	O
apoA	B
-	I
I	I
and	O
HDL	B
levels	O
,	O
were	O
used	O
.	O

Mice	O
were	O
fed	O
the	O
following	O
four	O
diets	O
:	O
control	O
(	O
C	O
)	O
,	O
high	O
-	O
fat	O
/	O
high	O
-	O
cholesterol	O
(	O
HF	O
)	O
,	O
control	O
and	O
1	O
%	O
cholate	O
(	O
CA	O
)	O
and	O
HF	O
+	O
CA	O
.	O

Dietary	O
CA	O
reduced	O
plasma	O
HDL	B
levels	O
by	O
35	O
%	O
in	O
NTg	O
and	O
250	O
%	O
in	O
apoAI	B
-	O
Tg	O
mice	O
,	O
independent	O
of	O
the	O
fat	O
or	O
cholesterol	O
content	O
of	O
the	O
diet	O
.	O

Hepatic	O
apoA	B
-	I
I	I
mRNA	O
decreased	O
30	O
%	O
in	O
NTg	O
and	O
180	O
%	O
in	O
apoAI	B
-	O
Tg	O
mice	O
.	O

Hepatic	O
apoA	B
-	I
I	I
synthesis	O
and	O
apoA	B
-	I
I	I
mRNA	O
transcription	O
rates	O
also	O
decreased	O
in	O
parallel	O
with	O
apoA	B
-	I
I	I
mRNA	O
levels	O
,	O
suggesting	O
that	O
the	O
CA	O
-	O
induced	O
decreases	O
in	O
plasma	O
apoA	B
-	I
I	I
levels	O
occurred	O
primarily	O
via	O
decreasing	O
apoA	B
-	I
I	I
mRNA	O
transcription	O
rates	O
.	O

An	O
HF	O
diet	O
increased	O
HDL	B
levels	O
1.8	O
-	O
fold	O
in	O
NTg	O
and	O
1.5	O
-	O
fold	O
in	O
apoAI	B
-	O
Tg	O
mice	O
.	O

Addition	O
of	O
CA	O
to	O
the	O
HF	O
diet	O
lowered	O
HDL	B
levels	O
by	O
1.6	O
-	O
fold	O
in	O
NTg	O
and	O
2	O
.	O
5	O
-	O
fold	O
in	O
apoAI	B
-	O
Tg	O
mice	O
.	O

Transfection	O
studies	O
with	O
the	O
apoA	B
-	I
I	I
promoter	O
suggested	O
the	O
presence	O
of	O
a	O
putative	O
cis	O
-	O
acting	O
element	O
responsible	O
for	O
the	O
CA	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
the	O
apoA	B
-	I
I	I
promoter	O
activity	O
.	O

Measurements	O
of	O
apoA	B
-	I
I	I
regulatory	I
protein-1	I
(	O
ARP-1	B
)	O
mRNA	O
,	O
a	O
negative	O
regulator	O
of	O
the	O
apoA	B
-	I
I	I
gene	O
in	O
the	O
mouse	O
liver	O
showed	O
that	O
CA	O
increased	O
the	O
ARP-1	B
mRNA	O
levels	O
.	O

Because	O
apoA	B
-	I
I	I
gene	O
transcription	O
alone	O
was	O
not	O
sufficient	O
to	O
account	O
for	O
the	O
lowering	O
of	O
plasma	O
HDL	B
levels	O
,	O
scavenger	B
receptor	I
-	I
B1	I
(	O
SR	B
-	I
B1	I
)	O
and	O
hepatic	B
lipase	I
(	O
HL	B
)	O
mRNAs	O
levels	O
were	O
quantitated	O
.	O

The	O
levels	O
of	O
SR	B
-	I
B1	I
and	O
HL	B
mRNA	O
were	O
not	O
changed	O
by	O
dietary	O
CA	O
.	O

These	O
studies	O
suggest	O
that	O
dietary	O
cholate	O
regulates	O
plasma	O
levels	O
of	O
apoA	B
-	I
I	I
primarily	O
by	O
a	O
transcriptional	O
mechanism	O
via	O
a	O
putative	O
bile	O
acid	O
response	O
element	O
involving	O
a	O
negative	O
regulator	O
of	O
apoA	B
-	I
I	I
,	O
and	O
partly	O
by	O
an	O
unidentified	O
post	O
-	O
transcriptional	O
mechanism	O
.	O

The	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
alpha	I
(	O
PPARalpha	B
)	O
regulates	O
bile	O
acid	O
biosynthesis	O
.	O

Fibrates	O
are	O
a	O
group	O
of	O
hypolipidemic	O
agents	O
that	O
efficiently	O
lower	O
serum	O
triglyceride	O
levels	O
by	O
affecting	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
lipid	O
metabolism	O
.	O

These	O
effects	O
are	O
exerted	O
via	O
the	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
alpha	I
(	O
PPARalpha	B
)	O
.	O

In	O
addition	O
,	O
fibrates	O
also	O
lower	O
serum	O
cholesterol	O
levels	O
,	O
suggesting	O
a	O
possible	O
link	O
between	O
the	O
PPARalpha	B
and	O
cholesterol	O
metabolism	O
.	O

Bile	O
acid	O
formation	O
represents	O
an	O
important	O
pathway	O
for	O
elimination	O
of	O
cholesterol	O
,	O
and	O
the	O
sterol	B
12alpha	I
-	I
hydroxylase	I
is	O
a	O
branch	O
-	O
point	O
enzyme	O
in	O
the	O
bile	O
acid	O
biosynthetic	O
pathway	O
,	O
which	O
determines	O
the	O
ratio	O
of	O
cholic	O
acid	O
to	O
chenodeoxycholic	O
acid	O
.	O

Treatment	O
of	O
mice	O
for	O
1	O
week	O
with	O
the	O
peroxisome	O
proliferator	O
WY-14,643	O
or	O
fasting	O
for	O
24	O
h	O
both	O
induced	O
the	O
sterol	O
12alpha	B
-	I
hydroxylase	I
mRNA	O
in	O
liver	O
.	O

Using	O
the	O
PPARalpha	B
knockout	O
mouse	O
model	O
,	O
we	O
show	O
that	O
the	O
induction	O
by	O
both	O
treatments	O
was	O
dependent	O
on	O
the	O
PPARalpha	B
.	O

A	O
reporter	O
plasmid	O
containing	O
a	O
putative	O
peroxisome	O
proliferator	O
-	O
response	O
element	O
(	O
PPRE	O
)	O
identified	O
in	O
the	O
rat	O
sterol	O
12alpha	B
-	I
hydroxylase	I
promoter	O
region	O
was	O
activated	O
by	O
treatment	O
with	O
WY-14,643	O
in	O
HepG2	O
cells	O
,	O
being	O
dependent	O
on	O
co	O
-	O
transfection	O
with	O
a	O
PPARalpha	B
expression	O
plasmid	O
.	O

The	O
rat	O
12alpha	B
-	I
hydroxylase	I
PPRE	O
bound	O
in	O
vitro	O
translated	O
PPARalpha	B
and	O
retinoid	B
X	I
receptor	I
alpha	I
,	O
albeit	O
weakly	O
,	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Treatment	O
of	O
wild	O
-	O
type	O
mice	O
with	O
WY-14,643	O
for	O
1	O
week	O
resulted	O
in	O
an	O
increased	O
relative	O
amount	O
of	O
cholic	O
acid	O
,	O
an	O
effect	O
that	O
was	O
abolished	O
in	O
the	O
PPARalpha	B
null	O
mice	O
,	O
verifying	O
the	O
functionality	O
of	O
the	O
PPRE	O
in	O
vivo	O
.	O

Nuclear	O
and	O
chloroplast	O
poly	B
(	I
A	I
)	I
polymerases	I
from	O
plants	O
share	O
a	O
novel	O
biochemical	O
property	O
.	O

Poly	B
(	I
A	I
)	I
polymerases	I
are	O
centrally	O
involved	O
in	O
the	O
process	O
of	O
mRNA	O
3	O
'	O
end	O
formation	O
in	O
eukaryotes	O
.	O

In	O
animals	O
and	O
yeast	O
,	O
this	O
enzyme	O
works	O
as	O
part	O
of	O
a	O
large	O
multimeric	O
complex	O
to	O
add	O
polyadenylate	O
tracts	O
to	O
the	O
3	O
'	O
ends	O
of	O
precursor	O
RNAs	O
in	O
the	O
nucleus	O
.	O

Plant	O
nuclear	O
enzymes	O
remain	O
largely	O
uncharacterized	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
an	O
initial	O
analysis	O
of	O
plant	O
nuclear	O
poly	B
(	I
A	I
)	I
polymerases	I
(	O
nPAPs	B
)	O
.	O

An	O
enzyme	O
purified	O
from	O
pea	O
nuclear	O
extracts	O
possesses	O
many	O
features	O
that	O
are	O
seen	O
with	O
the	O
enzymes	O
from	O
yeast	O
and	O
mammals	O
.	O

However	O
,	O
the	O
pea	O
enzyme	O
possesses	O
the	O
ability	O
to	O
polyadenylate	O
RNAs	O
that	O
are	O
associated	O
with	O
polynucleotide	B
phosphorylase	I
(	O
PNP	B
)	O
,	O
a	O
chloroplast	O
-	O
localized	O
enzyme	O
involved	O
in	O
RNA	O
turnover	O
.	O

Similar	O
behavior	O
is	O
not	O
seen	O
with	O
the	O
yeast	O
poly	B
(	I
A	I
)	I
polymerase	I
(	O
PAP	B
)	O
.	O

A	O
fusion	O
protein	O
consisting	O
of	O
glutathione	B
-	I
S	I
-	I
transferase	I
and	O
the	O
active	O
domain	O
of	O
an	O
Arabidopsis	O
-	O
encoded	O
nuclear	O
poly	B
(	I
A	I
)	I
polymerase	I
was	O
also	O
able	O
to	O
utilize	O
PNP	B
,	O
indicating	O
that	O
the	O
activity	O
of	O
the	O
pea	O
enzyme	O
was	O
due	O
to	O
an	O
interaction	O
between	O
the	O
pea	O
nPAP	B
and	O
PNP	B
,	O
and	O
not	O
to	O
other	O
factors	O
that	O
might	O
copurify	O
with	O
the	O
pea	O
enzyme	O
.	O

These	O
results	O
suggest	O
the	O
existence	O
,	O
in	O
plant	O
nuclei	O
,	O
of	O
factors	O
related	O
to	O
PNP	B
,	O
and	O
an	O
interaction	O
between	O
such	O
factors	O
and	O
poly	B
(	I
A	I
)	I
polymerases	I
.	O

Deficient	O
mineralization	O
of	O
intramembranous	O
bone	O
in	O
vitamin	B
D-24-hydroxylase	I
-	O
ablated	O
mice	O
is	O
due	O
to	O
elevated	O
1,25-dihydroxyvitamin	O
D	O
and	O
not	O
to	O
the	O
absence	O
of	O
24,25-dihydroxyvitamin	O
D	O
.	O

The	O
25-hydroxyvitamin	B
D-24-hydroxylase	I
enzyme	O
(	O
24-OHase	B
)	O
is	O
responsible	O
for	O
the	O
catabolic	O
breakdown	O
of	O
1,25-dihydroxyvitamin	O
D	O
[	O
1,25	O
(	O
OH	O
)	O
2D	O
]	O
,	O
the	O
active	O
form	O
of	O
vitamin	O
D	O
.	O

The	O
24	B
-	I
OHase	I
enzyme	O
can	O
also	O
act	O
on	O
the	O
25-hydroxyvitamin	O
D	O
substrate	O
to	O
generate	O
24,25-dihydroxyvitamin	O
D	O
,	O
a	O
metabolite	O
whose	O
physiological	O
importance	O
remains	O
unclear	O
.	O

We	O
report	O
that	O
mice	O
with	O
a	O
targeted	O
inactivating	O
mutation	O
of	O
the	O
24-OHase	B
gene	O
had	O
impaired	O
1,25	O
(	O
OH	O
)	O
2D	O
catabolism	O
.	O

Surprisingly	O
,	O
complete	O
absence	O
of	O
24	B
-	I
OHase	I
activity	O
during	O
development	O
leads	O
to	O
impaired	O
intramembranous	O
bone	O
mineralization	O
.	O

This	O
phenotype	O
was	O
rescued	O
by	O
crossing	O
the	O
24-OHase	B
mutant	O
mice	O
to	O
mice	O
harboring	O
a	O
targeted	O
mutation	O
in	O
the	O
vitamin	B
D	I
receptor	I
gene	O
,	O
confirming	O
that	O
the	O
elevated	O
1,25	O
(	O
OH	O
)	O
2D	O
levels	O
,	O
acting	O
through	O
the	O
vitamin	B
D	I
receptor	I
,	O
were	O
responsible	O
for	O
the	O
observed	O
accumulation	O
of	O
osteoid	O
.	O

Our	O
results	O
confirm	O
the	O
physiological	O
importance	O
of	O
the	O
24	B
-	I
OHase	I
enzyme	O
for	O
maintaining	O
vitamin	O
D	O
homeostasis	O
,	O
and	O
they	O
reveal	O
that	O
24,25-dihydroxyvitamin	O
D	O
is	O
a	O
dispensable	O
metabolite	O
during	O
bone	O
development	O
.	O

Crystal	O
structure	O
of	O
the	O
BMP-2	B
-	O
BRIA	B
ectodomain	O
complex	O
.	O

Bone	B
morphogenetic	I
proteins	I
(	O
BMPs	B
)	O
belong	O
to	O
the	O
large	O
transforming	B
growth	I
factor	I
-	I
beta	I
(	I
TGF	I
-	I
beta	I
)	I
superfamily	I
of	O
multifunctional	O
cytokines	B
.	O

BMP-2	B
can	O
induce	O
ectopic	O
bone	O
and	O
cartilage	O
formation	O
in	O
adult	O
vertebrates	O
and	O
is	O
involved	O
in	O
central	O
steps	O
in	O
early	O
embryonal	O
development	O
in	O
animals	O
.	O

Signaling	O
by	O
these	O
cytokines	B
requires	O
binding	O
of	O
two	O
types	O
of	O
transmembrane	O
serine	B
/	I
threonine	I
receptor	I
kinase	I
chains	O
classified	O
as	O
type	O
I	O
and	O
type	O
II	O
.	O

Here	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
human	O
dimeric	O
BMP-2	B
in	O
complex	O
with	O
two	O
high	O
affinity	O
BMP	B
receptor	I
IA	I
extracellular	O
domains	O
(	O
BRIAec	B
)	O
.	O

The	O
receptor	O
chains	O
bind	O
to	O
the	O
'	O
wrist	O
'	O
epitopes	O
of	O
the	O
BMP-2	B
dimer	O
and	O
contact	O
both	O
BMP-2	B
monomers	O
.	O

No	O
contacts	O
exist	O
between	O
the	O
receptor	O
domains	O
.	O

The	O
model	O
reveals	O
the	O
structural	O
basis	O
for	O
discrimination	O
between	O
type	O
I	O
and	O
type	O
II	O
receptors	O
and	O
the	O
variability	O
of	O
receptor	O
-	O
ligand	O
interactions	O
that	O
is	O
seen	O
in	O
BMP	B
-	O
TGF	B
-	I
beta	I
systems	O
.	O

Modulation	O
of	O
TFIIH	B
-	I
associated	I
kinase	I
activity	O
by	O
complex	O
formation	O
and	O
its	O
relationship	O
with	O
CTD	O
phosphorylation	O
of	O
RNA	B
polymerase	I
II	I
.	O

BACKGROUND	O
:	O

The	O
general	O
transcription	B
factor	I
TFIIH	B
plays	O
important	O
roles	O
in	O
initiation	O
and	O
the	O
transition	O
to	O
elongation	O
steps	O
of	O
transcription	O
by	O
RNA	B
polymerase	I
II	I
(	O
PolII	B
)	O
.	O

Both	O
roles	O
are	O
dependent	O
on	O
the	O
protein	B
kinase	I
,	O
DNA	O
-	O
dependent	O
ATPase	B
and	O
DNA	B
helicase	I
activities	O
of	O
TFIIH	B
.	O

However	O
,	O
how	O
these	O
enzyme	O
activities	O
of	O
TFIIH	B
contribute	O
to	O
transcription	O
has	O
remained	O
elusive	O
.	O

TFIIH	B
consists	O
of	O
nine	O
subunits	O
,	O
and	O
one	O
of	O
them	O
,	O
Cdk7	B
,	O
possesses	O
kinase	B
activity	O
.	O

Here	O
the	O
substrate	O
specificities	O
of	O
TFIIH	B
and	O
two	O
forms	O
of	O
the	O
Cdk7	B
-	O
containing	O
kinase	B
complex	O
are	O
compared	O
,	O
and	O
the	O
relationship	O
between	O
transcription	O
activity	O
and	O
the	O
TFIIH	B
-	O
dependent	O
phosphorylation	O
of	O
the	O
carboxy	O
terminal	O
domain	O
of	O
the	O
largest	O
subunit	O
of	O
PolII	B
(	O
CTD	O
)	O
is	O
studied	O
.	O

RESULTS	O
:	O

We	O
prepared	O
TFIIH	B
and	O
two	O
Cdk7	B
-	O
containing	O
kinase	B
complexes	O
,	O
Cdk7	B
/	O
Cyclin	B
H	I
and	O
CAK	B
(	O
Cdk7	B
/	O
Cyclin	B
H	I
/	O
MAT1	B
)	O
.	O

Consistent	O
with	O
previous	O
reports	O
,	O
CAK	B
strongly	O
phosphorylated	O
Cdk2	B
,	O
Cdk4	B
,	O
CTD	O
and	O
intact	O
PolII	B
.	O

In	O
contrast	O
,	O
Cdk7	B
/	O
Cyclin	B
H	I
,	O
which	O
lacks	O
MAT1	B
,	O
did	O
not	O
phosphorylate	O
these	O
substrates	O
,	O
except	O
for	O
weak	O
phosphorylation	O
of	O
Cdk2	B
.	O

The	O
kinase	B
activity	O
of	O
TFIIH	B
displayed	O
stronger	O
substrate	O
preference	O
for	O
Cdk4	B
than	O
did	O
CAK	B
.	O

In	O
addition	O
,	O
TFIIH	B
phosphorylation	O
of	O
PolII	B
was	O
stimulated	O
by	O
TFIIE	B
both	O
in	O
solution	O
and	O
during	O
preinitiation	O
complex	O
formation	O
,	O
whereas	O
Cdk7	B
/	O
Cyclin	B
H	I
and	O
CAK	B
phosphorylation	O
of	O
PolII	B
was	O
not	O
.	O

In	O
combination	O
with	O
other	O
general	O
transcription	B
factors	I
,	O
TFIIH	B
,	O
but	O
not	O
Cdk7	B
/	O
CycH	B
or	O
CAK	B
,	O
promoted	O
transcription	O
on	O
a	O
linear	O
DNA	O
template	O
.	O

This	O
transcription	O
was	O
well	O
correlated	O
with	O
TFIIE	B
stimulated	O
TFIIH	B
phosphorylation	O
of	O
serine	O
at	O
position	O
5	O
(	O
Ser-5	O
)	O
within	O
the	O
heptapeptide	O
repeat	O
of	O
the	O
PolII	B
CTD	O
.	O

CONCLUSION	O
:	O

These	O
results	O
provide	O
clues	O
about	O
the	O
roles	O
of	O
CTD	O
phosphorylation	O
at	O
Ser-5	O
in	O
transcription	O
.	O

Early	O
inflammatory	O
response	O
after	O
elective	O
abdominal	O
aortic	O
aneurysm	O
repair	O
:	O
a	O
comparison	O
between	O
endovascular	O
procedure	O
and	O
conventional	O
surgery	O
.	O

OBJECTIVE	O
:	O

To	O
determine	O
the	O
nature	O
of	O
and	O
to	O
compare	O
the	O
inflammatory	O
responses	O
induced	O
by	O
(	O
1	O
)	O
endovascular	O
and	O
(	O
2	O
)	O
conventional	O
abdominal	O
aortic	O
aneurysm	O
(	O
AAA	O
)	O
repair	O
.	O
Material	O
and	O
Methods	O
:	O
Twelve	O
consecutive	O
patients	O
undergoing	O
elective	O
infrarenal	O
AAA	O
repair	O
were	O
prospectively	O
studied	O
.	O

Seven	O
patients	O
were	O
selected	O
for	O
endovascular	O
procedures	O
(	O
the	O
EAAA	O
group	O
)	O
;	O
five	O
patients	O
underwent	O
open	O
surgery	O
(	O
the	O
OAAA	O
group	O
)	O
.	O

Three	O
control	O
patients	O
undergoing	O
carotid	O
thromboendarterectomy	O
were	O
also	O
included	O
.	O

Serial	O
peripheral	O
venous	O
blood	O
samples	O
were	O
collected	O
preoperatively	O
,	O
immediately	O
after	O
declamping	O
or	O
placement	O
of	O
the	O
endograft	O
,	O
and	O
at	O
hours	O
1	O
,	O
3	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
48	O
,	O
and	O
72	O
.	O

Acute	O
phase	O
response	O
expression	O
of	O
peripheral	O
T	O
lymphocyte	O
and	O
monocyte	O
activation	O
markers	O
and	O
adhesion	B
molecules	I
(	O
flow	O
cytometry	O
)	O
,	O
soluble	O
levels	O
of	O
cell	B
adhesion	I
molecules	I
(	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
)	O
,	O
cytokine	B
(	O
tumor	B
necrosis	I
factor	I
alpha	I
,	O
interleukin-6	B
,	O
and	O
interleukin-8	B
)	O
release	O
(	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
)	O
,	O
and	O
liberation	O
of	O
complement	O
products	O
(	O
nephelometry	O
)	O
were	O
measured	O
.	O

RESULTS	O
:	O

Regarding	O
acute	O
phase	O
response	O
,	O
the	O
EAAA	O
and	O
OAAA	O
groups	O
showed	O
significant	O
increases	O
in	O
C	B
-	I
reactive	I
protein	I
(	O
P	O
<	O
.001	O
and	O
P	O
=	O
.001	O
)	O
,	O
body	O
temperature	O
(	O
P	O
=	O
.035	O
and	O
P	O
=	O
.048	O
)	O
,	O
and	O
leukocyte	O
count	O
(	O
P	O
<	O
.001	O
and	O
P	O
<	O
.001	O
)	O
.	O

Similar	O
time	O
course	O
patterns	O
were	O
observed	O
with	O
respect	O
to	O
body	O
temperature	O
(	O
P	O
=	O
.372	O
)	O
.	O

Statistically	O
significant	O
different	O
patterns	O
were	O
demonstrated	O
for	O
C	B
-	I
reactive	I
protein	I
(	O
P	O
=	O
.032	O
)	O
and	O
leukocyte	O
count	O
(	O
P	O
=	O
.002	O
)	O
.	O

Regarding	O
leukocyte	O
activation	O
,	O
a	O
significant	O
upregulation	O
of	O
peripheral	O
T	O
lymphocyte	O
CD38	B
expression	O
was	O
observed	O
in	O
the	O
OAAA	O
group	O
only	O
(	O
P	O
=	O
.001	O
)	O
.	O

Analysis	O
of	O
markers	O
such	O
as	O
CD69	B
,	O
CD40L	B
,	O
CD25	B
,	O
and	O
CD54	B
revealed	O
no	O
perioperative	O
fluctuations	O
in	O
any	O
group	O
.	O

Regarding	O
circulating	O
cell	O
adhesion	O
molecules	O
,	O
the	O
EAAA	O
and	O
OAAA	O
groups	O
displayed	O
significant	O
increases	O
in	O
soluble	O
intercellular	B
adhesion	I
molecule-1	I
(	O
P	O
=	O
.003	O
and	O
P	O
=	O
.001	O
)	O
;	O
there	O
was	O
no	O
intergroup	O
difference	O
(	O
P	O
=	O
.193	O
)	O
.	O

All	O
groups	O
demonstrated	O
high	O
soluble	O
von	B
Willebrand	I
factor	I
levels	O
(	O
P	O
=	O
.018	O
,	O
P	O
=	O
.	O
007	O
,	O
and	O
P	O
=	O
.027	O
)	O
,	O
there	O
being	O
no	O
differences	O
in	O
the	O
patterns	O
(	O
P	O
=	O
.	O
772	O
)	O
.	O

Otherwise	O
,	O
soluble	O
vascular	B
cell	I
adhesion	I
molecule	I
-	I
1	I
,	O
soluble	O
E	B
-	I
selectin	I
,	O
and	O
soluble	O
P	B
-	I
selectin	I
did	O
not	O
appear	O
to	O
vary	O
in	O
any	O
group	O
.	O

Regarding	O
cytokine	B
release	O
,	O
although	O
a	O
tendency	O
toward	O
high	O
tumor	B
necrosis	I
factor	I
alpha	I
and	O
interleukin-8	B
levels	O
was	O
noticed	O
in	O
the	O
EAAA	O
group	O
,	O
global	O
time	O
course	O
effects	O
failed	O
to	O
reach	O
statistical	O
significance	O
(	O
P	O
=	O
.543	O
and	O
P	O
=	O
.080	O
)	O
.	O

In	O
contrast	O
,	O
interleukin-6	B
showed	O
elevations	O
in	O
all	O
groups	O
(	O
P	O
=	O
.058	O
,	O
P	O
<	O
.001	O
,	O
and	O
P	O
=	O
.004	O
)	O
.	O

Time	O
course	O
patterns	O
did	O
not	O
differ	O
between	O
the	O
EAAA	O
and	O
OAAA	O
groups	O
(	O
P	O
=	O
.840	O
)	O
.	O

Regarding	O
complement	O
activation	O
,	O
the	O
C3d	B
/	O
C3	B
ratio	O
disclosed	O
significant	O
postoperative	O
elevations	O
in	O
the	O
EAAA	O
and	O
OAAA	O
groups	O
(	O
P	O
=	O
.013	O
and	O
P	O
=	O
.009	O
)	O
.	O

This	O
complement	O
product	O
release	O
was	O
reduced	O
in	O
the	O
EAAA	O
group	O
(	O
P	O
<	O
.001	O
)	O
.	O

CONCLUSIONS	O
:	O

The	O
current	O
study	O
indicated	O
that	O
both	O
endovascular	O
and	O
coventional	O
AAA	O
repair	O
induced	O
significant	O
inflammatory	O
responses	O
.	O

Our	O
findings	O
showed	O
that	O
there	O
were	O
no	O
large	O
differences	O
between	O
the	O
procedures	O
with	O
respect	O
to	O
circulating	O
cell	O
adhesion	B
molecule	I
and	O
cytokine	B
release	O
.	O

Moreover	O
,	O
the	O
endoluminal	O
approach	O
produced	O
a	O
limited	O
response	O
in	O
terms	O
of	O
acute	O
phase	O
reaction	O
,	O
T	O
lymphocyte	O
activation	O
,	O
and	O
complement	O
product	O
liberation	O
.	O

This	O
might	O
support	O
the	O
concept	O
that	O
endovascular	O
AAA	O
repair	O
represents	O
an	O
attractive	O
alternative	O
to	O
open	O
surgery	O
.	O

Given	O
the	O
relatively	O
small	O
sample	O
size	O
,	O
further	O
larger	O
studies	O
are	O
required	O
for	O
confirmation	O
of	O
our	O
observations	O
.	O

Regulation	O
of	O
the	O
promoter	O
activity	O
of	O
interferon	B
regulatory	I
factor-7	I
gene	O
.	O

Activation	O
by	O
interferon	B
snd	O
silencing	O
by	O
hypermethylation	O
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
virus	O
induces	O
expression	O
of	O
the	O
early	O
inflammatory	O
genes	O
has	O
not	O
yet	O
been	O
completely	O
elucidated	O
.	O

Previous	O
studies	O
indicated	O
that	O
the	O
virus	O
-	O
mediated	O
transcription	O
of	O
type	B
I	I
interferon	I
(	O
IFN	B
)	O
genes	O
required	O
activation	O
of	O
two	O
members	O
of	O
IFN	B
regulatory	I
factor	I
(	I
IRF	I
)	I
family	I
,	O
IRF-3	B
and	O
IRF-7	B
,	O
where	O
the	O
expression	O
of	O
IRF-7	B
was	O
found	O
to	O
be	O
indispensable	O
for	O
the	O
induction	O
of	O
IFNA	B
genes	O
.	O

To	O
determine	O
the	O
factors	O
that	O
regulate	O
expression	O
of	O
IRF-7	B
gene	O
,	O
as	O
well	O
as	O
its	O
inducibility	O
by	O
type	B
I	I
IFNs	I
,	O
we	O
have	O
isolated	O
and	O
characterized	O
the	O
promoter	O
and	O
first	O
intron	O
of	O
the	O
human	O
IRF-7	B
gene	O
.	O

This	O
region	O
shows	O
a	O
presence	O
of	O
two	O
potential	O
interferon	B
-	O
sensitive	O
response	O
elements	O
(	O
ISRE	O
/	O
IRF	O
-	O
E	O
)	O
.	O

However	O
,	O
only	O
the	O
ISRE	O
present	O
in	O
the	O
first	O
intron	O
was	O
functional	O
and	O
conferred	O
interferon	B
inducibility	O
in	O
a	O
transient	O
transfection	O
assay	O
.	O

Using	O
a	O
pull	O
-	O
down	O
assay	O
with	O
an	O
oligodeoxynucleotide	O
corresponding	O
to	O
this	O
ISRE	O
immobilized	O
to	O
magnetic	O
beads	O
,	O
we	O
have	O
demonstrated	O
that	O
this	O
ISRE	O
binds	O
ISGF3	B
complex	O
and	O
IRF-1	B
from	O
the	O
extract	O
of	O
IFN	B
-	O
treated	O
cells	O
but	O
not	O
from	O
the	O
untreated	O
cells	O
.	O

We	O
have	O
further	O
shown	O
that	O
the	O
previously	O
observed	O
lack	O
of	O
expression	O
of	O
IRF-7	B
in	O
2fTGH	O
fibrosarcoma	O
cell	O
line	O
,	O
correlated	O
with	O
hypermethylation	O
of	O
the	O
CpG	O
island	O
in	O
the	O
human	O
IRF-7	B
promoter	O
.	O

The	O
repression	O
of	O
the	O
promoter	O
activity	O
was	O
relieved	O
by	O
treatment	O
with	O
DNA	B
methyltransferase	I
inhibitor	O
5-aza	O
-	O
deoxycytidine	O
.	O

In	O
vitro	O
methylation	O
of	O
IRF-7	B
promoter	O
silenced	O
IRF-7	B
directed	O
expression	O
of	O
luciferase	B
gene	O
in	O
HeLa	O
cells	O
that	O
express	O
endogenous	O
IRF-7	B
gene	O
.	O

Whether	O
silencing	O
of	O
IRF-7	B
by	O
methylation	O
is	O
instrumental	O
for	O
the	O
process	O
of	O
tumorigenesis	O
remains	O
to	O
be	O
determined	O
.	O

Oxygen	O
and	O
haem	O
regulate	O
the	O
synthesis	O
of	O
peroxisomal	O
proteins	O
:	O
catalase	B
A	I
,	O
acyl	B
-	I
CoA	I
oxidase	I
and	O
Pex1p	B
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
;	O
the	O
regulation	O
of	O
these	O
proteins	O
by	O
oxygen	O
is	O
not	O
mediated	O
by	O
haem	O
.	O

Saccharomyces	O
cerevisiae	O
genes	O
related	O
to	O
respiration	O
are	O
typically	O
controlled	O
by	O
oxygen	O
and	O
haem	O
.	O

Usually	O
the	O
regulation	O
by	O
these	O
factors	O
is	O
co	O
-	O
ordinated	O
;	O
haem	O
is	O
indicated	O
as	O
the	O
oxygen	O
sensor	O
.	O

However	O
,	O
the	O
responsiveness	O
of	O
peroxisome	O
functions	O
to	O
these	O
regulatory	O
factors	O
is	O
poorly	O
understood	O
.	O

The	O
expression	O
of	O
CTA1	B
,	O
POX1	B
and	O
PEX1	B
genes	O
encoding	O
the	O
peroxisomal	O
proteins	O
catalase	B
A	I
,	O
acyl	B
-	I
CoA	I
oxidase	I
and	O
Pex1p	B
peroxin	B
respectively	O
was	O
studied	O
under	O
various	O
conditions	O
:	O
in	O
anaerobiosis	O
,	O
in	O
the	O
absence	O
of	O
haem	O
and	O
in	O
respiratory	O
incompetence	O
caused	O
by	O
the	O
lack	O
of	O
a	O
mitochondrial	O
genome	O
(	O
rho	O
(	O
0	O
)	O
)	O
.	O

The	O
influence	O
of	O
haem	O
deficiency	O
or	O
rho	O
(	O
0	O
)	O
on	O
peroxisomal	O
morphology	O
was	O
also	O
investigated	O
.	O

Respiratory	O
incompetence	O
has	O
no	O
effect	O
on	O
the	O
expression	O
of	O
CTA1	B
and	O
POX1	B
,	O
whereas	O
in	O
the	O
absence	O
of	O
haem	O
their	O
expression	O
is	O
markedly	O
decreased	O
.	O

The	O
synthesis	O
of	O
Pex1p	B
is	O
decreased	O
in	O
rho	O
(	O
0	O
)	O
cells	O
and	O
is	O
decreased	O
even	O
more	O
in	O
haem	O
-	O
deficient	O
cells	O
.	O

Nevertheless	O
,	O
peroxisomal	O
morphology	O
in	O
both	O
these	O
types	O
of	O
cell	O
does	O
not	O
differ	O
significantly	O
from	O
the	O
morphology	O
of	O
peroxisomes	O
in	O
wild	O
-	O
type	O
cells	O
.	O

The	O
down	O
-	O
regulating	O
effect	O
of	O
anoxia	O
on	O
the	O
expression	O
of	O
CTA1	B
and	O
POX1	B
is	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
haem	O
deficiency	O
and	O
is	O
not	O
reversed	O
by	O
the	O
addition	O
of	O
exogenous	O
haem	O
or	O
the	O
presence	O
of	O
endogenous	O
haem	O
.	O

Moreover	O
,	O
neither	O
of	O
these	O
genes	O
responds	O
to	O
the	O
known	O
haem	O
-	O
controlled	O
transcriptional	B
factor	I
Hap1p	B
.	O

In	O
contrast	O
with	O
the	O
other	O
two	O
genes	O
studied	O
,	O
PEX1	B
is	O
up	O
-	O
regulated	O
in	O
anaerobiosis	O
.	O

The	O
existence	O
of	O
one	O
or	O
more	O
novel	O
mechanisms	O
of	O
regulation	O
of	O
peroxisomal	O
genes	O
by	O
haem	O
and	O
oxygen	O
,	O
different	O
from	O
those	O
already	O
known	O
in	O
S.	O
cerevisiae	O
,	O
is	O
postulated	O
.	O

A	O
second	O
leukotriene	B
B	I
(	I
4	I
)	I
receptor	I
,	O
BLT2	B
.	O

A	O
new	O
therapeutic	O
target	O
in	O
inflammation	O
and	O
immunological	O
disorders	O
.	O

Leukotriene	O
B	O
(	O
4	O
)	O
(	O
LTB	O
(	O
4	O
)	O
)	O
is	O
a	O
potent	O
chemoattractant	O
and	O
activator	O
of	O
both	O
granulocytes	O
and	O
macrophages	O
.	O

The	O
actions	O
of	O
LTB	O
(	O
4	O
)	O
appear	O
to	O
be	O
mediated	O
by	O
a	O
specific	O
G	B
protein	I
-	I
coupled	I
receptor	I
(	O
GPCR	B
)	O
BLT1	B
,	O
originally	O
termed	O
BLT	B
(	O
Yokomizo	O
,	O
T.	O
,	O
T.	O
Izumi	O
,	O
K.	O
Chang	O
,	O
Y.	O
Takuwa	O
,	O
and	O
T.	O
Shimizu	O
.	O
1997	O
.	O
Nature	O
.	O
387	O
:	O
620	O
-	O
624	O
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
molecular	O
cloning	O
of	O
a	O
novel	O
GPCR	B
for	O
LTB	O
(	O
4	O
)	O
,	O
designated	O
BLT2	B
,	O
which	O
binds	O
LTB	O
(	O
4	O
)	O
with	O
a	O
Kd	O
value	O
of	O
23	O
nM	O
compared	O
with	O
1.1	O
nM	O
for	O
BLT1	B
,	O
but	O
still	O
efficiently	O
transduces	O
intracellular	O
signaling	O
.	O

BLT2	B
is	O
highly	O
homologous	O
to	O
BLT1	B
,	O
with	O
an	O
amino	O
acid	O
identity	O
of	O
45.2	O
%	O
,	O
and	O
its	O
open	O
reading	O
frame	O
is	O
located	O
in	O
the	O
promoter	O
region	O
of	O
the	O
BLT1	B
gene	O
.	O

BLT2	B
is	O
expressed	O
ubiquitously	O
,	O
in	O
contrast	O
to	O
BLT1	B
,	O
which	O
is	O
expressed	O
predominantly	O
in	O
leukocytes	O
.	O

Chinese	O
hamster	O
ovary	O
cells	O
expressing	O
BLT2	B
exhibit	O
LTB	O
(	O
4	O
)	O
-	O
induced	O
chemotaxis	O
,	O
calcium	O
mobilization	O
,	O
and	O
pertussis	B
toxin	I
-	O
insensitive	O
inhibition	O
of	O
adenylyl	B
cyclase	I
.	O

Several	O
BLT1	B
antagonists	O
,	O
including	O
U	O
75302	O
,	O
failed	O
to	O
inhibit	O
LTB	O
(	O
4	O
)	O
binding	O
to	O
BLT2	B
.	O

Thus	O
,	O
BLT2	B
is	O
a	O
pharmacologically	O
distinct	O
receptor	O
for	O
LTB	O
(	O
4	O
)	O
,	O
and	O
may	O
mediate	O
cellular	O
functions	O
in	O
tissues	O
other	O
than	O
leukocytes	O
.	O

BLT2	B
provides	O
a	O
novel	O
target	O
for	O
antiinflammatory	O
therapy	O
and	O
promises	O
to	O
expand	O
our	O
knowledge	O
of	O
LTB	O
(	O
4	O
)	O
function	O
.	O

The	O
location	O
of	O
the	O
gene	O
suggests	O
shared	O
transcriptional	O
regulation	O
of	O
these	O
two	O
receptors	O
.	O

Immunolocalization	O
of	O
androgen	B
receptors	I
and	O
aromatase	B
enzyme	O
in	O
the	O
adult	O
musk	O
shrew	O
brain	O
.	O

In	O
the	O
brain	O
and	O
other	O
tissues	O
,	O
estrogens	O
are	O
produced	O
by	O
aromatization	O
of	O
androgens	O
.	O

Biochemical	O
data	O
suggest	O
that	O
aromatase	B
enzyme	O
is	O
regulated	O
by	O
the	O
androgen	B
receptor	I
(	O
AR	B
)	O
.	O

Neurons	O
that	O
contain	O
either	O
AR	B
or	O
aromatase	B
(	O
AROM	B
)	O
enzyme	O
reside	O
in	O
many	O
of	O
the	O
same	O
brain	O
regions	O
.	O

In	O
this	O
report	O
,	O
we	O
examined	O
the	O
codistribution	O
of	O
AR	B
-	O
and	O
AROM	B
-	O
enzyme	O
-	O
immunoreactive	O
(	O
-	O
ir	O
)	O
neurons	O
in	O
several	O
regions	O
of	O
the	O
adult	O
male	O
and	O
female	O
musk	O
shrew	O
brain	O
.	O

Data	O
were	O
collected	O
from	O
the	O
intermediate	O
nucleus	O
of	O
the	O
lateral	O
septum	O
(	O
LS	O
)	O
,	O
medial	O
anterior	O
(	O
BNSTMA	O
)	O
and	O
medial	O
posterointerior	O
(	O
BNSTMP	O
)	O
divisions	O
of	O
the	O
bed	O
nucleus	O
of	O
the	O
stria	O
terminalis	O
,	O
medial	O
preoptic	O
area	O
(	O
mPOA	O
)	O
,	O
ventromedial	O
nucleus	O
of	O
the	O
hypothalamus	O
(	O
VMN	O
)	O
,	O
medial	O
(	O
MeA	O
)	O
,	O
cortical	O
and	O
central	O
nuclei	O
of	O
the	O
amygdala	O
.	O

Males	O
had	O
significantly	O
more	O
AR	B
-	O
ir	O
neurons	O
in	O
the	O
BNSTMP	O
,	O
mPOA	O
,	O
VMN	O
and	O
LS	O
as	O
compared	O
to	O
females	O
.	O

With	O
the	O
exception	O
of	O
the	O
BNSTMA	O
and	O
LS	O
,	O
males	O
had	O
more	O
AROM	B
-	O
ir	O
neurons	O
in	O
each	O
region	O
than	O
females	O
.	O

Furthermore	O
,	O
males	O
had	O
significantly	O
more	O
double	O
-	O
labeled	O
neurons	O
than	O
females	O
in	O
the	O
BNSTMP	O
,	O
mPOA	O
,	O
VMN	O
,	O
LS	O
and	O
MeA	O
.	O

The	O
percentage	O
of	O
AROM	B
-	O
ir	O
neurons	O
that	O
also	O
contained	O
AR	B
immunoreactivity	O
ranged	O
from	O
13	O
to	O
82	O
%	O
depending	O
on	O
sex	O
and	O
region	O
.	O

The	O
highest	O
percentage	O
of	O
dual	O
-	O
labeled	O
neurons	O
(	O
79	O
%	O
in	O
females	O
and	O
82	O
%	O
in	O
males	O
)	O
was	O
found	O
in	O
the	O
VMN	O
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
there	O
is	O
extensive	O
cellular	O
colocalization	O
of	O
AR	B
and	O
AROM	B
enzyme	O
in	O
specific	O
regions	O
of	O
the	O
musk	O
shrew	O
brain	O
.	O

We	O
propose	O
that	O
in	O
both	O
sexes	O
,	O
androgen	B
receptors	I
may	O
act	O
as	O
transcription	B
factors	I
to	O
regulate	O
AROM	B
enzyme	O
.	O

Activation	O
of	O
NFkappaB	B
is	O
necessary	O
for	O
IL-1beta	B
-	O
induced	O
cyclooxygenase-2	B
(	O
COX-2	B
)	O
expression	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

The	O
immediate	O
-	O
early	O
cyclooxygenase-2	B
(	O
COX-2	B
)	O
gene	O
encodes	O
an	O
inducible	O
prostaglandin	B
synthase	I
enzyme	O
which	O
is	O
implicated	O
in	O
inflammatory	O
and	O
proliferative	O
diseases	O
.	O

COX-2	B
is	O
highly	O
induced	O
during	O
cell	O
activation	O
by	O
various	O
factors	O
,	O
including	O
mitogens	O
,	O
hormones	O
and	O
cytokines	B
.	O

Since	O
pro	O
-	O
inflammatory	O
cytokine	B
IL-1beta	B
has	O
been	O
shown	O
to	O
induce	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
release	O
in	O
human	O
gingival	O
fibroblasts	O
(	O
HGF	O
)	O
,	O
here	O
we	O
analyzed	O
the	O
effect	O
of	O
IL-1beta	B
on	O
the	O
expression	O
of	O
COX-2	B
and	O
the	O
activation	O
of	O
NFkappaB	B
in	O
HGF	O
.	O

Northern	O
hybridization	O
analysis	O
revealed	O
that	O
IL-1beta	B
(	O
200	O
pg	O
/	O
ml	O
)	O
increased	O
the	O
expression	O
of	O
COX-2	B
mRNA	O
in	O
HGF	O
.	O

The	O
effect	O
of	O
IL-1beta	B
was	O
abrogated	O
by	O
herbimycin	O
A	O
,	O
a	O
protein	B
tyrosine	I
kinase	I
inhibitor	O
,	O
and	O
enhanced	O
by	O
orthovanadate	O
,	O
a	O
protein	B
tyrosine	I
phosphatase	I
inhibitor	O
.	O

IL-1beta	B
-	O
induced	O
PGE2	O
release	O
was	O
blocked	O
by	O
the	O
tyrosine	B
kinase	I
inhibitor	O
and	O
increased	O
by	O
the	O
tyrosine	B
phosphatase	I
inhibitor	O
.	O

The	O
results	O
of	O
transient	O
transfection	O
assays	O
using	O
chimeric	O
constructs	O
of	O
the	O
human	O
COX-2	B
promoter	O
(	O
nt	O
-	O
1432	O
approximately	O
+	O
59	O
)	O
ligated	O
to	O
a	O
luciferase	B
reporter	O
gene	O
indicated	O
that	O
IL-1beta	B
stimulated	O
the	O
transcriptional	O
activity	O
approximately	O
1.5	O
-	O
fold	O
.	O

Gel	O
mobility	O
shift	O
assays	O
with	O
a	O
radiolabelled	O
COX-2	B
-	O
NFkappaB	B
oligonucleotide	O
(	O
nts	O
-	O
223	O
to	O
-	O
214	O
)	O
revealed	O
an	O
increase	O
in	O
the	O
binding	O
of	O
nuclear	O
proteins	O
from	O
IL-1beta	B
-	O
stimulated	O
HGF	O
.	O

This	O
increase	O
of	O
DNA	O
-	O
protein	O
complex	O
formation	O
induced	O
by	O
IL-1beta	B
was	O
blocked	O
by	O
herbimycin	O
A	O
and	O
another	O
tyrosine	B
kinase	I
inhibitor	O
,	O
genistein	O
.	O

These	O
results	O
suggest	O
that	O
NFkappaB	B
is	O
an	O
important	O
transcription	B
factor	I
for	O
IL-1beta	B
-	O
induced	O
COX-2	B
gene	O
expression	O
,	O
and	O
is	O
involved	O
in	O
inducing	O
COX-2	B
gene	O
transcription	O
through	O
tyrosine	O
phosphorylation	O
in	O
HGF	O
.	O

Soluble	O
IL-6R	B
alpha	I
upregulated	O
IL-6	B
,	O
MMP-1	B
and	O
MMP-2	B
secretion	O
in	O
bone	O
marrow	O
stromal	O
cells	O
.	O

IL-6	B
mediates	O
its	O
activity	O
through	O
a	O
cell	O
surface	O
receptor	O
composed	O
of	O
a	O
signal	O
transducing	O
protein	O
,	O
CD130	B
,	O
and	O
a	O
ligand	O
-	O
binding	O
protein	O
which	O
exists	O
in	O
membrane	O
-	O
bound	O
form	O
(	O
CD126	B
)	O
or	O
in	O
soluble	O
form	O
(	O
sIL-6R	B
alpha	I
)	O
.	O

Interestingly	O
,	O
sIL-6R	B
alpha	I
combined	O
with	O
IL-6	B
is	O
able	O
to	O
interact	O
with	O
CD130	B
leading	O
to	O
the	O
intracellular	O
cascade	O
of	O
activation	O
.	O

In	O
the	O
present	O
study	O
,	O
using	O
flow	O
cytometry	O
,	O
we	O
show	O
that	O
stromal	O
cells	O
from	O
human	O
bone	O
marrow	O
(	O
BMSC	O
)	O
express	O
CD130	B
but	O
not	O
CD126	B
.	O

We	O
demonstrate	O
that	O
BMSC	O
are	O
responsive	O
to	O
IL-6	B
only	O
in	O
the	O
presence	O
of	O
exogenous	O
sIL-6R	B
alpha	I
.	O

Indeed	O
,	O
exogenous	O
sIL-6R	B
alpha	I
induces	O
in	O
BMSC	O
the	O
production	O
of	O
its	O
own	O
ligand	O
,	O
IL-6	B
,	O
and	O
of	O
both	O
MMP-1	B
and	O
MMP-2	B
,	O
two	O
matrix	O
metalloproteinases	O
involved	O
in	O
bone	O
resorption	O
and	O
in	O
tumour	O
spreading	O
,	O
respectively	O
.	O

Since	O
myeloma	O
cells	O
release	O
sIL-6R	B
alpha	I
in	O
the	O
close	O
vicinity	O
of	O
BMSC	O
,	O
these	O
data	O
suggest	O
a	O
role	O
for	O
this	O
factor	O
in	O
the	O
pathophysiology	O
of	O
multiple	O
myeloma	O
,	O
a	O
B	O
-	O
cell	O
malignancy	O
dependent	O
on	O
IL-6	B
for	O
its	O
growth	O
and	O
characterized	O
by	O
bone	O
destruction	O
.	O

Secretional	O
luciferase	B
of	O
the	O
luminous	O
shrimp	O
Oplophorus	O
gracilirostris	O
:	O
cDNA	O
cloning	O
of	O
a	O
novel	O
imidazopyrazinone	O
luciferase	B
(	I
1	I
)	I
.	O

The	O
deep	O
-	O
sea	O
shrimp	O
Oplophorus	O
gracilirostris	O
secretes	O
a	O
luciferase	B
that	O
catalyzes	O
the	O
oxidation	O
of	O
coelenterazine	O
to	O
emit	O
blue	O
light	O
.	O

The	O
luciferase	B
(	O
M	O
(	O
r	O
)	O
approx	O
.	O
106000	O
)	O
was	O
found	O
to	O
be	O
a	O
complex	O
composed	O
of	O
35	O
kDa	O
and	O
19	O
kDa	O
proteins	O
,	O
and	O
the	O
cDNAs	O
encoding	O
these	O
two	O
proteins	O
were	O
cloned	O
.	O

The	O
expression	O
of	O
the	O
cDNAs	O
in	O
bacterial	O
and	O
mammalian	O
cells	O
indicated	O
that	O
the	O
19	O
kDa	O
protein	O
,	O
not	O
the	O
35	O
kDa	O
protein	O
,	O
is	O
capable	O
of	O
catalyzing	O
the	O
luminescent	O
oxidation	O
of	O
coelenterazine	O
.	O

The	O
primary	O
sequence	O
of	O
the	O
35	O
kDa	O
protein	O
revealed	O
a	O
typical	O
leucine	O
-	O
rich	O
repeat	O
sequence	O
,	O
whereas	O
the	O
catalytic	O
19	O
kDa	O
protein	O
shared	O
no	O
homology	O
with	O
any	O
known	O
luciferases	B
including	O
various	O
imidazopyrazinone	O
luciferases	B
.	O

Tor	B
-	O
mediated	O
induction	O
of	O
autophagy	O
via	O
an	O
Apg1	B
protein	B
kinase	I
complex	O
.	O

Autophagy	O
is	O
a	O
membrane	O
trafficking	O
to	O
vacuole	O
/	O
lysosome	O
induced	O
by	O
nutrient	O
starvation	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
Tor	B
protein	O
,	O
a	O
phosphatidylinositol	B
kinase	I
-	O
related	O
kinase	B
,	O
is	O
involved	O
in	O
the	O
repression	O
of	O
autophagy	O
induction	O
by	O
a	O
largely	O
unknown	O
mechanism	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
protein	B
kinase	I
activity	O
of	O
Apg1	B
is	O
enhanced	O
by	O
starvation	O
or	O
rapamycin	O
treatment	O
.	O

In	O
addition	O
,	O
we	O
have	O
also	O
found	O
that	O
Apg13	B
,	O
which	O
binds	O
to	O
and	O
activates	O
Apg1	B
,	O
is	O
hyperphosphorylated	O
in	O
a	O
Tor	B
-	O
dependent	O
manner	O
,	O
reducing	O
its	O
affinity	O
to	O
Apg1	B
.	O

This	O
Apg1	B
-	O
Apg13	B
association	O
is	O
required	O
for	O
autophagy	O
,	O
but	O
not	O
for	O
the	O
cytoplasm	O
-	O
to	O
-	O
vacuole	O
targeting	O
(	O
Cvt	O
)	O
pathway	O
,	O
another	O
vesicular	O
transport	O
mechanism	O
in	O
which	O
factors	O
essential	O
for	O
autophagy	O
(	O
Apg	B
proteins	O
)	O
are	O
also	O
employed	O
under	O
vegetative	O
growth	O
conditions	O
.	O

Finally	O
,	O
other	O
Apg1	B
-	O
associating	O
proteins	O
,	O
such	O
as	O
Apg17	B
and	O
Cvt9	B
,	O
are	O
shown	O
to	O
function	O
specifically	O
in	O
autophagy	O
or	O
the	O
Cvt	O
pathway	O
,	O
respectively	O
,	O
suggesting	O
that	O
the	O
Apg1	B
complex	O
plays	O
an	O
important	O
role	O
in	O
switching	O
between	O
two	O
distinct	O
vesicular	O
transport	O
systems	O
in	O
a	O
nutrient	O
-	O
dependent	O
manner	O
.	O

The	O
enoyl-	B
[	I
acyl	I
-	I
carrier	I
-	I
protein	I
]	I
reductases	I
FabI	B
and	O
FabL	B
from	O
Bacillus	O
subtilis	O
.	O

Enoyl-	B
[	I
acyl	I
-	I
carrier	I
-	I
protein	I
]	I
(	I
ACP	I
)	I
reductase	I
is	O
a	O
key	O
enzyme	O
in	O
type	B
II	I
fatty	I
-	I
acid	I
synthases	I
that	O
catalyzes	O
the	O
last	O
step	O
in	O
each	O
elongation	O
cycle	O
.	O

The	O
FabI	B
component	O
of	O
Bacillus	O
subtilis	O
(	O
bsFabI	B
)	O
was	O
identified	O
in	O
the	O
genomic	O
data	O
base	O
by	O
homology	O
to	O
the	O
Escherichia	O
coli	O
protein	O
.	O

bsFabI	B
was	O
cloned	O
and	O
purified	O
and	O
exhibited	O
properties	O
similar	O
to	O
those	O
of	O
E.	O
coli	O
FabI	B
,	O
including	O
a	O
marked	O
preference	O
for	O
NADH	O
over	O
NADPH	O
as	O
a	O
cofactor	O
.	O

Overexpression	O
of	O
the	O
B.	O
subtilis	O
fabI	B
gene	O
complemented	O
the	O
temperature	O
-	O
sensitive	O
growth	O
phenotype	O
of	O
an	O
E.	O
coli	O
fabI	B
mutant	O
.	O

Triclosan	O
was	O
a	O
slow	O
-	O
binding	O
inhibitor	O
of	O
bsFabI	B
and	O
formed	O
a	O
stable	O
bsFabI	B
.	O
NAD	O
(	O
+	O
)	O
.	O

triclosan	O
ternary	O
complex	O
.	O

Analysis	O
of	O
the	O
B.	O
subtilis	O
genomic	O
data	O
base	O
revealed	O
a	O
second	O
open	O
reading	O
frame	O
(	O
ygaA	B
)	O
that	O
was	O
predicted	O
to	O
encode	O
a	O
protein	O
with	O
a	O
relatively	O
low	O
overall	O
similarity	O
to	O
FabI	B
,	O
but	O
contained	O
the	O
Tyr	O
-	O
Xaa	O
(	O
6	O
)	O
-	O
Lys	O
enoyl	B
-	I
ACP	I
reductase	I
catalytic	O
architecture	O
.	O

The	O
purified	O
YgaA	B
protein	O
catalyzed	O
the	O
NADPH	O
-	O
dependent	O
reduction	O
of	O
trans-2-enoyl	O
thioesters	O
of	O
both	O
N	O
-	O
acetylcysteamine	O
and	O
ACP	O
.	O

YgaA	B
was	O
reversibly	O
inhibited	O
by	O
triclosan	O
,	O
but	O
did	O
not	O
form	O
the	O
stable	O
ternary	O
complex	O
characteristic	O
of	O
the	O
FabI	B
proteins	O
.	O

Expression	O
of	O
YgaA	B
complemented	O
the	O
fabI	B
(	O
ts	O
)	O
defect	O
in	O
E.	O
coli	O
and	O
conferred	O
complete	O
triclosan	O
resistance	O
.	O

Single	O
knockouts	O
of	O
the	O
ygaA	B
or	O
fabI	B
gene	O
in	O
B.	O
subtilis	O
were	O
viable	O
,	O
but	O
double	O
knockouts	O
were	O
not	O
obtained	O
.	O

The	O
fabI	B
knockout	O
was	O
as	O
sensitive	O
as	O
the	O
wild	O
-	O
type	O
strain	O
to	O
triclosan	O
,	O
whereas	O
the	O
ygaA	B
knockout	O
was	O
250	O
-	O
fold	O
more	O
sensitive	O
to	O
the	O
drug	O
.	O

YgaA	B
was	O
renamed	O
FabL	B
to	O
denote	O
the	O
discovery	O
of	O
a	O
new	O
family	O
of	O
proteins	O
that	O
carry	O
out	O
the	O
enoyl	B
-	I
ACP	I
reductase	I
step	O
in	O
type	B
II	I
fatty	I
-	I
acid	I
synthases	I
.	O

Apolipoprotein	B
A4	I
-	O
1	O
/	O
2	O
polymorphism	O
and	O
response	O
of	O
serum	O
lipids	O
to	O
dietary	O
cholesterol	O
in	O
humans	O
.	O

The	O
response	O
of	O
serum	O
lipids	O
to	O
dietary	O
changes	O
is	O
to	O
some	O
extent	O
an	O
innate	O
characteristic	O
.	O

One	O
candidate	O
genetic	O
factor	O
that	O
may	O
affect	O
the	O
response	O
of	O
serum	O
lipids	O
to	O
a	O
change	O
in	O
cholesterol	O
intake	O
is	O
variation	O
in	O
the	O
apolipoprotein	B
A4	I
gene	O
,	O
known	O
as	O
the	O
APOA4	B
-	O
1	O
/	O
2	O
or	O
apoA	B
-	I
IVGln360His	I
polymorphism	O
.	O

However	O
,	O
previous	O
studies	O
showed	O
inconsistent	O
results	O
.	O

We	O
therefore	O
fed	O
10	O
men	O
and	O
23	O
women	O
with	O
the	O
APOA4	B
-	O
1	O
/	O
1	O
genotype	O
and	O
4	O
men	O
and	O
13	O
women	O
with	O
the	O
APOA4	B
-	O
1	O
/	O
2	O
or	O
-	O
2	O
/	O
2	O
genotype	O
(	O
carriers	O
of	O
the	O
APOA4	B
-	O
2	O
allele	O
)	O
two	O
diets	O
high	O
in	O
saturated	O
fat	O
,	O
one	O
containing	O
cholesterol	O
at	O
12.4	O
mg	O
/	O
MJ	O
,	O
136.4	O
mg	O
/	O
day	O
,	O
and	O
one	O
containing	O
cholesterol	O
at	O
86.2	O
mg	O
/	O
MJ	O
,	O
948.2	O
mg	O
/	O
day	O
.	O

Each	O
diet	O
was	O
supplied	O
for	O
29	O
days	O
in	O
crossover	O
design	O
.	O

The	O
mean	O
response	O
of	O
serum	O
low	B
density	I
lipoprotein	I
cholesterol	O
was	O
0.44	O
mmol	O
/	O
l	O
(	O
17	O
mg	O
/	O
dl	O
)	O
in	O
both	O
subjects	O
with	O
the	O
APOA4	B
-	I
1	I
/	I
1	I
genotype	O
and	O
in	O
subjects	O
with	O
the	O
APOA4	B
-	O
2	O
allele	O
[	O
95	O
%	O
confidence	O
interval	O
of	O
difference	O
in	O
response	O
,	O
-	O
0.20	O
to	O
0.19	O
mmol	O
/	O
l	O
(	O
-	O
8	O
to	O
7	O
mg	O
/	O
dl	O
)	O
]	O
.	O

The	O
mean	O
response	O
of	O
high	B
density	I
lipoprotein	I
cholesterol	O
was	O
also	O
similar	O
,	O
0.10	O
mmol	O
/	O
l	O
(	O
4	O
mg	O
/	O
dl	O
)	O
,	O
in	O
the	O
two	O
APOA-4	B
genotype	O
groups	O
[	O
95	O
%	O
confidence	O
interval	O
of	O
difference	O
in	O
response	O
,	O
-	O
0.07	O
to	O
0.08	O
mmol	O
/	O
l	O
(	O
-3	O
to	O
3	O
mg	O
/	O
dl	O
)	O
]	O
.	O

Thus	O
,	O
the	O
APOA4	B
-	O
1	O
/	O
2	O
polymorphism	O
did	O
not	O
affect	O
the	O
response	O
of	O
serum	O
lipids	O
to	O
a	O
change	O
in	O
the	O
intake	O
of	O
cholesterol	O
in	O
this	O
group	O
of	O
healthy	O
Dutch	O
subjects	O
who	O
consumed	O
a	O
background	O
diet	O
high	O
in	O
saturated	O
fat	O
.	O

Knowledge	O
of	O
the	O
APOA4	B
-	O
1	O
/	O
2	O
polymorphism	O
is	O
probably	O
not	O
a	O
generally	O
applicable	O
tool	O
for	O
the	O
identification	O
of	O
subjects	O
who	O
respond	O
to	O
a	O
change	O
in	O
cholesterol	O
intake	O
.	O

Collectins	B
and	O
collectin	B
receptors	I
in	O
innate	O
immunity	O
.	O

This	O
thesis	O
is	O
based	O
on	O
nine	O
papers	O
and	O
a	O
review	O
on	O
the	O
collectins	B
and	O
collectin	B
receptors	I
in	O
innate	O
immunity	O
.	O

The	O
collectins	B
are	O
a	O
family	O
of	O
proteins	O
in	O
which	O
the	O
individual	O
chains	O
consist	O
of	O
a	O
C	B
-	I
type	I
lectin	I
domain	O
attached	O
to	O
a	O
collagen	B
domain	O
via	O
an	O
alpha	O
-	O
coiled	O
neck	O
region	O
.	O

The	O
chains	O
are	O
organized	O
into	O
a	O
triple	O
collagen	O
helix	O
and	O
oligomerized	O
through	O
N	O
-	O
terminally	O
located	O
cysteines	O
.	O

The	O
collectins	B
have	O
a	O
dual	O
function	O
:	O
one	O
is	O
to	O
bind	O
specifically	O
to	O
carbohydrate	O
structures	O
on	O
the	O
surface	O
of	O
a	O
pathogen	O
;	O
the	O
other	O
is	O
subsequently	O
to	O
recruit	O
other	O
cells	O
and	O
molecules	O
to	O
destroy	O
the	O
pathogen	O
.	O

The	O
C	O
-	O
type	O
lectin	O
domains	O
contain	O
110	O
-	O
130	O
amino	O
-	O
acid	O
residues	O
arranged	O
in	O
a	O
conserved	O
sequence	O
pattern	O
which	O
allows	O
the	O
domain	O
to	O
fold	O
into	O
a	O
well	O
-	O
defined	O
tertiary	O
structure	O
.	O

Five	O
collectins	B
have	O
been	O
described	O
.	O

Lung	B
surfactant	I
proteins	I
A	I
and	I
D	I
(	O
SP	B
-	I
A	I
and	O
SP	B
-	I
D	I
)	O
are	O
mainly	O
found	O
in	O
the	O
surfactant	O
coating	O
the	O
luminal	O
surface	O
of	O
the	O
pulmonary	O
epithelial	O
cells	O
,	O
but	O
are	O
also	O
produced	O
by	O
cells	O
lining	O
the	O
gastrointestinal	O
tract	O
.	O

Mannan	B
-	I
binding	I
lectin	I
(	O
MBL	B
)	O
,	O
conglutinin	B
and	O
collectin-43	B
(	O
CL-43	B
)	O
are	O
serum	O
proteins	O
produced	O
by	O
the	O
liver	O
.	O

Conglutinin	B
and	O
CL-43	B
have	O
so	O
far	O
only	O
been	O
found	O
in	O
Bovidae	O
.	O

The	O
collectins	B
are	O
involved	O
in	O
innate	O
,	O
nonadaptive	O
immune	O
defense	O
.	O

They	O
bind	O
to	O
microbial	O
surface	O
carbohydrates	O
,	O
inducing	O
aggregation	O
and	O
thereby	O
impeding	O
infectivity	O
or	O
mediating	O
phagocytosis	O
through	O
specific	O
receptors	O
on	O
the	O
phagocytes	O
.	O

After	O
binding	O
microbial	O
carbohydrate	O
,	O
MBL	B
can	O
activate	O
the	O
complement	O
system	O
through	O
a	O
newly	O
discovered	O
pathway	O
which	O
makes	O
use	O
of	O
two	O
serine	B
proteases	I
(	O
MASP-1	B
and	O
MASP-2	B
)	O
to	O
activate	O
the	O
complement	B
factors	I
C4	B
and	O
C2	B
.	O

In	O
man	O
,	O
low	O
serum	O
MBL	B
concentrations	O
resulting	O
from	O
mutations	O
in	O
the	O
collagen	O
region	O
are	O
associated	O
with	O
a	O
common	O
opsonic	O
defect	O
.	O

CL-43	B
was	O
identified	O
as	O
a	O
new	O
collectin	O
by	O
its	O
calcium	O
-	O
dependent	O
binding	O
to	O
mannan	O
and	O
by	O
its	O
M	O
(	O
r	O
)	O
of	O
43	O
kDa	O
in	O
the	O
reduced	O
state	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
.	O

The	O
lectin	B
was	O
isolated	O
by	O
affinity	O
chromatography	O
on	O
mannan	O
-	O
Sepharose	O
,	O
absorption	O
with	O
rabbit	O
anti	O
-	O
bovine	O
Ig	B
coupled	O
to	O
Sepharose-4B	O
and	O
ion	O
-	O
exchange	O
chromatography	O
.	O

CL-43	B
shows	O
an	O
apparent	O
molecular	O
mass	O
of	O
120	O
kDa	O
in	O
the	O
unreduced	O
state	O
on	O
SDS	O
-	O
PAGE	O
and	O
elutes	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
750	O
kDa	O
on	O
gel	O
chromatography	O
under	O
nondissociating	O
conditions	O
.	O

Amino	O
-	O
acid	O
analysis	O
and	O
susceptibility	O
to	O
collagenase	B
digestion	O
indicated	O
that	O
CL-43	B
was	O
a	O
collectin	B
.	O

Electron	O
microscopy	O
of	O
purified	O
CL-43	B
revealed	O
only	O
rod	O
-	O
like	O
monomer	O
subunits	O
37.4	O
nm	O
long	O
.	O

Two	O
-	O
dimensional	O
gel	O
electrophoresis	O
showed	O
that	O
CL-43	B
has	O
two	O
isoforms	O
of	O
pI	O
4.9	O
and	O
5.3	O
respectively	O
,	O
corresponding	O
to	O
the	O
native	O
form	O
of	O
CL-43	B
and	O
a	O
truncated	O
form	O
which	O
lacks	O
the	O
first	O
9	O
amino	O
-	O
acid	O
residues	O
.	O

The	O
N	O
-	O
terminal	O
amino	O
-	O
acid	O
sequence	O
of	O
CL-43	B
was	O
used	O
to	O
design	O
primers	O
for	O
PCR	O
with	O
a	O
bovine	O
liver	O
cDNA	O
as	O
template	O
.	O

The	O
cDNA	O
of	O
CL-43	B
was	O
cloned	O
and	O
the	O
open	O
reading	O
frame	O
was	O
found	O
to	O
encode	O
a	O
protein	O
of	O
301	O
amino	O
-	O
acid	O
residues	O
,	O
including	O
an	O
N	O
-	O
terminal	O
region	O
of	O
28	O
residues	O
,	O
a	O
collagen	O
region	O
of	O
114	O
residues	O
and	O
a	O
neck	O
-	O
CRD	O
region	O
of	O
159	O
residues	O
.	O

The	O
amino	O
-	O
acid	O
sequence	O
of	O
CL-43	B
shows	O
74	O
%	O
identity	O
with	O
bovine	O
conglutinin	O
and	O
70	O
%	O
identity	O
with	O
bovine	O
SP	B
-	I
D	I
,	O
but	O
the	O
collagen	B
region	O
is	O
considerably	O
shorter	O
than	O
those	O
of	O
conglutinin	O
and	O
SP	B
-	I
D	I
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
CL-43	B
was	O
only	O
synthesized	O
in	O
bovine	O
liver	O
,	O
no	O
signal	O
being	O
detected	O
in	O
a	O
variety	O
of	O
other	O
bovine	O
tissues	O
,	O
including	O
lung	O
.	O

No	O
cross	O
-	O
hybridizing	O
signals	O
were	O
detected	O
in	O
mRNA	O
from	O
ovine	O
,	O
human	O
,	O
rat	O
or	O
mouse	O
liver	O
.	O

Since	O
CL-43	B
and	O
conglutinin	B
have	O
only	O
been	O
detected	O
in	O
members	O
of	O
the	O
Bovidae	O
,	O
it	O
is	O
probable	O
that	O
an	O
ancestral	O
gene	O
of	O
these	O
two	O
proteins	O
was	O
first	O
derived	O
from	O
a	O
SP	B
-	I
D	I
-	O
like	O
gene	O
and	O
that	O
this	O
ancestral	O
gene	O
underwent	O
duplication	O
during	O
evolution	O
.	O

The	O
carbohydrate	O
binding	O
profile	O
of	O
CL-43	B
was	O
analyzed	O
by	O
an	O
inhibition	O
assay	O
with	O
biotinylated	O
CL-43	B
,	O
using	O
solid	O
-	O
phase	O
mannan	O
as	O
the	O
ligand	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
)	O

Expression	O
of	O
the	O
ftsY	B
gene	O
,	O
encoding	O
a	O
homologue	O
of	O
the	O
alpha	O
subunit	O
of	O
mammalian	O
signal	B
recognition	I
particle	I
receptor	I
,	O
is	O
controlled	O
by	O
different	O
promoters	O
in	O
vegetative	O
and	O
sporulating	O
cells	O
of	O
Bacillus	O
subtilis	O
.	O

Bacillus	O
subtilis	O
FtsY	B
(	O
Srb	B
)	O
is	O
a	O
homologue	O
of	O
the	O
alpha	O
subunit	O
of	O
the	O
receptor	O
for	O
mammalian	O
signal	B
-	I
recognition	I
particle	I
(	O
SRP	B
)	O
and	O
is	O
essential	O
for	O
protein	O
secretion	O
and	O
vegetative	O
cell	O
growth	O
.	O

The	O
ftsY	B
gene	O
is	O
expressed	O
during	O
both	O
the	O
exponential	O
phase	O
and	O
sporulation	O
.	O

In	O
vegetative	O
cells	O
,	O
ftsY	B
is	O
transcribed	O
with	O
two	O
upstream	O
genes	O
,	O
rncS	B
and	O
smc	B
,	O
that	O
are	O
under	O
the	O
control	O
of	O
the	O
major	O
transcription	B
factor	I
sigma	B
(	I
A	I
)	I
.	O

During	O
sporulation	O
,	O
Northern	O
hybridization	O
detected	O
ftsY	B
mRNA	O
in	O
wild	O
-	O
type	O
cells	O
,	O
but	O
not	O
in	O
sporulating	O
cells	O
of	O
sigma	B
(	I
K	I
)	I
and	O
gerE	B
mutants	O
.	O

Therefore	O
,	O
ftsY	B
is	O
solely	O
expressed	O
during	O
sporulation	O
from	O
a	O
sigma	B
(	I
K	I
)	I
-	O
and	O
GerE	B
-	O
controlled	O
promoter	O
that	O
is	O
located	O
immediately	O
upstream	O
of	O
ftsY	B
inside	O
the	O
smc	B
gene	O
.	O

To	O
examine	O
the	O
role	O
of	O
FtsY	B
during	O
sporulation	O
,	O
the	O
B.	O
subtilis	O
strain	O
ISR39	O
was	O
constructed	O
,	O
a	O
ftsY	B
conditional	O
mutant	O
in	O
which	O
ftsY	B
expression	O
can	O
be	O
shut	O
off	O
during	O
spore	O
formation	O
but	O
not	O
during	O
the	O
vegetative	O
state	O
.	O

Electron	O
microscopy	O
showed	O
that	O
the	O
outer	O
coat	O
of	O
ISR39	O
spores	O
was	O
not	O
completely	O
assembled	O
and	O
immunoelectron	O
microscopy	O
localized	O
FtsY	B
to	O
the	O
inner	O
and	O
outer	O
coats	O
of	O
wild	O
-	O
type	O
spores	O
.	O

The	O
developing	O
role	O
of	O
cytokines	B
for	O
imaging	O
inflammation	O
and	O
infection	O
.	O

The	O
diagnosis	O
of	O
inflammatory	O
processes	O
is	O
an	O
important	O
goal	O
in	O
medicine	O
.	O

In	O
some	O
cases	O
the	O
diagnosis	O
is	O
easy	O
,	O
based	O
on	O
the	O
clinical	O
history	O
and	O
the	O
physical	O
examination	O
of	O
the	O
patient	O
.	O

Other	O
cases	O
are	O
more	O
difficult	O
to	O
diagnose	O
because	O
they	O
are	O
asymptomatic	O
or	O
with	O
non	O
-	O
specific	O
symptoms	O
.	O

Thus	O
,	O
several	O
imaging	O
techniques	O
have	O
been	O
developed	O
for	O
the	O
diagnosis	O
of	O
inflammatory	O
processes	O
,	O
from	O
the	O
simple	O
X	O
-	O
ray	O
to	O
the	O
more	O
sophisticated	O
computerised	O
tomography	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
nuclear	O
medicine	O
scan	O
.	O

They	O
provide	O
different	O
information	O
and	O
their	O
role	O
in	O
different	O
diseases	O
will	O
be	O
discussed	O
in	O
this	O
review	O
with	O
particular	O
emphasis	O
on	O
the	O
expanding	O
field	O
of	O
the	O
use	O
of	O
radiolabelled	O
cytokines	B
for	O
imaging	O
infection	O
/	O
inflammation	O
.	O

So	O
far	O
,	O
IL-1	B
,	O
IL-1ra	B
,	O
IL-2	B
,	O
IL-6	B
,	O
IL-8	B
,	O
IL-10	B
,	O
IL-12	B
p40	I
,	O
G	B
-	I
CSF	I
,	O
IFN	B
-	I
gamma	I
and	O
EGF	B
have	O
been	O
radiolabelled	O
for	O
in	O
vivo	O
targetting	O
of	O
different	O
leukocyte	O
subsets	O
with	O
promising	O
results	O
for	O
their	O
clinical	O
use	O
.	O

Kinetic	O
analysis	O
of	O
Sp1	B
-	O
mediated	O
transcriptional	O
activation	O
of	O
the	O
human	O
DNA	B
polymerase	I
beta	I
promoter	O
.	O

In	O
the	O
present	O
studies	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
Sp1	B
on	O
the	O
activation	O
of	O
the	O
human	O
DNA	B
polymerase	I
beta	I
(	O
beta	B
-	I
pol	I
)	O
,	O
a	O
TATA	O
-	O
less	O
promoter	O
.	O

A	O
HeLa	O
cell	O
nuclear	O
extract	O
(	O
NE	O
)	O
based	O
in	O
vitro	O
runoff	O
transcription	O
system	O
of	O
core	O
beta	B
-	I
pol	I
promoter	O
human	O
DNA	O
(	O
pbetaP8	O
)	O
three	O
-	O
step	O
kinetic	O
model	O
of	O
transcription	O
initiation	O
were	O
used	O
to	O
describe	O
the	O
kinetic	O
effect	O
of	O
Sp1	B
.	O

The	O
results	O
showed	O
that	O
distal	O
Sp1	B
-	O
binding	O
sites	O
in	O
the	O
core	O
beta	B
-	I
pol	I
promoter	O
are	O
important	O
for	O
transcriptional	O
activation	O
of	O
the	O
pbetaP8	O
promoter	O
.	O

A	O
detailed	O
kinetic	O
analysis	O
showed	O
that	O
Sp1	B
stimulates	O
the	O
activity	O
of	O
the	O
pbetaP8	O
promoter	O
through	O
distal	O
Sp1	B
-	O
binding	O
sites	O
by	O
increasing	O
the	O
amount	O
of	O
recruitment	O
,	O
instead	O
of	O
stimulating	O
the	O
apparent	O
rate	O
of	O
RPc	B
assembly	O
(	O
k1	O
)	O
.	O

There	O
was	O
no	O
significant	O
effect	O
of	O
Sp1	B
on	O
the	O
apparent	O
rate	O
of	O
open	O
complex	O
(	O
RPo	B
)	O
formation	O
(	O
k2	O
)	O
or	O
on	O
the	O
apparent	O
rate	O
of	O
promoter	O
clearance	O
(	O
k3	O
)	O
of	O
the	O
pbetaP8	O
promoter	O
.	O

These	O
studies	O
define	O
the	O
kinetic	O
mechanisms	O
by	O
which	O
Sp1	B
may	O
regulate	O
the	O
rate	O
of	O
transcript	O
formation	O
of	O
the	O
pbetaP8	O
promoter	O
,	O
and	O
these	O
results	O
may	O
have	O
implications	O
for	O
Sp1	B
regulation	O
of	O
TATA	O
-	O
less	O
promoters	O
.	O

The	O
transmembrane	O
domain	O
of	O
influenza	O
hemagglutinin	B
exhibits	O
a	O
stringent	O
length	O
requirement	O
to	O
support	O
the	O
hemifusion	O
to	O
fusion	O
transition	O
.	O

Glycosylphosphatidylinositol	O
-	O
anchored	O
influenza	O
hemagglutinin	B
(	O
GPI	O
-	O
HA	B
)	O
mediates	O
hemifusion	O
,	O
whereas	O
chimeras	O
with	O
foreign	O
transmembrane	O
(	O
TM	O
)	O
domains	O
mediate	O
full	O
fusion	O
.	O

A	O
possible	O
explanation	O
for	O
these	O
observations	O
is	O
that	O
the	O
TM	O
domain	O
must	O
be	O
a	O
critical	O
length	O
in	O
order	O
for	O
HA	B
to	O
promote	O
full	O
fusion	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
analyzed	O
biochemical	O
properties	O
and	O
fusion	O
phenotypes	O
of	O
HA	B
with	O
alterations	O
in	O
its	O
27	O
-	O
amino	O
acid	O
TM	O
domain	O
.	O

Our	O
mutants	O
included	O
sequential	O
2-amino	O
acid	O
(	O
Delta2	O
-	O
Delta14	O
)	O
and	O
an	O
11	O
-	O
amino	O
acid	O
deletion	O
from	O
the	O
COOH	O
-	O
terminal	O
end	O
,	O
deletions	O
of	O
6	O
or	O
8	O
amino	O
acids	O
from	O
the	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
and	O
middle	O
regions	O
,	O
and	O
a	O
deletion	O
of	O
12	O
amino	O
acids	O
from	O
the	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
end	O
of	O
the	O
TM	O
domain	O
.	O

We	O
also	O
made	O
several	O
point	O
mutations	O
in	O
the	O
TM	O
domain	O
.	O

All	O
of	O
the	O
mutants	O
except	O
Delta14	O
were	O
expressed	O
at	O
the	O
cell	O
surface	O
and	O
displayed	O
biochemical	O
properties	O
virtually	O
identical	O
to	O
wild	O
-	O
type	O
HA	B
.	O

All	O
the	O
mutants	O
that	O
were	O
expressed	O
at	O
the	O
cell	O
surface	O
promoted	O
full	O
fusion	O
,	O
with	O
the	O
notable	O
exception	O
of	O
deletions	O
of	O
>	O
10	O
amino	O
acids	O
.	O

A	O
mutant	O
in	O
which	O
11	O
amino	O
acids	O
were	O
deleted	O
was	O
severely	O
impaired	O
in	O
promoting	O
full	O
fusion	O
.	O

Mutants	O
in	O
which	O
12	O
amino	O
acids	O
were	O
deleted	O
(	O
from	O
either	O
end	O
)	O
mediated	O
only	O
hemifusion	O
.	O

Hence	O
,	O
a	O
TM	O
domain	O
of	O
17	O
amino	O
acids	O
is	O
needed	O
to	O
efficiently	O
promote	O
full	O
fusion	O
.	O

Addition	O
of	O
either	O
the	O
hydrophilic	O
HA	B
cytoplasmic	O
tail	O
sequence	O
or	O
a	O
single	O
arginine	O
to	O
Delta12	O
HA	B
,	O
the	O
hemifusion	O
mutant	O
that	O
terminates	O
with	O
15	O
(	O
hydrophobic	O
)	O
amino	O
acids	O
of	O
the	O
HA	B
TM	O
domain	O
,	O
restored	O
full	O
fusion	O
activity	O
.	O

Our	O
data	O
support	O
a	O
model	O
in	O
which	O
the	O
TM	O
domain	O
must	O
span	O
the	O
bilayer	O
to	O
promote	O
full	O
fusion	O
.	O

Stimulatory	O
effects	O
of	O
cartilage	B
-	I
derived	I
morphogenetic	I
proteins	I
1	I
and	I
2	I
on	O
osteogenic	O
differentiation	O
of	O
bone	O
marrow	O
stromal	O
cells	O
.	O

Cartilage	B
-	I
derived	I
morphogenetic	I
proteins	I
1	I
and	I
2	I
(	O
CDMP-1	B
and	O
CDMP-2	B
)	O
are	O
members	O
of	O
the	B
bone	I
morphogenetic	I
protein	I
(	I
BMP	I
)	I
family	I
which	O
play	O
an	O
important	O
role	O
in	O
embryonic	O
skeletal	O
development	O
.	O

Throughout	O
adult	O
life	O
,	O
bone	O
marrow	O
-	O
derived	O
precursor	O
cells	O
maintain	O
their	O
ability	O
to	O
differentiate	O
into	O
osteoblasts	O
in	O
response	O
to	O
local	O
growth	B
factors	I
.	O

This	O
study	O
examines	O
the	O
osteogenic	O
potential	O
of	O
CDMP-1	B
,	O
CDMP-2	B
,	O
BMP-6	B
and	O
osteogenic	B
protein	I
1	I
(	O
OP-1	B
)	O
in	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSC	O
)	O
and	O
investigates	O
the	O
endogenous	O
expression	O
of	O
CDMPs	B
/	O
BMPs	B
and	O
their	O
respective	O
activin	B
receptor	I
-	I
like	I
kinase	I
(	I
ALK	I
)	I
receptors	I
.	O

A	O
4	O
-	O
day	O
exposure	O
of	O
BMSC	O
to	O
CDMP-1	B
,	O
CDMP-2	B
,	O
BMP-6	B
,	O
and	O
OP-1	B
under	O
serum	O
-	O
free	O
conditions	O
stimulated	O
the	O
progression	O
of	O
the	O
osteogenic	O
lineage	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
as	O
evaluated	O
by	O
alkaline	B
phosphatase	I
activity	O
and	O
osteocalcin	B
synthesis	O
.	O

In	O
contrast	O
to	O
the	O
BMPs	B
,	O
CDMP-1	B
and	O
especially	O
CDMP-2	B
were	O
significantly	O
less	O
osteogenic	O
,	O
as	O
confirmed	O
by	O
Northern	O
blot	O
analysis	O
.	O

Moreover	O
,	O
BMSC	O
were	O
shown	O
to	O
express	O
endogenously	O
CDMP-2	B
,	O
BMP-2	B
to	I
-	I
6	I
and	O
ALK-1	B
,	I
-	I
2	I
,	I
-	I
3	I
,	I
-	I
5	I
and	I
-	I
6	I
.	O

Phenotypic	O
characterization	O
of	O
BMSC	O
by	O
RT	O
-	O
PCR	O
showed	O
transcripts	O
of	O
the	O
fat	O
marker	O
adipsin	O
and	O
the	O
prechondrocytic	O
marker	O
procollagen	B
type	I
IIA	I
;	O
however	O
,	O
we	O
were	O
unable	O
to	O
detect	O
the	O
mature	O
cartilage	O
markers	O
,	O
procollagen	B
type	I
IIB	I
and	O
aggrecan	B
,	O
even	O
after	O
growth	B
factor	I
treatment	O
.	O

Our	O
data	O
indicate	O
that	O
CDMP-1	B
,	O
CDMP-2	B
,	O
BMP-6	B
and	O
OP-1	B
enhance	O
the	O
osteogenic	O
phenotype	O
in	O
BMSC	O
,	O
with	O
CDMPs	B
being	O
clearly	O
less	O
osteogenic	O
than	O
BMPs	B
.	O

The	O
endogenous	O
expression	O
of	O
a	O
variety	O
of	O
CDMPs	B
/	O
BMPs	B
and	O
their	O
respective	O
ALK	B
receptors	I
,	O
suggests	O
a	O
possible	O
involvement	O
of	O
these	O
growth	B
factors	I
in	O
the	O
osteogenic	O
differentiation	O
of	O
bone	O
marrow	O
progenitor	O
cells	O
.	O

3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
/	I
delta5	I
--	I
>	I
4-isomerase	I
activity	O
associated	O
with	O
the	O
human	O
17beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
2	I
isoform	O
.	O

The	O
type	O
2	O
isoform	O
of	O
human	O
17beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
17betaHSD2	B
)	O
efficiently	O
catalyzes	O
the	O
oxidative	O
metabolism	O
of	O
androgens	O
and	O
estrogens	O
,	O
and	O
it	O
is	O
expressed	O
in	O
a	O
large	O
series	O
of	O
human	O
peripheral	O
tissues	O
.	O

To	O
obtain	O
a	O
better	O
understanding	O
of	O
the	O
regulation	O
of	O
local	O
steroid	O
biosynthesis	O
and	O
metabolism	O
in	O
human	O
tissues	O
,	O
we	O
have	O
established	O
a	O
dual	O
steroidogenic	O
activity	O
of	O
the	O
17betaHSD2	B
enzyme	O
after	O
transfection	O
of	O
human	O
17betaHSD2	B
-	O
transfected	O
human	O
embryonic	O
kidney	O
(	O
293	O
)	O
cells	O
.	O

After	O
transient	O
transfection	O
,	O
the	O
metabolism	O
of	O
testosterone	O
,	O
pregnenolone	O
,	O
and	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
in	O
intact	O
transfected	O
293	O
cells	O
was	O
evaluated	O
by	O
TLC	O
-	O
based	O
radiometric	O
assays	O
.	O

17betaHSD2	B
-	O
transfected	O
cells	O
converted	O
91	O
%	O
of	O
testosterone	O
(	O
1	O
micromol	O
/	O
L	O
)	O
into	O
androstenedione	O
in	O
a	O
2	O
-	O
h	O
incubation	O
period	O
.	O

In	O
addition	O
,	O
pregnenolone	O
(	O
1	O
micromol	O
/	O
L	O
)	O
was	O
converted	O
to	O
progesterone	O
(	O
18.5	O
%	O
)	O
,	O
whereas	O
DHEA	O
(	O
1	O
micromol	O
/	O
L	O
)	O
was	O
metabolized	O
to	O
androstenedione	O
(	O
8.3	O
%	O
conversion	O
)	O
in	O
a	O
15	O
-	O
h	O
incubation	O
period	O
.	O

The	O
kinetics	O
of	O
the	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
3betaHSD	B
)	O
and	O
17betaHSD2	B
activities	O
using	O
cell	O
homogenate	O
protein	O
of	O
stably	O
transfected	O
293	O
cells	O
indicated	O
that	O
the	O
catalytic	O
efficiency	O
(	O
apparent	O
catalytic	O
efficiency	O
=	O
maximum	O
velocity	O
/	O
Km	O
)	O
of	O
this	O
3betaHSD	B
activity	O
is	O
approximately	O
2000	O
-	O
fold	O
(	O
pregnenolone	O
as	O
substrate	O
)	O
or	O
3000	O
-	O
fold	O
(	O
DHEA	O
as	O
substrate	O
)	O
weaker	O
than	O
that	O
of	O
17betaHSD2	B
activity	O
.	O

It	O
is	O
noteworthy	O
,	O
however	O
,	O
that	O
the	O
apparent	O
catalytic	O
efficiency	O
of	O
the	O
HSD3B2	B
gene	O
product	O
is	O
only	O
approximately	O
50	O
-	O
fold	O
higher	O
than	O
that	O
of	O
the	O
3betaHSD	B
aspect	O
of	O
the	O
17betaHSD2	B
gene	O
product	O
.	O

Pregnenolone	O
or	O
DHEA	O
effectively	O
inhibited	O
17betaHSD2	B
activity	O
in	O
a	O
noncompetitive	O
fashion	O
.	O

Furthermore	O
,	O
the	O
potent	O
5alpha	B
-	I
reductase	I
/	I
3betaHSD	I
inhibitor	O
,	O
17beta	O
-	O
N	O
,	O
N	O
-	O
diethylcarbamoyl-4-methyl-4-aza-5alpha	O
-	O
androstane-3-one	O
,	O
inhibited	O
neither	O
3betaHSD	B
nor	O
17betaHSD2	B
activities	O
.	O

We	O
conclude	O
that	O
human	O
17betaHSD2	B
enzyme	O
exhibits	O
3betaHSD	B
activity	O
.	O

Notwithstanding	O
that	O
this	O
3betaHSD	B
activity	O
is	O
reduced	O
compared	O
to	O
17betaHSD	B
oxidative	O
activity	O
,	O
it	O
may	O
account	O
for	O
at	O
least	O
some	O
of	O
the	O
reports	O
of	O
3betaHSD	B
activity	O
found	O
in	O
human	O
peripheral	O
tissues	O
that	O
express	O
notable	O
amounts	O
of	O
the	O
17betaHSD2	B
isozyme	O
as	O
well	O
as	O
in	O
individuals	O
with	O
severe	O
classic	O
3betaHSD	B
deficiency	O
.	O

Crystal	O
structure	O
of	O
fibroblast	B
growth	I
factor	I
receptor	I
ectodomain	O
bound	O
to	O
ligand	O
and	O
heparin	O
.	O

Fibroblast	B
growth	I
factors	I
(	O
FGFs	B
)	O
are	O
a	O
large	O
family	O
of	O
structurally	O
related	O
proteins	O
with	O
a	O
wide	O
range	O
of	O
physiological	O
and	O
pathological	O
activities	O
.	O

Signal	O
transduction	O
requires	O
association	O
of	O
FGF	B
with	O
its	O
receptor	B
tyrosine	I
kinase	I
(	O
FGFR	B
)	O
and	O
heparan	O
sulphate	O
proteoglycan	O
in	O
a	O
specific	O
complex	O
on	O
the	O
cell	O
surface	O
.	O

Direct	O
involvement	O
of	O
the	O
heparan	O
sulphate	O
glycosaminoglycan	O
polysaccharide	O
in	O
the	O
molecular	O
association	O
between	O
FGF	B
and	O
its	O
receptor	O
is	O
essential	O
for	O
biological	O
activity	O
.	O

Although	O
crystal	O
structures	O
of	O
binary	O
complexes	O
of	O
FGF	B
-	O
heparin	O
and	O
FGF	B
-	O
FGFR	B
have	O
been	O
described	O
,	O
the	O
molecular	O
architecture	O
of	O
the	O
FGF	B
signalling	O
complex	O
has	O
not	O
been	O
elucidated	O
.	O

Here	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
the	O
FGFR2	B
ectodomain	O
in	O
a	O
dimeric	O
form	O
that	O
is	O
induced	O
by	O
simultaneous	O
binding	O
to	O
FGF1	B
and	O
a	O
heparin	O
decasaccharide	O
.	O

The	O
complex	O
is	O
assembled	O
around	O
a	O
central	O
heparin	O
molecule	O
linking	O
two	O
FGF1	B
ligands	O
into	O
a	O
dimer	O
that	O
bridges	O
between	O
two	O
receptor	O
chains	O
.	O

The	O
asymmetric	O
heparin	O
binding	O
involves	O
contacts	O
with	O
both	O
FGF1	B
molecules	O
but	O
only	O
one	O
receptor	O
chain	O
.	O

The	O
structure	O
of	O
the	O
FGF1	B
-	O
FGFR2	B
-	O
heparin	O
ternary	O
complex	O
provides	O
a	O
structural	O
basis	O
for	O
the	O
essential	O
role	O
of	O
heparan	O
sulphate	O
in	O
FGF	B
signalling	O
.	O

Gene	O
structure	O
and	O
promoter	O
variation	O
of	O
expressed	O
and	O
nonexpressed	O
variants	O
of	O
the	O
KIR2DL5	B
gene	O
.	O

Two	O
variants	O
of	O
the	O
novel	O
KIR2DL5	B
gene	O
(	O
KIR2DL5.1	B
and.2	I
)	O
were	O
identified	O
in	O
genomic	O
DNA	O
of	O
a	O
single	O
donor	O
.	O

However	O
,	O
only	O
the	O
KIR2DL5.1	B
variant	O
was	O
transcribed	O
in	O
PBMC	O
.	O

In	O
this	O
study	O
,	O
analysis	O
of	O
seven	O
additional	O
donors	O
reveals	O
two	O
new	O
variants	O
of	O
the	O
KIR2DL5	B
gene	O
and	O
indicates	O
that	O
transcription	O
,	O
or	O
its	O
lack	O
,	O
are	O
consistently	O
associated	O
with	O
particular	O
variants	O
of	O
this	O
gene	O
.	O

Comparison	O
of	O
the	O
complete	O
nucleotide	O
sequences	O
of	O
the	O
exons	O
and	O
introns	O
of	O
KIR2DL5.1	B
and	O
KIR2DL5.2	B
reveals	O
no	O
structural	O
abnormalities	O
,	O
but	O
similar	O
open	O
reading	O
frames	O
for	O
both	O
variants	O
.	O

In	O
contrast	O
,	O
the	O
promoter	O
region	O
of	O
KIR2DL5	B
shows	O
a	O
high	O
degree	O
of	O
sequence	O
polymorphism	O
that	O
is	O
likely	O
relevant	O
for	O
expression	O
.	O

Substitution	O
within	O
a	O
putative	O
binding	O
site	O
for	O
the	O
transcription	B
factor	I
acute	B
myeloid	I
leukemia	I
gene	I
1	I
could	O
determine	O
the	O
lack	O
of	O
expression	O
for	O
some	O
KIR2DL5	B
variants	O
.	O

Influence	O
of	O
vitamin	O
C	O
supplementation	O
on	O
cytokine	B
changes	O
following	O
an	O
ultramarathon	O
.	O

The	O
influence	O
of	O
vitamin	O
C	O
supplementation	O
on	O
the	O
pattern	O
of	O
change	O
in	O
plasma	O
cytokine	B
concentrations	O
was	O
measured	O
in	O
29	O
runners	O
following	O
a	O
90	O
-	O
km	O
ultramarathon	O
.	O

The	O
study	O
was	O
based	O
on	O
a	O
3	O
(	O
groups	O
)	O
by	O
4	O
(	O
blood	O
samples	O
at	O
16	O
prerace	O
,	O
postrace	O
,	O
and	O
24	O
h	O
and	O
48	O
h	O
postrace	O
)	O
repeated	O
measures	O
design	O
.	O

Groups	O
included	O
placebo	O
control	O
(	O
n	O
=	O
7	O
)	O
and	O
two	O
groups	O
supplementing	O
vitamin	O
C	O
at	O
500	O
mg	O
/	O
day	O
(	O
vit	O
C-500	O
,	O
n	O
=	O
10	O
)	O
or	O
1500	O
mg	O
/	O
day	O
(	O
vit	O
C-1500	O
,	O
n	O
=	O
12	O
)	O
for	O
7	O
days	O
before	O
the	O
race	O
,	O
on	O
race	O
day	O
,	O
and	O
for	O
2	O
days	O
after	O
the	O
race	O
.	O

All	O
measured	O
plasma	O
cytokine	B
concentrations	O
were	O
significantly	O
elevated	O
immediately	O
postrace	O
,	O
with	O
the	O
magnitude	O
of	O
increase	O
for	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
and	O
interleukin-1beta	B
(	O
IL-1beta	B
)	O
much	O
smaller	O
than	O
for	O
IL-6	B
,	O
IL-10	B
,	O
IL-8	B
,	O
and	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1RA	B
)	O
.	O

Cortisol	O
increased	O
in	O
all	O
groups	O
immediately	O
after	O
the	O
race	O
but	O
significantly	O
less	O
in	O
the	O
vit	O
C-1500	O
group	O
.	O

Group	O
x	O
time	O
interaction	O
statistics	O
were	O
not	O
significant	O
for	O
any	O
of	O
the	O
plasma	O
cytokines	B
.	O

However	O
,	O
when	O
the	O
placebo	O
and	O
vit	O
C-500	O
groups	O
were	O
combined	O
(	O
n	O
=	O
17	O
)	O
and	O
compared	O
with	O
the	O
vit	O
C-1500	O
group	O
(	O
n	O
=	O
12	O
)	O
,	O
immediate	O
postrace	O
plasma	O
concentrations	O
were	O
significantly	O
lower	O
in	O
the	O
vit	O
C-1500	O
group	O
for	O
IL-1RA	O
(	O
-	O
57	O
%	O
)	O
and	O
IL-10	O
(	O
-	O
57	O
%	O
)	O
,	O
with	O
a	O
trend	O
measured	O
for	O
IL-6	B
(	O
-	O
27	O
%	O
,	O
p	O
=	O
0.11	O
)	O
and	O
IL-8	O
(	O
-	O
26	O
%	O
,	O
p	O
=	O
0.14	O
)	O
.	O

In	O
summary	O
,	O
runners	O
completing	O
the	O
90	O
-	O
km	O
Comrades	O
Ultramarathon	O
experienced	O
strong	O
increases	O
in	O
concentrations	O
of	O
plasma	O
IL-6	B
,	O
IL-10	B
,	O
IL-1RA	B
,	O
and	O
IL-8	B
.	O

These	O
increases	O
were	O
attenuated	O
in	O
runners	O
ingesting	O
1500	O
mg	O
but	O
not	O
500	O
mg	O
vitamin	O
C	O
supplements	O
for	O
1	O
week	O
prior	O
to	O
the	O
race	O
and	O
on	O
race	O
day	O
.	O

A	O
ubiquitin	B
-	O
like	O
system	O
mediates	O
protein	O
lipidation	O
.	O

Autophagy	O
is	O
a	O
dynamic	O
membrane	O
phenomenon	O
for	O
bulk	O
protein	O
degradation	O
in	O
the	O
lysosome	O
/	O
vacuole	O
.	O

Apg8	B
/	O
Aut7	B
is	O
an	O
essential	O
factor	O
for	O
autophagy	O
in	O
yeast	O
.	O

We	O
previously	O
found	O
that	O
the	O
carboxy	O
-	O
terminal	O
arginine	O
of	O
nascent	O
Apg8	B
is	O
removed	O
by	O
Apg4	B
/	O
Aut2	B
protease	B
,	O
leaving	O
a	O
glycine	O
residue	O
at	O
the	O
C	O
terminus	O
.	O

Apg8	B
is	O
then	O
converted	O
to	O
a	O
form	O
(	O
Apg8-X	B
)	O
that	O
is	O
tightly	O
bound	O
to	O
the	O
membrane	O
.	O

Here	O
we	O
report	O
a	O
new	O
mode	O
of	O
protein	O
lipidation	O
.	O

Apg8	B
is	O
covalently	O
conjugated	O
to	O
phosphatidylethanolamine	O
through	O
an	O
amide	O
bond	O
between	O
the	O
C	O
-	O
terminal	O
glycine	O
and	O
the	O
amino	O
group	O
of	O
phosphatidylethanolamine	O
.	O

This	O
lipidation	O
is	O
mediated	O
by	O
a	O
ubiquitination	O
-	O
like	O
system	O
.	O

Apg8	B
is	O
a	O
ubiquitin	B
-	I
like	I
protein	I
that	O
is	O
activated	O
by	O
an	O
E1	O
protein	O
,	O
Apg7	B
(	O
refs	O
7	O
,	O
8	O
)	O
,	O
and	O
is	O
transferred	O
subsequently	O
to	O
the	O
E2	O
enzymes	O
Apg3	B
/	O
Aut1	B
(	O
ref	O
.	O
9	O
)	O
.	O

Apg7	B
activates	O
two	O
different	O
ubiquitin	B
-	I
like	I
proteins	I
,	O
Apg12	B
(	O
ref	O
.	O
10	O
)	O
and	O
Apg8	B
,	O
and	O
assigns	O
them	O
to	O
specific	O
E2	O
enzymes	O
,	O
Apg10	B
(	O
ref	O
.	O
11	O
)	O
and	O
Apg3	B
,	O
respectively	O
.	O

These	O
reactions	O
are	O
necessary	O
for	O
the	O
formation	O
of	O
Apg8	B
-	O
phosphatidylethanolamine	O
.	O

This	O
lipidation	O
has	O
an	O
essential	O
role	O
in	O
membrane	O
dynamics	O
during	O
autophagy	O
.	O

Interaction	O
of	O
the	O
retinoblastoma	B
protein	I
(	O
pRb	B
)	O
with	O
the	O
catalytic	B
subunit	I
of	I
DNA	I
polymerase	I
delta	I
(	I
p125	I
)	I
.	O

The	O
retinoblastoma	B
gene	O
product	O
(	O
pRb	B
)	O
interacts	O
with	O
many	O
cellular	O
proteins	O
to	O
function	O
in	O
the	O
control	O
of	O
cell	O
division	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
.	O

Several	O
pRb	B
binding	O
proteins	O
complex	O
with	O
pRb	B
through	O
an	O
amino	O
acid	O
sequence	O
called	O
the	O
LXCXE	O
motif	O
.	O

The	O
catalytic	B
subunit	I
of	I
DNA	I
polymerase	I
delta	I
(	I
p125	I
)	I
contains	O
a	O
LXCXE	O
motif	O
.	O

To	O
further	O
study	O
the	O
biochemical	O
function	O
of	O
this	O
polymerase	B
,	O
we	O
sought	O
to	O
determine	O
if	O
p125	B
interacts	O
with	O
pRb	B
.	O

Experiments	O
using	O
GST	B
-	O
pRb	B
fusion	O
proteins	O
showed	O
that	O
p125	B
from	O
breast	O
epithelial	O
(	O
MCF10A	O
)	O
cell	O
extracts	O
associates	O
with	O
pRb	B
.	O

In	O
addition	O
,	O
GST	B
-	O
p125	B
fusion	O
proteins	O
bound	O
pRb	B
from	O
the	O
same	O
cell	O
extracts	O
.	O

The	O
pRb	B
that	O
associated	O
with	O
GST	B
-	O
p125	B
was	O
largely	O
unphosphorylated	O
.	O

Coimmunoprecipitation	O
experiments	O
using	O
cell	O
cycle	O
synchronized	O
cells	O
revealed	O
that	O
p125	B
and	O
pRb	B
form	O
a	O
complex	O
predominantly	O
during	O
G1	O
phase	O
,	O
the	O
phase	O
during	O
which	O
pRb	B
is	O
mostly	O
unphosphorylated	O
.	O

In	O
vitro	O
phosphorylation	O
of	O
GST	B
-	O
pRb	B
by	O
the	O
cyclin	B
dependent	I
kinases	I
reduced	O
the	O
ability	O
of	O
p125	B
to	O
associate	O
with	O
GST	B
-	O
pRh	B
.	O

Addition	O
of	O
the	O
LXCXE	O
containing	O
protein	O
SV40	O
large	B
T	I
antigen	I
to	O
GST	B
-	O
pRb	B
blocks	O
the	O
ability	O
of	O
p125	B
to	O
associate	O
with	O
pRb	B
,	O
suggesting	O
that	O
it	O
may	O
be	O
through	O
a	O
LXCXE	O
sequence	O
by	O
which	O
p125	B
interacts	O
with	O
pRb	B
.	O

Finally	O
,	O
in	O
vitro	O
polymerase	B
assays	O
demonstrate	O
that	O
GST	B
-	O
pRb	B
fusion	O
protein	O
stimulates	O
DNA	B
polymerase	I
delta	I
activity	O
.	O

Adhesion	O
of	O
fibronectin	B
,	O
vitronectin	B
,	O
laminin	B
,	O
and	O
collagen	B
type	I
IV	I
to	O
intraocular	O
lens	O
materials	O
in	O
pseudophakic	O
human	O
autopsy	O
eyes	O
.	O

Part	O
1	O
:	O
histological	O
sections	O
.	O

PURPOSE	O
:	O

To	O
evaluate	O
fibronectin	B
,	O
vitronectin	B
,	O
laminin	B
,	O
and	O
collagen	B
type	I
IV	I
adhesion	O
to	O
poly	O
(	O
methyl	O
methacrylate	O
)	O
(	O
PMMA	O
)	O
,	O
silicone	O
,	O
hydrophobic	O
soft	O
acrylate	O
,	O
and	O
hydrogel	O
intraocular	O
lenses	O
(	O
IOLs	O
)	O
in	O
pseudophakic	O
human	O
autopsy	O
eyes	O
.	O

SETTING	O
:	O

Center	O
for	O
Research	O
on	O
Ocular	O
Therapeutics	O
and	O
Biodevices	O
,	O
Storm	O
Eye	O
Institute	O
,	O
Medical	O
University	O
of	O
South	O
Carolina	O
,	O
Charleston	O
,	O
South	O
Carolina	O
,	O
USA	O
.	O

METHODS	O
:	O

Thirty	O
-	O
eight	O
autopsy	O
eyes	O
containing	O
PMMA	O
,	O
silicone	O
,	O
hydrophobic	O
acrylate	O
,	O
or	O
hydrogel	O
IOLs	O
were	O
assessed	O
.	O

Histological	O
sections	O
were	O
prepared	O
from	O
each	O
eye	O
,	O
and	O
immunohistochemical	O
analyses	O
were	O
performed	O
for	O
fibronectin	B
,	O
vitronectin	B
,	O
laminin	B
,	O
and	O
collagen	B
type	I
IV	I
.	O

One	O
hundred	O
fifty	O
-	O
two	O
specimens	O
were	O
analyzed	O
.	O

RESULTS	O
:	O

A	O
sandwich	O
-	O
like	O
structure	O
(	O
anterior	O
or	O
posterior	O
capsule	O
/	O
fibronectin	B
/	O
1	O
cell	O
layer	O
/	O
fibronectin	B
/	O
IOL	O
surface	O
)	O
was	O
seen	O
in	O
12	O
of	O
14	O
autopsy	O
eyes	O
with	O
soft	O
acrylate	O
IOLs	O
,	O
3	O
of	O
10	O
with	O
a	O
PMMA	O
IOL	O
(	O
P	O
=	O
.0094	O
)	O
,	O
1	O
of	O
10	O
with	O
a	O
silicone	O
IOL	O
(	O
P	O
=	O
.0022	O
)	O
,	O
and	O
0	O
of	O
4	O
with	O
a	O
hydrogel	O
IOL	O
(	O
P	O
=	O
.	O
0041	O
)	O
.	O

The	O
thicker	O
fibrocellular	O
tissue	O
on	O
the	O
inner	O
surface	O
of	O
the	O
anterior	O
or	O
posterior	O
capsule	O
that	O
was	O
in	O
contact	O
with	O
silicone	O
IOLs	O
was	O
lined	O
with	O
collagen	B
type	I
IV	I
.	O

Vitronectin	B
and	O
laminin	B
were	O
not	O
found	O
at	O
the	O
fibrocellular	O
tissue	O
-	O
IOL	O
interface	O
in	O
any	O
specimen	O
.	O

CONCLUSIONS	O
:	O

This	O
study	O
seems	O
to	O
confirm	O
the	O
sandwich	O
theory	O
of	O
posterior	O
capsule	O
opacification	O
in	O
eyes	O
with	O
an	O
IOL	O
and	O
suggests	O
that	O
fibronectin	B
may	O
be	O
the	O
major	O
extracellular	O
protein	O
responsible	O
for	O
the	O
attachment	O
of	O
hydrophobic	O
soft	O
acrylate	O
(	O
AcrySof	O
(	O
R	O
)	O
)	O
IOLs	O
to	O
the	O
capsular	O
bag	O
.	O

This	O
may	O
represent	O
a	O
true	O
bioactive	O
bond	O
between	O
the	O
IOL	O
and	O
lens	O
epithelial	O
cells	O
or	O
between	O
the	O
IOL	O
and	O
the	O
capsular	O
bag	O
and	O
may	O
be	O
one	O
reason	O
the	O
PCO	O
and	O
neodymium	O
:	O
YAG	O
capsulotomy	O
rates	O
are	O
lower	O
in	O
eyes	O
with	O
a	O
soft	O
acrylate	O
IOL	O
.	O

BLyS	B
BINDS	O
TO	O
B	O
CELLS	O
WITH	O
HIGH	O
AFFINITY	O
AND	O
INDUCES	O
ACTIVATION	O
OF	O
THE	O
TRANSCRIPTION	B
FACTORS	I
NF	B
-	I
kappaB	I
AND	O
ELF-1	B
.	O

B	B
lymphocyte	I
stimulator	I
(	O
BLyS	B
)	O
is	O
a	O
novel	O
member	O
of	O
the	O
TNF	B
family	I
of	O
proteins	O
expressed	O
by	O
myeloid	O
cells	O
as	O
membrane	O
-	O
bound	O
and	O
soluble	O
forms	O
.	O

BLyS	B
was	O
shown	O
to	O
act	O
specifically	O
on	O
B	O
cells	O
,	O
inducing	O
proliferation	O
and	O
immunoglobulin	B
production	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
characterize	O
binding	O
of	O
radiolabeled	O
BLyS	B
to	O
its	O
cognate	O
receptor	O
on	O
human	O
B	O
lymphocytes	O
and	O
examine	O
intracellular	O
events	O
initiated	O
by	O
BLyS	B
binding	O
.	O

Similar	O
to	O
other	O
TNF	B
family	I
members	O
,	O
BLyS	B
is	O
present	O
in	O
solution	O
as	O
a	O
homotrimer	O
as	O
determined	O
by	O
gel	O
filtration	O
chromatography	O
and	O
light	O
scattering	O
analysis	O
.	O

BLyS	B
binding	O
to	O
B	O
cells	O
is	O
specific	O
as	O
other	O
TNF	B
family	I
members	O
tested	O
did	O
not	O
compete	O
for	O
(	O
125	O
)	O
I	O
-	O
BLyS	B
binding	O
.	O

Analysis	O
of	O
equilibrium	O
binding	O
of	O
(	O
125	O
)	O
I	O
-	O
labeled	O
BLyS	B
to	O
purified	O
human	O
tonsillar	O
B	O
cells	O
demonstrated	O
saturable	O
binding	O
.	O

Scatchard	O
analysis	O
of	O
the	O
binding	O
data	O
revealed	O
a	O
single	O
class	O
of	O
high	O
-	O
affinity	O
binding	O
on	O
human	O
B	O
cells	O
with	O
approximately	O
2600	O
binding	O
sites	O
per	O
cell	O
and	O
an	O
apparent	O
dissociation	O
constant	O
(	O
K	O
(	O
D	O
)	O
)	O
of	O
about	O
0.1	O
nM	O
.	O

In	O
addition	O
we	O
report	O
that	O
BLyS	B
binding	O
to	O
B	O
cells	O
results	O
in	O
the	O
activation	O
of	O
NF	B
-	I
kappaB	I
and	O
the	O
Ets	B
family	I
transcription	I
factor	I
,	O
ELF-1	B
,	O
and	O
in	O
the	O
induction	O
of	O
mRNA	O
for	O
Polo	B
-	I
like	I
kinase	I
(	O
PLK	B
)	O
.	O

Characterization	O
of	O
cytokine	B
,	O
growth	B
factor	I
receptor	I
,	O
costimulatory	O
and	O
adhesion	B
molecule	I
expression	O
patterns	O
of	O
bone	O
marrow	O
blasts	O
in	O
relapsed	O
childhood	O
B	O
cell	O
precursor	O
all	O
.	O

Relapse	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukaemia	O
(	O
ALL	O
)	O
comprises	O
a	O
leading	O
challenge	O
of	O
investigation	O
.	O

Characterization	O
of	O
leukaemic	O
cells	O
regarding	O
their	O
potency	O
to	O
express	O
growth	O
factors	O
and	O
surface	O
molecules	O
can	O
provide	O
insight	O
into	O
their	O
aberrant	O
biology	O
.	O

Thus	O
,	O
we	O
analyzed	O
bone	O
marrow	O
blasts	O
from	O
10	O
children	O
with	O
relapsed	O
B	O
cell	O
precursor	O
ALL	O
.	O

The	O
gene	O
and	O
protein	O
expression	O
of	O
essential	O
haematopoietic	O
growth	B
factors	I
(	O
IL-2	B
,	O
IL-4	B
,	O
IL-7	B
,	O
IL-10	B
,	O
IL-15	B
,	O
IFN	B
-	I
gamma	I
,	O
G	B
-	I
CSFR	I
)	O
,	O
their	O
corresponding	O
receptors	O
as	O
well	O
as	O
the	O
expression	O
pattern	O
of	O
adhesion	B
molecules	I
(	O
ICAM-1	B
,	O
CD58	B
)	O
and	O
costimulatory	O
proteins	O
(	O
CD40	B
,	O
CD40L	B
,	O
B7.1	B
,	O
B7.2	B
,	O
CD28	B
,	O
MHC	B
-	I
I	I
and	I
II	I
)	O
was	O
analyzed	O
by	O
RT	O
-	O
PCR	O
and	O
flow	O
cytometry	O
.	O

Constitutive	O
gene	O
expression	O
was	O
found	O
for	O
IL-7	B
,	O
IL-10	B
,	O
IL-15	B
and	O
IFN	B
-	I
gamma	I
and	O
their	O
corresponding	O
receptors	O
.	O

Flow	O
-	O
cytometric	O
analysis	O
showed	O
that	O
IL-10R	B
,	O
IL-7Ralpha	B
,	O
IL-4Ralpha	B
and	O
the	O
gamma	B
(	I
c	I
)	I
chain	O
are	O
constitutively	O
expressed	O
,	O
and	O
that	O
some	O
cells	O
bear	O
the	O
G	B
-	I
CSFR	I
.	O

IL-10	B
and	O
IL-15	B
protein	O
-	O
producing	O
leukaemic	O
cells	O
were	O
easily	O
detectable	O
.	O

The	O
neoplastic	O
cells	O
mainly	O
lack	O
B7.1	B
,	O
and	O
ICAM-1	B
is	O
mostly	O
decreased	O
.	O

Furthermore	O
,	O
high	O
CD40	B
,	O
and	O
,	O
surprisingly	O
,	O
CD40L	B
expression	O
could	O
be	O
found	O
.	O

These	O
studies	O
show	O
that	O
ALL	O
cells	O
are	O
likely	O
to	O
be	O
sensitive	O
to	O
many	O
growth	B
factors	I
and	O
some	O
factors	O
are	O
produced	O
by	O
the	O
neoplastic	O
cell	O
itself	O
.	O

The	O
secretion	O
of	O
IL-10	B
by	O
leukaemic	O
cells	O
,	O
and	O
the	O
absence	O
or	O
downregulation	O
of	O
conventional	O
adhesion	O
and	O
costimulatory	O
molecules	O
might	O
represent	O
an	O
effective	O
mechanism	O
of	O
escape	O
of	O
immune	O
surveillance	O
in	O
relapsed	O
ALL	O
.	O

Unexpected	O
presence	O
of	O
defective	O
glpR	B
alleles	O
in	O
various	O
strains	O
of	O
Escherichia	O
coli	O
.	O

Alleles	O
of	O
glpR	B
associated	O
with	O
the	O
same	O
GlpR	B
(	O
-	O
)	O
phenotype	O
produce	O
substitutions	O
in	O
different	O
conserved	O
portions	O
of	O
the	O
glycerol	B
3-phosphate	I
repressor	I
which	O
are	O
not	O
part	O
of	O
the	O
helix	O
-	O
turn	O
-	O
helix	O
motif	O
.	O

Analysis	O
of	O
the	O
effects	O
on	O
growth	O
and	O
enzyme	O
expression	O
show	O
that	O
glucose	O
repression	O
of	O
glycerol	O
utilization	O
is	O
not	O
dependent	O
on	O
a	O
functional	O
repressor	O
.	O

Insulinotropic	O
hormone	O
glucagon	B
-	I
like	I
peptide	I
1	I
(	O
GLP-1	B
)	O
activation	O
of	O
insulin	B
gene	O
promoter	O
inhibited	O
by	O
p38	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
.	O

The	O
insulin	B
gene	O
promoter	O
contains	O
many	O
transcriptional	O
response	O
elements	O
that	O
predispose	O
the	O
gene	O
to	O
a	O
wide	O
range	O
of	O
regulatory	O
signals	O
.	O

Glucagon	B
-	I
like	I
peptide	I
1	I
(	O
GLP-1	B
)	O
stimulates	O
insulin	B
gene	O
transcription	O
by	O
intracellular	O
second	O
messenger	O
cascades	O
leading	O
to	O
direct	O
transcription	B
factor	I
activation	O
or	O
to	O
the	O
up	O
-	O
regulation	O
of	O
insulin	B
promoter	O
specific	O
transcription	B
factors	I
.	O

In	O
these	O
studies	O
,	O
we	O
have	O
identified	O
a	O
novel	O
regulatory	O
signaling	O
mechanism	O
acting	O
on	O
the	O
rat	O
insulin	B
1	I
promoter	O
(	O
rINS1	B
)	O
in	O
the	O
INS	B
-	I
1	I
beta	O
-	O
cell	O
line	O
.	O

In	O
the	O
presence	O
of	O
stimulatory	O
concentrations	O
of	O
GLP-1	B
(	O
0.1	O
--	O
100	O
nM	O
)	O
on	O
rINS1	B
activity	O
,	O
inhibition	O
of	O
p38	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
(	O
p38	B
MAPK	I
)	O
using	O
SB	O
203580	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
promoter	O
activity	O
(	O
maximum	O
3	O
-	O
fold	O
)	O
over	O
GLP	B
-	I
1	I
alone	O
,	O
as	O
determined	O
by	O
rINS1	B
promoter	O
-	O
luciferase	B
reporter	O
gene	O
expression	O
.	O

This	O
effect	O
was	O
revealed	O
to	O
be	O
mediated	O
via	O
the	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
of	O
rINS1	B
,	O
because	O
site	O
directed	O
mutagenesis	O
of	O
the	O
CRE	O
motif	O
in	O
rINS1	B
abolished	O
the	O
increased	O
response	O
to	O
SB	O
203580	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
p38	B
MAPK	I
uncovered	O
a	O
similar	O
,	O
more	O
pronounced	O
,	O
response	O
in	O
the	O
expression	O
of	O
a	O
generic	O
CRE	O
promoter	O
driven	O
reporter	O
gene	O
.	O

Time	O
course	O
dose	O
-	O
response	O
studies	O
indicate	O
that	O
the	O
p38	B
MAPK	I
induced	O
inhibitory	O
response	O
may	O
involve	O
expression	O
of	O
immediate	O
early	O
genes	O
(	O
IEGs	O
)	O
;	O
maximum	O
repression	O
of	O
rINS1	B
activity	O
occurred	O
after	O
4	O
h	O
of	O
treatment	O
,	O
comparable	O
with	O
regulatory	O
responses	O
by	O
IEGs	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
demonstrate	O
a	O
novel	O
signaling	O
mechanism	O
whereby	O
p38	B
MAPK	I
represses	O
rINS1	B
promoter	O
activity	O
in	O
response	O
to	O
GLP	B
-	I
1	I
,	O
suggesting	O
the	O
involvement	O
of	O
a	O
robust	O
regulatory	O
control	O
by	O
p38	B
MAPK	I
in	O
insulin	B
gene	O
expression	O
.	O

The	O
relevance	O
of	O
this	O
mechanism	O
may	O
be	O
most	O
apparent	O
during	O
periods	O
of	O
cellular	O
stress	O
in	O
which	O
p38	B
MAPK	I
activity	O
is	O
stimulated	O
.	O

In	O
this	O
regard	O
,	O
reduced	O
insulin	O
expression	O
levels	O
caused	O
by	O
chronic	O
hyperglycemia	O
(	O
glucotoxicity	O
)	O
and	O
/	O
or	O
hyperlipidemia	O
(	O
lipotoxicity	O
)	O
may	O
be	O
a	O
direct	O
consequence	O
of	O
this	O
mechanism	O
.	O

Directly	O
linked	O
soluble	O
IL-6	B
receptor	I
-	O
IL-6	B
fusion	O
protein	O
induces	O
astrocyte	O
differentiation	O
from	O
neuroepithelial	O
cells	O
via	O
activation	O
of	O
STAT3	B
.	O

Signals	O
of	O
interleukin	B
6	I
(	O
IL-6	B
)	O
are	O
transduced	O
by	O
binding	O
of	O
IL-6	B
to	O
its	O
cell	O
surface	O
receptor	O
(	O
IL-6R	B
)	O
and	O
subsequent	O
association	O
of	O
the	O
resultant	O
IL-6	B
/	O
IL-6R	B
complex	O
with	O
gp130	B
,	O
the	O
signal	O
transducing	O
receptor	O
component	O
utilized	O
in	O
common	O
by	O
all	O
the	O
IL-6	B
family	I
of	I
cytokines	I
.	O

A	O
soluble	O
form	O
of	O
IL-6R	B
(	O
sIL-6R	B
)	O
,	O
which	O
lacks	O
transmembrane	O
and	O
cytoplasmic	O
regions	O
,	O
retains	O
the	O
ability	O
to	O
bind	O
IL-6	B
and	O
signal	O
through	O
gp130	B
.	O

We	O
show	O
here	O
that	O
a	O
fusion	O
protein	O
of	O
sIL-6R	B
and	O
IL-6	B
without	O
a	O
polypeptide	O
linker	O
,	O
termed	O
FP6	O
,	O
induces	O
differentiation	O
of	O
astrocytes	O
from	O
fetal	O
mouse	O
neuroepithelial	O
cells	O
as	O
potently	O
as	O
a	O
representative	O
IL-6	B
family	I
cytokine	I
,	O
leukaemia	B
inhibitory	I
factor	I
(	O
LIF	B
)	O
.	O

FP6	O
has	O
a	O
potential	O
to	O
activate	O
a	O
transcription	B
factor	I
,	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
3	I
(	O
STAT3	B
)	O
,	O
and	O
mitogen	B
-	I
activated	I
protein	I
kinases	I
,	O
ERK1	B
and	O
ERK2	B
,	O
in	O
these	O
cells	O
as	O
does	O
LIF	B
.	O

FP6	O
activates	O
a	O
promoter	O
of	O
the	O
gene	O
for	O
an	O
astrocytic	O
marker	O
,	O
glial	B
fibrillary	I
acidic	I
protein	I
(	O
GFAP	B
)	O
,	O
in	O
neuroepithelial	O
cells	O
.	O

This	O
activation	O
is	O
virtually	O
abolished	O
by	O
ectopic	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
STAT3	B
,	O
or	O
by	O
introducing	O
a	O
point	O
mutation	O
into	O
the	O
STAT3	B
response	O
element	O
located	O
in	O
the	O
GFAP	B
promoter	O
.	O

These	O
results	O
suggest	O
that	O
FP6	O
induces	O
astrocyte	O
differentiation	O
from	O
neuroepithelial	O
cells	O
through	O
STAT3	B
activation	O
and	O
that	O
FP6	O
could	O
be	O
of	O
use	O
as	O
a	O
substitute	O
for	O
natural	O
IL-6	B
family	I
cytokines	I
.	O

Stromal	O
and	O
epithelial	O
expression	O
of	O
tumor	O
markers	O
hyaluronic	O
acid	O
and	O
HYAL1	B
hyaluronidase	B
in	O
prostate	O
cancer	O
.	O

Hyaluronic	O
acid	O
(	O
HA	O
)	O
,	O
a	O
glycosaminoglycan	O
,	O
regulates	O
cell	O
adhesion	O
and	O
migration	O
.	O

Hyaluronidase	B
(	O
HAase	B
)	O
,	O
an	O
endoglycosidase	B
,	O
degrades	O
HA	O
into	O
small	O
angiogenic	O
fragments	O
.	O

Using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
-	O
like	O
assay	O
,	O
we	O
found	O
increased	O
HA	O
levels	O
(	O
3	O
-	O
8	O
-	O
fold	O
)	O
in	O
prostate	O
cancer	O
(	O
CaP	O
)	O
tissues	O
when	O
compared	O
with	O
normal	O
(	O
NAP	O
)	O
and	O
benign	O
(	O
BPH	O
)	O
tissues	O
.	O

The	O
majority	O
(	O
approximately	O
75	O
-	O
80	O
%	O
)	O
of	O
HA	O
in	O
prostate	O
tissues	O
was	O
found	O
to	O
exist	O
in	O
the	O
free	O
form	O
.	O

Primary	O
CaP	O
fibroblast	O
and	O
epithelial	O
cells	O
secreted	O
3	O
-	O
8	O
-	O
fold	O
more	O
HA	O
than	O
respective	O
NAP	O
and	O
BPH	O
cultures	O
.	O

Only	O
CaP	O
epithelial	O
cells	O
and	O
established	O
CaP	O
lines	O
secreted	O
HAase	B
and	O
the	O
secretion	O
increased	O
with	O
tumor	O
grade	O
and	O
metastasis	O
.	O

The	O
pH	O
activity	O
profile	O
and	O
optimum	O
(	O
4.2	O
;	O
range	O
4.0	O
-	O
4.3	O
)	O
of	O
CaP	O
HAase	B
was	O
identical	O
to	O
the	O
HYAL1	B
-	O
type	O
HAase	B
present	O
in	O
human	O
serum	O
and	O
urine	O
.	O

Full	O
-	O
length	O
HYAL1	B
transcript	O
and	O
splice	O
variants	O
were	O
detected	O
in	O
CaP	O
cells	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
,	O
cloning	O
,	O
and	O
sequencing	O
.	O

Immunoblotting	O
confirmed	O
secretion	O
of	O
a	O
approximately	O
60	O
-	O
kDa	O
HYAL1	B
-	O
related	O
protein	O
by	O
CaP	O
cells	O
.	O

Immunohistochemistry	O
showed	O
minimal	O
HA	O
and	O
HYAL1	B
staining	O
in	O
NAP	O
and	O
BPH	O
tissues	O
.	O

However	O
,	O
a	O
stromal	O
and	O
epithelial	O
pattern	O
of	O
HA	O
and	O
HYAL1	B
expression	O
was	O
observed	O
in	O
CaP	O
tissues	O
.	O

While	O
high	O
HA	O
staining	O
was	O
observed	O
in	O
tumor	O
-	O
associated	O
stroma	O
,	O
HYAL1	B
staining	O
in	O
tumor	O
cells	O
increased	O
with	O
tumor	O
grade	O
and	O
metastasis	O
.	O

The	O
gel	O
-	O
filtration	O
column	O
profiles	O
of	O
HA	O
species	O
in	O
NAP	O
,	O
BPH	O
,	O
and	O
CaP	O
tissues	O
were	O
different	O
.	O

While	O
the	O
higher	O
molecular	O
mass	O
and	O
intermediate	O
size	O
HA	O
was	O
found	O
in	O
all	O
tissues	O
,	O
the	O
HA	O
fragments	O
were	O
found	O
only	O
in	O
CaP	O
tissues	O
.	O

In	O
particular	O
,	O
the	O
high	O
-	O
grade	O
CaP	O
tissues	O
,	O
which	O
showed	O
both	O
elevated	O
HA	O
and	O
HYAL1	B
levels	O
,	O
contained	O
angiogenic	O
HA	O
fragments	O
.	O

The	O
stromal	O
-	O
epithelial	O
HA	O
and	O
HYAL1	B
expression	O
may	O
promote	O
angiogenesis	O
in	O
CaP	O
and	O
may	O
serve	O
as	O
prognostic	O
markers	O
for	O
CaP	O
.	O

A	O
family	O
of	O
AP-2	B
proteins	O
down	O
-	O
regulate	O
manganese	B
superoxide	I
dismutase	I
expression	O
.	O

Manganese	B
superoxide	I
dismutase	I
(	O
Mn	B
-	I
SOD	I
)	O
is	O
a	O
primary	O
antioxidant	O
enzyme	O
whose	O
expression	O
is	O
essential	O
for	O
life	O
in	O
oxygen	O
.	O

Mn	B
-	I
SOD	I
has	O
tumor	O
suppressor	O
activity	O
in	O
a	O
wide	O
variety	O
of	O
tumors	O
and	O
transformed	O
cell	O
systems	O
.	O

Our	O
initial	O
observations	O
revealed	O
that	O
Mn	B
-	I
SOD	I
expression	O
was	O
inversely	O
correlated	O
with	O
expression	O
of	O
AP-2	B
transcription	B
factors	I
in	O
normal	O
human	O
fibroblasts	O
and	O
their	O
SV-40	O
transformed	O
counterparts	O
.	O

Thus	O
we	O
hypothesized	O
that	O
AP-2	B
may	O
down	O
-	O
regulate	O
Mn	B
-	I
SOD	I
expression	O
.	O

To	O
examine	O
the	O
functional	O
role	O
of	O
AP-2	B
on	O
Mn	B
-	I
SOD	I
promoter	O
transactivation	O
we	O
cotransfected	O
AP-2	B
-	O
deficient	O
HepG2	O
cells	O
with	O
a	O
human	O
Mn	B
-	I
SOD	I
promoter	O
-	O
reporter	O
construct	O
and	O
expression	O
vectors	O
encoding	O
each	O
of	O
the	O
three	O
known	O
AP-2	B
family	I
members	O
.	O

Our	O
results	O
indicated	O
that	O
AP-2	B
could	O
significantly	O
repress	O
Mn	B
-	I
SOD	I
promoter	O
activity	O
,	O
and	O
that	O
this	O
repression	O
was	O
both	O
Mn	B
-	I
SOD	I
promoter	O
and	O
AP-2	B
-	O
specific	O
.	O

The	O
three	O
AP-2	B
proteins	O
appeared	O
to	O
play	O
distinct	O
roles	O
in	O
Mn	B
-	I
SOD	I
gene	O
regulation	O
.	O

Moreover	O
,	O
although	O
all	O
three	O
AP-2	B
proteins	O
could	O
repress	O
the	O
Mn	B
-	I
SOD	I
promoter	O
,	O
AP-2alpha	B
and	O
AP-2gamma	B
were	O
more	O
active	O
in	O
this	O
regard	O
than	O
AP-2beta	B
.	O

Transcriptional	O
repression	O
by	O
AP-2	B
was	O
not	O
a	O
general	O
effect	O
in	O
this	O
system	O
,	O
because	O
another	O
AP-2	B
-	O
responsive	O
gene	O
,	O
c	B
-	I
erbB	I
-	I
3	I
,	O
was	O
transactivated	O
by	O
AP-2	B
.	O

Repression	O
of	O
Mn	B
-	I
SOD	I
by	O
AP-2	B
was	O
dependent	O
on	O
DNA	O
binding	O
,	O
and	O
expression	O
of	O
AP-2B	B
,	O
a	O
dominant	O
negative	O
incapable	O
of	O
DNA	O
binding	O
,	O
relieved	O
the	O
repression	O
on	O
Mn	B
-	I
SOD	I
promoter	O
and	O
reactivated	O
Mn	B
-	I
SOD	I
expression	O
in	O
the	O
AP-2	B
abundant	O
SV40	O
-	O
transformed	O
fibroblast	O
cell	O
line	O
MRC-5VA	O
.	O

These	O
results	O
indicate	O
that	O
AP-2	B
-	O
mediated	O
transcriptional	O
repression	O
contributes	O
to	O
the	O
constitutively	O
low	O
expression	O
of	O
Mn	B
-	I
SOD	I
in	O
SV40	O
-	O
transformed	O
fibroblasts	O
and	O
suggest	O
a	O
mechanism	O
for	O
Mn	B
-	I
SOD	I
down	O
-	O
regulation	O
in	O
cancer	O
.	O

Visualization	O
of	O
unwinding	O
activity	O
of	O
duplex	O
RNA	O
by	O
DbpA	B
,	O
a	O
DEAD	O
box	O
helicase	B
,	O
at	O
single	O
-	O
molecule	O
resolution	O
by	O
atomic	O
force	O
microscopy	O
.	O

The	O
Escherichia	O
coli	O
protein	O
DbpA	B
is	O
unique	O
in	O
its	O
subclass	O
of	O
DEAD	O
box	O
RNA	B
helicases	I
,	O
because	O
it	O
possesses	O
ATPase	B
-	O
specific	O
activity	O
toward	O
the	O
peptidyl	B
transferase	I
center	O
in	O
23S	O
rRNA	O
.	O

Although	O
its	O
remarkable	O
ATPase	B
activity	O
had	O
been	O
well	O
defined	O
toward	O
various	O
substrates	O
,	O
its	O
RNA	B
helicase	I
activity	O
remained	O
to	O
be	O
characterized	O
.	O

Herein	O
,	O
we	O
show	O
by	O
using	O
biochemical	O
assays	O
and	O
atomic	O
force	O
microscopy	O
that	O
DbpA	B
exhibits	O
ATP	O
-	O
stimulated	O
unwinding	O
activity	O
of	O
RNA	O
duplex	O
regardless	O
of	O
its	O
primary	O
sequence	O
.	O

This	O
work	O
presents	O
an	O
attempt	O
to	O
investigate	O
the	O
action	O
of	O
DEAD	O
box	O
proteins	O
by	O
a	O
single	O
-	O
molecule	O
visualization	O
methodology	O
.	O

Our	O
atomic	O
force	O
microscopy	O
images	O
enabled	O
us	O
to	O
observe	O
directly	O
the	O
unwinding	O
reaction	O
of	O
a	O
DEAD	O
box	O
helicase	B
on	O
long	O
stretches	O
of	O
double	O
-	O
stranded	O
RNA	O
.	O

Specifically	O
,	O
we	O
could	O
differentiate	O
between	O
the	O
binding	O
of	O
DbpA	B
to	O
RNA	O
in	O
the	O
absence	O
of	O
ATP	O
and	O
the	O
formation	O
of	O
a	O
Y	O
-	O
shaped	O
intermediate	O
after	O
its	O
progression	O
through	O
double	O
-	O
stranded	O
RNA	O
in	O
the	O
presence	O
of	O
ATP	O
.	O

Recent	O
studies	O
have	O
questioned	O
the	O
designation	O
of	O
DbpA	B
,	O
in	O
particular	O
,	O
and	O
DEAD	O
box	O
proteins	O
in	O
general	O
as	O
RNA	B
helicases	I
.	O

However	O
,	O
accumulated	O
evidence	O
and	O
the	O
results	O
reported	O
herein	O
suggest	O
that	O
these	O
proteins	O
are	O
indeed	O
helicases	B
that	O
resemble	O
in	O
many	O
aspects	O
the	O
DNA	B
helicases	I
.	O

Expression	O
and	O
functional	O
analysis	O
of	O
chemokine	B
receptors	I
in	O
human	O
peripheral	O
blood	O
leukocyte	O
populations	O
.	O

Emerging	O
evidence	O
indicates	O
that	O
chemokine	B
receptor	I
expression	O
patterns	O
are	O
critical	O
in	O
determining	O
the	O
spectrum	O
of	O
action	O
of	O
the	O
chemokines	B
.	O

We	O
have	O
analysed	O
the	O
expression	O
patterns	O
of	O
17	O
chemokine	B
receptors	I
and	O
two	O
orphan	O
chemokine	B
receptor	I
-	O
like	O
genes	O
in	O
various	O
freshly	O
prepared	O
human	O
peripheral	O
blood	O
leucocyte	O
populations	O
,	O
including	O
neutrophils	O
,	O
lymphocytes	O
,	O
and	O
naÃ?Â¯ve	O
and	O
differentiated	O
monocytes	O
using	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
TaqMan	O
)	O
.	O

This	O
is	O
the	O
first	O
comprehensive	O
study	O
of	O
chemokine	B
receptor	I
expression	O
in	O
such	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O

Human	O
peripheral	O
blood	O
leukocyte	O
populations	O
were	O
found	O
to	O
express	O
a	O
wide	O
range	O
of	O
chemokine	B
receptors	I
that	O
varies	O
depending	O
on	O
cell	O
type	O
and	O
differentiation	O
state	O
.	O

Novel	O
expression	O
patterns	O
of	O
certain	O
chemokine	B
receptors	I
were	O
seen	O
during	O
our	O
analysis	O
.	O

For	O
example	O
,	O
the	O
orphan	O
chemokine	B
receptor	I
HCR	B
was	O
expressed	O
at	O
very	O
high	O
levels	O
by	O
both	O
primary	O
neutrophils	O
and	O
primary	O
monocytes	O
,	O
and	O
was	O
further	O
upregulated	O
on	O
neutrophil	O
activation	O
and	O
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
.	O

When	O
neutrophil	O
calcium	O
transients	O
were	O
measured	O
in	O
response	O
to	O
a	O
panel	O
of	O
30	O
different	O
chemokines	B
the	O
results	O
clearly	O
correlated	O
with	O
the	O
chemokine	B
receptor	I
expression	O
profile	O
.	O

For	O
example	O
strong	O
calcium	O
responses	O
were	O
seen	O
in	O
neutrophils	O
following	O
stimulation	O
with	O
the	O
CXCR1	B
and	O
CXCR2	B
ligands	O
,	O
interleukin	B
(	I
IL-	I
)	I
8	I
,	O
GCP-2	B
and	O
Gro	B
-	I
beta	I
.	O

These	O
data	O
have	O
implications	O
for	O
the	O
study	O
of	O
the	O
functional	O
responses	O
of	O
leukocytes	O
to	O
external	O
stimuli	O
and	O
will	O
aid	O
in	O
our	O
understanding	O
of	O
general	O
leukocyte	O
biology	O
.	O

Case	O
-	O
control	O
study	O
of	O
ovarian	O
cancer	O
and	O
polymorphisms	O
in	O
genes	O
involved	O
in	O
catecholestrogen	O
formation	O
and	O
metabolism	O
.	O

Steroid	O
hormones	O
,	O
such	O
as	O
estrogens	O
,	O
appear	O
to	O
be	O
associated	O
with	O
ovarian	O
carcinogenesis	O
,	O
but	O
the	O
precise	O
biological	O
mechanisms	O
are	O
unclear	O
.	O

Polymorphisms	O
in	O
genes	O
that	O
regulate	O
the	O
concentration	O
of	O
estrogens	O
and	O
their	O
metabolites	O
may	O
contribute	O
directly	O
to	O
the	O
individual	O
variation	O
in	O
ovarian	O
cancer	O
risk	O
through	O
a	O
mechanism	O
involving	O
oxidative	O
stress	O
or	O
indirectly	O
by	O
influencing	O
ovarian	O
cancer	O
susceptibility	O
associated	O
with	O
ovulation	O
and	O
reproduction	O
.	O

We	O
conducted	O
a	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
of	O
primary	O
ovarian	O
cancer	O
between	O
1993	O
and	O
1999	O
in	O
Hawaii	O
to	O
test	O
several	O
genetic	O
and	O
related	O
hypotheses	O
.	O

A	O
personal	O
interview	O
and	O
blood	O
specimen	O
were	O
obtained	O
in	O
the	O
subjects	O
'	O
homes	O
.	O

In	O
a	O
sample	O
of	O
129	O
epithelial	O
ovarian	O
cancer	O
cases	O
and	O
144	O
controls	O
,	O
we	O
compared	O
the	O
frequencies	O
of	O
several	O
polymorphisms	O
in	O
genes	O
that	O
regulate	O
steroid	O
hormone	O
metabolism	O
and	O
catecholestrogen	O
formation	O
.	O

Multivariate	O
unconditional	O
logistic	O
regression	O
was	O
used	O
to	O
model	O
the	O
association	O
of	O
each	O
genetic	O
polymorphism	O
separately	O
after	O
adjusting	O
for	O
age	O
,	O
ethnicity	O
,	O
and	O
other	O
covariates	O
.	O

The	O
high	O
-	O
activity	O
Val432	O
allele	O
of	O
the	O
CYP1B1	B
gene	O
,	O
which	O
may	O
be	O
linked	O
to	O
oxidative	O
stress	O
through	O
elevated	O
4-hydroxylated	O
catecholestrogen	O
formation	O
,	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ovarian	O
cancer	O
.	O

The	O
Val	O
/	O
Leu	O
genotype	O
for	O
CYP1B1	B
was	O
associated	O
with	O
an	O
odds	O
ratio	O
of	O
1.8	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1.0	O
-	O
3.3	O
)	O
and	O
the	O
Val	O
/	O
Val	O
genotype	O
with	O
an	O
odds	O
ratio	O
of	O
3.8	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1.2	O
-	O
11.4	O
)	O
compared	O
with	O
the	O
Leu	O
/	O
Leu	O
genotype	O
(	O
P	O
=	O
0.005	O
)	O
.	O

Tobacco	O
smokers	O
with	O
at	O
least	O
one	O
CYP1A1	B
(	O
MspI	O
)	O
m2	O
allele	O
,	O
one	O
CYP1B1	B
Val	O
allele	O
,	O
one	O
COMT	B
Met	O
allele	O
,	O
or	O
two	O
CYP1A2	B
A	O
alleles	O
were	O
at	O
significantly	O
increased	O
risk	O
of	O
ovarian	O
cancer	O
compared	O
to	O
never	O
-	O
smokers	O
with	O
CYP1A1	B
(	O
MspI	O
)	O
ml	O
/	O
ml	O
,	O
CYP1B1	B
Leu	O
/	O
Leu	O
,	O
COMT	B
Val	O
/	O
Val	O
,	O
or	O
CYP1A2	B
A	O
/	O
A	O
genotypes	O
,	O
respectively	O
.	O

We	O
found	O
a	O
positive	O
statistical	O
interaction	O
(	O
P	O
=	O
0.03	O
)	O
between	O
tobacco	O
smoking	O
and	O
the	O
CYP1A1	B
(	O
MspI	O
)	O
polymorphism	O
on	O
the	O
risk	O
of	O
ovarian	O
cancer	O
.	O

None	O
of	O
the	O
other	O
gene	O
-	O
environment	O
(	O
pregnancy	O
,	O
oral	O
contraceptive	O
pill	O
use	O
)	O
or	O
gene	O
-	O
gene	O
interactions	O
were	O
statistically	O
significant	O
.	O

Although	O
not	O
significant	O
,	O
there	O
was	O
a	O
suggestion	O
that	O
the	O
effect	O
of	O
the	O
CYP1B1	B
Val	O
allele	O
was	O
reduced	O
substantially	O
in	O
the	O
presence	O
of	O
the	O
high	O
-	O
activity	O
COMT	B
Met	O
allele	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
CYP1B1	B
-	O
Val	O
allele	O
and	O
perhaps	O
other	O
genetic	O
polymorphisms	O
in	O
combination	O
with	O
environmental	O
or	O
hormonal	O
exposures	O
are	O
susceptibility	O
factors	O
for	O
ovarian	O
cancer	O
.	O

Cathepsin	B
S	I
regulates	O
the	O
expression	O
of	O
cathepsin	B
L	I
and	O
the	O
turnover	O
of	O
gamma	B
-	I
interferon	I
-	I
inducible	I
lysosomal	I
thiol	I
reductase	I
in	O
B	O
lymphocytes	O
.	O

Loading	O
of	O
antigenic	O
peptide	O
fragments	O
on	O
major	B
histocompatibility	I
complex	I
class	I
II	I
molecules	O
is	O
essential	O
for	O
generation	O
of	O
CD4	B
(	O
+	O
)	O
T	O
cell	O
responses	O
and	O
occurs	O
after	O
cathepsin	B
-	O
mediated	O
degradation	O
of	O
the	O
invariant	B
chain	I
chaperone	B
molecule	O
.	O

Cathepsins	B
are	O
expressed	O
differentially	O
in	O
antigen	O
presenting	O
cells	O
,	O
and	O
mice	O
deficient	O
in	O
cathepsin	B
S	I
or	O
cathepsin	B
L	I
exhibit	O
severely	O
impaired	O
antigen	O
presentation	O
in	O
peripheral	O
lymphoid	O
organs	O
and	O
the	O
thymus	O
,	O
respectively	O
.	O

To	O
determine	O
whether	O
these	O
defects	O
are	O
due	O
solely	O
to	O
the	O
block	O
in	O
invariant	B
chain	I
cleavage	O
,	O
we	O
used	O
cathepsin	B
-	O
deficient	O
B	O
cells	O
to	O
examine	O
the	O
role	O
of	O
cathepsins	B
S	I
and	I
B	I
in	O
the	O
degradation	O
of	O
other	O
molecules	O
important	O
in	O
the	O
class	O
II	O
presentation	O
pathway	O
.	O

Our	O
data	O
indicate	O
that	O
neither	O
cathepsin	B
S	I
nor	I
B	I
is	O
critical	O
for	O
H-2	B
M	I
degradation	O
or	O
processing	O
of	O
precursor	O
gamma	B
-	I
interferon	I
-	I
inducible	I
lysosomal	I
thiol	I
reductase	I
(	O
GILT	B
)	O
to	O
a	O
mature	O
thiol	B
reductase	I
,	O
but	O
suggest	O
a	O
role	O
for	O
cathepsin	B
S	I
in	O
the	O
turnover	O
of	O
mature	O
GILT	B
and	O
in	O
regulating	O
levels	O
of	O
mature	O
cathepsin	B
L	I
protein	O
in	O
B	O
cells	O
.	O

Despite	O
the	O
presence	O
of	O
mature	O
cathepsin	B
L	I
protein	O
,	O
no	O
enzyme	O
activity	O
could	O
be	O
detected	O
in	O
B	O
cells	O
or	O
dendritic	O
cells	O
.	O

These	O
experiments	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
these	O
functionally	O
important	O
enzymes	O
may	O
be	O
regulated	O
.	O

IFN	B
-	I
beta1b	I
augments	O
glucocorticoid	O
-	O
induced	O
suppression	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
production	O
by	O
increasing	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
on	O
a	O
human	O
monocytic	O
cell	O
line	O
.	O

We	O
studied	O
the	O
effect	O
of	O
recombinant	O
interferon	B
-	I
beta1b	I
(	O
IFN	B
-	I
beta1b	I
)	O
on	O
the	O
sensitivity	O
to	O
glucocorticoids	O
(	O
GC	O
)	O
and	O
on	O
the	O
number	O
of	O
GC	B
receptors	I
(	O
GCR	B
)	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
THP-1	O
.	O

We	O
found	O
that	O
IFN	B
-	I
beta1b	I
augments	O
the	O
suppressive	O
effect	O
that	O
dexamethasone	O
has	O
on	O
the	O
stimulated	O
production	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
most	O
likely	O
related	O
to	O
the	O
increased	O
number	O
of	O
GCR	B
observed	O
after	O
exposure	O
to	O
IFN	B
-	I
beta1b	I
.	O

This	O
provides	O
a	O
possible	O
clue	O
to	O
the	O
mechanism	O
of	O
action	O
of	O
IFN	B
-	I
beta	I
in	O
multiple	O
sclerosis	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
human	O
galactose	B
3-O	I
-	I
sulfotransferase	I
that	O
transfers	O
sulfate	O
to	O
gal	O
beta	O
1	O
--	O
>	O
3galNAc	O
residue	O
in	O
O	O
-	O
glycans	O
.	O

We	O
have	O
identified	O
a	O
novel	O
galactose	B
3-O	I
-	I
sulfotransferase	I
,	O
termed	O
Gal3ST	B
-	I
4	I
,	O
by	O
analysis	O
of	O
an	O
expression	O
sequence	O
tag	O
using	O
the	O
amino	O
acid	O
sequence	O
of	O
human	O
cerebroside	B
3'-sulfotransferase	I
(	O
Gal3ST-1	B
)	O
.	O

The	O
isolated	O
cDNA	O
contains	O
a	O
single	O
open	O
reading	O
frame	O
coding	O
for	O
a	O
protein	O
of	O
486	O
amino	O
acids	O
with	O
a	O
type	O
II	O
transmembrane	O
topology	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
Gal3ST-4	B
revealed	O
33	O
%	O
,	O
39	O
%	O
,	O
and	O
30	O
%	O
identity	O
to	O
human	O
Gal3ST-1	B
,	O
Gal	B
beta	I
1	I
--	I
>	I
3	I
/	I
4GlcNAc	I
:	I
-->3'-sulfotransferase	I
(	O
Gal3ST-2	B
)	O
and	O
Gal	B
beta	I
1	I
--	I
>	I
4GlcNAc	I
:	I
--	I
>	I
3	I
'	I
-	I
sulfotransferase	I
(	O
Gal3ST	B
-	I
3	I
)	O
,	O
respectively	O
.	O

The	O
Gal3ST-4	B
gene	O
comprised	O
at	O
least	O
four	O
exons	O
and	O
was	O
located	O
on	O
human	O
chromosome	O
7q22	O
.	O

Expression	O
of	O
Gal3ST-4	B
in	O
COS-7	O
cells	O
produced	O
a	O
sulfotransferase	B
activity	O
that	O
catalyzes	O
the	O
transfer	O
of	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfate	O
to	O
the	O
C-3	O
'	O
position	O
of	O
Gal	O
beta	O
1	O
--	O
>	O
3GalNAc	O
alpha	O
1-O	O
-	O
Bn	O
.	O

Gal3ST-4	B
recognizes	O
Gal	O
beta	O
1	O
--	O
>	O
3GalNAc	O
and	O
Gal	O
beta	O
1	O
--	O
>	O
3	O
(	O
GlcNAc	O
beta	O
1	O
--	O
>	O
6	O
)	O
GalNAc	O
as	O
good	O
substrates	O
,	O
but	O
not	O
Gal	O
beta	O
1	O
--	O
>	O
3GalNAc	O
(	O
OH	O
)	O
or	O
Gal	O
beta	O
1	O
-->3	O
/	O
4GlcNAc	O
.	O

Asialofetuin	O
is	O
also	O
a	O
good	O
substrate	O
,	O
and	O
the	O
sulfation	O
was	O
found	O
exclusively	O
in	O
O	O
-	O
linked	O
glycans	O
that	O
consist	O
of	O
the	O
Gal	O
beta	O
1	O
--	O
>	O
3GalNAc	O
moiety	O
,	O
suggesting	O
that	O
the	O
enzyme	O
is	O
specific	O
for	O
O	O
-	O
linked	O
glycans	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
2.5	O
-	O
kilobase	O
mRNA	O
for	O
the	O
enzyme	O
is	O
expressed	O
extensively	O
in	O
various	O
tissues	O
.	O

These	O
results	O
suggest	O
that	O
Gal3ST-4	B
is	O
the	O
fourth	O
member	O
of	O
a	O
Gal	B
:	I
--	I
>	I
3	I
-	I
sulfotransferase	I
family	I
and	O
that	O
the	O
four	O
members	O
,	O
Gal3ST-1	B
,	O
Gal3ST-2	B
,	O
Gal3ST-3	B
,	O
and	O
Gal3ST-4	B
,	O
are	O
responsible	O
for	O
sulfation	O
of	O
different	O
acceptor	O
substrates	O
.	O

Protein	B
tyrosine	I
kinase	I
regulates	O
FAS	B
-	O
mediated	O
apoptosis	O
in	O
human	O
BCG	O
-	O
infected	O
monocytes	O
.	O

Apoptosis	O
of	O
monocytes	O
/	O
macrophages	O
has	O
emerged	O
as	O
a	O
central	O
regulatory	O
event	O
in	O
the	O
defense	O
against	O
mycobacterial	O
infections	O
.	O

The	O
involvement	O
of	O
protein	B
tyrosine	I
kinases	I
(	O
PTK	B
)	O
in	O
Fas	B
-	O
mediated	O
apoptosis	O
in	O
T	O
cells	O
is	O
well	O
established	O
,	O
but	O
the	O
possible	O
role	O
of	O
PTK	B
in	O
Fas	B
-	O
dependent	O
death	O
of	O
human	O
bacillus	O
Calmette	O
-	O
Guerin	O
(	O
BCG	O
)	O
-	O
infected	O
monocytes	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
first	O
examined	O
the	O
expression	O
and	O
function	O
of	O
Fas	B
on	O
BCG	O
-	O
infected	O
human	O
monocytes	O
by	O
flow	O
cytometry	O
.	O

The	O
results	O
demonstrated	O
that	O
BCG	O
-	O
infected	O
monocytes	O
expressed	O
significant	O
Fas	B
protein	O
levels	O
.	O

In	O
addition	O
,	O
engagement	O
of	O
the	O
Fas	B
antigen	O
with	O
its	O
agonistic	O
antibody	O
(	O
Ab	O
)	O
resulted	O
in	O
apoptosis	O
of	O
monocytes	O
,	O
as	O
monitored	O
by	O
DNA	O
analysis	O
and	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
(	O
FACS	O
)	O
analysis	O
.	O

The	O
apoptotic	O
action	O
of	O
Fas	B
was	O
suppressed	O
significantly	O
by	O
genistein	O
,	O
indicating	O
a	O
role	O
for	O
PTK	B
in	O
this	O
death	O
process	O
.	O

Consistent	O
with	O
this	O
observation	O
,	O
herbimycin	O
A	O
and	O
tyrphostin	O
,	O
two	O
selective	O
tyrosine	B
kinase	I
inhibitors	O
with	O
different	O
mechanisms	O
of	O
action	O
,	O
effectively	O
inhibited	O
Fas	B
-	O
mediated	O
apoptosis	O
of	O
BCG	O
-	O
infected	O
monocytes	O
,	O
as	O
demonstrated	O
by	O
DNA	O
content	O
analysis	O
.	O

Moreover	O
,	O
we	O
confirmed	O
the	O
effect	O
of	O
genistein	O
,	O
herbimycin	O
A	O
,	O
and	O
tyrphostin	O
by	O
examining	O
apoptosis	O
with	O
the	O
terminal	B
transferase	I
dUTP	O
nick	O
endlabeling	O
(	O
TUNEL	O
)	O
assay	O
.	O

Collectively	O
,	O
these	O
data	O
demonstrate	O
that	O
Fas	B
-	O
induced	O
apoptosis	O
may	O
represent	O
an	O
important	O
mechanism	O
for	O
eliminating	O
BCG	O
-	O
activated	O
human	O
monocytes	O
and	O
that	O
this	O
apoptosis	O
is	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
signaling	O
via	O
a	O
PTK	B
pathway	O
.	O

Quaternary	O
structure	O
of	O
the	O
ATPase	B
complex	O
of	O
human	O
26S	O
proteasomes	O
determined	O
by	O
chemical	O
cross	O
-	O
linking	O
.	O

The	O
26S	O
proteasome	O
is	O
the	O
major	O
protease	B
responsible	O
for	O
nonlysosomal	O
protein	O
degradation	O
in	O
eukaryotic	O
cells	O
.	O

The	O
enzyme	O
is	O
composed	O
of	O
two	O
subparticles	O
:	O
the	O
20S	O
proteasome	O
,	O
and	O
a	O
19S	B
regulatory	I
particle	I
(	O
PA700	B
)	O
which	O
binds	O
to	O
the	O
ends	O
of	O
the	O
20S	O
proteasome	O
cylinder	O
and	O
accounts	O
for	O
ATP	O
dependence	O
and	O
substrate	O
specificity	O
.	O

Among	O
the	O
approximately	O
18	O
subunits	O
of	O
PA700	B
regulator	I
,	O
six	O
are	O
ATPases	B
.	O

The	O
ATPases	B
presumably	O
recognize	O
,	O
unfold	O
,	O
and	O
translocate	O
substrates	O
into	O
the	O
interior	O
of	O
the	O
26S	O
proteasome	O
.	O

It	O
is	O
generally	O
believed	O
that	O
the	O
ATPases	B
form	O
a	O
hexameric	O
ring	O
.	O

By	O
means	O
of	O
chemical	O
cross	O
-	O
linking	O
,	O
immunoprecipitation	O
,	O
and	O
blotting	O
,	O
we	O
have	O
determined	O
that	O
the	O
ATPases	B
are	O
organized	O
in	O
the	O
order	O
S6	O
-	O
S6	O
'	O
-	O
S10b	B
-	O
S8	O
-	O
S4-S7	O
.	O

Additionally	O
,	O
we	O
found	O
cross	O
-	O
links	O
between	O
the	O
ATPase	B
S10b	I
and	O
the	O
20S	B
proteasome	I
subunit	I
alpha6	I
.	O

Together	O
with	O
the	O
previously	O
known	O
interaction	O
between	O
S8	O
and	O
alpha1	O
and	O
between	O
S4	O
and	O
alpha7	O
,	O
these	O
data	O
establish	O
the	O
relative	O
orientations	O
of	O
ATPases	B
with	O
respect	O
to	O
the	O
20S	O
proteasome	O
.	O

Characterization	O
of	O
the	O
gene	O
family	O
encoding	O
alternative	B
oxidase	I
from	O
Candida	O
albicans	O
.	O

Candida	O
albicans	O
possesses	O
a	O
cyanide	O
-	O
resistant	O
respiratory	O
pathway	O
mediated	O
by	O
alternative	B
oxidase	I
(	O
AOX	B
)	O
,	O
which	O
seems	O
to	O
be	O
encoded	O
by	O
a	O
gene	O
family	O
with	O
two	O
members	O
.	O

Cloning	O
and	O
expression	O
of	O
AOX1a	B
,	O
one	O
of	O
the	O
genes	O
encoding	O
alternative	B
oxidase	I
from	O
C.	O
albicans	O
,	O
has	O
previously	O
been	O
reported	O
[	O
Huh	O
and	O
Kang	O
(	O
1999	O
)	O
J.	O
Bacteriol	O
.	O
181	O
,	O
4098	O
-	O
4102	O
]	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
the	O
isolation	O
of	O
another	O
gene	O
coding	O
for	O
alternative	B
oxidase	I
,	O
designated	O
AOX1b	B
.	O

AOX1b	B
contains	O
a	O
continuous	O
open	O
reading	O
frame	O
that	O
encodes	O
a	O
polypeptide	O
consisting	O
of	O
365	O
amino	O
acids	O
.	O

Interestingly	O
,	O
AOX1a	B
and	O
AOX1b	B
were	O
found	O
to	O
be	O
located	O
in	O
tandem	O
on	O
one	O
of	O
the	O
chromosomes	O
of	O
C.	O
albicans	O
.	O

The	O
presence	O
of	O
cyanide	O
in	O
the	O
culture	O
medium	O
remarkably	O
retarded	O
the	O
growth	O
of	O
the	O
aox1a	B
/	O
aox1a	B
mutants	O
.	O

The	O
growth	O
of	O
the	O
aox1b	B
/	O
aox1b	B
mutants	O
and	O
the	O
aox1a	B
/	O
aox1a	B
aox1b	B
/	O
aox1b	B
double	O
mutants	O
was	O
almost	O
completely	O
inhibited	O
in	O
the	O
same	O
medium	O
.	O

beta	B
-	I
Galactosidase	I
reporter	O
assays	O
indicated	O
that	O
,	O
whereas	O
AOX1a	B
was	O
expressed	O
constitutively	O
,	O
the	O
expression	O
of	O
AOX1b	B
was	O
dependent	O
on	O
growth	O
phase	O
and	O
was	O
induced	O
by	O
treatment	O
with	O
cyanide	O
,	O
antimycin	O
A	O
,	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
,	O
menadione	O
and	O
paraquat	O
.	O

Growth	O
of	O
the	O
cells	O
in	O
media	O
with	O
non	O
-	O
fermentable	O
carbon	O
sources	O
also	O
enhanced	O
the	O
expression	O
of	O
AOX1b	B
.	O

CaSLN1	B
,	O
which	O
encodes	O
a	O
histidine	B
kinase	I
,	O
seems	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
AOX	B
expression	O
in	O
C.	O
albicans	O
on	O
the	O
basis	O
of	O
the	O
observation	O
that	O
the	O
activity	O
of	O
cyanide	O
-	O
resistant	O
respiration	O
and	O
the	O
expression	O
level	O
of	O
AOX	B
in	O
the	O
casln1	B
/	O
casln1	B
mutants	O
were	O
found	O
to	O
be	O
significantly	O
low	O
under	O
normal	O
conditions	O
and	O
slightly	O
increased	O
in	O
the	O
presence	O
of	O
respiratory	O
inhibitors	O
compared	O
with	O
the	O
wild	O
-	O
type	O
strain	O
.	O

Like	O
AOX1a	B
,	O
AOX1b	B
could	O
also	O
be	O
functionally	O
expressed	O
in	O
AOX	B
-	O
deficient	O
Saccharomyces	O
cerevisiae	O
and	O
confer	O
cyanide	O
-	O
resistant	O
respiration	O
on	O
the	O
organism	O
.	O

The	O
hemidesmosomal	O
protein	O
bullous	B
pemphigoid	I
antigen	I
1	I
and	O
the	O
integrin	B
beta	I
4	I
subunit	O
bind	O
to	O
ERBIN	B
.	O

Molecular	O
cloning	O
of	O
multiple	O
alternative	O
splice	O
variants	O
of	O
ERBIN	B
and	O
analysis	O
of	O
their	O
tissue	O
expression	O
.	O

The	O
bullous	B
pemphigoid	I
antigen	I
1	I
(	O
eBPAG1	B
)	O
is	O
a	O
constituent	O
of	O
hemidesmosomes	O
(	O
HDs	O
)	O
,	O
cell	O
-	O
substrate	O
adhesion	O
complexes	O
in	O
stratified	O
epithelia	O
.	O

Although	O
its	O
COOH	O
terminus	O
interacts	O
with	O
intermediate	O
filaments	O
,	O
its	O
NH	O
(	O
2	O
)	O
terminus	O
is	O
important	O
for	O
its	O
recruitment	O
into	O
HDs	O
.	O

To	O
identify	O
proteins	O
that	O
interact	O
with	O
the	O
NH	O
(	O
2	O
)	O
terminus	O
of	O
human	O
eBPAG1	B
,	O
we	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
which	O
uncovered	O
a	O
protein	O
belonging	O
to	O
the	O
LAP	B
/	I
LERP	I
(	I
for	I
LRR	I
and	I
PDZ	I
domain	I
)	I
protein	I
family	I
with	O
16	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
leucine	O
-	O
rich	O
repeats	O
and	O
a	O
COOH	O
-	O
terminal	O
PDZ	O
domain	O
.	O

The	O
gene	O
for	O
this	O
LAP	B
/	O
LERP	O
protein	O
comprises	O
at	O
least	O
26	O
exons	O
located	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
.	O

In	O
most	O
human	O
tissues	O
,	O
several	O
transcripts	O
were	O
detected	O
differing	O
in	O
the	O
coding	O
region	O
situated	O
upstream	O
of	O
or	O
within	O
the	O
PDZ	O
domain	O
.	O

One	O
of	O
the	O
encoded	O
variants	O
was	O
found	O
to	O
correspond	O
to	O
the	O
recently	O
described	O
protein	O
ERBIN	B
.	O

In	O
yeast	O
and	O
in	O
vitro	O
binding	O
experiments	O
,	O
ERBIN	B
was	O
shown	O
to	O
interact	O
not	O
only	O
with	O
eBPAG1	B
but	O
also	O
with	O
the	O
COOH	O
-	O
terminal	O
region	O
of	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
integrin	B
beta4	I
subunit	O
,	O
another	O
component	O
of	O
HDs	O
.	O

Antibodies	O
raised	O
against	O
the	O
COOH	O
terminus	O
showed	O
that	O
ERBIN	B
is	O
expressed	O
in	O
keratinocytes	O
.	O

In	O
transfected	O
epithelial	O
cells	O
the	O
protein	O
,	O
however	O
,	O
was	O
not	O
localized	O
in	O
HDs	O
but	O
was	O
either	O
diffusely	O
distributed	O
over	O
the	O
cytoplasm	O
or	O
concentrated	O
at	O
the	O
basolateral	O
plasma	O
membrane	O
.	O

Because	O
ERBIN	B
had	O
been	O
shown	O
previously	O
to	O
interact	O
with	O
the	O
transmembrane	O
tyrosine	B
kinase	I
receptor	I
Erb	B
-	I
B2	I
,	O
which	O
in	O
turn	O
associates	O
with	O
the	O
integrin	B
beta4	I
subunit	O
,	O
we	O
suggest	O
that	O
ERBIN	B
provides	O
a	O
link	O
between	O
HD	O
assembly	O
and	O
Erb	B
-	I
B2	I
receptor	O
signaling	O
.	O

MÃ?Â¼llerian	B
inhibiting	I
substance	I
signaling	O
uses	O
a	O
bone	B
morphogenetic	I
protein	I
(	O
BMP	B
)	O
-	O
like	O
pathway	O
mediated	O
by	O
ALK2	B
and	O
induces	O
SMAD6	B
expression	O
.	O

Signal	O
reception	O
of	O
MÃ?Â¼llerian	B
inhibiting	I
substance	I
(	O
MIS	B
)	O
in	O
the	O
mesenchyme	O
around	O
the	O
embryonic	O
MÃ?Â¼llerian	O
duct	O
in	O
the	O
male	O
is	O
essential	O
for	O
regression	O
of	O
the	O
duct	O
.	O

Deficiency	O
of	O
MIS	B
or	O
of	O
the	O
MIS	B
type	I
II	I
receptor	I
,	O
MISRII	B
,	O
results	O
in	O
abnormal	O
reproductive	O
development	O
in	O
the	O
male	O
due	O
to	O
the	O
maintenance	O
of	O
the	O
duct	O
.	O

MIS	B
is	O
a	O
member	O
of	O
the	O
transforming	B
growth	I
factor	I
-	I
beta	I
(	I
TGFbeta	I
)	I
superfamily	I
of	O
secreted	O
protein	O
hormones	O
that	O
signal	O
through	O
receptor	O
complexes	O
of	O
type	B
I	I
and	I
type	I
II	I
serine	I
/	I
threonine	I
kinase	I
receptors	I
.	O

To	O
investigate	O
candidate	O
MIS	B
type	I
I	I
receptors	I
,	O
we	O
examined	O
reporter	O
construct	O
activation	O
by	O
MIS	B
.	O

The	O
bone	B
morphogenetic	I
protein	I
(	O
BMP	B
)	O
-	O
responsive	O
Tlx2	B
and	O
Xvent2	B
promoter	O
-	O
driven	O
reporter	O
constructs	O
were	O
stimulated	O
by	O
MIS	B
but	O
the	O
TGFbeta	B
/	O
activin	B
-	O
induced	O
p3TP	O
-	O
lux	B
or	O
CAGA	O
-	O
luc	B
reporter	O
constructs	O
were	O
not	O
.	O

The	O
induction	O
of	O
Tlx2	B
-	O
luc	B
was	O
dependent	O
upon	O
the	O
kinase	B
activity	O
of	O
MISRII	B
and	O
was	O
blocked	O
by	O
a	O
dominant	O
negative	O
truncated	O
ALK2	B
(	O
tALK2	B
)	O
receptor	O
but	O
not	O
by	O
truncated	O
forms	O
of	O
the	O
other	O
BMP	B
type	I
I	I
receptors	I
ALK1	B
,	O
ALK3	B
,	O
or	O
ALK6	B
.	O

MIS	B
induced	O
activation	O
of	O
a	O
Gal4DBD	O
-	O
Smad1	B
but	O
not	O
a	O
Gal4DBD	O
-	O
Smad2	B
fusion	O
protein	O
.	O

This	O
activation	O
could	O
also	O
be	O
blocked	O
by	O
tALK2	B
.	O

The	O
BMP	B
-	O
induced	O
inhibitory	O
Smad	B
,	O
Smad6	B
,	O
was	O
up	O
-	O
regulated	O
by	O
MIS	B
endogenously	O
in	O
Leydig	O
cell	O
-	O
derived	O
lines	O
and	O
is	O
expressed	O
in	O
male	O
but	O
not	O
female	O
MÃ?Â¼llerian	O
duct	O
mesenchyme	O
.	O

ALK6	B
has	O
been	O
shown	O
to	O
function	O
as	O
an	O
MIS	B
type	I
I	I
receptor	I
.	O

Investigation	O
of	O
the	O
pattern	O
of	O
ALK2	B
,	O
MISRII	B
,	O
and	O
ALK6	B
in	O
the	O
developing	O
urogenital	O
system	O
demonstrated	O
overlapping	O
expression	O
of	O
ALK2	B
and	O
MISRII	B
in	O
the	O
mesenchyme	O
surrounding	O
the	O
duct	O
while	O
ALK6	B
was	O
observed	O
only	O
in	O
the	O
epithelium	O
.	O

Examination	O
of	O
ALK6	B
-	O
/	O
-	O
male	O
animals	O
revealed	O
no	O
defect	O
in	O
duct	O
regression	O
.	O

The	O
reporter	O
construct	O
analysis	O
,	O
pattern	O
of	O
expression	O
of	O
the	O
receptors	O
,	O
and	O
analysis	O
of	O
ALK6	B
-	O
deficient	O
animals	O
suggest	O
that	O
ALK2	B
is	O
the	O
MIS	B
type	I
I	I
receptor	I
involved	O
in	O
MÃ?Â¼llerian	O
duct	O
regression	O
.	O

SET	B
-	O
related	O
cell	B
division	I
autoantigen-1	I
(	O
CDA1	B
)	O
arrests	O
cell	O
growth	O
.	O

We	O
used	O
an	O
autoimmune	O
serum	O
from	O
a	O
patient	O
with	O
discoid	O
lupus	O
erythematosus	O
to	O
clone	O
a	O
cDNA	O
of	O
2808	O
base	O
pairs	O
.	O

Its	O
open	O
reading	O
frame	O
of	O
2079	O
base	O
pairs	O
encodes	O
a	O
predicted	O
polypeptide	O
of	O
693	O
amino	O
acids	O
named	O
CDA1	B
(	O
cell	B
division	I
autoantigen-1	I
)	O
.	O

CDA1	B
has	O
a	O
predicted	O
molecular	O
mass	O
of	O
79,430	O
Daltons	O
and	O
a	O
pI	O
of	O
4.26	O
.	O

The	O
size	O
of	O
the	O
cDNA	O
is	O
consistent	O
with	O
its	O
estimated	O
mRNA	O
size	O
.	O

CDA1	B
comprises	O
an	O
N	O
-	O
terminal	O
proline	O
-	O
rich	O
domain	O
,	O
a	O
central	O
basic	O
domain	O
,	O
and	O
a	O
C	O
-	O
terminal	O
bipartite	O
acidic	O
domain	O
.	O

It	O
has	O
four	O
putative	O
nuclear	O
localization	O
signals	O
and	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
cAMP	B
and	I
cGMP	I
-	I
dependent	I
kinases	I
,	O
protein	B
kinase	I
C	I
,	O
thymidine	B
kinase	I
,	O
casein	B
kinase	I
II	I
,	O
and	O
cyclin	B
-	I
dependent	I
kinases	I
(	O
CDKs	B
)	O
.	O

CDA1	B
is	O
phosphorylated	O
in	O
HeLa	O
cells	O
and	O
by	O
cyclin	B
D1	I
/	O
CDK4	B
,	O
cyclin	B
A	I
/	O
CDK2	B
,	O
and	O
cyclin	B
B	I
/	O
CDK1	B
in	O
vitro	O
.	O

Its	O
basic	O
and	O
acidic	O
domains	O
contain	O
regions	O
homologous	O
to	O
almost	O
the	O
entire	O
human	O
leukemia	O
-	O
associated	O
SET	B
protein	O
.	O

The	O
same	O
basic	O
region	O
is	O
also	O
homologous	O
to	O
nucleosome	O
assembly	O
proteins	O
,	O
testis	O
TSPY	B
protein	O
,	O
and	O
an	O
uncharacterized	O
brain	O
protein	O
.	O

CDA1	B
is	O
present	O
in	O
the	O
nuclear	O
fraction	O
of	O
HeLa	O
cells	O
and	O
localizes	O
to	O
the	O
nucleus	O
and	O
nucleolus	O
in	O
HeLa	O
cells	O
transfected	O
with	O
CDA1	B
or	O
its	O
N	O
terminus	O
containing	O
all	O
four	O
nuclear	O
localization	O
signals	O
.	O

Its	O
acidic	O
C	O
terminus	O
localizes	O
mainly	O
to	O
the	O
cytoplasm	O
.	O

CDA1	B
levels	O
are	O
low	O
in	O
serum	O
-	O
starved	O
cells	O
,	O
increasing	O
dramatically	O
with	O
serum	O
stimulation	O
.	O

Expression	O
of	O
the	O
CDA1	B
transgene	O
,	O
but	O
not	O
its	O
N	O
terminus	O
,	O
arrests	O
HeLa	O
cell	O
growth	O
,	O
colony	O
numbers	O
,	O
cell	O
density	O
,	O
and	O
bromodeoxyuridine	O
uptake	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
ability	O
of	O
CDA1	B
to	O
arrest	O
cell	O
growth	O
is	O
abolished	O
by	O
mutation	O
of	O
the	O
two	O
CDK	B
consensus	O
phosphorylation	O
sites	O
.	O

We	O
propose	O
that	O
CDA1	B
is	O
a	O
negative	O
regulator	O
of	O
cell	O
growth	O
and	O
that	O
its	O
activity	O
is	O
regulated	O
by	O
its	O
expression	O
level	O
and	O
phosphorylation	O
.	O

Yeast	O
histone	B
deposition	O
protein	O
Asf1p	B
requires	O
Hir	B
proteins	O
and	O
PCNA	B
for	O
heterochromatic	O
silencing	O
.	O

BACKGROUND	O
:	O

Position	O
-	O
dependent	O
gene	O
silencing	O
in	O
yeast	O
involves	O
many	O
factors	O
,	O
including	O
the	O
four	O
HIR	B
genes	O
and	O
nucleosome	B
assembly	I
proteins	I
Asf1p	B
and	O
chromatin	B
assembly	I
factor	I
I	I
(	O
CAF	B
-	I
I	I
,	O
encoded	O
by	O
the	O
CAC1	B
-	I
3	I
genes	O
)	O
.	O

Both	O
cac	B
Delta	O
asfl	B
Delta	O
and	O
cac	B
Delta	O
hir	B
Delta	O
double	O
mutants	O
display	O
synergistic	O
reductions	O
in	O
heterochromatic	O
gene	O
silencing	O
.	O

However	O
,	O
the	O
relationship	O
between	O
the	O
contributions	O
of	O
HIR	B
genes	O
and	O
ASF1	B
to	O
silencing	O
has	O
not	O
previously	O
been	O
explored	O
.	O

RESULTS	O
:	O

Our	O
biochemical	O
and	O
genetic	O
studies	O
of	O
yeast	O
Asf1p	B
revealed	O
links	O
to	O
Hir	B
protein	O
function	O
.	O

In	O
vitro	O
,	O
an	O
active	O
histone	B
deposition	I
complex	I
was	O
formed	O
from	O
recombinant	O
yeast	O
Asf1p	B
and	O
histones	B
H3	I
and	O
H4	B
that	O
lack	O
a	O
newly	O
synthesized	O
acetylation	O
pattern	O
.	O

This	O
Asf1p	B
/	O
H3	B
/	O
H4	B
complex	O
generated	O
micrococcal	B
nuclease	I
--	O
resistant	O
DNA	O
in	O
the	O
absence	O
of	O
DNA	O
replication	O
and	O
stimulated	O
nucleosome	O
assembly	O
activity	O
by	O
recombinant	O
yeast	O
CAF	B
-	I
I	I
during	O
DNA	O
synthesis	O
.	O

Also	O
,	O
Asf1p	B
bound	O
to	O
the	O
Hir1p	B
and	O
Hir2p	B
proteins	O
in	O
vitro	O
and	O
in	O
cell	O
extracts	O
.	O

In	O
vivo	O
,	O
the	O
HIR1	B
and	O
ASF1	B
genes	O
contributed	O
to	O
silencing	O
the	O
heterochromatic	O
HML	O
locus	O
via	O
the	O
same	O
genetic	O
pathway	O
.	O

Deletion	O
of	O
either	O
HIR1	B
or	O
ASF1	B
eliminated	O
telomeric	O
gene	O
silencing	O
in	O
combination	O
with	O
pol30	B
--	O
8	O
,	O
encoding	O
an	O
altered	O
form	O
of	O
the	O
DNA	B
polymerase	I
processivity	O
factor	O
PCNA	B
that	O
prevents	O
CAF	B
-	I
I	I
from	O
contributing	O
to	O
silencing	O
.	O

Conversely	O
,	O
other	O
pol30	B
alleles	O
prevented	O
Asf1	B
/	O
Hir	B
proteins	O
from	O
contributing	O
to	O
silencing	O
.	O

CONCLUSIONS	O
:	O

Yeast	O
CAF	B
-	I
I	I
and	O
Asf1p	B
cooperate	O
to	O
form	O
nucleosomes	O
in	O
vitro	O
.	O

In	O
vivo	O
,	O
Asf1p	B
and	O
Hir	B
proteins	O
physically	O
interact	O
and	O
together	O
promote	O
heterochromatic	O
gene	O
silencing	O
in	O
a	O
manner	O
requiring	O
PCNA	B
.	O

This	O
Asf1	B
/	O
Hir	B
silencing	O
pathway	O
functionally	O
overlaps	O
with	O
CAF	B
-	I
I	I
activity	O
.	O

The	O
gene	O
for	O
alternative	B
oxidase-2	I
(	O
AOX2	B
)	O
from	O
Arabidopsis	O
thaliana	O
consists	O
of	O
five	O
exons	O
unlike	O
other	O
AOX	B
genes	O
and	O
is	O
transcribed	O
at	O
an	O
early	O
stage	O
during	O
germination	O
.	O

We	O
investigated	O
the	O
expressions	O
of	O
genes	O
for	O
alternative	B
oxidase	I
(	O
AOX1a	B
,	O
AOX1b	B
,	O
AOX1c	B
and	O
AOX2	B
)	O
and	O
genes	O
for	O
cytochrome	B
c	I
oxidase	I
(	O
COX5b	B
and	O
COX6b	B
)	O
during	O
germination	O
of	O
Arabidopsis	O
thaliana	O
,	O
and	O
examined	O
oxygen	O
uptakes	O
of	O
the	O
alternative	O
respiration	O
and	O
the	O
cytochrome	B
respiration	O
in	O
imbibed	O
Arabidopsis	O
seeds	O
.	O

A	O
Northern	O
blot	O
analysis	O
showed	O
that	O
AOX2	B
mRNA	O
has	O
already	O
accumulated	O
in	O
dry	O
seeds	O
and	O
subsequently	O
decreased	O
,	O
whereas	O
accumulation	O
ofAOX1a	B
mRNA	O
was	O
less	O
abundant	O
from	O
0	O
hours	O
to	O
48	O
hours	O
after	O
imbibition	O
and	O
then	O
increased	O
.	O

The	O
increase	O
of	O
the	O
capacity	O
of	O
the	O
alternative	O
pathway	O
appeared	O
to	O
be	O
dependent	O
on	O
the	O
expressions	O
of	O
both	O
AOX2	B
and	O
AOX1a	B
.	O

On	O
the	O
other	O
hand	O
,	O
steady	O
-	O
state	O
mRNA	O
levels	O
of	O
COX5b	B
and	O
COX6b	B
were	O
gradually	O
increased	O
during	O
germination	O
,	O
and	O
the	O
capacity	O
of	O
the	O
cytochrome	B
pathway	O
was	O
correlated	O
with	O
the	O
increase	O
of	O
expressions	O
of	O
the	O
COX	B
genes	O
.	O

Antimycin	O
A	O
,	O
the	O
respiratory	O
inhibitor	O
,	O
strongly	O
increased	O
the	O
expression	O
of	O
AOX1a	B
but	O
had	O
no	O
effect	O
on	O
the	O
expression	O
of	O
AOX2	B
.	O

A	O
5	O
'	O
RACE	O
analysis	O
showed	O
that	O
AOX2	B
consists	O
of	O
five	O
exons	O
,	O
which	O
is	O
different	O
from	O
the	O
case	O
of	O
most	O
AOX	B
genes	O
identified	O
so	O
far	O
.	O

Analysis	O
of	O
subcellular	O
localization	O
of	O
AOX2	B
using	O
green	B
fluorescent	I
protein	I
indicated	O
that	O
the	O
AOX2	B
protein	O
is	O
imported	O
into	O
the	O
mitochondria	O
.	O

Direct	O
interaction	O
of	O
the	O
Rab3	B
effector	O
RIM	B
with	O
Ca2	B
+	I
channels	I
,	O
SNAP-25	B
,	O
and	O
synaptotagmin	B
.	O

To	O
define	O
the	O
role	O
of	O
the	O
Rab3	B
-	I
interacting	I
molecule	I
RIM	B
in	O
exocytosis	O
we	O
searched	O
for	O
additional	O
binding	O
partners	O
of	O
the	O
protein	O
.	O

We	O
found	O
that	O
the	O
two	O
C	O
(	O
2	O
)	O
domains	O
of	O
RIM	B
display	O
properties	O
analogous	O
to	O
those	O
of	O
the	O
C	O
(	O
2	O
)	O
B	O
domain	O
of	O
synaptotagmin	B
-	I
I	I
.	O

Thus	O
,	O
RIM	B
-	O
C	O
(	O
2	O
)	O
A	O
and	O
RIM	B
-	O
C	O
(	O
2	O
)	O
B	O
bind	O
in	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
independent	O
manner	O
to	O
alpha1B	B
,	O
the	O
pore	O
-	O
forming	O
subunit	O
of	O
N	B
-	I
type	I
Ca	I
(	I
2	I
+	I
)	I
channels	I
(	O
EC	O
(	O
50	O
)	O
=	O
approximately	O
20	O
nm	O
)	O
.	O

They	O
also	O
weakly	O
interact	O
with	O
the	O
alpha1C	B
but	O
not	O
the	O
alpha1D	B
subunit	O
of	O
L	B
-	I
type	I
Ca	I
(	I
2	I
+	I
)	I
channels	I
.	O

In	O
addition	O
,	O
the	O
C	O
(	O
2	O
)	O
domains	O
of	O
RIM	O
associate	O
with	O
SNAP-25	B
and	O
synaptotagmin	B
-	I
I	I
.	O

The	O
binding	O
affinities	O
for	O
these	O
two	O
proteins	O
are	O
203	O
and	O
24	O
nm	O
,	O
respectively	O
,	O
for	O
RIM	B
-	O
C	O
(	O
2	O
)	O
A	O
and	O
224	O
and	O
16	O
nm	O
for	O
RIM	B
-	O
C	O
(	O
2	O
)	O
B	O
.	O

The	O
interactions	O
of	O
the	O
C	O
(	O
2	O
)	O
domains	O
of	O
RIM	B
with	O
SNAP-25	B
and	O
synaptotagmin	B
-	I
I	I
are	O
modulated	O
by	O
Ca	O
(	O
2	O
+	O
)	O
.	O

Thus	O
,	O
in	O
the	O
presence	O
of	O
Ca	O
(	O
2	O
+	O
)	O
(	O
EC	O
(	O
50	O
)	O
=	O
approximately	O
75	O
microm	O
)	O
the	O
interaction	O
with	O
synaptotagmin	B
-	I
I	I
is	O
increased	O
,	O
whereas	O
SNAP-25	B
binding	O
is	O
reduced	O
.	O

Synaptotagmin	B
-	I
I	I
binding	O
is	O
abolished	O
by	O
mutations	O
in	O
two	O
positively	O
charged	O
amino	O
acids	O
in	O
the	O
C	O
(	O
2	O
)	O
domains	O
of	O
RIM	B
and	O
by	O
the	O
addition	O
of	O
inositol	O
polyphosphates	O
.	O

We	O
propose	O
that	O
the	O
Rab3	B
effector	O
RIM	B
is	O
a	O
scaffold	O
protein	O
that	O
participates	O
through	O
its	O
multiple	O
binding	O
partners	O
in	O
the	O
docking	O
and	O
fusion	O
of	O
secretory	O
vesicles	O
at	O
the	O
release	O
sites	O
.	O

Molecular	O
analysis	O
of	O
estrogen	O
induction	O
of	O
preproenkephalin	B
gene	O
expression	O
and	O
its	O
modulation	O
by	O
thyroid	O
hormones	O
.	O

Estrogen	B
receptors	I
(	O
ER	B
)	O
and	O
thyroid	B
hormone	I
receptors	I
(	O
TR	B
)	O
are	O
ligand	O
-	O
dependent	O
nuclear	O
transcription	B
factors	I
.	O

Estrogen	O
-	O
induced	O
preproenkephalin	B
(	O
PPE	B
)	O
gene	O
expression	O
in	O
the	O
hypothalamus	O
is	O
directly	O
related	O
to	O
estrogen	O
-	O
induced	O
lordosis	O
behavior	O
in	O
the	O
rat	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
the	O
PPE	B
mRNA	O
level	O
in	O
the	O
ventromedial	O
hypothalamus	O
of	O
female	O
rats	O
was	O
significantly	O
decreased	O
by	O
ovariectomy	O
.	O

This	O
decrease	O
was	O
reversed	O
by	O
estrogen	O
replacement	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Using	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
,	O
functional	O
estrogen	O
response	O
elements	O
(	O
ERE	O
)	O
were	O
identified	O
between	O
-	O
437	O
and	O
-	O
145	O
base	O
pairs	O
(	O
bp	O
)	O
of	O
the	O
rat	O
PPE	B
gene	O
promoter	O
region	O
.	O

Two	O
ERE	O
-	O
like	O
elements	O
are	O
present	O
between	O
-	O
405	O
and	O
-	O
364	O
of	O
the	O
rat	O
PPE	B
gene	O
promoter	O
,	O
which	O
bind	O
ERalpha	B
as	O
demonstrated	O
by	O
EMSA	O
.	O

Estrogen	O
produced	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
CAT	B
activity	O
in	O
cotransfection	O
assays	O
with	O
ERalpha	B
expression	O
vector	O
and	O
a	O
437PPE	B
-	O
CAT	B
reporter	O
construct	O
containing	O
437	O
bp	O
of	O
the	O
rat	O
PPE	B
gene	O
promoter	O
and	O
the	O
CAT	B
reporter	O
gene	O
.	O

This	O
estrogen	O
-	O
induced	O
PPE	B
promoter	O
activity	O
was	O
inhibited	O
by	O
liganded	O
-	O
TR	B
in	O
transient	O
cotransfection	O
assays	O
.	O

Analysis	O
of	O
DNA	O
-	O
protein	O
interactions	O
by	O
EMSA	O
revealed	O
that	O
both	O
ERalpha	B
and	O
TR	B
(	I
alpha1	I
and	I
beta1	I
)	I
could	O
bind	O
to	O
the	O
EREs	O
in	O
the	O
rat	O
PPE	B
gene	O
promoter	O
.	O

Furthermore	O
,	O
estrogen	O
induction	O
of	O
PPE	B
mRNA	O
in	O
the	O
ventromedial	O
hypothalamus	O
of	O
the	O
ovariectomized	O
female	O
rat	O
was	O
significantly	O
attenuated	O
by	O
concomitant	O
administration	O
of	O
triiodothyronine	O
.	O

These	O
results	O
suggest	O
that	O
estrogen	O
regulation	O
of	O
the	O
hypothalamic	O
PPE	B
gene	O
expression	O
is	O
mediated	O
through	O
an	O
estrogen	B
-	I
receptor	I
complex	O
directly	O
interacting	O
with	O
the	O
functional	O
EREs	O
in	O
its	O
promoter	O
region	O
;	O
and	O
that	O
this	O
estrogen	O
effect	O
can	O
be	O
modified	O
by	O
thyroid	O
hormones	O
.	O

Genomic	O
organization	O
and	O
chromosomal	O
localization	O
of	O
the	O
Asna1	B
gene	O
,	O
a	O
mouse	O
homologue	O
of	O
a	O
bacterial	O
arsenic	O
-	O
translocating	O
ATPase	B
gene	O
.	O

The	O
plasmid	O
encoded	O
ArsA	B
ATPase	I
in	O
Escherichia	O
coli	O
is	O
the	O
catalytic	O
component	O
of	O
an	O
oxyanion	O
pump	O
that	O
is	O
responsible	O
for	O
resistance	O
to	O
arsenicals	O
and	O
antimonials	O
.	O

Arsenite	O
or	O
antimonite	O
allosterically	O
activates	O
the	O
ArsA	B
ATPase	I
activity	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
the	O
mouse	O
homologue	O
(	O
Asna1	B
)	O
of	O
the	O
bacterial	O
arsA	B
gene	O
.	O

The	O
Asna1	B
gene	O
encodes	O
an	O
open	O
reading	O
frame	O
of	O
348	O
amino	O
acids	O
and	O
exhibits	O
27	O
%	O
identity	O
to	O
the	O
bacterial	O
ArsA	B
protein	O
and	O
99	O
%	O
similarity	O
to	O
its	O
human	O
counterpart	O
(	O
hASNA-1	B
)	O
.	O

The	O
Asna1	B
mRNA	O
is	O
a	O
approximately	O
1.3	O
kb	O
transcript	O
and	O
is	O
present	O
at	O
high	O
levels	O
in	O
kidney	O
and	O
testis	O
,	O
moderate	O
levels	O
in	O
brain	O
,	O
liver	O
,	O
lung	O
and	O
skin	O
,	O
and	O
low	O
levels	O
in	O
heart	O
,	O
small	O
intestine	O
,	O
spleen	O
,	O
stomach	O
,	O
and	O
thymus	O
.	O

A	O
negligible	O
amount	O
of	O
Asna1	B
transcript	O
is	O
detected	O
in	O
skeletal	O
muscle	O
.	O

We	O
have	O
also	O
characterized	O
the	O
genomic	O
structure	O
of	O
the	O
Asna1	B
gene	O
.	O

The	O
gene	O
spans	O
over	O
7	O
kb	O
and	O
consists	O
of	O
seven	O
exons	O
and	O
six	O
introns	O
.	O

All	O
splice	O
sites	O
conform	O
to	O
the	O
GT	O
-	O
AG	O
rule	O
,	O
except	O
for	O
the	O
splice	O
donor	O
site	O
of	O
intron	O
4	O
that	O
is	O
GC	O
instead	O
of	O
GT	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
indicates	O
that	O
the	O
Asna1	B
gene	O
is	O
localized	O
in	O
the	O
C3	O
-	O
D1	O
region	O
of	O
mouse	O
chromosome	O
8	O
.	O

Escherichia	O
coli	O
SecA	B
helicase	B
activity	O
is	O
not	O
required	O
in	O
vivo	O
for	O
efficient	O
protein	O
translocation	O
or	O
autogenous	O
regulation	O
.	O

SecA	B
is	O
an	O
essential	O
ATP	O
-	O
driven	O
motor	O
protein	O
that	O
binds	O
to	O
preproteins	O
and	O
the	O
translocon	O
to	O
promote	O
protein	O
translocation	O
across	O
the	O
eubacterial	O
plasma	O
membrane	O
.	O

Escherichia	O
coli	O
SecA	B
contains	O
seven	O
conserved	O
motifs	O
characteristic	O
of	O
superfamily	O
II	O
of	O
DNA	B
and	I
RNA	I
helicases	I
,	O
and	O
it	O
has	O
been	O
shown	O
previously	O
to	O
possess	O
RNA	B
helicase	I
activity	O
.	O

SecA	B
has	O
also	O
been	O
shown	O
to	O
be	O
an	O
autogenous	O
repressor	O
that	O
binds	O
to	O
its	O
translation	O
initiation	O
region	O
on	O
secM	B
-	O
secA	B
mRNA	O
,	O
thereby	O
blocking	O
and	O
dissociating	O
30	O
S	O
ribosomal	O
subunits	O
.	O

Here	O
we	O
show	O
that	O
SecA	B
is	O
an	O
ATP	O
-	O
dependent	O
helicase	B
that	O
unwinds	O
a	O
mimic	O
of	O
the	O
repressor	O
helix	O
of	O
secM	B
-	O
secA	B
mRNA	O
.	O

Mutational	O
analysis	O
of	O
the	O
seven	O
conserved	O
helicase	B
motifs	O
in	O
SecA	B
allowed	O
us	O
to	O
identify	O
mutants	O
that	O
uncouple	O
SecA	B
-	O
dependent	O
protein	O
translocation	O
activity	O
from	O
its	O
helicase	B
activity	O
.	O

Helicase	B
-	O
defective	O
secA	B
mutants	O
displayed	O
normal	O
protein	O
translocation	O
activity	O
and	O
autogenous	O
repression	O
of	O
secA	B
in	O
vivo	O
.	O

Our	O
studies	O
indicate	O
that	O
SecA	B
helicase	B
activity	O
is	O
nonessential	O
and	O
does	O
not	O
appear	O
to	O
be	O
necessary	O
for	O
efficient	O
protein	O
secretion	O
and	O
secA	B
autoregulation	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
18S	O
rRNA	O
gene	O
and	O
matK	B
gene	O
sequences	O
of	O
Panax	O
vietnamensis	O
and	O
five	O
related	O
species	O
.	O

Panax	O
vietnamensis	O
was	O
discovered	O
recently	O
in	O
Vietnam	O
.	O

Its	O
bamboo	O
-	O
like	O
rhizomes	O
,	O
called	O
Vietnamese	O
Ginseng	O
,	O
have	O
attracted	O
considerable	O
attention	O
because	O
of	O
their	O
specific	O
pharmacological	O
activities	O
.	O

In	O
order	O
to	O
define	O
the	O
taxonomic	O
position	O
of	O
this	O
new	O
species	O
and	O
include	O
it	O
in	O
the	O
molecular	O
authentication	O
of	O
Ginseng	O
drugs	O
,	O
the	O
18S	O
ribosomal	O
RNA	O
gene	O
and	O
matK	B
gene	O
sequences	O
of	O
P.	O
vietnamensis	O
were	O
determined	O
and	O
compared	O
with	O
those	O
of	O
its	O
related	O
taxa	O
,	O
P.	O
japonicus	O
var	O
.	O
major	O
and	O
P.	O
pseudo	O
-	O
ginseng	O
subsp	O
.	O
himalaicus	O
,	O
besides	O
previously	O
reported	O
P.	O
ginseng	O
,	O
P.	O
japonicus	O
and	O
P.	O
quinquefolius	O
.	O

The	O
18S	O
rRNA	O
gene	O
sequences	O
were	O
found	O
to	O
be	O
1809	O
bps	O
in	O
length	O
.	O

The	O
sequence	O
of	O
P.	O
vietnamensis	O
was	O
identical	O
to	O
that	O
of	O
P.	O
quinquefolius	O
,	O
and	O
presented	O
one	O
base	O
substitution	O
from	O
those	O
of	O
both	O
P.	O
japonicus	O
var	O
.	O
major	O
and	O
P.	O
pseudo	O
-	O
ginseng	O
subsp	O
.	O
himalaicus	O
.	O

The	O
matK	B
gene	O
sequences	O
of	O
6	O
taxa	O
were	O
found	O
to	O
be	O
1509	O
bps	O
in	O
length	O
.	O

The	O
sequence	O
of	O
P.	O
vietnamensis	O
differed	O
from	O
those	O
of	O
P.	O
japonicus	O
var	O
.	O
major	O
,	O
P.	O
pseudo	O
-	O
ginseng	O
subsp	O
.	O
himalaicus	O
,	O
P.	O
ginseng	O
,	O
P.	O
japonicus	O
and	O
P.	O
quinquefolius	O
at	O
4	O
,	O
5	O
,	O
9	O
,	O
9	O
and	O
10	O
nucleotide	O
positions	O
,	O
respectively	O
.	O

The	O
phylogenetic	O
tree	O
reconstructed	O
by	O
the	O
combined	O
18S	O
rRNA	O
-	O
matK	B
gene	O
analysis	O
using	O
the	O
maximum	O
parsimony	O
method	O
showed	O
that	O
P.	O
vietnamensis	O
was	O
sympatric	O
with	O
other	O
Panax	O
species	O
and	O
had	O
a	O
close	O
relationship	O
with	O
P.	O
japonicus	O
var	O
.	O
major	O
and	O
P.	O
pseudo	O
-	O
ginseng	O
subsp	O
.	O
himalaicus	O
.	O

Characterization	O
of	O
inhibitors	O
acting	O
at	O
the	O
synthetase	B
site	O
of	O
Escherichia	O
coli	O
asparagine	B
synthetase	I
B	I
.	O

Asparagine	B
synthetase	I
catalyzes	O
the	O
ATP	O
-	O
dependent	O
formation	O
of	O
L	O
-	O
asparagine	O
from	O
L	O
-	O
aspartate	O
and	O
L	O
-	O
glutamine	O
,	O
via	O
a	O
beta	O
-	O
aspartyl	O
-	O
AMP	O
intermediate	O
.	O

Since	O
interfering	O
with	O
this	O
enzyme	O
activity	O
might	O
be	O
useful	O
for	O
treating	O
leukemia	O
and	O
solid	O
tumors	O
,	O
we	O
have	O
sought	O
small	O
-	O
molecule	O
inhibitors	O
of	O
Escherichia	O
coli	O
asparagine	B
synthetase	I
B	I
(	O
AS	B
-	I
B	I
)	O
as	O
a	O
model	O
system	O
for	O
the	O
human	O
enzyme	O
.	O

Prior	O
work	O
showed	O
that	O
L	O
-	O
cysteine	O
sulfinic	O
acid	O
competitively	O
inhibits	O
this	O
enzyme	O
by	O
interfering	O
with	O
L	O
-	O
aspartate	O
binding	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
cysteine	O
sulfinic	O
acid	O
is	O
also	O
a	O
partial	O
substrate	O
for	O
E.	O
coli	O
asparagine	B
synthetase	I
,	O
acting	O
as	O
a	O
nucleophile	O
to	O
form	O
the	O
sulfur	O
analogue	O
of	O
beta	O
-	O
aspartyl	O
-	O
AMP	O
,	O
which	O
is	O
subsequently	O
hydrolyzed	O
back	O
to	O
cysteine	O
sulfinic	O
acid	O
and	O
AMP	O
in	O
a	O
futile	O
cycle	O
.	O

While	O
cysteine	O
sulfinic	O
acid	O
did	O
not	O
itself	O
constitute	O
a	O
clinically	O
useful	O
inhibitor	O
of	O
asparagine	B
synthetase	I
B	I
,	O
these	O
results	O
suggested	O
that	O
replacing	O
this	O
linkage	O
by	O
a	O
more	O
stable	O
analogue	O
might	O
lead	O
to	O
a	O
more	O
potent	O
inhibitor	O
.	O

A	O
sulfoximine	O
reported	O
recently	O
by	O
Koizumi	O
et	O
al.	O
as	O
a	O
competitive	O
inhibitor	O
of	O
the	O
ammonia	O
-	O
dependent	O
E.	O
coli	O
asparagine	B
synthetase	I
A	I
(	O
AS	B
-	I
A	I
)	O
[	O
Koizumi	O
,	O
M.	O
,	O
Hiratake	O
,	O
J.	O
,	O
Nakatsu	O
,	O
T.	O
,	O
Kato	O
,	O
H.	O
,	O
and	O
Oda	O
,	O
J.	O
(	O
1999	O
)	O
J.	O
Am	O
.	O
Chem	O
.	O
Soc	O
.	O
121	O
,	O
5799	O
-	O
5800	O
]	O
can	O
be	O
regarded	O
as	O
such	O
a	O
species	O
.	O

We	O
found	O
that	O
this	O
sulfoximine	O
also	O
inhibited	O
AS	B
-	I
B	I
,	O
effectively	O
irreversibly	O
.	O

Unlike	O
either	O
the	O
cysteine	O
sulfinic	O
acid	O
interaction	O
with	O
AS	B
-	I
B	I
or	O
the	O
sulfoximine	O
interaction	O
with	O
AS	B
-	I
A	I
,	O
only	O
AS	B
-	I
B	I
productively	O
engaged	O
in	O
asparagine	O
synthesis	O
could	O
be	O
inactivated	O
by	O
the	O
sulfoximine	O
;	O
free	O
enzyme	O
was	O
unaffected	O
even	O
after	O
extended	O
incubation	O
with	O
the	O
sulfoximine	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
the	O
notion	O
that	O
sulfur	O
-	O
containing	O
analogues	O
of	O
aspartate	O
can	O
serve	O
as	O
platforms	O
for	O
developing	O
useful	O
inhibitors	O
of	O
AS	B
-	I
B	I
.	O

Human	O
B	B
cell	I
-	I
attracting	I
chemokine	I
1	I
(	O
BCA-1	B
;	O
CXCL13	B
)	O
is	O
an	O
agonist	O
for	O
the	O
human	O
CXCR3	B
receptor	O
.	O

The	O
CXC	B
chemokine	I
CXCL13	B
,	O
known	O
as	O
BCA-1	B
(	O
B	B
cell	I
-	I
attracting	I
chemokine	I
1	I
)	O
or	O
BLC	B
(	O
B	B
-	I
lymphocyte	I
chemoattractant	I
)	O
,	O
has	O
been	O
identified	O
as	O
an	O
efficacious	O
attractant	O
selective	O
for	O
B	O
lymphocytes	O
.	O

The	O
chemokine	B
receptor	I
BLR1	B
(	O
Burkitt	B
's	I
lymphoma	I
receptor	I
1	I
)	O
/	O
CXCR5	B
expressed	O
by	O
all	O
mature	O
B	O
cells	O
has	O
to	O
date	O
been	O
identified	O
as	O
the	O
only	O
known	O
receptor	O
for	O
BCA-1	B
.	O

As	O
the	O
loss	O
of	O
the	O
BLR1	B
/	O
CXCR5	B
receptor	O
is	O
sufficient	O
to	O
disrupt	O
organization	O
of	O
follicles	O
in	O
spleen	O
and	O
Peyer	O
's	O
patches	O
,	O
BCA-1	B
may	O
act	O
as	O
a	O
B	O
cell	O
homing	O
chemokine	B
.	O

Nonetheless	O
,	O
BCA-1	B
has	O
not	O
been	O
tested	O
against	O
all	O
known	O
chemokine	B
receptors	I
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
human	O
BCA-1	B
competes	O
with	O
radiolabeled	O
interferon	B
gamma	I
(	I
IFN	I
-	I
gamma	I
)	I
inducible	I
protein	I
10	I
(	O
IP-10	B
)	O
for	O
binding	O
to	O
the	O
human	O
CXCR3	B
receptor	O
expressed	O
in	O
Ba	O
/	O
F3	O
and	O
293EBNA	O
cell	O
lines	O
.	O

Furthermore	O
,	O
human	O
BCA-1	B
is	O
an	O
efficacious	O
attractant	O
for	O
human	O
CXCR3	B
transfected	O
cells	O
;	O
BCA-1	B
-	O
induced	O
chemotaxis	O
is	O
inhibited	O
by	O
a	O
monoclonal	O
antibody	O
against	O
human	O
CXCR3	B
.	O

In	O
these	O
cells	O
,	O
as	O
in	O
human	O
B	O
lymphocytes	O
expressing	O
CXCR5	B
,	O
BCA-1	B
does	O
not	O
induce	O
a	O
calcium	O
flux	O
.	O

Indeed	O
,	O
BCA-1	B
attenuates	O
the	O
calcium	O
flux	O
induced	O
by	O
IP-10	B
.	O

In	O
addition	O
,	O
human	O
BCA-1	B
is	O
an	O
agonist	O
in	O
stimulating	O
GTP	O
gamma	O
S	O
binding	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
human	O
BCA-1	B
is	O
a	O
specific	O
and	O
functional	O
G	B
-	I
protein	I
-	O
linked	O
chemotactic	O
ligand	O
for	O
the	O
human	O
CXCR3	B
receptor	O
.	O

The	O
biological	O
significance	O
of	O
this	O
new	O
finding	O
is	O
supported	O
by	O
our	O
recent	O
observation	O
that	O
human	O
BCA-1	B
induces	O
chemotaxis	O
of	O
activated	O
T	O
cells	O
and	O
the	O
BCA-1	B
-	O
induced	O
chemotaxis	O
is	O
inhibited	O
by	O
a	O
monoclonal	O
antibody	O
against	O
human	O
CXCR3	B
.	O

Luteal	O
expression	O
of	O
cytochrome	B
P450	I
side	I
-	I
chain	I
cleavage	I
,	O
steroidogenic	B
acute	I
regulatory	I
protein	I
,	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
,	O
and	O
20alpha	B
-	I
hydroxysteroid	I
dehydrogenase	I
genes	O
in	O
late	O
pregnant	O
rats	O
:	O
effect	O
of	O
luteinizing	B
hormone	I
and	O
RU486	O
.	O

A	O
decrease	O
in	O
serum	O
progesterone	O
at	O
the	O
end	O
of	O
pregnancy	O
is	O
essential	O
for	O
the	O
induction	O
of	O
parturition	O
in	O
rats	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
LH	B
participates	O
in	O
this	O
process	O
through	O
:	O
1	O
)	O
inhibiting	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
3beta	B
-	I
HSD	I
)	O
activity	O
and	O
2	O
)	O
stimulating	O
progesterone	O
catabolism	O
by	O
inducing	O
20alpha	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	B
20alpha	I
-	I
HSD	I
)	O
activity	O
.	O

The	O
objective	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
the	O
effect	O
of	O
LH	B
and	O
progesterone	O
on	O
the	O
luteal	O
expression	O
of	O
the	O
steroidogenic	B
acute	I
regulatory	I
protein	I
(	O
StAR	B
)	O
,	O
cytochrome	B
P450	I
side	I
-	I
chain	I
cleavage	I
(	O
P450	B
(	I
scc	I
)	I
)	O
,	O
3beta	B
-	I
HSD	I
,	O
and	O
20alpha	B
-	I
HSD	I
genes	O
.	O

Gene	O
expression	O
was	O
analyzed	O
by	O
Northern	O
blot	O
analysis	O
24	O
and	O
48	O
h	O
after	O
administration	O
of	O
LH	B
or	O
vehicle	O
on	O
Day	O
19	O
of	O
pregnancy	O
.	O

StAR	B
and	O
3beta	B
-	I
HSD	I
mRNA	O
levels	O
were	O
lower	O
in	O
LH	B
-	O
treated	O
rats	O
than	O
in	O
rats	O
administered	O
with	O
vehicle	O
at	O
both	O
time	O
points	O
studied	O
.	O

P450	B
(	I
scc	I
)	I
mRNA	O
levels	O
were	O
unaffected	O
by	O
LH	B
.	O

The	O
20alpha	B
-	I
HSD	I
mRNA	O
levels	O
were	O
not	O
different	O
between	O
LH	B
and	O
control	O
rats	O
24	O
h	O
after	O
treatment	O
;	O
however	O
,	O
greater	O
expression	O
of	O
20alpha	B
-	I
HSD	I
,	O
with	O
respect	O
to	O
controls	O
,	O
was	O
observed	O
in	O
LH	B
-	O
treated	O
rats	O
48	O
h	O
after	O
treatment	O
.	O

Luteal	O
progesterone	O
content	O
dropped	O
in	O
LH	B
-	O
treated	O
rats	O
at	O
both	O
time	O
points	O
studied	O
,	O
whereas	O
serum	O
progesterone	O
decreased	O
after	O
48	O
h	O
only	O
.	O

In	O
a	O
second	O
set	O
of	O
experiments	O
,	O
the	O
anti	O
-	O
progesterone	O
RU486	O
was	O
injected	O
intrabursally	O
on	O
Day	O
20	O
of	O
pregnancy	O
.	O

RU486	O
had	O
no	O
effect	O
on	O
3beta	B
-	I
HSD	I
or	O
P450	B
(	I
scc	I
)	I
expression	O
but	O
increased	O
20alpha	B
-	I
HSD	I
mRNA	O
levels	O
after	O
8	O
h	O
treatment	O
.	O

In	O
conclusion	O
,	O
the	O
luteolytic	O
effect	O
of	O
LH	B
is	O
mediated	O
by	O
a	O
drop	O
in	O
StAR	B
and	O
3beta	B
-	I
HSD	I
expression	O
without	O
effect	O
on	O
P450	B
(	I
scc	I
)	I
expression	O
.	O

We	O
also	O
provide	O
the	O
first	O
in	O
vivo	O
evidence	O
indicating	O
that	O
a	O
decrease	O
in	O
luteal	O
progesterone	O
content	O
may	O
be	O
an	O
essential	O
step	O
toward	O
the	O
induction	O
of	O
20alpha	B
-	I
HSD	I
expression	O
at	O
the	O
end	O
of	O
pregnancy	O
in	O
rats	O
.	O

Molecular	O
cloning	O
of	O
a	O
gene	O
encoding	O
matrix	B
metalloproteinase	I
-	I
like	I
protein	I
from	O
Gnathostoma	O
spinigerum	O
.	O

The	O
advanced	O
third	O
-	O
stage	O
larvae	O
(	O
aL3	O
)	O
of	O
Gnathostoma	O
spinigerum	O
contain	O
a	O
24	O
kDa	O
glycoprotein	O
with	O
diagnostic	O
potential	O
.	O

Immunoscreening	O
with	O
the	O
monoclonal	O
antibody	O
to	O
the	O
24	O
-	O
kDa	O
protein	O
(	O
mAb	O
GN6	O
/	O
24	O
)	O
has	O
identified	O
a	O
cDNA	O
clone	O
with	O
an	O
insert	O
of	O
932	O
base	O
pairs	O
(	O
bp	O
)	O
.	O

The	O
insert	O
contains	O
a	O
full	O
-	O
length	O
gene	O
of	O
732	O
bp	O
encoding	O
a	O
protein	O
that	O
is	O
33	O
-	O
39	O
%	O
similar	O
to	O
matrix	B
metalloproteinases	I
(	O
MMPs	B
)	O
of	O
Caenorhabditis	O
elegans	O
and	O
several	O
lower	O
and	O
higher	O
vertebrates	O
.	O

The	O
MMP	B
-	I
like	I
protein	I
of	O
G.	O
spinigerum	O
possesses	O
the	O
catalytic	O
domain	O
,	O
but	O
lacks	O
the	O
propeptide	O
and	O
hemopexin	B
-	O
like	O
domains	O
found	O
in	O
other	O
MMPs	B
.	O

A	O
signal	O
peptide	O
of	O
23	O
amino	O
acids	O
at	O
its	O
amino	O
terminus	O
indicates	O
that	O
it	O
is	O
a	O
secretory	O
protein	O
,	O
which	O
is	O
confirmed	O
by	O
Western	O
blot	O
analysis	O
showing	O
the	O
presence	O
of	O
the	O
24	O
kDa	O
protein	O
in	O
the	O
excretory	O
-	O
secretory	O
products	O
of	O
aL3	O
.	O

International	O
collaborative	O
study	O
:	O
evaluation	O
of	O
proposed	O
International	O
Reference	O
Reagent	O
of	O
pertussis	O
antiserum	O
(	O
mouse	O
)	O
97	O
/	O
642	O
.	O

A	O
freeze	O
dried	O
preparation	O
of	O
mouse	O
serum	O
in	O
vials	O
coded	O
97	O
/	O
642	O
containing	O
antibodies	O
to	O
five	O
pertussis	O
antigens	O
[	O
pertussis	B
toxin	I
(	O
PT	B
)	O
,	O
filamentous	B
hemagglutinin	I
(	O
FHA	B
)	O
,	O
pertactin	B
(	O
PRN	B
)	O
,	O
fimbriae	B
type	I
2	I
and	I
3	I
(	O
Fim	B
2	I
and	I
3	I
)	O
]	O
has	O
been	O
assessed	O
for	O
its	O
suitability	O
as	O
an	O
international	O
reference	O
reagent	O
in	O
an	O
international	O
collaborative	O
study	O
by	O
thirteen	O
laboratories	O
in	O
nine	O
countries	O
.	O

This	O
serum	O
has	O
been	O
compared	O
with	O
U.S	O
.	O

Standard	O
Pertussis	O
Antiserum	O
(	O
mouse	O
)	O
Lot	O
No.	O
1	O
(	O
US	O
Lot	O
1	O
)	O
,	O
which	O
has	O
been	O
in	O
use	O
since	O
1995	O
,	O
for	O
antibodies	O
for	O
each	O
antigen	O
.	O

Calibration	O
of	O
the	O
proposed	O
International	O
Reference	O
Reagent	O
of	O
Pertussis	O
Antiserum	O
(	O
pIRR	O
)	O
in	O
terms	O
of	O
US	O
Lot	O
1	O
gives	O
results	O
which	O
are	O
broadly	O
consistent	O
between	O
laboratories	O
for	O
antibodies	O
to	O
each	O
antigen	O
,	O
although	O
the	O
between	O
-	O
laboratory	O
differences	O
are	O
larger	O
than	O
those	O
seen	O
for	O
comparison	O
of	O
identical	O
sera	O
.	O

Calibration	O
of	O
two	O
positive	O
control	O
sera	O
in	O
terms	O
of	O
the	O
pIRR	O
gave	O
similar	O
between	O
laboratory	O
variability	O
of	O
estimates	O
to	O
that	O
obtained	O
when	O
the	O
same	O
sera	O
were	O
calibrated	O
in	O
terms	O
of	O
US	O
Lot	O
1	O
.	O

Overall	O
continuity	O
of	O
estimates	O
is	O
maintained	O
if	O
units	O
are	O
assigned	O
to	O
the	O
pIRR	O
based	O
on	O
its	O
calibration	O
in	O
terms	O
of	O
US	O
Lot	O
1	O
in	O
this	O
study	O
.	O

Data	O
presently	O
available	O
indicate	O
that	O
the	O
pIRR	O
is	O
sufficiently	O
stable	O
to	O
serve	O
as	O
a	O
reference	O
reagent	O
.	O

It	O
was	O
therefore	O
recommended	O
,	O
with	O
the	O
agreement	O
of	O
all	O
participants	O
,	O
that	O
the	O
preparation	O
in	O
vials	O
coded	O
97	O
/	O
642	O
be	O
established	O
as	O
the	O
First	O
International	O
Reference	O
Reagent	O
for	O
Pertussis	O
Antiserum	O
,	O
mouse	O
,	O
with	O
assigned	O
unitages	O
16	O
units	O
of	O
anti	O
-	O
PT	B
per	O
vial	O
,	O
143	O
units	O
of	O
anti	O
-	O
FHA	B
per	O
vial	O
and	O
30	O
units	O
of	O
anti	O
-	O
PRN	B
per	O
vial	O
based	O
on	O
its	O
calibration	O
in	O
terms	O
of	O
US	O
Lot	O
1	O
.	O

These	O
unitages	O
are	O
also	O
consistent	O
with	O
calibration	O
of	O
97	O
/	O
642	O
in	O
terms	O
of	O
the	O
Japanese	O
preparations	O
JNIH-11	O
for	O
anti	O
-	O
FHA	B
and	O
of	O
JNIH-12	O
for	O
anti	O
-	O
PT	B
.	O

Purified	O
antigens	O
for	O
Fim	B
2	I
and	O
Fim	B
3	I
are	O
not	O
readily	O
available	O
and	O
an	O
arbitrary	O
value	O
of	O
32	O
units	O
per	O
vial	O
is	O
suggested	O
for	O
anti	O
-	O
Fim	B
2	I
and	I
3	I
mixture	O
.	O

These	O
recommendations	O
were	O
agreed	O
by	O
the	O
Expert	O
Committee	O
on	O
Biological	O
Standardization	O
of	O
the	O
World	O
Health	O
Organization	O
.	O

Histone	B
deacetylase	I
as	O
a	O
new	O
target	O
for	O
cancer	O
chemotherapy	O
.	O

Trichostatin	O
A	O
(	O
TSA	O
)	O
and	O
trapoxin	O
(	O
TPX	O
)	O
,	O
inhibitors	O
of	O
the	O
eukaryotic	O
cell	O
cycle	O
and	O
inducers	O
of	O
morphological	O
reversion	O
of	O
transformed	O
cells	O
,	O
inhibit	O
histone	B
deacetylase	I
(	O
HDAC	B
)	O
at	O
nanomolar	O
concentrations	O
.	O

Recently	O
,	O
FK228	O
(	O
also	O
known	O
as	O
FR901228	O
and	O
depsipeptide	O
)	O
and	O
MS-275	O
.	O

antitumor	O
agents	O
structurally	O
unrelated	O
to	O
TSA	O
,	O
have	O
been	O
shown	O
to	O
be	O
potent	O
HDAC	B
inhibitors	O
.	O

These	O
inhibitors	O
activate	O
the	O
expression	O
of	O
p21Waf1	B
in	O
a	O
p53	B
-	O
independent	O
manner	O
.	O

Changes	O
in	O
the	O
expression	O
of	O
regulators	O
of	O
the	O
cell	O
cycle	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
with	O
increased	O
histone	B
acetylation	O
may	O
be	O
responsible	O
for	O
the	O
cell	O
cycle	O
arrest	O
and	O
antitumor	O
activity	O
of	O
HDAC	B
inhibitors	O
.	O

TSA	O
has	O
been	O
suggested	O
to	O
block	O
the	O
catalytic	O
reaction	O
by	O
chelating	O
a	O
zinc	O
ion	O
in	O
the	O
active	O
site	O
pocket	O
through	O
its	O
hydroxamic	O
acid	O
group	O
.	O

On	O
the	O
other	O
hand	O
,	O
an	O
epoxyketone	O
has	O
been	O
suggested	O
to	O
be	O
the	O
functional	O
group	O
of	O
TPX	O
capable	O
of	O
alkylating	O
the	O
enzyme	O
.	O

We	O
synthesized	O
a	O
novel	O
TPX	O
analogue	O
containing	O
a	O
hydroxamic	O
acid	O
instead	O
of	O
the	O
epoxyketone	O
.	O

The	O
hybrid	O
compound	O
,	O
called	O
cyclic	O
hydroxamic	O
-	O
acid	O
-	O
containing	O
peptide	O
1	O
(	O
CHAP1	O
)	O
inhibited	O
HDAC	B
at	O
low	O
nanomolar	O
concentrations	O
.	O

The	O
HDAC1	B
inhibition	O
by	O
CHAPI	O
was	O
reversible	O
,	O
as	O
is	O
that	O
by	O
TSA	O
,	O
in	O
contrast	O
to	O
irreversible	O
inhibition	O
by	O
TPX	O
.	O

Interestingly	O
,	O
HDAC6	B
,	O
but	O
not	O
HDAC1	B
or	O
HDAC4	B
,	O
was	O
resistant	O
to	O
TPX	O
and	O
CHAP1	O
,	O
while	O
TSA	O
inhibited	O
these	O
HDACs	B
to	O
a	O
similar	O
degree	O
.	O

CHAP31	O
,	O
the	O
strongest	O
HDAC	B
inhibitor	O
obtained	O
from	O
a	O
variety	O
of	O
CHAP	O
derivatives	O
,	O
exhibited	O
antitumor	O
activity	O
in	O
BDF1	O
mice	O
bearing	O
B16	O
/	O
BL6	O
tumor	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
CHAP31	O
is	O
promising	O
as	O
a	O
novel	O
therapeutic	O
agent	O
for	O
cancer	O
treatment	O
,	O
and	O
that	O
CHAP	O
may	O
serve	O
as	O
a	O
basis	O
for	O
new	O
HDAC	B
inhibitors	O
and	O
be	O
useful	O
for	O
combinatorial	O
synthesis	O
and	O
high	O
-	O
throughput	O
screening	O
.	O

Molecular	O
control	O
of	O
acid	B
phosphatase	I
secretion	O
into	O
the	O
rhizosphere	O
of	O
proteoid	O
roots	O
from	O
phosphorus	O
-	O
stressed	O
white	O
lupin	O
.	O

White	O
lupin	O
(	O
Lupinus	O
albus	O
)	O
grown	O
under	O
P	O
deficiency	O
displays	O
a	O
suite	O
of	O
highly	O
coordinated	O
adaptive	O
responses	O
.	O

Included	O
among	O
these	O
is	O
secretion	O
of	O
copious	O
amounts	O
of	O
acid	B
phosphatase	I
(	O
APase	B
)	O
.	O

Although	O
numerous	O
reports	O
document	O
that	O
plants	O
secrete	O
APases	B
in	O
response	O
to	O
P	O
deficiency	O
,	O
little	O
is	O
known	O
of	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
this	O
process	O
.	O

Here	O
we	O
characterize	O
the	O
secreted	O
APase	B
protein	O
,	O
cDNA	O
,	O
and	O
gene	O
from	O
white	O
lupin	O
.	O

The	O
secreted	O
APase	B
enzyme	O
is	O
a	O
glycoprotein	O
with	O
broad	O
substrate	O
specificity	O
.	O

It	O
is	O
synthesized	O
as	O
a	O
preprotein	O
with	O
a	O
deduced	O
M	O
(	O
r	O
)	O
of	O
52,000	O
containing	O
a	O
31	O
-	O
amino	O
acid	O
presequence	O
.	O

Analysis	O
of	O
the	O
presequence	O
predicts	O
that	O
the	O
protein	O
is	O
targeted	O
to	O
outside	O
the	O
cell	O
.	O

The	O
processed	O
protein	O
has	O
a	O
predicted	O
M	O
(	O
r	O
)	O
of	O
49,000	O
but	O
migrates	O
as	O
a	O
protein	O
with	O
M	O
(	O
r	O
)	O
of	O
70,000	O
on	O
sodium	O
dodecyl	O
sulfate	O
gels	O
.	O

This	O
is	O
likely	O
due	O
to	O
glycosylation	O
.	O

Enhanced	O
expression	O
is	O
fairly	O
specific	O
to	O
proteoid	O
roots	O
of	O
P	O
-	O
stressed	O
plants	O
and	O
involves	O
enhanced	O
synthesis	O
of	O
both	O
enzyme	O
protein	O
and	O
mRNA	O
.	O

Secreted	O
APase	B
appears	O
to	O
be	O
encoded	O
by	O
a	O
single	O
gene	O
containing	O
seven	O
exons	O
interrupted	O
by	O
six	O
introns	O
.	O

The	O
5	O
'	O
-	O
upstream	O
putative	O
promoter	O
of	O
the	O
white	O
lupin	O
-	O
secreted	O
APase	B
contains	O
a	O
50	O
-	O
base	O
pair	O
region	O
having	O
72	O
%	O
identity	O
to	O
an	O
Arabidopsis	O
APase	B
promoter	O
that	O
is	O
responsive	O
to	O
P	O
deficiency	O
.	O

The	O
white	O
lupin	O
-	O
secreted	O
APase	B
promoter	O
and	O
targeting	O
sequence	O
may	O
be	O
useful	O
tools	O
for	O
genetically	O
engineering	O
important	O
proteins	O
from	O
plant	O
roots	O
.	O

Organization	O
of	O
the	O
human	O
tarbp2	B
gene	O
reveals	O
two	O
promoters	O
that	O
are	O
repressed	O
in	O
an	O
astrocytic	O
cell	O
line	O
.	O

TRBP1	B
and	O
TRBP2	B
are	O
isoforms	O
of	O
a	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	O
protein	O
that	O
differ	O
in	O
their	O
N	O
-	O
terminal	O
end	O
and	O
were	O
each	O
identified	O
by	O
binding	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
trans	O
-	O
activation	O
-	O
responsive	O
RNA	O
.	O

TRBP1	B
and	O
TRBP2	B
also	O
bind	O
and	O
modulate	O
the	O
function	O
of	O
the	O
double	B
-	I
stranded	I
RNA	I
-	I
activated	I
protein	I
kinase	I
,	O
protein	B
kinase	I
R	I
.	O

Both	O
proteins	O
increase	O
long	O
terminal	O
repeat	O
expression	O
in	O
human	O
and	O
murine	O
cells	O
,	O
and	O
their	O
gene	O
has	O
been	O
mapped	O
to	O
human	O
chromosome	O
12	O
.	O

We	O
have	O
isolated	O
and	O
characterized	O
the	O
complete	O
tarbp2	B
gene	O
(	O
5493	O
bp	O
)	O
coding	O
for	O
the	O
two	O
TRBP	B
proteins	O
.	O

Two	O
adjacent	O
promoters	O
initiate	O
transcription	O
of	O
alternative	O
first	O
exons	O
for	O
TRBP1	B
and	O
TRBP2	B
mRNAs	O
that	O
are	O
spliced	O
onto	O
common	O
downstream	O
exons	O
.	O

TRBP2	B
transcription	O
and	O
translation	O
start	O
sites	O
are	O
localized	O
within	O
the	O
first	O
intron	O
of	O
TRBP1	B
.	O

TRBP	B
promoters	O
are	O
TATA	O
-	O
less	O
but	O
have	O
CCAAT	O
boxes	O
,	O
a	O
CpG	O
island	O
,	O
and	O
several	O
potential	O
binding	O
sites	O
for	O
transcriptional	B
factors	I
.	O

Promoter	O
deletion	O
analysis	O
identified	O
two	O
regions	O
from	O
position	O
-	O
1397	O
to	O
-	O
330	O
for	O
TRBP1	B
and	O
from	O
position	O
-	O
330	O
to	O
+	O
38	O
for	O
TRBP2	B
that	O
are	O
important	O
for	O
promoter	O
function	O
.	O

TRBP2	B
promoter	O
activity	O
was	O
expressed	O
at	O
a	O
higher	O
level	O
compared	O
with	O
TRBP1	B
promoter	O
.	O

In	O
addition	O
,	O
a	O
specific	O
down	O
-	O
regulation	O
of	O
TRBP1	B
and	O
TRBP2	B
promoter	O
activity	O
was	O
identified	O
in	O
human	O
astrocytic	O
cell	O
line	O
U251MG	O
compared	O
with	O
HeLa	O
cells	O
.	O

This	O
minimal	O
TRBP	B
promoter	O
activity	O
may	O
account	O
for	O
minimal	O
HIV-1	O
replication	O
in	O
astrocytes	O
.	O

Identification	O
of	O
the	O
cellular	O
receptor	O
for	O
anthrax	O
toxin	O
.	O

The	O
tripartite	O
toxin	O
secreted	O
by	O
Bacillus	O
anthracis	O
,	O
the	O
causative	O
agent	O
of	O
anthrax	O
,	O
helps	O
the	O
bacterium	O
evade	O
the	O
immune	O
system	O
and	O
can	O
kill	O
the	O
host	O
during	O
a	O
systemic	O
infection	O
.	O

Two	O
components	O
of	O
the	O
toxin	O
enzymatically	O
modify	O
substrates	O
within	O
the	O
cytosol	O
of	O
mammalian	O
cells	O
:	O
oedema	B
factor	I
(	O
OF	B
)	O
is	O
an	O
adenylate	B
cyclase	I
that	O
impairs	O
host	O
defences	O
through	O
a	O
variety	O
of	O
mechanisms	O
including	O
inhibiting	O
phagocytosis	O
;	O
lethal	B
factor	I
(	O
LF	B
)	O
is	O
a	O
zinc	O
-	O
dependent	O
protease	B
that	O
cleaves	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
kinase	I
and	O
causes	O
lysis	O
of	O
macrophages	O
.	O

Protective	B
antigen	I
(	O
PA	B
)	O
,	O
the	O
third	O
component	O
,	O
binds	O
to	O
a	O
cellular	O
receptor	O
and	O
mediates	O
delivery	O
of	O
the	O
enzymatic	O
components	O
to	O
the	O
cytosol	O
.	O

Here	O
we	O
describe	O
the	O
cloning	O
of	O
the	O
human	O
PA	O
receptor	O
using	O
a	O
genetic	O
complementation	O
approach	O
.	O

The	O
receptor	O
,	O
termed	O
ATR	B
(	O
anthrax	B
toxin	I
receptor	I
)	O
,	O
is	O
a	O
type	O
I	O
membrane	O
protein	O
with	O
an	O
extracellular	O
von	B
Willebrand	I
factor	I
A	O
domain	O
that	O
binds	O
directly	O
to	O
PA	O
.	O

In	O
addition	O
,	O
a	O
soluble	O
version	O
of	O
this	O
domain	O
can	O
protect	O
cells	O
from	O
the	O
action	O
of	O
the	O
toxin	O
.	O

A	O
Golgi	O
-	O
associated	O
PDZ	O
domain	O
protein	O
modulates	O
cystic	B
fibrosis	I
transmembrane	I
regulator	I
plasma	O
membrane	O
expression	O
.	O

We	O
identified	O
a	O
novel	O
cystic	B
fibrosis	I
transmembrane	I
conductance	I
regulator	I
(	O
CFTR	B
)	O
-	O
associating	O
,	O
PDZ	O
domain	O
-	O
containing	O
protein	O
,	O
CAL	B
(	O
CFTR	B
associated	I
ligand	I
)	O
containing	O
two	O
predicted	O
coiled	O
-	O
coiled	O
domains	O
and	O
one	O
PDZ	O
domain	O
.	O

The	O
PDZ	O
domain	O
of	O
CAL	B
binds	O
to	O
the	O
C	O
terminus	O
of	O
CFTR	B
.	O

Although	O
CAL	B
does	O
not	O
have	O
any	O
predicted	O
transmembrane	O
domains	O
,	O
CAL	B
is	O
associated	O
with	O
membranes	O
mediated	O
by	O
a	O
region	O
containing	O
the	O
coiled	O
-	O
coil	O
domains	O
.	O

CAL	B
is	O
located	O
primarily	O
at	O
the	O
Golgi	O
apparatus	O
,	O
co	O
-	O
localizing	O
with	O
trans	O
-	O
Golgi	O
markers	O
and	O
is	O
sensitive	O
to	O
Brefeldin	O
A	O
treatment	O
.	O

Immunoprecipitation	O
experiments	O
suggest	O
that	O
CAL	B
exists	O
as	O
a	O
multimer	O
.	O

Overexpression	O
of	O
CAL	B
reduces	O
CFTR	B
chloride	O
currents	O
in	O
mammalian	O
cells	O
and	O
decreases	O
expression	O
,	O
rate	O
of	O
insertion	O
and	O
half	O
-	O
life	O
of	O
CFTR	B
in	O
the	O
plasma	O
membrane	O
.	O

The	O
Na	B
(	I
+	I
)	I
/	I
H	I
(	I
+	I
)	I
exchanger	I
regulatory	I
factor	I
,	O
NHE	B
-	I
RF	I
,	O
a	O
subplasma	O
membrane	O
PDZ	O
domain	O
protein	O
,	O
restores	O
cell	O
surface	O
expression	O
of	O
CFTR	B
and	O
chloride	O
currents	O
.	O

In	O
addition	O
,	O
NHE	B
-	I
RF	I
inhibits	O
the	O
binding	O
of	O
CAL	B
to	O
CFTR	B
.	O

CAL	B
modulates	O
the	O
surface	O
expression	O
of	O
CFTR	B
.	O

CAL	B
favors	O
retention	O
of	O
CFTR	B
within	O
the	O
cell	O
,	O
whereas	O
NHE	B
-	I
RF	I
favors	O
surface	O
expression	O
by	O
competing	O
with	O
CAL	B
for	O
the	O
binding	O
of	O
CFTR	B
.	O

Thus	O
,	O
the	O
regulation	O
of	O
CFTR	B
in	O
the	O
plasma	O
membrane	O
involves	O
the	O
dynamic	O
interaction	O
between	O
at	O
least	O
two	O
PDZ	O
domain	O
proteins	O
.	O

Crystal	O
structure	O
of	O
Arp2	B
/	I
3	I
complex	I
.	O

We	O
determined	O
a	O
crystal	O
structure	O
of	O
bovine	O
Arp2	B
/	I
3	I
complex	I
,	O
an	O
assembly	O
of	O
seven	O
proteins	O
that	O
initiates	O
actin	B
polymerization	O
in	O
eukaryotic	O
cells	O
,	O
at	O
2.0	O
angstrom	O
resolution	O
.	O

Actin	B
-	I
related	I
protein	I
2	I
(	O
Arp2	B
)	O
and	O
Arp3	B
are	O
folded	O
like	O
actin	B
,	O
with	O
distinctive	O
surface	O
features	O
.	O

Subunits	O
ARPC2	B
p34	I
and	O
ARPC4	B
p20	I
in	O
the	O
core	O
of	O
the	O
complex	O
associate	O
through	O
long	O
carboxyl	O
-	O
terminal	O
alpha	O
helices	O
and	O
have	O
similarly	O
folded	O
amino	O
-	O
terminal	O
alpha	O
/	O
beta	O
domains	O
.	O

ARPC1	B
p40	I
is	O
a	O
seven	O
-	O
blade	O
beta	O
propeller	O
with	O
an	O
insertion	O
that	O
may	O
associate	O
with	O
the	O
side	O
of	O
an	O
actin	B
filament	O
.	O

ARPC3	B
p21	I
and	O
ARPC5	B
p16	I
are	O
globular	O
alpha	O
-	O
helical	O
subunits	O
.	O

We	O
predict	O
that	O
WASp	B
/	O
Scar	B
proteins	O
activate	O
Arp2	B
/	I
3	I
complex	I
by	O
bringing	O
Arp2	B
into	O
proximity	O
with	O
Arp3	B
for	O
nucleation	O
of	O
a	O
branch	O
on	O
the	O
side	O
of	O
a	O
preexisting	O
actin	B
filament	O
.	O

Thromboembolic	O
disease	O
and	O
antithrombotic	O
therapy	O
in	O
newborns	O
.	O

This	O
update	O
uses	O
an	O
evidence	O
based	O
approach	O
to	O
analyze	O
and	O
present	O
the	O
epidemiology	O
of	O
neonatal	O
thrombosis	O
,	O
etiologies	O
,	O
currently	O
used	O
techniques	O
for	O
diagnosis	O
with	O
their	O
limitations	O
,	O
and	O
current	O
therapeutic	O
approaches	O
.	O

In	O
addition	O
,	O
the	O
approaches	O
to	O
both	O
prevention	O
and	O
optimal	O
therapies	O
are	O
discussed	O
.	O

In	O
Section	O
I	O
Dr.	O
Paul	O
Monagle	O
addresses	O
the	O
epidemiology	O
of	O
neonatal	O
thrombosis	O
outside	O
of	O
the	O
central	O
nervous	O
system	O
in	O
both	O
arterial	O
and	O
venous	O
locations	O
,	O
and	O
those	O
that	O
occur	O
in	O
utero	O
.	O

The	O
specific	O
contributions	O
of	O
catheters	O
and	O
congenital	O
prothrombotic	O
disorders	O
are	O
delineated	O
.	O

Dr.	O
Monagle	O
also	O
describes	O
currently	O
used	O
techniques	O
for	O
the	O
diagnosis	O
of	O
thrombotic	O
events	O
as	O
well	O
as	O
their	O
limitations	O
and	O
the	O
current	O
therapeutic	O
approaches	O
.	O

In	O
Section	O
II	O
,	O
Dr.	O
Gabrielle	O
deVeber	O
reviews	O
the	O
epidemiology	O
of	O
neonatal	O
thrombosis	O
within	O
the	O
central	O
nervous	O
system	O
,	O
in	O
both	O
arterial	O
and	O
venous	O
locations	O
and	O
those	O
that	O
occur	O
in	O
utero	O
.	O

The	O
neurological	O
presentation	O
,	O
risk	O
factors	O
including	O
congenital	O
prothrombotic	O
disorders	O
,	O
anatomical	O
distribution	O
,	O
diagnostic	O
tests	O
,	O
use	O
of	O
antithrombotic	O
therapy	O
and	O
neurologic	O
outcome	O
of	O
neonates	O
with	O
either	O
sinovenous	O
thrombosis	O
or	O
arterial	O
ischemic	O
stroke	O
are	O
discussed	O
.	O

In	O
Section	O
III	O
,	O
Dr.	O
Anthony	O
Chan	O
reviews	O
the	O
current	O
approaches	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
neonatal	O
thrombosis	O
.	O

Information	O
on	O
the	O
differences	O
in	O
the	O
response	O
of	O
neonates	O
compared	O
to	O
adults	O
to	O
antithrombotic	O
therapy	O
and	O
new	O
approaches	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
thrombosis	O
in	O
neonates	O
are	O
emphasized	O
.	O

Intergenic	O
mRNA	O
molecules	O
resulting	O
from	O
trans	O
-	O
splicing	O
.	O

Accumulated	O
recent	O
evidence	O
is	O
indicating	O
that	O
alternative	O
splicing	O
represents	O
a	O
generalized	O
process	O
that	O
increases	O
the	O
complexity	O
of	O
human	O
gene	O
expression	O
.	O

Here	O
we	O
show	O
that	O
mRNA	O
production	O
may	O
not	O
necessarily	O
be	O
limited	O
to	O
single	O
genes	O
,	O
as	O
human	O
liver	O
also	O
has	O
the	O
potential	O
to	O
produce	O
a	O
variety	O
of	O
hybrid	O
cytochrome	B
P450	I
3A	I
mRNA	O
molecules	O
.	O

The	O
four	O
known	O
cytochrome	B
P450	I
3A	I
genes	O
in	O
humans	O
,	O
CYP3A4	B
,	O
CYP3A5	B
,	O
CYP3A7	B
,	O
and	O
CYP3A43	B
,	O
share	O
a	O
high	O
degree	O
of	O
similarity	O
,	O
consist	O
of	O
13	O
exons	O
with	O
conserved	O
exon	O
-	O
intron	O
boundaries	O
,	O
and	O
form	O
a	O
cluster	O
on	O
chromosome	O
7	O
.	O

The	O
chimeric	O
CYP3A	B
mRNA	O
molecules	O
described	O
herein	O
are	O
characterized	O
by	O
CYP3A43	B
exon	O
1	O
joined	O
at	O
canonical	O
splice	O
sites	O
to	O
distinct	O
sets	O
of	O
CYP3A4	B
or	O
CYP3A5	B
exons	O
.	O

Because	O
the	O
CYP3A43	B
gene	O
is	O
in	O
a	O
head	O
-	O
to	O
-	O
head	O
orientation	O
with	O
the	O
CYP3A4	B
and	O
CYP3A5	B
genes	O
,	O
bypassing	O
transcriptional	O
termination	O
can	O
not	O
account	O
for	O
the	O
formation	O
of	O
hybrid	O
CYP3A	B
mRNAs	O
.	O

Thus	O
,	O
the	O
mechanism	O
generating	O
these	O
molecules	O
has	O
to	O
be	O
an	O
RNA	O
processing	O
event	O
that	O
joins	O
exons	O
of	O
independent	O
pre	O
-	O
mRNA	O
molecules	O
,	O
i.e.	O
trans	O
-	O
splicing	O
.	O

Using	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
,	O
the	O
ratio	O
of	O
one	O
CYP3A43	B
/	I
3A4	I
intergenic	O
combination	O
was	O
estimated	O
to	O
be	O
approximately	O
0.15	O
%	O
that	O
of	O
the	O
CYP3A43	B
mRNAs	O
.	O

Moreover	O
,	O
trans	O
-	O
splicing	O
has	O
been	O
found	O
not	O
to	O
interfere	O
with	O
polyadenylation	O
.	O

Heterologous	O
expression	O
of	O
the	O
chimeric	O
species	O
composed	O
of	O
CYP3A43	B
exon	O
1	O
joined	O
to	O
exons	O
2	O
-	O
13	O
of	O
CYP3A4	B
revealed	O
catalytic	O
activity	O
toward	O
testosterone	O
.	O

Angiogenesis	O
-	O
dependent	O
diseases	O
.	O

There	O
is	O
accumulating	O
evidence	O
that	O
leukemias	O
and	O
other	O
hematologic	O
diseases	O
are	O
angiogenesis	O
-	O
dependent	O
.	O

Therefore	O
,	O
angiogenesis	O
inhibitors	O
may	O
be	O
useful	O
adjuncts	O
to	O
conventional	O
therapies	O
in	O
the	O
treatment	O
of	O
these	O
diseases	O
.	O

When	O
all	O
conventional	O
therapy	O
has	O
failed	O
,	O
an	O
angiogenesis	O
inhibitor	O
may	O
be	O
successfully	O
used	O
alone	O
,	O
as	O
has	O
been	O
demonstrated	O
in	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
by	O
thalidomide	O
.	O

The	O
experimental	O
and	O
clinical	O
evidence	O
that	O
the	O
efficacy	O
of	O
thalidomide	O
against	O
multiple	O
myeloma	O
is	O
mediated	O
in	O
part	O
by	O
its	O
antiangiogenic	O
activity	O
is	O
presented	O
here	O
.	O

In	O
current	O
clinical	O
trials	O
throughout	O
the	O
United	O
States	O
,	O
angiogenesis	O
inhibitors	O
are	O
being	O
used	O
against	O
cancer	O
in	O
combination	O
with	O
conventional	O
chemotherapy	O
or	O
radiotherapy	O
.	O

Angiogenesis	O
inhibitors	O
are	O
also	O
being	O
used	O
in	O
combination	O
with	O
each	O
other	O
.	O

This	O
practice	O
may	O
increase	O
as	O
different	O
angiogenesis	O
inhibitors	O
become	O
more	O
widely	O
available	O
.	O

Transcription	B
factors	I
NF	B
-	I
Y	I
and	O
Sp1	B
are	O
important	O
determinants	O
of	O
the	O
promoter	O
activity	O
of	O
the	O
bovine	O
and	O
human	O
neuronal	O
nicotinic	B
receptor	I
beta	I
4	I
subunit	O
genes	O
.	O

The	O
beta4	O
subunit	O
is	O
a	O
component	O
of	O
the	O
neuronal	O
nicotinic	B
acetylcholine	I
receptors	I
which	O
control	O
catecholamine	O
secretion	O
in	O
bovine	O
adrenomedullary	O
chromaffin	O
cells	O
.	O

The	O
promoter	O
of	O
the	O
gene	O
coding	O
for	O
this	O
subunit	O
was	O
characterized	O
.	O

A	O
proximal	O
region	O
(	O
from	O
minus	O
sign99	O
to	O
minus	O
sign64	O
)	O
was	O
responsible	O
for	O
the	O
transcriptional	O
activity	O
observed	O
in	O
chromaffin	O
,	O
C2C12	O
,	O
and	O
COS	O
cells	O
.	O

Within	O
this	O
region	O
two	O
cis	O
-	O
acting	O
elements	O
that	O
bind	O
transcription	B
factors	I
Sp1	B
and	O
NF	B
-	I
Y	I
were	O
identified	O
.	O

Mutagenesis	O
of	O
the	O
two	O
elements	O
indicated	O
that	O
they	O
cooperate	O
for	O
the	O
basal	O
transcription	O
activity	O
of	O
the	O
promoter	O
.	O

The	O
human	O
beta4	O
promoter	O
,	O
that	O
was	O
also	O
characterized	O
,	O
shared	O
structural	O
and	O
functional	O
homologies	O
with	O
the	O
bovine	O
promoter	O
.	O

Thus	O
,	O
two	O
adjacent	O
binding	O
elements	O
for	O
Sp1	B
and	O
NF	B
-	I
Y	I
were	O
detected	O
.	O

Whereas	O
the	O
Sp1	B
site	O
was	O
an	O
important	O
determinant	O
of	O
the	O
promoter	O
activity	O
,	O
the	O
NF	B
-	I
Y	I
site	O
may	O
have	O
cell	O
-	O
specific	O
effects	O
.	O

Given	O
that	O
these	O
promoters	O
showed	O
no	O
structural	O
or	O
functional	O
homology	O
with	O
the	O
previously	O
characterized	O
rat	O
beta4	O
subunit	O
promoter	O
(	O
Bigger	O
,	O
C.	O
B.	O
,	O
Casanova	O
,	O
E.	O
A.	O
,	O
and	O
Gardner	O
,	O
P.	O
D.	O
(	O
1996	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
271	O
,	O
32842	O
-	O
-	O
32848	O
)	O
except	O
for	O
the	O
involvement	O
of	O
an	O
Sp1	B
binding	O
element	O
,	O
we	O
propose	O
that	O
constitutive	O
expression	O
of	O
the	O
beta4	O
subunit	O
gene	O
in	O
these	O
three	O
close	O
species	O
may	O
be	O
controlled	O
by	O
the	O
general	O
transcription	B
factor	I
Sp1	B
.	O

Nevertheless	O
,	O
other	O
components	O
could	O
determine	O
species	O
-	O
specific	O
beta4	O
subunit	O
expression	O
.	O

Solution	O
structures	O
of	O
the	O
YAP65	B
WW	O
domain	O
and	O
the	O
variant	O
L30	O
K	O
in	O
complex	O
with	O
the	O
peptides	O
GTPPPPYTVG	O
,	O
N-	O
(	O
n	O
-	O
octyl	O
)	O
-	O
GPPPY	O
and	O
PLPPY	O
and	O
the	O
application	O
of	O
peptide	O
libraries	O
reveal	O
a	O
minimal	O
binding	O
epitope	O
.	O

The	O
single	O
mutation	O
L30	O
K	O
in	O
the	O
Hu	O
-	O
Yap65	B
WW	O
domain	O
increased	O
the	O
stability	O
of	O
the	O
complex	O
with	O
the	O
peptide	O
GTPPPPYTVG	O
(	O
K	O
(	O
d	O
)	O
=	O
40	O
(	O
+	O
/-	O
5	O
)	O
microM	O
)	O
.	O

Here	O
we	O
report	O
the	O
refined	O
solution	O
structure	O
of	O
this	O
complex	O
by	O
NMR	O
spectroscopy	O
and	O
further	O
derived	O
structure	O
-	O
activity	O
relationships	O
by	O
using	O
ligand	O
peptide	O
libraries	O
with	O
truncated	O
sequences	O
and	O
a	O
substitution	O
analysis	O
that	O
yielded	O
acetyl	O
-	O
PPPPY	O
as	O
the	O
smallest	O
high	O
-	O
affinity	O
binding	O
peptide	O
(	O
K	O
(	O
d	O
)	O
=	O
60	O
microM	O
)	O
.	O

The	O
structures	O
of	O
two	O
new	O
complexes	O
with	O
weaker	O
binding	O
ligands	O
chosen	O
based	O
on	O
these	O
results	O
(	O
N-	O
(	O
n	O
-	O
octyl	O
)	O
-GPPPYNH	O
(	O
2	O
)	O
and	O
Ac	O
-	O
PLPPY	O
)	O
comprising	O
the	O
wild	O
-	O
type	O
WW	O
domain	O
of	O
Hu	O
-	O
Yap65	B
were	O
determined	O
.	O

Comparison	O
of	O
the	O
structures	O
of	O
the	O
three	O
complexes	O
were	O
useful	O
for	O
identifying	O
the	O
molecular	O
basis	O
of	O
high	O
-	O
affinity	O
:	O
hydrophobic	O
and	O
specific	O
interactions	O
between	O
the	O
side	O
-	O
chains	O
of	O
Y28	O
and	O
W39	O
and	O
P5	O
'	O
and	O
P4	O
'	O
,	O
respectively	O
,	O
and	O
hydrogen	O
bonds	O
between	O
T37	O
(	O
donnor	O
)	O
and	O
P5	O
'	O
(	O
acceptor	O
)	O
and	O
between	O
W39	O
(	O
donnor	O
)	O
and	O
T2	O
'	O
(	O
acceptor	O
)	O
stabilize	O
the	O
complex	O
.	O
The	O
structure	O
of	O
the	O
complex	O
L30	O
K	O
Hu	O
-	O
Yap65	B
WW	O
domain	O
/	O
GTPPPPYTVG	O
is	O
compared	O
to	O
the	O
published	O
crystal	O
structure	O
of	O
the	O
dystrophin	B
WW	O
domain	O
bound	O
to	O
a	O
segment	O
of	O
the	O
beta	B
-	I
dystroglycan	I
protein	O
and	O
to	O
the	O
solution	O
structure	O
of	O
the	O
first	O
Nedd4	B
WW	O
domain	O
and	O
its	O
prolin	O
-	O
rich	O
ligand	O
,	O
suggesting	O
that	O
WW	O
sequences	O
bind	O
proline	O
-	O
rich	O
peptides	O
in	O
an	O
evolutionary	O
conserved	O
fashion	O
.	O

The	O
position	O
equivalent	O
to	O
T22	O
in	O
the	O
Hu	O
-	O
Yap65	B
WW	O
domain	O
sequence	O
is	O
seen	O
as	O
responsible	O
for	O
differentiation	O
in	O
the	O
binding	O
mode	O
among	O
the	O
WW	O
domains	O
of	O
group	O
I	O
.	O

Liposome	O
-	O
encapsulated	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
enhances	O
the	O
effects	O
of	O
radiation	O
against	O
human	O
colon	O
tumor	O
xenografts	O
.	O

Recent	O
reports	O
have	O
shown	O
that	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
can	O
augment	O
the	O
effects	O
of	O
radiation	O
against	O
certain	O
tumor	O
types	O
.	O

However	O
,	O
the	O
high	O
concentrations	O
of	O
intravenous	O
infusion	O
of	O
TNF	B
-	I
alpha	I
needed	O
to	O
cause	O
tumor	O
regression	O
can	O
induce	O
many	O
systemic	O
side	O
effects	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
determine	O
if	O
TNF	B
-	I
alpha	I
encapsulated	O
in	O
sterically	O
stabilized	O
(	O
Stealth	O
,	O
ALZA	O
Corporation	O
,	O
Mountain	O
View	O
,	O
CA	O
)	O
,	O
PEGylated	O
liposomes	O
(	O
SL	O
)	O
augments	O
the	O
antitumor	O
effects	O
of	O
radiation	O
and	O
to	O
compare	O
its	O
efficacy	O
and	O
possible	O
toxicity	O
with	O
free	O
TNF	B
-	I
alpha	I
in	O
the	O
LS174	O
T	O
human	O
colon	O
tumor	O
xenograft	O
model	O
.	O

Nude	O
mice	O
were	O
injected	O
subcutaneously	O
(	O
s.c	O
.	O
)	O
with	O
LS174	O
T	O
cells	O
and	O
treated	O
intravenously	O
(	O
i.v	O
.	O
)	O
with	O
Stealth	O
-	O
liposomal	O
TNF	B
-	I
alpha	I
(	O
SL	O
-	O
TNF	O
-	O
alpha	O
)	O
with	O
and	O
without	O
radiation	O
or	O
TNF	B
-	I
alpha	I
with	O
or	O
without	O
radiation	O
when	O
tumor	O
size	O
was	O
approximately	O
200	O
mm	O
(	O
3	O
)	O
.	O

In	O
phase	O
1	O
,	O
a	O
significant	O
decrease	O
(	O
p	O
=	O
0.047	O
)	O
in	O
tumor	O
growth	O
was	O
observed	O
with	O
radiation	O
at	O
day	O
21	O
but	O
not	O
with	O
SL	O
-	O
TNF	B
-	I
alpha	I
or	O
free	O
TNF	B
-	I
alpha	I
alone	O
.	O

By	O
the	O
end	O
of	O
phase	O
1	O
(	O
day	O
27	O
)	O
with	O
continued	O
treatments	O
,	O
the	O
SL	O
-	O
TNF	B
-	I
alpha	I
plus	O
radiation	O
group	O
had	O
significantly	O
smaller	O
tumors	O
(	O
p	O
=	O
0.044	O
)	O
than	O
those	O
in	O
the	O
free	O
TNF	B
-	I
alpha	I
plus	O
radiation	O
group	O
.	O

In	O
phase	O
2	O
,	O
where	O
a	O
similar	O
tumor	O
growth	O
reduction	O
pattern	O
was	O
observed	O
,	O
the	O
addition	O
of	O
TNF	B
-	I
alpha	I
to	O
radiation	O
,	O
either	O
as	O
free	O
protein	O
or	O
within	O
SL	O
,	O
increased	O
lymphocyte	O
activation	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
numbers	O
in	O
both	O
blood	O
and	O
spleen	O
.	O

The	O
effect	O
was	O
generally	O
more	O
pronounced	O
with	O
SL	O
-	O
TNF	B
-	I
alpha	I
.	O

Systemic	O
toxicity	O
,	O
based	O
on	O
hematologic	O
analyses	O
and	O
body	O
weight	O
,	O
was	O
absent	O
or	O
minimal	O
.	O

Collectively	O
,	O
the	O
data	O
show	O
that	O
pretreatment	O
with	O
SL	O
-	O
TNF	B
-	I
alpha	I
can	O
enhance	O
more	O
effectively	O
,	O
and	O
possibly	O
more	O
safely	O
,	O
the	O
effects	O
of	O
radiation	O
against	O
human	O
colon	O
tumor	O
xenografts	O
than	O
can	O
free	O
TNF	B
-	I
alpha	I
and	O
that	O
the	O
increased	O
antitumor	O
action	O
may	O
involve	O
upregulation	O
of	O
lymphocytes	O
.	O

Identification	O
of	O
a	O
novel	O
human	O
cytokine	B
gene	O
in	O
the	O
interleukin	B
gene	O
cluster	O
on	O
chromosome	O
2q12	O
-	O
14	O
.	O

Genes	O
in	O
the	O
interleukin-1	B
(	O
IL-1	B
)	O
gene	O
cluster	O
on	O
human	O
chromosome	O
2	O
play	O
an	O
important	O
role	O
in	O
mediating	O
inflammatory	O
responses	O
and	O
are	O
associated	O
with	O
numerous	O
diseases	O
.	O

We	O
have	O
identified	O
a	O
novel	O
IL-1	B
-	O
like	O
gene	O
,	O
IL-1F10	B
,	O
on	O
human	O
chromosome	O
2q13	O
-	O
14.1	O
near	O
the	O
IL-1	B
receptor	I
antagonist	I
gene	O
(	O
IL-1RN	B
)	O
.	O

The	O
IL1F10	B
gene	O
is	O
encoded	O
by	O
5	O
exons	O
spanning	O
over	O
7.8	O
kb	O
of	O
genomic	O
DNA	O
.	O

The	O
1008	O
-	O
bp	O
IL-1F10	B
cDNA	O
encodes	O
a	O
152	O
-	O
amino	O
acid	O
protein	O
that	O
shares	O
between	O
41	O
%	O
and	O
43	O
%	O
amino	O
acid	O
identity	O
with	O
human	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1Ra	B
)	O
and	O
FIL-1delta	B
,	O
respectively	O
.	O

IL-1F10	B
shares	O
characteristics	O
of	O
the	O
IL-1Ra	B
family	I
,	O
including	O
key	O
amino	O
acid	O
consensus	O
sequences	O
and	O
a	O
similar	O
genomic	O
structure	O
.	O

By	O
multitissue	O
first	O
-	O
strand	O
cDNA	O
PCR	O
analysis	O
,	O
IL-1F10	B
mRNA	O
is	O
expressed	O
in	O
heart	O
,	O
placenta	O
,	O
fetal	O
liver	O
,	O
spleen	O
,	O
thymus	O
,	O
and	O
tonsil	O
.	O

The	O
expression	O
in	O
a	O
variety	O
of	O
immune	O
tissues	O
and	O
similarity	O
to	O
IL-1Ra	B
suggest	O
a	O
role	O
of	O
IL-1F10	B
in	O
the	O
inflammatory	O
response	O
.	O

Identification	O
of	O
novel	O
Plasmodium	O
gallinaceum	O
zygote	O
-	O
and	O
ookinete	O
-	O
expressed	O
proteins	O
as	O
targets	O
for	O
blocking	O
malaria	O
transmission	O
.	O

The	O
development	O
of	O
transmission	O
-	O
blocking	O
vaccines	O
is	O
one	O
approach	O
to	O
malaria	O
control	O
.	O

To	O
identify	O
novel	O
Plasmodium	O
zygote	O
-	O
and	O
ookinete	O
-	O
secreted	O
proteins	O
as	O
targets	O
of	O
blocking	O
malaria	O
transmission	O
,	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
were	O
produced	O
against	O
parasite	O
-	O
secreted	O
proteins	O
found	O
in	O
Plasmodium	O
gallinaceum	O
ookinete	O
culture	O
supernatants	O
.	O

Four	O
MAbs-1A6	O
,	O
2A5	O
,	O
2B5	O
,	O
and	O
4B6	O
-	O
were	O
identified	O
that	O
bound	O
to	O
P.	O
gallinaceum	O
zygotes	O
and	O
ookinetes	O
in	O
diverse	O
patterns	O
in	O
terms	O
of	O
spatial	O
localization	O
on	O
parasites	O
,	O
time	O
course	O
of	O
antigen	O
expression	O
,	O
and	O
Western	O
immunoblot	O
patterns	O
.	O

MAbs	O
2A5	O
and	O
4B6	O
recognized	O
more	O
than	O
one	O
protein	O
band	O
as	O
detected	O
by	O
Western	O
immunoblot	O
of	O
P.	O
gallinaceum	O
ookinete	O
supernatants	O
.	O

Beginning	O
at	O
0	O
h	O
postfertilization	O
,	O
MAb	O
2A5	O
recognized	O
a	O
diverse	O
set	O
of	O
antigens	O
;	O
at	O
10	O
h	O
postfertilization	O
,	O
MAb	O
4B6	O
recognized	O
several	O
antigens	O
as	O
well	O
.	O

MAb	O
1A6	O
recognized	O
a	O
single	O
approximately	O
17	O
-	O
kDa	O
protein	O
,	O
and	O
2B5	O
recognized	O
a	O
single	O
approximately	O
32	O
-	O
kDa	O
protein	O
at	O
15	O
h	O
postfertilization	O
.	O

In	O
membrane	O
feeding	O
assays	O
to	O
assess	O
the	O
effect	O
of	O
these	O
MAbs	O
on	O
P.	O
gallinaceum	O
infectivity	O
for	O
Aedes	O
aegypti	O
mosquitoes	O
,	O
the	O
addition	O
of	O
MAbs	O
1A6	O
and	O
2B5	O
to	O
infectious	O
blood	O
meals	O
significantly	O
inhibited	O
oocyst	O
development	O
in	O
the	O
mosquito	O
midgut	O
.	O

In	O
contrast	O
,	O
MAb	O
2A5	O
seemed	O
to	O
enhance	O
infectivity	O
.	O

These	O
results	O
demonstrate	O
that	O
Plasmodium	O
ookinetes	O
secrete	O
proteins	O
(	O
in	O
addition	O
to	O
previously	O
characterized	O
chitinases	O
)	O
that	O
may	O
be	O
targets	O
for	O
blocking	O
malaria	O
transmission	O
.	O

Future	O
investigation	O
of	O
ookinete	O
-	O
secreted	O
neutralization	O
-	O
sensitive	O
molecules	O
should	O
provide	O
valuable	O
insight	O
into	O
mechanisms	O
by	O
which	O
ookinetes	O
exit	O
the	O
blood	O
meal	O
,	O
penetrate	O
and	O
transverse	O
the	O
peritrophic	O
matrix	O
,	O
and	O
invade	O
the	O
mosquito	O
midgut	O
epithelium	O
.	O

A	O
reassessment	O
of	O
the	O
International	O
Study	O
Group	O
criteria	O
for	O
the	O
diagnosis	O
(	O
classification	O
)	O
of	O
BehÃ?Â§et	O
's	O
syndrome	O
.	O

OBJECTIVE	O
:	O

Patients	O
with	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
and	O
Crohn	O
's	O
disease	O
(	O
CD	O
)	O
were	O
not	O
represented	O
in	O
the	O
diseased	O
controls	O
group	O
that	O
had	O
been	O
utilised	O
in	O
the	O
development	O
of	O
the	O
International	O
Study	O
Group	O
(	O
ISG	O
)	O
criteria	O
for	O
the	O
diagnosis	O
of	O
BehÃ?Â§et	O
's	O
syndrome	O
(	O
BS	O
)	O
.	O

Having	O
similar	O
features	O
,	O
both	O
of	O
these	O
conditions	O
can	O
pose	O
problems	O
in	O
the	O
differential	O
diagnosis	O
of	O
BS	O
.	O

Moreover	O
,	O
there	O
has	O
been	O
a	O
recent	O
awareness	O
of	O
coexistence	O
of	O
BS	O
and	O
familial	O
Mediterranean	O
fever	O
(	O
FMF	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
reassess	O
the	O
performance	O
of	O
ISG	O
criteria	O
among	O
patients	O
with	O
BS	O
and	O
other	O
rheumatological	O
conditions	O
,	O
specifically	O
including	O
those	O
with	O
CD	O
,	O
UC	O
,	O
and	O
FMF	O
.	O

METHODS	O
:	O

302	O
consecutive	O
patients	O
with	O
BS	O
and	O
438	O
patients	O
with	O
other	O
rheumatological	O
conditions	O
were	O
surveyed	O
for	O
the	O
presence	O
or	O
absence	O
of	O
the	O
features	O
of	O
BS	O
by	O
means	O
of	O
a	O
standard	O
form	O
which	O
had	O
been	O
prepared	O
according	O
to	O
ISG	O
criteria	O
.	O

All	O
control	O
patients	O
with	O
a	O
history	O
of	O
oral	O
ulcer	O
had	O
a	O
pathergy	O
test	O
and	O
an	O
eye	O
examination	O
by	O
an	O
experienced	O
ophthalmologist	O
with	O
a	O
slit	O
lamp	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
ISG	O
criteria	O
were	O
calculated	O
.	O

RESULTS	O
:	O

Seven	O
of	O
302	O
patients	O
with	O
BS	O
(	O
2	O
%	O
)	O
did	O
not	O
fulfill	O
the	O
ISG	O
criteria	O
while	O
5	O
of	O
438	O
controls	O
(	O
1	O
%	O
)	O
fulfilled	O
the	O
ISG	O
criteria	O
.	O

CONCLUSION	O
:	O

In	O
this	O
study	O
ISG	O
criteria	O
performed	O
well	O
in	O
correctly	O
classifying	O
BS	O
.	O

Further	O
specificity	O
studies	O
might	O
be	O
considered	O
in	O
CD	O
.	O

Involvement	O
of	O
BMP-2	B
signaling	O
in	O
a	O
cartilage	O
cap	O
in	O
osteochondroma	O
.	O

This	O
study	O
describes	O
the	O
distributions	O
of	O
bone	B
morphogenetic	I
protein	I
(	I
BMP	I
)	I
-	I
2	I
as	O
well	O
as	O
mRNAs	O
for	O
BMP	B
receptor	I
type	I
IB	I
(	O
BMPRIB	B
)	O
.	O

collagen	B
types	I
II	I
(	I
Col	I
II	I
)	I
and	I
III	I
(	I
Col	I
III	I
)	I
in	O
a	O
growing	O
""""	O
cartilage	O
cap	O
""""	O
of	O
osteochondroma	O
.	O

In	O
situ	O
hybridization	O
and	O
immunohistochemical	O
study	O
were	O
performed	O
using	O
histological	O
sections	O
obtained	O
during	O
surgery	O
.	O

BMP-2	B
was	O
detected	O
in	O
mesenchymal	O
cells	O
in	O
the	O
outer	O
fibrous	O
layer	O
and	O
chondrocytes	O
in	O
the	O
inner	O
cartilaginous	O
matrix	O
,	O
positive	O
for	O
Col	B
III	I
and	O
Col	B
II	I
,	O
respectively	O
.	O

BMPRIB	B
mRNA	O
was	O
distributed	O
in	O
chondrocytes	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
provide	O
observational	O
evidence	O
of	O
the	O
involvement	O
of	O
BMP-2	B
signaling	O
in	O
the	O
pathogenesis	O
of	O
cartilage	O
cap	O
of	O
osteochondroma	O
.	O

and	O
suggests	O
the	O
role	O
of	O
BMP-2	B
in	O
the	O
growth	O
of	O
cartilage	O
cap	O
in	O
osteochondroma	O
.	O

Identification	O
and	O
molecular	O
characterisation	O
of	O
hordoindolines	O
from	O
barley	O
grain	O
.	O

Grain	O
texture	O
in	O
barley	O
is	O
an	O
important	O
quality	O
character	O
as	O
soft	O
-	O
textured	O
cultivars	O
have	O
better	O
malting	O
quality	O
.	O

In	O
wheat	O
,	O
texture	O
is	O
considered	O
to	O
be	O
determined	O
by	O
the	O
puroindolines	O
,	O
a	O
group	O
of	O
basic	O
hydrophobic	O
proteins	O
present	O
on	O
the	O
surface	O
of	O
the	O
starch	O
granule	O
.	O

Hard	O
wheats	O
have	O
been	O
proposed	O
to	O
lack	O
puroindoline	B
a	I
or	O
to	O
have	O
mutant	O
forms	O
of	O
puroindoline	B
b	I
which	O
do	O
not	O
bind	O
to	O
the	O
granule	O
surface	O
.	O

Analysis	O
of	O
six	O
barley	O
cultivars	O
(	O
three	O
soft	O
-	O
textured	O
and	O
three	O
hard	O
)	O
showed	O
that	O
all	O
contained	O
proteins	O
homologous	O
to	O
wheat	O
puroindoline	B
b	I
,	O
but	O
PCR	O
analysis	O
failed	O
to	O
show	O
any	O
differences	O
in	O
amino	O
acid	O
sequences	O
similar	O
to	O
those	O
which	O
have	O
been	O
proposed	O
to	O
determine	O
textural	O
differences	O
in	O
wheat	O
.	O

Southern	O
blot	O
analysis	O
showed	O
two	O
hordoindoline	B
b	I
genes	O
which	O
were	O
isolated	O
and	O
shown	O
to	O
encode	O
proteins	O
with	O
94	O
%	O
sequence	O
identity	O
.	O

Expression	O
of	O
hordoindoline	B
b	I
mRNA	O
occurred	O
in	O
the	O
starchy	O
endosperm	O
and	O
aleurone	O
layer	O
of	O
the	O
developing	O
seed	O
,	O
but	O
not	O
in	O
the	O
embryo	O
.	O

Analysis	O
of	O
seven	O
soft	O
-	O
and	O
six	O
hard	O
-	O
textured	O
barley	O
varieties	O
showed	O
that	O
all	O
contained	O
hordoindoline	B
a	O
except	O
two	O
hard	O
varieties	O
(	O
Sundance	O
,	O
Hart	O
)	O
which	O
were	O
subsequently	O
shown	O
to	O
both	O
lack	O
hordoindoline	B
a	I
mRNA	O
.	O

It	O
was	O
therefore	O
concluded	O
that	O
there	O
is	O
not	O
a	O
clear	O
relationship	O
between	O
the	O
presence	O
of	O
hordoindoline	B
a	O
and	O
grain	O
texture	O
in	O
barley	O
.	O

Immunohistochemical	O
analysis	O
of	O
epidermal	B
growth	I
factor	I
receptor	I
family	I
members	O
in	O
stage	O
I	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

BACKGROUND	O
:	O

To	O
elucidate	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
epidermal	B
growth	I
factor	I
receptor	I
family	I
members	O
(	O
ErbB-1	B
,	O
neu	B
/	O
ErbB-2	B
,	O
ErbB-3	B
,	O
and	O
ErbB-4	B
)	O
and	O
tumor	O
recurrence	O
.	O

METHODS	O
:	O

We	O
used	O
immunohistochemistry	O
to	O
examine	O
the	O
expression	O
of	O
four	O
epidermal	B
growth	I
factor	I
receptor	I
family	I
members	O
in	O
73	O
patients	O
with	O
stage	O
I	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

RESULTS	O
:	O

Using	O
Cox	O
univariate	O
analysis	O
,	O
we	O
determined	O
that	O
angiolymphatic	O
tumor	O
emboli	O
and	O
non	O
-	O
well	O
-	O
differentiated	O
tumor	O
cells	O
were	O
two	O
significant	O
conventional	O
pathologic	O
predictors	O
of	O
tumor	O
recurrence	O
,	O
and	O
that	O
ErbB-1	B
and	O
ErbB-3	B
were	O
also	O
significant	O
predictors	O
.	O

Co	O
-	O
expression	O
of	O
ErbB-1	B
+	I
,	I
-3	I
+	O
,	O
or	O
expression	O
of	O
three	O
or	O
more	O
epidermal	B
growth	I
factor	I
receptor	I
family	I
members	O
had	O
a	O
significant	O
effect	O
on	O
lung	O
cancer	O
recurrence	O
.	O

A	O
stepwise	O
multivariate	O
Cox	O
proportional	O
hazards	O
regression	O
analysis	O
provided	O
a	O
predictive	O
model	O
for	O
tumor	O
recurrence	O
.	O

CONCLUSIONS	O
:	O

The	O
present	O
study	O
shows	O
that	O
in	O
patients	O
with	O
a	O
non	O
-	O
well	O
-	O
differentiated	O
tumor	O
,	O
overexpression	O
of	O
ErbB-3	B
is	O
a	O
useful	O
marker	O
for	O
predicting	O
tumor	O
recurrence	O
.	O

The	O
present	O
study	O
also	O
confirmed	O
that	O
ErbB-1	B
expression	O
increased	O
in	O
proportion	O
to	O
the	O
loss	O
of	O
tumor	O
differentiation	O
.	O

The	O
correlation	O
between	O
ErbB-3	B
and	O
distant	O
metastasis	O
was	O
good	O
.	O

CD40	B
ligation	O
induces	O
macrophage	O
IL-10	B
and	O
TNF	B
-	I
alpha	I
production	O
:	O
differential	O
use	O
of	O
the	O
PI3	B
K	I
and	O
p42	B
/	I
44	I
MAPK	I
-	O
pathways	O
.	O

Interleukin	B
10	I
(	O
IL-10	B
)	O
is	O
an	O
anti	O
-	O
inflammatory	O
cytokine	B
produced	O
in	O
the	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
joint	O
by	O
macrophages	O
/	O
monocytes	O
and	O
infiltrating	O
peripheral	O
blood	O
derived	O
lymphocytes	O
.	O

Recent	O
data	O
suggest	O
a	O
role	O
for	O
physical	O
cell	O
-	O
to	O
-	O
cell	O
interactions	O
in	O
the	O
production	O
of	O
IL-10	B
.	O

In	O
this	O
report	O
,	O
we	O
have	O
investigated	O
the	O
signalling	O
mechanisms	O
involved	O
in	O
IL-10	B
production	O
by	O
peripheral	O
blood	O
-	O
derived	O
macrophages	O
upon	O
interaction	O
with	O
fixed	O
CD40L	B
transfectants	O
.	O

IL-10	B
and	O
tumour	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
are	O
produced	O
by	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
(	O
M	B
-	I
CSF	I
)	O
-	O
primed	O
monocytes	O
/	O
macrophages	O
in	O
response	O
to	O
CD40	B
ligation	O
.	O

The	O
utilization	O
of	O
the	O
inhibitors	O
,	O
wortmannin	O
and	O
LY294002	O
,	O
demonstrated	O
a	O
role	O
for	O
phosphatidylinositol	B
3-kinase	I
(	O
PI3	B
K	I
)	O
whereas	O
rapamycin	O
demonstrated	O
p70	B
S6	I
-	I
kinase	I
(	O
p70S6	B
K	I
)	O
involvement	O
in	O
the	O
production	O
of	O
IL-10	B
by	O
these	O
monocytes	O
.	O

The	O
production	O
of	O
TNF	B
-	I
alpha	I
was	O
enhanced	O
by	O
wortmannin	O
and	O
LY294002	O
,	O
suggesting	O
negative	O
regulation	O
by	O
PI3	B
K	I
;	O
however	O
,	O
it	O
was	O
dependent	O
on	O
p70S6	B
K	I
suggesting	O
a	O
PI3	B
K	I
-	O
independent	O
mechanism	O
of	O
p70S6	O
K	O
activation	O
.	O

One	O
alternative	O
pathway	O
that	O
activates	O
p70S6	B
K	I
independently	O
of	O
PI3	B
K	I
and	O
also	O
differentiates	O
between	O
IL-10	B
and	O
TNF	B
-	I
alpha	I
is	O
the	O
p42	B
/	I
44	I
mitogen	I
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
,	O
which	O
regulates	O
TNF	B
-	I
alpha	I
production	O
in	O
a	O
PI3	B
K	I
-	O
independent	O
manner	O
.	O

These	O
observations	O
suggest	O
that	O
CD40	B
ligation	O
induces	O
macrophage	O
IL-10	B
and	O
TNF	B
-	I
alpha	I
production	O
,	O
the	O
mechanism	O
of	O
which	O
is	O
p70S6	B
K	I
-	O
dependent	O
yet	O
bifurcates	O
at	O
the	O
level	O
of	O
PI3	B
K	I
and	O
p42	B
/	I
44	I
MAPK	I
.	O

Adeno	O
-	O
associated	O
virus	O
vector	O
-	O
mediated	O
triple	O
gene	O
transfer	O
of	O
dopamine	O
synthetic	O
enzymes	O
.	O

OBJECTIVE	O
:	O

To	O
explore	O
triple	O
gene	O
transfer	O
of	O
dopamine	O
synthetic	O
enzymes	O
with	O
separate	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
vectors	O
.	O

METHODS	O
:	O

The	O
genes	O
for	O
dopamine	O
synthetic	O
enzymes	O
,	O
tyrosine	B
hydroxylase	I
(	O
TH	B
)	O
,	O
aromatic	B
L	I
-	I
amino	I
acid	I
decarboxylase	I
(	O
AADC	B
)	O
,	O
and	O
GTP	B
cyclohydrolase	I
I	I
(	O
GCH	B
,	O
an	O
enzyme	O
critical	O
for	O
tetrahydrobiopterin	O
synthesis	O
)	O
were	O
contransduced	O
into	O
293	O
cells	O
with	O
separate	O
AAV	O
vectors	O
.	O

Expressions	O
of	O
TH	B
,	O
AADC	B
and	O
GCH	B
were	O
detected	O
by	O
Western	O
blot	O
analysis	O
.	O

Intracellular	O
dopamine	O
level	O
was	O
assayed	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O

RESULTS	O
:	O

TH	B
,	O
AADC	B
and	O
GCH	B
were	O
effectively	O
coexpressed	O
in	O
transduced	O
cells	O
with	O
three	O
separate	O
AAV	O
vectors	O
,	O
AAV	O
-	O
TH	B
,	O
AAV	O
-	O
AADC	B
and	O
AAV	O
-	O
GCH	B
.	O

Furthermore	O
,	O
the	O
coexpression	O
resulted	O
in	O
an	O
effectively	O
spontaneous	O
dopamine	O
production	O
in	O
cotransduced	O
cells	O
.	O

CONCLUSION	O
:	O

The	O
triple	O
transduction	O
of	O
TH	B
,	O
AADC	B
and	O
GCH	B
genes	O
with	O
separate	O
AAV	O
vectors	O
is	O
effective	O
,	O
which	O
might	O
be	O
important	O
to	O
gene	O
therapy	O
for	O
Parkinson	O
's	O
disease	O
.	O

ARL2	B
and	O
BART	B
enter	O
mitochondria	O
and	O
bind	O
the	O
adenine	B
nucleotide	I
transporter	I
.	O

The	O
ADP	B
-	I
ribosylation	I
factor	I
-	I
like	I
2	I
(	O
ARL2	B
)	O
GTPase	B
and	O
its	O
binding	O
partner	O
binder	B
of	I
ARL2	I
(	O
BART	B
)	O
are	O
ubiquitously	O
expressed	O
in	O
rodent	O
and	O
human	O
tissues	O
and	O
are	O
most	O
abundant	O
in	O
brain	O
.	O

Both	O
ARL2	B
and	O
BART	B
are	O
predominantly	O
cytosolic	O
,	O
but	O
a	O
pool	O
of	O
each	O
was	O
found	O
associated	O
with	O
mitochondria	O
in	O
a	O
protease	B
-	O
resistant	O
form	O
.	O

ARL2	B
was	O
found	O
to	O
lack	O
covalent	O
N	O
-	O
myristoylation	O
,	O
present	O
on	O
all	O
other	O
members	O
of	O
the	O
ARF	B
family	I
,	O
thereby	O
preserving	O
the	O
N	O
-	O
terminal	O
amphipathic	O
alpha	O
-	O
helix	O
as	O
a	O
potential	O
mitochondrial	O
import	O
sequence	O
.	O

An	O
overlay	O
assay	O
was	O
developed	O
to	O
identify	O
binding	O
partners	O
for	O
the	O
BART	B
.	O
ARL2	B
.	O
GTP	O
complex	O
and	O
revealed	O
a	O
specific	O
interaction	O
with	O
a	O
protein	O
in	O
bovine	O
brain	O
mitochondria	O
.	O

Purification	O
and	O
partial	O
microsequencing	O
identified	O
the	O
protein	O
as	O
an	O
adenine	B
nucleotide	I
transporter	I
(	O
ANT	B
)	O
.	O

The	O
overlay	O
assay	O
was	O
performed	O
on	O
mitochondria	O
isolated	O
from	O
five	O
different	O
tissues	O
from	O
either	O
wild	O
-	O
type	O
or	O
transgenic	O
mice	O
deleted	O
for	O
ANT1	B
.	O

Results	O
confirmed	O
that	O
ANT1	B
is	O
the	O
predominant	O
binding	O
partner	O
for	O
the	O
BART	B
.	O
ARL2	B
.	O
GTP	O
complex	O
and	O
that	O
the	O
structurally	O
homologous	O
ANT2	B
protein	O
does	O
not	O
bind	O
the	O
complex	O
.	O

Cardiac	O
and	O
skeletal	O
muscle	O
mitochondria	O
from	O
ant1	B
(	O
-	O
)	O
/	O
ant1	B
(	O
-	O
)	O
mice	O
had	O
increased	O
levels	O
of	O
ARL2	B
,	O
relative	O
to	O
that	O
seen	O
in	O
mitochondria	O
from	O
wild	O
-	O
type	O
animals	O
.	O

We	O
conclude	O
that	O
the	O
amount	O
of	O
ARL2	B
in	O
mitochondria	O
is	O
subject	O
to	O
regulation	O
via	O
an	O
ANT1	B
-	O
sensitive	O
pathway	O
in	O
muscle	O
tissues	O
.	O

A	O
major	O
marker	O
for	O
normal	O
tension	O
glaucoma	O
:	O
association	O
with	O
polymorphisms	O
in	O
the	O
OPA1	B
gene	O
.	O

Normal	O
tension	O
glaucoma	O
(	O
NTG	O
)	O
is	O
a	O
major	O
form	O
of	O
glaucoma	O
,	O
associated	O
with	O
intraocular	O
pressures	O
that	O
are	O
within	O
the	O
statistically	O
normal	O
range	O
of	O
the	O
population	O
.	O

OPA1	B
,	O
the	O
gene	O
responsible	O
for	O
autosomal	O
dominant	O
optic	O
atrophy	O
represents	O
an	O
excellent	O
candidate	O
gene	O
for	O
NTG	O
,	O
as	O
the	O
clinical	O
phenotypes	O
are	O
similar	O
and	O
OPA1	B
is	O
expressed	O
in	O
the	O
retina	O
and	O
optic	O
nerve	O
.	O

Eighty	O
-	O
three	O
well	O
-	O
characterized	O
NTG	O
patients	O
were	O
screened	O
for	O
mutations	O
in	O
OPA1	B
by	O
heteroduplex	O
analysis	O
and	O
bi	O
-	O
directional	O
sequencing	O
.	O

Sequences	O
found	O
to	O
be	O
altered	O
in	O
NTG	O
subjects	O
were	O
examined	O
for	O
variations	O
in	O
100	O
population	O
controls	O
.	O

A	O
second	O
cohort	O
of	O
80	O
NTG	O
patients	O
and	O
86	O
population	O
controls	O
was	O
subsequently	O
screened	O
to	O
determine	O
whether	O
the	O
initial	O
findings	O
could	O
be	O
replicated	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
on	O
intervening	O
sequence	O
(	O
IVS	O
)	O
8	O
(	O
IVS8	O
+	O
4	O
C	O
/	O
T	O
)	O
was	O
found	O
to	O
be	O
strongly	O
associated	O
with	O
the	O
occurrence	O
of	O
NTG	O
in	O
both	O
cohorts	O
(	O
chi	O
(	O
2	O
)	O
=	O
7.97	O
,	O
P	O
=	O
0.005	O
in	O
the	O
first	O
cohort	O
,	O
chi	O
(	O
2	O
)	O
=	O
9.93	O
,	O
P	O
=	O
0.002	O
in	O
the	O
second	O
cohort	O
;	O
odds	O
ratio	O
3.1	O
(	O
95	O
%	O
CI	O
:	O
1.8	O
-	O
5.6	O
)	O
.	O
A	O
second	O
SNP	O
(	O
IVS8	O
+	O
32	O
T	O
/	O
C	O
)	O
appeared	O
to	O
be	O
associated	O
with	O
disease	O
in	O
the	O
first	O
cohort	O
(	O
chi	O
(	O
2	O
)	O
=	O
4.71	O
,	O
P	O
=	O
0.030	O
)	O
,	O
but	O
this	O
finding	O
could	O
not	O
be	O
replicated	O
in	O
the	O
second	O
cohort	O
.	O

In	O
the	O
combined	O
cohort	O
,	O
the	O
compound	O
at	O
-	O
risk	O
genotype	O
IVS8	O
+	O
4	O
C	O
/	O
T	O
,	O
+	O
32	O
T	O
/	O
C	O
was	O
strongly	O
associated	O
with	O
the	O
occurrence	O
of	O
NTG	O
(	O
chi	O
(	O
2	O
)	O
=	O
22.04	O
,	O
P	O
=	O
0.00001	O
after	O
correcting	O
for	O
testing	O
four	O
genotypes	O
)	O
.	O

These	O
results	O
indicate	O
that	O
polymorphisms	O
in	O
the	O
OPA1	B
gene	O
are	O
associated	O
with	O
NTG	O
and	O
may	O
be	O
a	O
marker	O
for	O
the	O
disease	O
.	O

Caspase-2	B
can	O
trigger	O
cytochrome	B
C	I
release	O
and	O
apoptosis	O
from	O
the	O
nucleus	O
.	O

The	O
cysteine	B
proteases	I
specific	O
for	O
aspartic	O
residues	O
,	O
known	O
as	O
caspases	B
,	O
are	O
localized	O
in	O
different	O
subcellular	O
compartments	O
and	O
play	O
specific	O
roles	O
during	O
the	O
regulative	O
and	O
the	O
executive	O
phase	O
of	O
the	O
cell	O
death	O
process	O
.	O

Here	O
we	O
investigated	O
the	O
subcellular	O
localization	O
of	O
caspase-2	B
in	O
healthy	O
cells	O
and	O
during	O
the	O
execution	O
of	O
the	O
apoptotic	O
program	O
.	O

We	O
have	O
found	O
that	O
caspase-2	B
is	O
a	O
nuclear	O
resident	O
protein	O
and	O
that	O
its	O
import	O
into	O
the	O
nucleus	O
is	O
regulated	O
by	O
two	O
different	O
nuclear	O
localization	O
signals	O
.	O

We	O
have	O
shown	O
that	O
in	O
an	O
early	O
phase	O
of	O
apoptosis	O
caspase-2	B
can	O
trigger	O
mitochondrial	O
dysfunction	O
from	O
the	O
nucleus	O
without	O
relocalizing	O
into	O
the	O
cytoplasm	O
.	O

Release	O
of	O
cytochrome	B
c	I
occurs	O
in	O
the	O
absence	O
of	O
overt	O
alteration	O
of	O
the	O
nuclear	O
pores	O
and	O
changes	O
of	O
the	O
nuclear	O
/	O
cytoplasmic	O
barrier	O
.	O

Addition	O
of	O
leptomycin	O
B	O
,	O
an	O
inhibitor	O
of	O
nuclear	O
export	O
,	O
did	O
not	O
interfere	O
with	O
the	O
ability	O
of	O
caspase-2	B
to	O
trigger	O
cytochrome	B
c	I
release	O
.	O

Only	O
during	O
the	O
late	O
phase	O
of	O
the	O
apoptotic	O
process	O
can	O
caspase-2	B
relocalize	O
in	O
the	O
cytoplasm	O
,	O
as	O
consequence	O
of	O
an	O
increase	O
in	O
the	O
diffusion	O
limits	O
of	O
the	O
nuclear	O
pores	O
.	O

Taken	O
together	O
these	O
data	O
indicate	O
the	O
existence	O
of	O
a	O
nuclear	O
/	O
mitochondrial	O
apoptotic	O
pathway	O
elicited	O
by	O
caspase-2	B
.	O

Mrnp41	B
(	O
Rae	B
1p	I
)	O
associates	O
with	O
microtubules	O
in	O
HeLa	O
cells	O
and	O
in	O
neurons	O
.	O

Mrnp41	B
(	O
hRae1p	B
)	O
is	O
an	O
evolutionarily	O
highly	O
conserved	O
protein	O
,	O
which	O
is	O
a	O
potential	O
component	O
of	O
mRNP	O
particles	O
and	O
plays	O
a	O
role	O
in	O
nuclear	O
mRNA	O
export	O
.	O

The	O
protein	O
is	O
mainly	O
localized	O
at	O
the	O
nuclear	O
pore	O
complex	O
,	O
but	O
is	O
also	O
associated	O
with	O
distinct	O
nuclear	O
domains	O
and	O
with	O
a	O
meshwork	O
of	O
numerous	O
small	O
particles	O
in	O
the	O
cytoplasm	O
(	O
Kraemer	O
and	O
Blobel	O
(	O
1997	O
)	O
:	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
91	O
,	O
1519	O
-	O
1523	O
)	O
.	O

We	O
show	O
that	O
the	O
cytoplasmic	O
pattern	O
of	O
mrnp41	B
is	O
sensitive	O
to	O
treatment	O
with	O
the	O
microtubule	O
(	O
MT	O
)	O
-	O
depolymerizing	O
drug	O
nocodazole	O
which	O
causes	O
disappearance	O
of	O
mrnp41	B
from	O
the	O
cell	O
periphery	O
and	O
concentration	O
around	O
the	O
nucleus	O
.	O

By	O
immunofluorescence	O
we	O
demonstrate	O
that	O
mrnp41	B
colocalizes	O
with	O
MT	O
in	O
HeLa	O
cells	O
and	O
displays	O
an	O
MT	O
-	O
like	O
distribution	O
in	O
cultured	O
neurons	O
.	O

Association	O
of	O
mrnp41	B
with	O
MT	O
is	O
further	O
demonstrated	O
by	O
copurification	O
with	O
MT	O
from	O
pig	O
brain	O
throughout	O
several	O
steps	O
of	O
polymerization	O
and	O
depolymerization	O
.	O

Separation	O
of	O
MT	B
-	I
associated	I
proteins	I
(	O
MAPs	B
)	O
by	O
phosphocellulose	O
(	O
PC	O
)	O
chromatography	O
showed	O
copurification	O
of	O
mrnp41	B
with	O
MAPs	B
.	O

These	O
data	O
show	O
an	O
association	O
of	O
mrnp41	B
with	O
MT	O
and	O
,	O
moreover	O
,	O
demonstrate	O
that	O
an	O
intact	O
MT	O
system	O
is	O
necessary	O
for	O
dispersion	O
of	O
mrnp41	B
-	O
containing	O
particles	O
to	O
the	O
cellular	O
periphery	O
.	O

The	O
essential	O
role	O
of	O
mrnp41	B
in	O
spindle	O
pole	O
separation	O
and	O
cell	O
cycle	O
progression	O
may	O
also	O
be	O
related	O
to	O
its	O
ability	O
to	O
bind	O
to	O
MTs	O
.	O

Functional	O
implications	O
of	O
the	O
localization	O
and	O
activity	O
of	O
acid	B
-	I
sensitive	I
channels	I
in	O
rat	O
peripheral	O
nervous	O
system	O
.	O

Acid	B
-	I
sensitive	I
ion	I
channels	I
(	O
ASIC	B
)	O
are	O
proton	O
-	O
gated	O
ion	B
channels	I
expressed	O
in	O
neurons	O
of	O
the	O
mammalian	O
central	O
and	O
peripheral	O
nervous	O
systems	O
.	O

The	O
functional	O
role	O
of	O
these	O
channels	O
is	O
still	O
uncertain	O
,	O
but	O
they	O
have	O
been	O
proposed	O
to	O
constitute	O
mechanoreceptors	B
and/or	O
nociceptors	B
.	O

We	O
have	O
raised	O
specific	O
antibodies	O
for	O
ASIC1	B
,	O
ASIC2	B
,	O
ASIC3	B
,	O
and	O
ASIC4	B
to	O
examine	O
the	O
distribution	O
of	O
these	O
proteins	O
in	O
neurons	O
from	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
and	O
to	O
determine	O
their	O
subcellular	O
localization	O
.	O

Western	O
blot	O
analysis	O
demonstrates	O
that	O
all	O
four	O
ASIC	B
proteins	O
are	O
expressed	O
in	O
DRG	O
and	O
sciatic	O
nerve	O
.	O

Immunohistochemical	O
experiments	O
and	O
functional	O
measurements	O
of	O
unitary	O
currents	O
from	O
the	O
ASICs	B
with	O
the	O
patch	O
-	O
clamp	O
technique	O
indicate	O
that	O
ASIC1	B
localizes	O
to	O
the	O
plasma	O
membrane	O
of	O
small	O
-	O
,	O
medium	O
-	O
,	O
and	O
large	O
-	O
diameter	O
cells	O
,	O
whereas	O
ASIC2	B
and	O
ASIC3	B
are	O
preferentially	O
in	O
medium	O
to	O
large	O
cells	O
.	O

Neurons	O
coexpressing	O
ASIC2	B
and	O
ASIC3	B
form	O
predominantly	O
heteromeric	O
ASIC2	B
-	I
3	I
channels	I
.	O

Two	O
spliced	O
forms	O
,	O
ASIC2a	B
and	O
ASIC2b	B
,	O
colocalize	O
in	O
the	O
same	O
population	O
of	O
DRG	O
neurons	O
.	O

Within	O
cells	O
,	O
the	O
ASICs	B
are	O
present	O
mainly	O
on	O
the	O
plasma	O
membrane	O
of	O
the	O
soma	O
and	O
cellular	O
processes	O
.	O

Functional	O
studies	O
indicate	O
that	O
the	O
pH	O
sensitivity	O
for	O
inactivation	O
of	O
ASIC1	B
is	O
much	O
higher	O
than	O
the	O
one	O
for	O
activation	O
;	O
hence	O
,	O
increases	O
in	O
proton	O
concentration	O
will	O
inactivate	O
the	O
channel	O
.	O

These	O
functional	O
properties	O
and	O
localization	O
in	O
DRG	O
have	O
profound	O
implications	O
for	O
the	O
putative	O
functional	O
roles	O
of	O
ASICs	B
in	O
the	O
nervous	O
system	O
.	O

Peritoneal	O
and	O
hemodialysis	O
:	O
I	O
.	O

Differences	O
in	O
patient	O
characteristics	O
at	O
initiation	O
.	O

BACKGROUND	O
:	O

Comparisons	O
of	O
mortality	O
outcomes	O
between	O
peritoneal	O
dialysis	O
(	O
PD	O
)	O
and	O
hemodialysis	O
(	O
HD	O
)	O
patients	O
have	O
shown	O
varying	O
results	O
,	O
which	O
may	O
be	O
caused	O
by	O
the	O
unequally	O
distributed	O
clinical	O
conditions	O
of	O
patients	O
at	O
initiation	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
evaluated	O
the	O
clinical	O
characteristics	O
of	O
105	O
,	O
954	O
patients	O
at	O
the	O
initiation	O
of	O
PD	O
and	O
HD	O
,	O
using	O
the	O
U.S.	O
national	O
incidence	O
data	O
on	O
treated	O
end	O
-	O
stage	O
renal	O
disease	O
from	O
the	O
Medical	O
Evidence	O
Form	O
,	O
1995	O
to	O
1997	O
.	O

METHODS	O
:	O

A	O
general	O
linear	O
model	O
was	O
used	O
to	O
analyze	O
differences	O
of	O
age	O
,	O
albumin	B
,	O
creatinine	O
,	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
,	O
and	O
hematocrit	O
;	O
categorical	O
data	O
analysis	O
to	O
evaluate	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
grouped	O
into	O
four	O
categories	O
:	O
<	O
19	O
,	O
19	O
-	O
25	O
(	O
<	O
25	O
)	O
,	O
25	O
-	O
30	O
(	O
<	O
30	O
)	O
,	O
and	O
30	O
+	O
;	O
and	O
logistic	O
regression	O
to	O
assess	O
the	O
likelihood	O
of	O
initiating	O
PD	O
versus	O
HD	O
.	O

Diabetics	O
(	O
DM	O
)	O
were	O
analyzed	O
separately	O
from	O
non	O
-	O
diabetics	O
(	O
NDM	O
)	O
.	O

Explanatory	O
variables	O
in	O
the	O
logistic	O
regression	O
included	O
incidence	O
year	O
,	O
race	O
,	O
gender	O
,	O
age	O
,	O
BMI	O
,	O
albumin	B
,	O
creatinine	O
,	O
BUN	O
,	O
and	O
hematocrit	O
.	O

Race	O
included	O
white	O
and	O
black	O
.	O

Age	O
was	O
categorized	O
into	O
four	O
groups	O
:	O
20	O
-	O
44	O
,	O
45	O
-	O
64	O
,	O
65	O
-	O
74	O
,	O
and	O
75	O
+	O
.RESULTS	O
:	O

At	O
the	O
initiation	O
of	O
dialysis	O
PD	O
patients	O
were	O
approximately	O
6	O
years	O
younger	O
(	O
P	O
<	O
0.0001	O
)	O
than	O
HD	O
patients	O
.	O

PD	O
patients	O
also	O
had	O
higher	O
(	O
P	O
<	O
0.0001	O
)	O
albumin	B
(	O
+	O
0.35	O
g	O
/	O
dL	O
for	O
DM	O
and	O
+	O
0.23	O
g	O
/	O
dL	O
for	O
NDM	O
)	O
and	O
hematocrit	O
(	O
+	O
1.64	O
%	O
for	O
DM	O
and	O
+	O
1.71	O
%	O
for	O
NDM	O
)	O
levels	O
,	O
and	O
lower	O
(	O
P	O
<	O
0.04	O
)	O
BUN	O
(	O
-	O
8.75	O
mg	O
/	O
dL	O
for	O
DM	O
and	O
-	O
5.24	O
mg	O
/	O
dL	O
for	O
NDM	O
)	O
and	O
creatinine	O
(	O
-	O
0.51	O
mg	O
/	O
dL	O
for	O
DM	O
and	O
-	O
0.23	O
mg	O
/	O
dL	O
for	O
NDM	O
)	O
levels	O
than	O
HD	O
patients	O
.	O

Whites	O
had	O
a	O
higher	O
(	O
P	O
<	O
0.0001	O
)	O
likelihood	O
of	O
starting	O
PD	O
than	O
blacks	O
,	O
and	O
patients	O
with	O
BMI	O
<	O
19	O
had	O
a	O
lower	O
(	O
P	O
<	O
0.0001	O
)	O
chance	O
of	O
beginning	O
on	O
PD	O
.	O

CONCLUSION	O
:	O

PD	O
patients	O
had	O
favorable	O
clinical	O
conditions	O
at	O
the	O
initiation	O
of	O
dialysis	O
,	O
which	O
should	O
be	O
taken	O
into	O
consideration	O
when	O
comparing	O
dialysis	O
outcomes	O
between	O
the	O
two	O
modalities	O
.	O

Allelic	O
polymorphism	O
synergizes	O
with	O
variable	O
gene	O
content	O
to	O
individualize	O
human	O
KIR	B
genotype	O
.	O

Killer	B
Ig	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
genes	O
are	O
a	O
multigene	O
family	O
on	O
human	O
chromosome	O
19	O
.	O

KIR	B
genes	O
occur	O
in	O
various	O
combinations	O
on	O
different	O
haplotypes	O
.	O

Additionally	O
,	O
KIR	B
genes	O
are	O
polymorphic	O
.	O

To	O
examine	O
how	O
allelic	O
polymorphism	O
diversifies	O
KIR	B
haplotypes	O
with	O
similar	O
or	O
identical	O
combinations	O
of	O
KIR	B
genes	O
,	O
we	O
devised	O
methods	O
for	O
discriminating	O
alleles	O
of	O
KIR2DL1	B
,	O
-	O
2DL3	B
,	O
-	O
3DL1	B
,	O
and	O
-	O
3DL2	B
.	O

These	O
methods	O
were	O
applied	O
to	O
143	O
individuals	O
from	O
34	O
families	O
to	O
define	O
98	O
independent	O
KIR	B
haplotypes	O
at	O
the	O
allele	O
level	O
.	O

Three	O
novel	O
3DL2	B
alleles	O
and	O
a	O
chimeric	O
3DL1	B
/	O
3DL2	B
sequence	O
were	O
also	O
identified	O
.	O

Among	O
the	O
A	O
group	O
haplotypes	O
were	O
22	O
different	O
combinations	O
of	O
2DL1	B
,	O
2DL3	B
,	O
3DL1	B
,	O
and	O
3DL2	B
alleles	O
.	O

Among	O
the	O
B	O
group	O
haplotypes	O
that	O
were	O
unambiguously	O
determined	O
were	O
15	O
distinct	O
haplotypes	O
involving	O
9	O
different	O
combinations	O
of	O
KIR	B
genes	O
.	O

A	O
and	O
B	O
haplotypes	O
both	O
exhibit	O
strong	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
between	O
2DL1	B
and	O
2DL3	B
alleles	O
,	O
and	O
between	O
3DL1	B
and	O
3DL2	B
alleles	O
.	O

In	O
contrast	O
,	O
there	O
was	O
little	O
LD	O
between	O
the	O
2DL1	B
/	O
2DL3	B
and	O
3DL1	B
/	O
3DL2	B
pairs	O
that	O
define	O
the	O
two	O
halves	O
of	O
the	O
KIR	B
gene	O
complex	O
.	O

The	O
synergistic	O
combination	O
of	O
allelic	O
polymorphism	O
and	O
variable	O
gene	O
content	O
individualize	O
KIR	B
genotype	O
to	O
an	O
extent	O
where	O
unrelated	O
individuals	O
almost	O
always	O
have	O
different	O
KIR	B
types	O
.	O

This	O
level	O
of	O
diversity	O
likely	O
reflects	O
strong	O
pressure	O
from	O
pathogens	O
on	O
the	O
human	O
NK	O
cell	O
response	O
.	O

[	O
A	O
cross	O
-	O
sectional	O
study	O
on	O
the	O
effects	O
of	O
microcystin	O
in	O
drinking	O
water	O
to	O
the	O
health	O
of	O
human	O
beings	O
]	O

OBJECTIVE	O
:	O

To	O
understand	O
the	O
effects	O
of	O
microcystin	O
(	O
MC	O
)	O
in	O
drinking	O
water	O
on	O
health	O
of	O
human	O
beings	O
.	O

METHODS	O
:	O

In	O
Taixing	O
,	O
a	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
in	O
two	O
middle	O
schools	O
with	O
different	O
types	O
of	O
drinking	O
water	O
,	O
from	O
which	O
111	O
and	O
92	O
students	O
were	O
randomly	O
selected	O
and	O
investigated	O
.	O

Blood	O
samples	O
from	O
all	O
individuals	O
were	O
collected	O
and	O
tested	O
for	O
serum	O
HBsAg	B
,	O
HBeAg	B
,	O
anti	O
-	O
HBe	B
,	O
anti	O
-	O
HBs	B
,	O
anti	O
-	O
HBc	B
with	O
enzyme	O
linked	O
immunoabsorbent	O
assay	O
and	O
for	O
serum	O
alanine	B
aminotransferase	I
(	O
ALT	B
)	O
,	O
gamma	B
-	I
glutamyltransferase	I
(	O
gamma	B
-	I
GT	I
)	O
and	O
alkaline	B
phosphatase	I
(	O
ALP	B
)	O
contents	O
by	O
colorimetry	O
.	O

These	O
levels	O
of	O
enzymes	O
in	O
sera	O
were	O
compared	O
after	O
the	O
students	O
were	O
stratified	O
according	O
to	O
the	O
status	O
of	O
HBV	O
infection	O
.	O

RESULT	O
:	O

With	O
the	O
exclusion	O
of	O
the	O
effect	O
of	O
HBV	O
infection	O
,	O
three	O
enzymes	O
levels	O
in	O
sera	O
between	O
two	O
groups	O
of	O
students	O
showed	O
significant	O
differences	O
(	O
P	O
<	O
0.01	O
)	O
,	O
much	O
higher	O
in	O
exposure	O
group	O
than	O
those	O
in	O
control	O
group	O
.	O

CONCLUSION	O
:	O

MC	O
was	O
possibly	O
harmful	O
to	O
human	O
beings	O
in	O
drinking	O
water	O
and	O
induced	O
the	O
contents	O
of	O
some	O
enzymes	O
from	O
the	O
liver	O
of	O
human	O
beings	O
to	O
increase	O
in	O
sera	O
.	O

The	O
roX	B
genes	O
encode	O
redundant	O
male	O
-	O
specific	O
lethal	O
transcripts	O
required	O
for	O
targeting	O
of	O
the	O
MSL	B
complex	I
.	O

The	O
roX1	B
and	O
roX2	B
genes	O
of	O
Drosophila	O
produce	O
male	O
-	O
specific	O
non	O
-	O
coding	O
RNAs	O
that	O
co	O
-	O
localize	O
with	O
the	O
Male	B
-	I
Specific	I
Lethal	I
(	I
MSL	I
)	I
protein	I
complex	I
.	O

This	O
complex	O
mediates	O
up	O
-	O
regulation	O
of	O
the	O
male	O
X	O
chromosome	O
by	O
increasing	O
histone	B
H4	I
acetylation	O
,	O
thus	O
contributing	O
to	O
the	O
equalization	O
of	O
X	O
-	O
linked	O
gene	O
expression	O
between	O
the	O
sexes	O
.	O

Both	O
roX	B
genes	O
overlap	O
two	O
of	O
approximately	O
35	O
chromatin	O
entry	O
sites	O
,	O
DNA	O
sequences	O
proposed	O
to	O
act	O
in	O
cis	O
to	O
direct	O
the	O
MSL	B
complex	I
to	O
the	O
X	O
chromosome	O
.	O

Although	O
dosage	O
compensation	O
is	O
essential	O
in	O
males	O
,	O
an	O
intact	O
roX1	B
gene	O
is	O
not	O
required	O
by	O
either	O
sex	O
.	O

We	O
have	O
generated	O
flies	O
lacking	O
roX2	B
and	O
find	O
that	O
this	O
gene	O
is	O
also	O
non	O
-	O
essential	O
.	O

However	O
,	O
simultaneous	O
removal	O
of	O
both	O
roX	B
RNAs	O
causes	O
a	O
striking	O
male	O
-	O
specific	O
reduction	O
in	O
viability	O
accompanied	O
by	O
relocation	O
of	O
the	O
MSL	B
proteins	O
and	O
acetylated	O
histone	B
H4	I
from	O
the	O
X	O
chromosome	O
to	O
autosomal	O
sites	O
and	O
heterochromatin	O
.	O

Males	O
can	O
be	O
rescued	O
by	O
roX	B
cDNAs	O
from	O
autosomal	O
transgenes	O
,	O
demonstrating	O
the	O
genetic	O
separation	O
of	O
the	O
chromatin	O
entry	O
and	O
RNA	O
-	O
encoding	O
functions	O
.	O

Therefore	O
,	O
the	O
roX1	B
and	O
roX2	B
genes	O
produce	O
redundant	O
,	O
male	B
-	I
specific	I
lethal	I
transcripts	O
required	O
for	O
targeting	O
the	O
MSL	B
complex	I
.	O

Human	O
bronchial	O
epithelium	O
expresses	O
interleukin-9	B
receptors	I
and	O
releases	O
neutrophil	B
chemotactic	I
factor	I
.	O

Growing	O
evidence	O
obtained	O
from	O
human	O
genomic	O
analysis	O
and	O
antigen	O
-	O
challenged	O
transgenic	O
mice	O
suggests	O
that	O
interleukin-9	B
(	O
IL-9	B
)	O
is	O
a	O
candidate	O
factor	O
in	O
immunoglobulin	B
E	I
(	O
IgE	B
)	O
production	O
and	O
thus	O
is	O
thought	O
to	O
be	O
associated	O
with	O
bronchial	O
inflammation	O
and	O
bronchial	O
hyperresponsiveness	O
(	O
BHR	O
)	O
.	O

To	O
evaluate	O
the	O
expression	O
of	O
the	O
IL-9	B
receptor	I
and	O
its	O
effect	O
on	O
the	O
IL-9	B
human	O
bronchial	O
cell	O
line	O
BEAS-2B	O
cells	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
,	O
immunohistochemical	O
investigation	O
,	O
and	O
chemotaxis	O
assay	O
were	O
performed	O
.	O

The	O
components	O
of	O
the	O
IL-9	B
receptor	I
,	O
consisting	O
of	O
IL-9	B
receptor	I
alpha	I
(	O
CD129	B
)	O
and	O
IL-2	O
receptory	O
(	O
(	O
1	O
)	O
132	O
)	O
,	O
were	O
expressed	O
on	O
BEAS-2B	O
cells	O
as	O
determined	O
by	O
RT	O
-	O
PCR	O
and	O
flow	O
cytometry	O
.	O

BEAS-2B	O
cells	O
exposed	O
to	O
IL-9	B
released	O
neutrophil	O
chemotactic	O
activity	O
(	O
NCA	O
)	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
,	O
and	O
the	O
presence	O
of	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
(	O
G	B
-	I
CSF	I
)	O
was	O
also	O
detected	O
.	O

This	O
factor	O
is	O
primarily	O
involved	O
in	O
NCA	O
for	O
the	O
measurement	O
of	O
cytokines	B
and	O
in	O
the	O
inhibition	O
assay	O
of	O
neutrophil	O
chemotaxis	O
.	O

These	O
findings	O
suggest	O
that	O
bronchial	O
epithelial	O
cells	O
may	O
express	O
IL-9	B
receptors	I
,	O
and	O
that	O
IL-9	B
may	O
induce	O
airway	O
inflammation	O
through	O
the	O
release	O
of	O
G	B
-	I
CSF	I
from	O
bronchial	O
epithelial	O
cells	O
.	O

HIV-1	O
infection	O
in	O
rural	O
Africa	O
:	O
is	O
there	O
a	O
difference	O
in	O
median	O
time	O
to	O
AIDS	O
and	O
survival	O
compared	O
with	O
that	O
in	O
industrialized	O
countries	O
?	O

OBJECTIVES	O
:	O

To	O
describe	O
the	O
progression	O
times	O
of	O
HIV-1	O
infection	O
from	O
seroconversion	O
to	O
AIDS	O
and	O
to	O
death	O
,	O
and	O
time	O
from	O
first	O
developing	O
AIDS	O
to	O
death	O
in	O
rural	O
Uganda	O
.	O

Also	O
,	O
to	O
describe	O
the	O
proportion	O
of	O
individuals	O
within	O
the	O
cohort	O
dying	O
with	O
AIDS	O
and	O
the	O
CD4	B
lymphocyte	O
count	O
before	O
death	O
.	O

DESIGN	O
:	O

A	O
prospective	O
,	O
longitudinal	O
,	O
population	O
-	O
based	O
cohort	O
.	O

METHODS	O
:	O

Since	O
1990	O
,	O
107	O
HIV	O
-	O
prevalent	O
cases	O
,	O
168	O
incident	O
cases	O
and	O
235	O
HIV	O
-	O
seronegative	O
controls	O
have	O
been	O
recruited	O
into	O
a	O
cohort	O
in	O
rural	O
Uganda	O
.	O

Participants	O
are	O
recruited	O
from	O
the	O
general	O
population	O
and	O
they	O
are	O
reviewed	O
routinely	O
every	O
3	O
months	O
and	O
at	O
other	O
times	O
when	O
ill	O
.	O

RESULTS	O
:	O

The	O
median	O
time	O
from	O
seroconversion	O
to	O
death	O
was	O
9.8	O
years	O
.	O

Age	O
over	O
40	O
years	O
at	O
seroconversion	O
was	O
associated	O
with	O
more	O
rapid	O
progression	O
(	O
P	O
<	O
0.001	O
,	O
log	O
rank	O
test	O
)	O
.	O

For	O
the	O
first	O
4	O
years	O
of	O
the	O
study	O
,	O
HIV	O
contributed	O
little	O
to	O
the	O
death	O
rates	O
in	O
the	O
HIV	O
incident	O
cases	O
,	O
but	O
after	O
5	O
years	O
,	O
the	O
contribution	O
of	O
HIV	O
became	O
greater	O
and	O
was	O
particularly	O
marked	O
in	O
the	O
oldest	O
age	O
group	O
.	O

Survival	O
rates	O
in	O
the	O
cohort	O
were	O
similar	O
to	O
those	O
in	O
the	O
general	O
population	O
.	O

The	O
median	O
time	O
from	O
seroconversion	O
to	O
AIDS	O
was	O
9.4	O
years	O
and	O
from	O
AIDS	O
to	O
death	O
was	O
9.2	O
months	O
.	O

Of	O
those	O
infected	O
with	O
HIV-1	O
,	O
80	O
%	O
died	O
with	O
AIDS	O
and	O
20	O
%	O
had	O
a	O
CD4	B
count	O
<	O
10	O
x	O
106	O
cells	O
/	O
l	O
.	O

CONCLUSIONS	O
:	O

Survival	O
with	O
HIV-1	O
infection	O
is	O
similar	O
in	O
Africa	O
to	O
industrialized	O
countries	O
before	O
the	O
use	O
of	O
antiretroviral	O
therapy	O
;	O
when	O
they	O
do	O
die	O
,	O
many	O
of	O
those	O
in	O
Africa	O
are	O
severely	O
immunosuppressed	O
and	O
most	O
have	O
clinical	O
features	O
of	O
AIDS	O
.	O

Neural	O
progenitor	O
cells	O
of	O
the	O
neonatal	O
rat	O
anterior	O
subventricular	O
zone	O
express	O
functional	O
GABA	B
(	I
A	I
)	I
receptors	I
.	O

The	O
interneurons	O
of	O
the	O
olfactory	O
bulb	O
arise	O
from	O
precursor	O
cells	O
in	O
the	O
anterior	O
part	O
of	O
the	O
neonatal	O
subventricular	O
zone	O
,	O
the	O
SVZa	O
,	O
and	O
are	O
distinctive	O
in	O
that	O
they	O
possess	O
a	O
neuronal	O
phenotype	O
and	O
yet	O
undergo	O
cell	O
division	O
.	O

To	O
characterize	O
the	O
differentiation	O
of	O
neonatal	O
SVZa	O
progenitor	O
cells	O
,	O
we	O
analyzed	O
the	O
complement	O
of	O
ionotropic	O
neurotransmitter	O
receptors	O
that	O
they	O
express	O
in	O
vitro	O
.	O

For	O
this	O
analysis	O
,	O
we	O
tested	O
the	O
sensitivity	O
of	O
SVZa	O
progenitor	O
cells	O
to	O
gamma	O
-	O
amino	O
-	O
n	O
-	O
butyric	O
acid	O
(	O
GABA	O
)	O
,	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
,	O
kainate	O
,	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
,	O
and	O
acetylcholine	O
(	O
ACh	O
)	O
after	O
1	O
day	O
in	O
vitro	O
.	O

SVZa	O
progenitor	O
cells	O
had	O
chloride	O
currents	O
activated	O
by	O
GABA	O
and	O
muscimol	O
,	O
the	O
GABA	B
(	I
A	I
)	I
receptor	I
-	O
specific	O
agonist	O
,	O
but	O
were	O
insensitive	O
to	O
ATP	O
,	O
kainate	O
,	O
NMDA	O
,	O
and	O
ACh	O
.	O

In	O
addition	O
,	O
GABA	O
-	O
or	O
muscimol	O
-	O
activated	O
chloride	O
currents	O
were	O
blocked	O
nearly	O
completely	O
by	O
30	O
microM	O
bicuculline	O
,	O
the	O
GABA	B
(	I
A	I
)	I
receptor	I
-	O
specific	O
antagonist	O
,	O
suggesting	O
that	O
GABA	B
(	I
B	I
)	I
and	I
GABA	I
(	I
C	I
)	I
receptors	I
are	O
absent	O
.	O

Measurements	O
of	O
the	O
chloride	O
reversal	O
potential	O
by	O
gramicidin	O
-	O
perforated	O
patch	O
clamp	O
revealed	O
that	O
currents	O
generated	O
by	O
activation	O
of	O
GABA	B
(	I
A	I
)	I
receptors	I
were	O
inward	O
,	O
and	O
thus	O
,	O
depolarizing	O
.	O

A	O
set	O
of	O
complementary	O
experiments	O
was	O
undertaken	O
to	O
determine	O
by	O
reverse	O
transcription	O
and	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
whether	O
SVZa	O
progenitor	O
cells	O
express	O
the	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
coding	O
for	O
glutamic	B
acid	I
decarboxylase	I
67	I
(	O
GAD67	B
)	O
,	O
used	O
in	O
the	O
synthesis	O
of	O
GABA	O
and	O
for	O
GABA	B
(	I
A	I
)	I
receptor	I
subunits	O
.	O

Both	O
postnatal	O
day	O
(	O
P0	O
)	O
SVZa	O
and	O
olfactory	O
bulb	O
possessed	O
detectable	O
mRNA	O
coding	O
for	O
GAD67	B
.	O

In	O
P0	O
SVZa	O
,	O
the	O
GABA	B
(	I
A	I
)	I
receptor	I
subunits	O
detected	O
with	O
RT	O
-	O
PCR	O
included	O
alpha	O
2	O
-	O
4	O
,	O
beta	O
1	O
-	O
3	O
,	O
and	O
gamma	O
2S	O
(	O
short	O
form	O
)	O
.	O

By	O
comparison	O
,	O
the	O
P0	O
olfactory	O
bulb	O
expressed	O
all	O
of	O
the	O
subunits	O
detectable	O
in	O
the	O
SVZa	O
and	O
additional	O
subunit	O
mRNAs	O
:	O
alpha	O
1	O
,	O
alpha	O
5	O
,	O
gamma	O
1	O
,	O
gamma	O
2L	O
(	O
long	O
form	O
)	O
,	O
gamma	O
3	O
,	O
and	O
delta	O
subunit	O
mRNAs	O
.	O

Antibodies	O
recognizing	O
GABA	O
,	O
GAD	O
,	O
and	O
various	O
GABA	B
(	I
A	I
)	I
receptor	I
subunits	O
were	O
used	O
to	O
label	O
SVZa	O
cells	O
harvested	O
from	O
P0	O
-	O
1	O
rats	O
and	O
cultured	O
for	O
1	O
day	O
.	O

The	O
cells	O
were	O
immunoreactive	O
for	O
GABA	O
,	O
GAD	O
,	O
and	O
the	O
GABA	B
(	I
A	I
)	I
receptor	I
subunits	O
alpha	O
2	O
-	O
5	O
,	O
beta	O
1	O
-	O
3	O
,	O
and	O
gamma	O
2	O
.	O

To	O
relate	O
the	O
characteristics	O
of	O
GABA	B
(	I
A	I
)	I
receptors	I
in	O
cultured	O
SVZa	O
precursor	O
cells	O
to	O
particular	O
combinations	O
of	O
subunits	O
,	O
the	O
open	O
reading	O
frames	O
of	O
the	O
dominant	O
subunits	O
detected	O
by	O
RT	O
-	O
PCR	O
(	O
alpha	O
2	O
-	O
4	O
,	O
beta	O
3	O
,	O
and	O
gamma	O
2S	O
)	O
were	O
cloned	O
into	O
a	O
mammalian	O
cell	O
expression	O
vector	O
and	O
different	O
combinations	O
were	O
transfected	O
into	O
Chinese	O
hamster	O
ovary	O
-	O
K1	O
(	O
CHO	O
-	O
K1	O
)	O
cells	O
.	O

A	O
comparison	O
of	O
the	O
sensitivity	O
to	O
inhibition	O
by	O
zinc	O
of	O
GABA	B
(	I
A	I
)	I
receptors	I
in	O
SVZa	O
precursor	O
cells	O
and	O
in	O
CHO	O
-	O
K1	O
cells	O
expressing	O
various	O
combinations	O
of	O
recombinant	O
GABA	B
(	I
A	I
)	I
receptor	I
subunits	O
suggested	O
that	O
the	O
gamma	O
2S	O
subunit	O
was	O
present	O
and	O
functional	O
in	O
the	O
GABA	B
(	I
A	I
)	I
receptor	I
chloride	B
channel	I
complex	O
.	O

Thus	O
,	O
SVZa	O
precursor	O
cells	O
are	O
GABAergic	O
and	O
a	O
subset	O
of	O
the	O
GABA	B
(	I
A	I
)	I
receptor	I
subunits	O
detected	O
in	O
the	O
olfactory	O
bulb	O
was	O
found	O
in	O
the	O
SVZa	O
,	O
as	O
might	O
be	O
expected	O
because	O
SVZa	O
progenitor	O
cells	O
migrate	O
to	O
the	O
bulb	O
as	O
they	O
differentiate	O
.	O

Fine	O
mapping	O
of	O
the	O
chromosome	O
2p12	O
-	O
16	O
dyslexia	O
susceptibility	O
locus	O
:	O
quantitative	O
association	O
analysis	O
and	O
positional	O
candidate	O
genes	O
SEMA4F	B
and	O
OTX1	B
.	O

A	O
locus	O
on	O
chromosome	O
2p12	O
-	O
16	O
has	O
been	O
implicated	O
in	O
dyslexia	O
susceptibility	O
by	O
two	O
independent	O
linkage	O
studies	O
,	O
including	O
our	O
own	O
study	O
of	O
119	O
nuclear	O
twin	O
-	O
based	O
families	O
,	O
each	O
with	O
at	O
least	O
one	O
reading	O
-	O
disabled	O
child	O
.	O

Nonetheless	O
,	O
no	O
variant	O
of	O
any	O
gene	O
has	O
been	O
reported	O
to	O
show	O
association	O
with	O
dyslexia	O
,	O
and	O
no	O
consistent	O
clinical	O
evidence	O
exists	O
to	O
identify	O
candidate	O
genes	O
with	O
any	O
strong	O
a	O
priori	O
logic	O
.	O

We	O
used	O
21	O
microsatellite	O
markers	O
spanning	O
2p12	O
-	O
16	O
to	O
refine	O
our	O
1-LOD	O
unit	O
linkage	O
support	O
interval	O
to	O
12cM	O
between	O
D2S337	O
and	O
D2S286	O
.	O

Then	O
,	O
in	O
quantitative	O
association	O
analysis	O
,	O
two	O
microsatellites	O
yielded	O
P	O
values	O
<	O
0.05	O
across	O
a	O
range	O
of	O
reading	O
-	O
related	O
measures	O
(	O
D2S2378	O
and	O
D2S2114	O
)	O
.	O

The	O
exon	O
/	O
intron	O
borders	O
of	O
two	O
positional	O
candidate	O
genes	O
within	O
the	O
region	O
were	O
characterized	O
,	O
and	O
the	O
exons	O
were	O
screened	O
for	O
polymorphisms	O
.	O

The	O
genes	O
were	O
Semaphorin4F	B
(	O
SEMA4F	B
)	O
,	O
which	O
encodes	O
a	O
protein	O
involved	O
in	O
axonal	O
growth	O
cone	O
guidance	O
,	O
and	O
OTX1	B
,	O
encoding	O
a	O
homeodomain	O
transcription	B
factor	I
involved	O
in	O
forebrain	O
development	O
.	O

Two	O
non	O
-	O
synonymous	O
single	O
nucleotide	O
polymorphisms	O
were	O
found	O
in	O
SEMA4F	B
,	O
each	O
with	O
a	O
heterozygosity	O
of	O
0.03	O
.	O

One	O
intronic	O
single	O
nucleotide	O
polymorphism	O
between	O
exons	O
12	O
and	O
13	O
of	O
SEMA4F	B
was	O
tested	O
for	O
quantitative	O
association	O
,	O
but	O
no	O
significant	O
association	O
was	O
found	O
.	O

Only	O
one	O
single	O
nucleotide	O
polymorphism	O
was	O
found	O
in	O
OTX1	B
,	O
which	O
was	O
exonic	O
but	O
silent	O
.	O

Our	O
data	O
therefore	O
suggest	O
that	O
linkage	O
with	O
reading	O
disability	O
at	O
2p12	O
-	O
16	O
is	O
not	O
caused	O
by	O
coding	O
variants	O
of	O
SEMA4F	B
or	O
OTX1	B
.	O

Our	O
study	O
outlines	O
the	O
approach	O
necessary	O
for	O
the	O
identification	O
of	O
genetic	O
variants	O
causing	O
dyslexia	O
susceptibility	O
in	O
an	O
epidemiological	O
population	O
of	O
dyslexics	O
.	O

Association	O
of	O
dopamine	B
D	I
(	I
3	I
)	I
receptors	I
with	O
actin	B
-	I
binding	I
protein	I
280	I
(	O
ABP-280	B
)	O
.	O

Proteins	O
that	O
bind	O
to	O
G	B
protein	I
-	I
coupled	I
receptors	I
have	O
been	O
identified	O
as	O
regulators	O
of	O
receptor	O
localization	O
and	O
signaling	O
.	O

In	O
our	O
previous	O
studies	O
,	O
a	O
cytoskeletal	O
protein	O
,	O
actin	B
-	I
binding	I
protein	I
280	I
(	O
ABP-280	B
)	O
,	O
was	O
found	O
to	O
associate	O
with	O
the	O
third	O
cytoplasmic	O
loop	O
of	O
dopamine	B
D	I
(	I
2	I
)	I
receptors	I
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
ABP-280	B
also	O
interacts	O
with	O
dopamine	B
D	I
(	I
3	I
)	I
receptors	I
,	O
but	O
not	O
with	O
D	B
(	I
4	I
)	I
receptors	I
.	O

Similar	O
to	O
the	O
dopamine	B
D	I
(	I
2	I
)	I
receptor	I
,	O
the	O
D	B
(	I
3	I
)	I
/	O
ABP-280	B
association	O
is	O
of	O
signaling	O
importance	O
.	O

In	O
human	O
melanoma	O
M2	O
cells	O
lacking	O
ABP-280	B
,	O
D	B
(	I
3	I
)	I
receptors	I
were	O
unable	O
to	O
inhibit	O
forskolin	O
-	O
stimulated	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
production	O
significantly	O
.	O

D	B
(	I
4	I
)	I
receptors	I
,	O
however	O
,	O
exhibited	O
a	O
similar	O
degree	O
of	O
inhibition	O
of	O
forskolin	O
-	O
stimulated	O
cAMP	O
production	O
in	O
ABP-280	B
-	O
deficient	O
M2	O
cells	O
and	O
ABP-280	B
-	O
replent	O
M2	O
subclones	O
(	O
A7	O
cells	O
)	O
.	O

Further	O
experiments	O
revealed	O
that	O
the	O
D	B
(	I
3	I
)	I
/	O
ABP-280	B
interaction	O
was	O
critically	O
dependent	O
upon	O
a	O
36	O
amino	O
acid	O
carboxyl	O
domain	O
of	O
the	O
D	B
(	I
3	I
)	I
receptor	I
third	O
loop	O
,	O
which	O
is	O
conserved	O
in	O
the	O
D	B
(	I
2	I
)	I
receptor	I
but	O
not	O
in	O
the	O
D	B
(	I
4	I
)	I
receptor	I
.	O

Our	O
results	O
demonstrate	O
a	O
subtype	O
-	O
specific	O
regulation	O
of	O
dopamine	B
D	I
(	I
2	I
)	I
-	I
family	I
receptor	I
signaling	O
by	O
the	O
cytoskeletal	O
protein	O
ABP-280	B
.	O

Fibroblast	B
growth	I
factor-10	I
is	O
a	O
mitogen	O
for	O
urothelial	O
cells	O
.	O

Fibroblast	B
growth	I
factor	I
(	I
FGF	I
)	I
-	I
10	I
plays	O
an	O
important	O
role	O
in	O
regulating	O
growth	O
,	O
differentiation	O
,	O
and	O
repair	O
of	O
the	O
urothelium	O
.	O

This	O
process	O
occurs	O
through	O
a	O
paracrine	O
cascade	O
originating	O
in	O
the	O
mesenchyme	O
(	O
lamina	O
propria	O
)	O
and	O
targeting	O
the	O
epithelium	O
(	O
urothelium	O
)	O
.	O

In	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
(	O
i	O
)	O
fibroblasts	O
of	O
the	O
human	O
lamina	O
propria	O
were	O
the	O
cell	O
type	O
that	O
synthesized	O
FGF-10	B
RNA	O
and	O
(	O
ii	O
)	O
the	O
FGF-10	B
gene	O
is	O
located	O
at	O
the	O
5p12	O
-	O
p13	O
locus	O
of	O
chromosome	O
5	O
.	O

Recombinant	O
(	O
r	O
)	O
preparations	O
of	O
human	O
FGF-10	B
were	O
found	O
to	O
induce	O
proliferation	O
of	O
human	O
urothelial	O
cells	O
in	O
vitro	O
and	O
of	O
transitional	O
epithelium	O
of	O
wild	O
-	O
type	O
and	O
FGF7	B
-	O
null	O
mice	O
in	O
vivo	O
.	O

Mechanistic	O
studies	O
with	O
human	O
cells	O
indicated	O
two	O
modes	O
of	O
FGF-10	B
action	O
:	O
(	O
i	O
)	O
translocation	O
of	O
rFGF	B
-	I
10	I
into	O
urothelial	O
cell	O
nuclei	O
and	O
(	O
ii	O
)	O
a	O
signaling	O
cascade	O
that	O
begins	O
with	O
the	O
heparin	O
-	O
dependent	O
phosphorylation	O
of	O
tyrosine	O
residues	O
of	O
surface	O
transmembrane	O
receptors	O
.	O

The	O
normal	O
urothelial	O
phenotype	O
,	O
that	O
of	O
quiescence	O
,	O
is	O
proposed	O
to	O
be	O
typified	O
by	O
negligible	O
levels	O
of	O
FGF-10	B
.	O

During	O
proliferative	O
phases	O
,	O
levels	O
of	O
FGF-10	B
rise	O
at	O
the	O
urothelial	O
cell	O
surface	O
and/or	O
within	O
urothelial	O
cell	O
nuclei	O
.	O

An	O
understanding	O
of	O
how	O
FGF-10	B
works	O
in	O
conjunction	O
with	O
these	O
other	O
processes	O
will	O
lead	O
to	O
better	O
management	O
of	O
many	O
diseases	O
of	O
the	O
bladder	O
and	O
urinary	O
tract	O
.	O

Identification	O
of	O
a	O
domain	O
conferring	O
nucleotide	O
binding	O
to	O
the	O
N	B
-	I
acetyl	I
-	I
d	I
-	I
glucosamine	I
2-epimerase	I
(	O
Renin	B
binding	I
protein	I
)	O
.	O

Renin	B
binding	I
protein	I
(	O
RnBP	B
)	O
,	O
a	O
cellular	O
renin	B
inhibitor	O
,	O
has	O
been	O
identified	O
as	O
the	O
enzyme	O
N	B
-	I
acetyl	I
-	I
D	I
-	I
glucosamine	I
(	I
GlcNAc	I
)	I
2-epimerase	I
.	O

Our	O
recent	O
studies	O
demonstrated	O
that	O
rat	O
GlcNAc	B
2-epimerase	I
has	O
a	O
ten	O
-	O
times	O
higher	O
affinity	O
for	O
ATP	O
,	O
dATP	O
,	O
and	O
ddATP	O
than	O
the	O
human	O
enzyme	O
[	O
Takahashi	O
,	O
S.	O
et	O
al.	O
(	O
2001	O
)	O
J.	O
Biochem	O
.	O
130	O
,	O
815	O
-	O
821	O
]	O
.	O

To	O
identify	O
the	O
domain	O
conferring	O
nucleotide	O
binding	O
to	O
GlcNAc	B
2-epimerase	I
,	O
we	O
constructed	O
a	O
series	O
of	O
chimeric	O
enzymes	O
successively	O
replacing	O
the	O
three	O
domains	O
of	O
the	O
human	O
enzyme	O
(	O
N	O
-	O
terminal	O
,	O
middle	O
,	O
and	O
C	O
-	O
terminal	O
domains	O
)	O
with	O
the	O
corresponding	O
domains	O
of	O
the	O
rat	O
enzyme	O
.	O

Chimeras	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
JM109	O
cells	O
under	O
the	O
control	O
of	O
the	O
Taq	B
promoter	O
.	O

The	O
purified	O
chimeric	O
enzymes	O
had	O
GlcNAc	B
2-epimerase	I
activity	O
and	O
inhibited	O
renin	B
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
recombinant	O
human	O
and	O
rat	O
enzymes	O
required	O
catalytic	O
amounts	O
of	O
ATP	O
with	O
apparent	O
K	O
(	O
m	O
)	O
values	O
of	O
73	O
and	O
5.5	O
microM	O
,	O
respectively	O
.	O

Chimeric	O
enzymes	O
of	O
HHR	O
,	O
RHH	O
,	O
and	O
RHR	O
(	O
H	O
,	O
human	O
type	O
domain	O
;	O
R	O
,	O
rat	O
type	O
domain	O
)	O
had	O
nearly	O
the	O
same	O
nucleotide	O
specificity	O
as	O
the	O
human	O
GlcNAc	B
2-epimerase	I
.	O

On	O
the	O
other	O
hand	O
,	O
HRR	O
,	O
HRH	O
,	O
and	O
RRH	O
chimeras	O
had	O
the	O
same	O
nucleotide	O
specificity	O
as	O
the	O
rat	O
enzyme	O
.	O

These	O
results	O
indicate	O
that	O
the	O
middle	O
domain	O
of	O
the	O
GlcNAc	B
2-epimerase	I
molecule	O
participates	O
in	O
the	O
specificity	O
for	O
and	O
binding	O
of	O
nucleotides	O
,	O
and	O
that	O
nucleotides	O
are	O
essential	O
to	O
form	O
the	O
catalytic	O
domain	O
of	O
the	O
enzyme	O
.	O

Sec34	B
is	O
implicated	O
in	O
traffic	O
from	O
the	O
endoplasmic	O
reticulum	O
to	O
the	O
Golgi	O
and	O
exists	O
in	O
a	O
complex	O
with	O
GTC-90	B
and	O
ldlBp	B
.	O

Sec34p	B
/	O
Grd20p	B
has	O
been	O
implicated	O
in	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-	O
to	O
-	O
Golgi	O
transport	O
and/or	O
post	O
-	O
Golgi	O
trafficking	O
events	O
and	O
exists	O
in	O
a	O
protein	O
complex	O
consisting	O
of	O
at	O
least	O
eight	O
subunits	O
in	O
yeast	O
.	O

Although	O
the	O
mammalian	O
counterpart	O
(	O
Sec34	B
)	O
of	O
Sec34p	B
has	O
been	O
molecularly	O
identified	O
,	O
its	O
role	O
and	O
interacting	O
partners	O
remain	O
undefined	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
prepared	O
antibodies	O
specifically	O
against	O
the	O
recombinant	O
N	O
-	O
terminal	O
fragment	O
of	O
Sec34	B
that	O
recognize	O
a	O
polypeptide	O
of	O
about	O
93	O
kDa	O
and	O
label	O
the	O
Golgi	O
apparatus	O
.	O

In	O
a	O
well	O
-	O
characterized	O
semi	O
-	O
intact	O
cell	O
assay	O
that	O
reconstitutes	O
transport	O
of	O
the	O
envelope	O
glycoprotein	O
(	O
VSVG	O
)	O
of	O
vesicular	O
stomatitis	O
virus	O
from	O
the	O
ER	O
to	O
the	O
Golgi	O
apparatus	O
,	O
anti	O
-	O
Sec34	B
antibodies	O
inhibited	O
the	O
transport	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
inhibition	O
by	O
anti	O
-	O
Sec34	B
antibodies	O
could	O
be	O
neutralized	O
by	O
a	O
noninhibitory	O
amount	O
of	O
the	O
antigen	O
.	O

Large	O
-	O
scale	O
immunoprecipitation	O
of	O
rat	O
liver	O
cytosol	O
with	O
immobilized	O
anti	O
-	O
Sec34	B
antibodies	O
has	O
co	O
-	O
immunoprecipitated	O
GTC-90	B
and	O
ldlBp	B
,	O
two	O
peripheral	O
Golgi	O
proteins	O
previously	O
shown	O
to	O
exist	O
in	O
separate	O
protein	O
complexes	O
.	O

Two	O
mammalian	O
homologues	O
(	O
Dor1	B
and	O
Cod1	B
)	O
of	O
the	O
yeast	O
Sec34	B
complex	O
were	O
similarly	O
recovered	O
in	O
the	O
Sec34	B
immunoprecipitates	O
.	O

When	O
expressed	O
in	O
transfected	O
cells	O
,	O
epitope	O
-	O
tagged	O
ldlCp	B
and	O
Cod2	B
were	O
co	O
-	O
immunoprecipitated	O
with	O
anti	O
-	O
Sec34	B
antibodies	O
with	O
efficiencies	O
comparable	O
to	O
that	O
observed	O
for	O
tagged	O
ldlBp	B
,	O
Dor1	B
,	O
and	O
Cod1	B
.	O

Direct	O
interactions	O
of	O
Sec34	B
with	O
ldlBp	B
and	O
ldlCp	B
were	O
further	O
demonstrated	O
in	O
vitro	O
.	O

These	O
results	O
suggest	O
that	O
Sec34	B
,	O
GTC-90	B
,	O
and	O
ldlBp	B
/	O
ldlCp	B
are	O
part	O
of	O
the	O
same	O
protein	O
complex	O
(	O
es	O
)	O
that	O
regulates	O
diverse	O
aspects	O
of	O
Golgi	O
function	O
,	O
including	O
transport	O
from	O
the	O
ER	O
to	O
the	O
Golgi	O
apparatus	O
.	O

GGA	B
proteins	O
associate	O
with	O
Golgi	O
membranes	O
through	O
interaction	O
between	O
their	O
GGAH	O
domains	O
and	O
ADP	B
-	I
ribosylation	I
factors	I
.	O

ADP	B
-	I
ribosylation	I
factors	I
(	O
ARFs	B
)	O
are	O
a	O
family	O
of	O
small	B
GTPases	I
that	O
are	O
involved	O
in	O
various	O
aspects	O
of	O
membrane	O
trafficking	O
events	O
.	O

These	O
include	O
ARF1	B
-	I
ARF6	I
,	O
which	O
are	O
divided	O
into	O
three	O
classes	O
on	O
the	O
basis	O
of	O
similarity	O
in	O
the	O
primary	O
structure	O
:	O
Class	O
I	O
,	O
ARF1-ARF3	B
;	O
Class	O
II	O
,	O
ARF4	B
and	O
ARF5	B
;	O
and	O
Class	O
III	O
,	O
ARF6	B
.	O

Previous	O
studies	O
identified	O
a	O
novel	O
family	O
of	O
potential	O
ARF	B
effectors	O
,	O
termed	O
GGA1	B
-	I
GGA3	I
,	O
which	O
interact	O
specifically	O
with	O
GTP	O
-	O
bound	O
ARF1	B
and	O
ARF3	B
and	O
are	O
localized	O
to	O
the	O
trans	O
-	O
Golgi	O
network	O
(	O
TGN	O
)	O
or	O
its	O
related	O
compartment	O
(	O
s	O
)	O
(	O
GGA	B
is	O
an	O
abbreviation	O
for	O
Golgi	B
-	I
localizing	I
,	I
gamma	I
-	I
adaptin	I
ear	I
homology	I
domain	I
,	I
ARF	I
-	I
binding	I
protein	I
)	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
shown	O
that	O
ARF	B
proteins	O
belonging	O
to	O
the	O
three	O
classes	O
,	O
ARF1	B
,	O
ARF5	B
and	O
ARF6	B
,	O
can	O
interact	O
with	O
all	O
GGA	B
proteins	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
assay	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Segmentation	O
of	O
GGA	B
proteins	O
and	O
isolation	O
of	O
GGA	B
mutants	O
defective	O
in	O
ARF	B
binding	O
have	O
revealed	O
that	O
a	O
limited	O
region	O
within	O
the	O
GGA	B
homology	O
domain	O
,	O
which	O
is	O
conserved	O
in	O
the	O
GGA	B
family	I
,	O
is	O
essential	O
for	O
ARF	B
binding	O
.	O

Expression	O
in	O
cells	O
of	O
GTPase	B
-	O
restricted	O
mutants	O
of	O
ARF1	B
and	O
ARF5	B
blocks	O
dissociation	O
of	O
GGA	B
proteins	O
from	O
membranes	O
induced	O
by	O
brefeldin	O
A	O
.	O

However	O
,	O
neither	O
of	O
the	O
ARF	B
mutants	O
recruits	O
GGA	B
mutants	O
defective	O
in	O
ARF	B
binding	O
.	O

On	O
the	O
basis	O
of	O
these	O
observations	O
,	O
we	O
conclude	O
that	O
at	O
least	O
ARF1	B
(	O
Class	O
I	O
)	O
and	O
ARF5	B
(	O
Class	O
II	O
)	O
in	O
their	O
GTP	O
-	O
bound	O
state	O
cause	O
recruitment	O
of	O
GGA	B
proteins	O
on	O
to	O
TGN	O
membranes	O
.	O

In	O
contrast	O
,	O
on	O
the	O
basis	O
of	O
similar	O
experiments	O
,	O
ARF6	B
(	O
Class	O
III	O
)	O
may	O
be	O
involved	O
in	O
recruitment	O
of	O
GGA	B
proteins	O
to	O
other	O
compartments	O
,	O
possibly	O
early	O
endosomes	O
.	O

Human	O
CAP1	B
is	O
a	O
key	O
factor	O
in	O
the	O
recycling	O
of	O
cofilin	B
and	O
actin	B
for	O
rapid	O
actin	B
turnover	O
.	O

Cofilin	B
-	O
ADF	B
(	O
actin	B
-	I
depolymerizing	I
factor	I
)	O
is	O
an	O
essential	O
driver	O
of	O
actin	B
-	O
based	O
motility	O
.	O

We	O
discovered	O
two	O
proteins	O
,	O
p65	B
and	O
p55	B
,	O
that	O
are	O
components	O
of	O
the	O
actin	B
-	O
cofilin	B
complex	O
in	O
a	O
human	O
HEK293	O
cell	O
extract	O
and	O
identified	O
p55	B
as	O
CAP1	B
/	O
ASP56	B
,	O
a	O
human	O
homologue	O
of	O
yeast	O
CAP	B
/	O
SRV2	B
(	O
cyclase	B
-	I
associated	I
protein	I
)	O
.	O

CAP	B
is	O
a	O
bifunctional	O
protein	O
with	O
an	O
N	O
-	O
terminal	O
domain	O
that	O
binds	O
to	O
Ras	B
-	O
responsive	O
adenylyl	B
cyclase	I
and	O
a	O
C	O
-	O
terminal	O
domain	O
that	O
inhibits	O
actin	B
polymerization	O
.	O

Surprisingly	O
,	O
we	O
found	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
CAP1	B
,	O
but	O
not	O
the	O
C	O
-	O
terminal	O
domain	O
,	O
is	O
responsible	O
for	O
the	O
interaction	O
with	O
the	O
actin	B
-	O
cofilin	B
complex	O
.	O

The	O
N	O
-	O
terminal	O
domain	O
of	O
CAP1	B
was	O
also	O
found	O
to	O
accelerate	O
the	O
depolymerization	O
of	O
F	B
-	I
actin	I
at	O
the	O
pointed	O
end	O
,	O
which	O
was	O
further	O
enhanced	O
in	O
the	O
presence	O
of	O
cofilin	B
and/or	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
CAP1	B
.	O

Moreover	O
,	O
CAP1	B
and	O
its	O
C	O
-	O
terminal	O
domain	O
were	O
observed	O
to	O
facilitate	O
filament	O
elongation	O
at	O
the	O
barbed	O
end	O
and	O
to	O
stimulate	O
ADP	O
-	O
ATP	O
exchange	O
on	O
G	B
-	I
actin	I
,	O
a	O
process	O
that	O
regenerates	O
easily	O
polymerizable	O
G	B
-	I
actin	I
.	O

Although	O
cofilin	B
inhibited	O
the	O
nucleotide	O
exchange	O
on	O
G	B
-	I
actin	I
even	O
in	O
the	O
presence	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
CAP1	B
,	O
its	O
N	O
-	O
terminal	O
domain	O
relieved	O
this	O
inhibition	O
.	O

Thus	O
,	O
CAP1	B
plays	O
a	O
key	O
role	O
in	O
speeding	O
up	O
the	O
turnover	O
of	O
actin	B
filaments	O
by	O
effectively	O
recycling	O
cofilin	B
and	O
actin	B
and	O
through	O
its	O
effect	O
on	O
both	O
ends	O
of	O
actin	B
filament	O
.	O

The	O
type	B
XIII	I
collagen	I
ectodomain	O
is	O
a	O
150	O
-	O
nm	O
rod	O
and	O
capable	O
of	O
binding	O
to	O
fibronectin	B
,	O
nidogen-2	B
,	O
perlecan	B
,	O
and	O
heparin	O
.	O

Type	B
XIII	I
collagen	I
consists	O
of	O
a	O
short	O
N	O
-	O
terminal	O
intracellular	O
domain	O
,	O
a	O
transmembrane	O
domain	O
,	O
and	O
a	O
collagenous	O
ectodomain	O
,	O
and	O
it	O
is	O
found	O
at	O
many	O
sites	O
of	O
cell	O
adhesion	O
.	O

We	O
report	O
on	O
the	O
characterization	O
of	O
recombinant	O
type	B
XIII	I
collagen	I
.	O

The	O
shed	O
ectodomain	O
was	O
purified	O
from	O
insect	O
cell	O
culture	O
medium	O
and	O
shown	O
to	O
form	O
240	O
-	O
kDa	O
trimers	O
with	O
a	O
T	O
(	O
m	O
)	O
of	O
42	O
degrees	O
C	O
.	O

Correct	O
chain	O
association	O
into	O
a	O
triple	O
-	O
helical	O
conformation	O
was	O
confirmed	O
by	O
limited	O
pepsin	B
digestion	O
and	O
CD	O
spectroscopy	O
.	O

Rotary	O
shadowing	O
electron	O
microscopy	O
of	O
the	O
ectodomain	O
revealed	O
it	O
to	O
be	O
a	O
150	O
-	O
nm	O
rod	O
with	O
two	O
flexible	O
hinges	O
separating	O
31	O
-	O
,	O
52	O
-	O
,	O
and	O
68	O
-	O
nm	O
portions	O
.	O

The	O
rods	O
represent	O
the	O
collagenous	O
domains	O
1	O
-	O
3	O
,	O
and	O
the	O
hinges	O
coincide	O
with	O
the	O
non	O
-	O
collagenous	O
domains	O
2	O
and	O
3	O
.	O

By	O
using	O
surface	O
plasmon	O
resonance	O
analysis	O
,	O
the	O
ectodomain	O
showed	O
interaction	O
with	O
immobilized	O
fibronectin	B
,	O
nidogen-2	B
,	O
and	O
perlecan	B
with	O
K	O
(	O
D	O
)	O
values	O
in	O
the	O
nanomolar	O
range	O
.	O

The	O
binding	O
sites	O
of	O
type	B
XIII	I
collagen	I
for	O
fibronectin	B
were	O
localized	O
to	O
the	O
collagenous	O
domains	O
,	O
whereas	O
the	O
binding	O
activities	O
for	O
nidogen-2	B
and	O
perlecan	B
resided	O
in	O
the	O
pepsin	B
-	O
sensitive	O
portions	O
of	O
the	O
ectodomain	O
.	O

Furthermore	O
,	O
the	O
ectodomain	O
bound	O
significantly	O
to	O
heparin	O
,	O
which	O
also	O
inhibited	O
shedding	O
of	O
the	O
ectodomain	O
in	O
insect	O
cell	O
cultures	O
.	O

The	O
results	O
reveal	O
that	O
type	B
XIII	I
collagen	I
is	O
notably	O
distinct	O
in	O
its	O
structure	O
compared	O
with	O
other	O
cell	O
-	O
surface	O
proteins	O
,	O
and	O
the	O
in	O
vitro	O
binding	O
with	O
fibronectin	B
,	O
heparin	O
,	O
and	O
two	O
basement	O
membrane	O
components	O
is	O
indicative	O
of	O
multiple	O
cell	O
-	O
matrix	O
interactions	O
in	O
which	O
this	O
ubiquitously	O
expressed	O
protein	O
participates	O
.	O

Mutational	O
analysis	O
of	O
K28	O
preprotoxin	O
processing	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

K28	O
killer	O
strains	O
of	O
Saccharomyces	O
cerevisiae	O
are	O
permanently	O
infected	O
with	O
a	O
cytoplasmic	O
persisting	O
dsRNA	O
virus	O
encoding	O
a	O
secreted	O
alpha	O
/	O
beta	O
heterodimeric	O
protein	O
toxin	O
that	O
kills	O
sensitive	O
cells	O
by	O
cell	O
-	O
cycle	O
arrest	O
and	O
inhibition	O
of	O
DNA	O
synthesis	O
.	O

In	O
vivo	O
processing	O
of	O
the	O
345	O
aa	O
toxin	O
precursor	O
(	O
preprotoxin	O
;	O
pptox	O
)	O
involves	O
multiple	O
internal	O
and	O
carboxy	O
-	O
terminal	O
cleavage	O
events	O
by	O
the	O
prohormone	O
convertases	O
Kex2p	B
and	O
Kex1p	B
.	O

By	O
site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
preprotoxin	O
gene	O
and	O
phenotypic	O
analysis	O
of	O
its	O
in	O
vivo	O
effects	O
it	O
is	O
now	O
demonstrated	O
that	O
secretion	O
of	O
a	O
biological	O
active	O
virus	O
toxin	O
requires	O
signal	B
peptidase	I
cleavage	O
after	O
Gly	O
(	O
36	O
)	O
and	O
Kex2p	O
-	O
mediated	O
processing	O
at	O
the	O
alpha	O
subunit	O
N	O
terminus	O
(	O
after	O
Glu	O
-	O
Arg	O
(	O
49	O
)	O
)	O
,	O
the	O
alpha	O
subunit	O
C	O
terminus	O
(	O
after	O
Ser	O
-	O
Arg	O
(	O
149	O
)	O
)	O
and	O
at	O
the	O
beta	O
subunit	O
N	O
terminus	O
(	O
after	O
Lys	O
-	O
Arg	O
(	O
245	O
)	O
)	O
.	O

The	O
mature	O
C	O
terminus	O
of	O
the	O
beta	O
subunit	O
is	O
trimmed	O
by	O
Kex1p	B
,	O
which	O
removes	O
the	O
terminal	O
Arg	O
(	O
345	O
)	O
residue	O
,	O
thus	O
uncovering	O
the	O
toxin	O
'	O
s	O
endoplasmic	O
reticulum	O
targeting	O
signal	O
(	O
HDEL	O
)	O
which	O
-	O
-	O
in	O
a	O
sensitive	O
target	O
cell	O
--	O
is	O
essential	O
for	O
retrograde	O
toxin	O
transport	O
.	O

Interestingly	O
,	O
both	O
toxin	O
subunits	O
are	O
covalently	O
linked	O
by	O
a	O
single	O
disulfide	O
bond	O
between	O
alpha	O
-	O
Cys	O
(	O
56	O
)	O
and	O
beta	O
-	O
Cys	O
(	O
340	O
)	O
,	O
and	O
expression	O
of	O
a	O
mutant	O
toxin	O
in	O
which	O
beta	O
-	O
Cys	O
(	O
340	O
)	O
had	O
been	O
replaced	O
by	O
Ser	O
(	O
340	O
)	O
resulted	O
in	O
the	O
secretion	O
of	O
a	O
non	O
-	O
toxic	O
alpha	O
/	O
beta	O
heterodimer	O
that	O
is	O
blocked	O
in	O
retrograde	O
transport	O
and	O
incapable	O
of	O
entering	O
the	O
yeast	O
cell	O
cytosol	O
,	O
indicating	O
that	O
one	O
important	O
in	O
vivo	O
function	O
of	O
beta	O
-	O
Cys	O
(	O
340	O
)	O
might	O
be	O
to	O
ensure	O
accessibility	O
of	O
the	O
toxin	O
'	O
s	O
beta	O
subunit	O
C	O
terminus	O
to	O
the	O
HDEL	O
receptor	O
of	O
the	O
target	O
cell	O
.	O

Steroidogenic	O
enzyme	O
gene	O
expression	O
in	O
the	O
human	O
brain	O
.	O

mRNA	O
,	O
protein	O
and	O
activity	O
for	O
the	O
enzymes	O
required	O
for	O
the	O
synthesis	O
of	O
adrenal	O
corticosteroids	O
have	O
been	O
demonstrated	O
in	O
rat	O
brains	O
by	O
several	O
laboratories	O
.	O

In	O
this	O
study	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
determine	O
whether	O
mRNA	O
for	O
these	O
enzymes	O
are	O
expressed	O
in	O
the	O
human	O
amygdala	O
,	O
caudate	O
nucleus	O
,	O
cerebellum	O
,	O
corpus	O
callosum	O
,	O
hippocampus	O
,	O
spinal	O
cord	O
,	O
and	O
thalamus	O
.	O

Published	O
sequences	O
for	O
the	O
human	O
adrenal	O
enzymes	O
were	O
used	O
to	O
construct	O
primers	O
.	O

Results	O
:	O
mRNAs	O
encoding	O
cholesterol	B
side	I
-	I
chain	I
cleavage	I
enzyme	I
(	O
CYP11A	B
gene	O
)	O
,	O
17beta	B
-	I
hydroxylase	I
(	O
CYP17	B
)	O
,	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
3beta	B
-	I
HSD	I
)	O
,	O
21-hydroxylase	B
(	O
CYP21	B
)	O
,	O
11beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
11beta	B
-	I
HSD2	I
)	O
and	O
glucocorticoid	B
and	I
mineralocorticoid	I
receptors	I
were	O
detectable	O
in	O
all	O
anatomical	O
regions	O
evaluated	O
.	O

The	O
11beta	B
-	I
hydroxylase	I
mRNA	O
was	O
detected	O
in	O
all	O
except	O
cerebellum	O
and	O
hippocampus	O
.	O

The	O
aldosterone	B
synthase	I
mRNA	O
was	O
not	O
found	O
in	O
amygdala	O
,	O
cerebellum	O
or	O
hippocampus	O
.	O

Levels	O
of	O
transcripts	O
were	O
10	O
(	O
-1	O
)	O
-10	O
(	O
-7	O
)	O
-	O
fold	O
lower	O
than	O
those	O
in	O
the	O
adrenal	O
,	O
with	O
corpus	O
callosum	O
and	O
spinal	O
cord	O
having	O
the	O
highest	O
concentrations	O
.	O

Enzyme	O
activity	O
or	O
relevance	O
is	O
yet	O
unknown	O
.	O

The	O
mitochondrial	O
12S	O
gene	O
is	O
a	O
suitable	O
marker	O
of	O
populations	O
of	O
Sarcoptes	O
scabiei	O
from	O
wombats	O
,	O
dogs	O
and	O
humans	O
in	O
Australia	O
.	O

We	O
sequenced	O
part	O
of	O
the	O
mitochondrial	O
12S	O
ribosomal	O
RNA	O
gene	O
of	O
23	O
specimens	O
of	O
Sarcoptes	O
scabiei	O
from	O
eight	O
wombats	O
,	O
one	O
dog	O
and	O
three	O
humans	O
.	O

Twelve	O
of	O
the	O
326	O
nucleotide	O
positions	O
varied	O
among	O
these	O
mites	O
and	O
there	O
were	O
nine	O
haplotypes	O
(	O
sequences	O
)	O
that	O
differed	O
by	O
1	O
-	O
8	O
nucleotides	O
.	O

Phylogenetic	O
analyses	O
indicated	O
that	O
these	O
mites	O
were	O
from	O
two	O
lineages	O
:	O
(	O
1	O
)	O
mites	O
from	O
wombats	O
from	O
Victoria	O
,	O
Australia	O
,	O
and	O
mites	O
from	O
the	O
humans	O
and	O
dog	O
from	O
the	O
Northern	O
Territory	O
,	O
Australia	O
(	O
haplotypes	O
1	O
-	O
4	O
,	O
9	O
)	O
;	O
and	O
(	O
2	O
)	O
mites	O
from	O
the	O
humans	O
and	O
dog	O
from	O
the	O
Northern	O
Territory	O
(	O
haplotypes	O
5	O
-	O
8	O
)	O
.	O

Mites	O
from	O
the	O
three	O
different	O
hosts	O
(	O
wombats	O
,	O
a	O
dog	O
and	O
humans	O
)	O
had	O
not	O
diverged	O
phylogenetically	O
;	O
rather	O
,	O
these	O
mites	O
had	O
similar	O
12S	O
sequences	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
these	O
mites	O
from	O
wombats	O
,	O
humans	O
and	O
a	O
dog	O
are	O
closely	O
related	O
,	O
and	O
that	O
they	O
diverged	O
from	O
a	O
common	O
ancestor	O
relatively	O
recently	O
.	O

This	O
conclusion	O
is	O
consistent	O
with	O
the	O
argument	O
that	O
people	O
and/or	O
their	O
dogs	O
introduced	O
to	O
Australia	O
the	O
S.	O
scabiei	O
mites	O
that	O
infect	O
wombats	O
in	O
Australia	O
.	O

So	O
,	O
S.	O
scabiei	O
,	O
which	O
has	O
been	O
blamed	O
for	O
the	O
extinction	O
of	O
populations	O
of	O
wombats	O
in	O
Australia	O
,	O
may	O
be	O
a	O
parasitic	O
mite	O
that	O
was	O
introduced	O
to	O
Australia	O
with	O
people	O
and/or	O
their	O
dogs	O
.	O

These	O
data	O
show	O
that	O
the	O
mitochondrial	O
12S	O
rRNA	O
gene	O
may	O
be	O
a	O
suitable	O
population	O
marker	O
of	O
S.	O
scabiei	O
from	O
wombats	O
,	O
dogs	O
and	O
humans	O
in	O
Australia	O
.	O

Novel	O
intercellular	O
communication	O
system	O
in	O
Escherichia	O
coli	O
that	O
confers	O
antibiotic	O
resistance	O
between	O
physically	O
separated	O
populations	O
.	O

AIMS	O
:	O

To	O
determine	O
whether	O
intercellular	O
signalling	O
can	O
occur	O
between	O
physically	O
separated	O
populations	O
of	O
Escherichia	O
coli	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Intercellular	O
signalling	O
between	O
physically	O
discrete	O
populations	O
of	O
E.	O
coli	O
BL21	O
was	O
analysed	O
in	O
bi	O
-	O
partite	O
Petri	O
dishes	O
.	O

Transfer	O
of	O
a	O
growth	O
-	O
promoting	O
signal	O
resulted	O
in	O
induction	O
of	O
resistance	O
to	O
the	O
antibiotic	O
ampicillin	O
.	O

Optimal	O
expression	O
of	O
the	O
signal	O
occurred	O
when	O
the	O
signalling	O
population	O
was	O
established	O
as	O
a	O
bacterial	O
lawn	O
for	O
24	O
h	O
.	O

This	O
represented	O
an	O
entry	O
into	O
the	O
stationary	O
phase	O
of	O
growth	O
,	O
as	O
indicated	O
by	O
the	O
expression	O
profile	O
of	O
the	O
RNA	B
polymerase	I
subunit	I
sigma38	I
(	O
sigmaS	B
;	O
sigma	B
S	I
)	O
.	O

The	O
growth	O
-	O
promoting	O
effect	O
was	O
also	O
observed	O
when	O
E.	O
coli	O
DH5alpha	O
(	O
luxS	B
-	O
)	O
was	O
used	O
as	O
the	O
signalling	O
population	O
.	O

Preventing	O
passage	O
of	O
air	O
between	O
the	O
two	O
populations	O
resulted	O
in	O
a	O
complete	O
cessation	O
of	O
the	O
growth	O
-	O
promoting	O
effect	O
.	O

CONCLUSIONS	O
:	O

A	O
growth	O
-	O
promoting	O
signal	O
occurs	O
between	O
physically	O
separated	O
cultures	O
of	O
E.	O
coli	O
.	O

The	O
exact	O
nature	O
of	O
the	O
signal	O
remains	O
to	O
be	O
determined	O
but	O
does	O
not	O
involve	O
the	O
production	O
of	O
autoinducer-2	O
from	O
the	O
luxS	B
gene	O
.	O

Signal	O
transmission	O
is	O
likely	O
to	O
involve	O
airborne	O
transfer	O
of	O
a	O
signal	O
species	O
.	O

SIGNIFICANCE	O
AND	O
IMPACT	O
OF	O
THE	O
STUDY	O
:	O

Intercellular	O
signalling	O
systems	O
exist	O
in	O
bacteria	O
that	O
enable	O
antibiotic	O
resistance	O
to	O
be	O
conferred	O
between	O
physically	O
separated	O
populations	O
.	O

An	O
essential	O
role	O
for	O
DNA	B
methyltransferase	I
DNMT3B	B
in	O
cancer	O
cell	O
survival	O
.	O

Abnormal	O
methylation	O
and	O
associated	O
silencing	O
of	O
tumor	O
suppressor	O
genes	O
is	O
a	O
common	O
feature	O
of	O
many	O
types	O
of	O
cancers	O
.	O

The	O
observation	O
of	O
persistent	O
methylation	O
in	O
human	O
cancer	O
cells	O
lacking	O
the	O
maintenance	O
methyltransferase	B
DNMT1	B
suggests	O
the	O
involvement	O
of	O
other	O
DNA	B
methyltransferases	I
in	O
gene	O
silencing	O
in	O
cancer	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
evaluated	O
methylation	O
and	O
gene	O
expression	O
in	O
cancer	O
cells	O
specifically	O
depleted	O
of	O
DNMT3A	B
or	O
DNMT3B	B
,	O
de	O
novo	O
methyltransferases	B
that	O
are	O
expressed	O
in	O
adult	O
tissues	O
.	O

Here	O
we	O
have	O
shown	O
that	O
depletion	O
of	O
DNMT3B	B
,	O
but	O
not	O
DNMT3A	B
,	O
induced	O
apoptosis	O
of	O
human	O
cancer	O
cells	O
but	O
not	O
normal	O
cells	O
.	O

DNMT3B	B
depletion	O
reactivated	O
methylation	O
-	O
silenced	O
gene	O
expression	O
but	O
did	O
not	O
induce	O
global	O
or	O
juxtacentromeric	O
satellite	O
demethylation	O
as	O
did	O
specific	O
depletion	O
of	O
DNMT1	B
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
DNMT3B	B
depletion	O
was	O
rescued	O
by	O
exogenous	O
expression	O
of	O
either	O
of	O
the	O
splice	O
variants	O
DNMT3B2	B
or	O
DNMT3B3	B
but	O
not	O
DNMT1	B
.	O

These	O
results	O
indicate	O
that	O
DNMT3B	B
has	O
significant	O
site	O
selectivity	O
that	O
is	O
distinct	O
from	O
DNMT1	B
,	O
regulates	O
aberrant	O
gene	O
silencing	O
,	O
and	O
is	O
essential	O
for	O
cancer	O
cell	O
survival	O
.	O

Polymorphism	O
at	O
GSTM1	B
,	O
GSTM3	B
and	O
GSTT1	B
gene	O
loci	O
and	O
susceptibility	O
to	O
oral	O
cancer	O
in	O
an	O
Indian	O
population	O
.	O

This	O
study	O
evaluates	O
the	O
influence	O
of	O
genetic	O
polymorphism	O
at	O
GSTM1	B
,	O
GSTM3	B
and	O
GSTT1	B
gene	O
loci	O
on	O
oral	O
cancer	O
risk	O
among	O
Indians	O
habituated	O
to	O
the	O
use	O
of	O
,	O
smokeless	O
tobacco	O
,	O
bidi	O
or	O
cigarette	O
.	O

DNA	O
extracted	O
from	O
white	O
blood	O
cells	O
of	O
297	O
cancer	O
patients	O
and	O
450	O
healthy	O
controls	O
by	O
the	O
proteinase	B
K	I
phenol	O
-	O
chloroform	O
extraction	O
procedure	O
were	O
analyzed	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
PCR	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analyses	O
.	O

Lifetime	O
tobacco	O
exposure	O
was	O
evaluated	O
as	O
a	O
risk	O
factor	O
in	O
relation	O
to	O
the	O
polymorphism	O
at	O
the	O
GST	B
gene	O
loci	O
using	O
logistic	O
regression	O
analysis	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
distribution	O
of	O
the	O
GSTM3	B
and	O
GSTT1	B
genotypes	O
between	O
oral	O
cancer	O
patients	O
and	O
controls	O
.	O

In	O
contrast	O
,	O
a	O
significant	O
3	O
-	O
fold	O
increase	O
in	O
risk	O
was	O
seen	O
for	O
patients	O
with	O
the	O
GSTM1	B
null	O
genotype	O
(	O
age	O
adjusted	O
OR	O
=	O
3.2	O
,	O
95	O
%	O
CI	O
2.4	O
-	O
4.3	O
)	O
.	O

The	O
impact	O
of	O
the	O
GSTM1	B
null	O
genotype	O
on	O
oral	O
cancer	O
risk	O
was	O
also	O
analyzed	O
in	O
separate	O
groups	O
of	O
individuals	O
with	O
different	O
tobacco	O
habits	O
.	O

The	O
odds	O
ratio	O
associated	O
with	O
the	O
GSTM1	B
null	O
genotype	O
was	O
3.7	O
(	O
95	O
%	O
CI	O
2.0	O
-	O
7.1	O
)	O
in	O
tobacco	O
chewers	O
,	O
3.7	O
(	O
5	O
%	O
CI	O
1.3	O
-	O
7.9	O
)	O
in	O
bidi	O
smokers	O
and	O
5.7	O
(	O
95	O
%	O
CI	O
2.0	O
-	O
16.3	O
)	O
in	O
cigarette	O
smokers	O
.	O

Furthermore	O
,	O
increased	O
lifetime	O
exposure	O
to	O
chewing	O
tobacco	O
appeared	O
to	O
be	O
associated	O
with	O
a	O
2	O
-	O
fold	O
increase	O
in	O
oral	O
cancer	O
risk	O
in	O
GSTM1	B
null	O
individuals	O
.	O

The	O
results	O
suggest	O
that	O
the	O
GSTM1	B
null	O
genotype	O
is	O
a	O
risk	O
factor	O
for	O
development	O
of	O
oral	O
cancer	O
among	O
Indian	O
tobacco	O
habitues	O
.	O

Subunit	B
H	I
of	I
the	I
V	I
-	I
ATPase	I
binds	O
to	O
the	O
medium	B
chain	I
of	I
adaptor	I
protein	I
complex	I
2	I
and	O
connects	O
Nef	B
to	O
the	O
endocytic	O
machinery	O
.	O

Nef	B
is	O
an	O
accessory	O
protein	O
of	O
human	O
and	O
simian	O
immunodeficiency	O
viruses	O
(	O
HIV	O
and	O
SIV	O
)	O
that	O
is	O
required	O
for	O
efficient	O
viral	O
infectivity	O
and	O
pathogenicity	O
.	O

It	O
decreases	O
the	O
expression	O
of	O
CD4	B
on	O
the	O
surface	O
of	O
infected	O
cells	O
.	O

V1H	B
is	O
the	O
regulatory	O
subunit	B
H	I
of	I
the	I
vacuolar	I
membrane	I
ATPase	I
(	O
V	B
-	I
ATPase	I
)	O
.	O

Previously	O
,	O
the	O
interaction	O
between	O
Nef	B
and	O
V1H	B
has	O
been	O
found	O
to	O
facilitate	O
the	O
internalization	O
of	O
CD4	B
,	O
suggesting	O
that	O
V1H	B
could	O
connect	O
Nef	B
to	O
the	O
endocytic	O
machinery	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
V1H	B
binds	O
to	O
the	O
C	O
-	O
terminal	O
flexible	O
loop	O
in	O
Nef	B
from	O
HIV-1	O
and	O
to	O
the	O
medium	B
chain	I
(	I
mu2	I
)	I
of	I
the	I
adaptor	I
protein	I
complex	I
2	I
(	O
AP-2	B
)	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
interaction	O
sites	O
of	O
V1H	B
and	O
mu2	B
were	O
mapped	O
to	O
a	O
central	O
region	O
in	O
V1H	B
from	O
positions	O
133	O
to	O
363	O
,	O
which	O
contains	O
4	O
armadillo	B
repeats	O
,	O
and	O
to	O
the	O
N	O
-	O
terminal	O
adaptin	B
-	O
binding	O
domain	O
in	O
mu2	B
from	O
positions	O
1	O
to	O
145	O
.	O

Fusing	O
Nef	B
to	O
V1H	B
reproduced	O
the	O
appropriate	O
trafficking	O
of	O
Nef	B
.	O

This	O
chimera	O
internalized	O
CD4	B
even	O
in	O
the	O
absence	O
of	O
the	O
C	O
-	O
terminal	O
flexible	O
loop	O
in	O
Nef	B
.	O

Finally	O
,	O
blocking	O
the	O
expression	O
of	O
V1H	B
decreased	O
the	O
enhancement	O
of	O
virion	O
infectivity	O
by	O
Nef	B
.	O

Thus	O
,	O
V1H	B
can	O
function	O
as	O
an	O
adaptor	O
for	O
interactions	O
between	O
Nef	B
and	O
AP-2	B
.	O

Mastermind	B
mediates	O
chromatin	O
-	O
specific	O
transcription	O
and	O
turnover	O
of	O
the	O
Notch	B
enhancer	O
complex	O
.	O

Signaling	O
through	O
the	O
Notch	B
pathway	O
activates	O
the	O
proteolytic	O
release	O
of	O
the	O
Notch	B
intracellular	O
domain	O
(	O
ICD	O
)	O
,	O
a	O
dedicated	O
transcriptional	O
coactivator	O
of	O
CSL	O
enhancer	O
-	O
binding	O
proteins	O
.	O

Here	O
we	O
show	O
that	O
chromatin	O
-	O
dependent	O
transactivation	O
by	O
the	O
recombinant	O
Notch	B
ICD	O
-	O
CBF1	B
enhancer	O
complex	O
in	O
vitro	O
requires	O
an	O
additional	O
coactivator	O
,	O
Mastermind	B
(	O
MAM	B
)	O
.	O

MAM	B
provides	O
two	O
activation	O
domains	O
necessary	O
for	O
Notch	B
signaling	O
in	O
mammalian	O
cells	O
and	O
in	O
Xenopus	O
embryos	O
.	O

We	O
show	O
that	O
the	O
central	O
MAM	B
activation	O
domain	O
(	O
TAD1	O
)	O
recruits	O
CBP	B
/	O
p300	B
to	O
promote	O
nucleosome	O
acetylation	O
at	O
Notch	B
enhancers	O
and	O
activate	O
transcription	O
in	O
vitro	O
.	O

We	O
also	O
find	O
that	O
MAM	B
expression	O
induces	O
phosphorylation	O
and	O
relocalization	O
of	O
endogenous	O
CBP	B
/	O
p300	B
proteins	O
to	O
nuclear	O
foci	O
in	O
vivo	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
coexpression	O
with	O
MAM	B
and	O
CBF1	B
strongly	O
enhances	O
phosphorylation	O
and	O
proteolytic	O
turnover	O
of	O
the	O
Notch	B
ICD	O
in	O
vivo	O
.	O

Enhanced	O
phosphorylation	O
of	O
the	O
ICD	O
and	O
p300	B
requires	O
a	O
glutamine	O
-	O
rich	O
region	O
of	O
MAM	B
(	O
TAD2	O
)	O
that	O
is	O
essential	O
for	O
Notch	B
transcription	O
in	O
vivo	O
.	O

Thus	O
MAM	B
may	O
function	O
as	O
a	O
timer	O
to	O
couple	O
transcription	O
activation	O
with	O
disassembly	O
of	O
the	O
Notch	B
enhancer	O
complex	O
on	O
chromatin	O
.	O

Molecular	O
misreading	O
of	O
the	O
ubiquitin	B
B	I
gene	O
and	O
hepatic	O
mallory	O
body	O
formation	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O

Molecular	O
misreading	O
of	O
the	O
ubiquitin	B
B	I
gene	O
has	O
been	O
documented	O
in	O
the	O
cerebral	O
cortex	O
of	O
patients	O
with	O
Alzheimer	O
's	O
disease	O
and	O
Down	O
syndrome	O
.	O

This	O
novel	O
process	O
consists	O
of	O
the	O
unfaithful	O
conversion	O
of	O
genomic	O
information	O
into	O
aberrant	O
transcripts	O
and	O
its	O
subsequent	O
translation	O
into	O
+	O
1	O
proteins	O
.	O

METHODS	O
:	O

Because	O
Mallory	O
bodies	O
(	O
MBs	O
)	O
also	O
contain	O
ubiquitinated	O
proteins	O
,	O
we	O
stained	O
11	O
autopsied	O
and	O
6	O
biopsied	O
MB	O
-	O
containing	O
livers	O
from	O
patients	O
with	O
steatohepatitis	O
with	O
an	O
antibody	O
to	O
ubiquitin	B
(	O
+	O
1	O
)	O
to	O
look	O
for	O
the	O
presence	O
of	O
mutant	O
(	O
ubiquitin	B
(	O
+	O
1	O
)	O
)	O
protein	O
.	O

Antibodies	O
to	O
wild	O
-	O
type	O
ubiquitin	B
were	O
used	O
to	O
document	O
the	O
presence	O
of	O
MBs	O
in	O
all	O
cases	O
.	O

RESULTS	O
:	O

Ubiquitin	B
(	O
+	O
1	O
)	O
immunoreactivity	O
was	O
detected	O
in	O
all	O
MB	O
-	O
containing	O
livers	O
with	O
steatohepatitis	O
;	O
no	O
ubiquitin	B
(	O
+	O
1	O
)	O
immunoreactivity	O
was	O
found	O
in	O
13	O
MB	O
-	O
free	O
liver	O
controls	O
.	O

A	O
subpopulation	O
(	O
about	O
one	O
third	O
of	O
the	O
MBs	O
)	O
of	O
the	O
MB	O
-	O
containing	O
hepatocytes	O
in	O
autopsied	O
livers	O
showed	O
ubiquitin	B
(	O
+	O
1	O
)	O
immunoreactivity	O
(	O
i.e.	O
,	O
ubiquitin	B
and	O
ubiquitin	B
(	O
+	O
1	O
)	O
colocalized	O
in	O
MBs	O
)	O
.	O

MB	O
-	O
containing	O
liver	O
biopsy	O
specimens	O
showed	O
colocalization	O
of	O
ubiquitin	B
and	O
ubiquitin	B
(	O
+	O
1	O
)	O
in	O
every	O
MB	O
.	O

Western	O
blot	O
analysis	O
showed	O
an	O
ubiquitin	B
(	O
+	O
1	O
)	O
band	O
of	O
11	O
kilodaltons	O
.	O

Molecular	O
misreading	O
of	O
the	O
ubiquitin	B
B	I
gene	O
(	O
DeltaGU	O
)	O
was	O
shown	O
in	O
one	O
of	O
the	O
livers	O
,	O
which	O
contained	O
numerous	O
MBs	O
using	O
an	O
expression	O
cloning	O
strategy	O
.	O

CONCLUSIONS	O
:	O

The	O
results	O
showed	O
that	O
molecular	O
misreading	O
of	O
the	O
ubiquitin	B
B	I
gene	O
occurred	O
in	O
hepatocytes	O
in	O
virtually	O
all	O
of	O
the	O
MB	O
-	O
containing	O
livers	O
tested	O
.	O

Ubiquitin	B
(	O
+	O
1	O
)	O
protein	O
was	O
only	O
found	O
within	O
the	O
MBs	O
and	O
therefore	O
may	O
act	O
by	O
interfering	O
with	O
the	O
degradation	O
of	O
the	O
MBs	O
because	O
ubiquitin	B
(	O
+	O
1	O
)	O
may	O
inhibit	O
proteolytic	O
function	O
of	O
the	O
proteasome	O
.	O

The	O
combination	O
of	O
soluble	O
IL-18Ralpha	B
and	O
IL-18Rbeta	B
chains	O
inhibits	O
IL-18	B
-	O
induced	O
IFN	B
-	I
gamma	I
.	O

Although	O
the	O
beta	B
chain	I
of	I
interleukin-18	I
receptor	I
(	B
IL-18Rbeta	I
)	O
is	O
required	O
for	O
signaling	O
,	O
the	O
soluble	O
(	O
extracellular	O
)	O
form	O
does	O
not	O
bind	O
IL-18	B
,	O
and	O
its	O
role	O
in	O
inhibiting	O
IL-18	B
is	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
both	O
the	O
soluble	O
human	O
IL-18	B
ligand	O
binding	O
alpha	O
chain	O
(	O
sIL-18Ralpha	B
)	O
and	O
the	O
sIL-18Rbeta	B
chain	O
were	O
investigated	O
for	O
inhibition	O
of	O
IL-18	B
-	O
induced	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
production	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
,	O
whole	O
blood	O
,	O
and	O
KG-1	O
macrophage	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
lines	O
.	O

Neutralization	O
of	O
IL-18	B
by	O
soluble	O
receptors	O
was	O
compared	O
with	O
that	O
of	O
the	O
IL-18	B
binding	I
protein	I
(	O
IL-18BP	B
)	O
.	O

An	O
equimolar	O
concentration	O
IL-18BP	B
inhibited	O
90	O
%	O
of	O
IL-18	B
activity	O
,	O
whereas	O
a	O
4	O
-	O
fold	O
molar	O
excess	O
of	O
sIL-18Ralpha	B
had	O
no	O
effect	O
.	O

A	O
dimeric	O
construct	O
of	O
sIL-18Ralpha	B
linked	O
to	O
the	O
Fc	O
domain	O
of	O
IgG1	B
(	O
sIL-18Ralpha	B
:	O
Fc	O
)	O
increased	O
IL-18	B
activity	O
2.5	O
-	O
fold	O
.	O

In	O
PBMC	O
stimulated	O
with	O
lypopolysaccharide	O
(	O
LPS	O
)	O
or	O
in	O
whole	O
blood	O
stimulated	O
with	O
Staphylococcus	O
epidermidis	O
,	O
3	O
nM	O
IL-18BP	B
reduced	O
IFN	B
-	I
gamma	I
by	O
80	O
%	O
,	O
whereas	O
IL-18Ralpha	B
:	O
Fc	O
had	O
no	O
effect	O
.	O

A	O
construct	O
of	O
the	O
sIL-18Rbeta	B
linked	O
to	O
Fc	O
(	O
sIL-18Rbeta	B
:	O
Fc	O
)	O
did	O
not	O
affect	O
IL-18	B
-	O
induced	O
IFN	B
-	I
gamma	I
even	O
at	O
80	O
-	O
fold	O
molar	O
excess	O
of	O
IL-18	B
.	O

However	O
,	O
the	O
combination	O
of	O
both	O
soluble	O
receptors	O
reduced	O
IFN	B
-	I
gamma	I
by	O
80	O
%	O
.	O

In	O
KG-1	O
cells	O
,	O
a	O
50	O
%	O
reduction	O
in	O
IL-18	B
activity	O
was	O
observed	O
using	O
an	O
80	O
-	O
fold	O
molar	O
excess	O
of	O
sIL-18Ralpha	B
:	O
Fc	O
but	O
only	O
in	O
the	O
presence	O
of	O
sIL-18Rbeta	B
:	O
Fc	O
.	O

Similarly	O
,	O
a	O
50	O
%	O
reduction	O
was	O
observed	O
using	O
sIL-18Rbeta	B
:	O
Fc	O
in	O
the	O
presence	O
of	O
a	O
molar	O
excess	O
of	O
sIL-18Ralpha	B
:	O
Fc	O
.	O

Similar	O
inhibition	O
was	O
observed	O
in	O
NK	O
cells	O
.	O

These	O
studies	O
reveal	O
that	O
the	O
combination	O
of	O
the	O
ligand	O
-	O
binding	O
and	O
the	O
nonligand	O
-	O
binding	O
extracellular	O
domains	O
of	O
IL-18R	B
is	O
needed	O
to	O
inhibit	O
IL-18	B
,	O
whereas	O
IL-18BP	B
neutralizes	O
at	O
equimolar	O
concentration	O
.	O

Distinct	O
sets	O
of	O
adjacent	O
heterogeneous	B
nuclear	I
ribonucleoprotein	I
(	I
hnRNP	I
)	I
A1	I
/	I
A2	I
binding	O
sites	O
control	O
5	O
'	O
splice	O
site	O
selection	O
in	O
the	O
hnRNP	B
A1	I
mRNA	O
precursor	O
.	O

In	O
the	O
heterogeneous	B
nuclear	I
ribonucleoprotein	I
(	I
hnRNP	I
)	I
A1	I
pre	O
-	O
mRNA	O
,	O
different	O
regions	O
in	O
the	O
introns	O
flanking	O
alternative	O
exon	O
7B	O
have	O
been	O
implicated	O
in	O
the	O
production	O
of	O
the	O
A1	B
and	O
A1B	B
mRNA	O
splice	O
isoforms	O
.	O

Among	O
these	O
,	O
the	O
CE1a	O
and	O
CE4	O
elements	O
,	O
located	O
downstream	O
of	O
common	O
exon	O
7	O
and	O
alternative	O
exon	O
7B	O
,	O
respectively	O
,	O
are	O
bound	O
by	O
hnRNP	B
A1	I
to	O
promote	O
skipping	O
of	O
exon	O
7B	O
in	O
vivo	O
and	O
distal	O
5	O
'	O
splice	O
site	O
selection	O
in	O
vitro	O
.	O

Here	O
,	O
we	O
report	O
that	O
CE1a	O
is	O
flanked	O
by	O
an	O
additional	O
high	O
affinity	O
A1	O
binding	O
site	O
(	O
CE1d	O
)	O
.	O

In	O
a	O
manner	O
similar	O
to	O
CE1a	O
,	O
CE1d	O
affects	O
5	O
'	O
splice	O
site	O
selection	O
in	O
vitro	O
.	O

Consistent	O
with	O
a	O
role	O
for	O
hnRNP	B
A1	I
in	O
the	O
activity	O
of	O
CE1d	O
,	O
a	O
mutation	O
that	O
abrogates	O
A1	O
binding	O
abolishes	O
distal	O
5	O
'	O
splice	O
site	O
activation	O
.	O

Moreover	O
,	O
the	O
ability	O
of	O
CE1d	O
to	O
stimulate	O
distal	O
5	O
'	O
splice	O
site	O
usage	O
is	O
lost	O
in	O
an	O
HeLa	O
extract	O
depleted	O
of	O
hnRNP	B
A	I
/	I
B	I
proteins	O
,	O
and	O
the	O
addition	O
of	O
recombinant	O
A1	B
restores	O
the	O
activity	O
of	O
CE1d	O
.	O

Notably	O
,	O
distal	O
5	O
'	O
splice	O
site	O
selection	O
mediated	O
by	O
A1	B
binding	O
sites	O
is	O
not	O
compromised	O
in	O
an	O
extract	O
prepared	O
from	O
mouse	O
cells	O
that	O
are	O
severely	O
deficient	O
in	O
hnRNP	B
A1	I
proteins	O
.	O

In	O
this	O
case	O
,	O
we	O
show	O
that	O
hnRNP	B
A2	I
compensates	O
for	O
the	O
A1	B
deficiency	O
.	O

Further	O
studies	O
with	O
the	O
CE4	O
element	O
reveal	O
that	O
it	O
also	O
consists	O
of	O
two	O
distinct	O
portions	O
(	O
CE4	O
m	O
and	O
CE4p	O
)	O
,	O
each	O
one	O
capable	O
of	O
promoting	O
distal	O
5	O
'	O
splice	O
site	O
use	O
in	O
an	O
hnRNP	B
A1	I
-	O
dependent	O
manner	O
.	O

The	O
presence	O
of	O
multiple	O
A1	B
/	O
A2	B
binding	O
sites	O
downstream	O
of	O
common	O
exon	O
7	O
and	O
alternative	O
exon	O
7B	O
probably	O
plays	O
an	O
important	O
role	O
in	O
maximizing	O
the	O
activity	O
of	O
hnRNP	B
A1	I
/	I
A2	I
proteins	O
.	O

A	O
role	O
for	O
ASIC3	B
in	O
the	O
modulation	O
of	O
high	O
-	O
intensity	O
pain	O
stimuli	O
.	O

Acid	B
-	I
sensing	I
ion	I
channel	I
3	I
(	O
ASIC3	B
)	O
,	O
a	O
proton	B
-	I
gated	I
ion	I
channel	I
of	O
the	O
degenerins	B
/	I
epithelial	I
sodium	I
channel	I
(	I
DEG	I
/	I
ENaC	I
)	I
receptor	I
family	I
is	O
expressed	O
predominantly	O
in	O
sensory	O
neurons	O
including	O
nociceptive	O
neurons	O
responding	O
to	O
protons	O
.	O

To	O
study	O
the	O
role	O
of	O
ASIC3	B
in	O
pain	O
signaling	O
,	O
we	O
generated	O
ASIC3	B
knockout	O
mice	O
.	O

Mutant	O
animals	O
were	O
healthy	O
and	O
responded	O
normally	O
to	O
most	O
sensory	O
stimuli	O
.	O

However	O
,	O
in	O
behavioral	O
assays	O
for	O
pain	O
responses	O
,	O
ASIC3	B
null	O
mutant	O
mice	O
displayed	O
a	O
reduced	O
latency	O
to	O
the	O
onset	O
of	O
pain	O
responses	O
,	O
or	O
more	O
pain	O
-	O
related	O
behaviors	O
,	O
when	O
stimuli	O
of	O
moderate	O
to	O
high	O
intensity	O
were	O
used	O
.	O

This	O
unexpected	O
effect	O
seemed	O
independent	O
of	O
the	O
modality	O
of	O
the	O
stimulus	O
and	O
was	O
observed	O
in	O
the	O
acetic	O
acid	O
-	O
induced	O
writhing	O
test	O
(	O
0.6	O
vs.	O
0.1	O
-	O
0.5	O
%	O
)	O
,	O
in	O
the	O
hot	O
-	O
plate	O
test	O
(	O
52.5	O
and	O
55	O
vs.	O
50	O
degrees	O
C	O
)	O
,	O
and	O
in	O
tests	O
for	O
mechanically	O
induced	O
pain	O
(	O
tail	O
-	O
pinch	O
vs.	O
von	O
Frey	O
filaments	O
)	O
.	O

We	O
postulate	O
that	O
ASIC3	B
is	O
involved	O
in	O
modulating	O
moderate	O
-	O
to	O
high	O
-	O
intensity	O
pain	O
sensation	O
.	O

Connexin-43	B
interactions	O
with	O
ZO-1	B
and	O
alpha	B
-	I
and	I
beta	I
-	I
tubulin	I
.	O

Gap	O
junctions	O
are	O
composed	O
of	O
connexins	B
that	O
form	O
transmembrane	O
channels	O
between	O
adjacent	O
cells	O
.	O

The	O
C	O
-	O
terminal	O
tail	O
of	O
connexin-43	B
(	O
Cx43	B
)	O
,	O
the	O
most	O
widely	O
expressed	O
connexin	B
member	O
,	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
Cx43	B
channel	O
gating	O
.	O

Interestingly	O
,	O
channel	O
-	O
independent	O
processes	O
regulated	O
by	O
Cx43	B
have	O
also	O
been	O
postulated	O
.	O

In	O
our	O
studies	O
to	O
elucidate	O
the	O
mechanism	O
of	O
Cx43	B
channel	O
gating	O
by	O
growth	B
factors	I
and	O
to	O
explore	O
additional	O
functions	O
of	O
gap	O
junctions	O
,	O
we	O
have	O
identified	O
three	O
interacting	O
partners	O
of	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
Cx43	B
(	O
Cx43CT	B
)	O
.	O

(	O
i	O
)	O
the	O
c	B
-	I
Src	I
tyrosine	B
kinase	I
,	O
which	O
phosphorylates	O
Cx43CT	B
and	O
is	O
involved	O
in	O
G	B
protein	I
-	O
mediated	O
inhibition	O
of	O
Cx43	B
gap	O
junctional	O
communication	O
.	O

(	O
ii	O
)	O
the	O
ZO-1	B
'	O
scaffold	O
'	O
protein	O
,	O
which	O
might	O
recruit	O
signaling	O
proteins	O
into	O
Cx43	B
-	O
based	O
gap	O
junctions	O
.	O

(	O
iii	O
)	O
microtubules	O
(	O
consisting	O
of	O
alpha	B
/	I
beta	I
-	I
tubulin	I
dimers	O
)	O
,	O
which	O
extend	O
with	O
their	O
distal	O
ends	O
to	O
Cx43	B
-	O
based	O
gap	O
junctions	O
,	O
suggesting	O
that	O
Cx43	B
gap	O
junctions	O
may	O
play	O
a	O
novel	O
role	O
in	O
regulating	O
microtubule	O
stability	O
in	O
contacted	O
cells	O
.	O

Here	O
we	O
show	O
that	O
Cx43	B
binds	O
alpha	B
-	I
tubulin	I
equally	O
well	O
as	O
beta	B
-	I
tubulin	I
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
the	O
second	O
,	O
but	O
not	O
the	O
first	O
,	O
PDZ	O
domain	O
of	O
ZO-1	B
binds	O
directly	O
to	O
Cx43	B
,	O
and	O
we	O
confirm	O
that	O
the	O
very	O
C	O
-	O
terminal	O
isoleucine	O
residue	O
of	O
Cx43	B
is	O
critical	O
for	O
ZO-1	B
binding	O
.	O

Identification	O
of	O
a	O
novel	O
human	O
eicosanoid	B
receptor	I
coupled	O
to	O
G	B
(	I
i	I
/	I
o	I
)	I
.	O

We	O
have	O
conducted	O
an	O
in	O
silico	O
data	O
base	O
search	O
for	O
and	O
cloned	O
a	O
novel	O
G	B
-	I
protein	I
-	I
coupled	I
receptor	I
(	O
GPCR	B
)	O
named	O
TG1019	B
.	O

Dot	O
and	O
Northern	O
blotting	O
analyses	O
showed	O
that	O
transcripts	O
of	O
the	O
novel	O
GPCR	B
were	O
expressed	O
in	O
various	O
tissues	O
except	O
brain	O
,	O
and	O
the	O
expression	O
was	O
more	O
intense	O
in	O
liver	O
,	O
kidney	O
,	O
peripheral	O
leukocyte	O
,	O
lung	O
,	O
and	O
spleen	O
than	O
in	O
other	O
tissues	O
.	O

By	O
GTP	O
gamma	O
S	O
binding	O
assay	O
using	O
the	O
TG1019	B
-	O
G	B
alpha	I
(	I
i1	I
)	I
-	O
protein	O
fusion	O
expressed	O
in	O
insect	O
cells	O
,	O
eicosanoids	O
,	O
and	O
polyunsaturated	O
fatty	O
acids	O
such	O
as	O
5-oxo-6E,8Z,11Z,14Z	O
-	O
eicosatetraenoic	O
acid	O
(	O
5-oxo	O
-	O
ETE	O
)	O
,	O
5	O
(	O
S	O
)	O
-hydroperoxy-6E,8Z	O
,	O
11Z,14Z	O
-	O
eicosatetraenoic	O
acid	O
,	O
and	O
arachidonic	O
acid	O
were	O
identified	O
to	O
exhibit	O
agonistic	O
activities	O
against	O
TG1019	B
.	O

5-oxo	O
-	O
ETE	O
was	O
the	O
most	O
potent	O
to	O
enhance	O
the	O
specific	O
binding	O
by	O
6	O
-	O
fold	O
at	O
a	O
maximum	O
effect	O
dose	O
of	O
submicromolar	O
to	O
micromolar	O
order	O
with	O
an	O
ED	O
(	O
50	O
)	O
value	O
of	O
5.7	O
nM	O
.	O

Conversely	O
,	O
polyunsaturated	O
fatty	O
acids	O
such	O
as	O
docosahexaenoic	O
acid	O
and	O
eicosapentaenoic	O
acid	O
showed	O
antagonistic	O
activities	O
against	O
TG1019	B
.	O

In	O
Chinese	O
hamster	O
ovary	O
cells	O
transiently	O
expressing	O
TG1019	B
,	O
the	O
forskolin	O
-	O
stimulated	O
production	O
of	O
cAMP	O
was	O
inhibited	O
up	O
to	O
approximately	O
70	O
%	O
by	O
5-oxo	O
-	O
ETE	O
,	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
33	O
nM	O
.	O

This	O
inhibition	O
was	O
sensitive	O
to	O
pretreatment	O
of	O
the	O
cells	O
with	O
pertussis	B
toxin	I
.	O

p52	B
Mediates	O
XPB	B
function	O
within	O
the	O
transcription	O
/	O
repair	O
factor	O
TFIIH	B
.	O

To	O
further	O
our	O
understanding	O
of	O
the	O
transcription	O
/	O
DNA	O
repair	O
factor	O
TFIIH	B
,	O
we	O
investigated	O
the	O
role	O
of	O
its	O
p52	B
subunit	O
in	O
TFIIH	B
function	O
.	O

Using	O
a	O
completely	O
reconstituted	O
in	O
vitro	O
transcription	O
or	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
system	O
,	O
we	O
show	O
that	O
deletion	O
of	O
the	O
C	O
-	O
terminal	O
region	O
of	O
p52	B
results	O
in	O
a	O
dramatic	O
reduction	O
of	O
TFIIH	B
NER	O
and	O
transcription	O
activities	O
.	O

This	O
mutation	O
prevents	O
promoter	O
opening	O
and	O
has	O
no	O
effect	O
on	O
the	O
other	O
enzymatic	O
activities	O
of	O
TFIIH	B
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
intact	O
p52	B
is	O
needed	O
to	O
anchor	O
the	O
XPB	B
helicase	I
within	O
TFIIH	B
,	O
providing	O
an	O
explanation	O
for	O
the	O
transcription	O
and	O
NER	O
defects	O
observed	O
with	O
the	O
mutant	O
p52	B
.	O

We	O
show	O
that	O
these	O
two	O
subunits	O
physically	O
interact	O
and	O
map	O
domains	O
involved	O
in	O
the	O
interface	O
.	O

Taken	O
together	O
,	O
our	O
results	O
show	O
that	O
the	O
p52	B
/	O
Tfb2	B
subunit	O
of	O
TFIIH	B
regulates	O
the	O
function	O
of	O
XPB	B
through	O
pair	O
-	O
wise	O
interactions	O
as	O
described	O
previously	O
for	O
p44	B
and	O
XPD	B
.	O

cGMP	B
-	I
dependent	I
protein	I
kinase	I
I	I
beta	I
physically	O
and	O
functionally	O
interacts	O
with	O
the	O
transcriptional	O
regulator	O
TFII	B
-	I
I	I
.	O

Transcriptional	O
regulation	O
of	O
the	O
fos	B
promoter	O
by	O
nitric	O
oxide	O
and	O
cGMP	O
can	O
occur	O
by	O
nuclear	O
translocation	O
of	O
cGMP	B
-	I
dependent	I
protein	I
kinase	I
I	I
(	O
G	B
-	I
kinase	I
I	I
)	O
(	O
Gudi	O
,	O
T.	O
,	O
Lohmann	O
,	O
S.	O
M.	O
,	O
and	O
Pilz	O
,	O
R.	O
B.	O
(	O
1997	O
)	O
Mol	O
.	O
Cell	O
.	O
Biol	O
.	O
17	O
,	O
5244	O
-	O
5254	O
)	O
.	O

To	O
identify	O
nuclear	O
targets	O
of	O
G	B
-	I
kinase	I
I	I
,	O
we	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
with	O
G	B
-	I
kinase	I
I	I
beta	I
as	O
bait	O
.	O

We	O
found	O
that	O
G	B
-	I
kinase	I
I	I
beta	I
interacted	O
specifically	O
with	O
TFII	B
-	I
I	I
,	O
an	O
unusual	O
transcriptional	O
regulator	O
that	O
associates	O
with	O
multiple	O
proteins	O
to	O
modulate	O
both	O
basal	O
and	O
signal	O
-	O
induced	O
transcription	O
.	O

By	O
using	O
purified	O
recombinant	O
proteins	O
,	O
the	O
interaction	O
was	O
mapped	O
to	O
the	O
N	O
-	O
terminal	O
93	O
amino	O
acids	O
of	O
G	B
-	I
kinase	I
I	I
beta	I
and	O
one	O
of	O
six	O
95	O
-	O
amino	O
acid	O
repeats	O
found	O
in	O
TFII	B
-	I
I	I
.	O

In	O
baby	O
hamster	O
kidney	O
cells	O
,	O
cGMP	O
analogs	O
enhanced	O
co	O
-	O
immunoprecipitation	O
of	O
G	B
-	I
kinase	I
I	I
beta	I
and	O
TFII	B
-	I
I	I
by	O
inducing	O
co	O
-	O
localization	O
of	O
both	O
proteins	O
in	O
the	O
nucleus	O
,	O
but	O
in	O
other	O
cell	O
types	O
containing	O
cytoplasmic	O
TFII	B
-	I
I	I
the	O
G	B
-	I
kinase	I
-	O
TFII	B
-	I
I	I
interaction	O
was	O
largely	O
cGMP	O
-	O
independent	O
.	O

G	B
-	I
kinase	I
phosphorylated	O
TFII	B
-	I
I	I
in	O
vitro	O
and	O
in	O
vivo	O
on	O
Ser	O
(	O
371	O
)	O
and	O
Ser	O
(	O
743	O
)	O
outside	O
of	O
the	O
interaction	O
domain	O
.	O

G	B
-	I
kinase	I
strongly	O
enhanced	O
TFII	B
-	I
I	I
transactivation	O
of	O
a	O
serum	O
-	O
response	O
element	O
-	O
containing	O
promoter	O
in	O
COS7	O
cells	O
,	O
and	O
this	O
effect	O
was	O
lost	O
when	O
Ser	O
(	O
371	O
)	O
and	O
Ser	O
(	O
743	O
)	O
of	O
TFII	B
-	I
I	I
were	O
mutated	O
.	O

TFII	B
-	I
I	I
by	O
itself	O
had	O
little	O
effect	O
on	O
a	O
full	O
-	O
length	O
fos	O
promoter	O
in	O
baby	O
hamster	O
kidney	O
cells	O
,	O
but	O
it	O
synergistically	O
enhanced	O
transcriptional	O
activation	O
by	O
G	B
-	I
kinase	I
I	I
beta	O
.	O

Binding	O
of	O
G	B
-	I
kinase	I
to	O
TFII	B
-	I
I	I
may	O
position	O
the	O
kinase	B
to	O
phosphorylate	O
and	O
regulate	O
TFII	B
-	I
I	I
and/or	O
factors	O
that	O
interact	O
with	O
TFII	B
-	I
I	I
at	O
the	O
serum	O
-	O
response	O
element	O
.	O

Live	O
-	O
cell	O
imaging	O
reveals	O
divergent	O
intracellular	O
dynamics	O
of	O
polyglutamine	O
disease	O
proteins	O
and	O
supports	O
a	O
sequestration	O
model	O
of	O
pathogenesis	O
.	O

Protein	O
misfolding	O
and	O
aggregation	O
are	O
central	O
features	O
of	O
the	O
polyglutamine	O
neurodegenerative	O
disorders	O
,	O
but	O
the	O
dynamic	O
properties	O
of	O
expanded	O
polyglutamine	O
proteins	O
are	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
use	O
fluorescence	O
recovery	O
after	O
photobleaching	O
(	O
FRAP	O
)	O
and	O
fluorescence	O
loss	O
in	O
photobleaching	O
(	O
FLIP	O
)	O
with	O
green	B
fluorescent	I
protein	I
fusion	O
proteins	O
to	O
study	O
polyglutamine	O
protein	O
kinetics	O
in	O
living	O
cells	O
.	O

Our	O
results	O
reveal	O
markedly	O
divergent	O
mobility	O
states	O
for	O
an	O
expanded	O
polyglutamine	O
protein	O
,	O
ataxin-3	B
,	O
and	O
establish	O
that	O
nuclear	O
inclusions	O
formed	O
by	O
this	O
protein	O
are	O
aggregates	O
.	O

Additional	O
studies	O
of	O
green	B
fluorescent	I
protein	I
-	O
tagged	O
cAMP	B
response	I
element	I
binding	I
protein	I
coexpressed	O
with	O
either	O
of	O
two	O
mutant	O
polyglutamine	O
proteins	O
,	O
ataxin	B
-	I
3	I
and	O
huntingtin	B
,	O
support	O
a	O
model	O
of	O
disease	O
in	O
which	O
coaggregation	O
of	O
transcriptional	O
components	O
contributes	O
to	O
pathogenesis	O
.	O

Finally	O
,	O
studies	O
of	O
a	O
third	O
polyglutamine	O
disease	O
protein	O
,	O
ataxin-1	B
,	O
reveal	O
unexpected	O
heterogeneity	O
in	O
the	O
dynamics	O
of	O
inclusions	O
formed	O
by	O
different	O
disease	O
proteins	O
,	O
a	O
finding	O
which	O
may	O
help	O
explain	O
disease	O
-	O
specific	O
elements	O
of	O
pathogenesis	O
in	O
these	O
neurodegenerative	O
disorders	O
.	O

The	O
mRNA	O
structure	O
has	O
potent	O
regulatory	O
effects	O
on	O
type	B
2	I
iodothyronine	I
deiodinase	I
expression	O
.	O

Type	B
2	I
deiodinase	I
(	O
D2	B
)	O
is	O
a	O
selenoenzyme	O
catalyzing	O
the	O
activation	O
of	O
T	O
(	O
4	O
)	O
to	O
T	O
(	O
3	O
)	O
.	O

D2	B
activity	O
/	O
mRNA	O
ratios	O
are	O
often	O
low	O
,	O
suggesting	O
that	O
there	O
is	O
significant	O
posttranscriptional	O
regulation	O
.	O

The	O
D2	B
mRNA	O
in	O
higher	O
vertebrates	O
is	O
more	O
than	O
6	O
kb	O
,	O
containing	O
long	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
(	O
UTRs	O
)	O
.	O

The	O
D2	B
5	O
'	O
UTRs	O
are	O
greater	O
than	O
600	O
nucleotides	O
and	O
contain	O
3	O
-	O
5	O
short	O
open	O
reading	O
frames	O
.	O

These	O
full	O
-	O
length	O
5	O
'	O
UTRs	O
reduce	O
the	O
D2	B
translation	O
efficiency	O
approximately	O
5	O
-	O
fold	O
.	O

The	O
inhibition	O
by	O
human	O
D2	B
5	O
'	O
UTR	O
is	O
localized	O
to	O
a	O
region	O
containing	O
the	O
first	O
short	O
open	O
reading	O
frame	O
encoding	O
a	O
tripeptide	O
-	O
MKG	O
.	O

This	O
inhibition	O
was	O
abolished	O
by	O
mutating	O
the	O
AUG	O
start	O
codon	O
and	O
weakened	O
by	O
modification	O
of	O
the	O
essential	O
purine	O
of	O
the	O
Kozak	O
consensus	O
.	O

Deletion	O
of	O
the	O
3.7	O
-	O
kb	O
3'UTR	O
of	O
the	O
chicken	O
D2	B
mRNA	O
increased	O
D2	B
activity	O
approximately	O
3.8	O
-	O
fold	O
due	O
to	O
an	O
increase	O
in	O
D2	B
mRNA	O
half	O
-	O
life	O
.	O

In	O
addition	O
,	O
alternatively	O
spliced	O
D2	B
mRNA	O
transcripts	O
similar	O
in	O
size	O
to	O
the	O
major	O
6	O
-	O
to	O
7	O
-	O
kb	O
D2	B
mRNAs	O
but	O
not	O
encoding	O
an	O
active	O
enzyme	O
are	O
present	O
in	O
both	O
human	O
and	O
chicken	O
tissues	O
.	O

Our	O
results	O
indicate	O
that	O
a	O
number	O
of	O
factors	O
reduce	O
the	O
D2	B
protein	O
levels	O
.	O

These	O
mechanisms	O
,	O
together	O
with	O
the	O
short	O
half	O
-	O
life	O
of	O
the	O
protein	O
,	O
ensure	O
limited	O
expression	O
of	O
this	O
key	O
regulator	O
of	O
T	O
(	O
4	O
)	O
activation	O
.	O

The	O
transcriptional	B
regulating	I
protein	I
of	I
132	I
kDa	I
(	O
TReP-132	B
)	O
enhances	O
P450scc	B
gene	O
transcription	O
through	O
interaction	O
with	O
steroidogenic	B
factor-1	I
in	O
human	O
adrenal	O
cells	O
.	O

The	O
human	O
P450scc	B
gene	O
is	O
regulated	O
by	O
the	O
tissue	O
-	O
specific	O
orphan	O
nuclear	O
receptor	O
,	O
steroidogenic	B
factor-1	I
(	O
SF-1	B
)	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
several	O
physiologic	O
processes	O
including	O
steroid	O
synthesis	O
,	O
adrenal	O
and	O
gonadal	O
development	O
,	O
and	O
sexual	O
differentiation	O
.	O

Several	O
studies	O
have	O
demonstrated	O
the	O
interaction	O
of	O
SF-1	B
with	O
different	O
proteins	O
.	O

However	O
,	O
it	O
is	O
clear	O
that	O
additional	O
factors	O
not	O
yet	O
identified	O
are	O
involved	O
with	O
SF-1	B
to	O
regulate	O
different	O
target	O
genes	O
.	O

Recently	O
,	O
it	O
was	O
demonstrated	O
that	O
a	O
novel	O
transcriptional	B
regulating	I
protein	I
of	I
132	I
kDa	I
(	O
TReP-132	B
)	O
regulates	O
expression	O
of	O
the	O
human	O
P450scc	B
gene	O
.	O

The	O
overexpression	O
of	O
TReP-132	B
in	O
adrenal	O
cells	O
increases	O
the	O
production	O
of	O
pregnenolone	O
,	O
which	O
is	O
associated	O
with	O
the	O
activation	O
of	O
P450scc	B
gene	O
expression	O
.	O

Considering	O
the	O
colocalization	O
of	O
TReP-132	B
and	O
SF-1	B
in	O
steroidogenic	O
tissues	O
such	O
as	O
the	O
adrenal	O
and	O
testis	O
,	O
and	O
the	O
presence	O
of	O
two	O
putative	O
LXXLL	O
motifs	O
in	O
TReP-132	B
that	O
can	O
potentially	O
interact	O
with	O
SF-1	B
,	O
the	O
relationship	O
between	O
these	O
two	O
factors	O
on	O
the	O
P450scc	B
gene	O
promoter	O
was	O
determined	O
.	O

The	O
coexpression	O
of	O
SF-1	B
and	O
TReP-132	B
in	O
adrenal	O
NCI	O
-	O
H295	O
cells	O
cooperates	O
to	O
increase	O
promoter	O
activity	O
.	O

Pull	O
-	O
down	O
experiments	O
demonstrated	O
the	O
interaction	O
between	O
TReP-132	B
and	O
SF-1	B
,	O
and	O
this	O
was	O
further	O
confirmed	O
in	O
intact	O
cells	O
by	O
coimmunoprecipitation	O
/	O
Western	O
blot	O
and	O
two	O
-	O
hybrid	O
analyses	O
.	O

Deletions	O
and	O
mutations	O
of	O
the	O
TReP-132	B
cDNA	O
sequence	O
demonstrate	O
that	O
SF-1	B
interaction	O
requires	O
the	O
LXXLL	O
motif	O
found	O
at	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
the	O
protein	O
.	O

Also	O
,	O
the	O
""""	O
proximal	O
activation	O
domain	O
""""	O
and	O
the	O
""""	O
AF-2	O
hexamer	O
""""	O
motif	O
of	O
SF-1	B
are	O
involved	O
in	O
interaction	O
with	O
TReP-132	B
.	O

Consistent	O
with	O
previous	O
studies	O
showing	O
interaction	O
between	O
CBP	B
/	O
p300	B
and	O
SF-1	B
or	O
TReP-132	B
,	O
the	O
coexpression	O
of	O
these	O
three	O
proteins	O
results	O
in	O
a	O
synergistic	O
effect	O
on	O
P450scc	B
gene	O
promoter	O
activity	O
.	O

Taken	O
together	O
the	O
results	O
in	O
this	O
study	O
identify	O
a	O
novel	O
function	O
of	O
TReP-132	B
as	O
a	O
partner	O
in	O
a	O
complex	O
with	O
SF-1	B
and	O
CBP	B
/	O
p300	B
to	O
regulate	O
gene	O
transcription	O
involved	O
in	O
steroidogenesis	O
.	O

Mass	O
spectrometric	O
analysis	O
of	O
GAP-43	B
/	O
neuromodulin	B
reveals	O
the	O
presence	O
of	O
a	O
variety	O
of	O
fatty	O
acylated	O
species	O
.	O

GAP-43	B
(	O
neuromodulin	B
)	O
is	O
a	O
protein	B
kinase	I
C	I
substrate	O
that	O
is	O
abundant	O
in	O
developing	O
and	O
regenerating	O
neurons	O
.	O

Thioester	O
-	O
linked	O
palmitoylation	O
at	O
two	O
cysteines	O
near	O
the	O
GAP-43	B
N	O
terminus	O
has	O
been	O
implicated	O
in	O
directing	O
membrane	O
binding	O
.	O

Here	O
,	O
we	O
use	O
mass	O
spectrometry	O
to	O
examine	O
the	O
stoichiometry	O
of	O
palmitoylation	O
and	O
the	O
molecular	O
identity	O
of	O
the	O
fatty	O
acid	O
(	O
s	O
)	O
attached	O
to	O
GAP-43	B
in	O
vivo	O
.	O

GAP-43	B
expressed	O
in	O
either	O
PC12	O
or	O
COS-1	O
cells	O
was	O
acetylated	O
at	O
the	O
N	O
-	O
terminal	O
methionine	O
.	O

Approximately	O
35	O
%	O
of	O
the	O
N	O
-	O
terminal	O
GAP	B
-	I
43	I
peptides	O
were	O
also	O
modified	O
by	O
palmitate	O
and/or	O
stearate	O
on	O
Cys	O
residues	O
.	O

Interestingly	O
,	O
a	O
variety	O
of	O
acylated	O
species	O
was	O
detected	O
,	O
in	O
which	O
one	O
of	O
the	O
Cys	O
residues	O
was	O
acylated	O
by	O
either	O
palmitate	O
or	O
stearate	O
,	O
or	O
both	O
Cys	O
residues	O
were	O
acylated	O
by	O
palmitates	O
or	O
stearates	O
or	O
a	O
combination	O
of	O
palmitate	O
and	O
stearate	O
.	O

Depalmitoylation	O
of	O
membrane	O
-	O
bound	O
GAP-43	B
did	O
not	O
release	O
the	O
protein	O
from	O
the	O
membrane	O
,	O
implying	O
that	O
additional	O
forces	O
function	O
to	O
maintain	O
membrane	O
binding	O
.	O

Indeed	O
,	O
mutation	O
of	O
four	O
basic	O
residues	O
within	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
GAP-43	B
dramatically	O
reduced	O
membrane	O
localization	O
of	O
GAP-43	B
without	O
affecting	O
palmitoylation	O
.	O

These	O
data	O
reveal	O
the	O
heterogeneous	O
nature	O
of	O
S	O
-	O
acylation	O
in	O
vivo	O
and	O
illustrate	O
the	O
power	O
of	O
mass	O
spectrometry	O
for	O
identification	O
of	O
key	O
regulatory	O
protein	O
modifications	O
.	O

Cloning	O
,	O
characterization	O
,	O
and	O
functional	O
studies	O
of	O
a	O
47	B
-	I
kDa	I
platelet	I
receptor	I
for	I
type	I
III	I
collagen	I
.	O

A	O
1.2	O
-	O
kb	O
cDNA	O
fragment	O
encoding	O
a	O
platelet	O
47	O
-	O
kDa	O
protein	O
has	O
been	O
isolated	O
from	O
a	O
human	O
bone	O
marrow	O
cDNA	O
library	O
by	O
using	O
a	O
degenerate	O
oligonucleotide	O
of	O
the	O
sequenced	O
amino	O
terminus	O
of	O
the	O
purified	O
platelet	O
protein	O
with	O
a	O
poly	O
(	O
dT	O
)	O
(	O
12	O
)	O
.	O
(	O
dG	O
)	O
by	O
polymerase	O
chain	O
reaction	O
.	O

A	O
computer	O
search	O
revealed	O
that	O
the	O
cDNA	O
represents	O
the	O
coding	O
sequence	O
of	O
a	O
protein	O
with	O
a	O
fragmentary	O
homology	O
to	O
several	O
proteins	O
.	O

Using	O
a	O
prokaryotic	O
expression	O
system	O
,	O
pBad	O
TOPO-47	O
cDNA	O
,	O
a	O
47	O
-	O
kDa	O
recombinant	O
protein	O
was	O
obtained	O
and	O
purified	O
to	O
apparent	O
homogeneity	O
by	O
nickel	O
-	O
nitrilotriacetic	O
acid	O
resin	O
and	O
collagen	O
affinity	O
column	O
.	O

The	O
recombinant	O
protein	O
binds	O
to	O
type	B
III	I
but	I
not	I
type	I
I	I
collagen	I
-	O
Sepharose	O
2B	O
affinity	O
columns	O
.	O

Anti	O
-	O
47	O
-	O
kDa	O
but	O
not	O
anti	O
-	O
65	O
-	O
kDa	O
antibody	O
inhibits	O
the	O
binding	O
of	O
the	O
recombinant	O
protein	O
to	O
the	O
type	B
III	I
collagen	I
-	O
coated	O
micro	O
titer	O
wells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Like	O
the	O
receptor	O
protein	O
purified	O
from	O
platelet	O
membranes	O
,	O
the	O
recombinant	O
protein	O
inhibits	O
type	B
III	I
collagen	I
-	O
induced	O
platelet	O
aggregation	O
also	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

We	O
have	O
defined	O
two	O
active	O
peptides	O
from	O
the	O
cloned	O
deduced	O
amino	O
acid	O
sequence	O
.	O

Both	O
peptides	O
inhibit	O
type	B
III	I
but	I
not	I
type	I
I	I
collagen	I
-	O
induced	O
platelet	O
aggregation	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

These	O
results	O
suggest	O
that	O
the	O
active	O
binding	O
site	O
of	O
the	O
platelet	B
receptor	I
to	I
type	I
III	I
collagen	I
resides	O
in	O
these	O
portions	O
of	O
the	O
protein	O
.	O

Cytological	O
grading	O
,	O
apoptosis	O
,	O
and	O
Bcl-2	B
protein	O
expression	O
in	O
breast	O
cancer	O
.	O

A	O
prospective	O
study	O
was	O
conducted	O
on	O
27	O
cases	O
of	O
infiltrating	O
duct	O
carcinoma	O
of	O
breast	O
diagnosed	O
by	O
fine	O
-	O
needle	O
aspirate	O
cytology	O
(	O
FNAC	O
)	O
,	O
subjected	O
to	O
mastectomy	O
following	O
the	O
FNA	O
diagnosis	O
.	O

Cytological	O
grading	O
,	O
Bcl-2	B
score	O
,	O
and	O
quantification	O
of	O
apoptotic	O
cell	O
count	O
were	O
done	O
on	O
FNA	O
material	O
.	O

Next	O
,	O
the	O
carcinomas	O
were	O
graded	O
on	O
the	O
corresponding	O
histopathological	O
sections	O
.	O

The	O
overall	O
concordance	O
between	O
cytological	O
and	O
histological	O
gradings	O
was	O
77.7	O
%	O
,	O
with	O
maximum	O
concordance	O
in	O
Grade	O
I	O
tumors	O
and	O
minimum	O
in	O
Grade	O
II	O
.	O

The	O
mean	O
apoptotic	O
rates	O
were	O
0.59	O
+	O
/-	O
0.722	O
,	O
2.11	O
+	O
/-	O
0.707	O
,	O
and	O
2.95	O
+	O
/-	O
0.854	O
in	O
Grades	O
I	O
,	O
II	O
,	O
and	O
III	O
,	O
respectively	O
.	O

Similarly	O
Bcl-2	B
scores	O
were	O
1.36	O
+	O
/-	O
0.82	O
,	O
0.22	O
+	O
/-	O
0.13	O
,	O
and	O
0.14	O
+	O
/-	O
0.116	O
,	O
in	O
Grades	O
I	O
,	O
II	O
,	O
and	O
III	O
lesions	O
,	O
respectively	O
.	O

When	O
the	O
cytological	O
grade	O
was	O
correlated	O
with	O
histological	O
grade	O
alone	O
,	O
and	O
subsequently	O
along	O
with	O
Bcl-2	B
scores	O
and	O
apoptotic	O
rates	O
,	O
there	O
was	O
a	O
significant	O
improvement	O
from	O
0.662	O
-	O
0.713	O
(	O
P	O
value	O
,	O
0.001	O
)	O
.	O

Adenovirus	O
oncoproteins	O
inactivate	O
the	O
Mre11	B
-	O
Rad50	B
-	O
NBS1	B
DNA	O
repair	O
complex	O
.	O

In	O
mammalian	O
cells	O
,	O
a	O
conserved	O
multiprotein	O
complex	O
of	O
Mre11	B
,	O
Rad50	B
and	O
NBS1	B
(	O
also	O
known	O
as	O
nibrin	B
and	O
p95	B
)	O
is	O
important	O
for	O
double	O
-	O
strand	O
break	O
repair	O
,	O
meiotic	O
recombination	O
and	O
telomere	O
maintenance	O
.	O

This	O
complex	O
forms	O
nuclear	O
foci	O
and	O
may	O
be	O
a	O
sensor	O
of	O
double	O
-	O
strand	O
breaks	O
.	O

In	O
the	O
absence	O
of	O
the	O
early	O
region	O
E4	B
,	O
the	O
double	O
-	O
stranded	O
DNA	O
genome	O
of	O
adenovirus	O
is	O
joined	O
into	O
concatemers	O
too	O
large	O
to	O
be	O
packaged	O
.	O

We	O
have	O
investigated	O
the	O
cellular	O
proteins	O
involved	O
in	O
this	O
concatemer	O
formation	O
and	O
how	O
they	O
are	O
inactivated	O
by	O
E4	B
products	O
during	O
a	O
wild	O
-	O
type	O
infection	O
.	O

Here	O
we	O
show	O
that	O
concatemerization	O
requires	O
functional	O
Mre11	B
and	O
NBS1	B
,	O
and	O
that	O
these	O
proteins	O
are	O
found	O
at	O
foci	O
adjacent	O
to	O
viral	O
replication	O
centres	O
.	O

Infection	O
with	O
wild	O
-	O
type	O
virus	O
results	O
in	O
both	O
reorganization	O
and	O
degradation	O
of	O
members	O
of	O
the	O
Mre11	B
-	O
Rad50	B
-	O
NBS1	B
complex	O
.	O

These	O
activities	O
are	O
mediated	O
by	O
three	O
viral	O
oncoproteins	O
that	O
prevent	O
concatemerization	O
.	O

This	O
targeting	O
of	O
cellular	O
proteins	O
involved	O
in	O
genomic	O
stability	O
suggests	O
a	O
mechanism	O
for	O
'	O
hit	O
-	O
and	O
-	O
run	O
'	O
transformation	O
observed	O
for	O
these	O
viral	O
oncoproteins	O
.	O

A	O
bimolecular	O
mechanism	O
of	O
HIV-1	O
Tat	B
protein	O
interaction	O
with	O
RNA	B
polymerase	I
II	I
transcription	O
elongation	O
complexes	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
element	O
is	O
regulated	O
by	O
the	O
essential	O
viral	O
Tat	B
protein	O
that	O
binds	O
to	O
the	O
viral	O
TAR	O
RNA	O
target	O
and	O
recruits	O
a	O
positive	B
transcription	I
elongation	I
complex	I
(	O
P	B
-	I
TEFb	I
)	O
.	O

We	O
have	O
used	O
a	O
stepwise	O
transcription	O
approach	O
and	O
a	O
highly	O
sensitive	O
assay	O
to	O
determine	O
the	O
dynamics	O
of	O
interactions	O
between	O
HIV-1	O
Tat	B
and	O
the	O
transcription	O
complexes	O
actively	O
engaged	O
in	O
elongation	O
.	O

Our	O
results	O
demonstrate	O
that	O
Tat	B
protein	O
associates	O
with	O
RNA	B
polymerase	I
II	I
complexes	O
during	O
early	O
transcription	O
elongation	O
after	O
the	O
promoter	O
clearance	O
and	O
before	O
the	O
synthesis	O
of	O
full	O
-	O
length	O
TAR	O
RNA	O
transcript	O
.	O

This	O
interaction	O
of	O
Tat	B
with	O
RNA	B
polymerase	I
II	I
elongation	O
complexes	O
is	O
P	B
-	I
TEFb	I
-	O
independent	O
.	O

Our	O
results	O
also	O
show	O
that	O
there	O
are	O
two	O
Tat	B
binding	O
sites	O
on	O
each	O
transcription	O
elongation	O
complex	O
;	O
one	O
is	O
located	O
on	O
TAR	O
RNA	O
and	O
the	O
other	O
one	O
on	O
RNA	B
polymerase	I
II	I
near	O
the	O
exit	O
site	O
for	O
nascent	O
mRNA	O
transcripts	O
.	O

These	O
findings	O
suggest	O
that	O
two	O
Tat	B
molecules	O
are	O
involved	O
in	O
performing	O
various	O
functions	O
during	O
a	O
single	O
round	O
of	O
HIV-1	O
mRNA	O
synthesis	O
.	O

Spectrin	B
-	O
like	O
repeats	O
from	O
dystrophin	B
and	O
alpha	B
-	I
actinin-2	I
are	O
not	O
functionally	O
interchangeable	O
.	O

Mutations	O
in	O
the	O
dystrophin	B
gene	O
result	O
in	O
Duchenne	O
muscular	O
dystrophy	O
(	O
DMD	O
)	O
.	O

Dystrophin	B
is	O
a	O
multidomain	O
protein	O
that	O
functions	O
to	O
stabilize	O
the	O
sarcolemmal	O
membrane	O
during	O
muscle	O
contraction	O
.	O

The	O
central	O
rod	O
domain	O
has	O
been	O
proposed	O
to	O
act	O
as	O
a	O
shock	O
absorber	O
,	O
as	O
a	O
force	O
transducer	O
or	O
as	O
a	O
spacer	O
separating	O
important	O
N	O
-	O
and	O
C	O
-	O
terminal	O
domains	O
that	O
interact	O
with	O
actin	B
and	O
the	O
dystrophin	B
-	O
glycoprotein	O
complex	O
(	O
DGC	O
)	O
.	O

Structure	O
/	O
function	O
studies	O
demonstrated	O
that	O
deletion	O
of	O
large	O
portions	O
of	O
the	O
rod	O
domain	O
can	O
result	O
in	O
the	O
production	O
of	O
smaller	O
,	O
yet	O
highly	O
functional	O
,	O
dystrophin	B
proteins	O
.	O

In	O
a	O
dramatic	O
example	O
,	O
a	O
'	O
micro	O
-	O
dystrophin	B
'	O
transgene	O
containing	O
only	O
four	O
dystrophin	B
spectrin	B
-	O
like	O
repeats	O
resulted	O
in	O
complete	O
correction	O
of	O
most	O
of	O
the	O
symptoms	O
associated	O
with	O
dystrophy	O
in	O
the	O
mdx	O
mouse	O
model	O
for	O
DMD	O
.	O

Dystrophin	B
shares	O
considerable	O
homology	O
with	O
the	O
multidomain	O
,	O
actin	B
-	O
crosslinking	O
protein	O
alpha	B
-	I
actinin	I
.	O

To	O
explore	O
the	O
hypothesis	O
that	O
the	O
dystrophin	B
rod	O
domain	O
acts	O
as	O
a	O
spacer	O
region	O
,	O
a	O
chimeric	O
micro	O
-	O
dystrophin	B
transgene	O
containing	O
the	O
four	O
-	O
repeat	O
rod	O
domain	O
of	O
alpha	B
-	I
actinin-2	I
was	O
expressed	O
in	O
mdx	O
mice	O
.	O

This	O
chimeric	O
transgene	O
was	O
incapable	O
of	O
correcting	O
the	O
morphological	O
pathology	O
of	O
the	O
mdx	O
mouse	O
,	O
but	O
still	O
functioned	O
to	O
assemble	O
the	O
DGC	O
at	O
the	O
membrane	O
and	O
provided	O
some	O
protection	O
from	O
contraction	O
-	O
induced	O
injury	O
.	O

These	O
data	O
demonstrated	O
that	O
different	O
spectrin	B
-	O
like	O
repeats	O
are	O
not	O
equivalent	O
,	O
and	O
reinforced	O
the	O
suggestion	O
that	O
the	O
dystrophin	B
rod	O
domain	O
is	O
not	O
merely	O
a	O
spacer	O
but	O
likely	O
contributes	O
an	O
important	O
mechanical	O
role	O
to	O
overall	O
dystrophin	B
function	O
.	O

PAX	B
genes	O
in	O
development	O
and	O
disease	O
:	O
the	O
role	O
of	O
PAX2	B
in	O
urogenital	O
tract	O
development	O
.	O

PAX	B
genes	O
play	O
an	O
important	O
role	O
in	O
fetal	O
development	O
.	O

Moreover	O
,	O
heterozygous	O
mutations	O
in	O
several	O
PAX	B
genes	O
cause	O
human	O
disease	O
.	O

Here	O
we	O
review	O
the	O
role	O
of	O
PAX2	B
in	O
kidney	O
development	O
,	O
focusing	O
on	O
the	O
morphological	O
effects	O
of	O
PAX2	B
mutations	O
.	O

We	O
discuss	O
the	O
role	O
of	O
PAX2	B
in	O
the	O
context	O
of	O
an	O
inhibitory	O
field	O
model	O
of	O
kidney	O
branching	O
morphogenesis	O
and	O
summarize	O
recent	O
progress	O
in	O
this	O
area	O
.	O

Cytoplasmic	B
serine	I
hydroxymethyltransferase	I
mediates	O
competition	O
between	O
folate	O
-	O
dependent	O
deoxyribonucleotide	O
and	O
S	O
-	O
adenosylmethionine	O
biosyntheses	O
.	O

Folate	O
-	O
dependent	O
one	O
-	O
carbon	O
metabolism	O
is	O
required	O
for	O
the	O
synthesis	O
of	O
purines	O
and	O
thymidylate	O
and	O
for	O
the	O
remethylation	O
of	O
homocysteine	O
to	O
methionine	O
.	O

Methionine	O
is	O
subsequently	O
adenylated	O
to	O
S	O
-	O
adenosylmethionine	O
(	O
SAM	O
)	O
,	O
a	O
cofactor	O
that	O
methylates	O
DNA	O
,	O
RNA	O
,	O
proteins	O
,	O
and	O
many	O
metabolites	O
.	O

Previous	O
experimental	O
and	O
theoretical	O
modeling	O
studies	O
have	O
indicated	O
that	O
folate	O
cofactors	O
are	O
limiting	O
for	O
cytoplasmic	O
folate	O
-	O
dependent	O
reactions	O
and	O
that	O
the	O
synthesis	O
of	O
DNA	O
precursors	O
competes	O
with	O
SAM	O
synthesis	O
.	O

Each	O
of	O
these	O
studies	O
concluded	O
that	O
SAM	O
synthesis	O
has	O
a	O
higher	O
metabolic	O
priority	O
than	O
dTMP	O
synthesis	O
.	O

The	O
influence	O
of	O
cytoplasmic	B
serine	I
hydroxymethyltransferase	I
(	O
cSHMT	B
)	O
on	O
this	O
competition	O
was	O
examined	O
in	O
MCF-7	O
cells	O
.	O

Increases	O
in	O
cSHMT	B
expression	O
inhibit	O
SAM	O
concentrations	O
by	O
two	O
proposed	O
mechanisms	O
:	O
(	O
1	O
)	O
cSHMT	B
-	O
catalyzed	O
serine	O
synthesis	O
competes	O
with	O
the	O
enzyme	O
methylenetetrahydrofolate	B
reductase	I
for	O
methylenetetrahydrofolate	O
in	O
a	O
glycine	O
-	O
dependent	O
manner	O
,	O
and	O
(	O
2	O
)	O
cSHMT	B
,	O
a	O
high	O
affinity	O
5	O
-	O
methyltetrahydrofolate	O
-	O
binding	O
protein	O
,	O
sequesters	O
this	O
cofactor	O
and	O
inhibits	O
methionine	O
synthesis	O
in	O
a	O
glycine	O
-	O
independent	O
manner	O
.	O

Stable	O
isotope	O
tracer	O
studies	O
indicate	O
that	O
cSHMT	B
plays	O
an	O
important	O
role	O
in	O
mediating	O
the	O
flux	O
of	O
one	O
-	O
carbon	O
units	O
between	O
dTMP	O
and	O
SAM	O
syntheses	O
.	O

We	O
conclude	O
that	O
cSHMT	B
has	O
three	O
important	O
functions	O
in	O
the	O
cytoplasm	O
:	O
(	O
1	O
)	O
it	O
preferentially	O
supplies	O
one	O
-	O
carbon	O
units	O
for	O
thymidylate	O
biosynthesis	O
,	O
(	O
2	O
)	O
it	O
depletes	O
methylenetetrahydrofolate	O
pools	O
for	O
SAM	O
synthesis	O
by	O
synthesizing	O
serine	O
,	O
and	O
(	O
3	O
)	O
it	O
sequesters	O
5-methyltetrahydrofolate	O
and	O
inhibits	O
SAM	O
synthesis	O
.	O

These	O
results	O
indicate	O
that	O
cSHMT	B
is	O
a	O
metabolic	O
switch	O
that	O
,	O
when	O
activated	O
,	O
gives	O
dTMP	O
synthesis	O
higher	O
metabolic	O
priority	O
than	O
SAM	O
synthesis	O
.	O

Elucidating	O
changes	O
in	O
surface	O
marker	O
expression	O
of	O
dendritic	O
cells	O
following	O
chemical	O
allergen	O
treatment	O
.	O

Dendritic	O
cells	O
(	O
DC	O
)	O
are	O
highly	O
specialized	O
antigen	O
-	O
presenting	O
cells	O
(	O
APC	O
)	O
located	O
in	O
lymphoid	O
and	O
many	O
nonlymphoid	O
tissues	O
,	O
and	O
Langerhans	O
cells	O
(	O
LC	O
)	O
,	O
a	O
specialized	O
form	O
of	O
DC	O
,	O
are	O
found	O
in	O
the	O
skin	O
.	O

LC	O
play	O
a	O
critical	O
role	O
in	O
the	O
induction	O
of	O
contact	O
dermatitis	O
and	O
therefore	O
have	O
become	O
a	O
focal	O
point	O
for	O
the	O
development	O
of	O
in	O
vitro	O
cell	O
-	O
based	O
methods	O
for	O
contact	O
sensitization	O
testing	O
.	O

Because	O
of	O
the	O
low	O
abundance	O
of	O
skin	O
-	O
derived	O
LC	O
,	O
methods	O
to	O
culture	O
DC	O
from	O
peripheral	O
blood	O
are	O
being	O
used	O
by	O
investigators	O
to	O
generate	O
LC	O
surrogates	O
to	O
examine	O
the	O
effects	O
of	O
sensitizing	O
chemicals	O
on	O
APC	O
.	O

It	O
has	O
been	O
reported	O
recently	O
that	O
chemical	O
allergens	O
can	O
induce	O
changes	O
in	O
the	O
expression	O
of	O
various	O
DC	O
surface	O
markers	O
and	O
it	O
has	O
been	O
suggested	O
that	O
the	O
measure	O
of	O
these	O
changes	O
in	O
surface	O
marker	O
expression	O
following	O
allergen	O
treatment	O
could	O
provide	O
the	O
basis	O
for	O
an	O
in	O
vitro	O
test	O
method	O
to	O
predict	O
the	O
contact	O
sensitization	O
potential	O
of	O
a	O
chemical	O
.	O

For	O
the	O
work	O
presented	O
here	O
,	O
DC	O
were	O
differentiated	O
from	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
-	O
DC	O
)	O
in	O
culture	O
medium	O
containing	O
GM	B
-	I
CSF	I
and	O
interleukin	B
(	I
IL	I
)	I
-	I
4	I
to	O
ensure	O
an	O
immature	O
phenotype	O
or	O
were	O
derived	O
from	O
the	O
KG	O
-	O
1	O
cell	O
line	O
(	O
KG-1	O
DC	O
)	O
using	O
a	O
defined	O
cytokine	B
cocktail	O
consisting	O
of	O
GM	B
-	I
CSF	I
,	O
IL	B
-	I
4	I
,	O
Flt	B
-	I
3	I
/	O
Flk	B
-	I
2	I
-	O
ligand	O
,	O
thrombopoietin	B
,	O
stem	B
cell	I
factor	I
,	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNFalpha	B
)	O
.	O

Surface	O
marker	O
expression	O
(	O
HLA	B
-	I
DR	I
,	O
CD54	B
,	O
CD80	B
,	O
and	O
CD86	B
)	O
on	O
these	O
DC	O
was	O
measured	O
by	O
flow	O
cytometry	O
after	O
48	O
h	O
treatment	O
with	O
the	O
known	O
chemical	O
allergens	O
dinitrofluorobenzene	O
(	O
DNFB	O
)	O
and	O
methylchloroisothiazolinone	O
/	O
methylisothiazolinone	O
(	O
MCI	O
/	O
MI	O
)	O
,	O
the	O
irritant	O
sodium	O
dodecyl	O
sulfate	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
and	O
TNFalpha	B
.	O

Treatment	O
of	O
PBMC	O
-	O
DC	O
with	O
either	O
MCI	O
/	O
MI	O
or	O
DNFB	O
induced	O
a	O
slight	O
upregulation	O
of	O
class	B
II	I
major	I
histocompatibility	I
(	I
MHC	I
)	I
expression	O
(	O
HLA	B
-	I
DR	I
)	O
,	O
whereas	O
LPS	O
and	O
TNFalpha	B
significantly	O
upregulated	O
CD54	B
and	O
slightly	O
upregulated	O
CD80	B
and	O
HLA	B
-	I
DR	I
expression	O
.	O

For	O
KG-1	O
DC	O
,	O
only	O
MCI	O
/	O
MI	O
upregulated	O
CD86	B
expression	O
,	O
whereas	O
TNFalpha	B
upregulated	O
CD54	B
and	O
slightly	O
upregulated	O
CD80	B
and	O
CD86	B
expression	O
.	O

SDS	O
had	O
no	O
effect	O
on	O
surface	O
marker	O
expression	O
in	O
either	O
PBMC	O
-	O
DC	O
or	O
KG-1	O
DC	O
.	O

Changes	O
in	O
surface	O
marker	O
expression	O
in	O
PBMC	O
-	O
DC	O
treated	O
with	O
chemical	O
allergens	O
were	O
detected	O
in	O
two	O
of	O
five	O
donors	O
,	O
suggesting	O
a	O
limited	O
sensitivity	O
of	O
PBMC	O
-	O
DC	O
under	O
these	O
defined	O
isolation	O
and	O
culture	O
conditions	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
presence	O
of	O
GM	B
-	I
CSF	I
and	O
IL	B
-	I
4	I
during	O
chemical	O
allergen	O
treatment	O
masked	O
the	O
ability	O
to	O
detect	O
changes	O
in	O
surface	O
marker	O
expression	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
under	O
these	O
culture	O
and	O
treatment	O
conditions	O
,	O
measurement	O
of	O
surface	O
marker	O
changes	O
in	O
vitro	O
using	O
PBMC	O
-	O
DC	O
or	O
KG-1	O
DC	O
does	O
not	O
provide	O
a	O
sensitive	O
in	O
vitro	O
method	O
with	O
sufficient	O
dynamic	O
range	O
for	O
assessing	O
the	O
contact	O
sensitization	O
potential	O
of	O
a	O
chemical	O
.	O

Pre	B
-	I
pro	I
-	I
B	I
cell	I
growth	I
-	I
stimulating	I
factor	I
(	O
PPBSF	B
)	O
upregulates	O
IL-7Ralpha	B
chain	O
expression	O
and	O
enables	O
pro	O
-	O
B	O
cells	O
to	O
respond	O
to	O
monomeric	O
IL-7	B
.	O

Although	O
pro	O
-	O
B	O
cells	O
are	O
well	O
represented	O
in	O
IL-7	B
knockout	O
(	O
KO	O
)	O
mice	O
,	O
they	O
express	O
abnormally	O
low	O
concentrations	O
of	O
the	O
interleukin-7	B
receptor	I
alpha	I
-	I
chain	I
(	O
IL-7Ralpha	B
)	O
and	O
do	O
not	O
generate	O
pre	O
-	O
B	O
cells	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
pro	O
-	O
B	O
cells	O
from	O
IL-7	B
KO	O
mice	O
can	O
be	O
induced	O
to	O
generate	O
pre	O
-	O
B	O
cells	O
and	O
immature	O
B	O
cells	O
by	O
exposure	O
to	O
recombinant	O
IL-7	B
(	O
rIL-7	B
)	O
in	O
vivo	O
but	O
not	O
in	O
vitro	O
.	O

Experiments	O
in	O
recombinant	B
activation	I
gene-1	I
(	O
RAG-1	B
)	O
KO	O
mice	O
indicate	O
that	O
the	O
in	O
vitro	O
unresponsiveness	O
of	O
IL-7	B
(	O
-	O
/	O
-	O
)	O
pro	O
-	O
B	O
cells	O
to	O
rIL-7	B
is	O
unrelated	O
to	O
the	O
absence	O
of	O
a	O
functional	O
pre	O
-	O
B	B
cell	I
receptor	I
(	O
pre	O
-	O
BCR	B
)	O
.	O

Rather	O
,	O
it	O
appears	O
to	O
be	O
due	O
to	O
the	O
suboptimal	O
expression	O
of	O
the	O
IL-7Ralpha	B
chain	O
.	O

Thus	O
,	O
IL-7	B
(	O
-	O
/	O
-	O
)	O
pro	O
-	O
B	O
cells	O
readily	O
respond	O
to	O
rIL-7	B
in	O
vitro	O
if	O
IL-7Ralpha	B
chain	O
expression	O
is	O
first	O
upregulated	O
by	O
exposure	O
to	O
IL-7	B
in	O
vivo	O
or	O
to	O
IL-7	B
(	O
+	O
/+	O
)	O
bone	O
marrow	O
(	O
BM	O
)	O
stromal	O
cells	O
or	O
conditioned	O
medium	O
(	O
CM	O
)	O
therefrom	O
in	O
vitro	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
pro	O
-	O
B	O
cells	O
from	O
IL-7	B
KO	O
mice	O
were	O
cultured	O
on	O
IL-7	B
(	O
-	O
/	O
-	O
)	O
BM	O
stromal	O
cells	O
in	O
the	O
presence	O
of	O
rIL-7	B
.	O

This	O
suggested	O
that	O
the	O
recently	O
described	O
pre	B
-	I
pro	I
-	I
B	I
cell	I
growth	I
-	I
stimulating	I
factor	I
(	O
PPBSF	B
)	O
,	O
a	O
self	O
-	O
assembling	O
hybrid	O
cytokine	B
comprising	O
IL-7	B
and	O
the	O
stromal	O
cell	O
-	O
derived	O
hepatocyte	B
growth	I
factor	I
beta	I
-	I
chain	I
(	O
HGFbeta	B
)	O
,	O
is	O
required	O
to	O
stimulate	O
pro	O
-	O
B	O
cells	O
from	O
IL-7	B
KO	O
mice	O
.	O

This	O
inference	O
was	O
verified	O
by	O
demonstrating	O
that	O
purified	O
PPBSF	B
upregulates	O
IL-7Ralpha	B
chain	O
expression	O
on	O
IL-7	B
(	O
-	O
/	O
-	O
)	O
pro	O
-	O
B	O
cells	O
in	O
vitro	O
and	O
enables	O
them	O
to	O
respond	O
to	O
rIL-7	B
in	O
a	O
stepwise	O
manner	O
.	O

We	O
,	O
therefore	O
,	O
postulate	O
that	O
PPBSF	B
is	O
the	O
operative	O
form	O
of	O
IL-7	B
that	O
normally	O
induces	O
IL-7Ralpha	B
(	O
lo	O
)	O
pre	O
-	O
pro	O
-	O
B	O
cells	O
to	O
proliferate	O
and	O
differentiate	O
into	O
IL-7Ralpha	B
(	O
hi	O
)	O
pro	O
-	O
B	O
cells	O
,	O
which	O
then	O
proliferate	O
and	O
differentiate	O
into	O
pre	O
-	O
B	O
cells	O
on	O
stimulation	O
with	O
monomeric	O
IL-7	B
.	O

Lon	B
protease	I
preferentially	O
degrades	O
oxidized	O
mitochondrial	B
aconitase	I
by	O
an	O
ATP	O
-	O
stimulated	O
mechanism	O
.	O

Mitochondrial	B
aconitase	I
is	O
sensitive	O
to	O
oxidative	O
inactivation	O
and	O
can	O
aggregate	O
and	O
accumulate	O
in	O
many	O
age	O
-	O
related	O
disorders	O
.	O

Here	O
we	O
report	O
that	O
Lon	B
protease	I
,	O
an	O
ATP	O
-	O
stimulated	O
mitochondrial	O
matrix	O
protein	O
,	O
selectively	O
recognizes	O
and	O
degrades	O
the	O
oxidized	O
,	O
hydrophobic	O
form	O
of	O
aconitase	B
after	O
mild	O
oxidative	O
modification	O
,	O
but	O
that	O
severe	O
oxidation	O
results	O
in	O
aconitase	B
aggregation	O
,	O
which	O
makes	O
it	O
a	O
poor	O
substrate	O
for	O
Lon	B
.	O

Similarly	O
,	O
a	O
morpholino	O
oligodeoxynucleotide	O
directed	O
against	O
the	O
lon	O
gene	O
markedly	O
decreases	O
the	O
amount	O
of	O
Lon	B
protein	O
,	O
Lon	B
activity	O
and	O
aconitase	B
degradation	O
in	O
WI-38	O
VA-13	O
human	O
lung	O
fibroblasts	O
and	O
causes	O
accumulation	O
of	O
oxidatively	O
modified	O
aconitase	B
.	O

The	O
ATP	O
-	O
stimulated	O
Lon	B
protease	I
may	O
be	O
an	O
essential	O
defence	O
against	O
the	O
stress	O
of	O
life	O
in	O
an	O
oxygen	O
environment	O
.	O

By	O
recognizing	O
minor	O
oxidative	O
changes	O
to	O
protein	O
structure	O
and	O
rapidly	O
degrading	O
the	O
mildly	O
modified	O
protein	O
,	O
Lon	B
protease	I
may	O
prevent	O
extensive	O
oxidation	O
,	O
aggregation	O
and	O
accumulation	O
of	O
aconitase	B
,	O
which	O
could	O
otherwise	O
compromise	O
mitochondrial	O
function	O
and	O
cellular	O
viability	O
.	O

Aconitase	B
is	O
probably	O
only	O
one	O
of	O
many	O
mitochondrial	O
matrix	O
proteins	O
that	O
are	O
preferentially	O
degraded	O
by	O
Lon	B
protease	I
after	O
oxidative	O
modification	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
bone	B
morphogenetic	I
protein-1	I
is	O
required	O
for	O
secretion	O
and	O
stability	O
of	O
the	O
protein	O
.	O

Bone	B
morphogenetic	I
protein	I
(	I
BMP	I
)	I
-	I
1	I
is	O
a	O
glycosylated	O
metalloproteinase	B
that	O
is	O
fundamental	O
to	O
the	O
synthesis	O
of	O
a	O
normal	O
extracellular	O
matrix	O
because	O
it	O
cleaves	O
type	B
I	I
procollagen	I
,	O
as	O
well	O
as	O
other	O
precursor	O
proteins	O
.	O

Sequence	O
analysis	O
suggests	O
that	O
BMP-1	B
has	O
six	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
(	O
i.e.	O
NXS	O
/	O
T	O
)	O
namely	O
:	O
Asn	O
(	O
91	O
)	O
(	O
prodomain	O
)	O
,	O
Asn	O
(	O
142	O
)	O
(	O
metalloproteinase	B
domain	O
)	O
,	O
Asn	O
(	O
332	O
)	O
and	O
Asn	O
(	O
363	O
)	O
(	O
CUB1	O
domain	O
)	O
,	O
Asn	O
(	O
599	O
)	O
(	O
CUB3	O
domain	O
)	O
,	O
and	O
Asn	O
(	O
726	O
)	O
in	O
the	O
C	O
-	O
terminal	O
-	O
specific	O
domain	O
.	O

In	O
this	O
study	O
we	O
showed	O
that	O
all	O
these	O
sites	O
are	O
N	O
-	O
glycosylated	O
with	O
complex	O
-	O
type	O
oligosaccharides	O
containing	O
sialic	O
acid	O
,	O
except	O
Asn	O
(	O
726	O
)	O
presumably	O
because	O
proline	O
occurs	O
immediately	O
C	O
-	O
terminal	O
of	O
threonine	O
in	O
the	O
consensus	O
sequence	O
.	O

Recombinant	O
BMP-1	B
molecules	O
lacking	O
all	O
glycosylation	O
sites	O
or	O
the	O
three	O
CUB	O
-	O
specific	O
sites	O
were	O
not	O
secreted	O
.	O

BMP-1	B
lacking	O
CUB	O
glycosylation	O
was	O
translocated	O
to	O
the	O
proteasome	O
for	O
degradation	O
.	O

BMP-1	B
molecules	O
lacking	O
individual	O
glycosylation	O
sites	O
were	O
efficiently	O
secreted	O
and	O
exhibited	O
full	O
procollagen	B
C	I
-	I
proteinase	I
activity	O
,	O
but	O
N332Q	O
and	O
N599Q	O
exhibited	O
a	O
slower	O
rate	O
of	O
cleavage	O
.	O

BMP-1	B
molecules	O
lacking	O
any	O
one	O
of	O
the	O
CUB	O
-	O
specific	O
glycosylation	O
sites	O
were	O
sensitive	O
to	O
thermal	O
denaturation	O
.	O

The	O
study	O
showed	O
that	O
the	O
glycosylation	O
sites	O
in	O
the	O
CUB	O
domains	O
of	O
BMP-1	B
are	O
important	O
for	O
secretion	O
and	O
stability	O
of	O
the	O
molecule	O
.	O

Cutting	O
edge	O
:	O
susceptibility	O
to	O
psoriatic	O
arthritis	O
:	O
influence	O
of	O
activating	O
killer	B
Ig	I
-	I
like	I
receptor	I
genes	O
in	O
the	O
absence	O
of	O
specific	O
HLA	B
-	I
C	I
alleles	O
.	O

NK	O
cell	O
activity	O
is	O
partially	O
controlled	O
through	O
interactions	O
between	O
killer	B
Ig	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
on	O
NK	O
cells	O
and	O
their	O
respective	O
HLA	B
class	I
I	I
ligands	O
.	O

Independent	O
segregation	O
of	O
HLA	B
and	O
KIR	B
genes	O
,	O
along	O
with	O
KIR	B
specificity	O
for	O
particular	O
HLA	B
allotypes	O
,	O
raises	O
the	O
possibility	O
that	O
any	O
given	O
individual	O
may	O
express	O
KIR	B
molecules	O
for	O
which	O
no	O
ligand	O
is	O
present	O
.	O

Inhibitory	O
receptor	O
genes	O
KIR2DL2	B
/	I
3	I
and	O
KIR2DL1	B
were	O
present	O
in	O
nearly	O
all	O
subjects	O
sampled	O
in	O
this	O
study	O
,	O
whereas	O
their	O
respective	O
activating	O
homologs	O
,	O
KIR2DS2	B
and	O
KIR2DS1	B
,	O
are	O
each	O
present	O
in	O
about	O
half	O
of	O
the	O
subjects	O
.	O

In	O
this	O
work	O
we	O
report	O
that	O
subjects	O
with	O
activating	O
KIR2DS1	B
and/or	O
KIR2DS2	B
genes	O
are	O
susceptible	O
to	O
developing	O
psoriatic	O
arthritis	O
,	O
but	O
only	O
when	O
HLA	B
ligands	O
for	O
their	O
homologous	O
inhibitory	O
receptors	O
,	O
KIR2DL1	B
and	O
KIR2DL2	B
/	I
3	I
,	O
are	O
missing	O
.	O

Absence	O
of	O
ligands	O
for	O
inhibitory	O
KIRs	B
could	O
potentially	O
lower	O
the	O
threshold	O
for	O
NK	O
(	O
and	O
/	O
or	O
T	O
)	O
cell	O
activation	O
mediated	O
through	O
activating	O
receptors	O
,	O
thereby	O
contributing	O
to	O
pathogenesis	O
of	O
psoriatic	O
arthritis	O
.	O

Drosophila	O
APC2	B
and	O
APC1	B
play	O
overlapping	O
roles	O
in	O
wingless	O
signaling	O
in	O
the	O
embryo	O
and	O
imaginal	O
discs	O
.	O

The	O
regulation	O
of	O
signal	O
transduction	O
plays	O
a	O
key	O
role	O
in	O
cell	O
fate	O
choices	O
,	O
and	O
its	O
disregulation	O
contributes	O
to	O
oncogenesis	O
.	O

This	O
duality	O
is	O
exemplified	O
by	O
the	O
tumor	O
suppressor	O
APC	B
.	O

Originally	O
identified	O
for	O
its	O
role	O
in	O
colon	O
tumors	O
,	O
APC	B
family	I
members	O
were	O
subsequently	O
shown	O
to	O
negatively	O
regulate	O
Wnt	B
signaling	O
in	O
both	O
development	O
and	O
disease	O
.	O

The	O
analysis	O
of	O
the	O
normal	O
roles	O
of	O
APC	B
proteins	O
is	O
complicated	O
by	O
the	O
presence	O
of	O
two	O
APC	B
family	I
members	O
in	O
flies	O
and	O
mice	O
.	O

Previous	O
work	O
demonstrated	O
that	O
,	O
in	O
some	O
tissues	O
,	O
single	O
mutations	O
in	O
each	O
gene	O
have	O
no	O
effect	O
,	O
raising	O
the	O
question	O
of	O
whether	O
there	O
is	O
functional	O
overlap	O
between	O
the	O
two	O
APCs	B
or	O
whether	O
APC	B
-	O
independent	O
mechanisms	O
of	O
Wnt	B
regulation	O
exist	O
.	O

We	O
addressed	O
this	O
by	O
eliminating	O
the	O
function	O
of	O
both	O
Drosophila	O
APC	B
genes	O
simultaneously	O
.	O

We	O
find	O
that	O
APC1	B
and	O
APC2	B
play	O
overlapping	O
roles	O
in	O
regulating	O
Wingless	B
signaling	O
in	O
the	O
embryonic	O
epidermis	O
and	O
the	O
imaginal	O
discs	O
.	O

Surprisingly	O
,	O
APC1	B
function	O
in	O
embryos	O
occurs	O
at	O
levels	O
of	O
expression	O
nearly	O
too	O
low	O
to	O
detect	O
.	O

Further	O
,	O
the	O
overlapping	O
functions	O
exist	O
despite	O
striking	O
differences	O
in	O
the	O
intracellular	O
localization	O
of	O
the	O
two	O
APC	B
family	I
members	O
.	O

Inhibition	O
of	O
silencing	O
and	O
accelerated	O
aging	O
by	O
nicotinamide	O
,	O
a	O
putative	O
negative	O
regulator	O
of	O
yeast	O
sir2	B
and	O
human	O
SIRT1	B
.	O

The	O
Saccharomyces	O
cerevisiae	O
Sir2	B
protein	O
is	O
an	O
NAD	O
(	O
+	O
)	O
-	O
dependent	O
histone	B
deacetylase	I
that	O
plays	O
a	O
critical	O
role	O
in	O
transcriptional	O
silencing	O
,	O
genome	O
stability	O
,	O
and	O
longevity	O
.	O

A	O
human	O
homologue	O
of	O
Sir2	B
,	O
SIRT1	B
,	O
regulates	O
the	O
activity	O
of	O
the	O
p53	B
tumor	I
suppressor	I
and	O
inhibits	O
apoptosis	O
.	O

The	O
Sir2	B
deacetylation	O
reaction	O
generates	O
two	O
products	O
:	O
O	O
-	O
acetyl	O
-	O
ADP	O
-	O
ribose	O
and	O
nicotinamide	O
,	O
a	O
precursor	O
of	O
nicotinic	O
acid	O
and	O
a	O
form	O
of	O
niacin	O
/	O
vitamin	O
B	O
(	O
3	O
)	O
.	O

We	O
show	O
here	O
that	O
nicotinamide	O
strongly	O
inhibits	O
yeast	O
silencing	O
,	O
increases	O
rDNA	O
recombination	O
,	O
and	O
shortens	O
replicative	O
life	O
span	O
to	O
that	O
of	O
a	O
sir2	B
mutant	O
.	O

Nicotinamide	O
abolishes	O
silencing	O
and	O
leads	O
to	O
an	O
eventual	O
delocalization	O
of	O
Sir2	B
even	O
in	O
G	O
(	O
1	O
)	O
-	O
arrested	O
cells	O
,	O
demonstrating	O
that	O
silent	O
heterochromatin	O
requires	O
continual	O
Sir2	B
activity	O
.	O

We	O
show	O
that	O
physiological	O
concentrations	O
of	O
nicotinamide	O
noncompetitively	O
inhibit	O
both	O
Sir2	B
and	O
SIRT1	B
in	O
vitro	O
.	O

The	O
degree	O
of	O
inhibition	O
by	O
nicotinamide	O
(	O
IC	O
(	O
50	O
)	O
<	O
50	O
microm	O
)	O
is	O
equal	O
to	O
or	O
better	O
than	O
the	O
most	O
effective	O
known	O
synthetic	O
inhibitors	O
of	O
this	O
class	O
of	O
proteins	O
.	O

We	O
propose	O
a	O
model	O
whereby	O
nicotinamide	O
inhibits	O
deacetylation	O
by	O
binding	O
to	O
a	O
conserved	O
pocket	O
adjacent	O
to	O
NAD	O
(	O
+	O
)	O
,	O
thereby	O
blocking	O
NAD	O
(	O
+	O
)	O
hydrolysis	O
.	O

We	O
discuss	O
the	O
possibility	O
that	O
nicotinamide	O
is	O
a	O
physiologically	O
relevant	O
regulator	O
of	O
Sir2	B
enzymes	O
.	O

Mot1p	B
is	O
essential	O
for	O
TBP	B
recruitment	O
to	O
selected	O
promoters	O
during	O
in	O
vivo	O
gene	O
activation	O
.	O

Recruitment	O
of	O
TATA	B
-	I
binding	I
protein	I
(	O
TBP	B
)	O
is	O
central	O
to	O
activation	O
of	O
transcription	O
by	O
RNA	B
polymerase	I
II	I
(	O
pol	B
II	I
)	O
.	O

This	O
depends	O
upon	O
co	O
-	O
activator	O
proteins	O
including	O
TBP	B
-	I
associated	I
factors	I
(	O
TAFs	B
)	O
.	O

Yeast	O
Mot1p	B
was	O
identified	O
as	O
a	O
general	O
transcriptional	O
repressor	O
in	O
genetic	O
screens	O
and	O
is	O
also	O
found	O
associated	O
with	O
TBP	B
.	O

To	O
obtain	O
insight	O
into	O
Mot1p	B
function	O
in	O
vivo	O
,	O
we	O
determined	O
the	O
mRNA	O
expression	O
profile	O
of	O
the	O
mot1	B
-	O
1	O
temperature	O
-	O
sensitive	O
(	O
Ts	O
)	O
strain	O
.	O

Unexpectedly	O
,	O
this	O
indicated	O
that	O
Mot1p	B
mostly	O
plays	O
a	O
positive	O
role	O
for	O
transcription	O
.	O

For	O
one	O
potential	O
activation	O
target	O
,	O
HXT2	B
,	O
we	O
analyzed	O
promoter	O
recruitment	O
of	O
Mot1p	B
,	O
TBP	B
,	O
Taf1p	B
(	O
Taf130p	B
)	O
and	O
pol	B
II	I
by	O
chromatin	O
immunoprecipitation	O
assays	O
.	O

Whereas	O
TBP	B
becomes	O
stably	O
associated	O
upon	O
activation	O
of	O
the	O
HXT2	B
and	O
HXT4	B
promoters	O
,	O
Mot1p	B
showed	O
only	O
a	O
transient	O
association	O
.	O

TBP	B
recruitment	O
was	O
compromised	O
in	O
two	O
different	O
mot1	B
mutant	O
strains	O
,	O
but	O
was	O
only	O
moderately	O
affected	O
in	O
a	O
taf1	B
Ts	O
strain	O
.	O

Together	O
,	O
our	O
data	O
indicate	O
that	O
Mot1p	B
can	O
assist	O
in	O
recruitment	O
of	O
TBP	B
on	O
promoters	O
during	O
gene	O
activation	O
in	O
vivo	O
.	O

Vpr	B
-	O
and	O
Nef	B
-	O
dependent	O
induction	O
of	O
RANTES	B
/	O
CCL5	B
in	O
microglial	O
cells	O
.	O

Microglia	O
are	O
pivotal	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
dementia	O
,	O
as	O
they	O
serve	O
as	O
the	O
major	O
target	O
of	O
HIV	O
infection	O
in	O
the	O
CNS	O
.	O

In	O
addition	O
,	O
activation	O
of	O
microglia	O
correlates	O
best	O
with	O
clinical	O
dementia	O
.	O

Although	O
the	O
beta	B
-	I
chemokine	I
RANTES	B
/	O
CCL5	B
is	O
important	O
in	O
modulating	O
HIV	O
infection	O
as	O
well	O
as	O
cellular	O
activation	O
,	O
no	O
information	O
is	O
available	O
regarding	O
how	O
its	O
expression	O
is	O
regulated	O
in	O
microglia	O
by	O
HIV-1	O
.	O

Here	O
we	O
report	O
that	O
RANTES	B
/	O
CCL5	B
expression	O
is	O
induced	O
in	O
microglia	O
by	O
HIV-1	O
,	O
but	O
that	O
this	O
requires	O
infection	O
by	O
HIV-1	O
.	O

This	O
conclusion	O
was	O
supported	O
by	O
(	O
1	O
)	O
the	O
delayed	O
kinetics	O
coinciding	O
with	O
viral	O
replication	O
;	O
(	O
2	O
)	O
the	O
lack	O
of	O
effect	O
of	O
X4	O
viruses	O
;	O
(	O
3	O
)	O
inhibition	O
by	O
the	O
reverse	B
transcriptase	I
inhibitor	O
AZT	O
,	O
and	O
(	O
4	O
)	O
the	O
lack	O
of	O
effect	O
of	O
cytokine	B
antagonists	O
or	O
antibodies	O
.	O

Interestingly	O
,	O
RANTES	B
/	O
CCL5	B
production	O
was	O
dependent	O
on	O
the	O
viral	O
accessory	O
protein	O
Vpr	B
,	O
in	O
addition	O
to	O
Nef	B
,	O
demonstrating	O
a	O
novel	O
role	O
for	O
Vpr	B
in	O
chemokine	B
induction	O
in	O
primary	O
macrophage	O
-	O
type	O
cells	O
.	O

Furthermore	O
,	O
the	O
specific	O
p38	B
MAP	I
kinase	I
inhibitor	O
SB203580	O
augmented	O
chemokine	B
expression	O
in	O
microglia	O
,	O
indicating	O
a	O
negative	O
role	O
played	O
by	O
p38	B
.	O

These	O
data	O
suggest	O
unique	O
features	O
of	O
RANTES	B
/	O
CCL5	B
regulation	O
by	O
HIV-1	O
in	O
human	O
microglial	O
cells	O
.	O

[	O
The	O
role	O
of	O
lipid	O
metabolism	O
in	O
Alzheimer	O
's	O
disease	O
]	O

Lipid	O
metabolism	O
in	O
the	O
central	O
nervous	O
system	O
has	O
been	O
focused	O
as	O
an	O
important	O
factor	O
of	O
Alzheimer	O
's	O
disease	O
,	O
since	O
the	O
apolipoprotein	B
E	I
gene	O
was	O
discovered	O
as	O
a	O
genetic	O
risk	O
for	O
the	O
disease	O
.	O

Lipid	O
metabolism	O
in	O
the	O
brain	O
,	O
showing	O
relatively	O
closed	O
environment	O
,	O
necessitates	O
lipid	O
reutilization	O
.	O

Cerebrospinal	O
fluid	O
contains	O
only	O
high	B
-	I
density	I
lipoproteins	I
composed	O
of	O
apoE	B
and	O
apoJ	B
secreted	O
from	O
astrocytes	O
and	O
of	O
apoA	B
-	I
I	I
and	O
apoA	B
-	I
II	I
transported	O
via	O
the	O
blood	O
brain	O
barrier	O
.	O

These	O
apolipoproteins	B
can	O
bind	O
to	O
beta	O
amyloid	O
and	O
possibly	O
relate	O
to	O
its	O
clearance	O
.	O

The	O
aggregation	O
of	O
phosphorylated	O
tau	B
,	O
found	O
in	O
neurofibrillary	O
tangles	O
in	O
Alzheimer	O
's	O
brain	O
,	O
is	O
also	O
found	O
in	O
the	O
brain	O
with	O
Niemann	O
-	O
Pick	O
disease	O
,	O
suggesting	O
that	O
the	O
impairment	O
of	O
lipid	O
transport	O
in	O
neuronal	O
cells	O
participates	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Mitochondrial	O
function	O
,	O
lipid	O
production	O
,	O
and	O
acetylcholine	O
production	O
are	O
closely	O
related	O
,	O
and	O
these	O
alterations	O
could	O
be	O
involved	O
in	O
cholinergic	O
dysfunction	O
in	O
Alzheimer	O
's	O
disease	O
.	O

The	O
regulation	O
of	O
lipid	O
metabolism	O
in	O
and	O
outside	O
the	O
brain	O
could	O
be	O
a	O
therapeutic	O
and	O
preventive	O
target	O
for	O
Alzheimer	O
's	O
disease	O
.	O

Molecular	O
characterization	O
of	O
the	O
growth	O
phase	O
-	O
dependent	O
expression	O
of	O
the	O
lsrA	B
gene	O
,	O
encoding	O
levansucrase	B
of	O
Rahnella	O
aquatilis	O
.	O

Expression	O
of	O
the	O
lsrA	B
gene	O
from	O
Rahnella	O
aquatilis	O
,	O
encoding	O
levansucrase	B
,	O
is	O
tightly	O
regulated	O
by	O
the	O
growth	O
phase	O
of	O
the	O
host	O
cell	O
;	O
low	O
-	O
level	O
expression	O
was	O
observed	O
in	O
the	O
early	O
phase	O
of	O
cell	O
growth	O
,	O
but	O
expression	O
was	O
significantly	O
stimulated	O
in	O
the	O
late	O
phase	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
regulation	O
occurred	O
at	O
the	O
level	O
of	O
transcription	O
.	O

The	O
promoter	O
region	O
was	O
identified	O
by	O
primer	O
extension	O
analysis	O
.	O

Two	O
opposite	O
genetic	O
elements	O
that	O
participate	O
in	O
the	O
regulation	O
of	O
lsrA	B
expression	O
were	O
identified	O
upstream	O
of	O
the	O
lsrA	B
gene	O
:	O
the	O
lsrS	B
gene	O
and	O
the	O
lsrR	B
region	O
.	O

The	O
lsrS	B
gene	O
encodes	O
a	O
protein	O
consisting	O
of	O
70	O
amino	O
acid	O
residues	O
(	O
M	O
(	O
r	O
)	O
,	O
8,075	O
)	O
,	O
which	O
positively	O
activated	O
lsrA	B
expression	O
approximately	O
20	O
-	O
fold	O
in	O
a	O
growth	O
phase	O
-	O
dependent	O
fashion	O
.	O

The	O
cis	O
-	O
acting	O
lsrR	B
region	O
,	O
which	O
repressed	O
lsrA	B
expression	O
about	O
10	O
-	O
fold	O
,	O
was	O
further	O
narrowed	O
to	O
two	O
DNA	O
regions	O
by	O
deletion	O
analysis	O
.	O

The	O
concerted	O
action	O
of	O
two	O
opposite	O
regulatory	O
functions	O
resulted	O
in	O
the	O
growth	O
phase	O
-	O
dependent	O
activation	O
of	O
gene	O
expression	O
in	O
Escherichia	O
coli	O
independent	O
of	O
the	O
stationary	O
sigma	B
factor	I
sigma	B
(	I
S	I
)	I
.	O

Structural	O
and	O
functional	O
variation	O
within	O
the	O
alanine	O
-	O
rich	O
repetitive	O
domain	O
of	O
streptococcal	O
antigen	B
I	I
/	I
II	I
.	O

Members	O
of	O
the	O
antigen	B
I	I
/	I
II	I
family	I
of	O
cell	O
surface	O
proteins	O
are	O
highly	O
conserved	O
,	O
multifunctional	O
adhesins	B
that	O
mediate	O
interactions	O
of	O
oral	O
streptococci	O
with	O
other	O
oral	O
bacteria	O
,	O
with	O
cell	O
matrix	O
proteins	O
(	O
e.g.	O
,	O
type	B
I	I
collagen	I
)	O
,	O
and	O
with	O
salivary	O
glycoproteins	O
,	O
e.g.	O
,	O
gp340	B
.	O

The	O
interaction	O
of	O
gp340	B
(	O
formerly	O
designated	O
salivary	B
agglutinin	I
)	O
with	O
Streptococcus	O
mutans	O
requires	O
an	O
alanine	O
-	O
rich	O
repetitive	O
domain	O
(	O
A	O
region	O
)	O
of	O
antigen	B
I	I
/	I
II	I
that	O
is	O
highly	O
conserved	O
in	O
all	O
members	O
of	O
this	O
family	O
of	O
proteins	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
A	O
regions	O
from	O
the	O
two	O
Streptococcus	O
gordonii	O
M5	O
antigen	B
I	I
/	I
II	I
proteins	O
(	O
SspA	B
and	O
SspB	B
)	O
interact	O
differently	O
with	O
the	O
salivary	O
gp340	B
glycoprotein	O
and	O
appear	O
to	O
be	O
structurally	O
distinct	O
.	O

Recombinant	O
polypeptides	O
encompassing	O
the	O
A	O
region	O
of	O
SspA	B
or	O
from	O
a	O
highly	O
related	O
S.	O
mutans	O
antigen	B
I	I
/	I
II	I
protein	O
(	O
SpaP	B
)	O
competitively	O
inhibited	O
the	O
interaction	O
of	O
gp340	B
with	O
intact	O
S.	O
gordonii	O
and	O
S.	O
mutans	O
cells	O
,	O
respectively	O
.	O

In	O
contrast	O
,	O
an	O
A	O
region	O
polypeptide	O
from	O
SspB	B
was	O
inactive	O
,	O
and	O
furthermore	O
,	O
it	O
did	O
not	O
bind	O
to	O
purified	O
gp340	B
in	O
vitro	O
.	O

Circular	O
dichroism	O
spectra	O
suggested	O
that	O
all	O
three	O
polypeptides	O
were	O
highly	O
alpha	O
-	O
helical	O
and	O
may	O
form	O
coiled	O
-	O
coil	O
structures	O
.	O

However	O
,	O
the	O
A	O
region	O
of	O
SspB	B
underwent	O
a	O
conformational	O
change	O
and	O
exhibited	O
reduced	O
alpha	O
-	O
helical	O
structure	O
at	O
pH	O
8.5	O
,	O
whereas	O
the	O
A	O
region	O
polypeptides	O
from	O
SspA	B
and	O
SpaP	B
were	O
relatively	O
stable	O
under	O
these	O
conditions	O
.	O

Melt	O
curves	O
also	O
indicated	O
that	O
at	O
physiological	O
pH	O
,	O
the	O
A	O
region	O
of	O
SspB	B
lost	O
alpha	O
-	O
helical	O
structure	O
more	O
rapidly	O
than	O
that	O
of	O
SspA	B
or	O
SpaP	B
when	O
the	O
temperature	O
was	O
increased	O
from	O
10	O
to	O
40	O
degrees	O
C	O
.	O

Furthermore	O
,	O
the	O
SspB	B
A	O
region	O
polypeptide	O
denatured	O
completely	O
at	O
a	O
temperature	O
that	O
was	O
7	O
to	O
9	O
degrees	O
C	O
lower	O
than	O
that	O
required	O
for	O
the	O
A	O
region	O
polypeptide	O
of	O
SspA	B
or	O
SpaP	B
.	O

The	O
full	O
-	O
length	O
SspB	B
protein	O
and	O
the	O
three	O
A	O
region	O
peptides	O
migrated	O
in	O
native	O
gel	O
electrophoresis	O
and	O
column	O
chromatography	O
with	O
apparent	O
molecular	O
masses	O
that	O
were	O
approximately	O
2	O
-	O
to	O
2.5	O
-	O
fold	O
greater	O
than	O
their	O
predicted	O
molecular	O
masses	O
.	O

However	O
,	O
sedimentation	O
equilibrium	O
ultracentrifugation	O
data	O
showed	O
that	O
the	O
A	O
region	O
peptides	O
sedimented	O
as	O
monomers	O
,	O
suggesting	O
that	O
the	O
peptides	O
may	O
form	O
nonglobular	O
intramolecular	O
coiled	O
-	O
coil	O
structures	O
under	O
the	O
experimental	O
conditions	O
used	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
A	O
region	O
of	O
SspB	B
is	O
less	O
stable	O
than	O
the	O
corresponding	O
A	O
regions	O
of	O
SspA	B
and	O
SpaP	B
and	O
that	O
this	O
structural	O
difference	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
functional	O
variation	O
observed	O
in	O
their	O
interactions	O
with	O
salivary	O
gp340	B
.	O

Mast	O
cell	O
-	O
restricted	O
p70	O
Stat6	B
isoform	O
is	O
a	O
product	O
of	O
selective	O
proteolysis	O
.	O

Signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
Stat	I
)	I
-	I
6	I
is	O
the	O
principle	O
Stat	B
protein	O
activated	O
by	O
interleukin	B
(	I
IL	I
)	I
-	I
4	I
.	O

We	O
defined	O
a	O
role	O
for	O
IL-4	B
in	O
mast	O
cell	O
homeostasis	O
through	O
inhibiting	O
expression	O
of	O
Kit	B
and	O
F	B
(	I
c	I
)	I
epsilonRI	I
,	O
and	O
by	O
inducing	O
mast	O
cell	O
apoptosis	O
.	O

These	O
effects	O
required	O
Stat6	B
expression	O
.	O

A	O
molecular	O
mechanism	O
by	O
which	O
Stat6	B
directs	O
these	O
inhibitory	O
actions	O
in	O
BMMC	O
was	O
potentially	O
elucidated	O
by	O
the	O
discovery	O
of	O
a	O
carboxyl	O
-	O
truncated	O
Stat6	B
isoform	O
.	O

Expression	O
of	O
this	O
70kDa	O
isoform	O
was	O
unique	O
to	O
cultured	O
mast	O
cells	O
and	O
mast	O
cell	O
lines	O
.	O

Furthermore	O
,	O
this	O
isoform	O
lacked	O
a	O
carboxyl	O
-	O
transactivation	O
domain	O
,	O
suggesting	O
that	O
it	O
might	O
behave	O
as	O
a	O
dominant	O
negative	O
isoform	O
.	O

To	O
better	O
understand	O
this	O
truncated	O
Stat6	B
,	O
we	O
characterized	O
its	O
origins	O
.	O

Using	O
Western	O
blotting	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
,	O
we	O
assessed	O
BMMC	O
p70	O
Stat6	B
expression	O
using	O
standard	O
and	O
enhanced	O
protease	O
inhibitor	O
cocktails	O
.	O

These	O
experiments	O
demonstrated	O
that	O
p70	O
Stat6	B
is	O
derived	O
by	O
proteolysis	O
during	O
sample	O
preparation	O
,	O
and	O
has	O
no	O
cellular	O
correlate	O
.	O

While	O
some	O
Stat	B
family	I
members	O
are	O
known	O
to	O
exist	O
as	O
naturally	O
occurring	O
truncated	O
forms	O
,	O
p70	O
Stat6	B
does	O
not	O
appear	O
to	O
be	O
such	O
a	O
case	O
.	O

Instead	O
,	O
the	O
very	O
high	O
concentrations	O
of	O
proteases	B
released	O
during	O
mast	O
cell	O
lysis	O
result	O
in	O
selective	O
proteolysis	O
of	O
the	O
full	O
-	O
length	O
Stat6	B
,	O
with	O
p70	O
being	O
the	O
major	O
degradation	O
product	O
.	O

Apocytochrome	B
c	I
blocks	O
caspase-9	B
activation	O
and	O
Bax	B
-	O
induced	O
apoptosis	O
.	O

Complex	O
networks	O
of	O
signaling	O
pathways	O
control	O
the	O
apoptotic	O
response	O
and	O
,	O
therefore	O
,	O
cell	O
survival	O
.	O

However	O
,	O
these	O
networks	O
converge	O
on	O
a	O
common	O
machinery	O
,	O
of	O
which	O
the	O
caspase	B
cysteine	I
proteases	I
are	O
key	O
components	O
.	O

Diverse	O
apoptotic	O
stimuli	O
release	O
holocytochrome	B
c	I
from	O
mitochondria	O
,	O
allowing	O
holocytochrome	B
c	I
to	O
bind	O
apoptotic	B
protease	I
activating	I
factor-1	I
(	O
Apaf-1	B
)	O
,	O
which	O
in	O
turn	O
binds	O
caspase-9	B
both	O
activating	O
this	O
caspase	B
and	O
forming	O
an	O
Apaf-1	B
/	O
caspase-9	B
holoenzyme	O
.	O

Cytochrome	B
c	I
lacking	O
heme	O
(	O
the	O
apo	O
form	O
)	O
can	O
not	O
support	O
caspase	B
activation	O
,	O
although	O
the	O
reason	O
for	O
this	O
has	O
not	O
been	O
studied	O
.	O

Here	O
we	O
show	O
that	O
apocytochrome	B
c	I
still	O
binds	O
Apaf-1	B
and	O
that	O
it	O
can	O
block	O
holo	O
-	O
dependent	O
caspase	B
activation	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

In	O
addition	O
we	O
show	O
that	O
overexpression	O
of	O
apocytochrome	B
c	I
blocks	O
Bax	B
-	O
induced	O
apoptosis	O
in	O
cells	O
.	O

Thus	O
it	O
is	O
possible	O
to	O
modulate	O
cell	O
survival	O
by	O
interfering	O
with	O
the	O
Apaf-1	B
/	O
cytochrome	B
c	I
interaction	O
.	O

Given	O
the	O
key	O
role	O
played	O
by	O
Apaf-1	B
/	O
cytochrome	B
c	I
in	O
the	O
apoptotic	O
process	O
,	O
and	O
the	O
role	O
of	O
apoptosis	O
in	O
degenerative	O
disease	O
,	O
this	O
interaction	O
may	O
serve	O
as	O
a	O
novel	O
therapeutic	O
target	O
.	O

MdmX	B
is	O
a	O
RING	B
finger	I
ubiquitin	I
ligase	I
capable	O
of	O
synergistically	O
enhancing	O
Mdm2	B
ubiquitination	O
.	O

It	O
has	O
been	O
well	O
documented	O
that	O
Mdm2	B
and	O
its	O
homologue	O
MdmX	B
not	O
only	O
are	O
critical	O
negative	O
regulators	O
of	O
the	O
tumor	B
suppressor	I
p53	I
but	O
that	O
both	O
Mdm2	B
and	O
MdmX	B
interact	O
to	O
affect	O
the	O
function	O
of	O
the	O
other	O
.	O

The	O
mechanisms	O
through	O
which	O
these	O
effects	O
are	O
manifested	O
,	O
however	O
,	O
remain	O
unclear	O
.	O

Although	O
Mdm2	B
has	O
been	O
established	O
as	O
a	O
RING	B
finger	I
ubiquitin	I
ligase	I
,	O
MdmX	B
has	O
not	O
been	O
shown	O
to	O
possess	O
this	O
activity	O
despite	O
the	O
extensive	O
sequence	O
homology	O
between	O
their	O
respective	O
RING	O
finger	O
domains	O
.	O

Here	O
we	O
demonstrate	O
that	O
MdmX	B
acts	O
as	O
a	O
ubiquitin	B
ligase	I
in	O
vitro	O
,	O
being	O
capable	O
of	O
autoubiquitination	O
,	O
as	O
well	O
as	O
mediating	O
the	O
ubiquitination	O
of	O
p53	B
.	O

The	O
addition	O
of	O
Mdm2	B
to	O
in	O
vitro	O
ubiquitination	O
assays	O
containing	O
MdmX	B
results	O
in	O
a	O
synergistic	O
increase	O
of	O
ubiquitin	B
conjugation	O
.	O

Analysis	O
of	O
the	O
resulting	O
ubiquitin	B
conjugates	O
reveals	O
that	O
this	O
observed	O
synergy	O
reflects	O
an	O
increase	O
in	O
Mdm2	B
ubiquitination	O
.	O

This	O
study	O
also	O
suggests	O
that	O
ubiquitination	O
of	O
Mdm2	B
and	O
MdmX	B
may	O
not	O
serve	O
as	O
a	O
signal	O
for	O
degradation	O
,	O
as	O
we	O
show	O
that	O
each	O
are	O
capable	O
of	O
synthesizing	O
non	O
-	O
lysine	O
48	O
polyubiquitin	O
chains	O
and	O
,	O
in	O
fact	O
,	O
utilize	O
multiple	O
lysine	O
linkages	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
a	O
more	O
active	O
role	O
for	O
MdmX	B
in	O
the	O
Mdm2	B
-	O
MdmX	B
-	O
p53	B
regulatory	O
network	O
than	O
has	O
been	O
proposed	O
previously	O
.	O

Inhibition	O
of	O
Tat	B
-	O
mediated	O
transactivation	O
and	O
HIV-1	O
replication	O
by	O
human	O
anti	O
-	O
hCyclinT1	B
intrabodies	O
.	O

Human	O
immunodeficiency	O
virus	O
,	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
requires	O
the	O
interaction	O
of	O
Tat	B
protein	O
with	O
the	O
human	O
cyclinT1	B
(	O
hCyclinT1	B
)	O
subunit	O
of	O
the	O
positive	B
transcription	I
elongation	I
factor	I
(	I
P	I
-	I
TEFb	I
)	I
complex	I
,	O
which	O
then	O
cooperatively	O
binds	O
to	O
transactivation	O
response	O
element	O
(	O
TAR	O
)	O
RNA	O
to	O
transactivate	O
HIV	O
transcription	O
.	O

In	O
this	O
report	O
,	O
a	O
non	O
-	O
immune	O
human	O
single	O
-	O
chain	O
antibody	O
(	O
sFv	O
)	O
phage	O
display	O
library	O
was	O
used	O
to	O
isolate	O
anti	O
-	O
hCyclinT1	B
sFvs	O
that	O
could	O
disrupt	O
hCyclinT1	B
-	O
Tat	B
interactions	O
.	O

The	O
N	O
-	O
terminal	O
272	O
residues	O
of	O
hCyclinT1	B
,	O
including	O
the	O
entire	O
cyclin	B
domains	O
and	O
the	O
Tat	B
.	O
TAR	O
recognition	O
motif	O
(	O
TRM	O
)	O
,	O
that	O
fully	O
support	O
Tat	B
transactivation	O
was	O
used	O
for	O
panning	O
,	O
and	O
of	O
the	O
five	O
unique	O
anti	O
-	O
hCyclinT1	B
sFvs	O
that	O
were	O
obtained	O
,	O
three	O
bound	O
to	O
the	O
cyclin	B
box	O
domains	O
and	O
two	O
bound	O
to	O
TRM	O
.	O

All	O
sFvs	O
could	O
be	O
expressed	O
as	O
intrabodies	O
at	O
high	O
levels	O
in	O
transiently	O
transfected	O
293	O
T	O
and	O
in	O
stable	O
Jurkat	O
and	O
SupT1	O
transfectants	O
and	O
could	O
specifically	O
co	O
-	O
immunoprecipitate	O
co	O
-	O
expressed	O
hCyclinT1	B
in	O
293	O
T	O
cells	O
with	O
varying	O
efficacy	O
without	O
disrupting	O
hCyclinT1	B
-	O
Cdk9	B
interactions	O
.	O

In	O
addition	O
,	O
two	O
sFv	O
clones	O
(	O
3R6	O
-	O
1	O
and	O
2R6	O
-	O
21	O
)	O
that	O
mapped	O
to	O
the	O
cyclin	B
box	O
domains	O
markedly	O
inhibited	O
Tat	B
-	O
mediated	O
transactivation	O
in	O
several	O
transiently	O
transfected	O
cell	O
lines	O
without	O
inhibiting	O
basal	O
transcription	O
or	O
inducing	O
apoptosis	O
.	O

When	O
HIV-1	O
challenge	O
studies	O
were	O
performed	O
on	O
stable	O
3R6	O
-	O
1	O
-	O
expressing	O
Jurkat	O
T	O
cells	O
,	O
near	O
complete	O
inhibition	O
of	O
viral	O
replication	O
was	O
obtained	O
at	O
a	O
low	O
challenge	O
dose	O
,	O
and	O
74	O
-	O
88	O
%	O
inhibition	O
to	O
HIV-1	O
replication	O
was	O
achieved	O
at	O
a	O
high	O
infection	O
dose	O
in	O
SupT1	O
cells	O
.	O

These	O
results	O
provide	O
proof	O
-	O
in	O
-	O
principle	O
that	O
anti	O
-	O
hCyclinT1	B
intrabodies	O
can	O
be	O
designed	O
to	O
block	O
HIV-1	O
replication	O
without	O
causing	O
cellular	O
toxicity	O
,	O
and	O
as	O
a	O
result	O
,	O
they	O
may	O
be	O
useful	O
agents	O
for	O
""""	O
intracellular	O
immunization	O
""""	O
-	O
based	O
gene	O
therapy	O
strategies	O
for	O
HIV	O
-	O
1	O
infection	O
/	O
AIDS	O
.	O

Furin	B
gene	O
(	O
fur	B
)	O
regulation	O
in	O
differentiating	O
human	O
megakaryoblastic	O
Dami	O
cells	O
:	O
involvement	O
of	O
the	O
proximal	O
GATA	O
recognition	O
motif	O
in	O
the	O
P1	O
promoter	O
and	O
impact	O
on	O
the	O
maturation	O
of	O
furin	B
substrates	O
.	O

The	O
convertase	O
furin	B
is	O
involved	O
in	O
the	O
maturation	O
of	O
key	O
growth	O
/	O
aggregation	O
mediators	O
synthesized	O
by	O
the	O
platelet	O
producers	O
,	O
megakaryocytes	O
,	O
but	O
the	O
regulation	O
of	O
furin	B
in	O
these	O
cells	O
remains	O
unknown	O
.	O

Computer	O
-	O
assisted	O
search	O
of	O
the	O
furin	B
promoter	O
sequence	O
revealed	O
multiple	O
potential	O
binding	O
motifs	O
for	O
GATA-1	O
,	O
suggesting	O
that	O
furin	B
is	O
expressed	O
and	O
regulated	O
in	O
these	O
cells	O
.	O

Using	O
megakaryoblastic	O
Dami	O
cells	O
,	O
we	O
observed	O
that	O
fur	O
mRNA	O
expression	O
increased	O
gradually	O
on	O
phorbol	O
12-myristate	O
13-acetate	O
-	O
induced	O
differentiation	O
,	O
reaching	O
maximum	O
levels	O
(	O
8.3	O
-	O
fold	O
increase	O
)	O
at	O
10	O
days	O
.	O

Transient	O
transfections	O
with	O
P1	O
,	O
P1A	O
,	O
or	O
P1B	O
fur	B
-	O
LUC	O
-	O
promoter	O
constructs	O
revealed	O
that	O
in	O
Dami	O
cells	O
,	O
the	O
P1	O
promoter	O
is	O
the	O
strongest	O
and	O
the	O
most	O
sensitive	O
to	O
forced	O
expression	O
of	O
GATA-1	B
.	O

Coexpression	O
of	O
GATA-1	B
and	O
its	O
comodulator	O
,	O
Friend	B
of	I
GATA-1	I
(	O
FOG-1	B
)	O
,	O
resulted	O
in	O
a	O
cooperative	O
increase	O
in	O
P1	O
activity	O
.	O

Deletion	O
analysis	O
indicated	O
that	O
important	O
GATA-1	B
-	O
regulated	O
sequences	O
are	O
located	O
in	O
the	O
most	O
proximal	O
region	O
of	O
the	O
P1	O
promoter	O
.	O

Further	O
analysis	O
revealed	O
2	O
potential	O
GATA	O
-	O
binding	O
motifs	O
at	O
positions	O
-	O
66	O
and	O
+	O
62	O
.	O

Point	O
mutation	O
of	O
each	O
of	O
the	O
2	O
motifs	O
indicated	O
that	O
the	O
intactness	O
of	O
the	O
first	O
GATA	O
site	O
is	O
required	O
for	O
full	O
basal	O
and	O
GATA-1	B
-	O
stimulated	O
promoter	O
activity	O
.	O

Finally	O
,	O
the	O
inhibition	O
of	O
furin	B
activity	O
through	O
gene	O
transfer	O
of	O
the	O
inhibitor	O
alpha1-AT	O
-	O
PDX	O
led	O
to	O
a	O
block	O
in	O
maturation	O
of	O
the	O
furin	B
substrates	O
transforming	B
growth	I
factor	I
-	I
beta1	I
and	O
platelet	B
-	I
derived	I
growth	I
factor	I
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
the	O
most	O
proximal	O
GATA	O
element	O
in	O
the	O
P1	O
promoter	O
is	O
needed	O
for	O
fur	B
gene	O
expression	O
in	O
megakaryoblastic	O
cells	O
.	O

They	O
also	O
suggest	O
that	O
proper	O
regulation	O
of	O
the	O
fur	B
gene	O
in	O
megakaryocytes	O
has	O
an	O
impact	O
on	O
the	O
activation	O
of	O
furin	B
substrates	O
involved	O
in	O
megakaryocyte	O
maturation	O
and	O
platelet	O
functions	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
novel	O
human	O
sphingosine-1-phosphate	B
phosphohydrolase	I
,	O
hSPP2	B
.	O

Sphingosine	O
1-phosphate	O
(	O
S1P	O
)	O
is	O
a	O
bioactive	O
lipid	O
molecule	O
that	O
acts	O
as	O
both	O
an	O
extracellular	O
signaling	O
mediator	O
and	O
an	O
intracellular	O
second	O
messenger	O
.	O

S1P	O
is	O
synthesized	O
from	O
sphingosine	O
by	O
sphingosine	B
kinase	I
and	O
is	O
degraded	O
either	O
by	O
S1P	B
lyase	I
or	O
by	O
S1P	B
phosphohydrolase	I
.	O

Recently	O
,	O
mammalian	O
S1P	B
phosphohydrolase	I
(	O
SPP1	B
)	O
was	O
identified	O
and	O
shown	O
to	O
constitute	O
a	O
novel	O
lipid	B
phosphohydrolase	I
family	I
,	O
the	O
SPP	B
family	I
.	O

In	O
this	O
study	O
we	O
have	O
identified	O
a	O
second	O
human	O
S1P	B
phosphohydrolase	I
,	O
SPP2	B
,	O
based	O
on	O
sequence	O
homology	O
to	O
human	O
SPP1	B
.	O

SPP2	B
exhibited	O
high	O
phosphohydrolase	B
activity	O
against	O
S1P	O
and	O
dihydrosphingosine	O
1-phosphate	O
.	O

The	O
dihydrosphingosine-1-phosphate	B
phosphohydrolase	I
activity	O
was	O
efficiently	O
inhibited	O
by	O
excess	O
S1P	O
but	O
not	O
by	O
lysophosphatidic	O
acid	O
,	O
phosphatidic	O
acid	O
,	O
or	O
glycerol	O
3-phosphate	O
,	O
indicating	O
that	O
SPP2	B
is	O
highly	O
specific	O
to	O
sphingoid	O
base	O
1	O
-	O
phosphates	O
.	O

Immunofluorescence	O
microscopic	O
analysis	O
demonstrated	O
that	O
SPP2	B
is	O
localized	O
to	O
the	O
endoplasmic	O
reticulum	O
.	O

Although	O
the	O
enzymatic	O
properties	O
and	O
localization	O
of	O
SPP2	B
were	O
similar	O
to	O
those	O
of	O
SPP1	B
,	O
the	O
tissue	O
-	O
specific	O
expression	O
pattern	O
of	O
SPP2	B
was	O
different	O
from	O
that	O
of	O
SPP1	B
.	O

Thus	O
,	O
SPP2	B
is	O
another	O
member	O
of	O
the	O
SPP	B
family	I
that	O
may	O
play	O
a	O
role	O
in	O
attenuating	O
intracellular	O
S1P	O
signaling	O
.	O

Regulation	O
of	O
the	O
hydrogenase-4	B
operon	I
of	O
Escherichia	O
coli	O
by	O
the	O
sigma	B
(	I
54	I
)	I
-	O
dependent	O
transcriptional	O
activators	O
FhlA	B
and	O
HyfR	B
.	O

The	O
hyf	B
locus	O
(	O
hyfABCDEFGHIJ	B
-	O
hyfR	B
-	O
focB	B
)	O
of	O
Escherichia	O
coli	O
encodes	O
a	O
putative	O
10	O
-	O
subunit	O
hydrogenase	B
complex	O
(	O
hydrogenase	B
-	I
4	I
[	O
Hyf	B
]	O
)	O
;	O
a	O
potential	O
sigma	B
(	I
54	I
)	I
-	O
dependent	O
transcriptional	O
activator	O
,	O
HyfR	B
(	O
related	O
to	O
FhlA	B
)	O
;	O
and	O
a	O
putative	O
formate	B
transporter	I
,	O
FocB	B
(	O
related	O
to	O
FocA	B
)	O
.	O

In	O
order	O
to	O
gain	O
insight	O
into	O
the	O
physiological	O
role	O
of	O
the	O
Hyf	B
system	O
,	O
we	O
investigated	O
hyf	B
expression	O
by	O
using	O
a	O
hyfA	B
-	O
lacZ	B
transcriptional	O
fusion	O
.	O

This	O
work	O
revealed	O
that	O
hyf	B
is	O
induced	O
under	O
fermentative	O
conditions	O
by	O
formate	O
at	O
a	O
low	O
pH	O
and	O
in	O
an	O
FhlA	B
-	O
dependent	O
fashion	O
.	O

Expression	O
was	O
sigma	B
(	I
54	I
)	I
dependent	O
and	O
was	O
inhibited	O
by	O
HycA	B
,	O
the	O
negative	O
transcriptional	O
regulator	O
of	O
the	O
formate	O
regulon	O
.	O

Thus	O
,	O
hyf	B
expression	O
resembles	O
that	O
of	O
the	O
hyc	B
operon	I
.	O

Primer	O
extension	O
analysis	O
identified	O
a	O
transcriptional	O
start	O
site	O
30	O
bp	O
upstream	O
of	O
the	O
hyfA	B
structural	O
gene	O
,	O
with	O
appropriately	O
located	O
-	O
24	O
and	O
-	O
12	O
boxes	O
indicative	O
of	O
a	O
sigma	B
(	I
54	I
)	I
-	O
dependent	O
promoter	O
.	O

No	O
reverse	O
transcriptase	O
PCR	O
product	O
could	O
be	O
detected	O
for	O
hyfJ	B
-	O
hyfR	B
,	O
suggesting	O
that	O
hyfR	B
-	O
focB	B
may	O
be	O
independently	O
transcribed	O
from	O
the	O
rest	O
of	O
the	O
hyf	B
operon	I
.	O

Expression	O
of	O
hyf	B
was	O
strongly	O
induced	O
(	O
approximately	O
1,000-fold	O
)	O
in	O
the	O
presence	O
of	O
a	O
multicopy	O
plasmid	O
expressing	O
hyfR	B
from	O
a	O
heterologous	O
promoter	O
.	O

This	O
induction	O
was	O
dependent	O
on	O
low	O
pH	O
,	O
anaerobiosis	O
,	O
and	O
postexponential	O
growth	O
and	O
was	O
weakly	O
enhanced	O
by	O
formate	O
.	O

The	O
hyfR	B
-	O
expressing	O
plasmid	O
increased	O
fdhF	B
-	O
lacZ	B
transcription	O
just	O
twofold	O
but	O
did	O
not	O
influence	O
the	O
expression	O
of	O
hycB	B
-	O
lacZ	B
.	O

Interestingly	O
,	O
inactivation	O
of	O
the	O
chromosomal	O
hyfR	B
gene	O
had	O
no	O
effect	O
on	O
hyfA	B
-	O
lacZ	B
expression	O
.	O

Purified	O
HyfR	B
was	O
found	O
to	O
specifically	O
interact	O
with	O
the	O
hyf	B
promoter	O
/	O
operator	O
region	O
.	O

Inactivation	O
of	O
the	O
hyf	B
operon	I
had	O
no	O
discernible	O
effect	O
on	O
growth	O
under	O
the	O
range	O
of	O
conditions	O
tested	O
.	O

No	O
Hyf	B
-	O
derived	O
hydrogenase	B
or	O
formate	B
dehydrogenase	I
activity	O
could	O
be	O
detected	O
,	O
and	O
no	O
Ni	O
-	O
containing	O
protein	O
corresponding	O
to	O
HyfG	B
was	O
observed	O
.	O

Quantitative	O
analysis	O
of	O
human	O
kallikrein	B
gene	I
14	I
expression	O
in	O
breast	O
tumours	O
indicates	O
association	O
with	O
poor	O
prognosis	O
.	O

KLK14	B
(	O
formerly	O
known	O
as	O
KLK	B
-	I
L6	I
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
human	O
kallikrein	B
gene	I
family	I
.	O

This	O
family	O
harbours	O
several	O
genes	O
aberrantly	O
expressed	O
in	O
various	O
cancers	O
as	O
well	O
as	O
established	O
(	O
PSA	B
/	O
hK3	B
,	O
hK2	B
)	O
and	O
potential	O
(	O
hK6	B
,	O
hK10	B
)	O
cancer	O
markers	O
.	O

Similar	O
to	O
other	O
kallikrein	B
genes	O
,	O
KLK14	B
was	O
found	O
to	O
be	O
regulated	O
by	O
steroid	O
hormones	O
,	O
particularly	O
androgens	O
and	O
progestins	O
,	O
in	O
breast	O
and	O
ovarian	O
cancer	O
cell	O
lines	O
.	O

Preliminary	O
studies	O
indicated	O
that	O
KLK14	B
is	O
differentially	O
expressed	O
in	O
breast	O
,	O
ovarian	O
,	O
prostatic	O
and	O
testicular	O
tumours	O
.	O

Given	O
the	O
above	O
,	O
we	O
determined	O
the	O
prognostic	O
significance	O
of	O
KLK14	B
expression	O
in	O
breast	O
cancer	O
.	O

We	O
studied	O
KLK14	B
expression	O
in	O
178	O
histologically	O
confirmed	O
epithelial	O
breast	O
carcinomas	O
by	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
correlated	O
with	O
clinicopathological	O
variables	O
(	O
tumour	O
stage	O
,	O
grade	O
,	O
histotype	O
etc	O
.	O
)	O
and	O
with	O
outcome	O
(	O
disease	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
)	O
,	O
monitored	O
over	O
a	O
median	O
of	O
76	O
months	O
.	O

KLK14	B
mRNA	O
levels	O
ranged	O
from	O
0	O
to	O
1	O
,	O
219	O
arbitrary	O
units	O
in	O
breast	O
cancer	O
tissues	O
,	O
with	O
a	O
mean	O
+	O
/-	O
s.e	O
.	O
of	O
136	O
+	O
/	O
-	O
22	O
.	O

An	O
optimal	O
cutoff	O
value	O
of	O
40.5	O
arbitrary	O
units	O
was	O
selected	O
,	O
to	O
categorise	O
tumours	O
as	O
KLK14	B
-	O
positive	O
or	O
negative	O
.	O

Higher	O
concentrations	O
of	O
KLK14	B
mRNA	O
were	O
more	O
frequently	O
found	O
in	O
patients	O
with	O
advanced	O
stage	O
(	O
III	O
)	O
disease	O
(	O
P	O
=	O
0.032	O
)	O
.	O

No	O
statistically	O
significant	O
association	O
was	O
found	O
between	O
KLK14	B
and	O
the	O
other	O
clinicopathological	O
variables	O
.	O

KLK14	B
overexpression	O
was	O
found	O
to	O
be	O
a	O
significant	O
predictor	O
of	O
decreased	O
disease	O
-	O
free	O
survival	O
(	O
hazard	O
ratio	O
of	O
2.31	O
,	O
P	O
=	O
0.001	O
)	O
and	O
overall	O
survival	O
(	O
hazard	O
ratio	O
of	O
2.21	O
,	O
P	O
=	O
0.005	O
)	O
.	O

Cox	O
multivariate	O
analysis	O
indicated	O
that	O
KLK14	B
was	O
an	O
independent	O
prognostic	O
indicator	O
of	O
disease	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
.	O

KLK14	B
also	O
has	O
independent	O
prognostic	O
value	O
in	O
subgroups	O
of	O
patients	O
with	O
a	O
tumour	O
size	O
<	O
/	O
=	O
2	O
cm	O
and	O
positive	O
nodal	O
,	O
oestrogen	B
receptor	I
and	O
progestin	B
receptor	I
status	O
.	O

We	O
conclude	O
that	O
KLK14	B
expression	O
,	O
as	O
assessed	O
by	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
,	O
is	O
an	O
independent	O
marker	O
of	O
unfavourable	O
prognosis	O
for	O
breast	O
cancer	O
.	O

Effects	O
of	O
dehydration	O
on	O
endocrine	O
regulation	O
of	O
the	O
electrolyte	O
and	O
fluid	O
balance	O
and	O
atrial	B
natriuretic	I
peptide	I
-	O
binding	O
sites	O
in	O
perinatally	O
malnourished	O
adult	O
male	O
rats	O
.	O

OBJECTIVE	O
:	O

The	O
first	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
,	O
under	O
basal	O
conditions	O
in	O
adult	O
male	O
rats	O
,	O
the	O
long	O
-	O
term	O
consequences	O
of	O
perinatal	O
maternal	O
food	O
restriction	O
on	O
the	O
plasma	O
concentrations	O
of	O
vasopressin	B
(	O
VP	B
)	O
,	O
aldosterone	O
and	O
atrial	B
natriuretic	I
peptide	I
(	O
ANP	B
)	O
and	O
on	O
plasma	O
renin	B
activity	O
(	O
PRA	O
)	O
.	O

Furthermore	O
,	O
under	O
these	O
same	O
conditions	O
,	O
the	O
hypothalamic	O
VP	B
gene	O
expression	O
as	O
well	O
as	O
the	O
density	O
(	O
B	O
(	O
max	O
)	O
)	O
,	O
affinity	O
(	O
K	O
(	O
d	O
)	O
)	O
and	O
gene	O
expression	O
of	O
ANP	B
receptors	I
were	O
determined	O
in	O
kidneys	O
and	O
adrenals	O
.	O

The	O
second	O
aim	O
of	O
this	O
work	O
was	O
to	O
examine	O
the	O
responsiveness	O
to	O
dehydration	O
in	O
perinatally	O
malnourished	O
rats	O
.	O

Thus	O
,	O
the	O
latter	O
parameters	O
were	O
studied	O
in	O
these	O
rats	O
after	O
72	O
h	O
water	O
deprivation	O
.	O

METHODS	O
:	O

This	O
study	O
was	O
conducted	O
on	O
4	O
-	O
Month	O
-	O
old	O
male	O
rats	O
from	O
mothers	O
exposed	O
to	O
50	O
%	O
food	O
restriction	O
(	O
FR50	O
)	O
during	O
the	O
last	O
week	O
of	O
gestation	O
and	O
lactation	O
and	O
on	O
age	O
-	O
matched	O
control	O
animals	O
(	O
C	O
)	O
.	O

At	O
this	O
stage	O
,	O
both	O
C	O
and	O
FR50	O
rats	O
were	O
killed	O
by	O
decapitation	O
between	O
0900	O
h	O
and	O
1000	O
h	O
in	O
order	O
to	O
determine	O
parameters	O
under	O
basal	O
conditions	O
or	O
after	O
72	O
h	O
water	O
deprivation	O
.	O

Plasma	O
VP	B
,	O
ANP	B
and	O
aldosterone	O
levels	O
and	O
PRA	O
were	O
determined	O
by	O
radioimmunoassay	O
.	O

Hypothalamic	O
VP	B
gene	O
expression	O
was	O
determined	O
in	O
the	O
paraventricular	O
nucleus	O
(	O
PVN	O
)	O
and	O
supraoptic	O
nucleus	O
(	O
SON	O
)	O
by	O
in	O
situ	O
hybridization	O
.	O

The	O
B	O
(	O
max	O
)	O
and	O
K	O
(	O
d	O
)	O
values	O
of	O
ANP	B
receptors	I
were	O
evaluated	O
from	O
Scatchard	O
plots	O
.	O

ANP	B
receptor	I
gene	O
expression	O
was	O
determined	O
by	O
Northern	O
blot	O
analysis	O
.	O

RESULTS	O
:	O

Under	O
basal	O
conditions	O
,	O
perinatal	O
malnutrition	O
reduced	O
body	O
weight	O
,	O
absolute	O
weight	O
of	O
kidneys	O
and	O
adrenals	O
,	O
and	O
haematocrit	O
.	O

Compared	O
with	O
control	O
rats	O
,	O
FR50	O
rats	O
had	O
significantly	O
greater	O
plasma	O
VP	B
and	O
aldosterone	O
levels	O
but	O
PRA	O
,	O
plasma	O
ANP	B
levels	O
,	O
plasma	O
osmolality	O
and	O
hypothalamic	O
VP	B
gene	O
expression	O
were	O
not	O
significantly	O
different	O
.	O

Perinatal	O
malnutrition	O
did	O
not	O
significantly	O
affect	O
glomerular	O
ANP	B
receptor	I
density	O
,	O
but	O
in	O
adrenals	O
it	O
decreased	O
both	O
B	O
(	O
max	O
)	O
and	O
K	O
(	O
d	O
)	O
values	O
of	O
ANP	B
-	I
B	I
receptors	I
(	O
biological	O
receptors	O
)	O
and	O
increased	O
B	O
(	O
max	O
)	O
of	O
ANP	B
-	I
C	I
receptors	I
(	O
clearance	O
receptors	O
)	O
.	O

ANP	B
-	I
B	I
(	I
A	I
)	I
(	I
receptor	I
subtype	I
A	I
of	I
ANP	I
-	I
B	I
receptors	I
)	I
receptor	I
gene	O
expression	O
was	O
not	O
significantly	O
affected	O
,	O
whereas	O
ANP	B
-	I
C	I
receptor	I
gene	O
expression	O
was	O
enhanced	O
in	O
both	O
adrenals	O
and	O
kidneys	O
in	O
FR50	O
rats	O
.	O

After	O
72	O
h	O
dehydration	O
,	O
control	O
rats	O
showed	O
a	O
significant	O
rise	O
in	O
haematocrit	O
,	O
plasma	O
osmolality	O
,	O
PRA	O
,	O
circulating	O
levels	O
of	O
VP	B
and	O
aldosterone	O
and	O
VP	B
gene	O
expression	O
in	O
both	O
PVN	O
and	O
SON	O
but	O
showed	O
a	O
decrease	O
in	O
plasma	O
ANP	B
levels	O
.	O

B	O
(	O
max	O
)	O
of	O
ANP	B
-	I
B	I
receptors	I
was	O
decreased	O
whereas	O
B	O
(	O
max	O
)	O
of	O
ANP	B
-	I
C	I
receptors	I
was	O
enhanced	O
in	O
both	O
adrenals	O
and	O
kidneys	O
.	O

ANP	B
-	I
B	I
(	I
A	I
)	I
receptor	I
gene	O
expression	O
was	O
not	O
significantly	O
affected	O
in	O
either	O
kidneys	O
or	O
adrenals	O
in	O
dehydrated	O
control	O
rats	O
.	O

Similarly	O
,	O
ANP	B
-	I
C	I
receptor	I
gene	O
expression	O
was	O
unaffected	O
in	O
kidneys	O
whereas	O
it	O
was	O
significantly	O
enhanced	O
in	O
adrenals	O
.	O

In	O
FR50	O
rats	O
,	O
the	O
effects	O
of	O
water	O
deprivation	O
were	O
qualitatively	O
similar	O
to	O
those	O
reported	O
in	O
controls	O
concerning	O
plasma	O
parameters	O
except	O
for	O
plasma	O
VP	B
levels	O
which	O
tended	O
to	O
rise	O
(	O
not	O
significant	O
)	O
but	O
this	O
increase	O
was	O
only	O
very	O
slight	O
compared	O
with	O
controls	O
.	O

Moreover	O
,	O
unlike	O
controls	O
,	O
VP	B
gene	O
expression	O
in	O
both	O
PVN	O
and	O
SON	O
was	O
not	O
enhanced	O
after	O
dehydration	O
in	O
FR50	O
rats	O
.	O

In	O
kidneys	O
,	O
dehydrated	O
FR50	O
rats	O
,	O
like	O
controls	O
,	O
upregulated	O
ANP	B
-	I
C	I
receptors	I
,	O
but	O
they	O
were	O
unable	O
to	O
downregulate	O
ANP	B
-	I
B	I
receptors	I
.	O

In	O
adrenals	O
,	O
unlike	O
controls	O
,	O
FR50	O
rats	O
enhanced	O
ANP	B
-	I
B	I
receptor	I
density	O
whereas	O
they	O
decreased	O
both	O
ANP	B
-	I
C	I
receptor	I
density	O
and	O
expression	O
after	O
72	O
h	O
dehydration	O
.	O

Similar	O
to	O
controls	O
,	O
the	O
expression	O
of	O
ANP	B
-	I
B	I
(	I
A	I
)	I
receptors	I
in	O
both	O
kidneys	O
and	O
adrenals	O
as	O
well	O
as	O
the	O
expression	O
of	O
ANP	B
-	I
C	I
receptors	I
in	O
kidneys	O
,	O
were	O
unaffected	O
in	O
dehydrated	O
FR50	O
rats	O
.	O

CONCLUSION	O
:	O

Perinatal	O
malnutrition	O
had	O
long	O
-	O
lasting	O
effects	O
on	O
regulation	O
of	O
the	O
fluid	O
and	O
electrolyte	O
balance	O
under	O
basal	O
conditions	O
.	O

The	O
main	O
effects	O
were	O
a	O
significant	O
rise	O
in	O
circulating	O
levels	O
of	O
VP	B
and	O
aldosterone	O
,	O
and	O
changes	O
in	O
density	O
of	O
adrenal	O
ANP	B
-	O
binding	O
sites	O
and	O
ANP	B
-	I
C	I
receptor	I
gene	O
expression	O
in	O
both	O
adrenals	O
and	O
kidneys	O
.	O

Perinatal	O
malnutrition	O
also	O
affects	O
the	O
responsiveness	O
to	O
water	O
deprivation	O
with	O
alterations	O
in	O
both	O
hypothalamic	O
VP	B
gene	O
expression	O
and	O
regulation	O
of	O
ANP	B
-	O
binding	O
sites	O
.	O

Hodgkin	O
's	O
lymphoma	O
cell	O
lines	O
are	O
characterized	O
by	O
frequent	O
aberrations	O
on	O
chromosomes	O
2p	O
and	O
9p	O
including	O
REL	B
and	O
JAK2	B
.	O

Four	O
Hodgkin	O
's	O
lymphoma	O
cell	O
lines	O
(	O
KM	O
-	O
H2	O
,	O
HDLM-2	O
,	O
L428	O
,	O
L1236	O
)	O
were	O
analyzed	O
for	O
cytogenetic	O
aberrations	O
,	O
applying	O
multiplex	O
fluorescence	O
in	O
situ	O
hybridization	O
,	O
chromosome	O
banding	O
and	O
comparative	O
genomic	O
hybridization	O
.	O

Each	O
line	O
was	O
characterized	O
by	O
a	O
highly	O
heterogeneous	O
pattern	O
of	O
karyotypic	O
changes	O
with	O
a	O
large	O
spectrum	O
of	O
different	O
translocated	O
chromosomes	O
(	O
range	O
22	O
-	O
57	O
)	O
.	O

A	O
recurrent	O
finding	O
in	O
all	O
cell	O
lines	O
was	O
the	O
presence	O
of	O
chromosomal	O
rearrangements	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
2	O
involving	O
the	O
REL	B
oncogene	O
locus	O
.	O

Furthermore	O
,	O
multiple	O
translocated	O
copies	O
of	O
telomeric	O
chromosomal	O
segments	O
were	O
frequently	O
detected	O
.	O

This	O
resulted	O
in	O
a	O
copy	O
number	O
increase	O
of	O
putative	O
oncogenes	O
,	O
e.g.	O
,	O
JAK2	B
(	O
9p24	O
)	O
in	O
3	O
cell	O
lines	O
,	O
FGFR3	B
(	O
4p16	O
)	O
and	O
CCND2	B
(	O
12p13	O
)	O
in	O
2	O
cell	O
lines	O
as	O
well	O
as	O
MYC	B
(	O
8q24	O
)	O
in	O
1	O
cell	O
line	O
.	O

Our	O
data	O
confirm	O
previous	O
cytogenetic	O
results	O
from	O
primary	O
Hodgkin	O
's	O
tumors	O
suggesting	O
an	O
important	O
pathogenic	O
role	O
of	O
REL	B
and	O
JAK2	B
in	O
this	O
disease	O
.	O

In	O
addition	O
,	O
they	O
provide	O
evidence	O
for	O
a	O
novel	O
cytogenetic	O
pathomechanism	O
leading	O
to	O
increased	O
copy	O
numbers	O
of	O
putative	O
oncogenes	O
from	O
terminal	O
chromosomal	O
regions	O
,	O
most	O
probably	O
in	O
the	O
course	O
of	O
chromosomal	O
stabilization	O
by	O
telomeric	O
capture	O
.	O

Two	O
different	O
modes	O
of	O
transcription	O
repression	O
of	O
the	O
Escherichia	O
coli	O
acetate	B
operon	I
by	O
IclR	B
.	O

IclR	B
is	O
a	O
repressor	O
for	O
the	O
Escherichia	O
coli	O
aceBAK	B
operon	I
,	O
which	O
encodes	O
isocitrate	B
lyase	I
(	O
aceB	B
)	O
,	O
malate	B
synthase	I
(	O
aceA	B
)	O
and	O
isocitrate	B
dehydroge	I
-	I
nase	I
kinase	I
/	I
phosphorylase	I
(	O
aceK	B
)	O
in	O
the	O
glyoxylate	O
bypass	O
.	O

IclR	B
also	O
represses	O
the	O
expression	O
of	O
iclR	B
in	O
an	O
autogenous	O
manner	O
.	O

DNase	B
I	I
footprinting	O
and	O
in	O
vitro	O
transcription	O
assays	O
indicated	O
that	O
IclR	B
binds	O
to	O
an	O
IclR	B
box	O
(	O
-	O
21	O
to	O
+	O
14	O
)	O
,	O
which	O
overlaps	O
the	O
iclR	B
promoter	O
and	O
thus	O
competes	O
with	O
the	O
RNA	B
polymerase	I
for	O
DNA	O
binding	O
,	O
leading	O
to	O
transcription	O
repression	O
.	O

In	O
the	O
case	O
of	O
the	O
aceBAK	B
operon	I
,	O
IclR	B
binds	O
to	O
IclR	B
box	O
II	O
between	O
-	O
52	O
and	O
-	O
19	O
of	O
the	O
aceB	B
promoter	O
and	O
interferes	O
with	O
binding	O
of	O
the	O
RNA	B
polymerase	I
to	O
this	O
promoter	O
.	O

A	O
secondary	O
IclR	B
binding	O
site	O
(	O
IclR	B
box	O
I	O
)	O
was	O
identified	O
between	O
-	O
125	O
and	O
-	O
99	O
of	O
the	O
aceB	B
promoter	O
.	O

IclR	B
binds	O
to	O
this	O
IclR	B
box	O
I	O
even	O
after	O
formation	O
of	O
the	O
aceB	B
promoter	O
open	O
complex	O
and	O
,	O
moreover	O
,	O
induces	O
disassembly	O
of	O
the	O
open	O
complex	O
,	O
leading	O
to	O
repression	O
of	O
aceB	B
transcription	O
.	O

In	O
parallel	O
,	O
the	O
location	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
RNA	B
polymerase	I
alpha	I
subunit	I
(	O
alphaCTD	O
)	O
on	O
DNA	O
is	O
shifted	O
close	O
to	O
the	O
IclR	B
box	O
I	O
,	O
indicating	O
that	O
direct	O
interaction	O
between	O
the	O
alphaCTD	O
and	O
the	O
IclR	B
box	O
I	O
-	O
associated	O
IclR	B
caused	O
the	O
repression	O
.	O

Transcriptional	O
repressor	O
germ	B
cell	I
-	I
less	I
(	O
GCL	B
)	O
and	O
barrier	B
to	I
autointegration	I
factor	I
(	O
BAF	B
)	O
compete	O
for	O
binding	O
to	O
emerin	B
in	O
vitro	O
.	O

Emerin	B
belongs	O
to	O
the	O
""""	O
LEM	O
domain	O
""""	O
family	O
of	O
nuclear	O
proteins	O
,	O
which	O
contain	O
a	O
characteristic	O
approximately	O
40	O
-	O
residue	O
LEM	O
motif	O
.	O

The	O
LEM	O
domain	O
mediates	O
direct	O
binding	O
to	O
barrier	B
to	I
autointegration	I
factor	I
(	O
BAF	B
)	O
,	O
a	O
conserved	O
10	O
-	O
kDa	O
chromatin	O
protein	O
essential	O
for	O
embryogenesis	O
in	O
Caenorhabditis	O
elegans	O
.	O

In	O
mammalian	O
cells	O
,	O
BAF	B
recruits	O
emerin	B
to	O
chromatin	O
during	O
nuclear	O
assembly	O
.	O

BAF	B
also	O
mediates	O
chromatin	O
decondensation	O
during	O
nuclear	O
assembly	O
.	O

The	O
LEM	O
domain	O
and	O
central	O
region	O
of	O
emerin	B
are	O
essential	O
for	O
binding	O
to	O
BAF	B
and	O
lamin	B
A	I
,	O
respectively	O
.	O

However	O
,	O
two	O
other	O
conserved	O
regions	O
of	O
emerin	B
lacked	O
ascribed	O
functions	O
,	O
suggesting	O
that	O
emerin	B
could	O
have	O
additional	O
partners	O
.	O

We	O
discovered	O
that	O
these	O
""""	O
unascribed	O
""""	O
domains	O
of	O
emerin	B
mediate	O
direct	O
binding	O
to	O
a	O
transcriptional	O
repressor	O
,	O
germ	B
cell	I
-	I
less	I
(	O
GCL	B
)	O
.	O

GCL	B
co	O
-	O
immunoprecipitates	O
with	O
emerin	O
from	O
HeLa	O
cells	O
.	O

We	O
determined	O
the	O
binding	O
affinities	O
of	O
emerin	B
for	O
GCL	B
,	O
BAF	B
,	O
and	O
lamin	B
A	I
and	O
analyzed	O
their	O
oligomeric	O
interactions	O
.	O

We	O
showed	O
that	O
emerin	B
forms	O
stable	O
complexes	O
with	O
either	O
lamin	B
A	I
plus	O
GCL	B
or	O
lamin	B
A	I
plus	O
BAF	B
.	O

Importantly	O
,	O
BAF	B
competed	O
with	O
GCL	B
for	O
binding	O
to	O
emerin	B
in	O
vitro	O
,	O
predicting	O
that	O
emerin	B
can	O
form	O
at	O
least	O
two	O
distinct	O
types	O
of	O
complexes	O
in	O
vivo	O
.	O

Loss	O
of	O
emerin	B
causes	O
Emery	O
-	O
Dreifuss	O
muscular	O
dystrophy	O
,	O
a	O
tissue	O
-	O
specific	O
inherited	O
disease	O
that	O
affects	O
skeletal	O
muscles	O
,	O
major	O
tendons	O
,	O
and	O
the	O
cardiac	O
conduction	O
system	O
.	O

Although	O
GCL	B
alone	O
can	O
not	O
explain	O
the	O
disease	O
mechanism	O
,	O
our	O
results	O
strongly	O
support	O
gene	O
expression	O
models	O
for	O
Emery	O
-	O
Dreifuss	O
muscular	O
dystrophy	O
by	O
showing	O
that	O
emerin	B
binds	O
directly	O
to	O
a	O
transcriptional	O
repressor	O
,	O
GCL	B
,	O
and	O
by	O
suggesting	O
that	O
emerin	B
-	O
repressor	O
complexes	O
might	O
be	O
regulated	O
by	O
BAF	B
.	O

Biochemical	O
roles	O
for	O
emerin	B
in	O
gene	O
expression	O
are	O
discussed	O
.	O

[	O
Mutation	O
analysis	O
of	O
KLF6	B
gene	O
in	O
human	O
nasopharyngeal	O
carcinomas	O
]	O

BACKGROUND	O
&	O
OBJECTIVE	O
:	O

Nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
cancers	O
in	O
South	O
China	O
and	O
Southeast	O
Asia	O
.	O

The	O
etiological	O
factor	O
is	O
believed	O
to	O
be	O
the	O
interaction	O
between	O
genetic	O
susceptibility	O
,	O
EBV	O
infection	O
and	O
environmental	O
factors	O
,	O
involved	O
in	O
the	O
multi	O
-	O
step	O
process	O
of	O
carcinogenesis	O
and	O
development	O
of	O
NPC	O
.	O

However	O
,	O
the	O
molecular	O
pathology	O
of	O
NPC	O
is	O
unclear	O
yet	O
.	O

Kruppel	B
-	I
like	I
factor	I
6	I
(	O
KLF6	B
)	O
is	O
a	O
ubiquitously	O
expressed	O
nuclear	O
transcription	B
factor	I
,	O
which	O
is	O
deleted	O
and/or	O
mutated	O
with	O
high	O
frequency	O
in	O
a	O
subset	O
of	O
prostate	O
cancer	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
KLF6	B
mutation	O
in	O
NPC	O
tumors	O
and	O
NPC	O
cell	O
lines	O
.	O

METHODS	O
:	O

Genomic	O
DNAs	O
from	O
19	O
NPC	O
tumor	O
biospies	O
and	O
3	O
NPC	O
cell	O
lines	O
were	O
used	O
in	O
mutation	O
detection	O
of	O
KLF6	B
coding	O
region	O
and	O
splice	O
sites	O
by	O
PCR	O
-	O
sequencing	O
.	O

100	O
chromosomes	O
from	O
50	O
random	O
healthy	O
individuals	O
were	O
used	O
as	O
control	O
.	O

RESULTS	O
:	O

In	O
3	O
of	O
19	O
NPC	O
tissues	O
,	O
3	O
different	O
mutations	O
(	O
Glu75Val	O
,	O
Ser136Arg	O
,	O
Arg243	O
Lys	O
)	O
in	O
KLF6	B
gene	O
were	O
found	O
by	O
PCR	O
-	O
sequencing	O
.	O

None	O
of	O
the	O
3	O
mutations	O
were	O
detected	O
in	O
the	O
50	O
random	O
healthy	O
individuals	O
.	O

CONCLUSION	O
:	O

KLF6	B
gene	O
may	O
be	O
involved	O
in	O
carcinogenesis	O
of	O
sporadic	O
NPC	O
.	O

BCR	B
/	O
ABL	B
alters	O
the	O
function	O
of	O
NK	O
cells	O
and	O
the	O
acquisition	O
of	O
killer	B
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
.	O

Natural	O
killer	O
(	O
NK	O
)	O
cells	O
decrease	O
in	O
function	O
during	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
progression	O
from	O
chronic	O
phase	O
to	O
blast	O
crisis	O
,	O
and	O
they	O
can	O
become	O
BCR	B
/	O
ABL	B
(	O
+	O
)	O
late	O
in	O
the	O
disease	O
course	O
.	O

To	O
study	O
this	O
altered	O
function	O
,	O
NK92	O
cells	O
were	O
transduced	O
with	O
the	O
BCR	B
/	O
ABL	B
oncogene	O
.	O

In	O
contrast	O
to	O
the	O
parental	O
cells	O
,	O
which	O
died	O
when	O
deprived	O
of	O
interleukin	B
2	I
(	O
IL-2	B
)	O
,	O
p210	O
(	O
+	O
)	O
NK92	O
cells	O
proliferated	O
and	O
survived	O
indefinitely	O
in	O
the	O
absence	O
of	O
IL-2	B
.	O

BCR	B
/	O
ABL	B
also	O
decreased	O
the	O
natural	O
cytotoxicity	O
of	O
NK92	O
cells	O
against	O
K562	O
targets	O
,	O
without	O
affecting	O
IL-2	B
,	O
interferon	B
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
,	O
or	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
production	O
.	O

Although	O
the	O
ABL	B
-	O
specific	O
tyrosine	B
kinase	I
inhibitor	O
imatinib	O
mesylate	O
(	O
STI-571	O
)	O
had	O
no	O
effect	O
on	O
parental	O
NK92	O
cells	O
,	O
it	O
markedly	O
decreased	O
the	O
growth	O
and	O
survival	O
of	O
IL-2	B
-	O
independent	O
p210	O
(	O
+	O
)	O
NK92	O
cells	O
.	O

In	O
contrast	O
to	O
the	O
parental	O
cell	O
line	O
,	O
serial	O
analysis	O
of	O
p210	O
(	O
+	O
)	O
NK92	O
cells	O
detected	O
small	O
populations	O
that	O
clonally	O
expressed	O
one	O
or	O
more	O
killer	B
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
.	O

Unlike	O
the	O
decreased	O
natural	O
cytotoxicity	O
,	O
the	O
function	O
of	O
the	O
activating	O
CD158j	B
receptor	O
remained	O
intact	O
.	O

Southern	O
blotting	O
and	O
hybridization	O
with	O
an	O
enhanced	O
green	B
fluorescence	I
protein	I
(	O
eGFP	B
)	O
probe	O
showed	O
that	O
KIR	B
(	O
-	O
)	O
and	O
KIR	B
(	O
+	O
)	O
NK92	O
cells	O
were	O
all	O
derived	O
from	O
the	O
same	O
clone	O
,	O
suggesting	O
that	O
KIR	B
acquisition	O
remains	O
dynamic	O
at	O
the	O
maturational	O
stage	O
represented	O
by	O
the	O
NK92	O
cell	O
line	O
.	O

When	O
tested	O
in	O
primary	O
CD56	B
(	O
+	O
bright	O
)	O
NK	O
cells	O
,	O
p210	O
induced	O
partial	O
IL-2	B
-	O
independent	O
growth	O
and	O
increased	O
KIR	B
expression	O
similar	O
to	O
findings	O
in	O
NK92	O
cells	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
show	O
that	O
BCR	B
/	O
ABL	B
,	O
well	O
known	O
for	O
its	O
effects	O
on	O
the	O
myeloid	O
lineage	O
,	O
can	O
alter	O
the	O
function	O
of	O
lymphoid	O
cells	O
,	O
which	O
may	O
be	O
associated	O
with	O
the	O
defect	O
in	O
innate	O
immunity	O
associated	O
with	O
CML	O
progression	O
.	O

Specific	O
stimulation	O
of	O
human	O
apurinic	B
/	I
apyrimidinic	I
endonuclease	I
by	O
heat	B
shock	I
protein	I
70	I
.	O

We	O
previously	O
demonstrated	O
the	O
stimulation	O
of	O
human	O
apurinic	B
/	I
apyrimidinic	I
endonuclease	I
1	I
(	O
HAP1	B
)	O
by	O
heat	B
shock	I
protein	I
70	I
(	O
HSP70	B
)	O
.	O

In	O
this	O
work	O
,	O
we	O
further	O
defined	O
the	O
functional	O
interaction	O
between	O
these	O
proteins	O
.	O

Digestion	O
of	O
HSP70	B
by	O
trypsin	B
released	O
48	O
and	O
43	O
kDa	O
amino	O
terminal	O
fragments	O
that	O
retained	O
the	O
ability	O
to	O
stimulate	O
HAP1	B
.	O

In	O
agreement	O
with	O
this	O
result	O
,	O
an	O
HSP70	B
N	O
-	O
terminal	O
deletion	O
mutant	O
protein	O
containing	O
amino	O
acids	O
1	O
-	O
385	O
was	O
comparable	O
to	O
the	O
full	O
-	O
length	O
protein	O
in	O
its	O
ability	O
to	O
enhance	O
HAP1	B
activity	O
.	O

HSP70	B
mutants	O
containing	O
carboxy	O
terminal	O
amino	O
acids	O
386	O
-	O
640	O
stimulated	O
HAP1	B
only	O
slightly	O
,	O
as	O
did	O
unrelated	O
proteins	O
.	O

These	O
results	O
implicate	O
the	O
amino	O
terminal	O
portion	O
of	O
HSP70	B
in	O
stimulating	O
the	O
activity	O
of	O
HAP1	B
.	O

Regulation	O
of	O
arginine	O
biosynthesis	O
in	O
the	O
psychropiezophilic	O
bacterium	O
Moritella	O
profunda	O
:	O
in	O
vivo	O
repressibility	O
and	O
in	O
vitro	O
repressor	O
-	O
operator	O
contact	O
probing	O
.	O

We	O
report	O
the	O
cloning	O
of	O
the	O
arginine	B
repressor	I
gene	O
from	O
the	O
psychropiezophilic	O
Gram	O
-	O
negative	O
bacterium	O
Moritella	O
profunda	O
,	O
the	O
purification	O
of	O
its	O
product	O
(	O
ArgR	B
(	O
Mp	O
)	O
)	O
,	O
the	O
identification	O
of	O
the	O
operator	O
in	O
the	O
bipolar	O
argECBFGH	B
(	I
A	I
)	I
operon	I
,	O
in	O
vivo	O
repressibility	O
studies	O
,	O
and	O
an	O
in	O
vitro	O
analysis	O
of	O
the	O
repressor	O
-	O
operator	O
interaction	O
,	O
including	O
binding	O
to	O
mutant	O
and	O
heterologous	O
arginine	O
operators	O
.	O

The	O
ArgR	B
(	O
Mp	O
)	O
subunit	O
shows	O
about	O
70	O
%	O
amino	O
acid	O
sequence	O
identity	O
with	O
Escherichia	O
coli	O
ArgR	B
(	O
ArgR	B
(	O
Ec	O
)	O
)	O
.	O

Binding	O
of	O
purified	O
hexameric	O
ArgR	B
(	O
Mp	O
)	O
to	O
the	O
control	O
region	O
of	O
the	O
divergent	O
operon	O
proved	O
to	O
be	O
arginine	O
-	O
dependent	O
,	O
sequence	O
-	O
specific	O
,	O
and	O
significantly	O
more	O
sensitive	O
to	O
heat	O
than	O
complex	O
formation	O
with	O
ArgR	B
(	O
Ec	O
)	O
.	O

ArgR	B
(	O
Mp	O
)	O
binds	O
E.coli	O
arginine	O
operators	O
very	O
efficiently	O
,	O
but	O
hardly	O
recognizes	O
the	O
operator	O
from	O
Bacillus	O
stearothermophilus	O
or	O
Thermotoga	O
maritima	O
.	O

ArgR	B
(	O
Mp	O
)	O
binds	O
to	O
a	O
single	O
site	O
overlapping	O
the	O
-	O
35	O
element	O
of	O
argC	B
(	O
P	O
)	O
,	O
but	O
not	O
argE	B
(	O
P	O
)	O
.	O

Therefore	O
,	O
the	O
arrangement	O
of	O
promoter	O
and	O
operator	O
sites	O
in	O
the	O
bipolar	O
argECBFGH	B
(	I
A	I
)	I
operon	I
of	O
M.profunda	O
is	O
very	O
different	O
from	O
the	O
organization	O
of	O
control	O
elements	O
in	O
the	O
bipolar	O
argECBH	B
operon	I
of	O
E.coli	O
,	O
where	O
both	O
promoters	O
overlap	O
the	O
common	O
operator	O
and	O
are	O
equally	O
repressible	O
.	O

We	O
demonstrate	O
that	O
M.profunda	O
argC	B
(	O
P	O
)	O
is	O
about	O
44	O
-	O
fold	O
repressible	O
,	O
whereas	O
argE	B
(	O
P	O
)	O
is	O
fully	O
constitutive	O
.	O

A	O
high	O
-	O
resolution	O
contact	O
map	O
of	O
the	O
ArgR	B
(	O
Mp	O
)	O
-	O
operator	O
interaction	O
was	O
established	O
by	O
enzymatic	O
and	O
chemical	O
footprinting	O
,	O
missing	O
contact	O
and	O
base	O
-	O
specific	O
premodification	O
binding	O
interference	O
studies	O
.	O

The	O
results	O
indicate	O
that	O
the	O
argC	B
operator	O
consists	O
of	O
two	O
ARG	B
box	O
-	O
like	O
sequences	O
(	O
18bp	O
imperfect	O
palindromes	O
)	O
separated	O
by	O
3bp	O
.	O

ArgR	B
(	O
Mp	O
)	O
binds	O
to	O
one	O
face	O
of	O
the	O
DNA	O
helix	O
and	O
establishes	O
contacts	O
with	O
two	O
major	O
groove	O
segments	O
and	O
the	O
intervening	O
minor	O
groove	O
of	O
each	O
ARG	B
box	O
,	O
whereas	O
the	O
minor	O
groove	O
segment	O
facing	O
the	O
repressor	O
at	O
the	O
center	O
of	O
the	O
operator	O
remains	O
largely	O
uncontacted	O
.	O

This	O
pattern	O
is	O
reminiscent	O
of	O
complex	O
formation	O
with	O
the	O
repressors	O
of	O
E.coli	O
and	O
B.stearothermophilus	O
,	O
and	O
suggests	O
that	O
each	O
ARG	B
box	O
is	O
contacted	O
by	O
two	O
ArgR	B
subunits	O
belonging	O
to	O
opposite	O
trimers	O
.	O

Moreover	O
,	O
the	O
premodification	O
interference	O
patterns	O
and	O
mutant	O
studies	O
clearly	O
indicate	O
that	O
the	O
inner	O
,	O
center	O
proximal	O
halves	O
of	O
each	O
ARG	B
box	O
in	O
the	O
M.profunda	O
argC	B
operator	O
are	O
more	O
important	O
for	O
complex	O
formation	O
and	O
repression	O
than	O
the	O
outermost	O
halves	O
.	O

A	O
close	O
inspection	O
of	O
sequence	O
conservation	O
and	O
of	O
single	O
base	O
-	O
pair	O
O	O
(	O
c	O
)	O
-	O
type	O
mutations	O
indicate	O
that	O
the	O
same	O
conclusion	O
can	O
be	O
generalized	O
to	O
E.coli	O
operators	O
.	O

A	O
eukaryotic	O
type	O
serine	B
/	I
threonine	I
kinase	I
and	I
phosphatase	I
in	O
Streptococcus	O
agalactiae	O
reversibly	O
phosphorylate	O
an	O
inorganic	B
pyrophosphatase	I
and	O
affect	O
growth	O
,	O
cell	O
segregation	O
,	O
and	O
virulence	O
.	O

Protein	O
phosphorylation	O
is	O
essential	O
for	O
the	O
regulation	O
of	O
cell	O
growth	O
,	O
division	O
,	O
and	O
differentiation	O
in	O
both	O
prokaryotes	O
and	O
eukaryotes	O
.	O

Signal	O
transduction	O
in	O
prokaryotes	O
was	O
previously	O
thought	O
to	O
occur	O
primarily	O
by	O
histidine	B
kinases	I
,	O
involved	O
in	O
two	O
-	O
component	O
signaling	O
pathways	O
.	O

Lately	O
,	O
bacterial	O
homologues	O
of	O
eukaryotic	O
-	O
type	O
serine	B
/	I
threonine	I
kinases	I
and	I
phosphatases	I
have	O
been	O
found	O
to	O
be	O
necessary	O
for	O
cellular	O
functions	O
such	O
as	O
growth	O
,	O
differentiation	O
,	O
pathogenicity	O
,	O
and	O
secondary	O
metabolism	O
.	O

The	O
Gram	O
-	O
positive	O
bacteria	O
Streptococcus	O
agalactiae	O
(	O
group	O
B	O
streptococci	O
,	O
GBS	O
)	O
is	O
an	O
important	O
human	O
pathogen	O
.	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
eukaryotic	O
-	O
type	O
serine	B
/	I
threonine	I
protein	I
kinase	I
(	O
Stk1	B
)	O
and	O
its	O
cognate	O
phosphatase	B
(	O
Stp1	B
)	O
in	O
GBS	O
.	O

Biochemical	O
assays	O
revealed	O
that	O
Stk1	B
has	O
kinase	B
activity	O
and	O
localizes	O
to	O
the	O
membrane	O
and	O
that	O
Stp1	B
is	O
a	O
soluble	O
protein	O
with	O
manganese	O
-	O
dependent	O
phosphatase	B
activity	O
on	O
Stk1	B
.	O

Mutations	O
in	O
these	O
genes	O
exhibited	O
pleiotropic	O
effects	O
on	O
growth	O
,	O
virulence	O
,	O
and	O
cell	O
segregation	O
of	O
GBS	O
.	O

Complementation	O
of	O
these	O
mutations	O
restored	O
the	O
wild	O
type	O
phenotype	O
linking	O
these	O
genes	O
to	O
the	O
regulation	O
of	O
various	O
cellular	O
processes	O
in	O
GBS	O
.	O

In	O
vitro	O
phosphorylation	O
of	O
cell	O
extracts	O
from	O
wild	O
type	O
and	O
mutant	O
strains	O
revealed	O
that	O
Stk1	B
is	O
essential	O
for	O
phosphorylation	O
of	O
six	O
GBS	O
proteins	O
.	O

We	O
have	O
identified	O
the	O
predominant	O
endogenous	O
substrate	O
of	O
both	O
Stk1	B
and	O
Stp1	B
as	O
a	O
manganese	B
-	I
dependent	I
inorganic	I
pyrophosphatase	I
(	O
PpaC	B
)	O
by	O
liquid	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry	O
.	O

These	O
results	O
suggest	O
that	O
these	O
eukaryotic	O
-	O
type	O
enzymes	O
regulate	O
pyrophosphatase	B
activity	O
and	O
other	O
cellular	O
functions	O
of	O
S.	O
agalactiae	O
.	O

Ubiquitin	B
-	O
proteasome	O
-	O
dependent	O
muscle	O
proteolysis	O
responds	O
slowly	O
to	O
insulin	B
release	O
and	O
refeeding	O
in	O
starved	O
rats	O
.	O

The	O
central	O
role	O
of	O
the	O
ubiquitin	B
-	O
proteasome	O
system	O
in	O
the	O
loss	O
of	O
skeletal	O
muscle	O
protein	O
in	O
many	O
wasting	O
conditions	O
has	O
been	O
well	O
established	O
.	O

However	O
,	O
it	O
is	O
unclear	O
what	O
factors	O
are	O
responsible	O
for	O
the	O
suppression	O
of	O
this	O
system	O
during	O
periods	O
of	O
protein	O
gain	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
these	O
studies	O
was	O
to	O
examine	O
the	O
short	O
-	O
term	O
effects	O
of	O
insulin	B
release	O
and	O
nutrients	O
on	O
skeletal	O
muscle	O
protein	O
turnover	O
in	O
young	O
rats	O
starved	O
for	O
48	O
h	O
,	O
and	O
then	O
infused	O
intravenously	O
with	O
amino	O
acids	O
(	O
AA	O
)	O
,	O
or	O
fed	O
an	O
oral	O
diet	O
.	O

Forty	O
-	O
eight	O
hours	O
of	O
starvation	O
(	O
i.e.	O
prolonged	O
starvation	O
in	O
young	O
rats	O
)	O
decreased	O
muscle	O
protein	O
synthesis	O
and	O
increased	O
proteasome	O
-	O
dependent	O
proteolysis	O
.	O

Four	O
-	O
hour	O
AA	O
infusion	O
and	O
4	O
h	O
of	O
refeeding	O
increased	O
plasma	O
insulin	B
release	O
and	O
AA	O
concentrations	O
,	O
and	O
stimulated	O
muscle	O
protein	O
synthesis	O
,	O
but	O
had	O
no	O
effect	O
on	O
either	O
total	O
or	O
proteasome	O
-	O
dependent	O
proteolysis	O
,	O
despite	O
decreased	O
plasma	O
corticosterone	O
concentrations	O
.	O

Both	O
muscle	O
proteasome	O
-	O
dependent	O
proteolysis	O
and	O
the	O
rate	O
of	O
ubiquitination	O
of	O
muscle	O
proteins	O
were	O
not	O
suppressed	O
until	O
10	O
h	O
of	O
refeeding	O
.	O

The	O
temporal	O
response	O
of	O
these	O
two	O
measurements	O
correlated	O
with	O
the	O
normalised	O
expression	O
of	O
the	O
14	O
-	O
kDa	O
E2	O
(	O
a	O
critical	O
enzyme	O
in	O
substrate	O
ubiquitination	O
in	O
muscle	O
)	O
and	O
the	O
expression	O
of	O
the	O
MSS1	B
subunit	O
of	O
the	O
19S	B
regulatory	I
complex	I
of	O
the	O
26S	O
proteasome	O
.	O

In	O
contrast	O
,	O
the	O
starvation	O
-	O
induced	O
increase	O
in	O
mRNA	O
levels	O
for	O
20S	O
proteasome	O
subunits	O
was	O
normalised	O
by	O
refeeding	O
within	O
24	O
h	O
in	O
muscle	O
,	O
and	O
6	O
h	O
in	O
jejunum	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
unlike	O
protein	O
synthesis	O
,	O
skeletal	O
muscle	O
proteasome	O
-	O
dependent	O
proteolysis	O
is	O
not	O
acutely	O
responsive	O
in	O
vivo	O
to	O
insulin	B
,	O
AA	O
,	O
and/or	O
nutrient	O
intake	O
in	O
refed	O
starved	O
rats	O
.	O

This	O
suggests	O
that	O
distinct	O
and	O
perhaps	O
independent	O
mechanisms	O
are	O
responsible	O
for	O
the	O
nutrient	O
-	O
dependent	O
regulation	O
of	O
protein	O
synthesis	O
and	O
ubiquitin	B
-	O
proteasome	O
-	O
dependent	O
proteolysis	O
following	O
a	O
prolonged	O
period	O
of	O
catabolism	O
.	O

Furthermore	O
,	O
factors	O
other	O
than	O
the	O
expression	O
of	O
ubiquitin	B
-	O
proteasome	O
pathway	O
components	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
suppression	O
of	O
skeletal	O
muscle	O
proteasome	O
-	O
dependent	O
proteolysis	O
by	O
nutrition	O
.	O

Cloning	O
and	O
sequence	O
analysis	O
of	O
a	O
mitochondrial	O
gene	O
cluster	O
encoding	O
cytochrome	B
C	I
oxidase	I
subunit	I
III	I
from	O
Trichoderma	O
pseudokoningii	O
.	O

A	O
mitochondrial	O
gene	O
cluster	O
encoding	O
cytochrome	B
c	I
oxidase	I
subunit	I
III	I
(	O
COX3	B
)	O
,	O
an	O
ORF	O
(	O
called	O
ORF250	O
)	O
similar	O
to	O
NADH	B
dehydrogenase	I
subunit	I
VI	I
(	O
ND6	B
)	O
,	O
ten	O
tRNA	O
molecules	O
,	O
partial	O
rRNA	O
small	O
subunit	O
and	O
rRNA	O
large	O
subunit	O
from	O
Trichoderma	O
pseudokoningii	O
S38	O
was	O
cloned	O
and	O
sequenced	O
.	O

These	O
genes	O
are	O
tandemly	O
clustered	O
on	O
the	O
mitochondrial	O
genome	O
of	O
Trichoderma	O
pseudokoningii	O
S38	O
.	O

Phylogenetic	O
analysis	O
showed	O
that	O
cytochrome	B
C	I
oxidase	I
subunits	I
III	I
exhibited	O
high	O
degree	O
of	O
similarity	O
to	O
sequences	O
from	O
Hypocrea	O
jecorina	O
,	O
Verticillium	O
lecanii	O
,	O
Podospora	O
anserine	O
,	O
Neurospora	O
crassa	O
and	O
Magnaporthe	O
grisea	O
(	O
99	O
,	O
90	O
,	O
84	O
,	O
82	O
and	O
79	O
%	O
identity	O
,	O
respectively	O
)	O
.	O

Prediction	O
of	O
transmembrane	O
helices	O
revealed	O
that	O
COX3	B
was	O
a	O
transmembrane	O
protein	O
.	O

Northern	O
dot	O
blot	O
analysis	O
showed	O
that	O
the	O
cytochrome	B
c	I
oxidase	I
subunits	I
III	I
gene	O
we	O
had	O
cloned	O
is	O
actively	O
transcribed	O
in	O
the	O
T.	O
pseudokoningii	O
mitochondria	O
.	O

Targeting	O
tuberculosis	O
and	O
malaria	O
through	O
inhibition	O
of	O
Enoyl	B
reductase	I
:	O
compound	O
activity	O
and	O
structural	O
data	O
.	O

Tuberculosis	O
and	O
malaria	O
together	O
result	O
in	O
an	O
estimated	O
5	O
million	O
deaths	O
annually	O
.	O

The	O
spread	O
of	O
multidrug	O
resistance	O
in	O
the	O
most	O
pathogenic	O
causative	O
agents	O
,	O
Mycobacterium	O
tuberculosis	O
and	O
Plasmodium	O
falciparum	O
,	O
underscores	O
the	O
need	O
to	O
identify	O
active	O
compounds	O
with	O
novel	O
inhibitory	O
properties	O
.	O

Although	O
genetically	O
unrelated	O
,	O
both	O
organisms	O
use	O
a	O
type	B
II	I
fatty	I
-	I
acid	I
synthase	I
system	O
.	O

Enoyl	B
acyl	I
carrier	I
protein	I
reductase	I
(	O
ENR	B
)	O
,	O
a	O
key	O
type	O
II	O
enzyme	O
,	O
has	O
been	O
repeatedly	O
validated	O
as	O
an	O
effective	O
antimicrobial	O
target	O
.	O

Using	O
high	O
throughput	O
inhibitor	O
screens	O
with	O
a	O
combinatorial	O
library	O
,	O
we	O
have	O
identified	O
two	O
novel	O
classes	O
of	O
compounds	O
with	O
activity	O
against	O
the	O
M.	O
tuberculosis	O
and	O
P.	O
falciparum	O
enzyme	O
(	O
referred	O
to	O
as	O
InhA	O
and	O
PfENR	O
,	O
respectively	O
)	O
.	O

The	O
crystal	O
structure	O
of	O
InhA	O
complexed	O
with	O
NAD	O
+	O
and	O
one	O
of	O
the	O
inhibitors	O
was	O
determined	O
to	O
elucidate	O
the	O
mode	O
of	O
binding	O
.	O

Structural	O
analysis	O
of	O
InhA	O
with	O
the	O
broad	O
spectrum	O
antimicrobial	O
triclosan	O
revealed	O
a	O
unique	O
stoichiometry	O
where	O
the	O
enzyme	O
contained	O
either	O
a	O
single	O
triclosan	O
molecule	O
,	O
in	O
a	O
configuration	O
typical	O
of	O
other	O
bacterial	O
ENR	B
:	O
triclosan	O
structures	O
,	O
or	O
harbored	O
two	O
triclosan	O
molecules	O
bound	O
to	O
the	O
active	O
site	O
.	O

Significantly	O
,	O
these	O
compounds	O
do	O
not	O
require	O
activation	O
and	O
are	O
effective	O
against	O
wild	O
-	O
type	O
and	O
drug	O
-	O
resistant	O
strains	O
of	O
M.	O
tuberculosis	O
and	O
P.	O
falciparum	O
.	O

Moreover	O
,	O
they	O
provide	O
broader	O
chemical	O
diversity	O
and	O
elucidate	O
key	O
elements	O
of	O
inhibitor	O
binding	O
to	O
InhA	O
for	O
subsequent	O
chemical	O
optimization	O
.	O

The	O
2b	B
protein	I
of	O
cucumoviruses	O
has	O
a	O
role	O
in	O
promoting	O
the	O
cell	O
-	O
to	O
-	O
cell	O
movement	O
of	O
pseudorecombinant	O
viruses	O
.	O

Pseudorecombinant	O
viruses	O
(	O
i.e.	O
,	O
those	O
containing	O
a	O
reassorted	O
genome	O
of	O
closely	O
related	O
multipartite	O
viruses	O
)	O
are	O
often	O
not	O
as	O
competitive	O
as	O
the	O
parental	O
viruses	O
.	O

The	O
role	O
of	O
the	O
2b	B
gene	O
in	O
hypervirulence	O
and	O
maintenance	O
of	O
a	O
progressive	O
infection	O
was	O
assessed	O
in	O
a	O
pseudorecombinant	O
virus	O
formed	O
between	O
RNAs	O
1	O
plus	O
2	O
of	O
Cucumber	O
mosaic	O
virus	O
(	O
CMV	O
)	O
and	O
RNA	O
3	O
of	O
Tomato	O
aspermy	O
virus	O
(	O
TAV	O
)	O
.	O

The	O
presence	O
of	O
RNA	O
3	O
of	O
TAV	O
was	O
found	O
to	O
affect	O
the	O
level	O
of	O
RNA	O
accumulation	O
but	O
not	O
the	O
level	O
of	O
virulence	O
.	O

By	O
contrast	O
,	O
the	O
2b	B
genes	O
of	O
both	O
TAV	O
and	O
a	O
hypervirulent	O
strain	O
of	O
CMV	O
(	O
WAII	O
-	O
CMV	O
)	O
were	O
found	O
to	O
affect	O
the	O
virulence	O
of	O
the	O
pseudorecombinant	O
viruses	O
but	O
not	O
the	O
levels	O
of	O
viral	O
RNA	O
accumulation	O
.	O

The	O
2b	B
gene	O
rather	O
than	O
the	O
overlapping	O
open	O
reading	O
frame	O
encoding	O
the	O
C	O
-	O
terminal	O
41	O
amino	O
acids	O
of	O
2a	B
protein	I
of	O
the	O
corresponding	O
virus	O
was	O
found	O
to	O
be	O
essential	O
for	O
promoting	O
infection	O
of	O
the	O
pseudorecombinant	O
viruses	O
in	O
planta	O
.	O

However	O
,	O
the	O
2b	B
gene	O
was	O
not	O
essential	O
for	O
replication	O
of	O
pseudorecombinant	O
viruses	O
containing	O
CMV	O
RNAs	O
1	O
plus	O
2	O
and	O
TAV	O
RNA	O
3	O
.	O

These	O
results	O
indicate	O
that	O
the	O
2b	B
protein	I
is	O
involved	O
in	O
promoting	O
the	O
cell	O
-	O
to	O
-	O
cell	O
movement	O
of	O
the	O
pseudorecombinant	O
viruses	O
.	O

These	O
data	O
also	O
suggest	O
the	O
existence	O
of	O
specific	O
interaction	O
between	O
the	O
TAV	O
2b	B
protein	I
and	O
either	O
RNA	O
3	O
or	O
its	O
encoded	O
proteins	O
,	O
which	O
may	O
be	O
critical	O
for	O
promoting	O
or	O
maintaining	O
infection	O
or	O
both	O
.	O

ArhGAP15	B
,	O
a	O
novel	O
human	O
RacGAP	B
protein	O
with	O
GTPase	B
binding	O
property	O
.	O

We	O
have	O
previously	O
described	O
a	O
partial	O
cDNA	O
sequence	O
encoding	O
a	O
RhoGAP	B
protein	O
,	O
GAP25	B
that	O
is	O
homologous	O
to	O
the	O
recently	O
reported	O
ArhGAP9	B
and	O
ArhGAP12	B
.	O

We	O
now	O
describe	O
a	O
related	O
new	O
member	O
ArhGAP15	B
that	O
shares	O
a	O
number	O
of	O
domain	O
similarities	O
,	O
including	O
a	O
pleckstrin	B
homology	O
(	O
PH	O
)	O
domain	O
,	O
a	O
RhoGAP	B
domain	O
and	O
a	O
novel	O
motif	O
N	O
-	O
terminal	O
to	O
the	O
GAP	B
domain	O
.	O

This	O
novel	O
motif	O
was	O
found	O
to	O
be	O
responsible	O
for	O
nucleotide	O
-	O
independent	O
Rac1	B
binding	O
.	O

Using	O
swop	O
mutants	O
of	O
Rac	B
/	O
Cdc42	B
,	O
we	O
have	O
established	O
that	O
the	O
binding	O
is	O
through	O
the	O
C	O
-	O
terminal	O
half	O
of	O
Rac1	B
.	O

The	O
GAP	B
domain	O
of	O
ArhGAP15	B
showed	O
specificity	O
towards	O
Rac1	B
in	O
vitro	O
.	O

The	O
PH	O
domain	O
is	O
required	O
for	O
ArhGAP15	B
to	O
localize	O
to	O
cell	O
periphery	O
and	O
over	O
-	O
expression	O
of	O
the	O
full	O
-	O
length	O
ArhGAP15	B
,	O
but	O
not	O
the	O
mutant	O
with	O
a	O
partial	O
deletion	O
of	O
the	O
PH	O
domain	O
,	O
resulted	O
in	O
an	O
increase	O
in	O
actin	B
stress	O
fibers	O
and	O
cell	O
contraction	O
.	O

These	O
morphological	O
effects	O
can	O
be	O
attenuated	O
by	O
the	O
co	O
-	O
expression	O
of	O
dominant	O
negative	O
Rac1	B
(	O
N17	O
)	O
.	O

HeLa	O
cells	O
expressing	O
ArhGAP15	B
were	O
also	O
resistant	O
to	O
phorbol	O
myristatate	O
acetate	O
treatment	O
,	O
suggesting	O
that	O
ArhGAP15	B
is	O
a	O
potential	O
regulator	O
of	O
Rac1	B
.	O

Overexpression	O
of	O
the	O
tumor	O
autocrine	B
motility	I
factor	I
receptor	I
Gp78	I
,	O
a	O
ubiquitin	B
protein	I
ligase	I
,	O
results	O
in	O
increased	O
ubiquitinylation	O
and	O
decreased	O
secretion	O
of	O
apolipoprotein	B
B100	I
in	O
HepG2	O
cells	O
.	O

Apolipoprotein	B
B100	I
(	O
apoB	B
)	O
is	O
a	O
large	O
(	O
520	O
-	O
kDa	O
)	O
complex	O
secretory	O
protein	O
;	O
its	O
secretion	O
is	O
regulated	O
posttranscriptionally	O
by	O
several	O
degradation	O
pathways	O
.	O

The	O
best	O
described	O
of	O
these	O
degradative	O
processes	O
is	O
co	O
-	O
translational	O
ubiquitinylation	O
and	O
proteasomal	O
degradation	O
of	O
nascent	O
apoB	B
,	O
involving	O
the	O
70	B
-	I
and	I
90	I
-	I
kDa	I
heat	I
shock	I
proteins	I
and	O
the	O
multiple	O
components	O
of	O
the	O
proteasomal	O
pathway	O
.	O

Ubiquitinylation	O
involves	O
several	O
proteins	O
,	O
including	O
ligases	B
called	O
E3s	B
,	O
that	O
coordinate	O
the	O
covalent	O
binding	O
of	O
ubiquitin	B
to	O
target	O
proteins	O
.	O

The	O
recent	O
discovery	O
that	O
tumor	O
autocrine	B
motility	I
factor	I
receptor	I
,	O
also	O
known	O
as	O
gp78	B
,	O
is	O
an	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-	O
associated	O
E3	B
,	O
raised	O
the	O
possibility	O
that	O
this	O
E3	B
might	O
be	O
involved	O
in	O
the	O
ER	O
-	O
associated	O
degradation	O
of	O
nascent	O
apoB	B
.	O

In	O
a	O
series	O
of	O
experiments	O
in	O
HepG2	O
cells	O
,	O
we	O
demonstrated	O
that	O
overexpression	O
of	O
gp78	B
was	O
sufficient	O
for	O
increased	O
ubiquitinylation	O
and	O
proteasomal	O
degradation	O
of	O
apoB	B
,	O
with	O
reduced	O
secretion	O
of	O
apoB	B
-	O
lipoproteins	O
.	O

This	O
action	O
of	O
gp78	B
was	O
specific	O
:	O
overexpression	O
of	O
the	O
protein	O
did	O
not	O
affect	O
secretion	O
of	O
either	O
albumin	B
or	O
apolipoprotein	B
AI	I
.	O

Furthermore	O
,	O
overexpression	O
of	O
a	O
cytosolic	O
E3	B
,	I
Itch	I
,	O
had	O
no	O
effect	O
on	O
apoB	B
secretion	O
.	O

Finally	O
,	O
using	O
an	O
in	O
vitro	O
translation	O
system	O
,	O
we	O
demonstrated	O
that	O
gp78	B
led	O
to	O
increased	O
ubiquitinylation	O
and	O
proteasomal	O
degradation	O
of	O
apoB48	B
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
an	O
ER	O
-	O
associated	O
protein	O
,	O
gp78	B
,	O
is	O
a	O
bona	O
fide	O
E3	B
ligase	I
in	O
the	O
apoB	B
ER	O
-	O
associated	O
degradation	O
pathway	O
.	O

Clinical	O
significance	O
of	O
antiphospholipid	O
protein	O
antibodies	O
.	O

Receiver	O
operating	O
characteristics	O
plot	O
analysis	O
.	O

OBJECTIVE	O
:	O

To	O
investigate	O
the	O
utility	O
of	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
in	O
determining	O
the	O
strength	O
of	O
association	O
between	O
various	O
antiphospholipid	O
and	O
anti	O
-	O
protein	O
cofactor	O
antibodies	O
(	O
aPA	O
)	O
and	O
thrombosis	O
,	O
pregnancy	O
morbidity	O
,	O
and	O
thrombocytopenia	O
.	O

METHODS	O
:	O

Clinical	O
and	O
laboratory	O
variables	O
were	O
retrospectively	O
studied	O
in	O
204	O
patients	O
:	O
160	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
22	O
with	O
lupus	O
-	O
like	O
syndrome	O
(	O
SLE	O
-	O
LS	O
)	O
,	O
and	O
22	O
with	O
primary	O
antiphospholipid	O
syndrome	O
(	O
APS	O
)	O
.	O

Laboratory	O
evaluation	O
included	O
detection	O
of	O
lupus	O
anticoagulant	O
(	O
LAC	O
)	O
and	O
measurement	O
of	O
IgG	B
and	O
IgM	B
anticardiolipin	O
(	O
aCL	O
)	O
,	O
antiphosphatidylserine	O
(	O
aPS	O
)	O
,	O
antiphosphatidylinositol	O
(	O
aPI	O
)	O
,	O
anti	O
-	O
beta	B
2	I
glycoprotein	I
I	I
(	O
a	O
beta	B
2GPI	I
)	O
,	O
and	O
antiprothrombin	O
(	O
aPT	B
)	O
antibodies	O
.	O

ROC	O
plot	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
clinical	O
accuracy	O
of	O
aPA	O
tests	O
,	O
and	O
calculate	O
cut	O
-	O
off	O
values	O
which	O
best	O
associate	O
with	O
clinical	O
symptoms	O
typical	O
for	O
APS	O
.	O

RESULTS	O
:	O

The	O
LAC	O
was	O
associated	O
with	O
a	O
history	O
of	O
thrombosis	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
:	O
3.04	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.5	O
-	O
6.2	O
]	O
and	O
even	O
more	O
strongly	O
with	O
recurrent	O
fetal	O
loss	O
(	O
OR	O
:	O
8.7	O
;	O
95	O
%	O
CI	O
:	O
2.8	O
-	O
26.7	O
)	O
.	O

ROC	O
plot	O
analysis	O
revealed	O
that	O
the	O
most	O
accurate	O
test	O
for	O
thrombosis	O
was	O
aCL	O
IgG	B
(	O
ROC	O
-	O
derived	O
cutoff	O
value	O
>	O
17.2	O
GPL	O
;	O
OR	O
:	O
3.69	O
;	O
95	O
%	O
CI	O
:	O
1.8	O
-	O
7.4	O
)	O
,	O
for	O
recurrent	O
fetal	O
loss	O
,	O
aPI	O
IgG	B
[	O
>	O
22.1	O
theoretical	O
units	O
(	O
TU	O
)	O
;	O
OR	O
:	O
6.21	O
;	O
95	O
%	O
CI	O
:	O
2.1	O
-	O
18.5	O
]	O
,	O
closely	O
followed	O
by	O
aCL	O
IgG	B
and	O
a	O
beta	B
2GPI	I
IgG	B
,	O
and	O
for	O
thrombocytopenia	O
aPS	O
IgM	B
(	O
>	O
6.7	O
TU	O
;	O
OR	O
:	O
1.9	O
;	O
95	O
%	O
CI	O
:	O
1.04	O
-	O
3.4	O
)	O
.	O

Among	O
182	O
autoimmune	O
patients	O
(	O
SLE	O
+	O
SLE	O
-	O
LS	O
)	O
,	O
6.6	O
%	O
presented	O
clinical	O
symptoms	O
of	O
APS	O
without	O
classic	O
aPA	O
(	O
LAC	O
and/or	O
aCL	O
)	O
,	O
but	O
with	O
elevated	O
levels	O
of	O
antibodies	O
against	O
other	O
phospholipids	O
,	O
mainly	O
aPI	O
IgM	B
.	O

CONCLUSION	O
:	O

A	O
laboratory	O
that	O
evaluates	O
APS	O
patients	O
should	O
establish	O
its	O
own	O
threshold	O
values	O
for	O
aPA	O
tests	O
.	O

We	O
suggest	O
that	O
ROC	O
plot	O
analysis	O
is	O
a	O
valuable	O
tool	O
in	O
establishing	O
cutoff	O
values	O
.	O

LAC	O
and	O
aCL	O
determinations	O
seem	O
sufficient	O
for	O
the	O
majority	O
of	O
laboratories	O
.	O

However	O
,	O
in	O
specialized	O
centers	O
other	O
tests	O
should	O
be	O
available	O
to	O
detect	O
those	O
patients	O
with	O
clinical	O
symptoms	O
for	O
APS	O
but	O
who	O
are	O
positive	O
for	O
antiphospholipid	O
antibodies	O
other	O
than	O
aCL	O
and	O
the	O
LAC	O
.	O

MASE1	O
and	O
MASE2	O
:	O
two	O
novel	O
integral	O
membrane	O
sensory	O
domains	O
.	O

Escherichia	O
coli	O
proteins	O
YegE	B
and	O
YaiC	B
contain	O
N	O
-	O
terminal	O
integral	O
membrane	O
regions	O
,	O
followed	O
by	O
the	O
putative	O
diguanylate	B
cyclase	I
(	O
GGDEF	O
,	O
DUF1	O
)	O
domains	O
.	O

The	O
membrane	O
domains	O
of	O
these	O
proteins	O
,	O
named	O
MASE1	O
(	O
membrane	O
-	O
associated	O
sensor	O
)	O
and	O
MASE2	O
,	O
respectively	O
,	O
were	O
found	O
in	O
other	O
bacterial	O
signaling	O
proteins	O
,	O
such	O
as	O
histidine	B
kinases	I
(	O
MASE1	O
)	O
and	O
an	O
adenylate	B
cyclase	I
(	O
MASE2	O
)	O
.	O

Although	O
the	O
nature	O
of	O
the	O
signals	O
sensed	O
by	O
MASE1	O
and	O
MASE2	O
is	O
still	O
unknown	O
,	O
MASE1	O
-	O
containing	O
receptors	O
appear	O
to	O
play	O
important	O
roles	O
in	O
bacteria	O
,	O
including	O
iron	O
and/or	O
oxygen	O
sensing	O
by	O
hemerythrine	O
-	O
containing	O
proteins	O
in	O
the	O
sulfate	O
-	O
reducing	O
bacterium	O
Desulfovibrio	O
vulgaris	O
.	O

Origin	O
of	O
lipid	O
A	O
species	O
modified	O
with	O
4-amino-4-deoxy	O
-	O
L	O
-	O
arabinose	O
in	O
polymyxin	O
-	O
resistant	O
mutants	O
of	O
Escherichia	O
coli	O
.	O

An	O
aminotransferase	B
(	O
ArnB	B
)	O
that	O
generates	O
UDP-4-deoxyl	O
-	O
L	O
-	O
arabinose	O
.	O

In	O
Escherichia	O
coli	O
and	O
Salmonella	O
typhimurium	O
,	O
addition	O
of	O
the	O
4-amino-4-deoxy	O
-	O
l	O
-	O
arabinose	O
(	O
l	O
-	O
Ara4N	O
)	O
moiety	O
to	O
the	O
phosphate	O
group	O
(	O
s	O
)	O
of	O
lipid	O
A	O
is	O
required	O
for	O
resistance	O
to	O
polymyxin	O
and	O
cationic	O
antimicrobial	O
peptides	O
.	O

We	O
have	O
proposed	O
previously	O
(	O
Breazeale	O
,	O
S.	O
D.	O
,	O
Ribeiro	O
,	O
A.	O
A.	O
,	O
and	O
Raetz	O
,	O
C.	O
R.	O
H.	O
(	O
2002	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
277	O
,	O
2886	O
-	O
2896	O
)	O
a	O
pathway	O
for	O
l	O
-	O
Ara4N	O
biosynthesis	O
that	O
begins	O
with	O
the	O
ArnA	O
-	O
catalyzed	O
C-4	O
""""	O
oxidation	O
and	O
C-6	O
""""	O
decarboxylation	O
of	O
UDP	O
-	O
glucuronic	O
acid	O
,	O
followed	O
by	O
the	O
C-4	O
""""	O
transamination	O
of	O
the	O
product	O
to	O
generate	O
the	O
novel	O
sugar	O
nucleotide	O
UDP	O
-	O
l	O
-	O
Ara4N	O
.	O

We	O
now	O
show	O
that	O
ArnB	B
(	O
PmrH	B
)	O
encodes	O
the	O
relevant	O
aminotransferase	B
.	O

ArnB	B
was	O
overexpressed	O
using	O
a	O
T7lac	O
promoter	O
-	O
driven	O
construct	O
and	O
shown	O
to	O
catalyze	O
the	O
reversible	O
transfer	O
of	O
the	O
amino	O
group	O
from	O
glutamate	O
to	O
the	O
acceptor	O
,	O
uridine	O
5'-	O
(	O
beta	O
-	O
l	O
-	O
threo	O
-	O
"pentapyranosyl-4""-ulose"	O
diphosphate	O
)	O
,	O
the	O
intermediate	O
that	O
is	O
synthesized	O
by	O
ArnA	B
from	O
UDP	O
-	O
glucuronic	O
acid	O
.	O

A	O
1.7	O
-	O
mg	O
sample	O
of	O
the	O
putative	O
UDP	O
-	O
l	O
-	O
Ara4N	O
product	O
generated	O
in	O
vitro	O
was	O
purified	O
by	O
ion	O
exchange	O
chromatography	O
,	O
and	O
its	O
structure	O
was	O
confirmed	O
by	O
1H	O
and	O
13C	O
NMR	O
spectroscopy	O
.	O

ArnB	B
,	O
which	O
is	O
a	O
cytoplasmic	O
protein	O
,	O
was	O
purified	O
to	O
homogeneity	O
from	O
an	O
overproducing	O
strain	O
of	O
E.	O
coli	O
and	O
shown	O
to	O
contain	O
a	O
pyridoxal	O
phosphate	O
cofactor	O
,	O
as	O
judged	O
by	O
ultraviolet	O
/	O
visible	O
spectrophotometry	O
.	O

The	O
pyridoxal	O
phosphate	O
was	O
converted	O
to	O
the	O
pyridoxamine	O
form	O
in	O
the	O
presence	O
of	O
excess	O
glutamate	O
.	O

A	O
simple	O
quantitative	O
radiochemical	O
assay	O
was	O
developed	O
for	O
ArnB	B
,	O
which	O
can	O
be	O
used	O
to	O
assay	O
the	O
enzyme	O
either	O
in	O
the	O
forward	O
or	O
the	O
reverse	O
direction	O
.	O

The	O
enzyme	O
is	O
highly	O
selective	O
for	O
glutamate	O
as	O
the	O
amine	O
donor	O
,	O
but	O
the	O
equilibrium	O
constant	O
in	O
the	O
direction	O
of	O
UDP	O
-	O
l	O
-	O
Ara4N	O
formation	O
is	O
unfavorable	O
(	O
approximately	O
0.1	O
)	O
.	O

ArnB	B
is	O
a	O
member	O
of	O
a	O
very	O
large	O
family	O
of	O
aminotransferases	B
,	O
but	O
closely	O
related	O
ArnB	B
orthologs	O
are	O
present	O
only	O
in	O
those	O
bacteria	O
capable	O
of	O
synthesizing	O
lipid	O
A	O
species	O
modified	O
with	O
the	O
l	O
-	O
Ara4N	O
moiety	O
.	O

Possible	O
cause	O
of	O
taurine	O
-	O
deficient	O
cardiomyopathy	O
:	O
potentiation	O
of	O
angiotensin	B
II	I
action	O
.	O

Taurine	O
,	O
an	O
amino	O
acid	O
that	O
exhibits	O
anti	O
-	O
angiotensin	B
II	I
and	O
osmoregulatory	O
activity	O
,	O
is	O
found	O
in	O
very	O
high	O
concentration	O
in	O
the	O
heart	O
.	O

When	O
the	O
intracellular	O
content	O
of	O
taurine	O
is	O
dramatically	O
reduced	O
,	O
the	O
heart	O
develops	O
contractile	O
defects	O
and	O
undergoes	O
an	O
eccentric	O
form	O
of	O
hypertrophy	O
.	O

The	O
development	O
of	O
myocyte	O
hypertrophy	O
has	O
been	O
largely	O
attributed	O
to	O
angiotensin	B
II	I
,	O
whose	O
growth	O
properties	O
are	O
antagonized	O
by	O
taurine	O
.	O

Overt	O
heart	O
failure	O
is	O
usually	O
associated	O
with	O
myocyte	O
death	O
,	O
including	O
death	O
due	O
to	O
angiotensin	B
II	I
-	O
induced	O
apoptosis	O
.	O

However	O
,	O
the	O
effect	O
of	O
taurine	O
deficiency	O
on	O
angiotensin	B
II	I
-	O
induced	O
apoptosis	O
has	O
not	O
been	O
examined	O
.	O

To	O
investigate	O
this	O
effect	O
,	O
taurine	O
-	O
deficient	O
cells	O
,	O
produced	O
by	O
incubating	O
rat	O
neonatal	O
cardiomyocytes	O
with	O
medium	O
containing	O
the	O
taurine	O
transport	O
inhibitor	O
,	O
beta	O
-	O
alanine	O
,	O
were	O
exposed	O
to	O
angiotensin	B
II	I
.	O

The	O
peptide	O
increased	O
terminal	B
deoxynucleotidyl	I
transferase	I
-	O
mediated	O
deoxyuridine	O
triphosphate	O
nick	O
end	O
-	O
labeling	O
(	O
TUNEL	O
)	O
staining	O
and	O
caspase	B
9	I
activation	O
more	O
in	O
the	O
taurine	O
-	O
deficient	O
than	O
the	O
normal	O
cell	O
.	O

Angiotensin	B
II	I
also	O
promoted	O
the	O
translocation	O
of	O
protein	B
kinase	I
C	I
(	I
PKC	I
)	I
epsilon	I
and	O
PKCdelta	B
,	O
the	O
expression	O
of	O
Bax	B
,	O
and	O
the	O
activation	O
of	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
,	O
effects	O
that	O
were	O
greater	O
in	O
the	O
taurine	O
-	O
deficient	O
cell	O
.	O

However	O
,	O
the	O
data	O
ruled	O
out	O
a	O
role	O
for	O
extracellular	B
signal	I
-	I
related	I
kinase	I
(	O
ERK	B
)	O
,	O
Bad	B
,	O
and	O
p38	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
in	O
the	O
beta	O
-	O
alanine	O
-	O
angiotensin	B
II	I
interaction	O
.	O

Because	O
PKC	B
and	O
JNK	B
affect	O
the	O
expression	O
and	O
phosphorylation	O
state	O
of	O
certain	O
Bcl-2	B
family	I
members	O
,	O
they	O
appear	O
to	O
contribute	O
to	O
the	O
potentiation	O
of	O
angiotensin	B
II	I
-	O
induced	O
apoptosis	O
by	O
taurine	O
deficiency	O
.	O

Polypeptide	O
components	O
of	O
oligomeric	O
legumin	B
-	O
like	O
thiamin	B
-	I
binding	I
protein	I
from	O
buckwheat	O
seeds	O
characterized	O
by	O
partial	O
amino	O
acid	O
sequencing	O
and	O
photoaffinity	O
labeling	O
.	O

Among	O
thiamin	B
-	I
binding	I
proteins	I
that	O
ubiquitously	O
occur	O
in	O
plant	O
seeds	O
,	O
that	O
of	O
common	O
buckwheat	O
became	O
a	O
model	O
of	O
extensive	O
studies	O
of	O
the	O
chemical	O
mechanism	O
of	O
ligand	O
-	O
protein	O
interaction	O
.	O

In	O
this	O
work	O
,	O
the	O
polypeptide	O
components	O
of	O
buckwheat	B
seed	I
thiamin	I
-	I
binding	I
protein	I
(	O
BSTBP	B
)	O
are	O
identified	O
and	O
characterized	O
.	O

We	O
suggest	O
that	O
BSTBP	B
is	O
probably	O
a	O
fraction	O
of	O
major	O
storage	O
13	B
S	I
globulin	I
(	O
legumin	B
)	O
,	O
has	O
an	O
average	O
molecular	O
mass	O
of	O
235	O
kDa	O
and	O
comprises	O
hexamers	O
of	O
57	O
-	O
kDa	O
and	O
38	O
-	O
kDa	O
subunits	O
in	O
variable	O
combinations	O
.	O

Each	O
subunit	O
is	O
a	O
pair	O
of	O
disulfide	O
-	O
linked	O
polypeptide	O
chains	O
,	O
36	O
kDa	O
plus	O
24	O
kDa	O
and	O
two	O
-	O
times	O
22	O
kDa	O
,	O
respectively	O
.	O

The	O
N	O
-	O
terminal	O
sequences	O
of	O
22	O
-	O
kDa	O
and	O
24	O
-	O
kDa	O
components	O
show	O
strict	O
homology	O
with	O
those	O
reported	O
for	O
""""	O
basic	O
subunits	O
""""	O
of	O
buckwheat	O
legumin	B
.	O

By	O
photoaffinity	O
labeling	O
of	O
BSTBP	B
with	O
4-azido-2-nitrobenzoylthiamine	O
,	O
it	O
is	O
shown	O
that	O
the	O
36	O
-	O
kDa	O
chain	O
plays	O
the	O
major	O
role	O
in	O
thiamin	O
binding	O
,	O
but	O
the	O
other	O
chains	O
may	O
also	O
be	O
variably	O
involved	O
.	O

Putative	O
thiamin	O
-	O
binding	O
fragments	O
are	O
identified	O
and	O
sequenced	O
.	O

Different	O
and	O
divergent	O
regulation	O
of	O
the	O
KIR2DL4	B
and	O
KIR3DL1	B
promoters	O
.	O

The	O
killer	B
Ig	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
are	O
a	O
family	O
of	O
highly	O
related	O
MHC	B
class	I
I	I
receptors	O
that	O
show	O
extreme	O
genetic	O
polymorphism	O
both	O
within	O
the	O
human	O
population	O
and	O
between	O
closely	O
related	O
primate	O
species	O
,	O
suggestive	O
of	O
rapid	O
evolutionary	O
diversification	O
.	O

Most	O
KIR	B
are	O
expressed	O
in	O
a	O
variegated	O
fashion	O
by	O
the	O
NK	O
population	O
,	O
giving	O
rise	O
to	O
an	O
NK	O
repertoire	O
of	O
specificities	O
for	O
MHC	B
class	I
I	I
.	O

We	O
compared	O
the	O
promoter	O
for	O
KIR3DL1	B
,	O
which	O
exhibits	O
variegated	O
gene	O
expression	O
,	O
with	O
that	O
for	O
KIR2DL4	B
,	O
which	O
is	O
expressed	O
by	O
all	O
NK	O
cell	O
clones	O
.	O

Maximum	O
transcriptional	O
activity	O
of	O
each	O
was	O
encoded	O
within	O
approximately	O
270	O
bp	O
upstream	O
of	O
the	O
translation	O
initiation	O
codon	O
.	O

The	O
KIR2DL4	B
promoter	O
drove	O
reporter	O
gene	O
expression	O
only	O
in	O
NK	O
cells	O
,	O
while	O
the	O
KIR3DL1	B
promoter	O
was	O
active	O
in	O
a	O
range	O
of	O
cell	O
types	O
,	O
suggesting	O
that	O
the	O
latter	O
requires	O
other	O
regulatory	O
elements	O
for	O
physiological	O
expression	O
.	O

In	O
NK	O
cells	O
,	O
reporter	O
gene	O
expression	O
driven	O
by	O
the	O
KIR2DL4	B
promoter	O
was	O
greater	O
than	O
that	O
driven	O
by	O
the	O
KIR3DL1	B
promoter	O
.	O

DNase	B
I	I
footprinting	O
revealed	O
that	O
transcription	B
factor	I
binding	O
sites	O
differ	O
between	O
the	O
two	O
promoters	O
.	O

The	O
data	O
indicate	O
that	O
while	O
the	O
promoters	O
of	O
these	O
two	O
KIR	B
genes	O
share	O
67	O
%	O
nucleotide	O
identity	O
,	O
they	O
have	O
evolved	O
distinct	O
properties	O
consistent	O
with	O
different	O
roles	O
in	O
regulating	O
the	O
generation	O
of	O
NK	O
repertoire	O
.	O

Restricted	O
spatial	O
expression	O
of	O
a	O
high	O
-	O
affinity	O
phosphate	B
transporter	I
in	O
potato	O
roots	O
.	O

Phosphorus	O
deficiency	O
limits	O
plant	O
growth	O
,	O
and	O
high	O
-	O
affinity	O
phosphate	B
transporters	I
,	O
of	O
the	O
Pht1	B
family	I
,	O
facilitate	O
phosphate	O
uptake	O
and	O
translocation	O
.	O

The	O
family	O
is	O
subdivided	O
into	O
root	O
specific	O
,	O
phosphate	O
deprivation	O
induced	O
members	O
and	O
those	O
also	O
expressed	O
in	O
leaves	O
.	O

An	O
antibody	O
to	O
StPT2	B
,	O
a	O
potato	O
root	O
specific	O
transporter	O
,	O
detected	O
two	O
bands	O
(	O
52	O
kDa	O
and	O
30	O
kDa	O
)	O
on	O
western	O
blots	O
of	O
root	O
plasma	O
membrane	O
extracts	O
that	O
were	O
most	O
intense	O
in	O
whole	O
extracts	O
from	O
the	O
root	O
tip	O
and	O
slightly	O
increased	O
throughout	O
the	O
root	O
in	O
response	O
to	O
phosphate	O
depletion	O
.	O

RT	O
-	O
PCR	O
,	O
using	O
StPT2	B
specific	O
primers	O
,	O
confirmed	O
these	O
findings	O
.	O

Low	O
power	O
confocal	O
immunofluorescent	O
images	O
showed	O
StPT2	B
expression	O
mainly	O
in	O
the	O
elongation	O
zone	O
at	O
the	O
root	O
tip	O
.	O

By	O
contrast	O
,	O
a	O
vacuolar	O
pyrophosphatase	B
and	O
a	O
plasma	O
membrane	O
ATPase	B
antibody	O
labelled	O
the	O
whole	O
root	O
.	O

High	O
power	O
images	O
showed	O
,	O
by	O
comparison	O
with	O
alpha	B
-	I
tubulin	I
,	O
cell	O
wall	O
and	O
plasma	O
membrane	O
ATPase	B
labelling	O
,	O
that	O
StPT2	B
was	O
in	O
the	O
epidermal	O
plasma	O
membrane	O
and	O
restricted	O
to	O
the	O
apical	O
surface	O
.	O

This	O
is	O
the	O
first	O
evidence	O
of	O
polar	O
plasma	O
membrane	O
localisation	O
of	O
a	O
plant	O
nutrient	O
transporter	O
and	O
is	O
consistent	O
with	O
a	O
role	O
for	O
StPT2	B
in	O
phosphate	O
capture	O
and	O
uptake	O
.	O

Purification	O
of	O
N	O
-	O
terminally	O
truncated	O
histone	B
H2A	I
-	O
monoubiquitin	O
conjugates	O
from	O
leukemic	O
cell	O
nuclei	O
:	O
probable	O
proteolytic	O
products	O
of	O
ubiquitinated	O
H2A	B
.	O

To	O
gain	O
insight	O
into	O
the	O
significance	O
of	O
nuclear	O
ubiquitinated	O
proteins	O
,	O
two	O
serial	O
extracts	O
prepared	O
from	O
various	O
leukemic	O
cells	O
were	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
ubiquitin	B
antibody	O
.	O

Two	O
previously	O
unidentified	O
ubiquitinated	O
proteins	O
with	O
molecular	O
masses	O
of	O
10	O
and	O
17	O
kDa	O
were	O
found	O
in	O
8	O
M	O
urea	O
-	O
soluble	O
extracts	O
,	O
obtained	O
from	O
Tris	O
-	O
buffer	O
-	O
insoluble	O
materials	O
,	O
of	O
acute	O
myeloid	O
leukemia	O
OCI	O
/	O
AML	O
1a	O
cells	O
and	O
the	O
cells	O
from	O
the	O
leukemia	O
patients	O
.	O

Both	O
proteins	O
were	O
successfully	O
purified	O
from	O
the	O
OCI	O
/	O
AML	O
1a	O
cells	O
and	O
identified	O
as	O
monoubiquitin	O
-	O
truncated	O
H2A	B
conjugates	O
,	O
the	O
10	O
kDa	O
ubiquitinated	O
H2A	B
(	O
115	O
-	O
129	O
)	O
and	O
the	O
17	O
kDa	O
ubiquitinated	O
H2A	B
(	O
54	O
-	O
129	O
)	O
,	O
suggesting	O
that	O
both	O
proteins	O
were	O
produced	O
by	O
limited	O
proteolysis	O
of	O
an	O
intact	O
form	O
(	O
23	O
kDa	O
)	O
of	O
ubiquitinated	O
H2A	B
(	O
1	O
-	O
129	O
)	O
.	O

The	O
17	O
kDa	O
protein	O
as	O
well	O
as	O
the	O
23	O
kDa	O
ubiquitinated	O
histone	B
H2A	I
were	O
localised	O
in	O
chromatin	O
fractions	O
of	O
the	O
OCI	O
/	O
AML	O
cells	O
and	O
released	O
by	O
high	O
concentrations	O
of	O
salt	O
in	O
a	O
micrococcal	O
nuclease	O
-	O
sensitive	O
manner	O
,	O
suggesting	O
their	O
association	O
with	O
chromatin	O
.	O

In	O
contrast	O
,	O
the	O
10	O
kDa	O
protein	O
remained	O
insoluble	O
even	O
when	O
the	O
nuclei	O
were	O
treated	O
with	O
nuclease	O
under	O
high	O
salt	O
concentrations	O
,	O
presumably	O
due	O
to	O
binding	O
to	O
the	O
nuclear	O
matrix	O
.	O

An	O
antibody	O
recognising	O
H2A	B
(	O
70	O
-	O
81	O
)	O
also	O
detected	O
the	O
17	O
kDa	O
protein	O
in	O
anti	O
-	O
ubiquitin	B
immunoprecipitates	O
obtained	O
from	O
the	O
OCI	O
/	O
AML	O
cell	O
nuclei	O
.	O

In	O
addition	O
,	O
the	O
17	O
kDa	O
protein	O
levels	O
in	O
THP-1	O
cells	O
were	O
transiently	O
increased	O
,	O
concomitant	O
with	O
a	O
decrease	O
in	O
the	O
23	O
kDa	O
ubiquitinated	O
H2A	B
,	O
by	O
treatment	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
or	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
,	O
both	O
of	O
which	O
induce	O
differentiation	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
probable	O
proteolytic	O
products	O
of	O
ubiquitinated	O
H2A	B
,	O
which	O
might	O
have	O
a	O
role	O
in	O
nuclear	O
functions	O
.	O

[	O
Metabolic	O
intolerance	O
to	O
exercise	O
]	O

Exercise	O
intolerance	O
(	O
EI	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
medical	O
attention	O
,	O
although	O
it	O
is	O
sometimes	O
difficult	O
to	O
come	O
to	O
a	O
final	O
diagnosis	O
.	O

However	O
,	O
there	O
is	O
a	O
group	O
of	O
patients	O
in	O
whom	O
EI	O
is	O
due	O
to	O
a	O
metabolic	O
dysfunction	O
.	O

McArdle	O
's	O
disease	O
(	O
type	O
V	O
glucogenosis	O
)	O
is	O
due	O
to	O
myophosphorylase	B
(	O
MPL	B
)	O
deficiency	O
.	O

The	O
ischemic	O
exercise	O
test	O
shows	O
a	O
flat	O
lactate	O
curve	O
.	O

The	O
most	O
frequent	O
mutations	O
in	O
the	O
PYGM	B
gene	O
(	O
MPL	B
gene	O
)	O
in	O
Spanish	O
patients	O
with	O
MPL	B
deficiency	O
are	O
R49X	O
and	O
W797R	O
.	O

Carnitine	B
palmitoyltransferase	I
(	I
CPT	I
)	I
II	I
deficiency	O
is	O
invariably	O
associated	O
to	O
repetitive	O
episodes	O
of	O
myoglobinuria	O
triggered	O
by	O
exercise	O
,	O
cold	O
,	O
fever	O
or	O
fasting	O
.	O

The	O
diagnosis	O
depends	O
on	O
the	O
demonstration	O
of	O
CPT	B
II	I
deficiency	O
in	O
muscle	O
.	O

The	O
most	O
frequent	O
mutation	O
in	O
the	O
CPT2	B
gene	O
is	O
the	O
S113L	O
.	O

Patients	O
with	O
muscle	O
adenylate	O
deaminase	O
deficiency	O
usually	O
show	O
either	O
a	O
mild	O
myopathy	O
or	O
no	O
symptom	O
.	O

The	O
diagnosis	O
is	O
based	O
on	O
the	O
absence	O
of	O
enzyme	O
activity	O
in	O
muscle	O
and	O
the	O
lack	O
of	O
rise	O
of	O
ammonia	O
in	O
the	O
forearm	O
ischemic	O
exercise	O
test	O
.	O

The	O
mutation	O
Q12X	O
in	O
the	O
AMPD1	B
gene	O
is	O
strongly	O
associated	O
with	O
the	O
disease	O
.	O

Exercise	O
intolerance	O
is	O
a	O
common	O
complaint	O
in	O
patients	O
with	O
mitochondrial	O
respiratory	O
chain	O
(	O
MRC	O
)	O
deficiencies	O
,	O
although	O
it	O
is	O
often	O
overshadowed	O
by	O
other	O
symptoms	O
and	O
signs	O
.	O

Only	O
recently	O
we	O
have	O
come	O
to	O
appreciate	O
that	O
exercise	O
intolerance	O
can	O
be	O
the	O
sole	O
presentation	O
of	O
defects	O
in	O
the	O
mtDNA	O
,	O
particularly	O
in	O
complex	O
I	O
,	O
complex	O
III	O
,	O
complex	O
IV	O
,	O
or	O
in	O
some	O
tRNAs	O
.	O

In	O
addition	O
,	O
myoglobinuria	O
can	O
be	O
observed	O
in	O
patients	O
under	O
statin	O
treatment	O
,	O
particularly	O
if	O
associated	O
with	O
fibrates	O
,	O
due	O
to	O
an	O
alteration	O
in	O
the	O
assembly	O
of	O
the	O
complex	O
IV	O
of	O
the	O
MRC	O
.	O

Protein	B
kinase	I
network	O
in	O
the	O
regulation	O
of	O
phosphorylation	O
and	O
dephosphorylation	O
of	O
smooth	O
muscle	O
myosin	B
light	I
chain	I
.	O

The	O
contraction	O
of	O
smooth	O
muscle	O
is	O
regulated	O
primarily	O
by	O
intracellular	O
Ca2	O
+	O
signal	O
.	O

It	O
is	O
well	O
established	O
that	O
the	O
elevation	O
of	O
the	O
cytosolic	O
Ca2	O
+	O
level	O
activates	O
myosin	B
light	I
chain	I
kinase	I
,	O
which	O
phosphorylates	O
20	O
kDa	O
regulatory	O
myosin	B
light	I
chain	I
and	O
activates	O
myosin	B
ATPase	I
.	O

The	O
simultaneous	O
measurement	O
of	O
cytosolic	O
Ca2	O
+	O
concentration	O
and	O
force	O
development	O
revealed	O
that	O
the	O
alteration	O
of	O
the	O
Ca2	O
+	O
-	O
sensitivity	O
of	O
the	O
contractile	O
apparatus	O
as	O
well	O
as	O
the	O
Ca2	O
+	O
signal	O
plays	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
smooth	O
muscle	O
contraction	O
.	O

The	O
fluctuation	O
of	O
an	O
extent	O
of	O
myosin	B
phosphorylation	O
for	O
a	O
given	O
change	O
in	O
Ca2	O
+	O
concentration	O
is	O
considered	O
to	O
contribute	O
to	O
the	O
major	O
mechanisms	O
regulating	O
the	O
Ca2	O
+	O
-	O
sensitivity	O
.	O

The	O
level	O
of	O
myosin	B
phosphorylation	O
is	O
determined	O
by	O
the	O
balance	O
between	O
phosphorylation	O
and	O
dephosphorylation	O
.	O

The	O
phosphorylation	O
level	O
for	O
a	O
given	O
Ca2	O
+	O
elevation	O
is	O
increased	O
either	O
by	O
Ca2	O
+	O
-	O
independent	O
activation	O
of	O
phosphorylation	O
process	O
or	O
inhibition	O
of	O
dephosphorylation	O
.	O

In	O
the	O
last	O
decade	O
,	O
the	O
isolation	O
and	O
cloning	O
of	O
myosin	B
phosphatase	I
facilitated	O
the	O
understanding	O
of	O
regulatory	O
mechanism	O
of	O
dephosphorylation	O
process	O
at	O
the	O
molecular	O
level	O
.	O

The	O
inhibition	O
of	O
myosin	B
phosphatase	I
can	O
be	O
achieved	O
by	O
(	O
1	O
)	O
alteration	O
of	O
hetrotrimeric	O
structure	O
,	O
(	O
2	O
)	O
phosphorylation	O
of	O
110	O
kDa	O
regulatory	O
subunit	O
MYPT1	B
at	O
the	O
specific	O
site	O
and	O
(	O
3	O
)	O
inhibitory	O
protein	O
CPI-17	B
upon	O
its	O
phosphorylation	O
.	O

Rho	B
-	I
kinase	I
was	O
first	O
identified	O
to	O
phosphorylate	O
MYPT1	B
,	O
and	O
later	O
many	O
kinases	B
were	O
found	O
to	O
phosphorylate	O
MYPT1	B
and	O
inhibit	O
dephosphorylation	O
of	O
myosin	B
.	O

Similarly	O
,	O
the	O
phosphorylation	O
of	O
CPI-17	B
can	O
be	O
catalysed	O
by	O
multiple	O
kinases	B
.	O

Moreover	O
,	O
the	O
myosin	B
light	I
chain	I
can	O
be	O
phosphorylated	O
by	O
not	O
only	O
authentic	O
myosin	B
light	I
chain	I
kinase	I
in	O
a	O
Ca2	O
+	O
-	O
dependent	O
manner	O
but	O
also	O
by	O
multiple	O
kinases	B
in	O
a	O
Ca2	O
+	O
-	O
independent	O
manner	O
,	O
thus	O
adding	O
a	O
novel	O
mechanism	O
to	O
the	O
regulation	O
of	O
the	O
Ca2	O
+	O
-	O
sensitivity	O
by	O
regulating	O
the	O
phosphorylation	O
process	O
.	O

It	O
is	O
now	O
clarified	O
that	O
the	O
protein	B
kinase	I
network	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
myosin	B
phosphorylation	O
and	O
dephosphorylation	O
.	O

However	O
,	O
the	O
physiological	O
role	O
of	O
each	O
component	O
remains	O
to	O
be	O
determined	O
.	O

One	O
approach	O
to	O
accomplish	O
this	O
purpose	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
the	O
dominant	O
negative	O
mutants	O
of	O
the	O
signalling	O
molecule	O
on	O
the	O
smooth	O
muscle	O
contraction	O
.	O

In	O
this	O
regards	O
,	O
a	O
protein	O
transduction	O
technique	O
utilizing	O
the	O
cell	O
-	O
penetrating	O
peptides	O
would	O
provide	O
a	O
useful	O
tool	O
.	O

In	O
the	O
preliminary	O
study	O
,	O
we	O
succeeded	O
in	O
introducing	O
a	O
fragment	O
of	O
MYPT1	B
into	O
the	O
arterial	O
strips	O
,	O
and	O
found	O
enhancement	O
of	O
contraction	O
.	O

Apolipoprotein	B
D	I
levels	O
are	O
elevated	O
in	O
prefrontal	O
cortex	O
of	O
subjects	O
with	O
Alzheimer	O
's	O
disease	O
:	O
no	O
relation	O
to	O
apolipoprotein	B
E	I
expression	O
or	O
genotype	O
.	O

BACKGROUND	O
:	O

Apolipoprotein	B
E	I
(	O
apoE	B
)	O
has	O
been	O
implicated	O
in	O
the	O
pathology	O
of	O
AD	O
ever	O
since	O
inheritance	O
of	O
the	O
epsilon4	O
allele	O
was	O
shown	O
to	O
be	O
an	O
important	O
risk	O
factor	O
for	O
the	O
development	O
of	O
AD	O
.	O

Apolipoprotein	B
D	I
(	O
apoD	B
)	O
is	O
elevated	O
in	O
association	O
with	O
several	O
central	O
nervous	O
system	O
disorders	O
,	O
including	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
and	O
has	O
been	O
proposed	O
to	O
be	O
an	O
especially	O
robust	O
marker	O
for	O
brain	O
regions	O
specifically	O
affected	O
by	O
particular	O
neuropathologies	O
.	O

Progressive	O
cognitive	O
decline	O
is	O
the	O
core	O
clinical	O
feature	O
of	O
AD	O
and	O
is	O
associated	O
with	O
disturbances	O
in	O
the	O
prefrontal	O
cortex	O
.	O

METHODS	O
:	O

We	O
measured	O
apoD	B
levels	O
in	O
prefrontal	O
cortex	O
samples	O
obtained	O
postmortem	O
from	O
20	O
autopsy	O
-	O
confirmed	O
AD	O
subjects	O
and	O
40	O
control	O
subjects	O
.	O

RESULTS	O
:	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
analysis	O
revealed	O
a	O
significant	O
increase	O
in	O
apoD	B
expression	O
in	O
AD	O
subjects	O
compared	O
with	O
control	O
subjects	O
(	O
.218	O
+	O
/-	O
.029	O
microg	O
/	O
mg	O
protein	O
vs.117	O
+	O
/-	O
.011	O
microg	O
/	O
mg	O
protein	O
;	O
p	O
=	O
0003	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
apoD	B
expression	O
between	O
early	O
-	O
onset	O
and	O
late	O
-	O
onset	O
Alzheimer	O
's	O
subjects	O
.	O

Apolipoprotein	B
D	I
expression	O
levels	O
were	O
not	O
correlated	O
with	O
apoE	B
levels	O
,	O
nor	O
were	O
they	O
correlated	O
with	O
inheritance	O
of	O
the	O
APOE	B
epsilon4	O
allele	O
.	O

CONCLUSIONS	O
:	O

These	O
findings	O
suggest	O
that	O
apoD	B
may	O
be	O
related	O
to	O
the	O
cognitive	O
decline	O
observed	O
in	O
AD	O
patients	O
and	O
that	O
apoD	B
and	O
apoE	B
likely	O
play	O
different	O
roles	O
in	O
the	O
pathogenesis	O
of	O
AD	O
.	O

New	O
members	O
of	O
the	O
Escherichia	O
coli	O
sigmaE	B
regulon	O
identified	O
by	O
a	O
two	O
-	O
plasmid	O
system	O
.	O

A	O
previously	O
established	O
method	O
,	O
based	O
on	O
a	O
two	O
-	O
plasmid	O
system	O
,	O
was	O
used	O
to	O
identify	O
promoters	O
recognized	O
by	O
RNA	B
polymerase	I
containing	O
the	O
extracytoplasmic	O
stress	O
response	O
sigma	B
factor	I
sigmaE	B
in	O
Escherichia	O
coli	O
.	O

In	O
addition	O
to	O
previously	O
identified	O
rpoE	B
-	O
dependent	O
promoters	O
,	O
11	O
new	O
promoters	O
potentially	O
directing	O
the	O
expression	O
of	O
15	O
genes	O
were	O
identified	O
that	O
were	O
active	O
only	O
after	O
over	O
-	O
expression	O
of	O
rpoE	B
.	O

The	O
promoters	O
were	O
confirmed	O
and	O
transcriptional	O
start	O
points	O
of	O
the	O
promoters	O
were	O
determined	O
by	O
primer	O
extension	O
analysis	O
and	O
S1	B
-	I
nuclease	I
mapping	O
.	O

All	O
the	O
promoters	O
contained	O
sequences	O
similar	O
to	O
the	O
consensus	O
sequence	O
of	O
rpoE	B
-	O
dependent	O
promoters	O
.	O

The	O
new	O
rpoE	B
-	O
dependent	O
promoters	O
governed	O
expression	O
of	O
genes	O
encoding	O
proteins	O
involved	O
in	O
primary	O
metabolism	O
(	O
fusA	B
,	O
tufA	B
,	O
recR	B
)	O
,	O
phospholipid	O
and	O
lipopolysaccharide	O
biosynthesis	O
(	O
psd	B
,	O
lpxP	B
)	O
,	O
signal	O
transduction	O
(	O
sixA	B
)	O
,	O
proposed	O
inner	O
or	O
outer	O
membrane	O
proteins	O
(	O
bacA	B
,	O
sbmA	B
,	O
smpA	B
,	O
yeaY	B
)	O
,	O
and	O
proteins	O
with	O
unknown	O
function	O
(	O
ybaB	B
,	O
yaiW	B
,	O
yiiS	B
,	O
yiiT	B
,	O
yfeY	B
)	O
.	O

Regulation	O
of	O
the	O
C	B
-	I
X	I
-	I
C	I
chemokine	I
,	O
mob-1	B
,	O
gene	O
expression	O
in	O
primary	O
rat	O
hepatocytes	O
.	O

The	O
chemokine	B
,	O
mob-1	B
,	O
is	O
involved	O
in	O
inflammatory	O
and	O
immune	O
responses	O
and	O
may	O
be	O
an	O
important	O
mediator	O
of	O
the	O
inflammatory	O
response	O
in	O
the	O
liver	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
upstream	O
signal	O
pathways	O
that	O
could	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
mob-1	B
expression	O
.	O

We	O
have	O
found	O
that	O
in	O
primary	O
rat	O
hepatocytes	O
the	O
isolation	O
and	O
subsequent	O
culture	O
of	O
these	O
cells	O
induced	O
mob-1	B
expression	O
.	O

A	O
similar	O
induction	O
of	O
mob-1	B
mRNA	O
was	O
observed	O
when	O
the	O
hepatocytes	O
were	O
stimulated	O
with	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
.	O

When	O
hepatocytes	O
were	O
stimulated	O
with	O
IFN	B
-	I
gamma	I
or	O
cytokine	B
mixture	O
(	O
IFN	B
-	I
gamma	I
,	O
interleukin-1beta	B
and	O
tumour	B
necrosis	I
factor	I
-	I
alpha	I
)	O
,	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
,	O
p38	B
and	O
extracellular	B
-	I
regulated	I
kinase	I
(	O
ERK	B
)	O
were	O
phosphorylated	O
,	O
suggesting	O
an	O
involvement	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinases	I
(	O
MAPK	B
)	O
in	O
the	O
induction	O
of	O
mob-1	B
expression	O
.	O

The	O
p38	B
kinase	B
inhibitor	O
,	O
SB	O
203580	O
,	O
and	O
the	O
NF	B
-	I
kappaB	I
inhibitor	O
,	O
MG-132	O
,	O
inhibited	O
the	O
induction	O
of	O
mob-1	B
mRNA	O
and	O
the	O
effects	O
were	O
not	O
additive	O
.	O

These	O
results	O
demonstrate	O
that	O
in	O
primary	O
rat	O
hepatocytes	O
the	O
transient	O
induction	O
of	O
mob-1	B
expression	O
was	O
regulated	O
by	O
p38	B
kinase	B
and	O
NF	B
-	I
kappaB	I
through	O
a	O
common	O
regulatory	O
pathway	O
.	O

A	O
synthetic	O
peptide	O
from	O
transforming	B
growth	I
factor	I
beta	I
type	I
III	I
receptor	I
inhibits	O
liver	O
fibrogenesis	O
in	O
rats	O
with	O
carbon	O
tetrachloride	O
liver	O
injury	O
.	O

Transforming	B
growth	I
factor	I
beta1	I
(	O
TGF	B
-	I
beta1	I
)	O
is	O
a	O
pleiotropic	O
cytokine	B
,	O
which	O
displays	O
potent	O
profibrogenic	O
effects	O
and	O
is	O
highly	O
expressed	O
in	O
fibrotic	O
livers	O
.	O

For	O
this	O
reason	O
,	O
development	O
of	O
TGF	B
-	I
B1	I
inhibitors	O
might	O
be	O
of	O
great	O
importance	O
to	O
control	O
liver	O
fibrogenesis	O
as	O
well	O
as	O
other	O
undesired	O
side	O
effects	O
due	O
to	O
this	O
cytokine	B
.	O

Potential	O
peptide	O
inhibitors	O
of	O
TGF	B
-	I
beta1	I
(	O
derived	O
from	O
TGF	B
-	I
beta1	I
and	O
from	O
its	O
type	O
III	O
receptor	O
)	O
were	O
tested	O
in	O
vitro	O
and	O
in	O
vivo	O
using	O
different	O
assays	O
.	O

Peptides	O
P11	O
and	O
P12	O
,	O
derived	O
from	O
TGF	B
-	I
beta1	I
,	O
and	O
P54	O
and	O
P144	O
,	O
derived	O
from	O
its	O
type	O
III	O
receptor	O
,	O
prevented	O
TGF	B
-	I
beta1	I
-	O
dependent	O
inhibition	O
of	O
MV1Lu	O
proliferation	O
in	O
vitro	O
and	O
markedly	O
reduced	O
binding	O
of	O
TGF	B
-	I
beta1	I
to	O
its	O
receptors	O
.	O

P144	O
blocked	O
TGF	B
-	I
beta1	I
-	O
dependent	O
stimulation	O
of	O
a	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
human	O
alpha2	B
(	I
I	I
)	I
collagen	I
promoter	O
.	O

Intraperitoneal	O
administration	O
of	O
P144	O
also	O
showed	O
potent	O
antifibrogenic	O
activity	O
in	O
vivo	O
in	O
the	O
liver	O
of	O
rats	O
receiving	O
CCl4	O
.	O

These	O
rats	O
also	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
number	O
of	O
activated	O
hepatic	O
stellate	O
cells	O
as	O
compared	O
with	O
those	O
treated	O
with	O
saline	O
only	O
.	O

These	O
results	O
suggest	O
that	O
short	O
synthetic	O
peptides	O
derived	O
from	O
TGF	B
-	I
beta1	I
type	I
III	I
receptor	I
may	O
be	O
of	O
value	O
in	O
reducing	O
liver	O
fibrosis	O
in	O
chronic	O
liver	O
injury	O
.	O

Ribosomal	O
RNA	O
and	O
ribosomal	O
proteins	O
in	O
corynebacteria	O
.	O

Ribosomal	O
RNAs	O
(	O
rRNAs	O
)	O
(	O
16S	O
,	O
23S	O
,	O
5S	O
)	O
encoded	O
by	O
the	O
rrn	O
operons	O
and	O
ribosomal	O
proteins	O
play	O
a	O
very	O
important	O
role	O
in	O
the	O
formation	O
of	O
ribosomes	O
and	O
in	O
the	O
control	O
of	O
translation	O
.	O

Five	O
copies	O
of	O
the	O
rrn	O
operon	O
were	O
reported	O
by	O
hybridization	O
studies	O
in	O
Brevibacterium	O
(	O
Corynebacterium	O
)	O
lactofermentum	O
but	O
the	O
genome	O
sequence	O
of	O
Corynebacterium	O
glutamicum	O
provided	O
evidence	O
for	O
six	O
rrn	O
copies	O
.	O

All	O
six	O
copies	O
of	O
the	O
C.	O
glutamicum	O
16S	O
rRNA	O
have	O
a	O
size	O
of	O
1523	O
bp	O
and	O
each	O
of	O
the	O
six	O
copies	O
of	O
the	O
5S	O
contain	O
120	O
bp	O
whereas	O
size	O
differences	O
are	O
found	O
between	O
the	O
six	O
copies	O
of	O
the	O
23S	O
rRNA	O
.	O

The	O
anti	O
-	O
Shine	O
-	O
Dalgarno	O
sequence	O
at	O
the	O
3'-end	O
of	O
the	O
16S	O
rRNA	O
was	O
5'-CCUCCUUUC-3	O
'	O
.	O

Each	O
rrn	O
operon	O
is	O
transcribed	O
as	O
a	O
large	O
precursor	O
rRNA	O
(	O
pre	O
-	O
rRNA	O
)	O
that	O
is	O
processed	O
by	O
RNaseIII	B
and	O
other	O
RNases	B
at	O
specific	O
cleavage	O
boxes	O
that	O
have	O
been	O
identified	O
in	O
the	O
C.	O
glutamicum	O
pre	O
-	O
rRNA	O
.	O

A	O
secondary	O
structure	O
of	O
the	O
C.	O
glutamicum	O
16S	O
rRNA	O
is	O
proposed	O
.	O

The	O
16S	O
rRNA	O
sequence	O
has	O
been	O
used	O
as	O
a	O
molecular	O
evolution	O
clock	O
allowing	O
the	O
deduction	O
of	O
a	O
phylogenetic	O
tree	O
of	O
all	O
Corynebacterium	O
species	O
.	O

In	O
C.	O
glutamicum	O
,	O
there	O
are	O
11	O
ribosomal	O
protein	O
gene	O
clusters	O
encoding	O
42	O
ribosomal	O
proteins	O
.	O

The	O
organization	O
of	O
some	O
of	O
the	O
ribosomal	O
protein	O
gene	O
cluster	O
is	O
identical	O
to	O
that	O
of	O
Escherichia	O
coli	O
whereas	O
in	O
other	O
clusters	O
the	O
organization	O
of	O
the	O
genes	O
is	O
rather	O
different	O
.	O

Some	O
specific	O
ribosomal	O
protein	O
genes	O
are	O
located	O
in	O
a	O
different	O
cluster	O
in	O
C.	O
glutamicum	O
when	O
compared	O
with	O
E.	O
coli	O
,	O
indicating	O
that	O
the	O
control	O
of	O
expression	O
of	O
these	O
genes	O
is	O
different	O
in	O
E.	O
coli	O
and	O
C.	O
glutamicum	O
.	O

Vitamin	O
D	O
inhibits	O
G1	O
to	O
S	O
progression	O
in	O
LNCaP	O
prostate	O
cancer	O
cells	O
through	O
p27Kip1	B
stabilization	O
and	O
Cdk2	B
mislocalization	O
to	O
the	O
cytoplasm	O
.	O

1,25-	O
(	O
OH	O
)	O
2	O
vitamin	O
D3	O
(	O
1,25-	O
(	O
OH	O
)	O
2D3	O
)	O
exerts	O
antiproliferative	O
effects	O
via	O
cell	O
cycle	O
regulation	O
in	O
a	O
variety	O
of	O
tumor	O
cells	O
,	O
including	O
prostate	O
.	O

We	O
have	O
previously	O
shown	O
that	O
in	O
the	O
human	O
prostate	O
cancer	O
cell	O
line	O
LN	O
-	O
CaP	O
,	O
1,25-	O
(	O
OH	O
)	O
2D3	O
mediates	O
an	O
increase	O
in	O
cyclin	B
-	I
dependent	I
kinase	I
inhibitor	I
p27Kip1	B
levels	O
,	O
inhibition	O
of	O
cyclin	B
-	I
dependent	I
kinase	I
2	I
(	O
Cdk2	B
)	O
activity	O
,	O
hypophosphorylation	O
of	O
retinoblastoma	B
protein	I
,	O
and	O
accumulation	O
of	O
cells	O
in	O
G1	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanism	O
whereby	O
1,25-	O
(	O
OH	O
)	O
2D3	O
increases	O
p27	B
levels	O
.	O

1,25-	O
(	O
OH	O
)	O
2D3	O
had	O
no	O
effect	O
on	O
p27	B
mRNA	O
levels	O
or	O
on	O
the	O
regulation	O
of	O
a	O
3.5	O
-	O
kb	O
fragment	O
of	O
the	O
p27	B
promoter	O
.	O

The	O
rate	O
of	O
p27	B
protein	O
synthesis	O
was	O
not	O
affected	O
by	O
1,25-	O
(	O
OH	O
)	O
2D3	O
as	O
measured	O
by	O
luciferase	B
activity	O
driven	O
by	O
the	O
5	O
'	O
-	O
and	O
3	O
'	O
-	O
untranslated	O
regions	O
of	O
p27	B
that	O
regulate	O
p27	B
protein	O
synthesis	O
.	O

Pulse	O
-	O
chase	O
analysis	O
of	O
35S	O
-	O
labeled	O
p27	B
revealed	O
an	O
increased	O
p27	B
protein	O
half	O
-	O
life	O
with	O
1,25-	O
(	O
OH	O
)	O
2D3	O
treatment	O
.	O

Because	O
Cdk2	B
-	O
mediated	O
phosphorylation	O
of	O
p27	B
at	O
Thr187	O
targets	O
p27	B
for	O
Skp2	B
-	O
mediated	O
degradation	O
,	O
we	O
examined	O
the	O
phosphorylation	O
status	O
of	O
p27	B
in	O
1,25-	O
(	O
OH	O
)	O
2D3	O
-	O
treated	O
cells	O
.	O

1,25-	O
(	O
OH	O
)	O
2D3	O
decreased	O
levels	O
of	O
Thr187	O
phosphorylated	O
p27	B
,	O
consistent	O
with	O
inhibition	O
of	O
Thr187	O
phosphorylation	O
-	O
dependent	O
p27	B
degradation	O
.	O

In	O
addition	O
,	O
1,25-	O
(	O
OH	O
)	O
2D3	O
reduced	O
Skp2	B
protein	O
levels	O
in	O
LNCaP	O
cells	O
.	O

Cdk2	B
is	O
activated	O
in	O
the	O
nucleus	O
by	O
Cdk	B
-	I
activating	I
kinase	I
through	O
Thr160	O
phosphorylation	O
and	O
by	O
cdc25A	B
phosphatase	I
via	O
Thr14	O
and	O
Tyr15	O
dephosphorylation	O
.	O

Interestingly	O
,	O
1,25-	O
(	O
OH	O
)	O
2D3	O
decreased	O
nuclear	O
Cdk2	B
levels	O
as	O
assessed	O
by	O
subcellular	O
fractionation	O
and	O
confocal	O
microscopy	O
.	O

Inhibition	O
of	O
Cdk2	B
by	O
1,25-	O
(	O
OH	O
)	O
2D3	O
may	O
thus	O
involve	O
two	O
mechanisms	O
:	O
1	O
)	O
reduced	O
nuclear	O
Cdk2	B
available	O
for	O
cyclin	B
binding	O
and	O
activation	O
and	O
2	O
)	O
impairment	O
of	O
cyclin	B
E	I
-	O
Cdk2	B
-	O
dependent	O
p27	B
degradation	O
through	O
cytoplasmic	O
mislocalization	O
of	O
Cdk2	B
.	O

These	O
data	O
suggest	O
that	O
Cdk2	B
mislocalization	O
is	O
central	O
to	O
the	O
antiproliferative	O
effects	O
of	O
1,25-	O
(	O
OH	O
)	O
2D3	O
.	O

The	O
respiratory	O
arsenate	B
reductase	I
from	O
Bacillus	O
selenitireducens	O
strain	O
MLS10	O
.	O

The	O
respiratory	O
arsenate	B
reductase	I
from	O
the	O
Gram	O
-	O
positive	O
,	O
haloalkaliphile	O
,	O
Bacillus	O
selenitireducens	O
strain	O
MLS10	O
was	O
purified	O
and	O
characterized	O
.	O

It	O
is	O
a	O
membrane	O
bound	O
heterodimer	O
(	O
150	O
kDa	O
)	O
composed	O
of	O
two	O
subunits	O
ArrA	B
(	O
110	O
kDa	O
)	O
and	O
ArrB	B
(	O
34	O
kDa	O
)	O
,	O
with	O
an	O
apparent	O
K	O
(	O
m	O
)	O
for	O
arsenate	O
of	O
34	O
microM	O
and	O
V	O
(	O
max	O
)	O
of	O
2.5	O
micromol	O
min	O
(	O
-1	O
)	O
mg	O
(	O
-1	O
)	O
.	O

Optimal	O
activity	O
occurred	O
at	O
pH	O
9.5	O
and	O
150	O
g	O
l	O
(	O
-1	O
)	O
of	O
NaCl	O
.	O

Metal	O
analysis	O
(	O
inductively	O
coupled	O
plasma	O
mass	O
spectrometry	O
)	O
of	O
the	O
holoenzyme	O
and	O
sequence	O
analysis	O
of	O
the	O
catalytic	O
subunit	O
(	O
ArrA	B
;	O
the	O
gene	O
for	O
which	O
was	O
cloned	O
and	O
sequenced	O
)	O
indicate	O
it	O
is	O
a	O
member	O
of	O
the	O
DMSO	B
reductase	I
family	I
of	O
molybdoproteins	O
.	O

Organization	O
of	O
the	O
mouse	O
Zfhx1b	B
gene	O
encoding	O
the	O
two	O
-	O
handed	O
zinc	O
finger	O
repressor	O
Smad	B
-	I
interacting	I
protein-1	I
.	O

SIP1	B
,	O
a	O
member	O
of	O
the	O
deltaEF1	B
family	I
of	O
two	O
-	O
handed	O
zinc	O
finger	O
transcriptional	O
repressors	O
,	O
has	O
been	O
identified	O
as	O
a	O
Smad	B
-	O
binding	O
protein	O
.	O

Recently	O
,	O
mutations	O
in	O
the	O
human	O
SIP1	B
gene	O
(	O
ZFHX1B	B
)	O
have	O
been	O
implicated	O
in	O
Hirschsprung	O
disease	O
.	O

Here	O
we	O
document	O
extensively	O
the	O
structure	O
and	O
transcriptional	O
pattern	O
of	O
the	O
mouse	O
SIP1	B
gene	O
(	O
Zfhx1b	B
)	O
and	O
compare	O
it	O
to	O
homologues	O
from	O
other	O
species	O
.	O

The	O
overall	O
structure	O
of	O
Zfhx1b	B
is	O
highly	O
similar	O
to	O
that	O
of	O
the	O
deltaEF1	B
gene	O
(	O
Zfhx1a	B
)	O
,	O
confirming	O
their	O
close	O
evolutionary	O
relationship	O
.	O

In	O
contrast	O
to	O
Zfhx1a	B
,	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
the	O
SIP1	B
-	O
encoding	O
mouse	O
gene	O
is	O
very	O
complex	O
and	O
includes	O
several	O
alternative	O
exons	O
.	O

The	O
corresponding	O
5'-UTR	O
splicing	O
pattern	O
seems	O
to	O
be	O
conserved	O
between	O
species	O
and	O
suggests	O
a	O
role	O
in	O
its	O
transcriptional	O
and/or	O
translational	O
regulation	O
.	O

The	O
gene	O
also	O
codes	O
for	O
an	O
antisense	O
transcript	O
that	O
is	O
highly	O
conserved	O
between	O
human	O
and	O
mouse	O
.	O

Extrinsic	O
proteins	O
of	O
photosystem	B
II	I
:	O
an	O
intermediate	O
member	O
of	O
PsbQ	B
protein	I
family	I
in	O
red	O
algal	O
PS	B
II	I
.	O

The	O
oxygen	O
-	O
evolving	O
photosystem	B
II	I
(	O
PS	B
II	I
)	O
complex	O
of	O
red	O
algae	O
contains	O
four	O
extrinsic	O
proteins	O
of	O
12	O
kDa	O
,	O
20	O
kDa	O
,	O
33	O
kDa	O
and	O
cyt	B
c-550	I
,	O
among	O
which	O
the	O
20	O
kDa	O
protein	O
is	O
unique	O
in	O
that	O
it	O
is	O
not	O
found	O
in	O
other	O
organisms	O
.	O

We	O
cloned	O
the	O
gene	O
for	O
the	O
20	O
-	O
kDa	O
protein	O
from	O
a	O
red	O
alga	O
Cyanidium	O
caldarium	O
.	O

The	O
gene	O
consists	O
of	O
a	O
leader	O
sequence	O
which	O
can	O
be	O
divided	O
into	O
two	O
parts	O
:	O
one	O
for	O
transfer	O
across	O
the	O
plastid	O
envelope	O
and	O
the	O
other	O
for	O
transfer	O
into	O
thylakoid	O
lumen	O
,	O
indicating	O
that	O
the	O
gene	O
is	O
encoded	O
by	O
the	O
nuclear	O
genome	O
.	O

The	O
sequence	O
of	O
the	O
mature	O
20	O
-	O
kDa	O
protein	O
has	O
low	O
but	O
significant	O
homology	O
with	O
the	O
extrinsic	O
17	O
-	O
kDa	O
(	O
PsbQ	B
)	O
protein	O
of	O
PS	B
II	I
from	O
green	O
algae	O
Volvox	O
Carteri	O
and	O
Chlamydomonas	O
reinhardtii	O
,	O
as	O
well	O
as	O
the	O
PsbQ	B
protein	O
of	O
higher	O
plants	O
and	O
PsbQ	B
-	O
like	O
protein	O
from	O
cyanobacteria	O
.	O

Cross	O
-	O
reconstitution	O
experiments	O
with	O
combinations	O
of	O
the	O
extrinsic	O
proteins	O
and	O
PS	B
IIs	I
from	O
the	O
red	O
alga	O
Cy	O
.	O
caldarium	O
and	O
green	O
alga	O
Ch	O
.	O
reinhardtii	O
showed	O
that	O
the	O
extrinsic	O
20	O
-	O
kDa	O
protein	O
was	O
functional	O
in	O
place	O
of	O
the	O
green	O
algal	O
17	O
-	O
kDa	O
protein	O
on	O
binding	O
to	O
the	O
green	O
algal	O
PS	B
II	I
and	O
restoration	O
of	O
oxygen	O
evolution	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
the	O
20	O
-	O
kDa	O
protein	O
is	O
the	O
ancestral	O
form	O
of	O
the	O
extrinsic	O
17	O
-	O
kDa	O
protein	O
in	O
green	O
algal	O
and	O
higher	O
plant	O
PS	B
IIs	I
.	O

This	O
provides	O
an	O
important	O
clue	O
to	O
the	O
evolution	O
of	O
the	O
oxygen	O
-	O
evolving	O
complex	O
from	O
prokaryotic	O
cyanobacteria	O
to	O
eukaryotic	O
higher	O
plants	O
.	O

The	O
gene	O
coding	O
for	O
the	O
extrinsic	O
20	O
-	O
kDa	O
protein	O
was	O
named	O
psbQ	B
'	I
(	I
prime	I
)	I
.	O

Interaction	O
with	O
Tap42	B
is	O
required	O
for	O
the	O
essential	O
function	O
of	O
Sit4	B
and	O
type	B
2A	I
phosphatases	I
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
Pph21	B
and	O
Pph22	B
are	O
the	O
two	O
catalytic	B
subunits	I
of	I
type	I
2A	I
phosphatase	I
(	O
PP2Ac	B
)	O
,	O
and	O
Sit4	B
is	O
a	O
major	O
form	O
of	O
2A	O
-	O
like	O
phosphatase	B
.	O

The	O
function	O
of	O
these	O
phosphatases	B
requires	O
their	O
association	O
with	O
different	O
regulatory	O
subunits	O
.	O

In	O
addition	O
to	O
the	O
conventional	O
regulatory	O
subunits	O
,	O
namely	O
,	O
the	O
A	O
and	O
B	O
subunits	O
for	O
Pph21	B
/	I
22	I
and	O
the	O
Sap	B
proteins	O
for	O
Sit4	B
,	O
these	O
phosphatases	B
have	O
been	O
found	O
to	O
associate	O
with	O
a	O
protein	O
termed	O
Tap42	B
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
Sit4	B
and	O
PP2Ac	B
interact	O
with	O
Tap42	B
via	O
an	O
N	O
-	O
terminal	O
domain	O
that	O
is	O
conserved	O
in	O
all	O
type	O
2A	O
and	O
2A	O
-	O
like	O
phosphatases	B
.	O

We	O
found	O
that	O
the	O
Sit4	B
phosphatase	B
in	O
the	O
sit4	B
-	O
102	O
strain	O
contains	O
a	O
reverse	O
-	O
of	O
-	O
charge	O
amino	O
acid	O
substitution	O
within	O
its	O
Tap42	B
binding	O
domain	O
and	O
is	O
defective	O
for	O
formation	O
of	O
the	O
Tap42	B
-	O
Sit4	B
complex	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
interaction	O
with	O
Tap42	B
is	O
required	O
for	O
the	O
activity	O
as	O
well	O
as	O
for	O
the	O
essential	O
function	O
of	O
Sit4	B
and	O
PP2Ac	B
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
Tap42	B
is	O
able	O
to	O
interact	O
with	O
two	O
other	O
2A	O
-	O
like	O
phosphatases	B
,	O
Pph3	B
and	O
Ppg1	B
.	O

Effect	O
of	O
MG132	O
,	O
a	O
proteasome	O
inhibitor	O
,	O
on	O
the	O
expression	O
of	O
growth	B
related	I
oncogene	I
protein	I
-	I
alpha	I
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

Growth	B
related	I
oncogene	I
protein	I
-	I
alpha	I
(	O
GRO	B
-	I
alpha	I
)	O
is	O
a	O
member	O
of	O
C	B
-	I
X	I
-	I
C	I
chemokine	I
and	O
plays	O
an	O
important	O
role	O
in	O
inflammatory	O
responses	O
.	O

Expression	O
of	O
GRO	B
gene	I
family	I
is	O
regulated	O
by	O
a	O
number	O
of	O
factors	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
addressed	O
the	O
possible	O
regulation	O
of	O
GRO	B
-	I
alpha	I
expression	O
by	O
ubiquitin	B
-	O
proteasome	O
system	O
.	O

Cultures	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
were	O
treated	O
with	O
a	O
proteasome	O
inhibitor	O
,	O
MG132	O
,	O
and	O
the	O
levels	O
of	O
GRO	B
-	I
alpha	I
mRNA	O
were	O
analyzed	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
or	O
northern	O
blotting	O
.	O

Levels	O
of	O
GRO	B
-	I
alpha	I
protein	O
in	O
the	O
cell	O
-	O
conditioned	O
medium	O
were	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

MG132	O
alone	O
increased	O
the	O
levels	O
of	O
GRO	B
-	I
alpha	I
mRNA	O
and	O
protein	O
;	O
however	O
,	O
it	O
did	O
not	O
affect	O
the	O
GRO	B
-	I
alpha	I
mRNA	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
inhibited	O
the	O
LPS	O
-	O
induced	O
decrease	O
in	O
IkappaB	B
levels	O
.	O

Other	O
proteasome	O
inhibitors	O
,	O
MG115	O
and	O
lactacystin	O
,	O
also	O
induced	O
the	O
expression	O
of	O
GRO	B
-	I
alpha	I
mRNA	O
.	O

MG132	O
induced	O
the	O
phosphorylation	O
of	O
p38	B
MAPK	I
,	O
MEK	B
and	O
JNK	B
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
SB203580	O
,	O
an	O
inhibitor	O
of	O
p38	B
MAPK	I
,	O
suppressed	O
the	O
MG132	O
-	O
induced	O
GRO	B
-	I
alpha	I
expression	O
,	O
but	O
pretreatment	O
of	O
the	O
cells	O
with	O
U0126	O
,	O
PD98059	O
or	O
SP600125	O
,	O
inhibitors	O
of	O
MEK1	B
/	I
2	I
or	O
JNK	B
,	O
did	O
not	O
influence	O
the	O
effect	O
of	O
MG132	O
.	O

We	O
conclude	O
that	O
MG132	O
upregulates	O
GRO	B
-	I
alpha	I
expression	O
in	O
vascular	O
endothelial	O
cells	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
the	O
activation	O
of	O
p38	B
MAPK	I
.	O

CC	B
-	I
chemokine	I
receptor	I
2	I
required	O
for	O
bleomycin	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O

MCP-1	B
,	O
which	O
signals	O
via	O
the	O
CC	B
chemokine	I
receptor	I
2	I
(	O
CCR2	B
)	O
,	O
is	O
induced	O
in	O
lung	O
fibrosis	O
that	O
is	O
accompanied	O
by	O
mononuclear	O
cell	O
recruitment	O
and	O
activation	O
of	O
lung	O
fibroblasts	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
CCR2	B
in	O
lung	O
fibrosis	O
,	O
CCR2	B
knockout	O
(	O
ko	O
)	O
mice	O
were	O
used	O
in	O
a	O
model	O
of	O
bleomycin	O
-	O
induced	O
lung	O
fibrosis	O
.	O

Wild	O
type	O
(	O
wt	O
)	O
and	O
ko	O
mice	O
were	O
injected	O
endotracheally	O
with	O
bleomycin	O
to	O
induce	O
lung	O
injury	O
and	O
fibrosis	O
,	O
and	O
then	O
analyzed	O
for	O
degree	O
of	O
lung	O
fibrosis	O
and	O
cytokine	B
expression	O
.	O

The	O
results	O
showed	O
significantly	O
reduced	O
fibrosis	O
in	O
ko	O
mice	O
as	O
evidenced	O
by	O
decreased	O
lung	O
type	B
I	I
collagen	I
gene	O
expression	O
and	O
hydroxyproline	O
content	O
relative	O
to	O
those	O
in	O
wt	O
mice	O
.	O

Lung	O
TNF	B
-	I
alpha	I
and	O
TGF	B
-	I
beta1	I
expression	O
was	O
significantly	O
lower	O
in	O
ko	O
vs.	O
wt	O
mice	O
,	O
while	O
MCP-1	B
expression	O
was	O
unaffected	O
.	O

Interestingly	O
,	O
lung	O
alpha	B
-	I
smooth	I
muscle	I
actin	I
(	O
alpha	B
-	I
SMA	I
)	O
expression	O
,	O
a	O
marker	O
for	O
myofibroblast	O
differentiation	O
,	O
was	O
also	O
decreased	O
in	O
ko	O
mice	O
,	O
which	O
was	O
confirmed	O
by	O
analysis	O
of	O
isolated	O
lung	O
fibroblasts	O
.	O

Fibroblasts	O
from	O
ko	O
mice	O
exhibited	O
decreased	O
responsiveness	O
to	O
TGF	B
-	I
beta1	I
induced	O
alpha	B
-	I
SMA	I
expression	O
,	O
which	O
was	O
associated	O
with	O
reduced	O
expression	O
of	O
TGF	B
-	I
beta	I
receptor	I
II	I
(	O
TbetaRII	B
)	O
and	O
Smad3	B
.	O

These	O
findings	O
suggest	O
that	O
CCR2	B
signaling	O
plays	O
a	O
key	O
role	O
in	O
bleomycin	O
-	O
induced	O
pulmonary	O
fibrosis	O
by	O
regulating	O
fibrogenic	O
cytokine	B
expression	O
and	O
fibroblast	O
responsiveness	O
to	O
TGF	B
-	I
beta	I
.	O

ApoE	B
phenotype	O
influences	O
plasma	O
ASP	B
in	O
hyperapoB	O
subjects	O
.	O

Acylation	B
stimulating	I
protein	I
(	O
ASP	B
)	O
is	O
increased	O
in	O
cardiovascular	O
patients	O
who	O
often	O
present	O
with	O
dyslipidemias	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
influence	O
of	O
apolipoprotein	B
E	I
(	O
apoE	B
)	O
phenotype	O
and	O
lipids	O
on	O
ASP	B
.	O

Plasma	O
ASP	B
,	O
lipids	O
and	O
apoE	B
phenotype	O
were	O
measured	O
in	O
407	O
subjects	O
and	O
separated	O
according	O
to	O
the	O
75th	O
percentile	O
of	O
apolipoprotein	B
B	I
(	O
apoB	B
)	O
into	O
a	O
HyperapoB	O
(	O
HB	O
)	O
group	O
(	O
apoB	O
=	O
152	O
+	O
/	O
-	O
34	O
mg	O
/	O
dl	O
,	O
117	O
men	O
,	O
80	O
women	O
)	O
and	O
a	O
normal	O
apoB	B
(	O
NB	O
)	O
group	O
(	O
apoB	O
=	O
88	O
+	O
/	O
-	O
19	O
mg	O
/	O
dl	O
,	O
126	O
men	O
,	O
84	O
women	O
)	O
.	O

Triglyceride	O
(	O
TG	O
)	O
,	O
cholesterol	O
and	O
LDL	B
cholesterol	O
were	O
significantly	O
increased	O
in	O
HB	O
versus	O
NB	O
but	O
there	O
was	O
no	O
difference	O
in	O
age	O
or	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O

HB	O
had	O
increased	O
ASP	B
(	O
42	O
%	O
>	O
75th	O
percentile	O
,	O
median	O
=	O
48.4	O
nM	O
,	O
P	O
<	O
0.001	O
)	O
versus	O
NB	O
(	O
36.5	O
nM	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
ASP	B
in	O
NB	O
with	O
any	O
apoE3	B
variant	O
(	O
E3	O
/	O
3	O
=	O
41	O
nM	O
,	O
n	O
=	O
98	O
;	O
E3	O
/	O
4	O
=	O
46	O
nM	O
,	O
n	O
=	O
55	O
;	O
E3	O
/	O
2	O
=	O
50	O
nM	O
,	O
n	O
=	O
41	O
)	O
,	O
but	O
ASP	B
was	O
increased	O
in	O
E2	O
/	O
2	O
(	O
126	O
nM	O
,	O
n	O
=	O
9	O
)	O
,	O
and	O
E4	O
/	O
4	O
(	O
186	O
nM	O
,	O
n	O
=	O
5	O
,	O
P	O
<	O
0.001	O
ANOVA	O
)	O
.	O

In	O
HB	O
,	O
ASP	B
was	O
increased	O
in	O
three	O
apoE	B
phenotypes	O
:	O
E2	O
/	O
4	O
(	O
209	O
nM	O
,	O
n=6	O
)	O
,	O
E2	O
/	O
2	O
(	O
135	O
nM	O
,	O
n	O
=	O
6	O
)	O
and	O
E4	O
/	O
4	O
(	O
189	O
nM	O
,	O
n	O
=	O
26	O
)	O
,	O
P	O
<	O
0.001	O
ANOVA	O
relative	O
to	O
the	O
other	O
apoE	B
phenotypes	O
(	O
E3	O
/	O
3	O
=	O
50	O
nM	O
,	O
n	O
=	O
102	O
;	O
E3	O
/	O
4	O
=	O
41	O
nM	O
,	O
n	O
=	O
40	O
;	O
E3	O
/	O
2	O
=	O
87	O
nM	O
,	O
n	O
=	O
17	O
)	O
with	O
a	O
wide	O
range	O
of	O
values	O
.	O

By	O
stepwise	O
regression	O
analysis	O
,	O
the	O
best	O
model	O
that	O
predicted	O
ASP	B
was	O
:	O
[	O
plasma	O
non	O
-	O
esterified	O
fatty	O
acid	O
(	O
NEFA	O
)	O
+	O
TG	O
+	O
cholesterol	O
]	O
,	O
where	O
r	O
=	O
0.407	O
,	O
P	O
=	O
0.001	O
.	O

These	O
data	O
suggest	O
that	O
apoE	B
phenotype	O
may	O
potentially	O
influence	O
ASP	B
,	O
although	O
primarily	O
in	O
rare	O
apoE	B
phenotypes	O
.	O

Specific	O
elevation	O
in	O
plasma	O
tissue	B
plasminogen	I
activator	I
antigen	O
concentrations	O
in	O
South	O
Asians	O
relative	O
to	O
Europeans	O
.	O

Elevated	O
levels	O
of	O
haemostatic	O
factors	O
including	O
tissue	B
plasminogen	I
activator	I
(	O
t	B
-	I
PA	I
)	O
antigen	O
are	O
associated	O
with	O
coronary	O
heart	O
disease	O
in	O
Europeans	O
but	O
data	O
in	O
South	O
Asians	O
are	O
sparse	O
.	O

We	O
performed	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
111	O
healthy	O
men	O
and	O
women	O
aged	O
40	O
-	O
55	O
years	O
(	O
56	O
European	O
and	O
55	O
Asian	O
)	O
frequency	O
matched	O
across	O
a	O
wide	O
range	O
of	O
body	O
mass	O
index	O
(	O
17	O
-	O
34	O
kg	O
/	O
m2	O
)	O
.	O

All	O
subjects	O
had	O
detailed	O
adiposity	O
and	O
metabolic	O
measurements	O
,	O
and	O
five	O
haemostatic	O
factors	O
were	O
determined	O
.	O

South	O
Asians	O
had	O
greater	O
insulin	B
resistance	O
than	O
Europeans	O
(	O
fasting	O
insulin	B
geometric	O
mean	O
,	O
7.1	O
versus	O
4.7	O
microU	O
/	O
ml	O
,	O
and	O
2	O
-	O
h	O
insulin	B
,	O
37.3	O
versus	O
14.1	O
microU	O
/	O
ml	O
,	O
respectively	O
)	O
.	O

There	O
were	O
no	O
significant	O
ethnic	O
differences	O
in	O
the	O
mean	O
concentrations	O
of	O
fibrinogen	B
,	O
factor	B
VII	I
,	O
von	B
Willebrand	I
factor	I
,	O
or	O
fibrin	B
D	O
-	O
dimer	O
(	O
P	O
>	O
0.10	O
)	O
.	O

However	O
,	O
the	O
t	B
-	I
PA	I
antigen	O
concentration	O
was	O
significantly	O
elevated	O
in	O
South	O
Asians	O
compared	O
with	O
Europeans	O
(	O
mean	O
,	O
10.6	O
versus	O
8.2	O
ng	O
/	O
ml	O
,	O
P	O
=	O
0.001	O
)	O
.	O

t	B
-	I
PA	I
correlated	O
positively	O
in	O
both	O
ethnic	O
groups	O
with	O
features	O
of	O
the	O
metabolic	O
syndrome	O
but	O
the	O
ethnic	O
difference	O
in	O
t	B
-	I
PA	I
persisted	O
after	O
adjustment	O
for	O
adiposity	O
,	O
metabolic	O
and	O
inflammatory	O
variables	O
(	O
beta	O
=	O
2.0	O
,	O
95	O
%	O
confidence	O
interval	O
=	O
0.5	O
-	O
3.6	O
,	O
P	O
=	O
0.012	O
)	O
.	O

We	O
therefore	O
hypothesize	O
that	O
elevated	O
t	B
-	I
PA	I
antigen	O
may	O
be	O
a	O
novel	O
mechanism	O
contributing	O
to	O
increased	O
cardiovascular	O
risk	O
in	O
South	O
Asians	O
.	O

The	O
l	O
-	O
isomer	O
-	O
selective	O
transport	O
of	O
aspartic	O
acid	O
is	O
mediated	O
by	O
ASCT2	B
at	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

Aspartic	O
acid	O
(	O
Asp	O
)	O
undergoes	O
l	O
-	O
isomer	O
-	O
selective	O
efflux	O
transport	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
.	O

This	O
transport	O
system	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
l	O
-	O
and	O
d	O
-	O
Asp	O
levels	O
in	O
the	O
brain	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
responsible	O
transporters	O
and	O
elucidate	O
the	O
mechanism	O
for	O
l	O
-	O
isomer	O
-	O
selective	O
Asp	O
transport	O
at	O
the	O
BBB	O
.	O

The	O
l	O
-	O
isomer	O
-	O
selective	O
uptake	O
of	O
Asp	O
by	O
conditionally	O
immortalized	O
mouse	O
brain	O
capillary	O
endothelial	O
cells	O
used	O
as	O
an	O
in	O
vitro	O
model	O
of	O
the	O
BBB	O
took	O
place	O
in	O
an	O
Na+	O
-	O
and	O
pH	O
-	O
dependent	O
manner	O
.	O

This	O
process	O
was	O
inhibited	O
by	O
system	O
ASC	O
substrates	O
such	O
as	O
l	O
-	O
alanine	O
and	O
l	O
-	O
serine	O
,	O
suggesting	O
that	O
system	O
ASC	B
transporters	I
,	O
ASCT1	B
and	O
ASCT2	B
,	O
are	O
involved	O
in	O
the	O
l	O
-	O
isomer	O
selective	O
transport	O
.	O

Indeed	O
,	O
l	O
-	O
Asp	O
uptake	O
by	O
oocytes	O
injected	O
with	O
either	O
ASCT1	B
or	O
ASCT2	B
cRNA	O
took	O
place	O
in	O
a	O
similar	O
manner	O
to	O
that	O
in	O
cultured	O
BBB	O
cells	O
,	O
whereas	O
no	O
significant	O
d	O
-	O
Asp	O
uptake	O
occurred	O
.	O

Although	O
both	O
ASCT1	B
and	O
ASCT2	B
mRNA	O
were	O
expressed	O
in	O
the	O
cultured	O
BBB	O
cells	O
,	O
the	O
expression	O
of	O
ASCT2	B
mRNA	O
was	O
6.7	O
-	O
fold	O
greater	O
than	O
that	O
of	O
ASCT1	B
.	O

Moreover	O
,	O
immunohistochemical	O
analysis	O
suggests	O
that	O
ASCT2	B
is	O
localized	O
at	O
the	O
abluminal	O
side	O
of	O
the	O
mouse	O
BBB	O
.	O

These	O
results	O
suggest	O
that	O
ASCT2	B
plays	O
a	O
key	O
role	O
in	O
l	O
-	O
isomer	O
-	O
selective	O
Asp	O
efflux	O
transport	O
at	O
the	O
BBB	O
.	O

A	O
Korean	O
kindred	O
with	O
autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
and	O
mental	O
retardation	O
.	O

BACKGROUND	O
:	O

A	O
Korean	O
family	O
had	O
distinctive	O
clinical	O
and	O
neuroimaging	O
features	O
and	O
carried	O
the	O
same	O
genetic	O
mutation	O
that	O
was	O
found	O
in	O
a	O
previously	O
described	O
Japanese	O
kindred	O
with	O
autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
.	O

OBJECTIVE	O
:	O

To	O
describe	O
the	O
first	O
Korean	O
family	O
with	O
autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
.	O

METHODS	O
:	O

Members	O
of	O
a	O
large	O
family	O
,	O
including	O
9	O
affected	O
individuals	O
from	O
3	O
generations	O
,	O
underwent	O
a	O
comprehensive	O
genetic	O
,	O
clinical	O
,	O
electroencephalographic	O
,	O
neuropsychological	O
,	O
and	O
neuroimaging	O
evaluation	O
.	O

Affected	O
members	O
were	O
tested	O
for	O
possible	O
mutations	O
in	O
transmembrane	O
regions	O
1	O
through	O
3	O
of	O
the	O
neuronal	B
nicotinic	I
acetylcholine	I
receptor	I
alpha4	I
subunit	O
(	O
CHRNA4	B
)	O
by	O
direct	O
sequencing	O
and	O
subsequent	O
restriction	O
analysis	O
.	O

RESULTS	O
:	O

Seizures	O
began	O
in	O
childhood	O
,	O
presenting	O
as	O
nocturnal	O
episodes	O
of	O
staring	O
,	O
confusion	O
,	O
shouting	O
,	O
perioral	O
movements	O
,	O
unintelligible	O
speech	O
,	O
and	O
hand	O
waving	O
.	O

Some	O
patients	O
had	O
ictal	O
or	O
interictal	O
epileptiform	O
activity	O
in	O
the	O
temporal	O
and/or	O
frontocentral	O
areas	O
.	O

Neurological	O
examination	O
and	O
brain	O
magnetic	O
resonance	O
imaging	O
results	O
showed	O
no	O
abnormalities	O
,	O
except	O
that	O
all	O
patients	O
available	O
for	O
testing	O
had	O
mild	O
to	O
moderate	O
mental	O
retardation	O
.	O

Fluorodeoxyglucose	O
F	O
18	O
with	O
positron	O
emission	O
tomography	O
showed	O
mild	O
decreased	O
glucose	O
uptake	O
in	O
the	O
superior	O
and	O
middle	O
frontal	O
regions	O
,	O
more	O
so	O
on	O
the	O
left	O
than	O
on	O
the	O
right	O
.	O

Patient	O
response	O
to	O
carbamazepine	O
was	O
poor	O
.	O

All	O
affected	O
members	O
were	O
heterozygous	O
for	O
the	O
CHRNA4	B
Ser252Leu	O
mutation	O
.	O

CONCLUSIONS	O
:	O

Disorders	O
associated	O
with	O
mutations	O
in	O
the	O
transmembrane	O
region	O
2	O
of	O
CHRNA4	B
are	O
genetically	O
and	O
phenotypically	O
heterogeneous	O
.	O

Distinctive	O
features	O
of	O
this	O
kindred	O
include	O
(	O
1	O
)	O
mental	O
retardation	O
in	O
all	O
affected	O
members	O
available	O
for	O
testing	O
,	O
(	O
2	O
)	O
abnormal	O
brain	O
findings	O
on	O
fluorodeoxyglucose	O
F	O
18	O
with	O
positron	O
emission	O
tomography	O
,	O
(	O
3	O
)	O
poor	O
response	O
to	O
carbamazepine	O
,	O
and	O
(	O
4	O
)	O
full	O
penetrance	O
.	O

Complete	O
sequencing	O
and	O
expression	O
of	O
three	O
complement	B
components	I
,	O
C1r	B
,	O
C4	B
and	O
C1	B
inhibitor	I
,	O
of	O
the	O
classical	O
activation	O
pathway	O
of	O
the	O
complement	O
system	O
in	O
rainbow	O
trout	O
Oncorhynchus	O
mykiss	O
.	O

Three	O
complement	B
components	I
,	O
C1r	B
,	O
C4	B
and	O
C1	B
inhibitor	I
,	O
of	O
the	O
classical	O
activation	O
pathway	O
have	O
been	O
fully	O
sequenced	O
and	O
their	O
expression	O
investigated	O
in	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
.	O

Trout	O
C1r	B
cDNA	O
encodes	O
a	O
707-amino	O
-	O
acid	O
(	O
aa	O
)	O
protein	O
with	O
a	O
theoretical	O
M	O
(	O
r	O
)	O
of	O
77,200	O
.	O

The	O
trout	O
translation	O
shows	O
highest	O
homology	O
with	O
carp	O
C1r	B
/	I
s	I
,	O
and	O
lower	O
,	O
equal	O
homologies	O
to	O
mammalian	O
C1r	B
and	O
C1s	B
,	O
and	O
MASPs	B
from	O
other	O
vertebrate	O
species	O
.	O

However	O
,	O
phylogenetic	O
analysis	O
and	O
structural	O
features	O
suggest	O
that	O
the	O
trout	O
sequence	O
,	O
together	O
with	O
the	O
two	O
carp	O
sequences	O
,	O
are	O
the	O
orthologues	O
of	O
mammalian	O
C1r	B
.	O

The	O
trout	O
C4	B
cDNA	O
encodes	O
a	O
1,724-aa	O
protein	O
with	O
a	O
theoretical	O
M	O
(	O
r	O
)	O
of	O
192,600	O
.	O

The	O
trout	O
translation	O
shows	O
higher	O
homologies	O
to	O
the	O
carp	O
C4B	B
and	O
medaka	O
C4	B
,	O
but	O
lower	O
homologies	O
to	O
C4	B
from	O
other	O
species	O
and	O
the	O
carp	O
C4A	B
.	O

It	O
has	O
a	O
predicted	O
signal	O
peptide	O
of	O
22	O
aa	O
,	O
a	O
alpha	O
-	O
chain	O
of	O
773	O
aa	O
,	O
a	O
beta	O
-	O
chain	O
of	O
635	O
aa	O
and	O
a	O
lambda	O
-	O
chain	O
of	O
288	O
aa	O
.	O

Trout	O
C1	B
inhibitor	I
cDNA	O
encodes	O
a	O
611	O
-	O
aa	O
protein	O
with	O
a	O
theoretical	O
M	O
(	O
r	O
)	O
of	O
68,700	O
.	O

The	O
trout	O
translation	O
has	O
a	O
C	O
-	O
terminal	O
serpin	B
domain	O
with	O
high	O
homologies	O
with	O
mammalian	O
counterparts	O
(	O
~37	O
%	O
identities	O
)	O
,	O
and	O
a	O
longer	O
N	O
-	O
terminus	O
,	O
with	O
no	O
significant	O
homology	O
to	O
other	O
serpins	B
,	O
which	O
contains	O
two	O
Ig	B
-	O
like	O
domains	O
.	O

A	O
molecule	O
containing	O
two	O
Ig	B
-	O
like	O
domains	O
followed	O
by	O
a	O
serpin	B
domain	O
,	O
has	O
also	O
been	O
found	O
in	O
an	O
EST	O
clone	O
from	O
another	O
bony	O
fish	O
,	O
the	O
Japanese	O
flounder	O
.	O

This	O
suggests	O
a	O
unique	O
structural	O
feature	O
of	O
C1	B
inhibitor	I
in	O
fish	O
.	O

The	O
functional	O
significance	O
of	O
the	O
Ig	B
domains	O
is	O
discussed	O
.	O

The	O
liver	O
is	O
the	O
major	O
site	O
of	O
expression	O
of	O
the	O
three	O
trout	O
complement	B
components	I
,	O
C1r	B
,	O
C4	B
and	O
C1	B
inhibitor	I
,	O
although	O
their	O
expression	O
is	O
also	O
detectable	O
in	O
other	O
tissues	O
.	O

The	O
extra	O
-	O
hepatic	O
expression	O
of	O
complement	O
genes	O
may	O
be	O
important	O
for	O
local	O
protection	O
and	O
inflammatory	O
responses	O
.	O

Low	O
-	O
level	O
constitutive	O
expression	O
of	O
the	O
three	O
components	O
was	O
also	O
detectable	O
in	O
a	O
trout	O
monocyte	O
/	O
macrophage	O
cell	O
line	O
RTS-11	O
,	O
but	O
only	O
the	O
expression	O
of	O
C4	B
could	O
be	O
upregulated	O
by	O
LPS	O
.	O

Increase	O
of	O
inflammatory	O
state	O
in	O
overweight	O
adults	O
with	O
combined	O
hyperlipidemia	O
.	O

BACKGROUND	O
AND	O
AIM	O
:	O

Elevated	O
levels	O
of	O
acute	O
phase	O
reactants	O
are	O
found	O
in	O
patients	O
with	O
cardiovascular	O
disease	O
.	O

It	O
is	O
suggested	O
that	O
adipose	O
tissue	O
is	O
a	O
determinant	O
of	O
a	O
low	O
level	O
of	O
inflammatory	O
state	O
in	O
overweight	O
persons	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
,	O
whether	O
combined	O
hyperlipidemia	O
,	O
which	O
is	O
an	O
important	O
factor	O
of	O
atherosclerosis	O
,	O
has	O
influence	O
on	O
the	O
inflammatory	O
response	O
in	O
overweight	O
adults	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Levels	O
of	O
soluble	O
cell	O
adhesion	B
molecules	I
sICAM-1	B
,	O
sE	B
-	I
selectin	I
and	O
sP	B
-	I
selectin	I
,	O
PAI-1	B
Ag	O
(	O
by	O
Elisa	O
test	O
)	O
,	O
orosomucoid	B
(	O
ORM	B
)	O
and	O
transferrin	B
(	O
TRF	B
)	O
(	O
by	O
microturbidimetry	O
)	O
and	O
fibrinogen	B
(	O
FBG	B
)	O
according	O
to	O
Clauss	O
were	O
examined	O
in	O
peripheral	O
blood	O
of	O
overweight	O
adults	O
(	O
n	O
33	O
,	O
body	O
mass	O
index	O
27.1	O
+	O
/-	O
1.8	O
kg	O
/	O
m2	O
)	O
with	O
combined	O
hyperlipidemia	O
and	O
in	O
equal	O
numbers	O
of	O
age	O
,	O
sex	O
and	O
BMI	O
matched	O
non	O
-	O
hyperlipidemic	O
group	O
.	O

Overweight	O
adults	O
with	O
combined	O
hyperlipidemia	O
had	O
significantly	O
higher	O
plasma	O
levels	O
of	O
sICAM-1	B
(	O
376.5	O
+	O
/-	O
107.4	O
ng	O
/	O
mL	O
vs	O
239.3	O
+	O
/-	O
60.4	O
ng	O
/	O
mL	O
;	O
p	O
<	O
0.001	O
)	O
,	O
sE	B
-	I
selectin	I
(	O
70.4	O
+	O
/-	O
20.2	O
ng	O
/	O
mL	O
vs	O
48.5	O
+	O
/-	O
25.6	O
ng	O
/	O
mL	O
;	O
p	O
=	O
0.005	O
)	O
,	O
sP	B
-	I
selectin	I
(	O
228.2	O
+	O
/-	O
88.6	O
ng	O
/	O
mL	O
vs	O
123.1	O
+	O
/-	O
45.3	O
ng	O
/	O
mL	O
;	O
p	O
<	O
0.001	O
)	O
and	O
positive	O
acute	O
phase	O
proteins	O
ORM	B
(	O
0.82	O
+	O
/-	O
0.16	O
g	O
/	O
L	O
vs	O
0.64	O
+	O
/-	O
0.20	O
g	O
/	O
L	O
;	O
p	O
=	O
0.005	O
)	O
,	O
FBG	B
(	O
3.42	O
+	O
/-	O
0.54	O
g	O
/	O
L	O
vs	O
2.74	O
+	O
/-	O
0.57	O
g	O
/	O
L	O
;	O
p	O
=	O
0.037	O
)	O
and	O
PAI-1	B
Ag	O
(	O
97.9	O
+	O
/-	O
40.6	O
ng	O
/	O
mL	O
vs	O
56.4	O
+	O
/-	O
25.6	O
ng	O
/	O
mL	O
;	O
p	O
<	O
0.05	O
)	O
,	O
and	O
a	O
decrease	O
of	O
negative	O
acute	O
phase	O
protein	O
TRF	B
(	O
2.14	O
+	O
/-	O
0.40	O
g	O
/	O
L	O
vs	O
2.77	O
+	O
/-	O
0.45	O
g	O
/	O
L	O
;	O
p	O
<	O
0.001	O
)	O
compared	O
to	O
the	O
results	O
in	O
overweight	O
non	O
-	O
hyperlipidemic	O
controls	O
.	O

CONCLUSIONS	O
:	O

It	O
is	O
suggested	O
that	O
overweight	O
adults	O
have	O
an	O
increase	O
of	O
inflammatory	O
response	O
dependent	O
on	O
hyperlipidemia	O
.	O

It	O
was	O
apparent	O
from	O
the	O
elevation	O
of	O
sE	B
--	I
selectin	I
,	O
sP	B
--	I
selectin	I
and	O
sICAM-1	B
and	O
from	O
an	O
increase	O
of	O
systemic	O
inflammatory	O
response	O
according	O
to	O
the	O
increase	O
of	O
""""	O
positive	O
""""	O
acute	O
phase	O
proteins	O
(	O
APRs	O
)	O
and	O
the	O
decrease	O
of	O
""""	O
negative	O
""""	O
APR	O
protein	O
levels	O
in	O
these	O
patients	O
.	O

Domain	O
shuffling	O
has	O
been	O
the	O
main	O
mechanism	O
forming	O
new	O
hominoid	O
killer	B
cell	I
Ig	I
-	I
like	I
receptors	I
.	O

The	O
killer	B
cell	I
Ig	I
-	I
like	I
receptor	I
(	I
KIR	I
)	I
gene	I
family	I
encodes	O
MHC	B
class	I
I	I
-	O
specific	O
receptors	O
,	O
which	O
regulate	O
NK	O
cell	O
responses	O
and	O
are	O
also	O
expressed	O
on	O
subpopulations	O
of	O
T	O
cells	O
.	O

KIR	B
haplotypes	O
vary	O
in	O
gene	O
content	O
,	O
which	O
,	O
in	O
combination	O
with	O
allelic	O
polymorphism	O
,	O
extensively	O
diversifies	O
the	O
KIR	B
genotype	O
both	O
within	O
and	O
between	O
human	O
populations	O
.	O

Species	O
comparison	O
indicates	O
that	O
formation	O
of	O
new	O
KIR	B
genes	O
and	O
loss	O
of	O
old	O
ones	O
are	O
frequent	O
events	O
,	O
so	O
that	O
few	O
genes	O
are	O
conserved	O
even	O
between	O
closely	O
related	O
species	O
.	O

In	O
this	O
regard	O
,	O
the	O
hominoids	O
define	O
a	O
time	O
frame	O
that	O
is	O
particularly	O
informative	O
for	O
understanding	O
the	O
processes	O
of	O
KIR	B
evolution	O
and	O
its	O
potential	O
impact	O
on	O
killer	O
cell	O
biology	O
.	O

KIR	B
cDNA	O
were	O
characterized	O
from	O
PBMC	O
of	O
three	O
gorillas	O
,	O
and	O
genomic	O
DNA	O
were	O
characterized	O
for	O
six	O
additional	O
individuals	O
.	O

Eleven	O
gorilla	O
KIR	B
genes	O
were	O
defined	O
.	O

With	O
attainment	O
of	O
these	O
data	O
,	O
a	O
set	O
of	O
75	O
KIR	B
sequences	O
representing	O
five	O
hominoid	O
species	O
was	O
assembled	O
,	O
which	O
also	O
included	O
rhesus	O
monkey	O
,	O
cattle	O
,	O
and	O
rodent	O
KIR	B
.	O

Searching	O
this	O
data	O
set	O
for	O
recombination	O
events	O
,	O
and	O
phylogenetic	O
analysis	O
using	O
Bayesian	O
methods	O
,	O
demonstrated	O
that	O
new	O
KIR	B
were	O
usually	O
the	O
result	O
of	O
recombination	O
between	O
loci	O
in	O
which	O
complete	O
protein	O
domains	O
were	O
shuffled	O
.	O

Further	O
phylogenetic	O
analysis	O
of	O
the	O
KIR	B
sequences	O
after	O
removal	O
of	O
confounding	O
recombined	O
segments	O
showed	O
that	O
only	O
two	O
KIR	B
genes	O
,	O
KIR2DL4	B
and	O
KIR2DL5	B
,	O
have	O
been	O
preserved	O
throughout	O
hominoid	O
evolution	O
,	O
and	O
one	O
of	O
them	O
,	O
KIR2DL4	B
,	O
is	O
also	O
common	O
to	O
rhesus	O
monkey	O
and	O
hominoids	O
.	O

Other	O
KIR	B
genes	O
represent	O
recombinant	O
forms	O
present	O
in	O
a	O
minority	O
of	O
species	O
,	O
often	O
only	O
one	O
,	O
as	O
exemplified	O
by	O
8	O
of	O
the	O
11	O
gorilla	O
KIR	B
genes	O
.	O

Interleukin-4	B
inhibits	O
platelet	B
-	I
derived	I
growth	I
factor	I
-	O
induced	O
preadipocyte	O
proliferation	O
.	O

Interleukin-4	B
(	O
IL-4	B
)	O
activates	O
STAT6	B
in	O
3T3-L1	O
preadipocytes	O
but	O
its	O
functional	O
role	O
is	O
not	O
known	O
.	O

In	O
this	O
report	O
,	O
we	O
first	O
assessed	O
interleukin-4	B
receptor	I
alpha	I
(	O
IL-4Ralpha	B
)	O
expression	O
during	O
adipogenesis	O
.	O

IL-4Ralpha	B
was	O
highly	O
expressed	O
in	O
proliferating	O
3T3-L1	O
preadipocytes	O
.	O

Receptor	O
expression	O
was	O
down	O
-	O
regulated	O
in	O
post	O
-	O
confluent	O
growth	O
arrested	O
preadipocytes	O
.	O

Induction	O
of	O
differentiation	O
led	O
to	O
a	O
transient	O
36	O
-	O
h	O
increase	O
in	O
expression	O
,	O
but	O
then	O
levels	O
decreased	O
to	O
undetectable	O
amounts	O
3	O
-	O
8	O
days	O
after	O
induction	O
of	O
differentiation	O
.	O

Depending	O
on	O
the	O
cell	O
type	O
,	O
IL-4	B
either	O
increases	O
or	O
decreases	O
cell	O
proliferation	O
.	O

In	O
growth	O
arrested	O
preconfluent	O
3T3-L1	O
preadipocytes	O
,	O
IL-4	B
alone	O
had	O
no	O
effect	O
on	O
preadipocyte	O
proliferation	O
.	O

In	O
contrast	O
,	O
IL-4	B
inhibited	O
platelet	B
-	I
derived	I
growth	I
factor	I
(	O
PDGF	B
-	I
BB	I
)	O
induced	O
preadipocyte	O
proliferation	O
.	O

PDGF	B
-	I
BB	I
,	O
but	O
not	O
IL-4	B
,	O
induced	O
STAT3	B
tyrosine	O
and	O
AKT	B
serine	O
phosphorylation	O
.	O

Both	O
PDGF	B
-	I
BB	I
and	O
IL-4	B
induced	O
STAT6	B
tyrosine	O
phosphorylation	O
,	O
but	O
the	O
bands	O
showed	O
distinct	O
electrophoretic	O
migration	O
patterns	O
.	O

IL-4	B
alone	O
and	O
IL-4	B
added	O
to	O
the	O
differentiation	O
cocktail	O
had	O
no	O
effect	O
on	O
adipocyte	O
formation	O
or	O
PPARgamma	B
expression	O
.	O

Collectively	O
,	O
these	O
studies	O
demonstrate	O
that	O
IL-4	B
inhibits	O
PDGF	B
-	I
BB	I
-	O
induced	O
preadipocyte	O
proliferation	O
,	O
possibly	O
through	O
STAT6	B
activation	O
.	O

The	O
pattern	O
of	O
IL-4	B
receptor	I
expression	O
suggests	O
that	O
the	O
effects	O
of	O
IL-4	B
are	O
targeted	O
primarily	O
towards	O
preadipocytes	O
.	O

Multiple	O
stress	O
signal	O
integration	O
in	O
the	O
regulation	O
of	O
the	O
complex	O
sigma	B
S	I
-	O
dependent	O
csiD	B
-	O
ygaF	B
-	O
gabDTP	B
operon	I
in	O
Escherichia	O
coli	O
.	O

The	O
csiD	B
-	O
ygaF	B
-	O
gabDTP	B
region	O
in	O
the	O
Escherichia	O
coli	O
genome	O
represents	O
a	O
cluster	O
of	O
sigma	B
S	I
-	O
controlled	O
genes	O
.	O

Here	O
,	O
we	O
investigated	O
promoter	O
structures	O
,	O
sigma	B
factor	I
dependencies	O
,	O
potential	O
co	O
-	O
regulation	O
and	O
environmental	O
regulatory	O
patterns	O
for	O
all	O
of	O
these	O
genes	O
.	O

We	O
find	O
that	O
this	O
region	O
constitutes	O
a	O
complex	O
operon	O
with	O
expression	O
being	O
controlled	O
by	O
three	O
differentially	O
regulated	O
promoters	O
:	O
(	O
i	O
)	O
csiDp	B
,	O
which	O
affects	O
the	O
expression	O
of	O
all	O
five	O
genes	O
,	O
is	O
cAMP	O
-	O
CRP	B
/	O
sigma	B
S	I
-	O
dependent	O
and	O
activated	O
exclusively	O
upon	O
carbon	O
starvation	O
and	O
stationary	O
phase	O
;	O
(	O
ii	O
)	O
gabDp1	B
,	O
which	O
is	O
sigma	B
S	I
-	O
dependent	O
and	O
exhibits	O
multiple	O
stress	O
induction	O
like	O
sigma	B
S	I
itself	O
;	O
and	O
(	O
iii	O
)	O
gabDp2	B
[	O
previously	O
suggested	O
by	O
Schneider	O
,	O
B.L.	O
,	O
Ruback	O
,	O
S.	O
,	O
Kiupakis	O
,	O
A.K.	O
,	O
Kasbarian	O
,	O
H.	O
,	O
Pybus	O
,	O
C.	O
,	O
and	O
Reitzer	O
,	O
L.	O
(	O
2002	O
)	O
J.	O
Bacteriol	O
.	O
184	O
:	O
6976	O
-	O
6986	O
]	O
,	O
which	O
appears	O
to	O
be	O
Nac	B
/	O
sigma	B
70	I
-	O
controlled	O
and	O
to	O
respond	O
to	O
poor	O
nitrogen	O
sources	O
.	O

In	O
addition	O
,	O
we	O
identify	O
a	O
novel	O
repressor	O
,	O
CsiR	B
,	O
which	O
modulates	O
csiDp	B
activity	O
in	O
a	O
temporal	O
manner	O
during	O
early	O
stationary	O
phase	O
.	O

Finally	O
,	O
we	O
propose	O
a	O
physiological	O
role	O
for	O
sigma	B
S	I
-	O
controlled	O
GabT	B
/	I
D	I
-	O
mediated	O
gamma	O
-	O
aminobutyrate	O
(	O
GABA	O
)	O
catabolism	O
and	O
glutamate	O
accumulation	O
in	O
general	O
stress	O
adaptation	O
.	O

This	O
physiological	O
role	O
is	O
reflected	O
by	O
the	O
activation	O
of	O
the	O
operon	O
-	O
internal	O
gabDp1	B
promoter	O
under	O
the	O
different	O
conditions	O
that	O
also	O
induce	O
sigma	B
S	I
,	O
which	O
include	O
shifts	O
to	O
acidic	O
pH	O
or	O
high	O
osmolarity	O
as	O
well	O
as	O
starvation	O
or	O
stationary	O
phase	O
.	O

Forest	O
tent	O
caterpillars	O
(	O
Malacosoma	O
disstria	O
)	O
induce	O
local	O
and	O
systemic	O
diurnal	O
emissions	O
of	O
terpenoid	O
volatiles	O
in	O
hybrid	O
poplar	O
(	O
Populus	O
trichocarpa	O
x	O
deltoides	O
)	O
:	O
cDNA	O
cloning	O
,	O
functional	O
characterization	O
,	O
and	O
patterns	O
of	O
gene	O
expression	O
of	O
(	B
-	I
)	I
-germacrene	I
D	I
synthase	I
,	O
PtdTPS1	B
.	O

Feeding	O
forest	O
tent	O
caterpillars	O
(	O
FTCs	O
)	O
induced	O
local	O
and	O
systemic	O
diurnal	O
emissions	O
of	O
(	O
-	O
)	O
-germacrene	O
D	O
,	O
along	O
with	O
(	O
E	O
)	O
-beta	O
-	O
ocimene	O
,	O
linalool	O
,	O
(	O
E	O
)	O
-4,8-dimethyl-1,3,7-nonatriene	O
(	O
DMNT	O
)	O
,	O
benzene	O
cyanide	O
,	O
and	O
(	O
E	O
,	O
E	O
)	O
-alpha	O
-	O
farnesene	O
,	O
from	O
leaves	O
of	O
hybrid	O
poplar	O
.	O

FTC	O
feeding	O
induced	O
substantially	O
higher	O
levels	O
of	O
volatiles	O
in	O
local	O
and	O
systemic	O
leaves	O
than	O
did	O
mechanical	O
wounding	O
.	O

A	O
full	O
-	O
length	O
poplar	O
sesquiterpene	B
synthase	I
cDNA	O
(	O
PtdTPS1	B
)	O
was	O
isolated	O
and	O
functionally	O
identified	O
as	O
(	B
-	I
)	I
-germacrene	I
D	I
synthase	I
.	O

Expression	O
of	O
PtdTPS1	B
,	O
expression	O
of	O
genes	O
of	O
early	O
,	O
intermediate	O
and	O
late	O
steps	O
in	O
terpenoid	O
biosynthesis	O
,	O
and	O
expression	O
of	O
a	O
lipoxygenase	B
gene	O
(	O
PtdLOX1	B
)	O
were	O
analyzed	O
in	O
local	O
FTC	O
-	O
infested	O
and	O
systemic	O
leaves	O
.	O

Transcript	O
levels	O
of	O
PtdTPS1	B
and	O
PtdLOX1	B
were	O
strongly	O
increased	O
in	O
response	O
to	O
herbivory	O
.	O

PtdTPS1	B
was	O
also	O
induced	O
by	O
mechanical	O
wounding	O
or	O
by	O
methyl	O
jasmonate	O
(	O
MeJA	O
)	O
treatment	O
.	O

FTC	O
feeding	O
did	O
not	O
affect	O
transcript	O
levels	O
of	O
3-hydroxy-3-methylglutaryl	B
-	I
CoA	I
reductase	I
(	O
HMGR	B
)	O
,	O
1-deoxy	B
-	I
d	I
-	I
xylulose	I
5-phosphate	I
reductoisomerase	I
(	O
DXR	B
)	O
,	O
and	O
isoprene	B
synthase	I
(	O
IPS	B
)	O
.	O

Two	O
other	O
TPS	B
genes	O
,	O
PtdTPS2	B
and	O
PtTPS3	B
,	O
and	O
farnesyl	B
diphosphate	I
synthase	I
were	O
only	O
very	O
transiently	O
induced	O
.	O

These	O
results	O
illustrate	O
differential	O
expression	O
of	O
terpenoid	O
pathway	O
genes	O
in	O
response	O
to	O
insect	O
feeding	O
and	O
a	O
key	O
function	O
of	O
(	B
-	I
)	I
-germacrene	I
D	I
synthase	I
PtdTPS1	B
for	O
herbivore	O
-	O
induced	O
local	O
and	O
systemic	O
volatile	O
emissions	O
in	O
hybrid	O
poplar	O
.	O

FTC	O
-	O
induced	O
transcripts	O
of	O
PtdTPS1	B
followed	O
diurnal	O
rhythm	O
.	O

Spatial	O
patterns	O
of	O
FTC	O
-	O
induced	O
PtdTPS1	B
transcript	O
accumulation	O
revealed	O
acropetal	O
but	O
not	O
basipetal	O
direction	O
of	O
the	O
systemic	O
response	O
.	O

Implications	O
for	O
tritrophic	O
poplar	O
-	O
FTC	O
-	O
predator	O
/	O
parasitoid	O
interactions	O
are	O
discussed	O
.	O

The	O
linker	O
region	O
between	O
the	O
helicase	B
and	O
primase	B
domains	O
of	O
the	O
gene	O
4	O
protein	O
of	O
bacteriophage	O
T7	O
.	O

Role	O
in	O
helicase	B
conformation	O
and	O
activity	O
.	O

The	O
gene	O
4	O
protein	O
of	O
bacteriophage	O
T7	O
provides	O
both	O
helicase	B
and	O
primase	B
activities	O
.	O

The	O
C	O
-	O
terminal	O
helicase	B
domain	O
is	O
responsible	O
for	O
DNA	O
-	O
dependent	O
dTTP	O
hydrolysis	O
,	O
translocation	O
,	O
and	O
DNA	O
unwinding	O
whereas	O
the	O
N	O
-	O
terminal	O
primase	B
domain	O
is	O
responsible	O
for	O
template	O
-	O
directed	O
oligoribonucleotide	O
synthesis	O
.	O

A	O
26	O
amino	O
acid	O
linker	O
region	O
(	O
residues	O
246	O
-	O
271	O
)	O
connects	O
the	O
two	O
domains	O
and	O
is	O
essential	O
for	O
the	O
formation	O
of	O
functional	O
hexamers	O
.	O

In	O
order	O
to	O
further	O
dissect	O
the	O
role	O
of	O
the	O
linker	O
region	O
,	O
three	O
residues	O
(	O
Ala257	O
,	O
Pro259	O
,	O
and	O
Asp263	O
)	O
that	O
was	O
disordered	O
in	O
the	O
crystal	O
structure	O
of	O
the	O
hexameric	O
helicase	B
fragment	O
were	O
substituted	O
with	O
all	O
amino	O
acids	O
,	O
and	O
the	O
altered	O
proteins	O
were	O
analyzed	O
for	O
their	O
ability	O
to	O
support	O
growth	O
of	O
T7	O
phage	O
lacking	O
gene	O
4	O
.	O

The	O
in	O
vivo	O
screening	O
revealed	O
Ala257	O
and	O
Asp263	O
to	O
be	O
essential	O
whereas	O
Pro259	O
could	O
be	O
replaced	O
with	O
any	O
amino	O
acid	O
without	O
loss	O
of	O
function	O
.	O

Selected	O
gene	O
4	O
proteins	O
with	O
substitution	O
for	O
Ala257	O
or	O
Asp263	O
were	O
purified	O
and	O
examined	O
for	O
their	O
ability	O
to	O
unwind	O
DNA	O
,	O
hydrolyze	O
dTTP	O
,	O
translocate	O
on	O
ssDNA	O
,	O
and	O
oligomerize	O
.	O

In	O
the	O
presence	O
of	O
Mg2	O
+	O
,	O
all	O
of	O
the	O
altered	O
proteins	O
oligomerize	O
.	O

However	O
,	O
in	O
the	O
absence	O
of	O
divalent	O
ion	O
,	O
alterations	O
at	O
position	O
257	O
increase	O
the	O
extent	O
of	O
oligomerization	O
whereas	O
those	O
at	O
position	O
263	O
reduce	O
oligomer	O
formation	O
.	O

Although	O
dTTP	O
hydrolysis	O
activity	O
is	O
reduced	O
only	O
2	O
-	O
3	O
-	O
fold	O
,	O
none	O
of	O
the	O
altered	O
gene	O
4	O
proteins	O
can	O
translocate	O
effectively	O
on	O
single	O
-	O
strand	O
DNA	O
,	O
and	O
they	O
can	O
not	O
mediate	O
the	O
unwinding	O
of	O
duplex	O
DNA	O
.	O

Primer	O
synthesis	O
catalyzed	O
by	O
the	O
altered	O
proteins	O
is	O
relatively	O
normal	O
on	O
a	O
short	O
DNA	O
template	O
but	O
it	O
is	O
severely	O
impaired	O
on	O
longer	O
templates	O
where	O
translocation	O
is	O
required	O
.	O

The	O
results	O
suggest	O
that	O
the	O
linker	O
region	O
not	O
only	O
connects	O
the	O
two	O
domains	O
of	O
the	O
gene	O
4	O
protein	O
and	O
participates	O
in	O
oligomerization	O
,	O
but	O
also	O
contributes	O
to	O
helicase	B
activity	O
by	O
mediating	O
conformations	O
within	O
the	O
functional	O
hexamer	O
.	O

Expression	O
of	O
the	O
chitobiose	B
operon	I
of	O
Escherichia	O
coli	O
is	O
regulated	O
by	O
three	O
transcription	B
factors	I
:	O
NagC	B
,	O
ChbR	B
and	O
CAP	B
.	O

The	O
chitobiose	B
operon	I
,	O
chbBCARFG	B
,	O
encodes	O
genes	O
for	O
the	O
transport	O
and	O
degradation	O
of	O
the	O
N	O
-	O
acetylglucosamine	O
disaccharide	O
,	O
chitobiose	O
.	O

Chitobiose	O
is	O
transported	O
by	O
the	O
phosphotransferase	B
system	I
(	O
PTS	B
)	O
producing	O
chitobiose-6P	O
which	O
is	O
hydrolysed	O
to	O
GlcNAc-6P	O
by	O
the	O
chbF	B
gene	O
product	O
and	O
then	O
further	O
degraded	O
by	O
the	O
nagBA	B
gene	O
products	O
.	O

Expression	O
of	O
the	O
chb	B
operon	I
is	O
repressed	O
by	O
NagC	B
,	O
which	O
regulates	O
genes	O
involved	O
in	O
amino	O
sugar	O
metabolism	O
.	O

The	O
inducer	O
for	O
NagC	B
is	O
GlcNAc-6P	O
.	O

NagC	B
binds	O
to	O
two	O
sites	O
separated	O
by	O
115	O
bp	O
and	O
the	O
transcription	O
start	O
point	O
of	O
the	O
chb	B
operon	I
lies	O
within	O
the	O
downstream	O
NagC	B
operator	O
.	O

In	O
addition	O
the	O
chb	B
operon	I
encodes	O
its	O
own	O
specific	O
regulator	O
,	O
ChbR	B
,	O
an	O
AraC	B
-	O
type	O
dual	O
repressor	O
-	O
activator	O
,	O
which	O
binds	O
to	O
two	O
direct	O
repeats	O
of	O
19	O
bp	O
located	O
between	O
the	O
two	O
NagC	B
sites	O
.	O

ChbR	B
is	O
necessary	O
for	O
transcription	O
activation	O
in	O
the	O
presence	O
of	O
chitobiose	O
in	O
vivo	O
.	O

Induction	O
of	O
the	O
operon	O
also	O
requires	O
CAP	B
,	O
which	O
binds	O
to	O
a	O
site	O
upstream	O
of	O
the	O
ChbR	B
repeats	O
.	O

In	O
the	O
absence	O
of	O
chitobiose	O
both	O
NagC	B
and	O
ChbR	B
act	O
as	O
repressors	O
.	O

Together	O
these	O
three	O
factors	O
cooperate	O
in	O
switching	O
chb	B
expression	O
from	O
the	O
repressed	O
to	O
the	O
activated	O
state	O
.	O

The	O
need	O
for	O
two	O
specific	O
inducing	O
signals	O
,	O
one	O
for	O
ChbR	B
to	O
activate	O
the	O
expression	O
of	O
the	O
operon	O
and	O
a	O
second	O
for	O
NagC	B
to	O
relieve	O
its	O
repression	O
,	O
ensure	O
that	O
the	O
chb	B
operon	I
is	O
only	O
induced	O
when	O
there	O
is	O
sufficient	O
flux	O
through	O
the	O
combined	O
chb	B
-	O
nag	B
metabolic	O
pathway	O
to	O
activate	O
expression	O
of	O
both	O
the	O
chb	B
and	I
nag	I
operons	I
.	O

La	B
protein	I
binding	O
at	O
the	O
GCAC	O
site	O
near	O
the	O
initiator	O
AUG	O
facilitates	O
the	O
ribosomal	O
assembly	O
on	O
the	O
hepatitis	O
C	O
virus	O
RNA	O
to	O
influence	O
internal	O
ribosome	O
entry	O
site	O
-	O
mediated	O
translation	O
.	O

Human	O
La	B
autoantigen	I
has	O
been	O
shown	O
to	O
influence	O
internal	O
initiation	O
of	O
translation	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
RNA	O
.	O

Previously	O
,	O
we	O
have	O
demonstrated	O
that	O
,	O
among	O
the	O
three	O
RRMs	O
of	O
La	B
protein	I
,	O
the	O
RRM2	O
interacts	O
with	O
HCV	O
internal	O
ribosome	O
entry	O
site	O
(	O
IRES	O
)	O
around	O
the	O
GCAC	O
motif	O
near	O
the	O
initiator	O
AUG	O
present	O
in	O
the	O
stem	O
region	O
of	O
stem	O
-	O
loop	O
IV	O
(	O
SL	O
IV	O
)	O
(	O
Pudi	O
,	O
R.	O
,	O
Abhiman	O
,	O
S.	O
,	O
Srinivasan	O
,	O
N.	O
,	O
and	O
Das	O
S.	O
(	O
2003	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
278	O
,	O
12231	O
-	O
12240	O
)	O
.	O

Here	O
,	O
we	O
have	O
demonstrated	O
that	O
the	O
mutations	O
in	O
the	O
GCAC	O
motif	O
,	O
which	O
altered	O
the	O
binding	O
to	O
RRM2	O
,	O
had	O
drastic	O
effect	O
on	O
HCV	O
IRES	O
-	O
mediated	O
translation	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
results	O
indicated	O
that	O
the	O
primary	O
sequence	O
of	O
the	O
stem	O
region	O
of	O
SL	O
IV	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
internal	O
initiation	O
.	O

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
the	O
mutations	O
also	O
altered	O
the	O
ability	O
to	O
bind	O
to	O
ribosomal	B
protein	I
S5	I
(	O
p25	O
)	O
,	O
through	O
which	O
40	O
S	O
ribosomal	O
subunit	O
is	O
known	O
to	O
contact	O
the	O
HCV	O
IRES	O
RNA	O
.	O

Interestingly	O
,	O
binding	O
of	O
La	B
protein	I
to	O
SL	O
IV	O
region	O
induced	O
significant	O
changes	O
in	O
the	O
circular	O
dichroism	O
spectra	O
of	O
the	O
HCV	O
RNA	O
indicating	O
conformational	O
alterations	O
that	O
might	O
assist	O
correct	O
positioning	O
of	O
the	O
initiation	O
complex	O
.	O

Finally	O
,	O
the	O
ribosome	O
assembly	O
analysis	O
using	O
sucrose	O
gradient	O
centrifugation	O
implied	O
that	O
the	O
mutations	O
within	O
SL	O
IV	O
of	O
HCV	O
IRES	O
impair	O
the	O
formation	O
of	O
functional	O
ribosomal	O
complexes	O
.	O

These	O
observations	O
strongly	O
support	O
the	O
hypothesis	O
that	O
La	B
protein	I
binding	O
near	O
the	O
initiator	O
AUG	O
facilitates	O
the	O
interactions	O
with	O
ribosomal	B
protein	I
S5	I
and	O
48	O
S	O
ribosomal	O
assembly	O
and	O
influences	O
the	O
formation	O
of	O
functional	O
initiation	O
complex	O
on	O
the	O
HCV	O
IRES	O
RNA	O
to	O
mediate	O
efficient	O
internal	O
initiation	O
of	O
translation	O
.	O

Suppressors	B
of	I
cytokine	I
signaling	I
regulate	O
Fc	B
receptor	I
signaling	O
and	O
cell	O
activation	O
during	O
immune	O
renal	O
injury	O
.	O

Suppressors	B
of	I
cytokine	I
signaling	I
(	O
SOCS	B
)	O
are	O
cytokine	B
-	O
inducible	O
proteins	O
that	O
modulate	O
receptor	O
signaling	O
via	O
tyrosine	B
kinase	I
pathways	O
.	O

We	O
investigate	O
the	O
role	O
of	O
SOCS	B
in	O
renal	O
disease	O
,	O
analyzing	O
whether	O
SOCS	B
regulate	O
IgG	B
receptor	I
(	O
FcgammaR	B
)	O
signal	O
pathways	O
.	O

In	O
experimental	O
models	O
of	O
immune	O
complex	O
(	O
IC	O
)	O
glomerulonephritis	O
,	O
the	O
renal	O
expression	O
of	O
SOCS	B
family	I
genes	O
,	O
mainly	O
SOCS-3	B
,	O
significantly	O
increased	O
,	O
in	O
parallel	O
with	O
proteinuria	O
and	O
renal	O
lesions	O
,	O
and	O
the	O
proteins	O
were	O
localized	O
in	O
glomeruli	O
and	O
tubulointerstitium	O
.	O

Induction	O
of	O
nephritis	O
in	O
mice	O
with	O
a	O
deficiency	O
in	O
the	O
FcgammaR	B
gamma	O
-	O
chain	O
(	O
gamma	O
(	O
-	O
/	O
-	O
)	O
mice	O
)	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
renal	O
expression	O
of	O
SOCS-3	B
and	O
SOCS-1	B
.	O

Moreover	O
,	O
blockade	O
of	O
FcgammaR	B
by	O
Fc	O
fragment	O
administration	O
in	O
rats	O
with	O
ongoing	O
nephritis	O
selectively	O
inhibited	O
SOCS-3	B
and	O
SOCS-1	B
,	O
without	O
affecting	O
cytokine	B
-	O
inducible	O
Src	B
homology	O
2	O
-	O
containing	O
protein	O
and	O
SOCS-2	B
.	O

In	O
cultured	O
human	O
mesangial	O
cells	O
(	O
MC	O
)	O
and	O
monocytes	O
,	O
IC	O
caused	O
a	O
rapid	O
and	O
transient	O
induction	O
of	O
SOCS-3	B
expression	O
.	O

Similar	O
kinetics	O
was	O
observed	O
for	O
SOCS-1	B
,	O
whereas	O
SOCS-2	B
expression	O
was	O
very	O
low	O
.	O

MC	O
from	O
gamma	O
(	O
-	O
/	O
-	O
)	O
mice	O
failed	O
to	O
respond	O
to	O
IC	O
activation	O
,	O
confirming	O
the	O
participation	O
of	O
FcgammaR	B
.	O

Interestingly	O
,	O
IC	O
induced	O
tyrosine	O
phosphorylation	O
of	O
SOCS-3	B
and	O
Tec	B
tyrosine	I
kinase	I
,	O
and	O
both	O
proteins	O
coprecipitated	O
in	O
lysates	O
from	O
IC	O
-	O
stimulated	O
MC	O
,	O
suggesting	O
intracellular	O
association	O
.	O

IC	O
also	O
activated	O
STAT	B
pathway	O
in	O
MC	O
,	O
which	O
was	O
suppressed	O
by	O
SOCS	B
overexpression	O
,	O
mainly	O
SOCS-3	B
.	O

In	O
SOCS-3	B
knockdown	O
studies	O
,	O
specific	O
antisense	O
oligonucleotides	O
inhibited	O
mesangial	O
SOCS-3	B
expression	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
IC	O
-	O
induced	O
STAT	B
activation	O
.	O

Our	O
results	O
indicate	O
that	O
SOCS	B
may	O
play	O
a	O
regulatory	O
role	O
in	O
FcgammaR	B
signaling	O
,	O
and	O
implicate	O
SOCS	B
as	O
important	O
modulators	O
of	O
cell	O
activation	O
during	O
renal	O
inflammation	O
.	O

Sporulation	O
regulatory	O
protein	O
GerE	B
from	O
Bacillus	O
subtilis	O
binds	O
to	O
and	O
can	O
activate	O
or	O
repress	O
transcription	O
from	O
promoters	O
for	O
mother	O
-	O
cell	O
-	O
specific	O
genes	O
.	O

The	O
mother	O
-	O
cell	O
line	O
of	O
gene	O
expression	O
during	O
sporulation	O
in	O
Bacillus	O
subtilis	O
is	O
a	O
hierarchical	O
cascade	O
consisting	O
of	O
at	O
least	O
four	O
temporally	O
controlled	O
gene	O
sets	O
,	O
the	O
first	O
three	O
of	O
which	O
each	O
contain	O
a	O
regulatory	O
gene	O
for	O
the	O
next	O
gene	O
set	O
in	O
the	O
pathway	O
.	O

gerE	B
,	O
a	O
member	O
of	O
the	O
penultimate	O
gene	O
set	O
,	O
is	O
a	O
regulatory	O
gene	O
whose	O
products	O
is	O
required	O
for	O
the	O
transcriptional	O
activation	O
of	O
genes	O
(	O
coat	O
protein	O
genes	O
cotB	B
and	O
cotC	B
)	O
in	O
the	O
last	O
gene	O
set	O
.	O

The	O
gerE	B
product	O
also	O
influences	O
the	O
expression	O
of	O
other	O
members	O
of	O
the	O
penultimate	O
gene	O
set	O
(	O
coat	O
protein	O
genes	O
cotA	B
and	O
cotD	B
appear	O
to	O
be	O
repressed	O
and	O
activated	O
,	O
respectively	O
)	O
.	O

We	O
now	O
report	O
that	O
the	O
purified	O
product	O
of	O
gerE	B
(	O
GerE	B
)	O
is	O
a	O
DNA	O
-	O
binding	O
protein	O
that	O
adheres	O
to	O
the	O
promoters	O
for	O
cotB	B
and	O
cotC	B
.	O

We	O
also	O
show	O
that	O
GerE	B
stimulates	O
cotB	B
and	O
cotC	B
transcription	O
in	O
vitro	O
by	O
RNA	B
polymerase	I
containing	O
the	O
mother	O
-	O
cell	O
sigma	B
factor	I
sigma	B
K	I
.	O

These	O
findings	O
support	O
the	O
view	O
that	O
GerE	B
is	O
a	O
positively	O
acting	O
,	O
regulatory	O
protein	O
whose	O
appearance	O
at	O
a	O
late	O
stage	O
of	O
development	O
directly	O
activates	O
the	O
transcription	O
of	O
genes	O
in	O
the	O
last	O
known	O
temporal	O
class	O
of	O
mother	O
-	O
cell	O
-	O
expressed	O
genes	O
.	O

In	O
addition	O
,	O
GerE	B
stimulates	O
cotD	B
transcription	O
and	O
inhibits	O
cotA	B
transcription	O
in	O
vitro	O
by	O
sigma	B
K	I
RNA	B
polymerase	I
,	O
as	O
expected	O
from	O
in	O
vivo	O
studies	O
,	O
and	O
,	O
unexpectedly	O
,	O
profoundly	O
inhibits	O
in	O
vitro	O
transcription	O
of	O
the	O
gene	O
(	O
sigK	B
)	O
that	O
encodes	O
sigma	B
K	I
.	O

The	O
effects	O
of	O
GerE	B
on	O
cotD	B
and	O
sigK	B
transcription	O
are	O
just	O
the	O
opposite	O
of	O
the	O
effects	O
exerted	O
by	O
the	O
earlier	O
-	O
appearing	O
,	O
mother	O
-	O
cell	O
regulatory	O
protein	O
spoIIID	B
,	O
suggesting	O
that	O
the	O
ordered	O
appearance	O
of	O
first	O
SpoIIID	B
,	O
then	O
GerE	B
,	O
ensures	O
proper	O
flow	O
of	O
the	O
regulatory	O
cascade	O
controlling	O
gene	O
expression	O
in	O
the	O
mother	O
cell	O
.	O

Characterization	O
of	O
B	O
-	O
and	O
T	O
-	O
cell	O
responses	O
and	O
HLA	B
-	I
DR4	I
binding	O
motifs	O
of	O
the	O
latex	O
allergen	O
Hev	B
b	I
6.01	I
(	O
prohevein	B
)	O
and	O
its	O
post	O
-	O
transcriptionally	O
formed	O
proteins	O
Hev	B
b	I
6.02	I
and	O
Hev	B
b	I
6.03	I
.	O

BACKGROUND	O
:	O

Multiple	O
immunoglobulin	B
E	I
(	O
IgE	B
)	O
-	O
binding	O
proteins	O
in	O
natural	O
rubber	O
latex	O
extracts	O
have	O
been	O
identified	O
.	O

In	O
the	O
case	O
of	O
Hev	B
b	I
6	I
a	O
differentiation	O
was	O
made	O
between	O
the	O
precursor	O
protein	O
prohevein	B
(	O
Hev	B
b	I
6.01	I
)	O
and	O
its	O
two	O
post	O
-	O
transcriptionally	O
formed	O
proteins	O
,	O
the	O
N	O
-	O
terminal	O
hevein	B
(	O
Hev	B
b	I
6.02	I
)	O
and	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
Hev	B
b	I
6.03	I
)	O
.	O

All	O
three	O
components	O
act	O
as	O
independent	O
allergens	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
a	O
detailed	O
analysis	O
of	O
the	O
T	O
-	O
cell	O
responses	O
and	O
the	O
IgE	B
-	O
binding	O
capacity	O
of	O
Hev	B
b	I
6.01	I
,	O
Hev	B
b	I
6.02	I
and	O
Hev	B
b	I
6.03	I
by	O
using	O
these	O
allergens	O
as	O
recombinant	O
maltose	O
-	O
binding	O
fusion	O
(	O
MBP	B
)	O
proteins	O
and	O
the	O
usage	O
of	O
synthetic	O
modified	O
hevein	B
peptides	O
.	O

METHODS	O
:	O

Latex	O
-	O
allergic	O
health	O
care	O
workers	O
(	O
HCWs	O
)	O
suffering	O
from	O
rhinitis	O
,	O
conjunctivitis	O
,	O
contact	O
urticaria	O
and	O
/	O
or	O
asthma	O
with	O
increased	O
specific	O
IgE	B
-	O
antibodies	O
to	O
latex	O
were	O
tested	O
for	O
their	O
IgE	B
-	O
binding	O
capacity	O
and	O
T	O
-	O
cell	O
reactivity	O
(	O
by	O
proliferation	O
response	O
)	O
to	O
the	O
recombinant	O
MBP	B
-	O
rHev	B
b	I
6.01	I
,	O
MBP	B
-	O
rHev	B
b	I
6.02	I
,	O
MBP	B
-	O
rHev	B
b	I
6.03	I
,	O
to	O
native	O
Hev	B
b	I
6.02	I
,	O
to	O
modified	O
hevein	O
peptides	O
and	O
wheat	B
germ	I
agglutinin	I
(	O
WGA	B
)	O
.	O

For	O
testing	O
of	O
the	O
human	B
leucocyte	I
antigen	I
(	I
HLA	I
)	I
class	I
II	I
restriction	O
of	O
MBP	B
-	O
rHev	B
b	I
6.01	I
induced	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PBMC	O
)	O
responses	O
,	O
monoclonal	O
antibodies	O
against	O
HLA	B
-	I
DR	I
,	O
HLA	B
-	I
DP	I
or	O
HLA	B
-	I
DQ	I
were	O
added	O
.	O

RESULTS	O
:	O

Seventeen	O
of	O
18	O
(	O
94	O
%	O
)	O
serum	O
samples	O
from	O
latex	O
-	O
allergic	O
HCWs	O
had	O
increased	O
levels	O
of	O
specific	O
IgE	B
to	O
MBP	B
-	O
rHev	B
b	I
6.01	I
,	O
16	O
(	O
89	O
%	O
)	O
to	O
MBP	B
-	O
rHev	B
b	I
6.02	I
and	O
13	O
(	O
72	O
%	O
)	O
to	O
MBP	B
-	O
rHev	B
b	I
6.03	I
.	O

A	O
significant	O
difference	O
existed	O
between	O
the	O
specific	O
IgE	B
-	O
values	O
of	O
MBP	B
-	O
rHev	B
b	I
6.02	I
and	O
MBP	B
-	O
rHev	B
b	I
6.03	I
(	O
P	O
<	O
0.01	O
)	O
.	O

Proliferation	O
responses	O
of	O
PBMC	O
of	O
the	O
same	O
18	O
latex	O
-	O
allergic	O
patients	O
were	O
positive	O
for	O
MBP	B
-	O
rHev	B
b	I
6.01	I
and	O
MBP	B
-	O
rHev	B
b	I
6.03	I
in	O
83	O
and	O
67	O
%	O
of	O
the	O
tested	O
PBMC	O
suspension	O
,	O
whereas	O
the	O
proliferation	O
responses	O
induced	O
with	O
MBP	B
-	O
rHev	B
b	I
6.02	I
or	O
native	O
Hev	B
b	I
6.02	I
were	O
very	O
low	O
(	O
5.6	O
and	O
22.2	O
%	O
)	O
.	O

Sera	O
from	O
nine	O
additional	O
latex	O
-	O
allergic	O
patients	O
showed	O
specific	O
IgE	B
binding	O
to	O
the	O
native	O
Hev	B
b	I
6.02	I
,	O
but	O
none	O
of	O
these	O
sera	O
showed	O
specific	O
IgE	B
binding	O
to	O
the	O
modified	O
Hev	B
b	I
6.02	I
-	O
peptides	O
[	O
whereby	O
all	O
eight	O
cysteine	O
residues	O
were	O
substituted	O
by	O
serine	O
(	O
C	O
--	O
>	O
S	O
)	O
or	O
by	O
alanine	O
(	O
C	O
--	O
>	O
A	O
)	O
]	O
.	O

Proliferation	O
responses	O
induced	O
by	O
the	O
modified	O
Hev	B
b	I
6.02	I
peptides	O
were	O
not	O
significantly	O
different	O
from	O
that	O
induced	O
by	O
Hev	B
b	I
6.02	I
.	O

Potential	O
HLA	B
-	I
DR4Dw4	I
(	O
DRB1	B
*	I
0401	I
)	O
-	O
restricted	O
T	O
-	O
cell	O
epitopes	O
of	O
Hev	B
b	I
6.01	I
predicted	O
by	O
two	O
computer	O
algorithms	O
were	O
only	O
found	O
in	O
the	O
Hev	B
b	I
6.03	I
-	O
part	O
of	O
Hev	B
b	I
6.01	I
.	O

CONCLUSION	O
:	O

In	O
the	O
Hev	B
b	I
6.01	I
precursor	O
the	O
regions	O
responsible	O
for	O
IgE	B
binding	O
and	O
those	O
for	O
inducing	O
the	O
T	O
-	O
cell	O
proliferation	O
responses	O
are	O
settled	O
in	O
different	O
parts	O
of	O
the	O
protein	O
.	O

The	O
Hev	B
b	I
6.02	I
domain	O
is	O
responsible	O
for	O
IgE	B
binding	O
and	O
carries	O
discontinuous	O
B	O
-	O
cell	O
epitopes	O
whereas	O
Hev	B
b	I
6.03	I
is	O
a	O
better	O
inducer	O
of	O
a	O
proliferation	O
response	O
and	O
contains	O
HLA	B
-	I
DR4	I
-	O
binding	O
motifs	O
.	O

2S	B
storage	I
protein	I
gene	O
of	O
Douglas	O
-	O
fir	O
:	O
characterization	O
and	O
activity	O
of	O
promoter	O
in	O
transgenic	O
tobacco	O
seeds	O
.	O

To	O
date	O
a	O
few	O
sequences	O
regulating	O
expression	O
of	O
conifer	O
seed	O
-	O
specific	O
genes	O
have	O
been	O
reported	O
.	O

To	O
characterize	O
Douglas	O
-	O
fir	O
(	O
Pseudotsuga	O
menziesii	O
[	O
Mirb	O
]	O
Franco	O
)	O
2S	B
albumin	I
storage	O
protein	O
genes	O
,	O
a	O
genomic	O
DNA	O
sequence	O
containing	O
upstream	O
promoter	O
sequences	O
was	O
isolated	O
by	O
screening	O
a	O
Douglas	O
-	O
fir	O
genomic	O
library	O
.	O

Sequence	O
analysis	O
of	O
the	O
Douglas	O
-	O
fir	O
gPm2S1	O
promoter	O
revealed	O
the	O
presence	O
of	O
RY	O
-	O
repeated	O
elements	O
(	O
GCATGC	O
)	O
,	O
and	O
multiple	O
E	O
-	O
box	O
motifs	O
(	O
CANNTG	O
)	O
and	O
ACGT	O
-	O
core	O
elements	O
,	O
features	O
characteristic	O
of	O
2S	B
storage	I
protein	I
genes	O
in	O
angiosperms	O
.	O

When	O
fused	O
to	O
the	O
GUS	B
reporter	O
gene	O
,	O
the	O
1.16	O
kb	O
Douglas	O
-fir	O
2S	B
promoter	O
sequence	O
was	O
sufficient	O
to	O
direct	O
transient	O
expression	O
in	O
both	O
developing	O
Douglas	O
-	O
fir	O
embryos	O
and	O
maternally	O
derived	O
haploid	O
megagametophytes	O
.	O

Analysis	O
of	O
this	O
promoter	O
construct	O
in	O
transgenic	O
tobacco	O
showed	O
that	O
expression	O
was	O
restricted	O
to	O
embryo	O
and	O
endosperm	O
in	O
developing	O
seeds	O
and	O
was	O
not	O
detected	O
in	O
vegetative	O
tissues	O
of	O
two	O
-	O
week	O
-	O
old	O
seedlings	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
both	O
structural	O
and	O
regulatory	O
elements	O
as	O
well	O
as	O
upstream	O
signaling	O
components	O
controlling	O
the	O
expression	O
of	O
2S	B
albumin	I
genes	O
are	O
highly	O
conserved	O
during	O
evolution	O
.	O

A	O
chitinase	B
indispensable	O
for	O
formation	O
of	O
protoplast	O
of	O
Schizophyllum	O
commune	O
in	O
basidiomycete	O
-	O
lytic	O
enzyme	O
preparation	O
produced	O
by	O
Bacillus	O
circulans	O
KA-304	O
.	O

KA	O
-	O
prep	O
,	O
a	O
culture	O
filtrate	O
of	O
Bacillus	O
circulans	O
KA	O
-	O
304	O
grown	O
on	O
a	O
cell	O
-	O
wall	O
preparation	O
of	O
Schizophyllum	O
commune	O
,	O
has	O
an	O
activity	O
to	O
form	O
protoplasts	O
from	O
S.	O
commune	O
mycelia	O
.	O

alpha-1,3-Glucanase	B
,	O
which	O
was	O
isolated	O
from	O
an	O
ammonium	O
sulfate	O
fraction	O
of	O
0	O
-	O
30	O
%	O
saturation	O
of	O
KA	O
-	O
prep	O
,	O
gave	O
the	O
protoplast	O
-	O
forming	O
activity	O
to	O
an	O
ammonium	O
sulfate	O
fraction	O
of	O
30	O
-	O
50	O
%	O
saturation	O
of	O
KA	O
-	O
prep	O
,	O
which	O
contained	O
chitinase	B
(	O
s	O
)	O
and	O
beta	B
-	I
glucanase	I
(	O
s	O
)	O
but	O
was	O
inactive	O
in	O
the	O
protoplast	O
formation	O
.	O

Chitinase	B
(	I
s	I
)	I
and	O
beta	B
-	I
glucanase	I
(	O
s	O
)	O
in	O
the	O
ammonium	O
sulfate	O
fraction	O
of	O
30	O
-	O
50	O
%	O
saturation	O
were	O
separated	O
by	O
DEAE	O
-	O
cellulofine	O
A	O
-	O
500	O
column	O
chromatography	O
,	O
and	O
the	O
protoplast	O
-	O
forming	O
activity	O
appeared	O
when	O
the	O
chitinase	B
preparation	O
was	O
mixed	O
with	O
the	O
alpha-1	B
,	I
3	I
-	I
glucanase	I
.	O

The	O
beta	B
-	I
glucanase	I
preparation	O
was	O
not	O
effective	O
for	O
the	O
protoplast	O
formation	O
whereas	O
its	O
addition	O
enhanced	O
the	O
protoplast	O
-	O
forming	O
activity	O
of	O
the	O
mixture	O
of	O
alpha-1,3-glucanase	B
and	O
the	O
chitinase	B
preparation	O
.	O

The	O
chitinase	B
preparation	O
contained	O
two	O
chitinases	B
(	O
chitinase	B
I	I
and	I
II	I
)	O
.	O

Chitinase	B
I	I
showed	O
the	O
protoplast	O
-	O
forming	O
activity	O
with	O
alpha-1,3-glucanase	B
,	O
but	O
chitinase	B
II	I
did	O
not	O
.	O

Chitinase	B
I	I
,	O
a	O
monomeric	O
protein	O
with	O
a	O
molecular	O
weight	O
of	O
41,000	O
,	O
was	O
active	O
toward	O
colloidal	O
chitin	O
and	O
ethylene	O
glycol	O
chitin	O
.	O

Chitinase	B
I	I
produced	O
predominantly	O
N	O
,	O
N'-diacetylchitobiose	O
and	O
N	O
,	O
N',N	O
"""-"	O
triacetylchitotriose	O
from	O
colloidal	O
chitin	O
,	O
and	O
the	O
enzyme	O
was	O
inactive	O
to	O
p	O
-	O
NP	O
-	O
beta	O
-	O
D	O
-	O
N	O
-	O
acetylglucosaminide	O
,	O
suggesting	O
that	O
it	O
was	O
an	O
endo	O
-	O
type	O
enzyme	O
.	O

The	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
chitinase	B
I	I
(	O
A	O
L	O
A	O
T	O
P	O
T	O
L	O
N	O
V	O
S	O
A	O
S	O
S	O
G	O
M	O
)	O
had	O
no	O
sequential	O
identity	O
to	O
those	O
of	O
known	O
chitinases	B
.	O

Transcription	O
activation	O
by	O
remodelling	O
of	O
a	O
nucleoprotein	O
assembly	O
:	O
the	O
role	O
of	O
NarL	B
at	O
the	O
FNR	B
-	O
dependent	O
Escherichia	O
coli	O
nir	B
promoter	O
.	O

Expression	O
from	O
the	O
Escherichia	O
coli	O
nir	B
promoter	O
is	O
co	O
-	O
dependent	O
on	O
both	O
the	O
FNR	B
protein	O
(	O
an	O
anaerobically	O
triggered	O
transcription	O
activator	O
)	O
and	O
NarL	B
or	O
NarP	B
proteins	O
(	O
transcription	O
activators	O
triggered	O
by	O
nitrite	O
and	O
nitrate	O
)	O
.	O

We	O
found	O
previously	O
that	O
FNR	B
binds	O
to	O
a	O
site	O
centred	O
at	O
position	O
-	O
41.5	O
at	O
the	O
nir	B
promoter	O
,	O
but	O
that	O
FNR	B
-	O
dependent	O
activation	O
is	O
repressed	O
by	O
IHF	B
binding	O
to	O
a	O
site	O
centred	O
at	O
position	O
-	O
88	O
(	O
IHF	B
I	O
)	O
and	O
Fis	B
binding	O
to	O
sites	O
centred	O
at	O
positions	O
-	O
142	O
(	O
Fis	B
I	O
)	O
and	O
+	O
23	O
(	O
Fis	B
II	O
)	O
.	O

Here	O
,	O
we	O
have	O
studied	O
the	O
binding	O
of	O
purified	O
IHF	B
,	O
Fis	B
and	O
FNR	B
to	O
the	O
nir	B
promoter	O
in	O
vitro	O
.	O

Our	O
results	O
show	O
that	O
the	O
nir	B
promoter	O
contains	O
a	O
second	O
IHF	B
site	O
at	O
position	O
-	O
115	O
(	O
IHF	B
II	O
)	O
and	O
a	O
third	O
Fis	B
site	O
at	O
position	O
-	O
97	O
(	O
Fis	B
III	O
)	O
,	O
and	O
that	O
IHF	B
,	O
Fis	B
and	O
FNR	B
can	O
bind	O
together	O
to	O
form	O
multiprotein	O
complexes	O
.	O

Surprisingly	O
,	O
IHF	B
binding	O
at	O
the	O
IHF	B
II	O
site	O
increases	O
FNR	B
-	O
dependent	O
activation	O
by	O
decreasing	O
the	O
repression	O
mediated	O
by	O
IHF	B
and	O
Fis	B
binding	O
at	O
the	O
other	O
sites	O
.	O

In	O
previous	O
work	O
,	O
we	O
found	O
that	O
NarL	B
or	O
NarP	B
activates	O
the	O
nir	B
promoter	O
by	O
binding	O
to	O
a	O
site	O
centred	O
at	O
position	O
-	O
69.5	O
and	O
counteracting	O
the	O
repressive	O
effects	O
of	O
IHF	B
and	O
Fis	B
.	O

We	O
now	O
show	O
that	O
NarL	B
can	O
displace	O
IHF	B
bound	O
at	O
the	O
IHF	B
I	O
site	O
,	O
but	O
IHF	B
is	O
unable	O
to	O
displace	O
bound	O
NarL	B
.	O

We	O
suggest	O
that	O
NarL	B
interferes	O
with	O
IHF	B
binding	O
at	O
the	O
nir	B
promoter	O
by	O
distorting	O
the	O
minor	O
groove	O
at	O
its	O
target	O
site	O
,	O
and	O
we	O
argue	O
that	O
the	O
resulting	O
activation	O
by	O
NarL	B
results	O
from	O
remodelling	O
of	O
the	O
local	O
nucleoprotein	O
structure	O
to	O
facilitate	O
FNR	B
-	O
dependent	O
transcription	O
.	O

Population	O
genetics	O
of	O
apolipoproteins	B
A	I
-	I
IV	I
,	I
E	I
,	I
and	I
H	I
,	O
and	O
the	O
angiotensin	B
converting	I
enzyme	I
(	O
ACE	B
)	O
:	O
associations	O
with	O
lipids	O
,	O
and	O
apolipoprotein	B
levels	O
in	O
American	O
Samoans	O
.	O

Distributions	O
of	O
alleles	O
at	O
three	O
apolipoprotein	B
loci	O
(	O
APO	B
E	I
,	O
APO	B
H	I
,	O
and	O
APO	B
A	I
-	I
IV	I
)	O
and	O
an	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
polymorphism	O
at	O
the	O
angiotensin	B
converting	I
enzyme	I
(	O
ACE	B
)	O
locus	O
among	O
274	O
American	O
Samoans	O
are	O
described	O
here	O
.	O

Genotypes	O
at	O
each	O
locus	O
are	O
examined	O
for	O
associations	O
with	O
quantitative	O
lipid	O
(	O
total	O
cholesterol	O
(	O
total	O
-c	O
)	O
,	O
LDL	B
-	O
cholesterol	O
(	O
LDL	B
-	O
c	O
)	O
,	O
HDL	B
-	O
cholesterol	O
(	O
HDL	B
-	O
c	O
)	O
,	O
and	O
triglycerides	O
)	O
and	O
apolipoprotein	B
(	O
APO	B
AI	I
,	O
APO	B
AII	I
,	O
APO	B
E	I
,	O
and	O
APO	B
B	I
)	O
levels	O
.	O

Genotype	O
frequencies	O
at	O
all	O
four	O
loci	O
are	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
.	O

The	O
most	O
common	O
APO	B
A	I
-	I
IV	I
genotype	O
(	O
1	O
-	O
1	O
)	O
was	O
observed	O
in	O
252	O
American	O
Samoans	O
(	O
97	O
%	O
)	O
.	O

The	O
three	O
most	O
common	O
APO	B
E	I
genotypes	O
were	O
3	O
-	O
3	O
(	O
47	O
%	O
)	O
,	O
3	O
-	O
4	O
(	O
30	O
%	O
)	O
,	O
and	O
2	O
-	O
3	O
(	O
12	O
%	O
)	O
.	O

The	O
most	O
frequent	O
APO	B
H	I
genotype	O
was	O
2	O
-	O
2	O
(	O
86	O
%	O
)	O
.	O

The	O
most	O
common	O
ACE	B
genotype	O
(	O
I	O
/	O
I	O
)	O
was	O
observed	O
in	O
75	O
%	O
of	O
sampled	O
individuals	O
,	O
and	O
23	O
%	O
were	O
I	O
/	O
D	O
heterozygotes	O
.	O

APO	B
E	I
genotypic	O
variation	O
was	O
associated	O
with	O
total	O
-	O
c	O
,	O
HDL	B
-	O
c	O
,	O
LDL	B
-	O
c	O
,	O
and	O
all	O
four	O
quantitative	O
apolipoproteins	B
(	I
AI	I
,	I
AII	I
,	I
E	I
,	I
and	I
B	I
)	I
.	O

APO	B
A	I
-	I
IV	I
genotypes	O
were	O
associated	O
significantly	O
with	O
total	O
cholesterol	O
,	O
LDL	B
-	O
c	O
,	O
and	O
APO	B
-	I
B	I
levels	O
.	O

APO	B
H	I
showed	O
little	O
association	O
with	O
any	O
quantitative	O
lipid	O
or	O
apolipoprotein	B
.	O

ACE	B
D	O
/	O
D	O
homozygotes	O
had	O
higher	O
AII	B
levels	O
.	O

ACE	B
showed	O
a	O
consistent	O
association	O
with	O
APO	B
AII	I
levels	O
,	O
with	O
either	O
APO	B
A	I
-	I
IV	I
or	O
APO	B
E	I
as	O
a	O
covariate	O
.	O

The	O
interaction	O
term	O
between	O
ACE	B
and	O
APO	B
E	I
was	O
also	O
significantly	O
associated	O
with	O
total	O
-	O
c	O
and	O
APO	B
E	I
levels	O
,	O
and	O
the	O
ACE	B
genotype	O
showed	O
a	O
significant	O
main	O
effect	O
on	O
APO	B
AI	I
levels	O
in	O
multivariate	O
analyses	O
.	O

Identification	O
and	O
characterization	O
of	O
ARHGAP24	B
and	O
ARHGAP25	B
genes	O
in	O
silico	O
.	O

RhoGAP	B
family	I
proteins	O
,	O
encoded	O
by	O
ARHGAP	B
family	I
genes	O
,	O
are	O
negative	O
regulators	O
of	O
Rho	B
family	I
GTPases	I
,	O
which	O
are	O
implicated	O
in	O
actin	B
remodeling	O
,	O
cell	O
polarity	O
control	O
,	O
and	O
cell	O
migration	O
.	O

Based	O
on	O
the	O
homology	O
with	O
ARHGAP22	B
,	O
we	O
identified	O
and	O
characterized	O
two	O
novel	O
ARHGAP	B
family	I
genes	O
,	O
ARHGAP24	B
and	O
ARHGAP25	B
.	O

FLJ33877	B
cDNA	O
(	O
AK091196.1	O
)	O
and	O
aberrant	O
DKFZp564	B
-	I
B1162	I
cDNA	O
(	O
NM_031305.1	O
)	O
were	O
derived	O
from	O
human	O
ARHGAP24	B
gene	O
.	O

Two	O
isoforms	O
of	O
KIAA0053	B
type	O
(	O
D29642.1	O
)	O
and	O
BM927439	O
type	O
were	O
derived	O
from	O
human	O
ARHGAP25	B
gene	O
due	O
to	O
alternative	O
splicing	O
(	O
alternative	O
promoter	O
)	O
.	O

Mouse	O
0610025G21	B
(	O
NM_029270.1	O
)	O
and	O
A130039I20	O
(	O
AK037710.1	O
)	O
were	O
representative	O
cDNAs	O
derived	O
from	O
mouse	O
Arhgap24	B
and	O
Arhgap25	B
genes	O
,	O
respectively	O
.	O

Exon	O
-	O
intron	O
structure	O
of	O
ARHGAP25	B
gene	O
at	O
human	O
chromosome	O
2p13	O
was	O
slightly	O
divergent	O
from	O
that	O
of	O
ARHGAP22	B
and	O
ARHGAP24	B
genes	O
.	O

MGC35285	B
,	O
MAPK8	B
and	O
C10orf64	B
genes	O
linked	O
to	O
ARHGAP22	B
gene	O
were	O
paralogs	O
of	O
PTPN13	B
,	O
MAPK10	B
and	O
WDFY3	B
genes	O
linked	O
to	O
ARHGAP24	B
gene	O
,	O
respectively	O
.	O

MGC35285	B
-	O
ARHGAP22	B
-	O
MAPK8	B
-	O
C10orf64	B
locus	O
at	O
human	O
chromosome	O
10q11	O
and	O
the	O
WDFY3	B
-	O
ARHGAP24	B
-	O
MAPK10	B
-	O
PTPN13	B
locus	O
at	O
human	O
chromosome	O
4q21	O
were	O
paralogous	O
regions	O
(	O
paralogons	O
)	O
within	O
the	O
human	O
genome	O
.	O

Human	O
ARHGAP24	B
showed	O
91.8	O
%	O
and	O
48.6	O
%	O
total	O
-	O
amino	O
-	O
acid	O
identity	O
with	O
mouse	O
Arhgap24	B
and	O
human	O
ARHGAP22	B
,	O
respectively	O
.	O

Human	O
ARHGAP25	B
showed	O
86.1	O
%	O
and	O
40.8	O
%	O
total	O
-	O
amino	O
-	O
acid	O
identity	O
with	O
mouse	O
Arhgap25	B
and	O
human	O
ARHGAP22	B
,	O
respectively	O
.	O

ARHGAP22	B
,	O
ARHGAP24	B
and	O
ARHGAP25	B
were	O
found	O
to	O
constitute	O
the	O
RhoGAP	B
subfamily	I
featured	O
by	O
Pleckstrin	B
homology	O
(	O
PH	O
)	O
domain	O
and	O
C	O
-	O
terminal	O
Coiled	O
-	O
coil	O
domain	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
identification	O
and	O
characterization	O
of	O
the	O
ARHGAP24	B
and	O
ARHGAP25	B
genes	O
.	O

Subdivision	O
of	O
flagellar	O
region	O
III	O
of	O
the	O
Escherichia	O
coli	O
and	O
Salmonella	O
typhimurium	O
chromosomes	O
and	O
identification	O
of	O
two	O
additional	O
flagellar	O
genes	O
.	O

The	O
many	O
genes	O
involved	O
in	O
flagellar	O
structure	O
and	O
function	O
in	O
Escherichia	O
coli	O
and	O
Salmonella	O
typhimurium	O
are	O
located	O
in	O
three	O
major	O
clusters	O
on	O
the	O
chromosome	O
:	O
flagellar	O
regions	O
I	O
,	O
II	O
and	O
III	O
.	O

We	O
have	O
found	O
that	O
region	O
III	O
does	O
not	O
consist	O
of	O
a	O
contiguous	O
set	O
of	O
flagellar	O
genes	O
,	O
as	O
was	O
thought	O
,	O
but	O
that	O
in	O
E.	O
coli	O
there	O
is	O
almost	O
7	O
kb	O
of	O
DNA	O
between	O
the	O
filament	O
cap	O
gene	O
,	O
fliD	B
,	O
and	O
the	O
next	O
known	O
flagellar	O
gene	O
,	O
fliE	B
;	O
a	O
similar	O
situation	O
occurs	O
in	O
S.	O
typhimurium	O
.	O

Most	O
of	O
this	O
DNA	O
is	O
unrelated	O
to	O
flagellar	O
function	O
,	O
since	O
a	O
mutant	O
in	O
which	O
5.4	O
kb	O
of	O
it	O
had	O
been	O
deleted	O
remained	O
fully	O
motile	O
and	O
chemotactic	O
as	O
judged	O
by	O
swarming	O
on	O
semi	O
-	O
solid	O
agar	O
.	O

We	O
have	O
therefore	O
subdivided	O
flagellar	O
region	O
III	O
into	O
two	O
regions	O
,	O
IIIa	O
and	O
IIIb	O
.	O

The	O
known	O
genes	O
in	O
region	O
IIIa	O
are	O
fliABCD	B
,	O
all	O
of	O
which	O
are	O
involved	O
in	O
filament	O
structure	O
and	O
assembly	O
,	O
while	O
region	O
IIIb	O
contains	O
genes	O
fliEFGHIJKLMNOPQR	B
,	O
all	O
of	O
which	O
are	O
related	O
to	O
formation	O
of	O
the	O
hook	O
(	O
basal	O
-	O
body	O
)	O
-	O
complex	O
or	O
to	O
even	O
earlier	O
assembly	O
events	O
.	O

We	O
have	O
found	O
that	O
fliD	B
,	O
the	O
last	O
known	O
gene	O
in	O
region	O
IIIa	O
,	O
is	O
immediately	O
followed	O
by	O
two	O
additional	O
genes	O
,	O
both	O
necessary	O
for	O
flagellation	O
,	O
which	O
we	O
have	O
designated	O
fliS	B
and	O
fliT	B
.	O

They	O
encode	O
small	O
proteins	O
with	O
deduced	O
molecular	O
masses	O
of	O
about	O
15	O
kDa	O
and	O
14	O
kDa	O
,	O
respectively	O
.	O

The	O
functions	O
of	O
FliS	B
and	O
FliT	B
remain	O
to	O
be	O
determined	O
,	O
but	O
they	O
do	O
not	O
appear	O
to	O
be	O
members	O
of	O
the	O
axial	O
family	O
of	O
structural	O
proteins	O
to	O
which	O
FliD	B
belongs	O
.	O

Gene	O
for	O
the	O
activating	O
natural	O
killer	O
cell	O
receptor	O
,	O
KIR2DS1	B
,	O
is	O
associated	O
with	O
susceptibility	O
to	O
psoriasis	O
vulgaris	O
.	O

Psoriasis	O
vulgaris	O
,	O
particularly	O
its	O
juvenile	O
form	O
,	O
is	O
strongly	O
associated	O
with	O
the	O
HLA	B
-	I
Cw*06	I
allele	O
encoding	O
the	O
HLA	B
-	I
Cw6	I
molecule	O
.	O

This	O
molecule	O
is	O
recognized	O
by	O
the	O
inhibitory	O
receptor	O
KIR2DL1	B
and	O
the	O
activatory	O
receptor	O
KIR2DS1	B
,	O
which	O
are	O
expressed	O
on	O
natural	O
killer	O
cells	O
and	O
subpopulations	O
of	O
T	O
lymphocytes	O
.	O

Humans	O
differ	O
by	O
the	O
presence	O
or	O
absence	O
of	O
particular	O
KIR	B
genes	O
.	O

We	O
hypothesized	O
that	O
either	O
activatory	O
KIR2DS1	B
or	O
inhibitory	O
KIR2DL1	B
gene	O
frequencies	O
might	O
be	O
different	O
in	O
psoriatic	O
patients	O
from	O
a	O
control	O
population	O
.	O

Therefore	O
,	O
we	O
compared	O
the	O
frequencies	O
of	O
KIR2D	B
inhibitory	O
(	O
L	O
)	O
and	O
activatory	O
(	O
S	O
)	O
genes	O
in	O
116	O
psoriasis	O
vulgaris	O
patients	O
and	O
in	O
123	O
healthy	O
controls	O
.	O

Fourteen	O
novel	O
gene	O
combinations	O
were	O
found	O
.	O

KIR2DS1	B
was	O
present	O
in	O
85	O
%	O
of	O
the	O
patients	O
,	O
but	O
only	O
in	O
51	O
%	O
of	O
the	O
controls	O
(	O
corrected	O
p	O
[	O
pc	O
]	O
<	O
0.0009	O
)	O
.	O

Similarly	O
,	O
HLA	B
-	I
Cw*06	I
was	O
much	O
more	O
frequent	O
in	O
patients	O
(	O
77	O
%	O
)	O
than	O
in	O
controls	O
(	O
17	O
%	O
;	O
pc	O
<	O
0.00002	O
)	O
.	O

Statistical	O
analysis	O
suggests	O
that	O
,	O
although	O
the	O
contribution	O
of	O
these	O
two	O
factors	O
to	O
psoriasis	O
is	O
partially	O
independent	O
,	O
they	O
interact	O
nevertheless	O
.	O

This	O
result	O
strongly	O
speaks	O
for	O
a	O
role	O
of	O
KIR2DS1	B
on	O
recognition	O
of	O
HLA	B
-	I
Cw6	I
in	O
susceptibility	O
to	O
psoriasis	O
.	O

Isolation	O
of	O
a	O
novel	O
KIR2DL3	B
-	O
specific	O
mAb	O
:	O
comparative	O
analysis	O
of	O
the	O
surface	O
distribution	O
and	O
function	O
of	O
KIR2DL2	B
,	O
KIR2DL3	B
and	O
KIR2DS2	B
.	O

In	O
recent	O
years	O
an	O
increasing	O
number	O
of	O
sequences	O
coding	O
for	O
new	O
KIRs	B
have	O
been	O
described	O
.	O

However	O
,	O
the	O
limited	O
availability	O
of	O
mAbs	O
with	O
unique	O
KIR	B
specificities	O
has	O
hindered	O
an	O
exhaustive	O
assessment	O
of	O
their	O
actual	O
function	O
,	O
HLA	B
-	O
specificity	O
,	O
expression	O
at	O
the	O
cell	O
surface	O
and	O
distribution	O
in	O
different	O
cell	O
populations	O
.	O

In	O
this	O
study	O
we	O
report	O
the	O
generation	O
of	O
a	O
novel	O
mAb	O
(	O
ECM41	O
)	O
specific	O
for	O
KIR2DL3	B
molecules	O
.	O

By	O
the	O
use	O
of	O
cell	O
transfectants	O
expressing	O
one	O
or	O
other	O
KIR	B
we	O
show	O
that	O
this	O
reagent	O
allows	O
discrimination	O
of	O
KIR2DL3	B
from	O
other	O
GL183	B
mAb	O
-	O
reactive	O
molecules	O
such	O
as	O
KIR2DL2	B
and	O
KIR2DS2	B
.	O

Moreover	O
we	O
show	O
that	O
this	O
novel	O
mAb	O
can	O
be	O
used	O
to	O
assess	O
the	O
surface	O
expression	O
and	O
distribution	O
of	O
KIR2DL3	B
in	O
different	O
polyclonal	O
NK	O
populations	O
and	O
in	O
NK	O
cell	O
clones	O
.	O

Along	O
this	O
line	O
,	O
we	O
were	O
able	O
to	O
analyze	O
the	O
HLA	B
class	I
I	I
specificity	O
of	O
NK	O
clones	O
expressing	O
either	O
KIR2DL3	B
or	O
KIR2DL2	B
,	O
two	O
inhibitory	O
receptors	O
that	O
were	O
so	O
far	O
serologically	O
undistinguishable	O
.	O

Finally	O
,	O
the	O
combined	O
use	O
of	O
GL183	B
and	O
ECM41	O
mAbs	O
in	O
redirected	O
killing	O
assays	O
allowed	O
us	O
to	O
investigate	O
the	O
functional	O
outcome	O
of	O
the	O
simultaneous	O
engagement	O
of	O
KIR2DL3	B
and	O
KIR2DS2	B
in	O
NK	O
cell	O
clones	O
co	O
-	O
expressing	O
KIRs	B
that	O
display	O
opposite	O
(	O
inhibitory	O
vs	O
activating	O
)	O
function	O
.	O

Two	O
arginine	B
repressors	I
regulate	O
arginine	O
biosynthesis	O
in	O
Lactobacillus	O
plantarum	O
.	O

The	O
repression	O
of	O
the	O
carAB	B
operon	I
encoding	O
carbamoyl	B
phosphate	I
synthase	I
leads	O
to	O
Lactobacillus	O
plantarum	O
FB331	O
growth	O
inhibition	O
in	O
the	O
presence	O
of	O
arginine	O
.	O

This	O
phenotype	O
was	O
used	O
in	O
a	O
positive	O
screening	O
to	O
select	O
spontaneous	O
mutants	O
deregulated	O
in	O
the	O
arginine	O
biosynthesis	O
pathway	O
.	O

Fourteen	O
mutants	O
were	O
genetically	O
characterized	O
for	O
constitutive	O
arginine	O
production	O
.	O

Mutations	O
were	O
located	O
either	O
in	O
one	O
of	O
the	O
arginine	B
repressor	I
genes	O
(	O
argR1	B
or	O
argR2	B
)	O
present	O
in	O
L.	O
plantarum	O
or	O
in	O
a	O
putative	O
ARG	B
operator	O
in	O
the	O
intergenic	O
region	O
of	O
the	O
bipolar	O
carAB	B
-	I
argCJBDF	I
operons	I
involved	O
in	O
arginine	O
biosynthesis	O
.	O

Although	O
the	O
presence	O
of	O
two	O
ArgR	B
regulators	O
is	O
commonly	O
found	O
in	O
gram	O
-	O
positive	O
bacteria	O
,	O
only	O
single	O
arginine	B
repressors	I
have	O
so	O
far	O
been	O
well	O
studied	O
in	O
Escherichia	O
coli	O
or	O
Bacillus	O
subtilis	O
.	O

In	O
L.	O
plantarum	O
,	O
arginine	O
repression	O
was	O
abolished	O
when	O
ArgR1	B
or	O
ArgR2	B
was	O
mutated	O
in	O
the	O
DNA	O
binding	O
domain	O
,	O
or	O
in	O
the	O
oligomerization	O
domain	O
or	O
when	O
an	O
A123D	O
mutation	O
occurred	O
in	O
ArgR1	B
.	O

A123	O
,	O
equivalent	O
to	O
the	O
conserved	O
residue	O
A124	O
in	O
E.	O
coli	O
ArgR	B
involved	O
in	O
arginine	O
binding	O
,	O
was	O
different	O
in	O
the	O
wild	O
-	O
type	O
ArgR2	B
.	O

Thus	O
,	O
corepressor	O
binding	O
sites	O
may	O
be	O
different	O
in	O
ArgR1	B
and	O
ArgR2	B
,	O
which	O
have	O
only	O
35	O
%	O
identical	O
residues	O
.	O

Other	O
mutants	O
harbored	O
wild	O
-	O
type	O
argR	B
genes	O
,	O
and	O
20	O
mutants	O
have	O
lost	O
their	O
ability	O
to	O
grow	O
in	O
normal	O
air	O
without	O
carbon	O
dioxide	O
enrichment	O
;	O
this	O
revealed	O
a	O
link	O
between	O
arginine	O
biosynthesis	O
and	O
a	O
still	O
-	O
unknown	O
CO2	O
-	O
dependent	O
metabolic	O
pathway	O
.	O

In	O
many	O
gram	O
-	O
positive	O
bacteria	O
,	O
the	O
expression	O
and	O
interaction	O
of	O
different	O
ArgR	B
-	O
like	O
proteins	O
may	O
imply	O
a	O
complex	O
regulatory	O
network	O
in	O
response	O
to	O
environmental	O
stimuli	O
.	O

Muscle	O
involvement	O
in	O
juvenile	O
idiopathic	O
arthritis	O
.	O

OBJECTIVE	O
:	O

An	O
observational	O
study	O
of	O
changes	O
in	O
muscle	O
structure	O
and	O
the	O
relation	O
to	O
muscle	O
strength	O
in	O
juvenile	O
idiopathic	O
arthritis	O
(	O
JIA	O
)	O
.	O

METHODS	O
:	O

Fifteen	O
children	O
and	O
teenagers	O
(	O
eight	O
girls	O
and	O
seven	O
boys	O
)	O
with	O
JIA	O
,	O
aged	O
9	O
-	O
19	O
yr	O
(	O
mean	O
age	O
16.1	O
)	O
,	O
were	O
studied	O
.	O

Muscle	O
biopsies	O
were	O
obtained	O
from	O
the	O
anterior	O
tibial	O
muscle	O
and	O
were	O
examined	O
using	O
histopathological	O
and	O
immunohistochemical	O
methods	O
.	O

Muscle	O
fibre	O
types	O
were	O
classified	O
and	O
fibre	O
areas	O
measured	O
.	O

As	O
markers	O
of	O
inflammation	O
,	O
the	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
I	I
and	I
class	I
II	I
and	O
the	O
membrane	B
attack	I
complex	I
(	O
MAC	B
)	O
were	O
analysed	O
.	O

Results	O
were	O
compared	O
with	O
biopsies	O
from	O
the	O
gastrocnemius	O
muscle	O
in	O
33	O
young	O
(	O
19	O
-	O
23	O
yr	O
)	O
healthy	O
controls	O
.	O

Isometric	O
and	O
isokinetic	O
muscle	O
strengths	O
were	O
measured	O
in	O
ankle	O
dorsiflexion	O
.	O

Strength	O
was	O
compared	O
with	O
reference	O
values	O
for	O
healthy	O
age	O
-	O
matched	O
controls	O
.	O

Nerve	O
conduction	O
velocities	O
were	O
recorded	O
in	O
the	O
peroneal	O
and	O
sural	O
nerves	O
.	O

RESULTS	O
:	O

Four	O
of	O
the	O
15	O
muscle	O
biopsies	O
were	O
morphologically	O
normal	O
.	O

Eleven	O
biopsies	O
showed	O
minor	O
unspecific	O
changes	O
.	O

Two	O
of	O
these	O
also	O
showed	O
minor	O
signs	O
of	O
inflammation	O
.	O

MHC	B
class	I
II	I
expression	O
was	O
found	O
in	O
4	O
/	O
15	O
patients	O
,	O
which	O
was	O
significantly	O
more	O
than	O
in	O
the	O
healthy	O
controls	O
(	O
P	O
=	O
0.0143	O
)	O
.	O

The	O
expression	O
of	O
MHC	B
class	I
I	I
and	O
MAC	B
did	O
not	O
differ	O
from	O
that	O
in	O
the	O
controls	O
.	O

The	O
mean	O
area	O
of	O
type	O
I	O
fibres	O
was	O
lower	O
than	O
that	O
of	O
type	O
IIA	O
fibres	O
in	O
12	O
/	O
13	O
biopsies	O
.	O

Muscle	O
strength	O
was	O
significantly	O
reduced	O
in	O
the	O
patient	O
group	O
.	O

There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
muscle	O
fibre	O
area	O
and	O
muscle	O
strength	O
.	O

Nerve	O
conduction	O
studies	O
were	O
normal	O
in	O
all	O
cases	O
.	O

CONCLUSIONS	O
:	O

Changes	O
in	O
leg	O
muscle	O
biopsies	O
appear	O
to	O
be	O
common	O
in	O
children	O
and	O
teenagers	O
with	O
JIA	O
.	O

The	O
presence	O
of	O
inflammatory	O
cells	O
in	O
the	O
muscle	O
and	O
expression	O
of	O
MHC	B
class	I
II	I
on	O
muscle	O
fibres	O
may	O
be	O
a	O
sign	O
of	O
inflammatory	O
myopathy	O
.	O

There	O
are	O
no	O
findings	O
of	O
type	O
II	O
muscle	O
fibre	O
hypotrophy	O
or	O
neuropathy	O
,	O
as	O
in	O
adults	O
with	O
RA	O
.	O

Cell	O
division	O
and	O
cell	O
survival	O
in	O
the	O
absence	O
of	O
survivin	B
.	O

The	O
survivin	B
protein	O
contains	O
structural	O
features	O
of	O
the	O
inhibitor	O
of	O
apoptosis	O
protein	O
family	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
survivin	B
is	O
essential	O
for	O
cell	O
survival	O
because	O
it	O
counteracts	O
an	O
otherwise	O
constitutive	O
propensity	O
to	O
apoptosis	O
during	O
mitosis	O
.	O

In	O
addition	O
,	O
survivin	B
appears	O
to	O
be	O
a	O
component	O
of	O
the	O
chromosomal	O
passenger	O
protein	O
complex	O
that	O
participates	O
in	O
multiple	O
facets	O
of	O
cell	O
division	O
.	O

Here	O
we	O
report	O
that	O
euploid	O
human	O
cells	O
do	O
not	O
die	O
in	O
the	O
absence	O
of	O
survivin	B
.	O

Instead	O
,	O
depletion	O
of	O
survivin	B
caused	O
defects	O
in	O
cell	O
division	O
,	O
followed	O
by	O
an	O
arrest	O
of	O
DNA	O
synthesis	O
due	O
to	O
activation	O
of	O
a	O
checkpoint	O
involving	O
the	O
tumor	B
suppressor	I
protein	I
p53	I
.	O

During	O
anaphase	O
mitosis	O
in	O
survivin	B
-	O
deficient	O
cells	O
,	O
sister	O
chromatids	O
disjoined	O
normally	O
,	O
but	O
one	O
or	O
more	O
of	O
the	O
sister	O
chromatids	O
frequently	O
lagged	O
behind	O
the	O
main	O
mass	O
of	O
segregating	O
chromosomes	O
,	O
probably	O
because	O
of	O
merotelic	O
kinetochore	O
attachments	O
.	O

Survivin	B
-	O
deficient	O
cells	O
initiated	O
but	O
failed	O
to	O
complete	O
cytokinesis	O
,	O
apparently	O
because	O
the	O
spindle	O
midzone	O
and	O
midbody	O
microtublues	O
were	O
absent	O
during	O
late	O
mitosis	O
.	O

The	O
abnormalities	O
of	O
both	O
chromosome	O
segregation	O
and	O
cytokinesis	O
could	O
be	O
attributed	O
to	O
a	O
defect	O
in	O
the	O
chromosomal	O
passenger	O
protein	O
complex	O
,	O
with	O
a	O
consequent	O
mislocalization	O
of	O
the	O
kinesin	B
-	I
like	I
motor	I
protein	I
MKLP-1	I
playing	O
a	O
more	O
immediate	O
role	O
in	O
the	O
microtubule	O
abnormalities	O
.	O

Depletion	O
of	O
another	O
chromosomal	O
passenger	O
protein	O
,	O
aurora	B
-	I
B	I
,	O
recapitulated	O
the	O
survivin	B
RNA	O
interference	O
phenotypes	O
.	O

We	O
conclude	O
that	O
survivin	B
can	O
be	O
essential	O
for	O
the	O
proliferation	O
of	O
normal	O
human	O
cells	O
by	O
virtue	O
of	O
its	O
contributions	O
to	O
accurate	O
sister	O
chromatid	O
segregation	O
and	O
assembly	O
/	O
stabilization	O
of	O
microtubules	O
in	O
late	O
mitosis	O
.	O

However	O
,	O
the	O
protein	O
is	O
not	O
inevitably	O
required	O
for	O
the	O
survival	O
of	O
normal	O
cells	O
.	O

Depletion	O
of	O
apolipoprotein	B
N	I
-	I
acyltransferase	I
causes	O
mislocalization	O
of	O
outer	O
membrane	O
lipoproteins	O
in	O
Escherichia	O
coli	O
.	O

Lipoproteins	O
in	O
Gram	O
-	O
negative	O
Enterobacteriaceae	O
carry	O
three	O
fatty	O
acids	O
on	O
the	O
N	O
-	O
terminal	O
cysteine	O
residue	O
,	O
two	O
as	O
a	O
diacylglyceride	O
and	O
one	O
through	O
an	O
N	O
-	O
linkage	O
following	O
signal	O
peptide	O
cleavage	O
.	O

Most	O
lipoproteins	O
are	O
anchored	O
in	O
the	O
outer	O
membrane	O
,	O
facing	O
the	O
periplasm	O
,	O
but	O
some	O
lipoproteins	O
remain	O
in	O
the	O
plasma	O
membrane	O
,	O
depending	O
on	O
the	O
amino	O
acid	O
at	O
position	O
+	O
2	O
,	O
immediately	O
after	O
the	O
fatty	O
-	O
acylated	O
cysteine	O
.	O

In	O
vitro	O
,	O
the	O
last	O
step	O
in	O
lipoprotein	O
maturation	O
,	O
N	O
-	O
acylation	O
of	O
apolipoproteins	B
by	O
the	O
plasma	O
membrane	O
apolipoprotein	B
N	I
-	I
acyltransferase	I
(	O
Lnt	B
)	O
,	O
is	O
necessary	O
for	O
efficient	O
recognition	O
of	O
outer	O
membrane	O
lipoproteins	O
by	O
the	O
Lol	B
system	O
,	O
which	O
transports	O
them	O
from	O
the	O
plasma	O
to	O
the	O
outer	O
membrane	O
(	O
Fukuda	O
,	O
A.	O
,	O
Matsuyama	O
,	O
S	O
.-	O
I.	O
,	O
Hara	O
,	O
T.	O
,	O
Nakayama	O
,	O
J.	O
,	O
Nagasawa	O
,	O
H.	O
,	O
and	O
Tokuda	O
,	O
H.	O
(	O
2002	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
277	O
,	O
43512	O
-	O
43518	O
)	O
.	O

To	O
study	O
the	O
role	O
of	O
Lnt	B
in	O
vivo	O
,	O
we	O
constructed	O
a	O
conditional	O
lnt	B
mutant	O
of	O
Escherichia	O
coli	O
.	O

The	O
apo	O
-	O
form	O
of	O
peptidoglycan	O
-	O
anchored	O
major	B
lipoprotein	I
(	O
Lpp	B
)	O
and	O
two	O
other	O
outer	O
membrane	O
lipoproteins	O
accumulated	O
in	O
the	O
plasma	O
membrane	O
when	O
lnt	B
expression	O
was	O
reduced	O
.	O

We	O
also	O
found	O
that	O
Lnt	B
is	O
an	O
essential	O
protein	O
in	O
E.	O
coli	O
and	O
that	O
the	O
lethality	O
is	O
partially	O
because	O
of	O
the	O
retention	O
of	O
apoLpp	B
in	O
the	O
plasma	O
membrane	O
.	O

Topology	O
mapping	O
of	O
Lnt	B
with	O
beta	B
-	I
galactosidase	I
and	O
alkaline	B
phosphatase	I
fusions	O
indicated	O
the	O
presence	O
of	O
six	O
membrane	O
-	O
spanning	O
segments	O
.	O

The	O
lnt	B
gene	O
in	O
a	O
mutant	O
of	O
Salmonella	O
enterica	O
displaying	O
thermosensitive	O
Lnt	B
activity	O
(	O
Gupta	O
,	O
S.	O
D.	O
,	O
Gan	O
,	O
K.	O
,	O
Schmid	O
,	O
M.	O
B.	O
,	O
and	O
Wu	O
,	O
H.	O
C.	O
(	O
1993	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
268	O
,	O
16551	O
-	O
16556	O
)	O
was	O
found	O
to	O
carry	O
a	O
mutation	O
causing	O
a	O
single	O
glutamate	O
to	O
lysine	O
substitution	O
at	O
a	O
highly	O
conserved	O
position	O
in	O
the	O
last	O
predicted	O
periplasmic	O
loop	O
of	O
the	O
protein	O
.	O

Endogenous	O
glucocorticoids	O
modulate	O
neutrophil	O
function	O
in	O
a	O
murine	O
model	O
of	O
haemolytic	O
uraemic	O
syndrome	O
.	O

Haemolytic	O
uraemic	O
syndrome	O
(	O
HUS	O
)	O
is	O
caused	O
by	O
Shiga	B
-	I
toxin	I
-	O
producing	O
Escherichia	O
coli	O
(	O
STEC	O
)	O
.	O

Although	O
,	O
Shiga	B
toxin	I
type	I
2	I
(	O
Stx2	B
)	O
is	O
responsible	O
for	O
the	O
renal	O
pathogenesis	O
observed	O
in	O
patients	O
,	O
the	O
inflammatory	O
response	O
,	O
including	O
cytokines	B
and	O
polymorphonuclear	O
neutrophils	O
(	O
PMN	O
)	O
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
HUS	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
Stx2	B
injection	O
generates	O
an	O
anti	O
-	O
inflammatory	O
reaction	O
characterized	O
by	O
endogenous	O
glucocorticoid	O
(	O
GC	O
)	O
secretion	O
,	O
which	O
attenuates	O
HUS	O
severity	O
in	O
mice	O
.	O

Here	O
,	O
we	O
analysed	O
the	O
effects	O
of	O
Stx2	B
on	O
the	O
pathogenic	O
function	O
of	O
PMN	O
and	O
the	O
potential	O
role	O
of	O
endogenous	O
GC	O
to	O
limit	O
PMN	O
activation	O
during	O
HUS	O
development	O
in	O
a	O
murine	O
model	O
.	O

For	O
this	O
purpose	O
we	O
assessed	O
the	O
functional	O
activity	O
of	O
isolated	O
PMN	O
after	O
in	O
vivo	O
treatment	O
with	O
Stx2	B
alone	O
or	O
in	O
simultaneous	O
treatment	O
with	O
Ru486	O
(	O
GC	B
receptor	I
antagonist	O
)	O
.	O

We	O
found	O
that	O
Stx2	B
increased	O
the	O
generation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
under	O
phobol	O
-	O
myristate	O
-	O
acetate	O
(	O
PMA	O
)	O
stimulation	O
and	O
that	O
the	O
simultaneous	O
treatment	O
with	O
Ru486	O
strengthened	O
this	O
effect	O
.	O

Conversely	O
,	O
both	O
treatments	O
significantly	O
inhibited	O
in	O
vitro	O
phagocytosis	O
.	O

Furthermore	O
,	O
Stx2	B
augmented	O
in	O
vitro	O
PMN	O
adhesion	O
to	O
fibrinogen	B
(	O
FGN	B
)	O
and	O
bovine	O
serum	B
albumin	I
(	O
BSA	B
)	O
but	O
not	O
to	O
collagen	B
type	I
I	I
(	O
CTI	B
)	O
.	O

Stx2	B
+	O
Ru486	O
caused	O
enhanced	O
adhesion	O
to	O
BSA	B
and	O
CTI	B
compared	O
to	O
Stx2	B
.	O

Whereas	O
Stx2	B
significantly	O
increased	O
migration	O
towards	O
N	O
-	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
(	O
fMLP	O
)	O
,	O
Stx2	B
+	O
Ru486	O
treatment	O
enhanced	O
and	O
accelerated	O
this	O
process	O
.	O

The	O
percentage	O
of	O
apoptotic	O
PMN	O
from	O
Stx2	B
-	O
treated	O
mice	O
was	O
higher	O
compared	O
with	O
controls	O
,	O
but	O
equal	O
to	O
Stx2	B
+	O
Ru486	O
treated	O
mice	O
.	O

We	O
conclude	O
that	O
Stx2	B
activates	O
PMN	O
and	O
that	O
the	O
absence	O
of	O
endogenous	O
GC	O
enhances	O
this	O
activation	O
suggesting	O
that	O
endogenous	O
GC	O
can	O
,	O
at	O
least	O
partially	O
,	O
counteract	O
PMN	O
inflammatory	O
functions	O
.	O

Interleukin-1beta	B
can	O
mediate	O
growth	O
arrest	O
and	O
differentiation	O
via	O
the	O
leukemia	B
inhibitory	I
factor	I
/	O
JAK	B
/	O
STAT	B
pathway	O
in	O
medullary	O
thyroid	O
carcinoma	O
cells	O
.	O

Interleukin-1beta	B
(	O
IL-1beta	B
)	O
is	O
a	O
pleiotropic	O
cytokine	B
that	O
can	O
induce	O
several	O
cellular	O
signal	O
transduction	O
pathways	O
.	O

Here	O
,	O
we	O
show	O
that	O
IL-1beta	B
can	O
induce	O
cell	O
cycle	O
arrest	O
and	O
differentiation	O
in	O
the	O
human	O
medullary	O
thyroid	O
carcinoma	O
(	O
MTC	O
)	O
cell	O
line	O
,	O
TT	O
.	O

IL-1beta	B
induces	O
cell	O
cycle	O
arrest	O
accompanied	O
by	O
morphological	O
changes	O
and	O
expression	O
of	O
the	O
neuroendocrine	O
marker	O
calcitonin	B
.	O

These	O
changes	O
are	O
blocked	O
by	O
the	O
MEK1	B
/	I
2	I
specific	O
inhibitor	O
U0126	O
,	O
indicating	O
that	O
MEK1	B
/	I
2	I
is	O
essential	O
for	O
IL-1beta	B
signaling	O
in	O
TT	O
cells	O
.	O

IL-1beta	B
induces	O
expression	O
of	O
leukemia	B
inhibitory	I
factor	I
(	O
LIF	B
)	O
and	O
activation	O
of	O
STAT3	B
via	O
the	O
MEK	B
/	O
ERK	B
pathway	O
.	O

This	O
activation	O
of	O
STAT3	B
could	O
be	O
abrogated	O
by	O
treatment	O
with	O
anti	O
-	O
LIF	B
neutralizing	O
antibody	O
or	O
anti	O
-	O
gp130	B
blocking	O
antibody	O
,	O
indicating	O
that	O
induction	O
of	O
LIF	B
expression	O
is	O
sufficient	O
and	O
essential	O
for	O
STAT3	B
activation	O
by	O
IL-1beta	B
.	O

In	O
addition	O
to	O
activation	O
of	O
the	O
LIF	B
/	O
JAK	B
/	O
STAT	B
pathway	O
,	O
IL-1beta	B
also	O
induced	O
an	O
MEK	B
/	O
ERK	B
-	O
mediated	O
intracellular	O
cell	O
-	O
autonomous	O
signaling	O
pathway	O
that	O
is	O
independently	O
sufficient	O
for	O
growth	O
arrest	O
and	O
differentiation	O
.	O

Thus	O
,	O
IL-1beta	B
activates	O
the	O
MEK	B
/	O
ERK	B
pathway	O
to	O
induce	O
growth	O
arrest	O
and	O
differentiation	O
in	O
MTC	O
cells	O
via	O
dual	O
independent	O
signaling	O
mechanisms	O
,	O
the	O
cell	O
-	O
extrinsic	O
LIF	B
/	O
JAK	B
/	O
STAT	B
pathway	O
,	O
and	O
the	O
cell	O
-	O
intrinsic	O
autonomous	O
signaling	O
pathway	O
.	O

Enzymes	O
involved	O
in	O
anaerobic	O
respiration	O
appear	O
to	O
play	O
a	O
role	O
in	O
Actinobacillus	O
pleuropneumoniae	O
virulence	O
.	O

Actinobacillus	O
pleuropneumoniae	O
,	O
the	O
etiological	O
agent	O
of	O
porcine	O
pleuropneumonia	O
,	O
is	O
able	O
to	O
survive	O
on	O
respiratory	O
epithelia	O
,	O
in	O
tonsils	O
,	O
and	O
in	O
the	O
anaerobic	O
environment	O
of	O
encapsulated	O
sequesters	O
.	O

It	O
was	O
previously	O
demonstrated	O
that	O
a	O
deletion	O
of	O
the	O
anaerobic	O
dimethyl	B
sulfoxide	I
reductase	I
gene	O
(	O
dmsA	B
)	O
results	O
in	O
attenuation	O
in	O
acute	O
disease	O
(	O
N.	O
Baltes	O
,	O
S.	O
Kyaw	O
,	O
I.	O
Hennig	O
-	O
Pauka	O
,	O
and	O
G.	O
F.	O
Gerlach	O
,	O
Infect	O
.	O
Immun	O
.	O
71	O
:	O
6784	O
-	O
6792	O
,	O
2003	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
using	O
two	O
-	O
dimensional	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
,	O
we	O
identified	O
an	O
aspartate	B
ammonia	I
-	I
lyase	I
(	O
AspA	B
)	O
which	O
is	O
upregulated	O
upon	O
induction	O
with	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
.	O

This	O
enzyme	O
is	O
involved	O
in	O
the	O
production	O
of	O
fumarate	O
,	O
an	O
alternative	O
electron	O
acceptor	O
under	O
anaerobic	O
conditions	O
.	O

The	O
coding	O
gene	O
(	O
aspA	B
)	O
was	O
cloned	O
and	O
shown	O
to	O
be	O
present	O
in	O
all	O
A.	O
pleuropneumoniae	O
serotype	O
reference	O
strains	O
.	O

The	O
transcriptional	O
start	O
point	O
was	O
identified	O
downstream	O
of	O
a	O
putative	O
FNR	B
binding	O
motif	O
,	O
and	O
BALF	O
-	O
dependent	O
activation	O
of	O
aspA	B
was	O
confirmed	O
by	O
construction	O
of	O
an	O
isogenic	O
A.	O
pleuropneumoniae	O
mutant	O
carrying	O
a	O
chromosomal	O
aspA	B
:	O
:	O
luxAB	B
transcriptional	O
fusion	O
.	O

Two	O
aspA	B
deletion	O
mutants	O
,	O
A.	O
pleuropneumoniae	O
DeltaaspA	O
and	O
A.	O
pleuropneumoniae	O
DeltaaspADeltadmsA	O
,	O
were	O
constructed	O
,	O
both	O
showing	O
reduced	O
growth	O
under	O
anaerobic	O
conditions	O
in	O
vitro	O
.	O

Pigs	O
challenged	O
with	O
either	O
of	O
the	O
two	O
mutants	O
in	O
an	O
aerosol	O
infection	O
model	O
showed	O
a	O
lower	O
lung	O
lesion	O
score	O
than	O
that	O
of	O
the	O
A.	O
pleuropneumoniae	O
wild	O
-	O
type	O
(	O
wt	O
)	O
controls	O
.	O

Pigs	O
challenged	O
with	O
A.	O
pleuropneumoniae	O
DeltaaspADeltadmsA	O
had	O
a	O
significantly	O
lower	O
clinical	O
score	O
,	O
and	O
this	O
mutant	O
was	O
rarely	O
reisolated	O
from	O
unaltered	O
lung	O
tissue	O
;	O
in	O
contrast	O
,	O
A.	O
pleuropneumoniae	O
DeltaaspA	O
and	O
the	O
A.	O
pleuropneumoniae	O
wt	O
were	O
consistently	O
reisolated	O
in	O
high	O
numbers	O
.	O

These	O
results	O
suggest	O
that	O
enzymes	O
involved	O
in	O
anaerobic	O
respiration	O
are	O
necessary	O
for	O
the	O
pathogen	O
's	O
ability	O
to	O
persist	O
on	O
respiratory	O
tract	O
epithelium	O
and	O
play	O
an	O
important	O
role	O
in	O
A.	O
pleuropneumoniae	O
pathogenesis	O
.	O

The	O
expression	O
of	O
intact	O
and	O
mutant	O
human	O
apoAI	B
/	I
CIII	I
/	I
AIV	I
/	I
AV	I
gene	O
cluster	O
in	O
transgenic	O
mice	O
.	O

The	O
apoAI	B
/	I
CIII	I
/	I
AIV	I
gene	O
cluster	O
is	O
involved	O
in	O
lipid	O
metabolism	O
and	O
has	O
a	O
complex	O
pattern	O
of	O
gene	O
expression	O
modulated	O
by	O
a	O
common	O
regulatory	O
element	O
,	O
the	O
apoCIII	B
enhancer	O
.	O

A	O
new	O
member	O
of	O
this	O
cluster	O
,	O
apolipoprotein	B
(	I
apo	I
)	I
AV	I
,	O
has	O
recently	O
been	O
discovered	O
as	O
a	O
novel	O
modifier	O
in	O
triglyceride	O
metabolism	O
.	O

To	O
determine	O
the	O
expression	O
of	O
all	O
four	O
apo	B
genes	O
in	O
combination	O
and	O
,	O
most	O
importantly	O
,	O
whether	O
the	O
transcription	O
of	O
apoAV	B
is	O
coregulated	O
by	O
the	O
apoCIII	B
enhancer	O
in	O
the	O
cluster	O
,	O
we	O
generated	O
an	O
intact	O
transgenic	O
line	O
carrying	O
the	O
116	O
-	O
kb	O
human	O
apoAI	B
/	I
CIII	I
/	I
AIV	I
/	I
AV	I
gene	O
cluster	O
and	O
a	O
mutant	O
transgenic	O
line	O
in	O
which	O
the	O
apoCIII	B
enhancer	O
was	O
deleted	O
from	O
the	O
116	O
-	O
kb	O
structure	O
.	O

We	O
demonstrated	O
that	O
the	O
apoCIII	B
enhancer	O
regulated	O
hepatic	O
and	O
intestinal	O
apoAI	B
,	O
apoCIII	B
,	O
and	O
apoAIV	B
expression	O
;	O
however	O
,	O
it	O
did	O
not	O
direct	O
the	O
newly	O
identified	O
apoAV	B
in	O
the	O
cluster	O
.	O

Furthermore	O
,	O
human	O
apo	B
genes	O
displayed	O
integrated	O
position	O
-	O
independent	O
expression	O
and	O
a	O
closer	O
approximation	O
of	O
copy	O
number	O
-	O
dependent	O
expression	O
in	O
the	O
intact	O
transgenic	O
mice	O
.	O

Because	O
apoCIII	B
and	O
apoAV	B
play	O
opposite	O
roles	O
in	O
triglyceride	O
homeostasis	O
,	O
we	O
analyzed	O
the	O
lipid	O
profiles	O
in	O
our	O
transgenic	O
mice	O
to	O
assess	O
the	O
effects	O
of	O
human	O
apoAI	B
gene	O
cluster	O
expression	O
on	O
lipid	O
metabolism	O
.	O

The	O
triglyceride	O
level	O
was	O
elevated	O
in	O
intact	O
transgenic	O
mice	O
but	O
decreased	O
in	O
mutant	O
ones	O
compared	O
with	O
nontransgenic	O
mice	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
human	O
apoAI	B
and	O
apoAIV	B
elevated	O
high	B
density	I
lipoprotein	I
cholesterol	O
in	O
transgenic	O
mice	O
fed	O
an	O
atherogenic	O
diet	O
.	O

In	O
conclusion	O
,	O
our	O
studies	O
with	O
human	O
apoAI	B
/	I
CIII	I
/	I
AIV	I
/	I
AV	I
gene	O
cluster	O
transgenic	O
models	O
showed	O
that	O
the	O
apoCIII	B
enhancer	O
regulated	O
expression	O
of	O
apoAI	B
,	O
apo	B
-	I
CIII	I
,	O
and	O
apoAIV	B
but	O
not	O
apoAV	B
in	O
vivo	O
and	O
showed	O
the	O
influences	O
of	O
expression	O
of	O
the	O
entire	O
cluster	O
on	O
lipid	O
metabolism	O
.	O

IL-8	B
promotes	O
cell	O
proliferation	O
and	O
migration	O
through	O
metalloproteinase	B
-	O
cleavage	O
proHB	B
-	I
EGF	I
in	O
human	O
colon	O
carcinoma	O
cells	O
.	O

Interleukin-8	B
(	O
IL-8	B
)	O
has	O
been	O
reported	O
to	O
promote	O
tumor	O
cell	O
growth	O
in	O
colon	O
cancer	O
cells	O
after	O
binding	O
to	O
its	O
receptors	O
,	O
which	O
are	O
members	O
of	O
the	O
G	B
-	I
protein	I
coupled	I
receptor	I
(	I
GPCR	I
)	I
family	I
.	O

Recent	O
studies	O
demonstrated	O
that	O
stimulation	O
of	O
GPCR	B
can	O
induce	O
shedding	O
of	O
epidermal	B
growth	I
factor	I
(	O
EGF	B
)	O
ligands	O
via	O
activation	O
of	O
a	B
disintegrin	I
and	I
metalloprotease	I
(	O
ADAM	B
)	O
,	O
with	O
subsequent	O
transactivation	O
of	O
the	O
EGF	B
receptor	I
(	O
EGFR	B
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
mechanisms	O
of	O
cell	O
proliferation	O
and	O
migration	O
stimulated	O
by	O
IL-8	B
in	O
a	O
human	O
colon	O
carcinoma	O
cell	O
line	O
(	O
Caco2	O
)	O
.	O

IL-8	B
increased	O
DNA	O
synthesis	O
of	O
Caco2	O
in	O
a	O
dose	O
dependent	O
manner	O
and	O
this	O
was	O
inhibited	O
by	O
ADAM	B
,	O
EGFR	B
kinase	B
,	O
and	O
MEK	B
inhibitors	O
.	O

IL-8	B
transiently	O
induced	O
EGFR	B
tyrosine	O
phosphorylation	O
after	O
5	O
-	O
90	O
min	O
and	O
this	O
was	O
completely	O
inhibited	O
by	O
ADAM	B
inhibitor	O
.	O

Neutralizing	O
antibody	O
against	O
HB	B
-	I
EGF	I
as	O
a	O
key	O
ligand	O
for	O
EGFR	B
also	O
blocked	O
transactivation	O
of	O
EGFR	B
and	O
cell	O
proliferation	O
by	O
IL-8	B
.	O

Since	O
IL-8	B
-	O
induced	O
cell	O
migration	O
was	O
further	O
suppressed	O
by	O
the	O
ADAM	B
inhibitor	O
and	O
the	O
HB	B
-	I
EGF	I
neutralizing	O
antibody	O
,	O
our	O
data	O
indicate	O
that	O
IL-8	B
induces	O
cell	O
proliferation	O
and	O
migration	O
by	O
an	O
ADAM	B
-	O
dependent	O
pathway	O
,	O
and	O
that	O
HB	B
-	I
EGF	I
plays	O
an	O
important	O
role	O
as	O
the	O
major	O
ligand	O
for	O
this	O
pathway	O
.	O

Lack	O
of	O
tumor	B
necrosis	I
factor	I
receptor	I
type	I
1	I
inhibits	O
liver	O
fibrosis	O
induced	O
by	O
carbon	O
tetrachloride	O
in	O
mice	O
.	O

Chronic	O
liver	O
injury	O
causes	O
liver	O
regeneration	O
,	O
resulting	O
in	O
fibrosis	O
.	O

The	O
proinflammatory	O
cytokine	B
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
many	O
acute	O
and	O
chronic	O
liver	O
diseases	O
.	O

TNF	B
has	O
pleiotropic	O
functions	O
,	O
but	O
its	O
role	O
in	O
liver	O
fibrosis	O
has	O
not	O
been	O
clarified	O
.	O

Chronic	O
repeated	O
injection	O
of	O
CCl4	O
induces	O
liver	O
fibrosis	O
in	O
mice	O
.	O

We	O
examined	O
whether	O
signaling	O
through	O
TNF	B
receptors	I
was	O
critical	O
for	O
this	O
process	O
,	O
using	O
mice	O
lacking	O
either	O
TNF	B
receptor	I
(	I
TNFR	I
)	I
type	I
1	I
or	O
TNFR	B
type	I
2	I
to	O
define	O
the	O
pathophysiologic	O
role	O
of	O
TNFR	B
signals	O
in	O
liver	O
fibrosis	O
.	O

Liver	O
fibrosis	O
caused	O
by	O
chronic	O
CCl4	O
exposure	O
was	O
TNF	B
-	O
dependent	O
;	O
histological	O
fibrosis	O
was	O
seen	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
TNFR-2	B
knockout	O
(	O
KO	O
)	O
mice	O
,	O
but	O
not	O
in	O
TNFR-1	B
KO	O
mice	O
.	O

Furthermore	O
,	O
a	O
marked	O
reduction	O
in	O
procollagen	O
and	O
TGF	B
-	I
beta	I
synthesis	O
was	O
observed	O
in	O
TNFR-1	B
KO	O
mice	O
,	O
which	O
also	O
had	O
little	O
detectable	O
NF	B
-	I
kappa	I
B	I
,	O
STAT3	B
,	O
and	O
AP1	B
binding	O
,	O
and	O
reduced	O
levels	O
of	O
liver	O
interleukin-6	B
(	O
IL-6	B
)	O
mRNA	O
compared	O
to	O
WT	O
and	O
TNFR-2	B
KO	O
mice	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
indicate	O
the	O
possibility	O
that	O
NF	B
-	I
kappa	I
B	I
,	O
STAT3	B
,	O
and	O
AP1	B
binding	O
by	O
signals	O
transduced	O
through	O
TNFR-1	B
plays	O
an	O
important	O
role	O
in	O
liver	O
fibrosis	O
formation	O
.	O

11	B
{	I
beta	I
}	I
-Hydroxysteroid	I
dehydrogenase	I
2	I
in	O
rat	O
leydig	O
cells	O
:	O
its	O
role	O
in	O
blunting	O
glucocorticoid	O
action	O
at	O
physiological	O
levels	O
of	O
substrate	O
.	O

Corticosterone	O
(	O
CORT	O
)	O
suppresses	O
Leydig	O
cell	O
steroidogenesis	O
by	O
inhibiting	O
the	O
expression	O
of	O
proteins	O
involved	O
in	O
testosterone	O
biosynthesis	O
including	O
steroidogenic	O
acute	O
regulatory	O
protein	O
and	O
steroidogenic	O
enzymes	O
.	O

In	O
most	O
cells	O
,	O
intracellular	O
glucocorticoid	O
levels	O
are	O
controlled	O
by	O
either	O
or	O
both	O
of	O
the	O
two	O
known	O
isoforms	O
of	O
11beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
11beta	B
HSD	I
)	O
:	O
the	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
reduced	O
-	O
dependent	O
low	O
-	O
affinity	O
type	B
I	I
11beta	I
HSD	I
(	O
11beta	B
HSD1	I
)	O
oxidoreductase	B
and	O
the	O
nicotinamide	O
adenine	O
dinucleotide	O
-	O
dependent	O
11beta	B
HSD2	I
high	O
-	O
affinity	O
unidirectional	O
oxidase	B
.	O

In	O
Leydig	O
cells	O
,	O
11beta	B
HSD1	I
alone	O
may	O
not	O
be	O
sufficient	O
to	O
prevent	O
glucocorticoid	O
-	O
mediated	O
suppression	O
due	O
to	O
its	O
low	O
affinity	O
for	O
CORT	O
at	O
basal	O
concentrations	O
.	O

The	O
high	O
-	O
affinity	O
unidirectional	O
11beta	B
HSD2	I
,	O
if	O
also	O
present	O
,	O
may	O
be	O
critical	O
for	O
lowering	O
intracellular	O
CORT	O
levels	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
11beta	B
HSD2	I
is	O
present	O
in	O
rat	O
Leydig	O
cells	O
by	O
PCR	O
amplification	O
,	O
immunohistochemical	O
staining	O
,	O
enzyme	O
histochemistry	O
,	O
immunoprecipitation	O
,	O
and	O
Western	O
blotting	O
.	O

Real	O
-	O
time	O
PCR	O
showed	O
a	O
6	O
-	O
fold	O
enrichment	O
of	O
11beta	B
HSD2	I
mRNA	O
in	O
these	O
cells	O
,	O
compared	O
with	O
whole	O
testis	O
and	O
that	O
the	O
amount	O
of	O
11beta	B
HSD2	I
message	O
was	O
about	O
1000	O
-	O
fold	O
lower	O
,	O
compared	O
with	O
11beta	B
HSD1	I
.	O

Diffuse	O
immunofluorescent	O
staining	O
of	O
11beta	B
HSD2	I
protein	O
in	O
the	O
Leydig	O
cell	O
cytoplasm	O
was	O
consistent	O
with	O
its	O
localization	O
in	O
the	O
smooth	O
endoplasm	O
reticulum	O
.	O

11beta	B
HSD1	I
or	O
11beta	B
HSD2	I
activities	O
were	O
selectively	O
inhibited	O
using	O
antisense	O
methodology	O
:	O
inhibition	O
of	O
11beta	B
HSD1	I
lowered	O
reductase	O
activity	O
by	O
60	O
%	O
and	O
oxidation	O
by	O
25	O
%	O
,	O
whereas	O
inhibition	O
of	O
11beta	B
HSD2	I
alone	O
suppressed	O
oxidase	B
activity	O
by	O
50	O
%	O
.	O

This	O
shows	O
that	O
the	O
high	O
-	O
affinity	O
,	O
low	O
-	O
capacity	O
11beta	B
HSD2	I
isoform	O
,	O
present	O
at	O
only	O
one	O
thousandth	O
the	O
level	O
of	O
the	O
low	O
-	O
affinity	O
isoform	O
may	O
significantly	O
affect	O
the	O
level	O
of	O
CORT	O
.	O

The	O
inhibition	O
of	O
either	O
11beta	B
HSD1	I
or	O
11beta	B
HSD2	I
significantly	O
lowered	O
testosterone	O
production	O
in	O
the	O
presence	O
of	O
CORT	O
.	O

These	O
data	O
suggest	O
that	O
both	O
types	B
I	I
and	I
II	I
11beta	I
HSD	I
in	O
Leydig	O
cells	O
play	O
a	O
protective	O
role	O
,	O
opposing	O
the	O
adverse	O
effects	O
of	O
excessive	O
CORT	O
on	O
testosterone	O
production	O
.	O

Angiotensin	B
II	I
increases	O
the	O
expression	O
of	O
lectin	B
-	I
like	I
oxidized	I
low	I
-	I
density	I
lipoprotein	I
receptor-1	I
in	O
human	O
vascular	O
smooth	O
muscle	O
cells	O
via	O
a	O
lipoxygenase	B
-	O
dependent	O
pathway	O
.	O

BACKGROUND	O
:	O

Lectin	B
-	I
like	I
oxidized	I
low	I
-	I
density	I
lipoprotein	I
receptor-1	I
(	O
LOX-1	B
)	O
is	O
a	O
membrane	O
protein	O
that	O
can	O
act	O
as	O
a	O
surface	O
endocytosis	O
receptor	O
for	O
oxidized	O
LDL	B
(	O
ox	O
-	O
LDL	B
)	O
.	O

As	O
increased	O
cellular	O
uptake	O
of	O
ox	O
-	O
LDL	B
by	O
macrophages	O
and	O
activated	O
smooth	O
muscle	O
cells	O
may	O
transform	O
these	O
cells	O
into	O
foam	O
cells	O
,	O
potential	O
interactions	O
among	O
LDL	B
oxidation	O
,	O
ox	O
-	O
LDL	B
uptake	O
,	O
and	O
regulators	O
of	O
vascular	O
smooth	O
muscle	O
cell	O
function	O
are	O
of	O
obvious	O
interest	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effect	O
of	O
angiotensin	B
II	I
(	O
AII	B
)	O
on	O
the	O
expression	O
of	O
LOX-1	B
and	O
ox	O
-	O
LDL	B
degradation	O
in	O
human	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMC	O
)	O
METHODS	O
:	O

We	O
performed	O
in	O
vitro	O
experiments	O
in	O
a	O
human	O
VSMC	O
line	O
(	O
T	O
/	O
G	O
HA	O
-	O
VSMC	O
)	O
derived	O
from	O
normal	O
aortic	O
VSMC	O
,	O
using	O
standards	O
methods	O
.	O

RESULTS	O
:	O

We	O
found	O
that	O
AII	B
(	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
increased	O
the	O
expression	O
of	O
LOX-1	B
(	O
approximately	O
2.5	O
-	O
fold	O
,	O
P	O
<	O
.0001	O
)	O
in	O
association	O
with	O
higher	O
degradation	O
of	O
ox	O
-	O
LDL	B
by	O
HA	O
-	O
SMC	O
(	O
from	O
4019	O
+	O
/-	O
529	O
ng	O
/	O
mg	O
cell	O
protein	O
to	O
6207	O
+	O
/-	O
287	O
ng	O
/	O
mg	O
cell	O
protein	O
;	O
P	O
=	O
.0033	O
)	O
.	O

AII	O
also	O
increased	O
the	O
expression	O
of	O
12-lipoxygenase	B
(	O
12-LO	B
)	O
and	O
15-lipoxygenase	B
(	O
15-LO	B
)	O
by	O
approximately	O
2.2	O
-	O
fold	O
(	O
P	O
=	O
.03	O
)	O
and	O
approximately	O
3	O
-	O
fold	O
(	O
P	O
=	O
.006	O
)	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
AII	B
(	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
increased	O
the	O
release	O
of	O
12	O
-	O
and	O
15-hydroxyeicosatetraenoic	O
acid	O
from	O
VSMC	O
within	O
10	O
min	O
approximately	O
3	O
-	O
fold	O
(	O
P	O
=	O
.03	O
)	O
and	O
50	O
%	O
(	O
P	O
<	O
.05	O
)	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O

Our	O
study	O
findings	O
provide	O
evidence	O
that	O
angiotensin	B
II	I
upregulates	O
LOX-1	B
and	O
12-LO	B
and	O
15-LO	B
expression	O
in	O
human	O
VSMC	O
,	O
thereby	O
potentially	O
providing	O
mechanisms	O
for	O
both	O
accelerated	O
LDL	B
oxidation	O
within	O
the	O
cell	O
and	O
the	O
internalization	O
of	O
exogenous	O
ox	O
-	O
LDL	B
,	O
two	O
processes	O
that	O
could	O
increase	O
the	O
susceptibility	O
of	O
human	O
VSMC	O
to	O
further	O
transformation	O
into	O
foam	O
cells	O
.	O

Isolation	O
by	O
improved	O
thermal	O
asymmetric	O
interlaced	O
PCR	O
and	O
characterization	O
of	O
a	O
seed	O
-	O
specific	O
2S	B
albumin	I
gene	O
and	O
its	O
promoter	O
from	O
grape	O
(	O
Vitis	O
vinifera	O
L.	O
)	O
.	O

A	O
seed	O
-	O
specific	O
2S	B
albumin	I
gene	O
and	O
its	O
promoter	O
region	O
of	O
grape	O
(	O
Vitis	O
vinifera	O
L.	O
)	O
were	O
isolated	O
using	O
an	O
improved	O
thermal	O
asymmetric	O
interlaced	O
PCR	O
that	O
allowed	O
efficient	O
amplification	O
of	O
target	O
sequence	O
of	O
up	O
to	O
3	O
kbp	O
in	O
length	O
directly	O
from	O
genomic	O
DNA	O
.	O

The	O
2S	B
albumin	I
VvAlb1	B
(	O
for	O
V.	O
vinifera	O
2S	B
albumin	I
1	I
)	O
gene	O
from	O
different	O
grape	O
cultivars	O
encompasses	O
a	O
coding	O
region	O
of	O
504	O
-	O
540	O
nucleotides	O
corresponding	O
to	O
a	O
deduced	O
amino	O
acid	O
sequence	O
of	O
167	O
-	O
179	O
residues	O
.	O

This	O
deduced	O
protein	O
contains	O
up	O
to	O
30	O
%	O
glutamine	O
residues	O
and	O
eight	O
cysteine	O
residues	O
arranged	O
in	O
a	O
pattern	O
highly	O
conserved	O
among	O
2S	B
albumins	I
for	O
disulfide	O
bond	O
formation	O
.	O

DNA	O
sequence	O
alignment	O
revealed	O
that	O
the	O
same	O
VvAlb1	B
gene	O
among	O
different	O
grape	O
cultivars	O
varied	O
greatly	O
,	O
including	O
an	O
insertion	O
of	O
up	O
to	O
36	O
bp	O
near	O
the	O
3	O
'	O
end	O
of	O
the	O
gene	O
sequence	O
isolated	O
from	O
'	O
Thompson	O
Seedless	O
'	O
.	O

DNA	O
sequence	O
analysis	O
indicated	O
that	O
several	O
conserved	O
seed	O
-	O
specific	O
regulatory	O
motifs	O
were	O
clustered	O
within	O
a	O
0.6	O
-	O
kbp	O
region	O
5	O
'	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

To	O
further	O
test	O
promoter	O
activity	O
,	O
the	O
sequence	O
of	O
this	O
region	O
was	O
used	O
to	O
drive	O
a	O
bifunctional	O
EGFP	B
/	O
NPTII	B
fusion	O
gene	O
in	O
Agrobacterium	O
-	O
mediated	O
transformation	O
of	O
grape	O
somatic	O
embryos	O
and	O
leaf	O
discs	O
of	O
grape	O
and	O
tobacco	O
(	O
Nicotiana	O
tabacum	O
L.	O
)	O
.	O

A	O
high	O
level	O
of	O
GFP	B
expression	O
,	O
comparable	O
with	O
that	O
derived	O
from	O
an	O
enhanced	O
double	O
CsVMV	O
promoter	O
,	O
was	O
observed	O
in	O
the	O
cotyledonary	O
but	O
not	O
hypocotyl	O
and	O
vegetative	O
tissues	O
of	O
grape	O
and	O
tobacco	O
.	O

These	O
results	O
suggest	O
that	O
the	O
VvAlb1	B
gene	O
promoter	O
isolated	O
is	O
capable	O
of	O
conferring	O
seed	O
-	O
specific	O
gene	O
expression	O
.	O

Immune	O
-	O
regulation	O
of	O
the	O
apolipoprotein	B
A	I
-	I
I	I
/	I
C	I
-	I
III	I
/	I
A	I
-	I
IV	I
gene	O
cluster	O
in	O
experimental	O
inflammation	O
.	O

Apolipoprotein	B
A	I
-	I
IV	I
is	O
a	O
member	O
of	O
the	O
apo	B
A	I
-	I
I	I
/	I
C	I
-	I
III	I
/	I
A	I
-	I
IV	I
gene	O
cluster	O
.	O

In	O
order	O
to	O
investigate	O
its	O
hypothetical	O
coordinated	O
regulation	O
,	O
an	O
acute	O
phase	O
was	O
induced	O
in	O
pigs	O
by	O
turpentine	O
oil	O
injection	O
.	O

The	O
hepatic	O
expression	O
of	O
the	O
gene	O
cluster	O
as	O
well	O
as	O
the	O
plasma	O
levels	O
of	O
apolipoproteins	B
were	O
monitored	O
at	O
different	O
time	O
periods	O
.	O

Furthermore	O
,	O
the	O
involvement	O
of	O
the	O
inflammatory	O
mediators	O
'	O
interleukins	B
1	I
and	I
6	I
and	O
tumor	B
necrosis	I
factor	I
in	O
the	O
regulation	O
of	O
this	O
gene	O
cluster	O
was	O
tested	O
in	O
cultured	O
pig	O
hepatocytes	O
,	O
incubated	O
with	O
those	O
mediators	O
and	O
apo	B
A	I
-	I
I	I
/	I
C	I
-	I
III	I
/	I
A	I
-	I
IV	I
gene	O
cluster	O
expression	O
at	O
the	O
mRNA	O
level	O
was	O
measured	O
.	O

In	O
response	O
to	O
turpentine	O
oil	O
-	O
induced	O
inflammation	O
,	O
a	O
decreased	O
hepatic	O
apo	B
A	I
-	I
IV	I
mRNA	O
expression	O
was	O
observed	O
(	O
independent	O
of	O
apo	B
A	I
-	I
I	I
and	O
apo	B
C	I
-	I
III	I
mRNA	O
)	O
not	O
correlating	O
with	O
the	O
plasma	O
protein	O
levels	O
.	O

The	O
distribution	O
of	O
plasma	O
apo	B
A	I
-	I
IV	I
experienced	O
a	O
shift	O
from	O
HDL	B
to	O
larger	O
particles	O
.	O

In	O
contrast	O
,	O
the	O
changes	O
in	O
apo	B
A	I
-	I
I	I
and	O
apo	B
C	I
-	I
III	I
mRNA	O
were	O
reflected	O
in	O
their	O
corresponding	O
plasma	O
levels	O
.	O

Addition	O
of	O
cytokines	B
to	O
cultured	O
pig	O
hepatocytes	O
also	O
decreased	O
apo	B
A	I
-	I
IV	I
and	O
apo	B
A	I
-	I
I	I
mRNA	O
levels	O
.	O

All	O
these	O
results	O
show	O
that	O
the	O
down	O
-	O
regulation	O
of	O
apolipoprotein	B
A	I
-	I
I	I
and	I
A	I
-	I
IV	I
messages	O
in	O
the	O
liver	O
may	O
be	O
mediated	O
by	O
interleukin	B
6	I
and	O
TNF	B
-	I
alpha	I
.	O

The	O
well	O
-	O
known	O
HDL	B
decrease	O
found	O
in	O
many	O
different	O
acute	O
-	O
phase	O
responses	O
also	O
appears	O
in	O
the	O
pig	O
due	O
to	O
the	O
decreased	O
expression	O
of	O
apolipoprotein	B
A	I
-	I
I	I
and	O
the	O
enlargement	O
of	O
the	O
apolipoprotein	B
A	I
-	I
IV	I
-	O
containing	O
HDL	B
.	O

Structure	O
and	O
function	O
of	O
RGD	O
peptides	O
derived	O
from	O
disintegrin	B
proteins	I
.	O

The	O
Arg	O
-	O
Gly	O
-	O
Asp	O
(	O
RGD	O
)	O
sequence	O
serves	O
as	O
the	O
primary	O
recognition	O
site	O
in	O
extracellular	O
matrix	O
proteins	O
,	O
and	O
peptides	O
containing	O
this	O
sequence	O
can	O
mimic	O
the	O
biological	O
activities	O
of	O
matrix	O
proteins	O
.	O

We	O
have	O
initiated	O
structure	O
-	O
function	O
studies	O
of	O
two	O
RGD	O
containing	O
peptides	O
,	O
RGD-5	O
(	O
AGGDD	O
)	O
and	O
cyclic	O
RGD-6	O
(	O
CARGDDC	O
)	O
.	O

Assays	O
have	O
shown	O
that	O
cyclic	O
RGD	O
-	O
peptides	O
inhibit	O
platelet	O
aggregation	O
more	O
efficiently	O
than	O
linear	O
ones	O
.	O

NMR	O
data	O
revealed	O
that	O
RGD-5	O
and	O
RGD-6	O
have	O
entirely	O
different	O
conformation	O
.	O

RGD-5	O
has	O
a	O
linear	O
extended	O
structure	O
and	O
RGD-6	O
has	O
a	O
stable	O
loop	O
conformation	O
.	O

In	O
RGD-5	O
the	O
guanidinium	O
group	O
of	O
Arg2	O
and	O
the	O
carboxyl	O
group	O
of	O
Asp4	O
lie	O
in	O
parallel	O
,	O
whereas	O
the	O
side	O
-	O
chains	O
of	O
Arg3	O
and	O
Asp5	O
of	O
RGD-6	O
are	O
located	O
in	O
different	O
planes	O
,	O
supporting	O
the	O
idea	O
that	O
the	O
stability	O
of	O
the	O
cyclic	O
form	O
derives	O
from	O
the	O
packing	O
of	O
the	O
side	O
chain	O
of	O
the	O
Arg	O
and	O
Asp	O
residues	O
.	O

The	O
structural	O
features	O
of	O
these	O
peptides	O
could	O
provide	O
a	O
basis	O
for	O
designing	O
new	O
drugs	O
against	O
diseases	O
related	O
to	O
platelet	O
aggregation	O
and	O
as	O
cancer	O
antagonists	O
.	O

Acclimation	O
to	O
diverse	O
environmental	O
stresses	O
caused	O
by	O
a	O
suppression	O
of	O
cytosolic	B
ascorbate	I
peroxidase	I
in	O
tobacco	O
BY-2	O
cells	O
.	O

The	O
active	O
oxygen	O
species	O
(	O
AOS	O
)	O
that	O
arise	O
from	O
normal	O
metabolic	O
processes	O
are	O
kept	O
under	O
tight	O
control	O
by	O
various	O
antioxidant	O
mechanisms	O
.	O

AOS	O
are	O
important	O
signal	O
molecules	O
that	O
regulate	O
many	O
physiological	O
processes	O
,	O
including	O
environmental	O
stress	O
responses	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
lowered	O
cytosolic	B
ascorbate	I
peroxidase	I
(	O
APX	B
)	O
activity	O
in	O
transgenic	O
tobacco	O
BY-2	O
cells	O
,	O
using	O
two	O
transformed	O
BY-2	O
cell	O
lines	O
,	O
cAPX	B
-	O
S2	O
and	O
cAPX	B
-	O
S3	O
,	O
resulting	O
from	O
co	O
-	O
suppression	O
by	O
expression	O
of	O
Arabidopsis	O
APX1	B
cDNA	O
under	O
the	O
cauliflower	O
mosaic	O
virus	O
(	O
CaMV	O
)	O
35S	O
promoter	O
.	O

cAPX	B
-	O
S2	O
and	O
cAPX	B
-	O
S3	O
possessed	O
50	O
and	O
75	O
%	O
lower	O
cytosolic	O
APX	B
activity	O
,	O
respectively	O
,	O
compared	O
with	O
that	O
in	O
the	O
untransformed	O
cells	O
.	O

Chemical	O
fluorescence	O
analysis	O
indicated	O
that	O
the	O
AOS	O
levels	O
were	O
markedly	O
higher	O
in	O
the	O
two	O
APX	B
-	O
suppressed	O
cell	O
lines	O
than	O
in	O
the	O
wild	O
-	O
type	O
cells	O
.	O

However	O
,	O
there	O
were	O
no	O
substantial	O
differences	O
in	O
the	O
activity	O
levels	O
of	O
the	O
various	O
other	O
antioxidant	O
enzymes	O
.	O

Interestingly	O
,	O
the	O
APX	B
-	O
suppressed	O
cells	O
showed	O
different	O
responses	O
and	O
tolerances	O
to	O
environmental	O
stresses	O
,	O
such	O
as	O
heat	O
and	O
salinity	O
.	O

Suppression	O
subtractive	O
hybridization	O
revealed	O
that	O
several	O
heat	O
-	O
and	O
salt	O
stress	O
-	O
inducible	O
genes	O
were	O
up	O
-	O
regulated	O
in	O
cAPX	B
-	O
S3	O
cells	O
.	O

HSP70	B
,	O
DnaJ	B
-	O
like	O
protein	O
and	O
purple	B
acid	I
phosphatase	I
were	O
among	O
the	O
constitutively	O
induced	O
genes	O
.	O

An	O
in	O
-	O
gel	O
kinase	B
assay	O
suggested	O
that	O
a	O
mitogen	B
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinase	I
of	O
approximately	O
46	O
kDa	O
was	O
predominantly	O
active	O
in	O
the	O
APX	B
-	O
suppressed	O
cells	O
,	O
and	O
transcript	O
levels	O
of	O
both	O
nicotiana	B
protein	I
kinase	I
1	I
(	O
NPK1	B
)	O
and	O
nucleoside	B
diphosphate	I
kinase	I
2	I
(	O
NDPK2	B
)	O
were	O
up	O
-	O
regulated	O
.	O

These	O
data	O
suggest	O
the	O
possibility	O
that	O
MAP	B
kinase	I
cascades	O
are	O
activated	O
by	O
subtle	O
imbalances	O
in	O
the	O
homeostasis	O
of	O
the	O
cellular	O
redox	O
status	O
caused	O
by	O
lowered	O
cytosolic	O
APX	B
activity	O
.	O

Transcript	O
profiling	O
of	O
immediate	O
early	O
genes	O
reveals	O
a	O
unique	O
role	O
for	O
activating	B
transcription	I
factor	I
3	I
in	O
mediating	O
activation	O
of	O
the	O
glycoprotein	B
hormone	I
alpha	I
-	O
subunit	O
promoter	O
by	O
gonadotropin	B
-	I
releasing	I
hormone	I
.	O

Recent	O
studies	O
profiling	O
immediate	O
early	O
gene	O
responses	O
to	O
GnRH	B
in	O
the	O
LbetaT2	O
gonadotrope	O
cell	O
model	O
revealed	O
increased	O
expression	O
of	O
numerous	O
genes	O
including	O
activating	B
transcription	I
factor	I
(	I
ATF	I
)	I
3	I
.	O

The	O
present	O
studies	O
demonstrate	O
similar	O
results	O
with	O
GnRH	B
administration	O
in	O
vivo	O
in	O
ovariectomized	O
mice	O
.	O

In	O
this	O
model	O
,	O
ATF3	B
mRNA	O
was	O
markedly	O
up	O
-	O
regulated	O
at	O
20	O
,	O
40	O
,	O
and	O
60	O
min	O
after	O
in	O
vivo	O
administration	O
of	O
a	O
GnRH	B
analog	O
.	O

In	O
alphaT3	O
-	O
1	O
gonadotrope	O
cells	O
,	O
ATF3	B
mRNA	O
and	O
protein	O
were	O
induced	O
by	O
GnRH	B
in	O
a	O
manner	O
consistent	O
with	O
in	O
vivo	O
observations	O
.	O

Pharmacological	O
studies	O
implicated	O
a	O
combined	O
role	O
for	O
the	O
activities	O
of	O
protein	B
kinase	I
C	I
isozymes	O
,	O
ERK	B
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
,	O
in	O
modulating	O
ATF3	B
expression	O
.	O

The	O
role	O
of	O
ATF3	B
was	O
further	O
investigated	O
in	O
the	O
activation	O
of	O
the	O
human	O
glycoprotein	B
hormone	I
alpha	I
-	O
subunit	O
gene	O
promoter	O
.	O

GnRH	B
induced	O
the	O
alpha	O
-	O
subunit	O
promoter	O
-	O
luciferase	B
reporter	O
approximately	O
16	O
-	O
fold	O
,	O
and	O
this	O
induction	O
was	O
completely	O
abolished	O
with	O
mutations	O
in	O
the	O
dual	O
cAMP	O
response	O
elements	O
(	O
CREs	O
)	O
or	O
the	O
combined	O
inhibition	O
of	O
GnRH	B
-	O
induced	O
ERK	B
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
.	O

GnRH	B
induced	O
recruitment	O
of	O
ATF3	B
,	O
c	B
-	I
Jun	I
,	O
and	O
c	B
-	I
Fos	I
to	O
the	O
dual	O
CREs	O
.	O

Overexpression	O
and	O
specific	O
knockdown	O
of	O
ATF3	B
by	O
small	O
inhibitory	O
RNA	O
implicate	O
a	O
functional	O
role	O
for	O
ATF3	B
in	O
mediating	O
activation	O
of	O
the	O
alpha	O
-	O
subunit	O
gene	O
promoter	O
.	O

These	O
studies	O
provide	O
clear	O
evidence	O
that	O
ATF3	B
is	O
a	O
key	O
immediate	O
early	O
gene	O
induced	O
by	O
GnRH	B
administration	O
in	O
vivo	O
and	O
in	O
the	O
alphaT3	O
-	O
1	O
gonadotrope	O
cell	O
model	O
.	O

These	O
studies	O
support	O
the	O
conclusion	O
that	O
the	O
dual	O
CREs	O
of	O
the	O
human	O
alpha	O
-	O
subunit	O
promoter	O
are	O
the	O
target	O
of	O
GnRH	B
-	O
induced	O
MAPK	B
regulation	O
through	O
ATF3	B
.	O

Simultaneous	O
expression	O
of	O
apolipoprotein	B
B	I
mRNA	I
editing	I
enzyme	I
and	O
scavenger	B
receptor	I
BI	I
mediated	O
by	O
a	O
therapeutic	O
gene	O
expression	O
system	O
.	O

Cardiovascular	O
diseases	O
are	O
often	O
accompanied	O
by	O
elevated	O
LDL	B
particles	O
and	O
endothelial	O
dysfunction	O
.	O

We	O
have	O
examined	O
the	O
possibility	O
of	O
concurrently	O
reducing	O
LDL	B
levels	O
and	O
modulating	O
endothelial	O
function	O
using	O
a	O
single	O
helper	O
-	O
dependent	O
adenovirus	O
vector	O
system	O
to	O
simultaneously	O
express	O
the	O
apolipoprotein	B
B	I
mRNA	I
editing	I
enzyme	I
(	O
Apobec1	B
)	O
and	O
the	O
scavenger	B
receptor	I
,	I
class	I
B	I
,	I
type	I
I	I
(	O
SR	B
-	I
BI	I
)	O
genes	O
under	O
the	O
control	O
of	O
separate	O
promoters	O
(	O
designated	O
HD	O
-	O
C2	O
)	O
.	O

Apobec1	B
edits	O
apoB	B
mRNA	O
at	O
nucleotide	O
C-6666	O
to	O
produce	O
truncated	O
apoB48	B
and	O
is	O
normally	O
expressed	O
in	O
small	O
intestine	O
only	O
.	O

SR	B
-	I
BI	I
is	O
a	O
receptor	O
for	O
multiple	O
ligands	O
with	O
distinct	O
tissue	O
-	O
specific	O
functions	O
.	O

Expression	O
of	O
Apobec1	B
in	O
HepG2	O
cells	O
resulted	O
in	O
apoB	B
mRNA	O
editing	O
,	O
leading	O
to	O
decreased	O
apoB100	B
abundance	O
(	O
to	O
6	O
%	O
of	O
control	O
)	O
and	O
the	O
appearance	O
of	O
apoB48	B
.	O

Editing	O
of	O
apoB	B
mRNA	O
in	O
HepG2	O
cells	O
resulted	O
in	O
decline	O
in	O
apoB	B
mRNA	O
levels	O
of	O
50	O
%	O
.	O

This	O
was	O
probably	O
the	O
result	O
of	O
nonsense	O
-	O
mediated	O
decay	O
of	O
edited	O
message	O
,	O
since	O
over	O
-	O
expression	O
of	O
Apobec1	B
increased	O
neither	O
Apobec1	B
complementary	I
factor	I
(	O
ACF	B
)	O
mRNA	O
nor	O
protein	O
abundance	O
.	O

Over	O
-	O
expression	O
of	O
SR	B
-	I
BI	I
in	O
human	O
endothelial	O
cells	O
activated	O
endothelial	B
nitric	I
oxide	I
synthase	I
(	O
eNOS	B
)	O
activity	O
by	O
phosphorylation	O
of	O
eNOS	B
at	O
residue	O
Ser	O
-	O
1177	O
in	O
the	O
presence	O
of	O
HDL	B
,	O
leading	O
to	O
increased	O
production	O
of	O
the	O
anti	O
-	O
atherogenic	O
molecule	O
nitric	O
oxide	O
(	O
NO	O
)	O
.	O

Taken	O
together	O
,	O
this	O
study	O
demonstrates	O
that	O
using	O
one	O
vector	O
delivery	O
system	O
to	O
express	O
two	O
genes	O
in	O
two	O
different	O
cell	O
types	O
results	O
in	O
the	O
cell	O
-	O
specific	O
beneficial	O
effects	O
of	O
decreasing	O
apoB100	B
production	O
and	O
increasing	O
eNOS	B
activities	O
.	O

This	O
combined	O
gene	O
expression	O
approach	O
may	O
provide	O
an	O
improved	O
therapeutic	O
strategy	O
by	O
targeting	O
multiple	O
sites	O
in	O
the	O
mechanism	O
of	O
cardiovascular	O
injury	O
.	O

Neuroprotective	O
potential	O
of	O
three	O
neuropeptides	O
PACAP	B
,	O
VIP	B
and	O
PHI	B
.	O

Pituitary	B
adenylate	I
cyclase	I
activating	I
polypeptide	I
(	O
PACAP	B
)	O
,	O
vasoactive	B
intestinal	I
peptide	I
(	O
VIP	B
)	O
and	O
peptide	B
histidine	I
-	I
isoleucine	I
(	O
PHI	B
)	O
,	O
are	O
structurally	O
related	O
endogenous	O
peptides	O
widely	O
expressed	O
in	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
and	O
showing	O
rich	O
profile	O
of	O
biological	O
activities	O
.	O

They	O
act	O
as	O
neurotransmitters	B
,	O
neuromodulators	O
and	O
neurotrophic	B
factors	B
.	O

Recently	O
,	O
their	O
neuroprotective	O
potential	O
has	O
been	O
revealed	O
in	O
numerous	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
.	O

Thus	O
,	O
PACAP	B
and	O
VIP	B
protected	O
the	O
cells	O
from	O
neurotoxic	O
effects	O
of	O
ethanol	O
,	O
hydrogen	O
peroxide	O
(	O
H2O2	O
,	O
beta	B
-	I
amyloid	I
and	O
glycoprotein	B
120	I
(	O
gp120	B
)	O
.	O
Moreover	O
,	O
PACAP	B
showed	O
neuroprotection	O
against	O
glutamate	O
,	O
human	O
prion	B
protein	I
fragment	O
106	O
-	O
126	O
[	O
PrP	B
(	O
106	O
-	O
126	O
)	O
]	O
and	O
C2	O
-	O
ceramide	O
.	O
Both	O
peptides	O
reduced	O
brain	O
damage	O
after	O
ischemia	O
and	O
ameliorated	O
neurological	O
deficits	O
in	O
a	O
model	O
of	O
Parkinson	O
's	O
disease	O
.	O
Neuroprotective	O
potential	O
of	O
PHI	B
has	O
not	O
been	O
thoroughly	O
investigated	O
yet	O
,	O
but	O
several	O
results	O
obtained	O
in	O
the	O
last	O
years	O
do	O
not	O
exclude	O
it	O
.	O

The	O
mechanism	O
underlying	O
neuroprotective	O
properties	O
of	O
PACAP	B
seems	O
to	O
involve	O
activation	O
of	O
adenylyl	B
cyclase	I
(	O
AC	B
)	O
--	O
>	O
cyclic	O
adenosine	O
3',5'-mono	O
-	O
phosphate	O
(	O
cAMP	O
)	O
--	O
>	O
protein	B
kinase	I
A	I
(	O
PKA	B
)	O
and	O
mitogen	B
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinase	I
pathways	O
,	O
and	O
inhibition	O
of	O
caspase-3	B
.	O

PACAP	B
can	O
also	O
,	O
yet	O
indirectly	O
,	O
stimulate	O
astrocytes	O
to	O
release	O
neuroprotective	O
factors	O
,	O
such	O
as	O
regulated	B
upon	I
activation	I
normal	I
T	I
cell	I
expressed	I
and	I
secreted	I
(	O
RANTES	B
)	O
and	O
macrophage	B
inflammatory	I
protein	I
1	I
(	O
MIP-1	B
)	O
chemokines	B
.	O

Neuroprotective	O
activity	O
of	O
VIP	B
seems	O
to	O
involve	O
an	O
indirect	O
mechanism	O
requiring	O
astrocytes	O
.	O

VIP	B
-	O
stimulated	O
astrocytes	O
secrete	O
neuroprotective	O
proteins	O
,	O
including	O
activity	B
-	I
dependent	I
neurotrophic	I
factor	I
(	O
ADNF	B
)	O
and	O
activity	B
-	I
dependent	I
neuroprotective	I
protein	I
(	O
ADNP	B
)	O
,	O
as	O
well	O
as	O
a	O
number	O
of	O
cytokines	B
.	O

However	O
,	O
in	O
the	O
activated	O
microglia	O
,	O
VIP	B
and	O
PACAP	B
are	O
capable	O
of	O
inhibiting	O
the	O
production	O
of	O
inflammatory	O
mediators	O
which	O
can	O
lead	O
to	O
neurodegenerative	O
processes	O
within	O
the	O
brain	O
.	O

In	O
conclusion	O
,	O
studies	O
carried	O
out	O
on	O
the	O
central	O
nervous	O
system	O
have	O
shown	O
that	O
PACAP	B
,	O
VIP	B
,	O
and	O
likely	O
PHI	B
,	O
are	O
endowed	O
with	O
a	O
neuroprotective	O
potential	O
,	O
which	O
renders	O
them	O
(	O
or	O
their	O
derivatives	O
)	O
promising	O
therapeutic	O
agents	O
in	O
several	O
psychoneurological	O
disorders	O
linked	O
to	O
neurodegeneration	O
.	O

Molecular	O
characterization	O
of	O
major	B
histocompatibility	I
complex	I
class	I
I	I
(	I
B	I
-	I
F	I
)	I
mRNA	O
variants	O
from	O
chickens	O
differing	O
in	O
resistance	O
to	O
Marek	O
's	O
disease	O
.	O

In	O
this	O
study	O
,	O
the	O
relative	O
distributions	O
of	O
two	O
alternatively	O
polyadenylated	O
chicken	O
major	B
histocompatibility	I
complex	I
(	O
MHC	B
)	O
mRNA	O
isoforms	O
of	O
approximately	O
1.5	O
and	O
1.9	O
kb	O
were	O
analysed	O
in	O
spleen	O
cells	O
from	O
chickens	O
homozygous	O
for	O
the	O
MHC	B
haplotypes	O
B21	B
and	O
B19v1	B
as	O
well	O
as	O
in	O
heterozygous	O
B19v1	B
/	O
B21	B
birds	O
.	O

Both	O
isoforms	O
are	O
likely	O
to	O
encode	O
classical	B
MHC	I
class	I
I	I
(	I
B	I
-	I
F	I
)	I
alpha	I
chains	O
.	O

The	O
B19v1	B
and	O
B21	B
MHC	I
haplotypes	O
confer	O
different	O
levels	O
of	O
protection	O
against	O
Marek	O
's	O
disease	O
(	O
MD	O
)	O
,	O
which	O
is	O
caused	O
by	O
infection	O
with	O
MD	O
virus	O
(	O
MDV	O
)	O
.	O

In	O
spleen	O
cells	O
,	O
MD	O
-	O
resistant	O
B21	B
birds	O
were	O
shown	O
to	O
have	O
the	O
highest	O
percentage	O
of	O
the	O
1.5	O
kb	O
variant	O
relative	O
to	O
the	O
total	O
MHC	B
class	I
I	I
expression	O
,	O
MD	O
-	O
susceptible	O
B19v1	B
birds	O
the	O
lowest	O
and	O
B19v1	B
/	O
B21	B
birds	O
an	O
intermediate	O
percentage	O
.	O

Infection	O
of	O
4	O
-	O
week	O
-	O
old	O
chickens	O
with	O
the	O
GA	O
strain	O
of	O
MDV	O
was	O
shown	O
to	O
cause	O
a	O
significant	O
increase	O
in	O
the	O
relative	O
amount	O
of	O
1.5	O
kb	O
transcripts	O
in	O
B21	B
birds	O
32	O
days	O
postinfection	O
(	O
dpi	O
)	O
.	O

Alternatively	O
polyadenylated	O
mRNA	O
isoforms	O
may	O
encode	O
identical	O
proteins	O
,	O
but	O
differences	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
can	O
influence	O
polyadenylation	O
,	O
mRNA	O
stability	O
,	O
intracellular	O
localization	O
and	O
translation	O
efficiency	O
.	O

It	O
was	O
shown	O
that	O
the	O
increased	O
1.5	O
kb	O
percentage	O
in	O
B21	B
birds	O
32	O
days	O
postinfection	O
may	O
be	O
a	O
result	O
of	O
a	O
change	O
in	O
the	O
choice	O
of	O
poly	O
(	O
A	O
)	O
site	O
rather	O
than	O
a	O
locus	O
-	O
specific	O
upregulated	O
transcription	O
of	O
the	O
BF1	B
gene	O
that	O
preferentially	O
expresses	O
the	O
1.5	O
kb	O
variant	O
.	O

Furthermore	O
,	O
the	O
3	O
'	O
end	O
of	O
the	O
1.5	O
kb	O
mRNA	O
variants	O
deriving	O
from	O
B19v1	B
and	O
B21	B
chickens	O
was	O
characterized	O
by	O
Rapid	O
Amplification	O
of	O
cDNA	O
Ends	O
(	O
RACE	O
)	O
and	O
sequencing	O
.	O

No	O
potentially	O
functional	O
elements	O
were	O
identified	O
in	O
the	O
3	O
'	O
UTR	O
of	O
the	O
RACE	O
products	O
corresponding	O
to	O
this	O
short	O
isoform	O
.	O

However	O
,	O
variation	O
in	O
polyadenylation	O
site	O
was	O
observed	O
between	O
the	O
BF1	B
and	O
BF2	B
mRNA	O
transcripts	O
and	O
alternative	O
splicing	O
-	O
out	O
of	O
the	O
sequence	O
(	O
exon	O
7	O
)	O
encoding	O
the	O
second	O
segment	O
of	O
the	O
cytoplasmic	O
part	O
of	O
the	O
mature	O
BF2	B
*	I
19	I
molecules	O
.	O

This	O
alternative	O
exon	O
7	O
splice	O
variant	O
was	O
also	O
detected	O
in	O
other	O
MD	O
-	O
susceptible	O
haplotypes	O
,	O
but	O
not	O
in	O
the	O
MD	O
-	O
resistant	O
B21	B
and	O
B21	B
-	O
like	O
haplotypes	O
,	O
suggesting	O
a	O
potential	O
role	O
of	O
exon	O
7	O
in	O
MHC	B
-	O
related	O
MD	O
resistance	O
.	O

Adaptor	O
heat	B
shock	I
protein	I
complex	I
formation	O
regulates	O
trafficking	O
of	O
the	O
asialoglycoprotein	B
receptor	I
.	O

In	O
the	O
asialoglycoprotein	B
receptor	I
(	O
ASGPR	B
)	O
endocytic	O
pathway	O
,	O
internalized	O
receptors	O
pass	O
through	O
early	O
,	O
recycling	O
,	O
and	O
sorting	O
endosomal	O
compartments	O
before	O
returning	O
to	O
the	O
cell	O
surface	O
.	O

Sorting	O
motifs	O
in	O
the	O
cytoplasmic	O
domain	O
(	O
CD	O
)	O
and	O
protein	O
interactions	O
with	O
these	O
sequences	O
presumably	O
direct	O
receptor	O
trafficking	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
association	O
of	O
a	O
potential	O
sorting	O
heat	B
shock	I
protein	I
(	I
HSP	I
)	I
heterocomplex	I
with	O
the	O
ASGPR	B
-	O
CD	O
was	O
regulated	O
by	O
casein	B
kinase	I
2	I
(	O
CK2	B
)	O
-	O
mediated	O
phosphorylation	O
.	O

Mass	O
spectrometry	O
and	O
immunoblot	O
analyses	O
identified	O
five	O
of	O
these	O
ASGPR	B
-	O
CD	O
-	O
associated	O
proteins	O
as	O
the	O
molecular	O
chaperones	B
glycoprotein	B
96	I
,	O
HSP70	B
,	O
HSP90	B
,	O
cyclophilin	B
A	I
,	O
and	O
FK	B
506	I
binding	I
protein	I
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
any	O
of	O
the	O
adaptor	B
protein	I
complexes	I
(	O
AP1	B
,	O
AP2	B
,	O
or	O
AP3	B
)	O
were	O
selectivity	O
associated	O
with	O
the	O
ASGPR	B
-	O
CD	O
.	O

In	O
conjunction	O
with	O
molecular	O
chaperones	B
,	O
AP2	B
and	O
AP1	B
were	O
recovered	O
from	O
a	O
CK2	B
phosphorylated	O
agarose	O
-	O
GSH	O
-	O
GST	B
-	O
ASGPR	B
-	O
CD	O
matrix	O
.	O

Binding	O
of	O
AP3	B
was	O
independent	O
of	O
the	O
phosphorylation	O
status	O
of	O
the	O
CD	O
matrix	O
.	O

Inhibition	O
of	O
CK2	B
-	O
mediated	O
phosphorylation	O
with	O
tetrabromobenzotriazole	O
prevented	O
AP	B
recovery	O
within	O
an	O
immunoadsorbed	O
ASGPR	B
complex	O
.	O

Rapamycin	O
,	O
which	O
dissociates	O
the	O
HSP	B
heterocomplex	I
from	O
ASGPR	B
-	O
CD	O
,	O
thereby	O
altering	O
receptor	O
trafficking	O
also	O
,	O
inhibited	O
AP	B
association	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
an	O
inhibitor	O
of	O
HSP90	B
heterocomplex	I
formation	O
,	O
geldanmycin	O
.	O

The	O
data	O
presented	O
provide	O
evidence	O
that	O
recruitment	O
of	O
AP1	B
and	O
AP2	B
,	O
which	O
is	O
necessary	O
for	O
appropriate	O
receptor	O
trafficking	O
,	O
is	O
mediated	O
by	O
the	O
interaction	O
of	O
AP	B
with	O
the	O
ASGPR	B
-	O
CD	O
-	O
bound	O
HSP	B
complex	I
.	O

Unusual	O
features	O
of	O
self	O
-	O
peptide	O
/	O
MHC	B
binding	O
by	O
autoimmune	O
T	O
cell	O
receptors	O
.	O

Structural	O
studies	O
on	O
T	B
cell	I
receptors	I
(	O
TCRs	B
)	O
specific	O
for	O
foreign	O
antigens	O
demonstrated	O
a	O
remarkably	O
similar	O
topology	O
characterized	O
by	O
a	O
central	O
,	O
diagonal	O
TCR	B
binding	O
mode	O
that	O
maximizes	O
interactions	O
with	O
the	O
MHC	B
bound	O
peptide	O
.	O

However	O
,	O
three	O
recent	O
structures	O
involving	O
autoimmune	O
TCRs	B
demonstrated	O
unusual	O
interactions	O
with	O
self	O
-	O
peptide	O
/	O
MHC	B
complexes	O
.	O

Two	O
TCRs	B
from	O
multiple	O
sclerosis	O
patients	O
bind	O
with	O
unconventional	O
topologies	O
,	O
and	O
both	O
TCRs	B
are	O
shifted	O
toward	O
the	O
peptide	O
N	O
terminus	O
and	O
the	O
MHC	B
class	I
II	I
beta	I
chain	O
helix	O
.	O

A	O
TCR	B
from	O
the	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
model	O
binds	O
in	O
a	O
conventional	O
orientation	O
,	O
but	O
the	O
structure	O
is	O
unusual	O
because	O
the	O
self	O
-	O
peptide	O
only	O
partially	O
fills	O
the	O
binding	O
site	O
.	O

For	O
all	O
three	O
TCRs	B
,	O
interaction	O
with	O
the	O
MHC	B
bound	O
self	O
-	O
peptide	O
is	O
suboptimal	O
,	O
and	O
only	O
two	O
or	O
three	O
TCR	B
loops	O
contact	O
the	O
peptide	O
.	O

Optimal	O
TCR	B
binding	O
modes	O
confer	O
a	O
competitive	O
advantage	O
for	O
antimicrobial	O
T	O
cells	O
during	O
an	O
infection	O
,	O
whereas	O
altered	O
binding	O
properties	O
may	O
permit	O
survival	O
of	O
a	O
subset	O
of	O
autoreactive	O
T	O
cells	O
during	O
thymic	O
selection	O
.	O

Screening	O
of	O
novel	O
cellulose	O
-	O
degrading	O
bacterium	O
and	O
its	O
application	O
to	O
denitrification	O
of	O
groundwater	O
.	O

To	O
establish	O
an	O
environmentally	O
friendly	O
groundwater	O
bioremediation	O
process	O
using	O
a	O
cellulose	O
carrier	O
combined	O
with	O
cellulose	O
-	O
utilizing	O
,	O
denitrifying	O
microorganisms	O
,	O
a	O
novel	O
psychrophilic	O
bacterium	O
,	O
designated	O
CL-5	O
,	O
which	O
can	O
degrade	O
a	O
commercial	O
-	O
based	O
cellulose	O
carrier	O
as	O
the	O
sole	O
carbon	O
source	O
,	O
was	O
screened	O
.	O

Since	O
the	O
denitrification	O
capability	O
of	O
CL-5	O
is	O
low	O
,	O
complex	O
microbial	O
systems	O
were	O
constructed	O
together	O
with	O
other	O
denitrifying	O
bacteria	O
designated	O
NR-1	O
and	O
NR-2	O
that	O
were	O
also	O
isolated	O
from	O
soil	O
.	O

The	O
nitrate	O
-	O
reducing	O
activities	O
of	O
mixed	O
cultures	O
were	O
much	O
higher	O
than	O
those	O
of	O
the	O
pure	O
cultures	O
of	O
CL-5	O
,	O
NR-1	O
and	O
NR-2	O
.	O

The	O
highest	O
N	O
(	O
2	O
)	O
O	O
and	O
N	O
(	O
2	O
)	O
formation	O
activities	O
were	O
observed	O
in	O
the	O
mixed	O
culture	O
of	O
CL-5+NR-2	O
.	O

A	O
splicing	O
repressor	O
domain	O
in	O
polypyrimidine	B
tract	I
-	I
binding	I
protein	I
.	O

Polypyrimidine	B
tract	I
-	I
binding	I
protein	I
(	O
PTB	B
)	O
is	O
an	O
hnRNP	O
with	O
four	O
RRM	O
type	O
domains	O
.	O

It	O
plays	O
roles	O
as	O
a	O
repressive	O
alternative	O
splicing	O
regulator	O
of	O
multilple	O
target	O
genes	O
,	O
as	O
well	O
as	O
being	O
involved	O
in	O
pre	O
-	O
mRNA	O
3	O
'	O
end	O
processing	O
,	O
mRNA	O
localization	O
,	O
stability	O
,	O
and	O
internal	O
ribosome	O
entry	O
site	O
-	O
mediated	O
translation	O
.	O

Here	O
we	O
have	O
used	O
a	O
tethered	O
function	O
assay	O
,	O
in	O
which	O
a	O
fusion	O
protein	O
of	O
PTB	B
and	O
the	O
bacteriophage	O
MS2	O
coat	B
protein	I
is	O
recruited	O
to	O
a	O
splicing	O
regulatory	O
site	O
by	O
binding	O
to	O
an	O
artificially	O
inserted	O
MS2	O
binding	O
site	O
.	O

Deletion	O
mutations	O
of	O
PTB	B
in	O
this	O
system	O
allowed	O
us	O
to	O
identify	O
RRM2	O
and	O
the	O
following	O
inter	O
-	O
RRM	O
linker	O
region	O
as	O
the	O
minimal	O
region	O
of	O
PTB	B
that	O
can	O
act	O
as	O
splicing	O
repressor	O
domain	O
when	O
recruited	O
to	O
RNA	O
.	O

Splicing	O
repression	O
by	O
the	O
minimal	O
repressor	O
domain	O
remained	O
cell	O
type	O
-	O
specific	O
and	O
dependent	O
upon	O
other	O
defined	O
regulatory	O
elements	O
in	O
the	O
alpha	B
-	I
tropomyosin	I
test	O
minigene	O
.	O

Our	O
results	O
highlight	O
the	O
fact	O
that	O
splicing	O
repression	O
by	O
PTB	B
can	O
be	O
uncoupled	O
from	O
the	O
mode	O
by	O
which	O
it	O
binds	O
to	O
RNA	O
.	O

Short	O
communication	O
:	O
impairment	O
of	O
membrane	O
markers	O
on	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
imbalance	O
of	O
cytokine	B
secretion	O
in	O
the	O
pathogenesis	O
of	O
multiple	O
sclerosis	O
active	O
phases	O
.	O

Multiple	O
sclerosis	O
(	O
MS	O
)	O
is	O
a	O
chronic	O
inflammatory	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

In	O
active	O
disease	O
,	O
a	O
transmigration	O
of	O
autoreactive	O
T	O
cells	O
to	O
myelin	O
antigens	O
recruited	O
from	O
the	O
peripheral	O
blood	O
(	O
PBMC	O
)	O
to	O
the	O
CNS	O
occurs	O
,	O
and	O
there	O
these	O
cells	O
prolong	O
their	O
survival	O
and	O
contribute	O
to	O
the	O
perpetuation	O
of	O
the	O
inflammation	O
.	O

In	O
the	O
active	O
local	O
lesions	O
of	O
MS	O
patients	O
,	O
these	O
cells	O
display	O
activation	O
and	O
apoptosis	O
surface	O
markers	O
and	O
secrete	O
a	O
range	O
of	O
cytokines	B
.	O

The	O
aim	O
of	O
this	O
research	O
is	O
to	O
study	O
on	O
PBMCs	O
and	O
in	O
the	O
serum	O
of	O
stable	O
and	O
active	O
MS	O
subjects	O
(	O
1	O
)	O
the	O
behavior	O
of	O
the	O
CD40	B
/	O
CD40L	B
system	O
and	O
the	O
consequent	O
balance	O
of	O
Th1	O
and	O
Th2	O
cytokines	B
and	O
(	O
2	O
)	O
the	O
apoptosis	O
marker	O
system	O
CD95	B
/	O
CD95L	B
and	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
-	O
binding	O
receptors	O
,	O
TNFRI	B
and	O
TNFRII	B
.	O

A	O
possible	O
excess	O
of	O
activation	O
marker	O
expression	O
affecting	O
and	O
driving	O
Th1	O
cytokine	B
production	O
or	O
a	O
parallel	O
impairment	O
of	O
apoptosis	O
may	O
contribute	O
to	O
MS	O
relapses	O
.	O

Our	O
results	O
may	O
indicate	O
that	O
a	O
dysregulation	O
of	O
early	O
activation	O
and	O
apoptosis	O
receptor	O
systems	O
and	O
a	O
profound	O
and	O
complex	O
imbalance	O
of	O
cytokine	B
production	O
occurred	O
in	O
the	O
peripheral	O
blood	O
of	O
MS	O
patients	O
.	O

This	O
impairment	O
could	O
account	O
for	O
active	O
phases	O
of	O
the	O
disease	O
.	O

ASB	O
proteins	O
interact	O
with	O
Cullin5	B
and	O
Rbx2	B
to	O
form	O
E3	B
ubiquitin	I
ligase	I
complexes	O
.	O

The	O
ankyrin	B
repeat	I
and	I
SOCS	I
box	I
(	I
ASB	I
)	I
family	I
is	O
composed	O
of	O
18	O
proteins	O
from	O
ASB1	B
to	O
ASB18	B
and	O
belongs	O
to	O
the	O
suppressor	B
of	I
cytokine	I
signaling	I
(	I
SOCS	I
)	I
box	I
protein	I
superfamily	I
.	O

ASB2	B
was	O
recently	O
shown	O
to	O
interact	O
with	O
a	O
certain	O
Cul	B
-	O
Rbx	B
module	O
to	O
form	O
an	O
E3	B
ubiquitin	I
(	I
Ub	I
)	I
ligase	I
complex	O
,	O
but	O
the	O
functional	O
composition	O
of	O
the	O
ASB	O
-	O
containing	O
E3	B
Ub	I
ligase	I
complexes	O
remains	O
to	O
be	O
characterized	O
.	O

Here	O
,	O
we	O
show	O
that	O
ASB	O
proteins	O
interact	O
with	O
Cul5	B
-	O
Rbx2	B
but	O
neither	O
Cul2	B
nor	O
Rbx1	B
in	O
cells	O
.	O

Mutational	O
analysis	O
revealed	O
that	O
the	O
highly	O
conserved	O
amino	O
acid	O
sequences	O
of	O
the	O
BC	O
box	O
and	O
Cul5	B
box	O
in	O
the	O
SOCS	B
box	O
of	O
ASB	O
proteins	O
were	O
essential	O
for	O
the	O
interaction	O
with	O
Cul5	B
-	O
Rbx2	B
.	O

Although	O
ASB	O
proteins	O
show	O
slight	O
divergences	O
from	O
the	O
consensus	O
sequences	O
of	O
the	O
BC	O
box	O
and	O
Cul5	B
box	O
,	O
all	O
five	O
tested	O
ASB	O
proteins	O
bound	O
to	O
Cul5	B
-	O
Rbx2	B
.	O

Furthermore	O
,	O
all	O
three	O
tested	O
ASB	O
complexes	O
containing	O
Cul5	B
-	O
Rbx2	B
were	O
found	O
to	O
have	O
E3	B
Ub	I
ligase	I
activity	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
ASB	B
family	I
proteins	O
interact	O
with	O
Cul5	B
-	O
Rbx2	B
to	O
form	O
E3	B
Ub	I
ligases	I
and	O
play	O
significant	O
roles	O
via	O
a	O
ubiquitination	O
-	O
mediated	O
pathway	O
.	O

Expression	O
of	O
TWEAK	B
and	O
its	O
receptor	O
Fn14	B
in	O
human	O
subcutaneous	O
adipose	O
tissue	O
.	O

Relationship	O
with	O
other	O
inflammatory	O
cytokines	B
in	O
obesity	O
.	O

TWEAK	B
,	O
a	O
cytokine	B
of	O
the	O
TNF	B
family	I
,	O
has	O
been	O
found	O
to	O
be	O
expressed	O
under	O
different	O
inflammatory	O
conditions	O
but	O
no	O
data	O
is	O
available	O
concerning	O
the	O
expression	O
of	O
this	O
cytokine	B
and	O
its	O
receptor	O
(	O
Fn14	B
)	O
in	O
human	O
obesity	O
.	O

In	O
the	O
present	O
work	O
we	O
have	O
evaluated	O
the	O
expression	O
of	O
many	O
pro	O
-	O
inflammatory	O
TNF	B
system	O
cytokines	B
(	O
TNF	B
-	I
alpha	I
,	O
TWEAK	B
and	O
their	O
respective	O
receptors	O
,	O
TNFR1	B
,	O
TNFR2	B
and	O
Fn14	B
)	O
in	O
human	O
adipose	O
tissue	O
of	O
84	O
subjects	O
some	O
with	O
different	O
degree	O
of	O
obesity	O
and	O
type	O
2	O
diabetes	O
,	O
and	O
its	O
relation	O
with	O
inflammation	O
by	O
also	O
measuring	O
the	O
expression	O
of	O
macrophage	O
marker	O
CD68	B
.	O

We	O
detected	O
expression	O
of	O
TWEAK	B
and	O
Fn14	B
in	O
isolated	O
mature	O
adipocytes	O
and	O
in	O
the	O
stromovascular	O
fraction	O
.	O

Additionally	O
,	O
we	O
found	O
that	O
LPS	O
upregulates	O
the	O
expression	O
of	O
both	O
genes	O
on	O
THP-1	O
human	O
monocytic	O
cell	O
line	O
.	O

TWEAK	B
was	O
expressed	O
in	O
adipose	O
tissue	O
of	O
all	O
studied	O
subjects	O
with	O
no	O
differences	O
between	O
obesity	O
group	O
,	O
and	O
was	O
associated	O
with	O
Fn14	B
expression	O
in	O
morbid	O
obese	O
,	O
mainly	O
in	O
women	O
with	O
type	O
2	O
diabetes	O
.	O

The	O
data	O
obtained	O
here	O
also	O
showed	O
that	O
TNF	B
-	I
alpha	I
and	O
TNFR2	B
mRNAs	O
were	O
significantly	O
more	O
expressed	O
in	O
subcutaneous	O
adipose	O
tissue	O
of	O
subjects	O
with	O
morbid	O
obesity	O
compared	O
to	O
obese	O
and	O
non	O
-	O
obese	O
subjects	O
.	O

In	O
contrast	O
,	O
TNFR1	B
gene	O
expression	O
was	O
negatively	O
associated	O
with	O
BMI	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
TNF	B
-	O
derived	O
pro	O
-	O
inflammatory	O
cytokines	B
are	O
increased	O
in	O
severe	O
obesity	O
,	O
where	O
macrophage	O
infiltrate	O
could	O
modulate	O
the	O
inflammatory	O
environment	O
through	O
activation	O
of	O
its	O
receptors	O
.	O

Action	O
of	O
intracellular	O
IL-1Ra	B
(	O
Type	O
1	O
)	O
is	O
independent	O
of	O
the	O
IL-1	B
intracellular	O
signalling	O
pathway	O
.	O

The	O
balance	O
between	O
IL-1	B
and	O
its	O
naturally	O
occurring	O
inhibitor	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1ra	B
)	O
is	O
critical	O
in	O
determining	O
the	O
inflammatory	O
response	O
.	O

Four	O
splice	O
variants	O
of	O
the	O
IL-1ra	B
gene	O
have	O
been	O
identified	O
;	O
one	O
secreted	O
(	O
sIL-1ra	B
)	O
and	O
three	O
intracellular	O
(	O
icIL-1ra1	B
-	I
3	I
)	O
.	O

The	O
biological	O
roles	O
of	O
the	O
intracellular	O
isoforms	O
remain	O
largely	O
unclear	O
.	O

We	O
wished	O
to	O
determine	O
whether	O
icIL	B
-	I
1ra1	I
had	O
intracellular	O
functions	O
regulating	O
IL-1	B
signalling	O
.	O

Signalling	O
was	O
determined	O
using	O
an	O
NF	B
-	I
kappaB	I
reporter	O
assay	O
measuring	O
induction	O
of	O
the	O
IL-8	B
promoter	O
in	O
transfected	O
cells	O
.	O

Over	O
-	O
expression	O
of	O
icIL-1ra1	B
in	O
HeLa	O
cells	O
had	O
no	O
effect	O
on	O
IL-1	B
stimulated	O
IL-8	B
activity	O
.	O

In	O
contrast	O
over	O
-	O
expression	O
of	O
sIL	B
-	I
ra	I
significantly	O
attenuated	O
IL-1	B
activity	O
.	O

In	O
addition	O
,	O
transfection	O
of	O
icIL-1ra1	B
in	O
HeLa	O
cells	O
did	O
not	O
cause	O
inhibition	O
of	O
IL-8	B
promoter	O
activity	O
following	O
over	O
-	O
expression	O
of	O
the	O
IL-1	B
signalling	O
components	O
MyD88	B
,	O
IRAK-1	B
,	O
TRAF-6	B
,	O
Ikappakappabeta	B
or	O
RelA	B
.	O

This	O
implies	O
that	O
icIL-1ra1	B
does	O
not	O
act	O
to	O
alter	O
IL-1	B
mediated	O
intracellular	O
signalling	O
in	O
this	O
system	O
.	O

We	O
investigated	O
whether	O
ATP	O
and/or	O
over	O
-	O
expression	O
of	O
the	O
P2X7	B
receptor	O
caused	O
icIL	B
-	I
1ra1	I
inhibition	O
of	O
IL-1beta	B
mediated	O
IL-8	B
reporter	O
activation	O
,	O
by	O
permitting	O
its	O
release	O
.	O

In	O
HeLa	O
cells	O
,	O
no	O
effect	O
of	O
icIL-1ra1	B
was	O
observed	O
in	O
ATP	O
stimulated	O
and/or	O
P2X7	B
transfected	O
cells	O
,	O
compared	O
to	O
a	O
significant	O
inhibition	O
in	O
sIL-1ra	B
transfected	O
cells	O
.	O

However	O
,	O
in	O
endothelial	O
cells	O
stimulated	O
with	O
ATP	O
,	O
the	O
released	O
fraction	O
was	O
effective	O
in	O
attenuating	O
IL-1beta	B
activation	O
of	O
the	O
IL-8	B
reporter	O
.	O

These	O
results	O
suggest	O
that	O
icIL	B
-	I
1ra1	I
does	O
not	O
act	O
at	O
an	O
intracellular	O
level	O
to	O
alter	O
IL-1	B
mediated	O
signalling	O
,	O
and	O
is	O
effective	O
in	O
inhibiting	O
IL-1	B
responses	O
only	O
when	O
released	O
in	O
an	O
ATP	O
-	O
dependent	O
and	O
cell	O
type	O
specific	O
manner	O
.	O

Aberrant	O
expression	O
of	O
cytoskeleton	O
proteins	O
in	O
hippocampus	O
from	O
patients	O
with	O
mesial	O
temporal	O
lobe	O
epilepsy	O
.	O

Mesial	O
temporal	O
lobe	O
epilepsy	O
(	O
MTLE	O
)	O
,	O
the	O
most	O
common	O
form	O
of	O
epilepsy	O
,	O
is	O
characterised	O
by	O
cytoarchitectural	O
abnormalities	O
including	O
neuronal	O
cell	O
loss	O
and	O
reactive	O
gliosis	O
in	O
hippocampus	O
.	O

Determination	O
of	O
aberrant	O
cytoskeleton	O
protein	O
expression	O
by	O
proteomics	O
techniques	O
may	O
help	O
to	O
understand	O
pathomechanism	O
that	O
is	O
still	O
elusive	O
.	O

We	O
searched	O
for	O
differential	O
expression	O
of	O
hippocampal	O
proteins	O
by	O
an	O
analytical	O
method	O
based	O
on	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
(	O
2-DE	O
)	O
coupled	O
with	O
mass	O
spectrometry	O
unambiguously	O
identifying	O
77	O
proteins	O
analysed	O
in	O
eight	O
control	O
and	O
eight	O
MTLE	O
hippocampi	O
.	O

Proteins	O
were	O
quantified	O
and	O
we	O
observed	O
18	O
proteins	O
that	O
were	O
altered	O
in	O
MTLE	O
.	O

Cytoskeleton	O
proteins	O
tubulin	B
alpha-1	I
chain	O
,	O
beta	B
-	I
tubulin	I
,	O
profilin	B
II	I
,	O
neuronal	B
tropomodulin	I
were	O
significantly	O
reduced	O
and	O
one	O
actin	O
spot	O
was	O
missing	O
,	O
whereas	O
ezrin	B
and	O
vinculin	B
were	O
significantly	O
increased	O
in	O
MTLE	O
.	O

Proteins	O
of	O
several	O
classes	O
as	O
e.g.	O
antioxidant	O
proteins	O
(	O
peroxiredoxins	B
3	I
and	I
6	I
)	O
,	O
chaperons	B
(	O
T	B
-	I
complex	I
protein	I
1-alpha	I
,	O
stress	B
-	I
induced	I
-	I
phosphoprotein	I
1	I
)	O
,	O
signaling	O
protein	O
MAP	B
kinase	I
kinase	I
1	I
,	O
synaptosomal	O
proteins	O
(	O
synaptotagmin	B
I	I
,	O
alpha	B
-	I
synuclein	I
)	O
,	O
NAD	B
-	I
dependent	I
deacetylase	I
sirtuin-2	I
and	O
26S	B
protease	I
regulatory	I
subunit	I
7	I
protein	O
,	O
neuronal	O
-	O
specific	O
septin	B
3	I
were	O
altered	O
in	O
MTLE	O
.	O

Taken	O
together	O
,	O
the	O
findings	O
may	O
represent	O
or	O
lead	O
to	O
cytoskeletal	O
impairment	O
;	O
aberrant	O
antioxidant	O
proteins	O
,	O
chaperons	B
,	O
MAP	B
kinase	I
kinase	I
1	I
and	O
NAD	B
-	I
dependent	I
deacetylase	I
sirtuin-2	I
may	O
have	O
been	O
involved	O
in	O
pathogenetic	O
mechanisms	O
and	O
altered	O
synaptosomal	O
protein	O
expression	O
possibly	O
reflects	O
synaptic	O
impairment	O
in	O
MTLE	O
.	O

arsRBOCT	B
arsenic	B
resistance	I
system	O
encoded	O
by	O
linear	O
plasmid	O
pHZ227	O
in	O
Streptomyces	O
sp.	O
strain	O
FR-008	O
.	O

In	O
the	O
arsenic	B
resistance	I
gene	O
cluster	O
from	O
the	O
large	O
linear	O
plasmid	O
pHZ227	O
,	O
two	O
novel	O
genes	O
,	O
arsO	B
(	O
for	O
a	O
putative	O
flavin	B
-	I
binding	I
monooxygenase	I
)	O
and	O
arsT	B
(	O
for	O
a	O
putative	O
thioredoxin	B
reductase	I
)	O
,	O
were	O
coactivated	O
and	O
cotranscribed	O
with	O
arsR1	B
-	O
arsB	B
and	O
arsC	B
,	O
respectively	O
.	O

Deletion	O
of	O
the	O
ars	B
gene	O
cluster	O
on	O
pHZ227	O
in	O
Streptomyces	O
sp.	O
strain	O
FR-008	O
resulted	O
in	O
sensitivity	O
to	O
arsenic	O
,	O
and	O
heterologous	O
expression	O
of	O
the	O
ars	B
gene	O
cluster	O
in	O
the	O
arsenic	O
-	O
sensitive	O
Streptomyces	O
strains	O
conferred	O
resistance	O
on	O
the	O
new	O
hosts	O
.	O

The	O
pHZ227	O
ArsB	B
protein	O
showed	O
homology	O
to	O
the	O
yeast	O
arsenite	O
transporter	O
Acr3p	B
.	O

The	O
pHZ227	O
ArsC	B
appears	O
to	O
be	O
a	O
bacterial	O
thioredoxin	O
-	O
dependent	O
ArsC	B
-	O
type	O
arsenate	B
reductase	I
with	O
four	O
conserved	O
cysteine	O
thioredoxin	O
-	O
requiring	O
motifs	O
.	O

Effect	O
of	O
chronic	O
tadalafil	O
administration	O
on	O
penile	O
hypoxia	O
induced	O
by	O
cavernous	O
neurotomy	O
in	O
the	O
rat	O
.	O

BACKGROUND	O
:	O

Numerous	O
men	O
develop	O
postprostatectomy	O
erectile	O
dysfunction	O
(	O
PPED	O
)	O
,	O
due	O
to	O
surgery	O
-	O
related	O
nervous	O
damage	O
.	O

PPED	O
is	O
often	O
refractory	O
to	O
phosphodiesterase	B
type	I
5	I
(	O
PDE5	B
)	O
inhibitors	O
therapy	O
.	O

AIM	O
:	O

To	O
verify	O
whether	O
chronic	O
tadalafil	O
(	O
CT	O
)	O
preserves	O
bilateral	O
cavernous	O
neurotomy	O
(	O
BCN	O
)	O
-	O
induced	O
penile	O
damage	O
and	O
hypo	O
-	O
oxygenation	O
.	O

METHODS	O
:	O

In	O
a	O
rat	O
model	O
of	O
BCN	O
we	O
evaluated	O
in	O
vitro	O
and	O
ex	O
vivo	O
effect	O
of	O
CT	O
treatment	O
(	O
2	O
mg	O
/	O
kg	O
,	O
daily	O
for	O
3	O
months	O
)	O
.	O

RESULTS	O
:	O

Bilateral	O
cavernous	O
neurotomy	O
induced	O
massive	O
hypoxia	O
and	O
decreased	O
muscle	O
/	O
fiber	O
ratio	O
,	O
completely	O
restored	O
by	O
CT	O
.	O

Hypersensitivity	O
of	O
hypoxic	O
tissues	O
to	O
the	O
relaxant	O
effect	O
of	O
the	O
endothelin	B
type	I
B	I
receptor	I
(	O
ETB	B
)	O
agonist	O
IRL-1620	O
was	O
observed	O
,	O
along	O
with	O
ETB	B
mRNA	O
and	O
protein	O
overexpression	O
.	O

CT	O
restored	O
sensitivity	O
to	O
IRL-1620	O
,	O
and	O
normalized	O
ETB	B
expression	O
.	O

Hypoxic	O
penis	O
showed	O
increased	O
sensitivity	O
to	O
the	O
relaxant	O
effect	O
of	O
the	O
nitric	O
oxide	O
donor	O
sodium	O
nitroprusside	O
(	O
SNP	O
)	O
,	O
while	O
acute	O
tadalafil	O
(	O
100	O
nM	O
)	O
did	O
not	O
amplify	O
the	O
SNP	O
effect	O
.	O

Accordingly	O
,	O
PDE5	B
mRNA	O
and	O
protein	O
were	O
reduced	O
in	O
BCN	O
penile	O
tissues	O
.	O

By	O
restoring	O
PDE5	B
,	O
CT	O
decreased	O
SNP	O
-	O
induced	O
relaxation	O
and	O
rescued	O
sensitivity	O
to	O
acute	O
tadalafil	O
.	O

However	O
,	O
in	O
hypoxic	O
penis	O
,	O
CT	O
normalizes	O
neither	O
acetylcholine	O
hyporesponsiveness	O
nor	O
neuronal	B
nitric	I
oxide	I
synthase	I
-	O
endothelial	B
nitric	I
oxide	I
synthase	I
expression	O
.	O

CONCLUSION	O
:	O

Chronic	O
tadalafil	O
restores	O
some	O
of	O
the	O
investigated	O
BCN	O
-	O
induced	O
alterations	O
,	O
including	O
PDE5	B
and	O
tadalafil	O
efficacy	O
.	O

Apo2l	B
/	O
Tumor	B
necrosis	I
factor	I
-	I
related	I
apoptosis	I
-	I
inducing	I
ligand	I
prevents	O
breast	O
cancer	O
-	O
induced	O
bone	O
destruction	O
in	O
a	O
mouse	O
model	O
.	O

Breast	O
cancer	O
is	O
the	O
most	O
common	O
carcinoma	O
that	O
metastasizes	O
to	O
bone	O
.	O

To	O
examine	O
the	O
efficacy	O
of	O
recombinant	O
soluble	O
Apo2	B
ligand	I
(	O
Apo2L	B
)	O
/	O
tumor	B
necrosis	I
factor	I
-	I
related	I
apoptosis	I
-	I
inducing	I
ligand	I
(	O
TRAIL	B
)	O
against	O
breast	O
cancer	O
growth	O
in	O
bone	O
,	O
we	O
established	O
a	O
mouse	O
model	O
in	O
which	O
MDA	O
-	O
MB-231	O
human	O
breast	O
cancer	O
cells	O
were	O
transplanted	O
directly	O
into	O
the	O
marrow	O
cavity	O
of	O
the	O
tibiae	O
of	O
athymic	O
nude	O
mice	O
producing	O
osteolytic	O
lesions	O
in	O
the	O
area	O
of	O
injection	O
.	O

All	O
vehicle	O
-	O
treated	O
control	O
animals	O
developed	O
large	O
lesions	O
that	O
established	O
in	O
the	O
marrow	O
cavity	O
,	O
eroded	O
the	O
cortical	O
bone	O
,	O
and	O
invaded	O
the	O
surrounding	O
soft	O
tissue	O
,	O
as	O
assessed	O
by	O
radiography	O
,	O
micro	O
-	O
computed	O
tomography	O
,	O
and	O
histology	O
.	O

In	O
contrast	O
,	O
animals	O
treated	O
with	O
recombinant	O
soluble	O
Apo2L	B
/	O
TRAIL	B
showed	O
significant	O
conservation	O
of	O
the	O
tibiae	O
,	O
with	O
85	O
%	O
reduction	O
in	O
osteolysis	O
,	O
90	O
%	O
reduction	O
in	O
tumor	O
burden	O
,	O
and	O
no	O
detectable	O
soft	O
tissue	O
invasion	O
.	O

Tumor	O
cells	O
explanted	O
from	O
Apo2L	B
/	O
TRAIL	B
-	O
treated	O
animals	O
were	O
significantly	O
more	O
resistant	O
to	O
the	O
effects	O
of	O
Apo2L	B
/	O
TRAIL	B
when	O
compared	O
with	O
the	O
cells	O
explanted	O
from	O
the	O
vehicle	O
-	O
treated	O
control	O
animals	O
,	O
suggesting	O
that	O
prolonged	O
treatment	O
with	O
Apo2	B
/	O
TRAIL	B
in	O
vivo	O
selects	O
for	O
a	O
resistant	O
phenotype	O
.	O

However	O
,	O
such	O
resistance	O
was	O
readily	O
reversed	O
when	O
Apo2L	B
/	O
TRAIL	B
was	O
used	O
in	O
combination	O
with	O
clinically	O
relevant	O
chemotherapeutic	O
drugs	O
,	O
including	O
taxol	O
,	O
etoposide	O
,	O
doxorubicin	O
,	O
cisplatin	O
,	O
or	O
the	O
histone	B
deacetylase	I
inhibitor	O
suberoylanilide	O
hydroxamic	O
acid	O
.	O

These	O
studies	O
show	O
for	O
the	O
first	O
time	O
that	O
Apo2L	B
/	O
TRAIL	B
can	O
prevent	O
breast	O
cancer	O
-	O
induced	O
bone	O
destruction	O
and	O
highlight	O
the	O
potential	O
of	O
this	O
ligand	O
for	O
the	O
treatment	O
of	O
metastatic	O
breast	O
cancer	O
in	O
bone	O
.	O

Role	O
of	O
Shigella	O
flexneri	O
2a	O
34	B
kDa	I
outer	I
membrane	I
protein	I
in	O
induction	O
of	O
protective	O
immune	O
response	O
.	O

Emergence	O
of	O
Shigella	O
vaccine	O
is	O
in	O
great	O
need	O
in	O
developing	O
countries	O
.	O

In	O
this	O
paper	O
we	O
have	O
shown	O
that	O
34	O
kDa	O
Shigella	O
flexneri	O
2a	O
outer	O
membrane	O
protein	O
has	O
a	O
role	O
in	O
eliciting	O
immune	O
responses	O
.	O

When	O
injected	O
parentarally	O
this	O
protein	O
gives	O
significant	O
protection	O
against	O
challenge	O
with	O
virulent	O
Shigella	O
flexneri	O
2a	O
.	O

Macrophages	O
activated	O
with	O
the	O
34	O
kDa	O
protein	O
resulted	O
in	O
the	O
dose	O
dependent	O
production	O
of	O
nitric	O
oxide	O
,	O
the	O
highly	O
reactive	O
free	O
radical	O
responsible	O
for	O
killing	O
of	O
invading	O
bacterial	O
pathogen	O
.	O

Also	O
,	O
treatment	O
of	O
murine	O
peritoneal	O
macrophages	O
with	O
the	O
34	O
kDa	O
protein	O
showed	O
dose	O
dependent	O
increase	O
in	O
the	O
production	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
and	O
interleukin-12	B
.	O

However	O
,	O
there	O
was	O
no	O
dose	O
dependent	O
increase	O
in	O
interleukin-10	B
production	O
.	O

These	O
data	O
indicated	O
that	O
the	O
34	B
kDa	I
outer	I
membrane	I
protein	I
has	O
the	O
ability	O
to	O
modulate	O
the	O
protective	O
immune	O
response	O
against	O
the	O
invading	O
bacterial	O
pathogen	O
,	O
mainly	O
through	O
TH1	O
mediated	O
pathway	O
.	O

So	O
,	O
the	O
34	B
kDa	I
outer	I
mebrane	I
protein	I
can	O
be	O
one	O
of	O
the	O
major	O
components	O
for	O
developing	O
subunit	O
vaccine	O
against	O
shigellosis	O
.	O

A	O
role	O
for	O
KIR	B
gene	O
variants	O
other	O
than	O
KIR2DS1	B
in	O
conferring	O
susceptibility	O
to	O
psoriasis	O
.	O

Recently	O
we	O
described	O
an	O
association	O
between	O
psoriasis	O
and	O
KIR2DS1	B
,	O
a	O
gene	O
for	O
a	O
stimulatory	O
natural	O
killer	O
cell	O
receptor	O
,	O
in	O
a	O
Polish	O
population	O
.	O

The	O
association	O
was	O
independently	O
reported	O
among	O
Japanese	O
and	O
confirmed	O
in	O
a	O
U.S.	O
population	O
.	O

Prompted	O
by	O
these	O
findings	O
,	O
we	O
reanalyzed	O
data	O
by	O
a	O
multivariate	O
approach	O
in	O
search	O
of	O
possible	O
effects	O
of	O
KIR	B
genes	O
other	O
than	O
KIR2DS1	B
(	O
non	O
-	O
KIR2DS1	B
)	O
.	O

The	O
methodology	O
was	O
based	O
on	O
a	O
stratified	O
analysis	O
and	O
multiple	O
logistic	O
regression	O
.	O

We	O
found	O
that	O
the	O
non	O
-	O
KIR2DS1	B
genes	O
had	O
joint	O
effects	O
comparable	O
to	O
or	O
stronger	O
than	O
the	O
effects	O
of	O
KIR2DS1	B
in	O
both	O
the	O
fraction	O
of	O
explained	O
variance	O
(	O
0.174	O
vs	O
0.204	O
,	O
respectively	O
,	O
for	O
KIR2DS1	B
and	O
non	O
-	O
KIR2DS1	B
)	O
and	O
the	O
statistical	O
significance	O
(	O
p	O
=	O
0.000008	O
vs	O
p	O
=	O
0.000001	O
,	O
respectively	O
)	O
.	O

When	O
individual	O
genes	O
were	O
considered	O
,	O
a	O
decrease	O
in	O
KIR2DS5	B
among	O
patients	O
vs	O
controls	O
(	O
OR	O
=	O
0.2	O
,	O
pcor	O
=	O
0.0005	O
)	O
and	O
a	O
decrease	O
in	O
KIR2DS3	B
restricted	O
to	O
KIR2DS1	B
-	O
positive	O
individuals	O
(	O
OR	O
=	O
0.2	O
,	O
pcor	O
=	O
0.005	O
)	O
were	O
evident	O
.	O

We	O
also	O
performed	O
a	O
multivariate	O
analysis	O
of	O
the	O
HLA	B
-	I
Cw	I
genotypes	O
but	O
failed	O
to	O
demonstrate	O
any	O
effects	O
in	O
addition	O
to	O
the	O
known	O
association	O
with	O
HLA	B
-	I
Cw*06	I
.	O

We	O
conclude	O
that	O
the	O
effect	O
of	O
the	O
KIR	B
genes	O
on	O
psoriasis	O
susceptibility	O
is	O
complex	O
,	O
extending	O
beyond	O
the	O
association	O
with	O
KIR2DS1	B
and	O
involving	O
protective	O
effects	O
and	O
interactions	O
.	O

Regulation	O
of	O
IL-8	B
by	O
Irsogladine	O
maleate	O
is	O
involved	O
in	O
abolishment	O
of	O
Actinobacillus	O
actinomycetemcomitans	O
-	O
induced	O
reduction	O
of	O
gap	O
-	O
junctional	O
intercellular	O
communication	O
.	O

Our	O
previous	O
report	O
has	O
shown	O
that	O
Irsogladine	O
maleate	O
(	O
IM	O
)	O
counters	O
and	O
obviates	O
the	O
reduction	O
in	O
gap	O
junction	O
intercellular	O
communication	O
(	O
GJIC	O
)	O
and	O
the	O
increase	O
in	O
IL-8	B
levels	O
,	O
respectively	O
,	O
induced	O
by	O
outer	O
membrane	O
protein	O
29	O
from	O
Actinobacillus	O
actinomycetemcomitans	O
(	O
A.	O
actinomycetemcomitans	O
)	O
in	O
cultured	O
human	O
gingival	O
epithelial	O
cells	O
(	O
HGEC	O
)	O
.	O

In	O
addition	O
,	O
IM	O
suppresses	O
the	O
increase	O
in	O
the	O
secretion	O
of	O
IL-8	B
caused	O
by	O
whole	O
live	O
A.	O
actinomycetemcomitans	O
.	O

These	O
findings	O
implicate	O
the	O
modulation	O
of	O
IL-8	B
levels	O
by	O
IM	O
in	O
abolishment	O
of	O
the	O
reduction	O
of	O
GJIC	O
in	O
HGEC	O
.	O

Tight	O
junctions	O
are	O
also	O
responsible	O
for	O
cell	O
-	O
cell	O
communication	O
.	O

Zonula	B
occludens	I
protein-1	I
(	O
ZO-1	B
)	O
is	O
a	O
major	O
tight	O
junction	O
protein	O
.	O

To	O
investigate	O
the	O
regulatory	O
mechanism	O
of	O
intercellular	O
communication	O
mediated	O
by	O
IM	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
focused	O
on	O
the	O
involvement	O
of	O
IL-8	B
in	O
A.	O
actinomycetemcomitans	O
-	O
induced	O
change	O
in	O
GJIC	O
and	O
ZO-1	B
expression	O
in	O
HGEC	O
.	O

IM	O
countered	O
the	O
A.	O
actinomycetemcomitans	O
-	O
induced	O
reduction	O
in	O
levels	O
of	O
Connexin	B
(	I
CX	I
)	I
43	I
,	O
suggesting	O
that	O
it	O
could	O
abolish	O
the	O
A.	O
actinomycetemcomitans	O
-	O
induced	O
reduction	O
in	O
GJIC	O
in	O
HGEC	O
.	O

CXCR-1	B
is	O
a	O
receptor	B
of	I
IL-8	I
.	O

The	O
simultaneous	O
addition	O
of	O
A.	O
actinomycetemcomitans	O
and	O
anti	O
-	O
CXCR-1	B
antibody	O
also	O
abrogated	O
the	O
repression	O
of	O
GJIC	O
and	O
CX43	B
expression	O
by	O
A.	O
actinomycetemcomitans	O
in	O
HGEC	O
,	O
although	O
the	O
anti	O
-	O
CXCR-1	B
antibody	O
was	O
less	O
effective	O
than	O
IM	O
.	O

IM	O
inhibited	O
the	O
IL-8	B
-	O
induced	O
reduction	O
in	O
CX43	B
levels	O
and	O
GJIC	O
in	O
HGEC	O
.	O

IM	O
countered	O
the	O
A.	O
actinomycetemcomitans	O
-	O
induced	O
reduction	O
in	O
the	O
expression	O
of	O
ZO-1	B
,	O
although	O
anti	O
-	O
CXCR-1	B
antibody	O
did	O
not	O
influence	O
the	O
decrease	O
in	O
ZO-1	B
mRNA	O
levels	O
caused	O
by	O
A.	O
actinomycetemcomitans	O
.	O

Furthermore	O
,	O
IL-8	B
had	O
little	O
effect	O
on	O
the	O
mRNA	O
levels	O
of	O
ZO-1	B
.	O

These	O
findings	O
suggest	O
that	O
IL-8	B
mediates	O
the	O
A.	O
actinomycetemcomitans	O
-	O
induced	O
reduction	O
of	O
GJIC	O
and	O
CX43	B
expression	O
in	O
HGEC	O
.	O

The	O
regulation	O
of	O
IL-8	B
levels	O
by	O
IM	O
in	O
HGEC	O
is	O
partially	O
involved	O
in	O
abrogation	O
of	O
the	O
reduction	O
of	O
GJIC	O
and	O
CX43	B
expression	O
by	O
A.	O
actinomycetemcomitans	O
.	O

Furthermore	O
,	O
the	O
regulatory	O
effect	O
of	O
IM	O
on	O
the	O
expression	O
of	O
CX43	B
and	O
ZO-1	B
is	O
different	O
.	O

4	B
-	I
1BB	I
-	O
mediated	O
amelioration	O
of	O
experimental	O
autoimmune	O
uveoretinitis	O
is	O
caused	O
by	O
indoleamine	B
2,3-dioxygenase	I
-	O
dependent	O
mechanisms	O
.	O

Interphotoreceptor	B
retinoid	I
binding	I
protein	I
(	O
IRBP	B
)	O
-	O
induced	O
experimental	O
autoimmune	O
uveoretinitis	O
(	O
EAU	O
)	O
is	O
a	O
CD4	B
+	O
T	O
cell	O
-	O
mediated	O
autoimmune	O
disease	O
.	O

Development	O
of	O
EAU	O
is	O
inhibited	O
by	O
treatment	O
with	O
an	O
agonistic	O
anti	O
-	O
4	B
-	I
1BB	I
mAb	O
.	O

Even	O
established	O
EAU	O
was	O
alleviated	O
by	O
anti	O
-	O
4	B
-	I
1BB	I
mAb	O
.	O

However	O
,	O
inhibition	O
of	O
4	B
-	I
1BB	I
/	O
4	B
-	I
1BB	I
ligand	I
(	O
4	B
-	I
1BBL	I
)	O
interaction	O
does	O
not	O
suppress	O
the	O
development	O
of	O
EAU	O
.	O

It	O
appears	O
that	O
cross	O
-	O
linking	O
of	O
4	B
-	I
1BB	I
evokes	O
an	O
active	O
antigen	O
-	O
specific	O
suppression	O
mechanism	O
rather	O
than	O
merely	O
blocking	O
4	B
-	I
1BB	I
/	O
4	B
-	I
1BBL	I
interaction	O
.	O

We	O
found	O
that	O
administration	O
of	O
anti	O
-	O
4	B
-	I
1BB	I
mAb	O
induced	O
massive	O
clonal	O
expansion	O
of	O
CD11c	B
+	O
CD8	B
+	O
T	O
cells	O
that	O
produced	O
IFN	B
-	I
gamma	I
,	O
resulting	O
in	O
accumulation	O
of	O
a	O
high	O
level	O
of	O
indoleamine	B
2,3-dioxygenase	I
(	O
IDO	B
)	O
in	O
CD11c	B
+	O
dendritic	O
cells	O
.	O

4	B
-	I
1BB	I
-	O
mediated	O
suppression	O
of	O
EAU	O
was	O
reversed	O
by	O
the	O
pharmacological	O
IDO	B
inhibitor	O
,	O
1-methyl	O
-	O
tryptophan	O
(	O
1-MT	O
)	O
.	O

These	O
studies	O
demonstrate	O
that	O
suppression	O
of	O
EAU	O
results	O
from	O
antigen	O
-	O
driven	O
,	O
4	B
-	I
1BB	I
-	O
mediated	O
expansion	O
of	O
novel	O
CD11c	B
+	O
CD8	B
+	O
T	O
cells	O
that	O
suppress	O
antigen	O
-	O
specific	O
CD4	B
+	O
T	O
cells	O
via	O
an	O
IDO	B
-	O
dependent	O
mechanism	O
.	O

Killer	B
Ig	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
genotype	O
and	O
HLA	B
ligand	O
combinations	O
in	O
ulcerative	O
colitis	O
susceptibility	O
.	O

Killer	B
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
are	O
expressed	O
on	O
natural	O
killer	O
cells	O
and	O
some	O
T	O
-	O
cell	O
subsets	O
and	O
produce	O
either	O
activation	O
or	O
inhibitory	O
signals	O
upon	O
binding	O
with	O
the	O
appropriate	O
human	B
leucocyte	I
antigen	I
(	O
HLA	B
)	O
ligand	O
on	O
target	O
cells	O
.	O

Recent	O
genetic	O
association	O
studies	O
have	O
implicated	O
KIR	B
genotype	O
in	O
the	O
development	O
of	O
several	O
inflammatory	O
conditions	O
.	O

Ulcerative	O
colitis	O
(	O
UC	O
)	O
is	O
an	O
inflammatory	O
disorder	O
of	O
the	O
colonic	O
mucosa	O
that	O
results	O
from	O
an	O
inappropriate	O
activation	O
of	O
the	O
immune	O
system	O
driven	O
by	O
host	O
bacterial	O
flora	O
.	O

We	O
developed	O
a	O
polymerase	O
chain	O
reaction	O
-	O
sequence	O
specific	O
primer	O
(	O
SSP	O
)	O
-	O
based	O
assay	O
to	O
genotype	O
194	O
UC	O
patients	O
and	O
216	O
control	O
individuals	O
for	O
14	O
KIR	B
genes	O
,	O
the	O
HLA	B
-	I
Cw	I
ligand	O
epitopes	O
of	O
the	O
KIR2D	B
receptors	O
and	O
a	O
polymorphism	O
of	O
the	O
lectin	B
-	O
like	O
-	O
activating	O
receptor	O
NKG2D	B
.	O

Initial	O
analysis	O
found	O
the	O
phenotype	O
frequency	O
of	O
KIR2DL2	B
and	O
-	O
2DS2	B
to	O
be	O
significantly	O
increased	O
in	O
the	O
UC	O
cohort	O
(	O
P	O
=	O
0.030	O
and	O
0.038	O
,	O
respectively	O
)	O
.	O

Logistic	O
regression	O
analysis	O
revealed	O
a	O
protective	O
effect	O
conferred	O
by	O
KIR2DL3	B
in	O
the	O
presence	O
of	O
its	O
ligand	O
HLA	B
-	I
Cw	I
group	O
1	O
(	O
P	O
=	O
0.019	O
)	O
.	O

These	O
results	O
suggest	O
that	O
KIR	B
genotype	O
and	O
HLA	B
ligand	O
interaction	O
may	O
contribute	O
to	O
the	O
genetic	O
susceptibility	O
of	O
UC	O
.	O

Blood	O
leukocyte	O
mRNA	O
expression	O
for	O
IL-10	B
,	O
IL-1Ra	B
,	O
and	O
IL-8	B
,	O
but	O
not	O
IL-6	B
,	O
increases	O
after	O
exercise	O
.	O

The	O
primary	O
purpose	O
of	O
this	O
project	O
was	O
to	O
study	O
exercise	O
-	O
induced	O
leukocyte	O
cytokine	B
mRNA	O
expression	O
.	O

Changes	O
in	O
plasma	O
cytokine	B
levels	O
and	O
blood	O
leukocyte	O
mRNA	O
expression	O
for	O
interleukin-6	B
(	O
IL-6	B
)	O
,	O
IL-8	B
,	O
IL	B
-	I
10	I
,	O
and	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1Ra	B
)	O
were	O
measured	O
in	O
12	O
athletes	O
following	O
2	O
h	O
of	O
intensive	O
cycling	O
(	O
approximately	O
64	O
%	O
Watts	O
(	O
max	O
)	O
)	O
while	O
ingesting	O
a	O
carbohydrate	O
or	O
placebo	O
beverage	O
(	O
randomized	O
and	O
double	O
blinded	O
)	O
.	O

Blood	O
samples	O
were	O
collected	O
30	O
min	O
preexercise	O
and	O
immediately	O
and	O
1	O
h	O
postexercise	O
.	O

Carbohydate	O
compared	O
with	O
placebo	O
ingestion	O
attenuated	O
exercise	O
-	O
induced	O
changes	O
in	O
plasma	O
cortisol	O
(	O
8.8	O
%	O
vs.	O
62	O
%	O
,	O
respectively	O
)	O
,	O
epinephrine	O
(	O
-	O
9.2	O
%	O
vs.	O
138	O
%	O
)	O
,	O
IL-6	B
(	O
10	O
-	O
fold	O
vs.	O
40	O
-	O
fold	O
)	O
,	O
IL-10	B
(	O
8.9	O
-	O
fold	O
vs.	O
26	O
-	O
fold	O
,	O
and	O
IL-1Ra	B
(	O
2.1	O
-	O
fold	O
vs.	O
5.6	O
-	O
fold	O
)	O
.	O
Significant	O
time	O
effects	O
were	O
measured	O
for	O
blood	O
leukocyte	O
IL-8	B
(	O
2.4	O
-	O
fold	O
increase	O
1	O
h	O
postexercise	O
)	O
,	O
IL-10	B
(	O
2.7	O
-	O
fold	O
increase	O
)	O
,	O
IL-1Ra	B
(	O
2.2	O
-	O
fold	O
increase	O
)	O
,	O
and	O
IL-6	B
(	O
0.8	O
-	O
fold	O
decrease	O
)	O
mRNA	O
content	O
,	O
with	O
no	O
significant	O
differences	O
between	O
Cho	O
and	O
Pla	O
test	O
conditions	O
.	O

In	O
summary	O
,	O
gene	O
expression	O
for	O
IL-8	B
,	O
IL-10	B
,	O
and	O
IL-1Ra	B
,	O
but	O
not	O
IL-6	B
,	O
is	O
increased	O
in	O
blood	O
leukocytes	O
taken	O
from	O
athletes	O
following	O
2	O
h	O
of	O
intensive	O
cycling	O
and	O
is	O
not	O
influenced	O
by	O
carbohydrate	O
compared	O
with	O
placebo	O
ingestion	O
.	O

mRNA	O
expression	O
was	O
high	O
enough	O
to	O
indicate	O
a	O
substantial	O
contribution	O
of	O
blood	O
leukocytes	O
to	O
plasma	O
levels	O
of	O
IL-8	B
,	O
IL-10	B
,	O
and	O
IL-1Ra	B
during	O
prolonged	O
exercise	O
.	O

A	O
homologue	O
of	O
the	O
3-oxoacyl	B
-	I
(	I
acyl	I
carrier	I
protein	I
)	I
synthase	I
III	I
gene	O
located	O
in	O
the	O
glycosylation	O
island	O
of	O
Pseudomonas	O
syringae	O
pv	O
.	O
tabaci	O
regulates	O
virulence	O
factors	O
via	O
N	O
-	O
acyl	O
homoserine	O
lactone	O
and	O
fatty	O
acid	O
synthesis	O
.	O

Pseudomonas	O
syringae	O
pv	O
.	O
tabaci	O
6605	O
possesses	O
a	O
genetic	O
region	O
involved	O
in	O
flagellin	B
glycosylation	O
.	O

This	O
region	O
is	O
composed	O
of	O
three	O
open	O
reading	O
frames	O
:	O
orf1	O
,	O
orf2	O
,	O
and	O
orf3	O
.	O

Our	O
previous	O
study	O
revealed	O
that	O
orf1	O
and	O
orf2	O
encode	O
glycosyltransferases	B
;	O
on	O
the	O
other	O
hand	O
,	O
orf3	O
has	O
no	O
role	O
in	O
posttranslational	O
modification	O
of	O
flagellin	B
.	O

Although	O
the	O
function	O
of	O
Orf3	O
remained	O
unclear	O
,	O
an	O
orf3	O
deletion	O
mutant	O
(	O
Deltaorf3	O
mutant	O
)	O
had	O
reduced	O
virulence	O
on	O
tobacco	O
plants	O
.	O

Orf3	O
shows	O
significant	O
homology	O
to	O
a	O
3	B
-	I
oxoacyl	I
-	I
(	I
acyl	I
carrier	I
protein	I
)	I
synthase	I
III	I
in	O
the	O
fatty	O
acid	O
elongation	O
cycle	O
.	O

The	O
Deltaorf3	O
mutant	O
had	O
a	O
significantly	O
reduced	O
ability	O
to	O
form	O
acyl	O
homoserine	O
lactones	O
(	O
AHLs	O
)	O
,	O
which	O
are	O
quorum	O
-	O
sensing	O
molecules	O
,	O
suggesting	O
that	O
Orf3	O
is	O
required	O
for	O
AHL	O
synthesis	O
.	O

In	O
comparison	O
with	O
the	O
wild	O
-	O
type	O
strain	O
,	O
swarming	O
motility	O
,	O
biosurfactant	O
production	O
,	O
and	O
tolerance	O
to	O
H2O2	O
and	O
antibiotics	O
were	O
enhanced	O
in	O
the	O
Deltaorf3	O
mutant	O
.	O

A	O
scanning	O
electron	O
micrograph	O
of	O
inoculated	O
bacteria	O
on	O
the	O
tobacco	O
leaf	O
surface	O
revealed	O
that	O
there	O
is	O
little	O
extracellular	O
polymeric	O
substance	O
matrix	O
surrounding	O
the	O
cells	O
in	O
the	O
Deltaorf3	O
mutant	O
.	O

The	O
phenotypes	O
of	O
the	O
Deltaorf3	O
mutant	O
and	O
an	O
AHL	O
synthesis	O
(	O
DeltapsyI	O
)	O
mutant	O
were	O
similar	O
,	O
although	O
the	O
mutant	O
-	O
specific	O
characteristics	O
were	O
more	O
extreme	O
in	O
the	O
Deltaorf3	O
mutant	O
.	O

The	O
swarming	O
motility	O
of	O
the	O
Deltaorf3	O
mutant	O
was	O
greater	O
than	O
that	O
of	O
the	O
DeltapsyI	O
mutant	O
.	O

This	O
was	O
attributed	O
to	O
the	O
synergistic	O
effects	O
of	O
the	O
overproduction	O
of	O
biosurfactants	O
and/or	O
alternative	O
fatty	O
acid	O
metabolism	O
in	O
the	O
Deltaorf3	O
mutant	O
.	O

Furthermore	O
,	O
the	O
amounts	O
of	O
iron	O
and	O
biosurfactant	O
seem	O
to	O
be	O
involved	O
in	O
biofilm	O
development	O
under	O
quorum	O
-	O
sensing	O
regulation	O
in	O
P.	O
syringae	O
pv	O
.	O
tabaci	O
6605	O
.	O

Influence	O
of	O
interleukin	B
IL-2	B
and	O
IL-12	B
+	O
IL-18	B
on	O
surface	O
expression	O
of	O
immunoglobulin	B
-	I
like	I
receptors	I
KIR2DL1	B
,	O
KIR2DL2	B
,	O
and	O
KIR3DL2	B
in	O
natural	O
killer	O
cells	O
.	O

Natural	O
killer	O
(	O
NK	O
)	O
cells	O
express	O
killer	O
cell	O
inhibitory	O
receptors	O
(	O
KIRs	B
)	O
that	O
recognize	O
polymorphic	O
class	B
I	I
MHC	I
molecules	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analyze	O
the	O
modulatory	O
effect	O
of	O
IL-2	B
alone	O
or	O
a	O
combination	O
of	O
IL-12	B
with	O
IL-18	B
on	O
surface	O
expression	O
of	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptors	I
KIR2DL1	B
,	O
KIR2DL2	B
,	O
and	O
KIR3DL2	B
in	O
NK	O
cells	O
.	O

Thus	O
,	O
it	O
was	O
found	O
that	O
IL-2	B
causes	O
a	O
significant	O
increase	O
in	O
the	O
proportion	O
of	O
cells	O
with	O
given	O
studied	O
receptors	O
.	O

Stimulation	O
by	O
a	O
mixture	O
of	O
IL-12	B
and	O
IL-18	B
caused	O
significant	O
increase	O
in	O
the	O
fraction	O
of	O
cells	O
with	O
the	O
KIR2DL1	B
and	O
KIR2DL2	B
,	O
however	O
no	O
significant	O
change	O
in	O
the	O
percentage	O
of	O
cells	O
with	O
KIR3DL2	B
receptor	O
on	O
their	O
surface	O
was	O
observed	O
.	O

The	O
results	O
of	O
the	O
study	O
show	O
the	O
presence	O
of	O
KIRs	B
on	O
both	O
resting	O
and	O
activated	O
NK	O
cells	O
,	O
this	O
may	O
suggest	O
that	O
KIRs	B
have	O
also	O
an	O
important	O
role	O
in	O
the	O
regulatory	O
processes	O
after	O
activation	O
of	O
this	O
subpopulation	O
of	O
cells	O
.	O

Cutting	O
edge	O
:	O
resistance	O
to	O
HIV-1	O
infection	O
among	O
African	O
female	O
sex	O
workers	O
is	O
associated	O
with	O
inhibitory	O
KIR	B
in	O
the	O
absence	O
of	O
their	O
HLA	B
ligands	O
.	O

NK	O
cells	O
are	O
regulated	O
in	O
part	O
by	O
killer	B
Ig	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
that	O
interact	O
with	O
HLA	B
molecules	O
on	O
potential	O
target	O
cells	O
.	O

KIR	B
and	O
HLA	B
loci	O
are	O
highly	O
polymorphic	O
and	O
certain	O
KIR	B
/	O
HLA	B
combinations	O
were	O
found	O
to	O
protect	O
against	O
HIV	O
disease	O
progression	O
.	O

We	O
show	O
in	O
this	O
study	O
that	O
KIR	B
/	O
HLA	B
interactions	O
also	O
influence	O
resistance	O
to	O
HIV	O
transmission	O
.	O

HIV	O
-	O
exposed	O
but	O
seronegative	O
female	O
sex	O
workers	O
in	O
Abidjan	O
,	O
CÃ?Â´te	O
d	O
'	O
Ivoire	O
,	O
frequently	O
possessed	O
inhibitory	O
KIR	B
genes	O
in	O
the	O
absence	O
of	O
their	O
cognate	O
HLA	B
genes	O
:	O
KIR2DL2	B
/	O
KIR2DL3	B
heterozygosity	O
in	O
the	O
absence	O
of	O
HLA	B
-	I
C1	I
and	O
KIR3DL1	B
homozygosity	O
in	O
the	O
absence	O
of	O
HLA	B
-	I
Bw4	I
.	O

HIV	O
-	O
seropositive	O
female	O
sex	O
workers	O
were	O
characterized	O
by	O
corresponding	O
inhibitory	O
KIR	B
/	O
HLA	B
pairings	O
:	O
KIR2DL3	B
homozygosity	O
together	O
with	O
HLA	B
-	I
C1	I
and	O
a	O
trend	O
toward	O
KIR3DL1	B
/	O
HLA	B
-	I
Bw4	I
homozygosity	O
.	O

Absence	O
of	O
ligands	O
for	O
inhibitory	O
KIR	B
could	O
lower	O
the	O
threshold	O
for	O
NK	O
cell	O
activation	O
.	O

In	O
addition	O
,	O
exposed	O
seronegatives	O
more	O
frequently	O
possessed	O
AB	O
KIR	B
genotypes	O
,	O
which	O
contain	O
more	O
activating	O
KIR	B
.	O

The	O
data	O
support	O
an	O
important	O
role	O
for	O
NK	O
cells	O
and	O
KIR	B
/	O
HLA	B
interactions	O
in	O
antiviral	O
immunity	O
.	O

Predominance	O
of	O
the	O
group	O
A	O
killer	O
Ig	O
-	O
like	O
receptor	O
haplotypes	O
in	O
Korean	O
patients	O
with	O
T1D	O
.	O

Type	O
1	O
diabetes	O
(	O
T1D	O
)	O
is	O
a	O
T	O
cell	O
-	O
mediated	O
autoimmune	O
disease	O
in	O
which	O
pancreatic	O
beta	O
cells	O
are	O
selectively	O
destroyed	O
.	O

Although	O
autoimmune	O
diseases	O
are	O
driven	O
by	O
inappropriate	O
adaptive	O
immunity	O
,	O
innate	O
immunity	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
T1D	O
.	O

To	O
study	O
the	O
potential	O
involvement	O
of	O
innate	O
immunity	O
in	O
the	O
pathogenesis	O
of	O
autoimmune	O
disease	O
,	O
we	O
investigated	O
associations	O
of	O
the	O
genes	O
for	O
14	O
different	O
killer	O
Ig	O
-	O
like	O
receptors	O
(	O
KIRs	B
)	O
,	O
the	O
well	O
-	O
characterized	O
receptors	O
in	O
natural	O
killer	O
cells	O
,	O
with	O
Korean	O
T1D	O
patients	O
.	O

Genetic	O
association	O
analyses	O
revealed	O
that	O
some	O
of	O
the	O
KIR	B
genes	O
were	O
associated	O
with	O
T1D	O
.	O

KIR2DL5	B
and	O
2DS2	B
genes	O
were	O
present	O
at	O
significantly	O
low	O
frequency	O
in	O
Korean	O
T1D	O
patients	O
(	O
P	O
<	O
10	O
(	O
-4	O
)	O
)	O
.	O

We	O
did	O
not	O
detect	O
any	O
influence	O
of	O
ligand	O
distribution	O
on	O
KIR	B
association	O
.	O

With	O
the	O
haplotype	O
assignments	O
,	O
53	O
%	O
of	O
the	O
KIR	B
haplotypes	O
in	O
the	O
control	O
are	O
of	O
type	O
A	O
.	O

Compared	O
with	O
the	O
control	O
(	O
P	O
<	O
10	O
(	O
-3	O
)	O
)	O
and	O
autoantibody	O
-	O
negative	O
patients	O
(	O
P	O
<	O
10	O
(	O
-2	O
)	O
)	O
,	O
the	O
group	O
A	O
haplotype	O
predominates	O
in	O
Korean	O
patients	O
with	O
T1D	O
.	O

The	O
KIR	B
gene	O
is	O
associated	O
with	O
T1D	O
and	O
distribution	O
differences	O
between	O
T1D	O
and	O
controls	O
were	O
not	O
influenced	O
by	O
the	O
HLA	B
genes	I
(	I
DR	I
-	I
DQ	I
-	I
A	I
-	I
C	I
)	I
.	O

T1D	O
,	O
at	O
least	O
in	O
Koreans	O
,	O
is	O
associated	O
with	O
KIR	B
genes	O
,	O
especially	O
in	O
the	O
group	O
A	O
KIR	B
haplotypes	O
.	O

There	O
is	O
a	O
close	O
relationship	O
between	O
innate	O
and	O
adaptive	O
immunity	O
.	O

Proteomics	O
-	O
based	O
identification	O
of	O
biomarkers	O
for	O
predicting	O
sensitivity	O
to	O
a	O
PI3	B
-	I
kinase	I
inhibitor	O
in	O
cancer	O
.	O

To	O
identify	O
biomarkers	O
for	O
predicting	O
sensitivity	O
to	O
phosphatidylinositol	B
3-kinase	I
(	O
PI3	B
K	I
)	O
inhibitors	O
,	O
we	O
have	O
developed	O
a	O
proteomics	O
-	O
based	O
approach	O
.	O

Using	O
surface	O
-	O
enhanced	O
laser	O
desorption	O
-	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
SELDI	O
-	O
TOF	O
MS	O
)	O
,	O
we	O
measured	O
the	O
expression	O
of	O
393	O
proteins	O
in	O
39	O
human	O
cancer	O
cell	O
lines	O
(	O
JFCR	O
-	O
39	O
)	O
,	O
and	O
combined	O
it	O
with	O
our	O
previously	O
established	O
chemosensitivity	O
database	O
to	O
select	O
for	O
proteins	O
whose	O
expressions	O
show	O
significant	O
correlations	O
to	O
drug	O
sensitivities	O
.	O

This	O
integrated	O
approach	O
allowed	O
us	O
to	O
identify	O
peaks	O
from	O
two	O
proteins	O
,	O
11.6	O
and	O
11.8	O
kDa	O
,	O
that	O
showed	O
significant	O
correlations	O
with	O
the	O
sensitivity	O
to	O
a	O
PI3	B
K	I
inhibitor	O
,	O
LY294002	O
.	O

We	O
found	O
that	O
the	O
11.8	O
kDa	O
protein	O
was	O
a	O
phosphorylated	O
form	O
of	O
the	O
11.6	O
kDa	O
protein	O
.	O

While	O
the	O
11.8	O
kDa	O
protein	O
showed	O
a	O
positive	O
correlation	O
with	O
the	O
sensitivity	O
to	O
LY294002	O
,	O
the	O
11.6	O
kDa	O
protein	O
showed	O
a	O
negative	O
correlation	O
with	O
that	O
of	O
the	O
LY294002	O
.	O

The	O
11.6	O
kDa	O
protein	O
was	O
purified	O
chromatographically	O
,	O
and	O
was	O
identified	O
by	O
SELDI	O
-	O
TOF	O
MS	O
as	O
the	O
ribosomal	B
P2	I
protein	O
,	O
which	O
possesses	O
two	O
prospective	O
phosphorylation	O
sites	O
.	O

These	O
results	O
suggested	O
that	O
the	O
phosphorylation	O
status	O
of	O
the	O
ribosomal	B
P2	I
was	O
responsible	O
for	O
determining	O
the	O
sensitivity	O
to	O
LY294002	O
,	O
and	O
that	O
the	O
ribosomal	B
P2	I
could	O
be	O
a	O
potential	O
biomarker	O
for	O
predicting	O
chemosensitivity	O
.	O

Discovery	O
and	O
characterization	O
of	O
a	O
Ca2	B
+	I
-independent	I
phosphatidylethanolamine	I
N	I
-	I
acyltransferase	I
generating	O
the	O
anandamide	O
precursor	O
and	O
its	O
congeners	O
.	O

N	O
-	O
Acylphosphatidylethanolamines	O
(	O
NAPEs	O
)	O
are	O
precursors	O
of	O
bioactive	O
N	O
-	O
acylethanolamines	O
,	O
including	O
the	O
endocannabinoid	O
anandamide	O
.	O

In	O
animal	O
tissues	O
,	O
NAPE	O
is	O
formed	O
by	O
transfer	O
of	O
a	O
fatty	O
acyl	O
chain	O
at	O
the	O
sn	O
-	O
1	O
position	O
of	O
glycerophospholipids	O
to	O
the	O
amino	O
group	O
of	O
phosphatidylethanolamine	O
(	O
PE	O
)	O
,	O
and	O
this	O
reaction	O
is	O
believed	O
to	O
be	O
the	O
principal	O
rate	O
-	O
limiting	O
step	O
in	O
N	O
-	O
acylethanolamine	O
synthesis	O
.	O

However	O
,	O
the	O
Ca2	O
+	O
-	O
dependent	O
,	O
membrane	O
-	O
associated	O
N	B
-	I
acyltransferase	I
(	O
NAT	B
)	O
responsible	O
for	O
this	O
reaction	O
has	O
not	O
yet	O
been	O
cloned	O
.	O

In	O
this	O
study	O
,	O
on	O
the	O
basis	O
of	O
the	O
functional	O
similarity	O
of	O
NAT	B
to	O
lecithin	B
-	I
retinol	I
acyltransferase	I
(	O
LRAT	B
)	O
,	O
we	O
examined	O
a	O
possible	O
PE	O
N	O
-	O
acylation	O
activity	O
in	O
two	O
rat	O
LRAT	B
homologous	O
proteins	O
.	O

Upon	O
overexpression	O
in	O
COS-7	O
cells	O
,	O
one	O
protein	O
,	O
named	O
rat	O
LRAT	B
-	I
like	I
protein	I
(	I
RLP	I
)	I
-	I
1	I
,	O
catalyzed	O
transfer	O
of	O
a	O
radioactive	O
acyl	O
group	O
from	O
phosphatidylcholine	O
(	O
PC	O
)	O
to	O
PE	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
radioactive	O
NAPE	O
.	O

However	O
,	O
the	O
RLP-1	B
activity	O
was	O
detected	O
mainly	O
in	O
the	O
cytosolic	O
rather	O
than	O
membrane	O
fraction	O
and	O
was	O
little	O
stimulated	O
by	O
Ca2	O
+	O
.	O

Moreover	O
,	O
RLP-1	B
did	O
not	O
show	O
selectivity	O
with	O
respect	O
to	O
the	O
sn-1	O
and	O
sn	O
-	O
2	O
positions	O
of	O
PC	O
as	O
an	O
acyl	O
donor	O
and	O
therefore	O
could	O
generate	O
N	O
-	O
arachidonoyl	O
-	O
PE	O
(	O
anandamide	O
precursor	O
)	O
from	O
2	O
-	O
arachidonoyl	O
-	O
PC	O
and	O
PE	O
.	O

In	O
contrast	O
,	O
under	O
the	O
same	O
assay	O
conditions	O
,	O
partially	O
purified	O
NAT	O
from	O
rat	O
brain	O
was	O
highly	O
Ca2	O
+	O
-	O
dependent	O
,	O
membrane	O
-	O
associated	O
,	O
and	O
specific	O
for	O
the	O
sn	O
-	O
1	O
-	O
acyl	O
group	O
of	O
PC	O
.	O

RLP-1	B
mRNA	O
was	O
expressed	O
predominantly	O
in	O
testis	O
among	O
various	O
rat	O
tissues	O
,	O
and	O
the	O
testis	O
cytosol	O
exhibited	O
an	O
RLP	B
-	I
1	I
-	O
like	O
activity	O
.	O

These	O
results	O
reveal	O
that	O
RLP-1	B
can	O
function	O
as	O
a	O
PE	O
N	B
-	I
acyltransferase	I
,	O
catalytically	O
distinguishable	O
from	O
the	O
known	O
Ca2	O
+	O
-	O
dependent	O
NAT	B
.	O

Apple	O
chlorotic	O
leaf	O
spot	O
virus	O
50	B
kDa	I
movement	I
protein	I
acts	O
as	O
a	O
suppressor	O
of	O
systemic	O
silencing	O
without	O
interfering	O
with	O
local	O
silencing	O
in	O
Nicotiana	O
benthamiana	O
.	O

Apple	O
chlorotic	O
leaf	O
spot	O
virus	O
(	O
ACLSV	O
)	O
is	O
the	O
type	O
species	O
of	O
the	O
genus	O
Trichovirus	O
and	O
its	O
single	O
-	O
stranded	O
,	O
plus	O
-	O
sense	O
RNA	O
genome	O
encodes	O
a	O
216	B
kDa	I
protein	I
(	O
P216	B
)	O
involved	O
in	O
replication	O
,	O
a	O
50	B
kDa	I
movement	I
protein	I
(	O
P50	B
)	O
and	O
a	O
21	B
kDa	I
coat	I
protein	I
(	O
CP	B
)	O
.	O

In	O
this	O
study	O
,	O
it	O
was	O
investigated	O
whether	O
these	O
proteins	O
might	O
have	O
RNA	O
silencing	O
-	O
suppressor	O
activities	O
by	O
Agrobacterium	O
-	O
mediated	O
transient	O
assay	O
in	O
the	O
green	B
fluorescent	I
protein	I
-	O
expressing	O
Nicotiana	O
benthamiana	O
line	O
16c	O
.	O

The	O
results	O
indicated	O
that	O
none	O
of	O
these	O
proteins	O
could	O
suppress	O
local	O
silencing	O
in	O
infiltrated	O
leaves	O
.	O

However	O
,	O
systemic	O
silencing	O
in	O
upper	O
leaves	O
induced	O
by	O
both	O
single	O
-	O
and	O
double	O
-	O
stranded	O
RNA	O
could	O
be	O
suppressed	O
by	O
P50	B
,	O
but	O
not	O
by	O
a	O
frame	O
-	O
shift	O
mutant	O
of	O
P50	B
,	O
P216	B
or	O
CP	B
.	O

Moreover	O
,	O
when	O
P50	B
was	O
expressed	O
separately	O
from	O
where	O
silencing	O
signals	O
were	O
generated	O
in	O
a	O
leaf	O
,	O
systemic	O
silencing	O
in	O
upper	O
leaves	O
was	O
inhibited	O
.	O

Collectively	O
,	O
our	O
data	O
indicate	O
that	O
P50	B
acts	O
as	O
a	O
suppressor	O
of	O
systemic	O
silencing	O
without	O
interfering	O
with	O
local	O
silencing	O
,	O
probably	O
by	O
inhibiting	O
the	O
movement	O
of	O
silencing	O
signals	O
.	O

Proteomic	O
comparison	O
of	O
Mycobacterium	O
avium	O
subspecies	O
paratuberculosis	O
grown	O
in	O
vitro	O
and	O
isolated	O
from	O
clinical	O
cases	O
of	O
ovine	O
paratuberculosis	O
.	O

Paratuberculosis	O
(	O
Johne	O
's	O
disease	O
)	O
poses	O
a	O
significant	O
economic	O
problem	O
to	O
beef	O
,	O
dairy	O
and	O
sheep	O
industries	O
worldwide	O
,	O
and	O
is	O
caused	O
by	O
Mycobacterium	O
avium	O
subspecies	O
paratuberculosis	O
.	O

In	O
this	O
study	O
,	O
2D	O
PAGE	O
was	O
used	O
as	O
a	O
tool	O
to	O
investigate	O
the	O
virulent	O
state	O
of	O
M.	O
avium	O
subsp	O
.	O
paratuberculosis	O
,	O
incorporating	O
the	O
technique	O
of	O
beating	O
the	O
organism	O
with	O
zirconium	O
/	O
silica	O
beads	O
to	O
provide	O
a	O
comprehensive	O
representation	O
of	O
its	O
proteome	O
.	O

A	O
direct	O
comparison	O
of	O
the	O
proteomes	O
of	O
M.	O
avium	O
subsp	O
.	O
paratuberculosis	O
scraped	O
from	O
the	O
terminal	O
ileum	O
of	O
ovine	O
paratuberculosis	O
cases	O
,	O
and	O
the	O
identical	O
strain	O
grown	O
in	O
vitro	O
,	O
is	O
presented	O
.	O

These	O
analyses	O
identified	O
a	O
set	O
of	O
10	O
proteins	O
whose	O
expression	O
is	O
upregulated	O
during	O
natural	O
infection	O
:	O
1-pyrroline-5-carboxylate	B
dehydrogenase	I
(	O
RocA	B
)	O
,	O
a	O
putative	O
acyl	B
-	I
CoA	I
dehydrogenase	I
(	O
FadE14	B
)	O
,	O
2-methylcitrate	B
dehydratase	I
(	B
2-mcd	I
)	O
,	O
arginosuccinate	B
synthase	I
(	O
ArgG	B
)	O
,	O
universal	B
stress	I
protein	I
(	O
usp	B
)	O
,	O
30S	B
ribosomal	I
protein	I
S2	I
(	O
RpsB	B
)	O
,	O
peptidyl	B
-	I
prolyl	I
cis	I
-	I
trans	I
isomerase	I
(	O
PpiA	B
)	O
,	O
luciferase	B
-	I
like	I
monooxygenase	I
(	O
(	B
lmo	I
)	I
)	O
,	O
thiosulfate	B
sulfurtransferase	I
(	O
SseA	B
)	O
and	O
ATP	O
-	O
dependent	O
Clp	B
protease	I
(	O
ClpB	B
)	O
.	O

Most	O
of	O
the	O
proteins	O
identified	O
do	O
not	O
have	O
obviously	O
related	O
functions	O
;	O
however	O
,	O
ArgG	B
and	O
RocA	B
function	O
in	O
the	O
same	O
pathway	O
,	O
and	O
may	O
have	O
a	O
concerted	O
action	O
for	O
energy	O
production	O
in	O
vivo	O
.	O

Sex	O
-	O
specific	O
,	O
independent	O
associations	O
of	O
insulin	B
resistance	O
with	O
erythrocyte	O
sedimentation	O
rate	O
in	O
apparently	O
healthy	O
subjects	O
.	O

Insulin	B
resistance	O
and	O
erythrocyte	O
sedimentation	O
rate	O
(	O
ESR	O
,	O
a	O
non	O
-	O
specific	O
marker	O
of	O
inflammation	O
)	O
are	O
known	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
.	O

Although	O
obesity	O
is	O
associated	O
with	O
increased	O
ESR	O
,	O
it	O
is	O
unclear	O
whether	O
insulin	B
resistance	O
is	O
associated	O
with	O
ESR	O
in	O
humans	O
.	O

The	O
relationship	O
between	O
insulin	B
resistance	O
and	O
ESR	O
was	O
studied	O
in	O
a	O
cross	O
-	O
sectional	O
,	O
health	O
-	O
area	O
based	O
study	O
of	O
140	O
(	O
89	O
men	O
and	O
51	O
women	O
)	O
apparently	O
healthy	O
Caucasians	O
subjects	O
.	O

ESR	O
,	O
additional	O
inflammatory	O
markers	O
[	O
soluble	O
tumor	B
necrosis	I
alpha	I
receptors	I
1	I
and	I
2	I
(	O
sTNFR1	B
and	O
sTNFR2	B
)	O
;	O
C	B
-	I
reactive	I
protein	I
(	O
CRP	B
)	O
]	O
,	O
and	O
insulin	B
sensitivity	O
(	O
SI	O
,	O
frequently	O
sampled	O
intravenous	O
glucose	O
tolerance	O
test	O
with	O
minimal	O
model	O
analysis	O
)	O
were	O
assessed	O
in	O
all	O
subjects	O
.	O

An	O
interaction	O
with	O
sex	O
was	O
documented	O
in	O
the	O
relationship	O
between	O
ESR	O
and	O
both	O
insulin	B
resistance	O
and	O
obesity	O
(	O
p	O
<	O
0.05	O
)	O
,	O
as	O
log	O
ESR	O
correlated	O
with	O
log	O
SI	O
in	O
men	O
(	O
r	O
=	O
-	O
0.29	O
,	O
p	O
=	O
0.009	O
)	O
,	O
but	O
not	O
in	O
women	O
(	O
r	O
=	O
-	O
0.14	O
,	O
p	O
=	O
0.33	O
)	O
,	O
and	O
correlated	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
in	O
women	O
(	O
r	O
=	O
0.49	O
,	O
p	O
=	O
<	O
0.0001	O
)	O
,	O
but	O
not	O
in	O
men	O
(	O
r	O
=	O
0.15	O
,	O
p	O
=	O
0.16	O
)	O
.	O

On	O
multivariate	O
analyses	O
,	O
these	O
associations	O
proved	O
to	O
be	O
independent	O
of	O
known	O
covariates	O
,	O
such	O
as	O
age	O
,	O
hematocrit	O
,	O
smoking	O
and	O
additional	O
inflammatory	O
markers	O
in	O
both	O
men	O
and	O
women	O
.	O

In	O
a	O
replication	O
study	O
,	O
variables	O
independently	O
associated	O
with	O
ESR	O
were	O
also	O
insulin	B
resistance	O
(	O
homeostasis	O
model	O
assessment	O
)	O
in	O
men	O
and	O
obesity	O
markers	O
(	O
either	O
BMI	O
or	O
fat	O
mass	O
)	O
in	O
women	O
.	O

In	O
conclusion	O
,	O
ESR	O
is	O
independently	O
associated	O
with	O
either	O
insulin	B
resistance	O
or	O
obesity	O
in	O
a	O
sex	O
-	O
specific	O
manner	O
.	O

These	O
findings	O
contribute	O
to	O
explain	O
the	O
known	O
relationship	O
of	O
this	O
inflammatory	O
marker	O
with	O
cardiovascular	O
disease	O
.	O

Establishment	O
and	O
characterization	O
of	O
porcine	O
Sertoli	O
cell	O
line	O
for	O
the	O
study	O
of	O
xenotransplantation	O
.	O

BACKGROUND	O
:	O

An	O
understanding	O
of	O
the	O
main	O
mechanism	O
that	O
determines	O
the	O
ability	O
of	O
immune	O
privilege	O
related	O
to	O
Sertoli	O
cells	O
(	O
SC	O
)	O
will	O
provide	O
clues	O
for	O
promoting	O
a	O
local	O
tolerogenic	O
environment	O
.	O

In	O
this	O
report	O
,	O
we	O
established	O
neonatal	O
porcine	O
SC	O
line	O
and	O
evaluated	O
their	O
characteristics	O
.	O

METHODS	O
:	O

SC	O
line	O
was	O
established	O
following	O
the	O
transfection	O
of	O
primary	O
SC	O
(	O
NPSC	O
)	O
from	O
the	O
testis	O
of	O
neonatal	O
pig	O
with	O
plasmid	O
pRNS-1	O
carrying	O
genes	O
for	O
neomycin	O
resistance	O
and	O
the	O
SV40	O
large	B
T	I
antigen	I
.	O

Immunohistochemistry	O
and	O
RT	O
-	O
PCR	O
were	O
performed	O
to	O
evaluate	O
the	O
character	O
of	O
immortalized	O
SC	O
lines	O
.	O

RESULTS	O
:	O

Our	O
immortalized	O
SC	O
line	O
(	O
iPS	O
)	O
proliferated	O
stably	O
and	O
had	O
a	O
phenotype	O
similar	O
to	O
NPSC	O
,	O
as	O
indicated	O
by	O
the	O
immunoexpression	O
of	O
follicle	B
stimulating	I
hormone	I
receptor	I
(	O
FSHR	B
)	O
,	O
and	O
mRNA	O
expression	O
of	O
androgen	B
receptor	I
(	O
AR	B
)	O
,	O
and	O
Wilms	B
'	I
tumor	I
antigen	I
(	O
WT1	B
)	O
.	O

Interestingly	O
,	O
NPSC	O
and	O
iPS	O
expressed	O
mRNA	O
of	O
complement	O
regulatory	O
proteins	O
(	O
CRP	O
)	O
such	O
as	O
membrane	B
cofactor	I
protein	I
(	O
CD46	B
)	O
,	O
decay	B
accelerating	I
factor	I
(	O
DAF	B
or	O
CD55	B
)	O
,	O
and	O
protectin	B
(	O
CD59	B
)	O
,	O
but	O
CD59	B
mRNA	O
expression	O
was	O
negligible	O
in	O
iPS	O
.	O

CONCLUSION	O
:	O

These	O
results	O
suggest	O
that	O
iPS	O
,	O
immortalized	O
by	O
the	O
introduction	O
of	O
SV40	O
T	O
,	O
retain	O
their	O
original	O
characteristics	O
,	O
except	O
for	O
the	O
relatively	O
low	O
expression	O
of	O
CD59	B
,	O
and	O
that	O
they	O
may	O
be	O
useful	O
for	O
future	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
of	O
immune	O
privilege	O
mechanisms	O
related	O
to	O
SC	O
.	O

The	O
origin	O
of	O
mammalian	O
plasma	O
amine	B
oxidases	I
.	O

Mammalian	O
blood	O
plasma	O
contains	O
considerable	O
activity	O
of	O
soluble	O
copper	B
-	I
containing	I
amine	I
oxidase	I
(	O
AOC	B
)	O
referred	O
to	O
as	O
plasma	O
or	O
serum	O
amine	B
oxidase	I
(	O
SAO	O
)	O
.	O

The	O
identity	O
and	O
origin	O
of	O
SAO	O
was	O
investigated	O
based	O
on	O
the	O
recent	O
characterization	O
of	O
four	O
porcine	O
AOC	B
genes	O
with	O
AOC1	B
encoding	O
diamine	B
oxidase	I
(	O
DAO	B
)	O
,	O
AOC2	B
retina	B
-	I
specific	I
amine	I
oxidase	I
(	O
RAO	B
)	O
,	O
AOC3	B
vascular	B
adhesion	I
protein-1	I
(	O
VAP-1	B
)	O
,	O
and	O
AOC4	B
a	O
VAP-1	B
homologue	O
that	O
is	O
expressed	O
mainly	O
in	O
the	O
liver	O
and	O
has	O
a	O
signal	O
peptide	O
sequence	O
instead	O
of	O
a	O
transmembrane	O
domain	O
at	O
its	O
N	O
-	O
terminus	O
.	O

Purification	O
and	O
characterization	O
of	O
the	O
major	O
amine	B
oxidase	I
activity	O
from	O
porcine	O
serum	O
showed	O
that	O
it	O
is	O
the	O
product	O
of	O
the	O
AOC4	B
gene	O
.	O

Intriguingly	O
,	O
all	O
mammals	O
possessing	O
a	O
functional	O
AOC4	B
gene	O
exhibit	O
high	O
plasma	O
amine	B
oxidase	I
activity	O
.	O

Humans	O
and	O
rodents	O
lack	O
a	O
functional	O
AOC4	B
gene	O
and	O
have	O
comparably	O
low	O
plasma	O
amine	B
oxidase	I
activity	O
that	O
is	O
probably	O
derived	O
from	O
partial	O
proteolytic	O
release	O
of	O
the	O
membrane	O
-	O
associated	O
AOC3	B
gene	O
product	O
VAP-1	B
.	O

Apyrases	B
(	O
nucleoside	B
triphosphate	I
-	I
diphosphohydrolases	I
)	O
play	O
a	O
key	O
role	O
in	O
growth	O
control	O
in	O
Arabidopsis	O
.	O

Expression	O
of	O
two	O
Arabidopsis	O
(	O
Arabidopsis	O
thaliana	O
)	O
apyrase	B
(	O
nucleoside	B
triphosphate	I
-	I
diphosphohydrolase	I
)	O
genes	O
with	O
high	O
similarity	O
,	O
APY1	B
and	O
APY2	B
,	O
was	O
analyzed	O
during	O
seedling	O
development	O
and	O
under	O
different	O
light	O
treatments	O
using	O
beta	B
-	I
glucuronidase	I
fusion	O
constructs	O
with	O
the	O
promoters	O
of	O
both	O
genes	O
.	O

As	O
evaluated	O
by	O
beta	B
-	I
glucuronidase	I
staining	O
and	O
independently	O
confirmed	O
by	O
other	O
methods	O
,	O
the	O
highest	O
expression	O
of	O
both	O
apyrases	B
was	O
in	O
rapidly	O
growing	O
tissues	O
and/or	O
tissues	O
that	O
accumulate	O
high	O
auxin	O
levels	O
.	O

Red	O
-	O
light	O
treatment	O
of	O
etiolated	O
seedlings	O
suppressed	O
the	O
protein	O
and	O
message	O
level	O
of	O
both	O
apyrases	O
at	O
least	O
as	O
rapidly	O
as	O
it	O
inhibited	O
hypocotyl	O
growth	O
.	O

Adult	O
apy1	B
and	O
apy2	B
single	O
mutants	O
had	O
near	O
-	O
normal	O
growth	O
,	O
but	O
apy1apy2	B
double	O
-	O
knockout	O
plants	O
were	O
dwarf	O
,	O
due	O
primarily	O
to	O
reduced	O
cell	O
elongation	O
.	O

Pollen	O
tubes	O
and	O
etiolated	O
hypocotyls	O
overexpressing	O
an	O
apyrase	B
had	O
faster	O
growth	O
rates	O
than	O
wild	O
-	O
type	O
plants	O
.	O

Growing	O
pollen	O
tubes	O
released	O
ATP	O
into	O
the	O
growth	O
medium	O
and	O
suppression	O
of	O
apyrase	B
activity	O
by	O
antiapyrase	O
antibodies	O
or	O
by	O
inhibitors	O
simultaneously	O
increased	O
medium	O
ATP	O
levels	O
and	O
inhibited	O
pollen	O
tube	O
growth	O
.	O

These	O
results	O
imply	O
that	O
APY1	B
and	O
APY2	B
,	O
like	O
their	O
homologs	O
in	O
animals	O
,	O
act	O
to	O
reduce	O
the	O
concentration	O
of	O
extracellular	O
nucleotides	O
,	O
and	O
that	O
this	O
function	O
is	O
important	O
for	O
the	O
regulation	O
of	O
growth	O
in	O
Arabidopsis	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
human	O
Mov34	B
MPN	O
domain	O
reveals	O
a	O
metal	O
-	O
free	O
dimer	O
.	O

The	O
26S	O
proteasome	O
is	O
a	O
large	O
protein	O
complex	O
involved	O
in	O
protein	O
degradation	O
.	O

We	O
have	O
shown	O
previously	O
that	O
the	O
PSMD7	B
/	O
Mov34	B
subunit	O
of	O
the	O
human	O
proteasome	O
contains	O
a	O
proteolytically	O
resistant	O
MPN	O
domain	O
.	O

MPN	O
domain	O
family	O
members	O
comprise	O
subunits	O
of	O
the	O
proteasome	O
,	O
COP9	B
-	O
signalosome	O
and	O
translation	B
initiation	I
factor	I
3	I
complexes	I
.	O

Here	O
,	O
the	O
crystal	O
structure	O
of	O
two	O
C	O
-	O
terminally	O
truncated	O
proteins	O
,	O
MPN	O
1	O
-	O
186	O
and	O
MPN	O
1	O
-	O
177	O
,	O
were	O
solved	O
to	O
1.96	O
and	O
3.0	O
A	O
resolution	O
,	O
respectively	O
.	O

MPN	O
1	O
-	O
186	O
is	O
formed	O
by	O
nine	O
beta	O
-	O
strands	O
surrounded	O
by	O
three	O
alpha	O
-	O
helices	O
plus	O
a	O
fourth	O
alpha	O
-	O
helix	O
at	O
the	O
C	O
terminus	O
.	O

This	O
final	O
alpha	O
-	O
helix	O
emerges	O
from	O
the	O
domain	O
core	O
and	O
folds	O
along	O
with	O
a	O
symmetrically	O
related	O
subunit	O
,	O
typical	O
of	O
a	O
domain	O
swap	O
.	O

The	O
crystallographic	O
dimer	O
is	O
consistent	O
with	O
size	O
-	O
exclusion	O
chromatography	O
and	O
DLS	O
analysis	O
showing	O
that	O
MPN	O
1	O
-	O
186	O
is	O
a	O
dimer	O
in	O
solution	O
.	O

MPN	O
1	O
-	O
186	O
shows	O
an	O
overall	O
architecture	O
highly	O
similar	O
to	O
the	O
previously	O
reported	O
crystal	O
structure	O
of	O
the	O
Archaeal	O
MPN	O
domain	O
AfJAMM	B
of	O
Archaeoglobus	O
fulgidus	O
.	O

However	O
,	O
previous	O
structural	O
and	O
biophysical	O
analyses	O
have	O
shown	O
that	O
neither	O
MPN	O
1	O
-	O
186	O
nor	O
full	O
-	O
length	O
human	O
Mov34	B
bind	O
metal	O
,	O
in	O
opposition	O
to	O
the	O
zinc	O
-	O
binding	O
AfJAMM	B
structures	O
.	O

The	O
zinc	O
ligand	O
residues	O
observed	O
in	O
AfJAMM	B
are	O
conserved	O
in	O
the	O
yeast	O
Rpn11	B
proteasome	O
and	O
Csn5	B
COP	B
-	O
signalosome	O
subunits	O
,	O
which	O
is	O
consistent	O
with	O
the	O
isopeptidase	B
activity	O
described	O
for	O
these	O
proteins	O
.	O

The	O
results	O
presented	O
here	O
show	O
that	O
,	O
although	O
the	O
MPN	O
domain	O
of	O
Mov34	B
shows	O
a	O
typical	O
metalloprotease	B
fold	O
,	O
it	O
is	O
unable	O
to	O
coordinate	O
a	O
metal	O
ion	O
.	O

This	O
finding	O
and	O
amino	O
acid	O
sequence	O
comparisons	O
can	O
explain	O
why	O
the	O
MPN	O
-	O
containing	O
proteins	O
Mov34	B
/	O
PSMD7	B
,	O
RPN8	B
,	O
Csn6	B
,	O
Prp8p	B
and	O
the	O
translation	B
initiation	I
factor	I
3	I
subunits	I
f	I
and	I
h	I
do	O
not	O
show	O
catalytic	O
isopeptidase	B
activity	O
,	O
allowing	O
us	O
to	O
propose	O
the	O
hypothesis	O
that	O
in	O
these	O
proteins	O
the	O
MPN	O
domain	O
has	O
a	O
primarily	O
structural	O
function	O
.	O

Genotype	O
-	O
phenotype	O
analysis	O
in	O
patients	O
with	O
giant	O
axonal	O
neuropathy	O
(	O
GAN	O
)	O
.	O

Giant	O
axonal	O
neuropathy	O
(	O
GAN	O
,	O
MIM	O
:	O
256850	O
)	O
is	O
a	O
devastating	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
an	O
early	O
onset	O
severe	O
peripheral	O
neuropathy	O
,	O
varying	O
central	O
nervous	O
system	O
involvement	O
and	O
strikingly	O
frizzly	O
hair	O
.	O

Giant	O
axonal	O
neuropathy	O
is	O
usually	O
caused	O
by	O
mutations	O
in	O
the	O
gigaxonin	B
gene	O
(	O
GAN	B
)	O
but	O
genetic	O
heterogeneity	O
has	O
been	O
demonstrated	O
for	O
a	O
milder	O
variant	O
of	O
this	O
disease	O
.	O

Here	O
,	O
we	O
report	O
ten	O
patients	O
referred	O
to	O
us	O
for	O
molecular	O
genetic	O
diagnosis	O
.	O

All	O
patients	O
had	O
typical	O
clinical	O
signs	O
suggestive	O
of	O
giant	O
axonal	O
neuropathy	O
.	O

In	O
seven	O
affected	O
individuals	O
,	O
we	O
found	O
disease	O
causing	O
mutations	O
in	O
the	O
gigaxonin	B
gene	O
affecting	O
both	O
alleles	O
:	O
two	O
splice	O
-	O
site	O
and	O
four	O
missense	O
mutations	O
,	O
not	O
reported	O
previously	O
.	O

Gigaxonin	B
binds	O
N	O
-	O
terminally	O
to	O
ubiquitin	B
activating	I
enzyme	I
E1	I
and	O
C	O
-	O
terminally	O
to	O
various	O
microtubule	O
associated	O
proteins	O
causing	O
their	O
ubiquitin	B
mediated	O
degradation	O
.	O

It	O
was	O
shown	O
for	O
a	O
number	O
of	O
gigaxonin	B
mutations	O
that	O
they	O
impede	O
this	O
process	O
leading	O
to	O
accumulation	O
of	O
microtubule	O
associated	O
proteins	O
and	O
there	O
by	O
impairing	O
cellular	O
functions	O
.	O

Vibrio	O
vulnificus	O
IlpA	O
-	O
induced	O
cytokine	B
production	O
is	O
mediated	O
by	O
Toll	B
-	I
like	I
receptor	I
2	I
.	O

Vibrio	O
vulnificus	O
is	O
a	O
pathogenic	O
bacterium	O
causing	O
primary	O
septicemia	O
,	O
which	O
follows	O
a	O
classical	O
septic	O
shock	O
pathway	O
,	O
including	O
an	O
overwhelming	O
inflammatory	O
cytokine	B
response	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
a	O
putative	O
lipoprotein	O
of	O
V.	O
vulnificus	O
,	O
encoded	O
by	O
the	O
ilpA	B
gene	O
,	O
as	O
one	O
of	O
the	O
surface	O
proteins	O
that	O
specifically	O
reacted	O
with	O
the	O
antibodies	O
raised	O
against	O
outer	O
membrane	O
proteins	O
of	O
V.	O
vulnificus	O
.	O

Using	O
a	O
mutant	O
V.	O
vulnificus	O
in	O
which	O
its	O
ilpA	B
gene	O
was	O
knocked	O
out	O
,	O
we	O
found	O
that	O
IlpA	B
is	O
important	O
in	O
the	O
production	O
of	O
interferon	B
-	I
gamma	I
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Production	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
and	O
interleukin-6	B
is	O
also	O
induced	O
by	O
the	O
recombinant	O
IlpA	B
(	O
rIlpA	B
)	O
in	O
human	O
monocytes	O
.	O

Lipidation	O
of	O
the	O
rIlpA	B
was	O
observed	O
by	O
in	O
vivo	O
labeling	O
in	O
Escherichia	O
coli	O
.	O

Experiments	O
using	O
the	O
mutant	O
IlpA	B
,	O
which	O
is	O
unable	O
to	O
be	O
modified	O
by	O
lipidation	O
,	O
indicate	O
that	O
the	O
lipid	O
moiety	O
of	O
this	O
protein	O
has	O
an	O
essential	O
property	O
for	O
cytokine	B
production	O
in	O
human	O
cells	O
.	O

Pretreatment	O
of	O
monocytes	O
with	O
antibodies	O
against	O
Toll	B
-	I
like	I
receptor	I
2	I
(	O
TLR2	B
)	O
inhibited	O
production	O
of	O
both	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
and	O
interleukin-6	B
.	O

The	O
role	O
of	O
TLR2	B
in	O
IlpA	B
-	O
induced	O
cytokine	B
production	O
was	O
confirmed	O
by	O
an	O
in	O
vitro	O
assay	O
,	O
in	O
which	O
only	O
the	O
TLR2	B
-	O
expressing	O
cells	O
showed	O
a	O
dramatic	O
induction	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
activity	O
by	O
rIlpA	B
.	O

In	O
addition	O
,	O
rIlpA	B
treatment	O
resulted	O
in	O
induction	O
of	O
TLR2	B
transcription	O
in	O
human	O
cells	O
.	O

In	O
comparison	O
with	O
the	O
wild	O
type	O
V.	O
vulnificus	O
,	O
the	O
ilpA	B
mutant	O
showed	O
a	O
reduced	O
mortality	O
in	O
mice	O
.	O

These	O
results	O
demonstrate	O
that	O
IlpA	B
of	O
V.	O
vulnificus	O
functions	O
as	O
an	O
immunostimulant	O
to	O
human	O
cells	O
via	O
TLR2	B
.	O

SLC1	B
and	O
SLC4	B
encode	O
partially	O
redundant	O
acyl	O
-	O
coenzyme	O
A	O
1-acylglycerol-3-phosphate	B
O	I
-	I
acyltransferases	I
of	O
budding	O
yeast	O
.	O

Phosphatidic	O
acid	O
is	O
the	O
intermediate	O
,	O
from	O
which	O
all	O
glycerophospholipids	O
are	O
synthesized	O
.	O

In	O
yeast	O
,	O
it	O
is	O
generated	O
from	O
lysophosphatidic	O
acid	O
,	O
which	O
is	O
acylated	O
by	O
Slc1p	B
,	O
an	O
sn-2-specific	O
,	O
acyl	O
-	O
coenzyme	O
A	O
-	O
dependent	O
1-acylglycerol-3-phosphate	B
O	I
-	I
acyltransferase	I
.	O

Deletion	O
of	O
SLC1	B
is	O
not	O
lethal	O
and	O
does	O
not	O
eliminate	O
all	O
microsomal	O
1-acylglycerol-3-phosphate	B
O	I
-	I
acyltransferase	I
activity	O
,	O
suggesting	O
that	O
an	O
additional	O
enzyme	O
may	O
exist	O
.	O

Here	O
we	O
show	O
that	O
SLC4	B
(	O
Yor175c	B
)	O
,	O
a	O
gene	O
of	O
hitherto	O
unknown	O
function	O
,	O
encodes	O
a	O
second	O
1-acyl	B
-	I
sn	I
-	I
glycerol-3-phosphate	I
acyltransferase	I
.	O

SLC4	B
harbors	O
a	O
membrane	O
-	O
bound	O
O	B
-	I
acyltransferase	I
motif	O
and	O
down	O
-	O
regulation	O
of	O
SLC4	B
strongly	O
reduces	O
1-acyl	B
-	I
sn	I
-	I
glycerol-3-phosphate	I
acyltransferase	I
activity	O
in	O
microsomes	O
from	O
slc1Delta	O
cells	O
.	O

The	O
simultaneous	O
deletion	O
of	O
SLC1	B
and	O
SLC4	B
is	O
lethal	O
.	O

Mass	O
spectrometric	O
analysis	O
of	O
lipids	O
from	O
slc1Delta	O
and	O
slc4Delta	O
cells	O
demonstrates	O
that	O
in	O
vivo	O
Slc1p	B
and	O
Slc4p	B
generate	O
almost	O
the	O
same	O
glycerophospholipid	O
profile	O
.	O

Microsomes	O
from	O
slc1Delta	O
and	O
slc4Delta	O
cells	O
incubated	O
with	O
[	O
14C	O
]	O
oleoyl	O
-	O
coenzyme	O
A	O
in	O
the	O
absence	O
of	O
lysophosphatidic	O
acid	O
and	O
without	O
CTP	O
still	O
incorporate	O
the	O
label	O
into	O
glycerophospholipids	O
,	O
indicating	O
that	O
Slc1p	B
and	O
Slc4p	B
can	O
also	O
use	O
endogenous	O
lysoglycerophospholipids	O
as	O
substrates	O
.	O

However	O
,	O
the	O
lipid	O
profiles	O
generated	O
by	O
microsomes	O
from	O
slc1Delta	O
and	O
slc4Delta	O
cells	O
are	O
different	O
,	O
and	O
this	O
suggests	O
that	O
Slc1p	B
and	O
Slc4p	B
have	O
a	O
different	O
substrate	O
specificity	O
or	O
have	O
access	O
to	O
different	O
lyso	O
-	O
glycerophospholipid	O
substrates	O
because	O
of	O
a	O
different	O
subcellular	O
location	O
.	O

Indeed	O
,	O
affinity	O
-	O
purified	O
Slc1p	B
displays	O
Mg2	O
+	O
-	O
dependent	O
acyltransferase	B
activity	O
not	O
only	O
toward	O
lysophosphatidic	O
acid	O
but	O
also	O
lyso	O
forms	O
of	O
phosphatidylserine	O
and	O
phosphatidylinositol	O
.	O

Thus	O
,	O
Slc1p	B
and	O
Slc4p	B
may	O
not	O
only	O
be	O
active	O
as	O
1-acylglycerol-3-phosphate	B
O	I
-	I
acyltransferases	I
but	O
also	O
be	O
involved	O
in	O
fatty	O
acid	O
exchange	O
at	O
the	O
sn-2-position	O
of	O
mature	O
glycerophospholipids	O
.	O

Use	O
of	O
the	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
method	O
for	O
mutational	O
screening	O
of	O
patients	O
with	O
familial	O
hypercholesterolaemia	O
(	O
FH	O
)	O
and	O
Familial	O
defective	O
apolipoprotein	B
B100	I
(	O
FDB	O
)	O
.	O

Familial	O
hypercholesterolaemia	O
(	O
FH	O
)	O
and	O
Familial	O
defective	O
apolipoprotein	B
B100	I
(	O
FDB	O
)	O
are	O
autosomal	O
dominant	O
inherited	O
diseases	O
of	O
lipid	O
metabolism	O
caused	O
by	O
mutations	O
in	O
the	O
low	B
density	I
lipoprotein	I
(	I
LDL	I
)	I
receptor	I
and	O
apolipoprotein	B
B	I
100	I
genes	O
.	O

FH	O
is	O
clinically	O
characterised	O
by	O
elevated	O
concentrations	O
of	O
total	O
cholesterol	O
(	O
TC	O
)	O
and	O
low	B
density	I
lipoprotein	I
cholesterol	O
(	O
LDL	B
-	O
C	O
)	O
,	O
presence	O
of	O
xanthomata	O
and	O
premature	O
atherosclerosis	O
.	O

Both	O
conditions	O
are	O
associated	O
with	O
coronary	O
artery	O
disease	O
but	O
may	O
be	O
clinically	O
indistinguishable	O
.	O

Seventy	O
-	O
two	O
(	O
72	O
)	O
FH	O
patients	O
were	O
diagnosed	O
based	O
on	O
the	O
Simon	O
Broome	O
's	O
criteria	O
.	O

Mutational	O
screening	O
was	O
performed	O
by	O
polymerase	B
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
.	O

Positive	O
mutations	O
were	O
subjected	O
to	O
DNA	O
sequencing	O
for	O
confirmation	O
of	O
the	O
mutation	O
.	O

We	O
successfully	O
amplified	O
all	O
exons	O
in	O
the	O
LDL	B
receptor	I
and	O
apo	B
B100	I
genes	O
.	O

DGGE	O
was	O
performed	O
in	O
all	O
exons	O
of	O
the	O
LDL	B
receptor	I
(	O
except	O
for	O
exons	O
4	O
-	O
3	O
'	O
,	O
18	O
and	O
promoter	O
region	O
)	O
and	O
apo	B
B100	I
genes	O
.	O

We	O
have	O
identified	O
four	O
different	O
mutations	O
in	O
the	O
LDL	B
receptor	I
gene	O
but	O
no	O
mutation	O
was	O
detected	O
in	O
the	O
apo	B
B	I
100	I
gene	O
.	O

The	O
apo	B
B100	I
gene	O
mutation	O
was	O
not	O
detected	O
on	O
DGGE	O
screening	O
as	O
sequencing	O
was	O
not	O
performed	O
for	O
negative	O
cases	O
on	O
DGGE	O
technique	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
C234S	O
mutation	O
(	O
exon	O
5	O
)	O
is	O
a	O
novel	O
mutation	O
worldwide	O
.	O

The	O
D69N	O
mutation	O
(	O
exon	O
3	O
)	O
has	O
been	O
reported	O
locally	O
while	O
the	O
R385W	O
(	O
exon	O
9	O
)	O
and	O
R716	O
G	O
(	O
exon	O
15	O
)	O
mutations	O
have	O
not	O
been	O
reported	O
locally	O
.	O

However	O
,	O
only	O
4	O
mutations	O
have	O
been	O
identified	O
among	O
14	O
/	O
72	O
patients	O
(	O
19.4	O
%	O
)	O
in	O
39	O
FH	O
families	O
.	O

Specificity	O
(	O
1	O
-	O
false	O
positive	O
)	O
of	O
this	O
technique	O
was	O
44.7	O
%	O
based	O
on	O
the	O
fact	O
that	O
42	O
/	O
76	O
(	O
55.3	O
%	O
)	O
samples	O
with	O
band	O
shifts	O
showed	O
normal	O
DNA	O
sequencing	O
results	O
.	O

A	O
more	O
sensitive	O
method	O
needs	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
in	O
order	O
to	O
fully	O
characterise	O
the	O
LDLR	B
and	O
apo	B
B100	I
genes	O
such	O
as	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
developed	O
the	O
DNA	O
analysis	O
for	O
FH	O
patients	O
using	O
PCR	O
-	O
DGGE	O
technique	O
.	O

DNA	O
analysis	O
plays	O
an	O
important	O
role	O
to	O
characterise	O
the	O
type	O
of	O
mutations	O
and	O
forms	O
an	O
adjunct	O
to	O
clinical	O
diagnosis	O
.	O

Microalbuminuria	O
is	O
a	O
negative	O
correlate	O
for	O
cognitive	O
function	O
in	O
older	O
adults	O
with	O
peripheral	O
arterial	O
disease	O
:	O
results	O
from	O
the	O
U.S.	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
1999	O
-	O
2002	O
.	O

OBJECTIVES	O
:	O

Microalbuminuria	O
(	O
MA	O
)	O
has	O
been	O
increasingly	O
identified	O
as	O
a	O
marker	O
of	O
cardiovascular	O
risk	O
.	O

Although	O
poor	O
cognitive	O
function	O
has	O
been	O
implicated	O
as	O
a	O
sequelae	O
of	O
increased	O
cardiovascular	O
burden	O
,	O
little	O
is	O
known	O
about	O
the	O
association	O
between	O
MA	O
and	O
cognitive	O
function	O
.	O

DESIGN	O
:	O

Population	O
-	O
based	O
cross	O
-	O
sectional	O
study	O
.	O

SETTINGS	O
:	O

National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
1999	O
-	O
2002	O
in	O
the	O
USA	O
.	O

SUBJECTS	O
:	O

2049	O
noninstitutionalized	O
adults	O
(	O
>	O
/	O
=	O
60	O
years	O
)	O
with	O
nonmissing	O
values	O
in	O
cognitive	O
test	O
,	O
urinary	O
albumin	B
-	O
to	O
-	O
creatinine	O
ratio	O
(	O
UACR	O
)	O
and	O
ankle	O
-	O
brachial	O
blood	O
pressure	O
index	O
(	O
ABPI	O
)	O
was	O
analysed	O
.	O

Participants	O
with	O
UACR	O
>	O
300	O
microg	O
mg	O
(	O
-1	O
)	O
were	O
excluded	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O

The	O
UACR	O
,	O
in	O
the	O
unit	O
of	O
microg	O
mg	O
(	O
-1	O
)	O
,	O
was	O
calculated	O
by	O
dividing	O
the	O
urinary	O
albumin	B
value	O
by	O
the	O
urinary	O
creatinine	O
concentration	O
.	O

MA	O
was	O
defined	O
as	O
UACR	O
between	O
30	O
and	O
300	O
microg	O
mg	O
(	O
-1	O
)	O
.	O

Cognitive	O
function	O
was	O
measured	O
by	O
a	O
2-min	O
Digit	O
Symbol	O
Substitution	O
Test	O
(	O
DSST	O
)	O
.	O

Peripheral	O
artery	O
disease	O
(	O
PAD	O
)	O
was	O
defined	O
as	O
an	O
ABPI	O
<	O
0.9	O
in	O
either	O
leg	O
.	O

RESULTS	O
:	O

Overall	O
speaking	O
,	O
MA	O
was	O
inversely	O
associated	O
with	O
DSST	O
score	O
after	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
race	O
,	O
body	O
mass	O
index	O
and	O
educational	O
level	O
(	O
regression	O
coefficient	O
=	O
-	O
2.8	O
,	O
P	O
=	O
0.002	O
)	O
.	O

There	O
was	O
an	O
effect	O
modification	O
of	O
PAD	O
on	O
the	O
association	O
between	O
MA	O
and	O
the	O
DSST	O
score	O
.	O

Amongst	O
participants	O
with	O
PAD	O
,	O
the	O
DSST	O
score	O
for	O
those	O
with	O
MA	O
was	O
lower	O
than	O
those	O
without	O
MA	O
(	O
beta	O
=	O
-	O
6.3	O
,	O
P	O
=	O
0.003	O
)	O
after	O
multivariate	O
adjustment	O
.	O

Moreover	O
,	O
participants	O
with	O
PAD	O
in	O
the	O
highest	O
quartile	O
of	O
UACR	O
had	O
significantly	O
lower	O
DSST	O
score	O
compared	O
to	O
those	O
in	O
the	O
lowest	O
quartile	O
(	O
beta	O
=	O
-	O
8.7	O
,	O
P	O
=	O
0.001	O
)	O
.	O

There	O
was	O
no	O
association	O
between	O
MA	O
and	O
cognitive	O
function	O
amongst	O
participants	O
without	O
PAD	O
.	O

We	O
observed	O
an	O
additive	O
effect	O
of	O
MA	O
and	O
PAD	O
on	O
DSST	O
score	O
.	O

Participants	O
with	O
both	O
MA	O
and	O
PAD	O
had	O
a	O
lower	O
mean	O
DSST	O
score	O
compared	O
to	O
those	O
without	O
both	O
conditions	O
(	O
beta	O
=	O
-	O
6.2	O
,	O
P	O
=	O
0.003	O
)	O
.	O

CONCLUSIONS	O
:	O

The	O
presence	O
of	O
MA	O
or	O
a	O
higher	O
level	O
of	O
urinary	O
albumin	B
excretion	O
was	O
inversely	O
associated	O
with	O
cognitive	O
function	O
in	O
participants	O
with	O
PAD	O
.	O

Regulation	O
of	O
spo0H	B
,	O
a	O
gene	O
coding	O
for	O
the	O
Bacillus	O
subtilis	O
sigma	B
H	I
factor	I
.	O

The	O
Bacillus	O
spo0H	B
gene	O
codes	O
for	O
sigma	B
H	I
,	O
which	O
,	O
as	O
part	O
of	O
the	O
RNA	B
polymerase	I
holoenzyme	O
E	B
sigma	I
H	I
,	O
is	O
responsible	O
for	O
the	O
transcription	O
of	O
several	O
genes	O
which	O
are	O
expressed	O
at	O
the	O
beginning	O
of	O
the	O
sporulation	O
process	O
.	O

In	O
this	O
communication	O
,	O
we	O
examined	O
the	O
regulation	O
of	O
the	O
spo0H	B
gene	O
of	O
Bacillus	O
subtilis	O
by	O
using	O
lacZ	B
reporter	O
gene	O
assays	O
,	O
quantitative	O
RNA	O
determinations	O
,	O
and	O
Western	O
immunoassay	O
.	O

The	O
expression	O
of	O
the	O
spo0H	B
gene	O
increases	O
as	O
the	O
culture	O
enters	O
the	O
mid	O
-	O
logarithmic	O
stage	O
of	O
growth	O
.	O

This	O
increased	O
expression	O
requires	O
the	O
genes	O
spo0A	B
,	O
spo0B	B
,	O
spo0E	B
,	O
and	O
spo0F	B
,	O
and	O
the	O
requirement	O
for	O
at	O
least	O
spo0A	B
and	O
spo0B	B
can	O
be	O
bypassed	O
when	O
the	O
abrB	B
gene	O
is	O
mutated	O
.	O

The	O
expression	O
of	O
the	O
spo0H	B
gene	O
is	O
constitutive	O
in	O
the	O
presence	O
of	O
the	O
abrB	B
mutation	O
,	O
being	O
expressed	O
at	O
higher	O
levels	O
during	O
vegetative	O
growth	O
.	O

In	O
addition	O
,	O
the	O
sof-1	B
mutation	O
,	O
in	O
the	O
spo0A	B
structural	O
gene	O
,	O
can	O
bypass	O
the	O
need	O
for	O
spo0F	B
in	O
spo0H	B
expression	O
.	O

The	O
transcriptional	O
start	O
site	O
of	O
spo0H	B
was	O
determined	O
by	O
using	O
RNA	O
made	O
in	O
vivo	O
as	O
well	O
as	O
in	O
vitro	O
.	O

These	O
studies	O
indicate	O
that	O
spo0H	B
is	O
transcribed	O
by	O
the	O
major	O
vegetative	O
RNA	B
polymerase	I
,	O
E	B
sigma	I
A	I
.	O
spo0H	B
RNA	O
and	O
sigma	B
H	I
levels	O
during	O
growth	O
are	O
not	O
identical	O
to	O
each	O
other	O
or	O
to	O
the	O
pattern	O
of	O
expression	O
of	O
spoVG	B
,	O
a	O
gene	O
transcribed	O
by	O
E	B
sigma	I
H	I
.	O

This	O
suggests	O
that	O
spo0H	B
is	O
regulated	O
posttranscriptionally	O
and	O
also	O
that	O
factors	O
in	O
addition	O
to	O
sigma	B
H	I
levels	O
are	O
involved	O
in	O
the	O
expression	O
of	O
genes	O
of	O
the	O
E	B
sigma	I
H	I
regulon	O
.	O

Deletion	O
of	O
spoIIAB	B
blocks	O
endospore	O
formation	O
in	O
Bacillus	O
subtilis	O
at	O
an	O
early	O
stage	O
.	O

During	O
an	O
early	O
stage	O
of	O
endospore	O
formation	O
in	O
Bacillus	O
subtilis	O
,	O
the	O
cell	O
divides	O
asymmetrically	O
into	O
two	O
compartments	O
that	O
follow	O
different	O
developmental	O
paths	O
.	O

The	O
differential	O
expression	O
of	O
genes	O
in	O
these	O
two	O
compartments	O
is	O
controlled	O
in	O
part	O
by	O
the	O
production	O
of	O
compartment	O
-	O
specific	O
transcription	O
factors	O
,	O
sigma	B
G	I
and	O
sigma	B
K	I
.	O

It	O
is	O
not	O
known	O
how	O
sigma	B
G	I
accumulation	O
is	O
restricted	O
to	O
one	O
of	O
the	O
two	O
compartments	O
,	O
the	O
forespore	O
.	O

However	O
,	O
the	O
observations	O
that	O
sigma	B
F	I
directs	O
transcription	O
of	O
the	O
structural	O
gene	O
for	O
sigma	B
G	I
and	O
that	O
sigma	B
F	I
activity	O
can	O
be	O
modified	O
by	O
the	O
product	O
of	O
a	O
gene	O
,	O
spoIIAB	B
,	O
has	O
led	O
us	O
to	O
investigate	O
the	O
role	O
of	O
spoIIAB	B
during	O
sporulation	O
.	O

We	O
have	O
isolated	O
mutants	O
that	O
carry	O
deletion	O
alleles	O
of	O
spoIIAB	B
.	O

Electron	O
microscopic	O
examination	O
of	O
these	O
mutants	O
revealed	O
that	O
these	O
mutations	O
blocked	O
endospore	O
formation	O
at	O
an	O
early	O
stage	O
before	O
septation	O
and	O
caused	O
extensive	O
cell	O
lysis	O
.	O

The	O
spoIIAB	B
deletion	O
alleles	O
caused	O
hyperexpression	O
of	O
genes	O
that	O
are	O
normally	O
expressed	O
exclusively	O
in	O
the	O
forespore	O
compartments	O
of	O
sporulating	O
wild	O
-	O
type	O
cells	O
,	O
whereas	O
these	O
alleles	O
reduced	O
expression	O
of	O
other	O
genes	O
,	O
including	O
spoIIE	B
,	O
which	O
is	O
expressed	O
before	O
septation	O
in	O
wild	O
-	O
type	O
cells	O
.	O

These	O
observations	O
confirm	O
that	O
spoIIAB	B
is	O
essential	O
for	O
sporulation	O
and	O
are	O
consistent	O
with	O
models	O
in	O
which	O
the	O
product	O
of	O
spoIIAB	B
plays	O
a	O
role	O
in	O
regulating	O
the	O
timing	O
and/or	O
compartment	O
specificity	O
of	O
sigma	B
F	I
-	O
and	O
sigma	B
G	I
-	O
directed	O
transcription	O
.	O

Genetic	O
evidence	O
that	O
RNA	B
polymerase	I
associated	O
with	O
sigma	B
A	I
factor	I
uses	O
a	O
sporulation	O
-	O
specific	O
promoter	O
in	O
Bacillus	O
subtilis	O
.	O

The	O
construction	O
of	O
allele	O
-	O
specific	O
suppressor	O
mutations	O
has	O
enabled	O
us	O
to	O
demonstrate	O
that	O
a	O
sporulation	O
-	O
specific	O
transcription	O
unit	O
in	O
Bacillus	O
subtilis	O
,	O
the	O
spoIIG	B
operon	I
,	O
is	O
transcribed	O
by	O
a	O
form	O
of	O
RNA	B
polymerase	I
associated	O
with	O
sigma	B
A	I
,	O
the	O
principal	O
sigma	B
factor	I
in	O
vegetative	O
cells	O
.	O

The	O
spoIIG	B
operon	I
encodes	O
sporulation	O
-	O
specific	O
factor	O
sigma	B
E	I
,	O
and	O
its	O
transcription	O
is	O
directed	O
from	O
a	O
promoter	O
that	O
is	O
activated	O
about	O
1	O
hr	O
after	O
the	O
onset	O
of	O
endospore	O
formation	O
.	O

This	O
promoter	O
contains	O
sequences	O
that	O
are	O
similar	O
to	O
those	O
found	O
at	O
the	O
-	O
10	O
and	O
-	O
35	O
regions	O
of	O
promoters	O
that	O
are	O
used	O
by	O
sigma	B
A	I
-	O
associated	O
RNA	B
polymerase	I
,	O
but	O
these	O
sigma	B
A	I
-	O
like	O
recognition	O
sequences	O
are	O
separated	O
by	O
22	O
base	O
pairs	O
rather	O
than	O
the	O
typical	O
17	O
or	O
18	O
base	O
pairs	O
.	O

We	O
have	O
found	O
that	O
substitution	O
of	O
an	O
arginyl	O
residue	O
for	O
the	O
glutamyl	O
residue	O
at	O
position	O
196	O
of	O
sigma	B
A	I
(	O
Glu-196	O
-	O
---	O
Arg	O
)	O
suppresses	O
the	O
deleterious	O
effect	O
of	O
a	O
thymidine	O
-	O
to	O
-	O
cytidine	O
base	O
substitution	O
at	O
position	O
-	O
11	O
in	O
the	O
spoIIG	B
promoter	O
.	O

This	O
suppression	O
was	O
allele	O
-	O
specific	O
,	O
since	O
it	O
did	O
not	O
suppress	O
the	O
effects	O
of	O
base	O
substitutions	O
in	O
other	O
positions	O
in	O
the	O
spoIIG	B
promoter	O
or	O
the	O
effects	O
of	O
a	O
thymidine	O
-	O
to	O
-	O
guanosine	O
change	O
at	O
-	O
11	O
.	O

These	O
results	O
support	O
a	O
model	O
in	O
which	O
a	O
form	O
of	O
RNA	B
polymerase	I
containing	O
sigma	B
A	I
is	O
utilized	O
in	O
an	O
unusual	O
manner	O
to	O
activate	O
the	O
transcription	O
of	O
the	O
spoIIG	B
operon	I
well	O
after	O
the	O
onset	O
of	O
endospore	O
formation	O
.	O

rpoD	B
operon	O
promoter	O
used	O
by	O
sigma	B
H	I
-	O
RNA	B
polymerase	I
in	O
Bacillus	O
subtilis	O
.	O

Three	O
promoters	O
direct	O
transcription	O
of	O
the	O
sigA	B
(	O
rpoD	B
)	O
operon	O
in	O
Bacillus	O
subtilis	O
.	O

Promoters	O
P1	O
and	O
P2	O
are	O
used	O
during	O
the	O
exponential	O
growth	O
phase	O
,	O
whereas	O
P3	O
is	O
used	O
only	O
during	O
the	O
stationary	O
phase	O
.	O

We	O
examined	O
the	O
use	O
of	O
these	O
promoters	O
in	O
promoter	O
-	O
probe	O
plasmids	O
and	O
found	O
that	O
expression	O
from	O
P3	O
was	O
prevented	O
by	O
a	O
mutation	O
in	O
spoOH	B
,	O
which	O
encodes	O
the	O
secondary	O
RNA	B
polymerase	I
sigma	I
factor	I
sigma	B
H	I
.	O

Moreover	O
,	O
we	O
found	O
that	O
sigma	B
H	I
-	O
containing	O
RNA	B
polymerase	I
efficiently	O
and	O
accurately	O
used	O
the	O
P3	O
promoter	O
in	O
vitro	O
.	O

Evidently	O
,	O
this	O
operon	O
,	O
which	O
is	O
essential	O
for	O
exponential	O
growth	O
,	O
is	O
transcribed	O
during	O
the	O
early	O
phase	O
of	O
sporulation	O
by	O
this	O
secondary	O
form	O
of	O
RNA	B
polymerase	I
.	O

Comparison	O
of	O
the	O
nucleotide	O
sequences	O
of	O
the	O
P3	O
promoter	O
and	O
the	O
spoVG	B
promoter	O
,	O
which	O
also	O
is	O
used	O
by	O
sigma	B
H	I
-	O
RNA	O
polymerase	O
,	O
revealed	O
sequences	O
at	O
the	O
-	O
10	O
and	O
-	O
35	O
regions	O
of	O
these	O
promoters	O
that	O
may	O
signal	O
recognition	O
of	O
promoters	O
by	O
sigma	B
H	I
-	O
RNA	B
polymerase	I
.	O

The	O
human	O
natural	O
killer	O
cell	O
receptor	O
for	O
major	B
histocompatibility	I
complex	I
class	I
I	I
molecules	O
.	O

Surface	O
modulation	O
of	O
p58	B
molecules	O
and	O
their	O
linkage	O
to	O
CD3	B
zeta	I
chain	O
,	O
Fc	B
epsilon	I
RI	I
gamma	I
chain	O
and	O
the	O
p56lck	B
kinase	B
.	O

The	O
natural	O
killer	O
cell	O
(	O
NK	O
)	O
-	O
specific	O
p58	B
surface	O
molecules	O
,	O
recognized	O
by	O
the	O
GL183	B
and	O
EB6	B
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
,	O
have	O
been	O
shown	O
to	O
represent	O
the	O
putative	O
NK	O
receptor	O
for	O
HLA	B
-	I
C	I
molecules	O
.	O

The	O
interaction	O
between	O
p58	B
receptors	O
and	O
HLA	B
-	I
C	I
results	O
in	O
inhibition	O
of	O
the	O
NK	O
-	O
mediated	O
target	O
cell	O
lysis	O
.	O

In	O
this	O
study	O
,	O
GL183	B
-	O
EB6	B
+	O
clones	O
(	O
Cw4	B
-	O
specific	O
)	O
,	O
after	O
mAb	O
-	O
induced	O
surface	O
modulation	O
of	O
EB6	B
molecules	O
,	O
acquired	O
the	O
ability	O
to	O
lyse	O
the	O
Cw4	B
+	O
C1R	O
cells	O
.	O

In	O
NK	O
clones	O
co	O
-	O
expressing	O
both	O
GL183	B
and	O
EB6	B
molecules	O
and	O
unable	O
to	O
kill	O
Cw3	B
-	O
protected	O
target	O
cells	O
,	O
the	O
mAb	O
-	O
induced	O
modulation	O
of	O
EB6	B
molecules	O
resulted	O
both	O
in	O
selective	O
co	O
-	O
modulation	O
of	O
GL183	B
molecules	O
and	O
in	O
the	O
lysis	O
of	O
Cw3	B
-	O
transfected	O
P815	O
murine	O
cells	O
.	O

In	O
line	O
with	O
the	O
co	O
-	O
modulation	O
experiments	O
we	O
also	O
show	O
that	O
the	O
GL183	B
and	O
EB6	B
molecules	O
can	O
be	O
co	O
-	O
immunoprecipitated	O
from	O
GL183	B
+	O
/	O
EB6	B
+	O
clones	O
after	O
cell	O
lysis	O
in	O
the	O
presence	O
of	O
digitonin	O
.	O

The	O
p58	B
receptor	O
also	O
revealed	O
an	O
association	O
with	O
molecules	O
belonging	O
to	O
the	O
zeta	B
family	I
(	O
i.e.	O
CD3	B
zeta	I
and	O
Fc	B
epsilon	I
RI	I
gamma	I
chains	O
)	O
.	O

Two	O
-	O
dimensional	O
diagonal	O
gel	O
analysis	O
of	O
the	O
p58	B
complex	O
immunoprecipitated	O
from	O
polyclonally	O
activated	O
p58	B
+	O
NK	O
cells	O
indicated	O
a	O
preferential	O
association	O
with	O
CD3	B
zeta	I
chains	O
either	O
in	O
the	O
form	O
of	O
covalently	O
linked	O
zeta	O
-	O
zeta	O
homodimers	O
or	O
in	O
the	O
form	O
of	O
zeta	O
-	O
gamma	O
heterodimers	O
,	O
while	O
gamma	O
-	O
gamma	O
homodimers	O
were	O
detectable	O
in	O
low	O
amounts	O
.	O

However	O
,	O
p58	B
+	O
clones	O
displaying	O
a	O
unique	O
association	O
with	O
gamma	O
-	O
gamma	O
homodimers	O
could	O
also	O
be	O
isolated	O
.	O

Probing	O
the	O
immunoprecipitated	O
p58	B
complex	O
with	O
anti	O
-	O
p56lck	B
antibody	O
also	O
revealed	O
an	O
association	O
with	O
this	O
member	O
of	O
the	O
src	B
family	I
.	O

In	O
addition	O
,	O
mAb	O
-	O
mediated	O
signaling	O
of	O
NK	O
clones	O
via	O
p58	B
molecules	O
induced	O
increments	O
of	O
p58	B
/	O
p56lck	B
association	O
.	O

However	O
,	O
under	O
the	O
same	O
experimental	O
conditions	O
that	O
induced	O
optimal	O
in	O
vivo	O
tyrosine	O
phosphorylation	O
of	O
the	O
CD16	B
-	O
associated	O
CD3	B
zeta	I
chains	O
,	O
no	O
tyrosine	O
phosphorylation	O
was	O
detected	O
in	O
the	O
p58	B
-	O
associated	O
CD3	B
zeta	I
chains	O
.	O

In	O
these	O
in	O
vivo	O
experiments	O
neither	O
anti	O
-	O
CD16	B
nor	O
anti	O
-	O
p58	B
mAb	O
could	O
induce	O
tyrosine	O
phosphorylation	O
of	O
the	O
gamma	O
chains	O
.	O

Finally	O
,	O
the	O
anti	O
-	O
p58	B
-	O
mediated	O
inhibition	O
of	O
the	O
NK	O
cell	O
triggering	O
via	O
CD16	B
molecules	O
was	O
not	O
accompanied	O
by	O
a	O
down	O
-	O
regulation	O
of	O
the	O
tyrosine	O
phosphorylation	O
of	O
the	O
CD16	B
-	O
associated	O
CD3	B
zeta	I
chains	O
.	O

Molecular	O
clones	O
of	O
the	O
p58	B
NK	O
cell	O
receptor	O
reveal	O
immunoglobulin	B
-	O
related	O
molecules	O
with	O
diversity	O
in	O
both	O
the	O
extra	O
-	O
and	O
intracellular	O
domains	O
.	O

Recognition	O
of	O
major	B
histocompatibility	I
class	I
I	I
molecules	O
on	O
target	O
cells	O
by	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
confers	O
selective	O
protection	O
from	O
NK	O
-	O
mediated	O
lysis	O
.	O

Cross	O
-	O
linking	O
of	O
the	O
p58	B
NK	O
receptor	O
,	O
involved	O
in	O
the	O
recognition	O
of	O
HLA	B
-	I
C	I
alleles	O
,	O
delivers	O
a	O
negative	O
signal	O
that	O
prevents	O
target	O
cell	O
lysis	O
.	O

Molecular	O
cloning	O
of	O
the	O
p58	B
NK	O
receptor	O
reported	O
here	O
revealed	O
a	O
new	O
member	O
of	O
the	O
immunoglobulin	B
superfamily	I
.	O

Five	O
distinct	O
p58	B
receptors	O
,	O
with	O
sequence	O
diversity	O
in	O
the	O
immunoglobulin	B
-	O
related	O
domains	O
,	O
were	O
identified	O
in	O
a	O
single	O
individual	O
.	O

All	O
NK	O
clones	O
tested	O
expressed	O
at	O
least	O
one	O
p58	B
member	O
.	O

Three	O
different	O
types	O
of	O
transmembrane	O
and	O
cytoplasmic	O
domains	O
exist	O
,	O
even	O
among	O
receptors	O
with	O
closely	O
related	O
extracellular	O
domains	O
.	O

These	O
data	O
revealed	O
a	O
repertoire	O
of	O
NK	O
cells	O
with	O
clonally	O
distributed	O
p58	B
receptors	O
exhibiting	O
diversity	O
in	O
both	O
extracellular	O
and	O
intracellular	O
domains	O
.	O

Cell	O
-	O
cell	O
signaling	O
pathway	O
activating	O
a	O
developmental	O
transcription	B
factor	I
in	O
Bacillus	O
subtilis	O
.	O

Transcription	O
in	O
the	O
mother	O
cell	O
at	O
early	O
stages	O
of	O
sporulation	O
in	O
Bacillus	O
subtilis	O
is	O
controlled	O
by	O
sigma	B
E	I
,	O
a	O
sigma	B
factor	I
that	O
is	O
synthesized	O
in	O
the	O
predivisional	O
cell	O
as	O
an	O
inactive	O
larger	O
precursor	O
,	O
pro	O
-	O
sigma	B
E	I
.	O

Activation	O
of	O
sigma	B
E	I
depends	O
on	O
sigma	B
F	I
,	O
the	O
factor	O
that	O
governs	O
transcription	O
in	O
the	O
forespore	O
.	O

Genetic	O
experiments	O
have	O
indicated	O
that	O
transduction	O
of	O
the	O
activation	O
signal	O
from	O
the	O
forespore	O
to	O
the	O
mother	O
cell	O
requires	O
the	O
products	O
of	O
some	O
genes	O
belonging	O
to	O
the	O
sigma	B
F	I
-	O
controlled	O
regulon	O
.	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
sigma	B
F	I
-	O
dependent	O
gene	O
,	O
csfX	B
,	O
encoding	O
a	O
protein	O
necessary	O
and	O
sufficient	O
for	O
triggering	O
processing	O
of	O
pro	O
-	O
sigma	B
E	I
.	O

The	O
CsfX	B
protein	O
contains	O
a	O
typical	O
amino	O
-	O
terminal	O
signal	O
sequence	O
suggesting	O
that	O
,	O
although	O
synthesized	O
in	O
the	O
forespore	O
,	O
it	O
may	O
act	O
across	O
the	O
septum	O
to	O
activate	O
the	O
membrane	O
-	O
bound	O
enzyme	O
that	O
is	O
responsible	O
for	O
pro	O
-	O
sigma	B
E	I
processing	O
in	O
the	O
mother	O
cell	O
.	O

Evidence	O
that	O
the	O
spoIIM	B
gene	O
of	O
Bacillus	O
subtilis	O
is	O
transcribed	O
by	O
RNA	B
polymerase	I
associated	O
with	O
sigma	B
E	I
.	O

We	O
have	O
investigated	O
the	O
temporal	O
and	O
spatial	O
regulation	O
of	O
spoIIM	B
,	O
a	O
gene	O
of	O
Bacillus	O
subtilis	O
whose	O
product	O
is	O
required	O
for	O
complete	O
septum	O
migration	O
and	O
engulfment	O
of	O
the	O
forespore	O
compartment	O
during	O
sporulation	O
.	O

The	O
spoIIM	B
promoter	O
was	O
found	O
to	O
become	O
active	O
about	O
2	O
h	O
after	O
the	O
initiation	O
of	O
sporulation	O
.	O

The	O
effects	O
of	O
mutations	O
on	O
the	O
expression	O
of	O
a	O
spoIIM	B
-	O
lacZ	B
fusion	O
were	O
most	O
consistent	O
with	O
its	O
utilization	O
by	O
sigma	B
-	I
E	I
-	O
associated	O
RNA	B
polymerase	I
(	O
E	B
sigma	I
E	I
)	O
.	O

A	O
unique	O
5	O
'	O
end	O
of	O
the	O
in	O
vivo	O
spoIIM	B
transcript	O
was	O
detected	O
by	O
primer	O
extension	O
analysis	O
and	O
was	O
determined	O
to	O
initiate	O
at	O
the	O
appropriate	O
distance	O
from	O
a	O
sequence	O
conforming	O
very	O
closely	O
to	O
the	O
consensus	O
for	O
genes	O
transcribed	O
by	O
E	B
sigma	I
E	I
.	O

A	O
partially	O
purified	O
preparation	O
of	O
E	B
sigma	I
E	I
produced	O
a	O
transcript	O
in	O
vitro	O
that	O
initiated	O
at	O
the	O
same	O
nucleotide	O
as	O
the	O
primer	O
extension	O
product	O
generated	O
from	O
in	O
vivo	O
RNA	O
.	O

Ectopic	O
induction	O
of	O
sigma	B
E	I
synthesis	O
during	O
growth	O
resulted	O
in	O
the	O
immediate	O
and	O
strong	O
expression	O
of	O
a	O
spoIIM	B
-	O
lacZ	B
fusion	O
,	O
but	O
an	O
identical	O
fusion	O
was	O
completely	O
unresponsive	O
to	O
induced	O
synthesis	O
of	O
either	O
sigma	B
F	I
or	O
sigma	B
G	I
under	O
similar	O
conditions	O
.	O

The	O
results	O
of	O
plasmid	O
integration	O
-	O
excision	O
experiments	O
in	O
which	O
the	O
spoIIM	B
gene	O
was	O
reversibly	O
disrupted	O
by	O
a	O
temperature	O
-	O
sensitive	O
integrational	O
vector	O
suggested	O
that	O
spoIIM	B
expression	O
is	O
required	O
in	O
the	O
forespore	O
compartment	O
,	O
but	O
direct	O
examination	O
of	O
subcellular	O
fractions	O
enriched	O
for	O
mother	O
cell	O
or	O
forespore	O
material	O
indicated	O
that	O
spoIIM	B
expression	O
can	O
not	O
be	O
confined	O
to	O
the	O
forespore	O
.	O

We	O
conclude	O
that	O
spoIIM	B
is	O
a	O
member	O
of	O
the	O
sigma	B
E	I
regulon	O
and	O
that	O
it	O
may	O
be	O
transcribed	O
exclusively	O
by	O
E	B
sigma	I
E	I
.	O

We	O
discuss	O
the	O
implications	O
of	O
this	O
conclusion	O
for	O
models	O
in	O
which	O
activation	O
of	O
sigma	B
E	I
in	O
the	O
mother	O
cell	O
is	O
proposed	O
to	O
be	O
a	O
part	O
of	O
the	O
mechanism	O
responsible	O
for	O
initiating	O
separate	O
programs	O
of	O
gene	O
activity	O
in	O
the	O
two	O
sporangium	O
compartments	O
.	O

Bacillus	O
subtilis	O
SpoIIID	B
protein	O
binds	O
to	O
two	O
sites	O
in	O
the	O
spoVD	B
promoter	O
and	O
represses	O
transcription	O
by	O
sigmaE	B
RNA	B
polymerase	I
.	O

The	O
Bacillus	O
subtilis	O
spoVD	B
gene	O
encodes	O
a	O
penicillin	O
-	O
binding	O
protein	O
required	O
for	O
spore	O
morphogenesis	O
.	O

SpoIIID	B
is	O
a	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
protein	O
that	O
activates	O
or	O
represses	O
the	O
transcription	O
of	O
many	O
different	O
genes	O
.	O

We	O
have	O
defined	O
the	O
spoVD	B
promoter	O
region	O
and	O
demonstrated	O
that	O
it	O
is	O
recognized	O
by	O
sigmaE	B
RNA	B
polymerase	I
in	O
vitro	O
and	O
that	O
SpoIIID	B
represses	O
spoVD	B
transcription	O
.	O

Two	O
strong	O
SpoIIID	B
-	O
binding	O
sites	O
were	O
mapped	O
in	O
the	O
spoVD	B
promoter	O
region	O
,	O
one	O
overlapping	O
the	O
-	O
35	O
region	O
and	O
the	O
other	O
encompassing	O
the	O
-	O
10	O
region	O
and	O
the	O
transcriptional	O
start	O
site	O
.	O

Genomic	O
organization	O
and	O
allelic	O
polymorphism	O
of	O
the	O
human	O
killer	O
cell	O
inhibitory	O
receptor	O
gene	O
KIR103	B
.	O

Killer	O
cell	O
inhibitory	O
receptors	O
(	O
KIR	B
)	O
belong	O
to	O
the	O
immunoglobulin	B
superfamily	I
of	O
molecules	O
and	O
are	O
expressed	O
on	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

The	O
KIRs	B
of	O
the	O
p58	B
/	I
p50	I
family	I
have	O
two	O
immunoglobulin	B
domains	O
and	O
are	O
ligands	O
for	O
HLA	B
-	I
Cw	I
antigens	O
,	O
whereas	O
the	O
p70	B
/	I
p70	I
delta	I
family	I
has	O
three	O
immunoglobulin	B
domains	O
and	O
comprises	O
ligands	O
for	O
HLA	B
-	I
B	I
antigens	O
and	O
possibly	O
some	O
HLA	B
-	I
A	I
antigens	O
.	O

Members	O
of	O
a	O
third	O
KIR	B
family	I
,	O
KIR103	B
,	O
have	O
two	O
immunoglobulin	B
domains	O
but	O
have	O
highest	O
nucleotide	O
sequence	O
homology	O
to	O
the	O
p70	B
family	I
.	O

The	O
ligands	O
for	O
KIR103	B
on	O
target	O
cells	O
are	O
currently	O
unknown	O
.	O

We	O
here	O
report	O
the	O
complete	O
genomic	O
organization	O
of	O
KIR103	B
.	O

It	O
spans	O
about	O
12	O
kb	O
of	O
DNA	O
and	O
consists	O
of	O
eight	O
exons	O
of	O
which	O
exon	O
1	O
and	O
exon	O
2	O
encode	O
the	O
leader	O
sequence	O
.	O

Exon	O
3	O
encodes	O
the	O
first	O
immunoglobulin	B
domain	O
(	O
gamma	O
1	O
)	O
,	O
and	O
exon	O
4	O
encodes	O
the	O
main	O
part	O
of	O
the	O
second	O
immunoglobulin	B
domain	O
(	O
gamma	O
3	O
)	O
,	O
which	O
also	O
contains	O
sequences	O
contributed	O
by	O
exon	O
5	O
and	O
exon	O
6	O
.	O

Exon	O
6	O
encodes	O
the	O
transmembrane	O
domain	O
,	O
whereas	O
exons	O
7	O
and	O
8	O
encode	O
most	O
of	O
the	O
cytoplasmic	O
domain	O
.	O

KIR103	B
is	O
polymorphic	O
,	O
and	O
two	O
alleles	O
,	O
103AS	B
and	O
103LP	B
,	O
are	O
defined	O
in	O
this	O
study	O
.	O

Additional	O
full	O
-	O
length	O
cDNA	O
clones	O
for	O
KIR103	B
have	O
been	O
isolated	O
and	O
are	O
shown	O
to	O
be	O
formed	O
by	O
alternative	O
mRNA	O
splicing	O
with	O
exon	O
skipping	O
.	O

Some	O
of	O
these	O
truncated	O
KIR103	B
cDNA	O
could	O
encode	O
shorter	O
transmembrane	O
molecules	O
,	O
whereas	O
others	O
lack	O
the	O
transmembrane	O
domain	O
and	O
are	O
candidate	O
genes	O
for	O
secreted	O
KIR	B
products	O
.	O

KIR103	B
is	O
localized	O
to	O
the	O
KIR	B
genetic	O
region	O
on	O
chromosome	O
19q13.4	O
.	O

Identification	B
and	O
characterization	O
of	O
sporulation	O
-	O
dependent	O
promoters	O
upstream	O
of	O
the	O
enterotoxin	B
gene	O
(	O
cpe	B
)	O
of	O
Clostridium	O
perfringens	O
.	O

Three	O
promoter	O
sites	O
(	O
P1	O
,	O
P2	O
,	O
and	O
P3	O
)	O
responsible	O
for	O
the	O
sporulation	O
-	O
associated	O
synthesis	O
of	O
Clostridium	O
perfringens	O
enterotoxin	B
,	O
a	O
common	O
cause	O
of	O
food	O
poisoning	O
in	O
humans	O
and	O
animals	O
,	O
were	O
identified	O
.	O

Nested	O
and	O
internal	O
deletions	O
of	O
the	O
cpe	O
promoter	O
region	O
were	O
made	O
to	O
narrow	O
down	O
the	O
location	O
of	O
promoter	O
elements	O
.	O

To	O
measure	O
the	O
effects	O
of	O
the	O
deletions	O
on	O
the	O
expression	O
of	O
cpe	B
,	O
translational	O
fusions	O
containing	O
the	O
promoter	O
deletions	O
were	O
made	O
with	O
the	O
gusA	B
gene	O
of	O
Escherichia	O
coli	O
,	O
which	O
codes	O
for	O
beta	B
-	I
glucuronidase	I
;	O
E.	O
coli	O
-	O
C.	O
perfringens	O
shuttle	O
vectors	O
carrying	O
the	O
fusions	O
were	O
introduced	O
into	O
C.	O
perfringens	O
by	O
electroporation	O
.	O

In	O
addition	O
,	O
in	O
vitro	O
transcription	O
assays	O
were	O
performed	O
with	O
the	O
cpe	O
promoter	O
region	O
as	O
the	O
DNA	O
template	O
for	O
extracts	O
made	O
from	O
sporulating	O
cells	O
.	O

SigE	B
and	O
SigK	B
are	O
sporulation	O
-	O
associated	O
sigma	B
factors	I
known	O
to	O
be	O
active	O
in	O
the	O
mother	O
cell	O
compartment	O
of	O
sporulating	O
cells	O
of	O
Bacillus	O
subtilis	O
,	O
the	O
same	O
compartment	O
in	O
which	O
enterotoxin	B
is	O
synthesized	O
in	O
C.	O
perfringens	O
.	O

Human	O
EZF	B
,	O
a	O
KrÃ?Â¼ppel	B
-	I
like	I
zinc	I
finger	I
protein	I
,	O
is	O
expressed	O
in	O
vascular	O
endothelial	O
cells	O
and	O
contains	O
transcriptional	O
activation	O
and	O
repression	O
domains	O
.	O

Members	O
of	O
the	O
erythroid	O
KrÃ?Â¼ppel	B
-	I
like	I
factor	I
(	I
EKLF	I
)	I
multigene	I
family	I
contain	O
three	O
C	O
-	O
terminal	O
zinc	O
fingers	O
,	O
and	O
they	O
are	O
typically	O
expressed	O
in	O
a	O
limited	O
number	O
of	O
tissues	O
.	O

EKLF	B
,	O
the	O
founding	O
member	O
,	O
transactivates	O
the	O
beta	B
-	I
globin	I
promoter	O
by	O
binding	O
to	O
the	O
CACCC	O
motif	O
.	O

EKLF	B
is	O
essential	O
for	O
expression	O
of	O
the	O
beta	B
-	I
globin	I
gene	O
as	O
demonstrated	O
by	O
gene	O
deletion	O
experiments	O
in	O
mice	O
.	O

Using	O
a	O
DNA	O
probe	O
from	O
the	O
zinc	O
finger	O
region	O
of	O
EKLF	B
,	O
we	O
cloned	O
a	O
cDNA	O
encoding	O
a	O
member	O
of	O
this	O
family	O
from	O
a	O
human	O
vascular	O
endothelial	O
cell	O
cDNA	O
library	O
.	O

Sequence	O
analysis	O
indicated	O
that	O
our	O
clone	O
,	O
hEZF	B
,	O
is	O
the	O
human	O
homologue	O
of	O
the	O
recently	O
reported	O
mouse	O
EZF	B
and	O
GKLF	B
.	O

hEZF	B
is	O
a	O
single	O
-	O
copy	O
gene	O
that	O
maps	O
to	O
chromosome	O
9q31	O
.	O

By	O
gel	O
mobility	O
shift	O
analysis	O
,	O
purified	O
recombinant	O
hEZF	B
protein	O
bound	O
specifically	O
to	O
a	O
probe	O
containing	O
the	O
CACCC	O
core	O
sequence	O
.	O

In	O
co	O
-	O
transfection	O
experiments	O
,	O
we	O
found	O
that	O
sense	O
but	O
not	O
antisense	O
hEZF	B
decreased	O
the	O
activity	O
of	O
a	O
reporter	O
plasmid	O
containing	O
the	O
CACCC	O
sequence	O
upstream	O
of	O
the	O
thymidine	B
kinase	I
promoter	O
by	O
6	O
-	O
fold	O
.	O

In	O
contrast	O
,	O
EKLF	B
increased	O
the	O
activity	O
of	O
the	O
reporter	O
plasmid	O
by	O
3	O
-	O
fold	O
.	O

By	O
fusing	O
hEZF	B
to	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
GAL4	B
,	O
we	O
mapped	O
a	O
repression	O
domain	O
in	O
hEZF	B
to	O
amino	O
acids	O
181	O
-	O
388	O
.	O

We	O
also	O
found	O
that	O
amino	O
acids	O
91	O
-	O
117	O
of	O
hEZF	B
confer	O
an	O
activation	O
function	O
on	O
the	O
GAL4	B
DNA	O
-	O
binding	O
domain	O
.	O

Role	O
of	O
Pho	B
-	I
P	I
in	O
transcriptional	O
regulation	O
of	O
genes	O
involved	O
in	O
cell	O
wall	O
anionic	O
polymer	O
biosynthesis	O
in	O
Bacillus	O
subtilis	O
.	O

tagA	B
,	O
tagD	B
,	O
and	O
tuaA	B
operons	O
are	O
responsible	O
for	O
the	O
synthesis	O
of	O
cell	O
wall	O
anionic	O
polymer	O
,	O
teichoic	O
acid	O
,	O
and	O
teichuronic	O
acid	O
,	O
respectively	O
,	O
in	O
Bacillus	O
subtilis	O
.	O

Under	O
phosphate	O
starvation	O
conditions	O
,	O
teichuronic	O
acid	O
is	O
synthesized	O
while	O
teichoic	O
acid	O
synthesis	O
is	O
inhibited	O
.	O

Expression	O
of	O
these	O
genes	O
is	O
controlled	O
by	O
PhoP	B
-	O
PhoR	B
,	O
a	O
two	O
-	O
component	O
system	O
.	O

It	O
has	O
been	O
proposed	O
that	O
Pho	B
-	I
P	I
plays	O
a	O
key	O
role	O
in	O
the	O
activation	O
of	O
tuaA	B
and	O
the	O
repression	O
of	O
tagA	B
and	O
tagD	B
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
the	O
role	O
of	O
Pho	B
-	I
P	I
in	O
the	O
switch	O
process	O
from	O
teichoic	O
acid	O
synthesis	O
to	O
teichuronic	O
acid	O
synthesis	O
,	O
by	O
using	O
an	O
in	O
vitro	O
transcription	O
system	O
.	O

The	O
results	O
indicate	O
that	O
PhoP	B
approximately	O
P	O
is	O
sufficient	O
to	O
repress	O
the	O
transcription	O
of	O
the	O
tagA	B
and	O
tagD	B
promoters	O
and	O
also	O
to	O
activate	O
the	O
transcription	O
of	O
the	O
tuaA	B
promoter	O
.	O

Interaction	O
of	O
human	O
suppressor	B
of	I
cytokine	I
signaling	I
(	I
SOCS	I
)	I
-	I
2	I
with	O
the	O
insulin	B
-	I
like	I
growth	I
factor	I
-	I
I	I
receptor	I
.	O

SOCS	B
(	O
suppressor	B
of	I
cytokine	I
signaling	I
)	O
proteins	O
have	O
been	O
shown	O
to	O
be	O
negative	O
regulators	O
of	O
cytokine	B
receptor	I
signaling	O
via	O
the	O
Janus	B
kinase	I
(	O
JAK	B
)	O
/	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	O
STAT	B
)	O
pathway	O
.	O

We	O
have	O
cloned	O
a	O
member	O
of	O
this	O
family	O
(	O
hSOCS-2	B
)	O
by	O
utilizing	O
the	O
insulin	B
-	I
like	I
growth	I
factor	I
I	I
receptor	I
(	O
IGF	B
-	I
IR	I
)	O
cytoplasmic	O
domain	O
as	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
of	O
a	O
human	O
fetal	O
brain	O
library	O
.	O

The	O
hSOCS-2	B
protein	O
interacted	O
strongly	O
with	O
the	O
activated	O
IGF	B
-	I
IR	I
and	O
not	O
with	O
a	O
kinase	B
negative	O
mutant	O
receptor	O
in	O
the	O
two	O
-	O
hybrid	O
assay	O
.	O

Mutation	O
of	O
receptor	O
tyrosines	O
950	O
,	O
1250	O
,	O
1251	O
,	O
and	O
1316	O
to	O
phenylalanine	O
or	O
deletion	O
of	O
the	O
COOH	O
-	O
terminal	O
93	O
amino	O
acids	O
did	O
not	O
result	O
in	O
decreased	O
interaction	O
of	O
the	O
receptor	O
with	O
hSOCS-2	B
protein	O
.	O

hSOCS-1	B
protein	O
also	O
interacted	O
strongly	O
with	O
IGF	B
-	I
IR	I
in	O
the	O
two	O
-	O
hybrid	O
assay	O
.	O

Glutathione	O
S	O
-	O
transferase	O
-	O
hSOCS-2	B
associated	O
with	O
activated	O
IGF	B
-	I
IR	I
in	O
lysates	O
of	O
mouse	O
fibroblasts	O
overexpressing	O
IGF	B
-	I
IR	I
.	O

Human	O
embryonic	O
kidney	O
cells	O
(	O
293	O
)	O
were	O
transiently	O
transfected	O
with	O
vectors	O
containing	O
IGF	B
-	I
IR	I
and	O
FLAG	O
epitope	O
-	O
tagged	O
hSOCS-2	B
.	O

After	O
IGF	B
-	I
I	I
stimulation	O
,	O
activated	O
IGF	B
-	I
IR	I
was	O
found	O
in	O
anti	O
-	O
FLAG	O
immunoprecipitates	O
and	O
,	O
conversely	O
,	O
FLAG	O
-	O
hSOCS-2	B
was	O
found	O
in	O
anti	O
IGF	B
-	I
IR	I
immunoprecipitates	O
.	O

Thus	O
,	O
hSOCS-2	B
interacted	O
with	O
IGF	B
-	I
IR	I
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

HSOCS-2	B
mRNA	O
was	O
expressed	O
in	O
many	O
human	O
fetal	O
and	O
adult	O
tissues	O
with	O
particularly	O
high	O
abundance	O
in	O
fetal	O
kidney	O
and	O
adult	O
heart	O
,	O
skeletal	O
muscle	O
,	O
pancreas	O
,	O
and	O
liver	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
SOCS	B
proteins	O
may	O
also	O
play	O
a	O
regulatory	O
role	O
in	O
IGF	B
-	I
I	I
receptor	I
signaling	O
.	O

The	O
yvyD	B
gene	O
of	O
Bacillus	O
subtilis	O
is	O
under	O
dual	O
control	O
of	O
sigmaB	B
and	O
sigmaH	B
.	O

During	O
a	O
search	O
by	O
computer	O
-	O
aided	O
inspection	O
of	O
two	O
-	O
dimensional	O
(	O
2D	O
)	O
protein	O
gels	O
for	O
sigmaB	B
-	O
dependent	O
general	O
stress	O
proteins	O
exhibiting	O
atypical	O
induction	O
profiles	O
,	O
a	O
protein	O
initially	O
called	O
Hst23	B
was	O
identified	O
as	O
a	O
product	O
of	O
the	O
yvyD	B
gene	O
of	O
Bacillus	O
subtilis	O
.	O

In	O
addition	O
to	O
the	O
typical	O
sigmaB	B
-	O
dependent	O
,	O
stress	O
-	O
and	O
starvation	O
-	O
inducible	O
pattern	O
,	O
yvyD	B
is	O
also	O
induced	O
in	O
response	O
to	O
amino	O
acid	O
depletion	O
.	O

By	O
primer	O
extension	O
of	O
RNA	O
isolated	O
from	O
the	O
wild	O
-	O
type	O
strain	O
and	O
appropriate	O
mutants	O
carrying	O
mutations	O
in	O
the	O
sigB	B
and/or	O
spo0H	B
gene	O
,	O
two	O
promoters	O
were	O
mapped	O
upstream	O
of	O
the	O
yvyD	B
gene	O
.	O

The	O
sigmaB	B
-	O
dependent	O
promoter	O
drives	O
expression	O
of	O
yvyD	B
under	O
stress	O
conditions	O
and	O
after	O
glucose	O
starvation	O
,	O
whereas	O
a	O
sigmaH	B
-	O
dependent	O
promoter	O
is	O
responsible	O
for	O
yvyD	B
transcription	O
following	O
amino	O
acid	O
limitation	O
.	O

Analysis	O
of	O
Northern	O
blots	O
revealed	O
that	O
yvyD	B
is	O
transcribed	O
monocistronically	O
and	O
confirmed	O
the	O
conclusions	O
drawn	O
from	O
the	O
primer	O
extension	O
experiments	O
.	O

The	O
analysis	O
of	O
the	O
protein	O
synthesis	O
pattern	O
in	O
amino	O
acid	O
-	O
starved	O
wild	O
-	O
type	O
and	O
relA	B
mutant	O
cells	O
showed	O
that	O
the	O
YvyD	B
protein	O
is	O
not	O
synthesized	O
in	O
the	O
relA	B
mutant	O
background	O
.	O

It	O
was	O
concluded	O
that	O
the	O
stringent	O
response	O
plays	O
a	O
role	O
in	O
the	O
activation	O
of	O
sigmaH	B
.	O

The	O
yvyD	B
gene	O
product	O
is	O
homologous	O
to	O
a	O
protein	O
which	O
might	O
modify	O
the	O
activity	O
of	O
sigma54	B
in	O
gram	O
-	O
negative	O
bacteria	O
.	O

The	O
expression	O
of	O
a	O
sigmaL	B
-	O
dependent	O
(	O
sigmaL	B
is	O
the	O
equivalent	O
of	O
sigma54	B
in	O
B.	O
subtilis	O
)	O
levD	B
-	O
lacZ	B
fusion	O
is	O
upregulated	O
twofold	O
in	O
a	O
yvyD	B
mutant	O
.	O

This	O
indicates	O
that	O
the	O
yvyD	B
gene	O
product	O
,	O
being	O
a	O
member	O
of	O
both	O
the	O
sigmaB	B
and	O
sigmaH	B
regulons	O
,	O
might	O
negatively	O
regulate	O
the	O
activity	O
of	O
the	O
sigmaL	B
regulon	O
.	O

We	O
conclude	O
that	O
(	O
i	O
)	O
systematic	O
,	O
computer	O
-	O
aided	O
analysis	O
of	O
2D	O
protein	O
gels	O
is	O
appropriate	O
for	O
the	O
identification	O
of	O
genes	O
regulated	O
by	O
multiple	O
transcription	B
factors	I
and	O
that	O
(	O
ii	O
)	O
YvyD	B
might	O
form	O
a	O
junction	O
between	O
the	O
sigmaB	B
and	O
sigmaH	B
regulons	O
on	O
one	O
side	O
and	O
the	O
sigmaL	B
regulon	O
on	O
the	O
other	O
.	O

Identification	O
of	O
target	O
promoters	O
for	O
the	O
Bacillus	O
subtilis	O
extracytoplasmic	O
function	O
sigma	B
factor	I
,	O
sigma	B
W	I
.	O

The	O
Bacillus	O
subtilis	O
sigW	B
gene	O
encodes	O
an	O
extracytoplasmic	B
function	I
(	I
ECF	I
)	I
sigma	I
factor	I
that	O
is	O
expressed	O
in	O
early	O
stationary	O
phase	O
from	O
a	O
sigW	B
-	O
dependent	O
autoregulatory	O
promoter	O
,	O
PW	O
.	O

Using	O
a	O
consensus	O
-	O
based	O
search	O
procedure	O
,	O
we	O
have	O
identified	O
15	O
operons	O
preceded	O
by	O
promoters	O
similar	O
in	O
sequence	O
to	O
PW	O
.	O

At	O
least	O
14	O
of	O
these	O
promoters	O
are	O
dependent	O
on	O
sigma	B
W	I
both	O
in	O
vivo	O
and	O
in	O
vitro	O
as	O
judged	O
by	O
lacZ	B
reporter	O
fusions	O
,	O
run	O
-	O
off	O
transcription	O
assays	O
and	O
nucleotide	O
resolution	O
start	O
site	O
mapping	O
.	O

We	O
conclude	O
that	O
sigma	B
W	I
controls	O
a	O
regulon	O
of	O
more	O
than	O
30	O
genes	O
,	O
many	O
of	O
which	O
encode	O
membrane	O
proteins	O
of	O
unknown	O
function	O
.	O

The	O
sigma	B
W	I
regulon	O
includes	O
a	O
penicillin	B
binding	I
protein	I
(	O
PBP4	B
*	I
)	O
and	O
a	O
co	O
-	O
transcribed	O
amino	B
acid	I
racemase	I
(	O
RacX	B
)	O
,	O
homologues	O
of	O
signal	B
peptide	I
peptidase	I
(	O
YteI	B
)	O
,	O
flotillin	B
(	O
YuaG	B
)	O
,	O
ABC	B
transporters	I
(	O
YknXYZ	B
)	O
,	O
non	B
-	I
haem	I
bromoperoxidase	I
(	O
YdjP	B
)	O
,	O
epoxide	B
hydrolase	I
(	O
YfhM	B
)	O
and	O
three	O
small	O
peptides	O
with	O
structural	O
similarities	O
to	O
bacteriocin	B
precursor	O
polypeptides	O
.	O

We	O
suggest	O
that	O
sigma	B
W	I
activates	O
a	O
large	O
stationary	O
-	O
phase	O
regulon	O
that	O
functions	O
in	O
detoxification	O
,	O
production	O
of	O
anti	O
-	O
microbial	O
compounds	O
or	O
both	O
.	O

